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This report is one of a series of three reports on the health of children and young people in New Zealand 
produced for the district health boards and the Ministry of Health, and it fits into the current reporting cycle as 
follows: 
Year 1: The Determinants of Health for Children and Young People (prepared during 2014) 
Year 2: The Health Status of Children and Young People (prepared during 2015) 
Year 3: Children and Young People with Chronic Conditions and Disabilities (to be prepared during 2016) 
It aims to provide an overview of the health status of children and young people in New Zealand, and to assist 
those working to improve child and youth health to use all of the available evidence when they are developing 
programmes and interventions to address child and youth health needs. 
Report sections and indicators 
This report is based on an Indicator Framework 1 developed in 2007 in which the indicators for each of the three 
reports in the series were identified. The indicators in this year’s report were developed from Craig et al’s 
indicators for the individual and whānau health and wellbeing stream. They are presented in the following 
sections:  
 Issues in infancy  
 Issues for all ages 0–24 year olds  
 Conditions of the respiratory system  
 Common communicable diseases 
 Unintentional injury 
 Reproductive health 
 Mental health 
Within each section, where possible, data are broken down by demographic factors such as age, gender, 
ethnicity, NZ Index of Deprivation decile, and district health board (DHB). When making comparisons between 
DHBs, readers should be aware that difference in disease rates may be the result of differences in DHB 
demographic characteristics (such as the age structure, ethnicity, and deprivation level of the population) and not 
assume that differences in disease rates represent differences in DHBs’ performance. 
In-depth topics 
In addition to providing an overview of a range of important health conditions affecting children and young 
people, this report also considers two issues as in-depth topics. These are: 
1. Young people’s sexual and reproductive health: This in-depth topic by Dr Judith Adams addresses the 
sexual and reproductive health needs of New Zealand’s young people. It does not include information relevant 
to the care of pregnant teenagers or teenage parents because a previous in-depth topic (in the 2012 report in this 
series of reports) entitled Services and Interventions for Women Experiencing Multiple Adversities in Pregnancy 
included a substantial section on services for teenage parents. It begins by reviewing the available data on the 
sexual health and behaviour of New Zealand’s young people. It then reviews sexuality education and the 
research relevant to determining the best ways to provide young people with the knowledge and understanding 
to take care of their sexual and reproductive health. Subsequent sections review the literature on sexual and 
reproductive health care services for young people and newer contraceptive options for young people, 
particularly long-acting reversible contraceptive methods. The final section summarises key points and offers 
some suggestions for improving young people’s sexual and reproductive health. 
2. Mental health issues in 15–24 year olds: This in-depth topic by Dr Michael Butchard explores mental health 
issues and services for youth and young adults aged 15-24 years. Its general focus is on the mental health 
service structure and primary level care. After providing a brief historical context, the current mental health 
services and access are summarised, and barriers to access, transitioning from child to adult care, workforce 
issues, the role of primary care, and school-based health services are discussed. Literature on primary level 
mental health, alcohol and other drug interventions, including e-interventions, is reviewed and summarised. The 
final section explores issues relevant to high-risk groups within the youth and young adult population especially 




Evidence for good practice 
Most sections in this year’s report conclude with a brief overview of government documents, guidelines and 
reviews of evidence for good practice relevant to the prevention and management of the issue. Appendix 1 
provides an overview of the methodology used to develop these reviews. The quality and depth of evidence 
available varies considerably from indicator to indicator. When developing new approaches in areas where there 
is currently no sound evidence base, an evaluation arm should be built into any proposed programmes from the 
beginning. The learnings gained from these evaluations are essential for ensuring interventions developed 
enhance the wellbeing of children and young people and make best use of available resources.  
Data quality, statistical significance, and demographic data  
Tests of statistical significance: To assist the reader to determine whether tests of statistical significance have 
been used in a particular section, Appendix 2, outlines how the significance of the associations presented has 
been signalled in the text with the words significant, or not significant in italics. If the words significant or not 
significant do not appear in the text, then the associations described do not imply statistical significance or non-
significance. 
Appendix 3 contains information on the data sources used to develop each indicator. It is advisable to read the 
contents of these appendices when interpreting any information in this report. To ensure anonymity, where 
numbers are less than five, these and their associated rates have been suppressed. 
Appendix 4 describes the use of ethnicity data in this report and Appendix 5 outlines the New Zealand 
Deprivation Index and how it is used. 
Overview of the health status of children and young people in New Zealand 
Figure 1 to Figure 5 on the following pages provide an overview of the indicators in this year’s report, 
summarising the range of the DHB rates in relation to the New Zealand rates for each indicator.  
Conclusions 
This report provides an overview of the health status of children and young people in New Zealand, and an entry 
point to the policy and evidence-based review literature, to assist with addressing child and youth health needs 
in a systematic and evidence-based manner. It is suggested that the Ministry of Health, DHBs and others 
working in the health sector use the epidemiological data in this report as a complement to knowledge of 
existing services and key stakeholders’ views. In addition, they should be mindful of existing Government 
policy, and that for any approaches developed to be effective, they need to be congruent with the evidence 
contained in the current literature. If there is no sound evidence base, planners should build an evaluation arm 


















1 Fetal deaths 211            7.49           7.53           5.50           9.33           
2 Preterm births 1,995         7.36           7.50           6.34           8.40           
3 Infant mortality 179            6.40           5.14           2.40           8.07           
4 Sudden unexpected death in infancy 25              0.89           1.01           0.43           2.47           
5 Ambulatory sensitive hospitalisations in 0–4 year olds* 9,723         70.01         66.48         37.37         88.48         
6 Acute upper respiratory tract infections in 0–14 year olds 2,811         6.89           6.49           4.27           10.71         
7 Tonsillectomy ± adenoidectomy in 0–14 year olds 1,731         4.24           3.48           2.29           7.18           
8 Otitis media in 0–14 year olds 353            0.87           0.58           0.22           0.99           
9 Grommets in 0–14 year olds 2,206         5.41           5.08           2.41           8.56           
10 Bronchiolitis in infants 2,975         109.76       84.58         37.88         130.83       
11 Pneumonia in 0–24 year olds 1,288         1.90           2.32           1.00           3.35           
12 Asthma in 0–24 year olds 2,908         4.29           4.68           1.94           6.19           
13 Bronchiectasis in 0–24 year olds 163            24.05         25.50         7.39           56.87         
14 Pertussis in under 1 year olds 53              1.96           2.40           0.90           7.36           
15 Meningococcal disease in 0–24 year olds 30              4.43           4.52           2.81           12.24         
16 Tuberculosis in 0–24 year olds 13              1.92           2.97           1.92           7.92           
17 Acute rheumatic fever in 0–24 year olds 99              14.61         14.34         2.05           44.27         
18 Rheumatic heart disease in 0–24 year olds 45              6.64           8.67           0.97           26.59         
19 Any skin infections in 0–24 year olds 4,493         6.63           7.52           3.65           11.83         
20 Gastroenteritis in 0–24 year olds 3,343         4.93           4.81           3.19           6.23           
21 Unintentional injury hospitalisations of 0–24 year olds 7,694         1,135.29    1,180.40    977.70       1,582.58    
22 Teenage births 2,070         31.13         24.40         13.50         46.51         
23 Clients aged 0–24 year olds seen by mental health services 4,390         3,197.91    3,748.47    2,777.20    6,052.86    
24 Mental health hospitalisations of 0–24 year olds 1,680         247.89       262.26       151.64       468.74       
25 Suicide among 0–24 year olds 53              7.92           8.75           5.74           23.64         
26 Intentional self-harm in 0–24 year olds 314            46.33         64.23         17.24         167.23        
* ED cases included DHB rate NZ rate  


















1 Fetal deaths 84               5.61            7.53           5.50           9.33           
2 Preterm births 1,071          7.42            7.50           6.34           8.40           
3 Infant mortality 94               6.31            5.14           2.40           8.07           
4 Sudden unexpected death in infancy 17               1.14            1.01           0.43           2.47           
5 Ambulatory sensitive hospitalisations in 0–4 year olds* 5,931          80.30          66.48         37.37         88.48         
6 Acute upper respiratory tract infections in 0–14 year olds 2,082          9.17            6.49           4.27           10.71         
7 Tonsillectomy ± adenoidectomy in 0–14 year olds 851             3.75            3.48           2.29           7.18           
8 Otitis media in 0–14 year olds 209             0.92            0.58           0.22           0.99           
9 Grommets in 0–14 year olds 1,130          4.98            5.08           2.41           8.56           
10 Bronchiolitis in infants 1,594          110.43        84.58         37.88         130.83       
11 Pneumonia in 0–24 year olds 886             2.51            2.32           1.00           3.35           
12 Asthma in 0–24 year olds 1,975          5.60            4.68           1.94           6.19           
13 Bronchiectasis in 0–24 year olds 53               15.04          25.50         7.39           56.87         
14 Pertussis in under 1 year olds 42               2.91            2.40           0.90           7.36           
15 Meningococcal disease in 0–24 year olds 18               5.11            4.52           2.81           12.24         
16 Tuberculosis in 0–24 year olds 8                 2.27            2.97           1.92           7.92           
17 Acute rheumatic fever in 0–24 year olds 50               14.19          14.34         2.05           44.27         
18 Rheumatic heart disease in 0–24 year olds 33               9.36            8.67           0.97           26.59         
19 Any skin infections in 0–24 year olds 3,316          9.41            7.52           3.65           11.83         
20 Gastroenteritis in 0–24 year olds 2,196          6.23            4.81           3.19           6.23           
21 Unintentional injury hospitalisations of 0–24 year olds 4,919          1,395.86     1,180.40    977.70       1,582.58    
22 Teenage births 1,161          34.49          24.40         13.50         46.51         
23 Clients aged 0–24 year olds seen by mental health services 3,876          5,443.82     3,748.47    2,777.20    6,052.86    
24 Mental health hospitalisations of 0–24 year olds 1,115          316.40        262.26       151.64       468.74       
25 Suicide among 0–24 year olds 42               12.04          8.75           5.74           23.64         
26 Intentional self-harm in 0–24 year olds 320             90.81          64.23         17.24         167.23        
* ED cases included DHB rate NZ rate  

















1 Fetal deaths 68              8.32           7.53           5.50           9.33           
2 Preterm births 551            7.31           7.50           6.34           8.40           
3 Infant mortality 56              6.91           5.14           2.40           8.07           
4 Sudden unexpected death in infancy 15              1.85           1.01           0.43           2.47           
5 Ambulatory sensitive hospitalisations in 0–4 year olds* 2,795         71.18         66.48         37.37         88.48         
6 Acute upper respiratory tract infections in 0–14 year olds 772            6.57           6.49           4.27           10.71         
7 Tonsillectomy ± adenoidectomy in 0–14 year olds 426            3.62           3.48           2.29           7.18           
8 Otitis media in 0–14 year olds 111            0.94           0.58           0.22           0.99           
9 Grommets in 0–14 year olds 733            6.23           5.08           2.41           8.56           
10 Bronchiolitis in infants 905            120.07       84.58         37.88         130.83       
11 Pneumonia in 0–24 year olds 542            2.94           2.32           1.00           3.35           
12 Asthma in 0–24 year olds 946            5.14           4.68           1.94           6.19           
13 Bronchiectasis in 0–24 year olds 69              37.46         25.50         7.39           56.87         
14 Pertussis in under 1 year olds 24              3.18           2.40           0.90           7.36           
15 Meningococcal disease in 0–24 year olds 13              7.06           4.52           2.81           12.24         
16 Tuberculosis in 0–24 year olds 5                2.71           2.97           1.92           7.92           
17 Acute rheumatic fever in 0–24 year olds 41              22.26         14.34         2.05           44.27         
18 Rheumatic heart disease in 0–24 year olds 24              13.03         8.67           0.97           26.59         
19 Any skin infections in 0–24 year olds 1,761         9.56           7.52           3.65           11.83         
20 Gastroenteritis in 0–24 year olds 838            4.55           4.81           3.19           6.23           
21 Unintentional injury hospitalisations of 0–24 year olds 2,574         1,397.34    1,180.40    977.70       1,582.58    
22 Teenage births 748            42.48         24.40         13.50         46.51         
23 Clients aged 0–24 year olds seen by mental health services 1,691         4,617.88    3,748.47    2,777.20    6,052.86    
24 Mental health hospitalisations of 0–24 year olds 488            264.92       262.26       151.64       468.74       
25 Suicide among 0–24 year olds 21              11.33         8.75           5.74           23.64         
26 Intentional self-harm in 0–24 year olds 121            65.69         64.23         17.24         167.23        
* ED cases included  DHB rate NZ rate  

















1 Fetal deaths 28              7.15           7.53           5.50           9.33           
2 Preterm births 274            7.47           7.50           6.34           8.40           
3 Infant mortality 23              5.91           5.14           2.40           8.07           
4 Sudden unexpected death in infancy 8                2.06           1.01           0.43           2.47           
5 Ambulatory sensitive hospitalisations in 0–4 year olds* 1,524         79.11         66.48         37.37         88.48         
6 Acute upper respiratory tract infections in 0–14 year olds 553            9.44           6.49           4.27           10.71         
7 Tonsillectomy ± adenoidectomy in 0–14 year olds 192            3.28           3.48           2.29           7.18           
8 Otitis media in 0–14 year olds 31              0.53           0.58           0.22           0.99           
9 Grommets in 0–14 year olds 299            5.10           5.08           2.41           8.56           
10 Bronchiolitis in infants 480            130.83       84.58         37.88         130.83       
11 Pneumonia in 0–24 year olds 272            3.01           2.32           1.00           3.35           
12 Asthma in 0–24 year olds 506            5.61           4.68           1.94           6.19           
13 Bronchiectasis in 0–24 year olds 19              21.05         25.50         7.39           56.87         
14 Pertussis in under 1 year olds 27              7.36           2.40           0.90           7.36           
15 Meningococcal disease in 0–24 year olds <5 s 4.52           2.81           12.24         
16 Tuberculosis in 0–24 year olds 0 .. 2.97           1.92           7.92           
17 Acute rheumatic fever in 0–24 year olds 32              35.46         14.34         2.05           44.27         
18 Rheumatic heart disease in 0–24 year olds 24              26.59         8.67           0.97           26.59         
19 Any skin infections in 0–24 year olds 1,068         11.83         7.52           3.65           11.83         
20 Gastroenteritis in 0–24 year olds 402            4.45           4.81           3.19           6.23           
21 Unintentional injury hospitalisations of 0–24 year olds 1,413         1,565.77    1,180.40    977.70       1,582.58    
22 Teenage births 394            46.51         24.40         13.50         46.51         
23 Clients aged 0–24 year olds seen by mental health services 1,075         5,955.21    3,748.47    2,777.20    6,052.86    
24 Mental health hospitalisations of 0–24 year olds 423            468.74       262.26       151.64       468.74       
25 Suicide among 0–24 year olds 14              15.52         8.75           5.74           23.64         
26 Intentional self-harm in 0–24 year olds 71              78.68         64.23         17.24         167.23        
* ED cases included DHB rate NZ rate  

















1 Fetal deaths 54              6.75           7.53           5.50           9.33           
2 Preterm births 604            7.76           7.50           6.34           8.40           
3 Infant mortality 43              5.41           5.14           2.40           8.07           
4 Sudden unexpected death in infancy 9                1.13           1.01           0.43           2.47           
5 Ambulatory sensitive hospitalisations in 0–4 year olds* 1,921         47.24         66.48         37.37         88.48         
6 Acute upper respiratory tract infections in 0–14 year olds 544            4.55           6.49           4.27           10.71         
7 Tonsillectomy ± adenoidectomy in 0–14 year olds 386            3.23           3.48           2.29           7.18           
8 Otitis media in 0–14 year olds 42              0.35           0.58           0.22           0.99           
9 Grommets in 0–14 year olds 735            6.14           5.08           2.41           8.56           
10 Bronchiolitis in infants 483            62.06         84.58         37.88         130.83       
11 Pneumonia in 0–24 year olds 357            1.89           2.32           1.00           3.35           
12 Asthma in 0–24 year olds 855            4.54           4.68           1.94           6.19           
13 Bronchiectasis in 0–24 year olds 15              7.96           25.50         7.39           56.87         
14 Pertussis in under 1 year olds 7                0.90           2.40           0.90           7.36           
15 Meningococcal disease in 0–24 year olds 10              5.31           4.52           2.81           12.24         
16 Tuberculosis in 0–24 year olds <5 s 2.97           1.92           7.92           
17 Acute rheumatic fever in 0–24 year olds <5 s 14.34         2.05           44.27         
18 Rheumatic heart disease in 0–24 year olds <5 s 8.67           0.97           26.59         
19 Any skin infections in 0–24 year olds 1,096         5.82           7.52           3.65           11.83         
20 Gastroenteritis in 0–24 year olds 782            4.15           4.81           3.19           6.23           
21 Unintentional injury hospitalisations of 0–24 year olds 2,057         1,091.41    1,180.40    977.70       1,582.58    
22 Teenage births 514            28.80         24.40         13.50         46.51         
23 Clients aged 0–24 year olds seen by mental health services 1,603         4,222.23    3,748.47    2,777.20    6,052.86    
24 Mental health hospitalisations of 0–24 year olds 572            303.49       262.26       151.64       468.74       
25 Suicide among 0–24 year olds 11              5.88           8.75           5.74           23.64         
26 Intentional self-harm in 0–24 year olds 98              52.00         64.23         17.24         167.23        
* ED cases included 
 
DHB rate NZ rate  
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BIRTHS AND PERINATAL DEATHS 
Introduction 
The following section briefly reviews the birth and perinatal period to provide a context for later sections. The 
following section uses the Birth Registration Dataset, the National Mortality Collection and the National 
Minimum Dataset to look at births and early deaths in New Zealand. 
Data source and methods 
Data sources 
Livebirths:  Birth registration dataset 
Deaths:  National Mortality Collection 
Definitions 
Total births are livebirths plus fetal deaths 
Fetal death is when the infant is born deceased, weighing 400 grams or more, or is issued from its mother after the 20th week of 
pregnancy2 
 Fetal death rate = number of fetal deaths per 1,000 total (live + still) births 
Perinatal death is fetal deaths and early neonatal deaths 
 Perinatal death rate = number of fetal and early neonatal deaths per 1,000 total (live + still) births 
Neonatal death is the death of a live-born infant before 28 completed days after birth, and comprises: 
 Early neonatal death is death of a live-born infant before seven days (168 completed hours) after birth 
 Late neonatal death is death of a live-born infant after seven days and before 28 completed days after birth 
Neonatal death rate = number of early and late neonatal deaths per 1,000 livebirths 
Early neonatal death rate = number of early neonatal deaths per 1,000 livebirths 
Late neonatal death rate = number of late neonatal deaths per 1,000 livebirths 
Notes on interpretation 
Note 1: An overview of the Birth Registration and National Minimum Datasets is provided in the Appendix 3. 
National trends and distribution 
Between 2008 and 2012 there were 319,934 births in New Zealand, an average of 63,987 per year. Of these, 
317,526 (99.2%) were live births and 2,408 were fetal deaths (also known as stillbirths). The fetal death rate in 
this time period was 7.53 deaths per 1,000 total births (Table 1). 
Between 2008 and 2012 there were 1,010 deaths of live-born infants in the first 27 days of life (neonatal deaths), 
an average of 202 deaths per year. Of these neonatal deaths, 821 were before seven days after birth (early 
neonatal deaths) and 189 deaths occurred after seven days but before 28 completed days after birth (late 
neonatal deaths). The early neonatal death rate was 2.59 deaths per 1,000 live births and the late neonatal death 
rate was 0.6 deaths per 1,000 live births (Table 1). 










Live births 317,526 63,505 .. .. 
Total births 319,934 63,987 .. .. 
Fetal deaths* 2,408 482 7.53 7.23–7.83 
Perinatal deaths* 3,229 646 10.09 9.75–10.4 
Neonatal deaths† 1,010 202 3.18 2.99–3.38 
Early neonatal deaths† 821 164 2.59 2.41–2.77 
Late neonatal deaths† 189 38 0.60 0.52–0.69 
Live births: birth registration dataset; Deaths: National Mortality Collection; * Rate per 1,000 total births; † Rate per 1,000 live 
births 
Deaths that occurred around the time of birth (perinatal deaths) include fetal deaths and early neonatal deaths. 
Between 2008 and 2012 there were 3,229 perinatal deaths in New Zealand, an average of 646 deaths per year 
(Table 1). 
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The fetal death rate fell between 1988–89 and 1994–95, but then increased to above the 1988–89 level and has 
remained stable since then, with year to year fluctuations around an average of 7.2 deaths per 1,000 total births. 
The neonatal death rate showed a significant fall from 4.69 deaths per 1,000 live births in 1988–89 to 3.13 
deaths per 1,000 live births in 2012. Between 1988–89 and 1994–95 the perinatal death rate followed a similar 
pattern to the fetal death rate and the rate of 9.73 deaths per 1,000 total births in 2012 is not significantly 
different from the rate of 10.48 deaths per 1,000 live births in 1988–89 (Figure 6).   
Figure 6. Fetal, perinatal and neonatal death rates, New Zealand 1988–2012 
 
Live births: birth registration dataset; Deaths: National Mortality Collection; * Rate per 1,000 total births; † Rate per 1,000 live 
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Midland region distribution and trends 
The number of births occurring between 2008 and 2012 ranged from 3,918 in Tairawhiti to 28,185 in Waikato. 
The majority of births in each DHB were live births (99.2 – 99.4%). The fetal death rate ranged from 5.61 fetal 
deaths per 1,000 total births in the Bay of Plenty to 8.32 in Lakes DHB, while neonatal deaths ranged from 3.14 
neonatal deaths per 1,000 live births in Taranaki to 4.23 in the Bay of Plenty (Table 2).  










Live births 27,974 5,595 .. .. 
Total births 28,185 5,637 .. .. 
Fetal deaths* 211 42 7.49 6.54–8.56 
Perinatal deaths* 294 59 10.43 9.31–11.69 
Neonatal deaths† 107 21 3.82 3.17–4.62 
Bay of Plenty 
Live births 14,888 2,978 .. .. 
Total births 14,972 2,994 .. .. 
Fetal deaths* 84 17 5.61 4.53–6.94 
Perinatal deaths* 131 26 8.75 7.38–10.37 
Neonatal deaths† 63 13 4.23 3.31–5.41 
Lakes DHB 
Live births 8,104 1,621 .. .. 
Total births 8,172 1,634 .. .. 
Fetal deaths* 68 14 8.32 6.57–10.53 
Perinatal deaths* 98 20 11.99 9.85–14.59 
Neonatal deaths† 33 7 4.07 2.91–5.71 
Tairawhiti 
Live births 3,890 778 .. .. 
Total births 3,918 784 .. .. 
Fetal deaths* 28 6 7.15 4.95–10.31 
Perinatal deaths* 43 9 10.97 8.16–14.75 
Neonatal deaths† 16 3 4.11 2.54–6.66 
Taranaki 
Live births 7,951 1,590 .. .. 
Total births 8,005 1,601 .. .. 
Fetal deaths* 54 11 6.75 5.17–8.79 
Perinatal deaths* 72 14 8.99 7.15–11.31 
Neonatal deaths† 25 5 3.14 2.13–4.63 








A fetal death is defined by the World Health Organization as “death prior to the complete expulsion or 
extraction from its mother of a product of conception, irrespective of the duration of pregnancy; the death is 
indicated by the fact that after such separation the fetus does not breathe or show any other evidence of life, such 
as beating of the heart, pulsation of the umbilical cord or definite movement of voluntary muscles”.3 Most 
countries require registration of fetal deaths but the gestation beyond which a fetal death must be registered 
varies between countries.3 In New Zealand, the Births, Deaths, Marriages, and Relationships Registration Act 
1995 requires that all stillbirths are registered and it defines a stillbirth as “a dead fetus that weighed at least 
400g when it issued from its mother or issued from its mother after the 20th week of pregnancy”.4 The Perinatal 
and Maternal Mortality Review Committee uses this definition to define a fetal death.5 Fetal deaths include both 
spontaneous deaths (often referred to as stillbirths) and deaths due to termination of pregnancy (for example 
because of severe congenital malformations). 
In high income countries around one in two hundred babies who reaches 22 weeks gestation or more is 
stillborn.6 There are many possible reasons why a baby may be stillborn. In developed countries major 
contributors to stillbirth are factors related to placental dysfunction and very pre-term birth.6 In a significant 
minority of cases (27% in New Zealand in 20125) no cause is identified. The most significant potentially 
modifiable risk factors for stillbirth are maternal obesity and smoking.5,6 




Numerator:  National Mortality Collection 
Denominator: Birth Registration Dataset (live births only) and National Mortality Collection 
Definition 
Fetal death is when the infant is born deceased, weighing 400 grams or more, or is issued from its mother after the 20th week of 
pregnancy.2 
Fetal deaths are further defined into: 
Intermediate: Fetal deaths occurring between 20 and 27 weeks gestation. 
Late:  Fetal deaths occurring 28+ weeks gestation. 
Unspecified: Fetal deaths occurring from 20 weeks or more gestation where the main fetal cause of death was 
unspecified and no additional fetal or maternal causes of death were listed. 
Fetal death rate = number of fetal deaths per 1,000 total (live + still) births 
For gestational age specific rates, the denominator was those remaining in utero at the specified gestational age (e.g. the 22 
week denominator excludes all births occurring at 20 and 21 weeks) 
In this section, the main (fetal) underlying cause of death was categorised into the following: congenital anomalies 
(chromosomal, CNS, CVS, other), malnutrition or slow fetal growth, extreme immaturity or low birth weight, intrauterine 
hypoxia: pre labour onset, intrauterine hypoxia: in labour or unspecified, congenital pneumonia, infections specific to perinatal 
period, fetal blood loss, unspecified cause, other causes. 
In addition, the first maternal cause of death (if present) was categorised into the following: incompetent cervix or premature 
rupture membranes, oligohydramnios, multiple pregnancy, placenta praevia or other placental separation or haemorrhage, 
other or unspecified placental anomalies, compression of umbilical cord, chorioamnionitis, maternal hypertensive disorders, 
placental transfusion syndrome, other causes. 
Notes on interpretation 
Note 1: Death registration data do not differentiate between spontaneous fetal deaths and late terminations of pregnancy. The 
admixture of spontaneous and induced fetal deaths is likely to be most prominent at earlier gestations (e.g. the high number of 
deaths attributed to congenital anomalies prior to 25 weeks gestation) and this must be taken into account when interpreting 
the data in this section. 
Note 2: 95% confidence intervals have been provided for the rate ratios in this section and where appropriate, the terms 
significant or not significant have been used to communicate the significance of the observed associations. Tests of statistical 
significance have not been applied to other data in this section, and thus (unless the terms significant or non-significant are 
specifically used) the associations described do not imply statistical significance or non-significance (see Appendix 2 for further 
discussion of this issue). 
Note 3: An overview of the Birth Registration and National Minimum Datasets is provided in Appendix 3. 
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National trends and distribution 
There were 2,390 fetal deaths in New Zealand from 2008 to 2012, an average of 478 deaths per year and a rate 
of 7.47 fetal deaths per 1,000 births. Just over half of the deaths (1,346 deaths, 56.3%) occurred between 20 and 
27 weeks gestation (intermediate fetal deaths) and 1,044 deaths (43.7%) occurred from 28 weeks gestation (late 
fetal deaths) (Table 3). 
Table 3. Fetal deaths, by type and main cause of fetal death, New Zealand 2008–2012 










95% CI Per cent 
Intermediate fetal deaths* 
Prematurity or low birth weight 173 35 0.54 0.47–0.63 12.9 
Congenital anomalies: chromosomal 152 30 0.48 0.41–0.56 11.3 
Congenital anomalies: CNS 115 23 0.36 0.30–0.43 8.5 
Congenital anomalies: CVS 100 20 0.31 0.26–0.38 7.4 
Congenital anomalies: other 147 29 0.46 0.39–0.54 10.9 
Malnutrition or slow fetal growth 108 22 0.34 0.28–0.41 8.0 
Congenital pneumonia 32 6 0.10 0.07–0.14 2.4 
Fetal blood loss 23 5 0.07 0.05–0.11 1.7 
Infections specific to perinatal period 22 4 0.07 0.05–0.10 1.6 
Hydrops fetalis (non-haemolytic disease) 20 4 0.06 0.04–0.10 1.5 
Intrauterine hypoxia 16 3 0.05 0.03–0.08 1.2 
Polycythaemia neonatorum 13 3 0.04 0.02–0.07 1.0 
Other causes 59 12 0.18 0.14–0.24 4.4 
Unspecified cause of fetal death 366 73 1.14 1.03–1.27 27.2 
Total 1,346 269 4.21 3.99–4.44 100.0 
Late fetal deaths† 
Malnutrition or slow fetal growth 122 24 0.38 0.32–0.46 11.7 
Intrauterine hypoxia 79 16 0.25 0.20–0.31 7.6 
Fetal blood loss 50 10 0.16 0.12–0.21 4.8 
Congenital anomalies: chromosomal 37 7 0.12 0.08–0.16 3.5 
Congenital anomalies: CNS 42 8 0.13 0.10–0.18 4.0 
Congenital anomalies: CVS 17 3 0.05 0.03–0.09 1.6 
Congenital anomalies: other 29 6 0.09 0.06–0.13 2.8 
Neonatal aspiration‡ 30 6 0.09 0.07–0.13 2.9 
Infections specific to perinatal period 25 5 0.08 0.05–0.12 2.4 
Prematurity or low birth weight 12 2 0.04 0.02–0.07 1.1 
Congenital pneumonia 8 2 0.03 0.01–0.05 0.8 
Hydrops fetalis (non-haemolytic disease) 8 2 0.03 0.01–0.05 0.8 
Other causes 64 13 0.20 0.16–0.26 6.1 
Unspecified cause of fetal death 521 104 1.64 1.50–1.78 49.9 
Total 1,044 209 3.28 3.08–3.48 100.0 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; * rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); † rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more); Neonatal aspiration‡ = Neonatal aspiration of meconium, amniotic fluid, or mucus 
The overall fetal death rate was stable from 2000 to 2012 with year-to-year fluctuations around an average of 
7.24 deaths per 1,000 births. Within this time period there was an overall decline in the rate of late fetal deaths 
from 3.23 to 2.83 deaths per 1,000 births of 28 weeks gestation or more and an increase in the rate of 
intermediate fetal deaths from 3.35 to 4.32 deaths per 1,000 births of 20 weeks gestation or more (Figure 7). 
Similar patterns over time were observed for all ethnic groups. Intermediate fetal death rates were consistently 
highest for the Asian/Indian ethnic group and late fetal death rates were consistently highest for the Pacific 
ethnic group (Figure 8). 
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Figure 7. Fetal deaths, by type, New Zealand 2000–2012 
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; * rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); †rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more); 2012* is a single year 
Figure 8. Fetal deaths, by type and ethnicity, New Zealand 2000–2012 
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; * rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); †rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more); Ethnicity is level 1 prioritised; 2012* is a single year  
Distribution by gestational age 
Between 2008 and 2012 fetal death rates were higher at gestational ages less than 25 weeks and more than 36 
weeks, with the highest rates of all at over 40 weeks gestational age (Figure 9). In interpreting these figures, 
note that the denominator was those fetuses remaining in utero at the specified gestational age. This means that 
the denominator at and beyond term is smaller than earlier in pregnancy and although the absolute number of 
fetal deaths is lower at later gestational ages, the risk is higher as fewer pregnancies continue past these 
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Figure 9. Fetal deaths, by gestational age, New Zealand 2008–2012 
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; rate per 
1,000 (live and stillborn) fetuses remaining in-utero at each gestational age 
Distribution by cause 
Between 2008 and 2012 a fetal cause of death was unspecified for 27.2% of intermediate fetal deaths and 49.9% 
of late fetal deaths. Where specified, the most frequent causes of intermediate fetal death were congenital 
anomalies, prematurity or low birth weight, and malnutrition or slow fetal growth. The most frequent causes of 
late fetal death were congenital anomalies, malnutrition or slow fetal growth, and intrauterine hypoxia (Figure 
10). 
Fetal death rates from prematurity or low birth weight were highest at 20–22 weeks gestation. Fetal death rates 
arising from congenital anomalies were highest at 20–22 weeks gestation and at 42 weeks gestation. The data 
did not distinguish between spontaneous fetal deaths and terminations of pregnancy and the higher fetal 
mortality rates at less than 25 weeks gestation must be interpreted with this in mind. Fetal death rates from 
malnutrition or slow fetal growth were highest at 41–42 weeks gestation (Figure 10). 
Figure 10. Fetal deaths, by gestational age and cause of death, New Zealand 2008–2012 
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; Rate per 
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There was no listed maternal cause for 45.7% of intermediate fetal deaths and 34.4% of late fetal deaths from 
2008 to 2012. Where listed, the most common maternal causes of intermediate fetal deaths were incompetent 
cervix or premature rupture of membranes, placenta praevia or placental separation and haemorrhage, 
chorioamnionitis, and other abnormalities of the placenta. The most commonly listed maternal causes for late 
fetal deaths were placenta praevia or placental separation and haemorrhage, other abnormalities of the placenta, 
and compression of the umbilical cord (Table 4).  
Table 4. Fetal deaths, by type and main maternal cause of fetal death, New Zealand 2008–2012 











95% CI Per cent 
Intermediate fetal deaths* 
Incompetent cervix/premature rupture of membranes 114 23 0.36 0.30–0.43 8.5 
Placenta praevia/placental separation and haemorrhage 113 23 0.35 0.29–0.42 8.4 
Chorioamnionitis 81 16 0.25 0.20–0.31 6.0 
Other abnormalities of placenta 62 12 0.19 0.15–0.25 4.6 
Maternal hypertensive disorders 45 9 0.14 0.11–0.19 3.3 
Multiple pregnancy 44 9 0.14 0.10–0.18 3.3 
Placental transfusion syndromes 42 8 0.13 0.10–0.18 3.1 
Oligohydramnios 38 8 0.12 0.09–0.16 2.8 
Compression of umbilical cord 26 5 0.08 0.06–0.12 1.9 
Other causes 166 33 0.52 0.45–0.60 12.3 
No listed maternal cause 615 123 1.92 1.78–2.08 45.7 
Total 1,346 269 4.21 3.99–4.44 100.0 
Late fetal deaths† 
Placenta praevia/placental separation and haemorrhage 97 19 0.30 0.25–0.37 9.3 
Other abnormalities of placenta 101 20 0.32 0.26–0.39 9.7 
Compression of umbilical cord 94 19 0.30 0.24–0.36 9.0 
Chorioamnionitis 51 10 0.16 0.12–0.21 4.9 
Maternal hypertensive disorders 41 8 0.13 0.09–0.17 3.9 
Multiple pregnancy 37 7 0.12 0.08–0.16 3.5 
Placental transfusion syndromes 21 4 0.07 0.04–0.10 2.0 
Oligohydramnios 20 4 0.06 0.04–0.10 1.9 
Incompetent cervix/premature rupture of membranes 19 4 0.06 0.04–0.09 1.8 
Other causes 204 41 0.64 0.56–0.73 19.5 
No listed maternal cause 359 72 1.13 1.02–1.25 34.4 
Total 1,044 209 3.28 3.08–3.48 100.0 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection. * rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); † rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more) 
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Distribution by demographic factors 
Between 2008 and 2012 there were disparities in rates of fetal death by the NZDep2013 Index of deprivation 
score, ethnicity, and maternal age with significantly higher rates in areas with the highest (deciles 9–10) 
NZDep2013 scores compared with deciles 1–8, significantly higher rates for Māori, Pacific and Asian/Indian 
ethnic groups compared with European/Other, and significantly higher rates for mothers aged under 25 and over 
34 years compared with mothers aged 25–34 years (Table 5).  
These patterns differed when comparing intermediate and late fetal deaths. Rates of intermediate fetal death 
were significantly higher for the Asian/Indian ethnic group compared with European/Other and also 
significantly higher for mothers aged under 20 years and over 34 years compared with mothers aged 30–34 
years. There were no significant differences in intermediate fetal death rates by NZDep2013 and no significant 
difference in rates between Māori, Pacific and European/Other ethnic groups. Rates of late fetal death were 
significantly higher in areas with the highest NZDep2013 scores (decile 9–10), significantly higher for Māori 
and Pacific ethnic groups compared with Asian/Indian and European/Other, and significantly higher for mothers 
aged 20–24 years as well as mothers aged under 20 years and over 34 years compared with mothers aged 25–34 
years (Table 6). 
Table 5. Fetal deaths, by demographic factor, New Zealand 2008–2012 
Variable Number Rate per 1,000 births Rate ratio 95% CI 
Fetal deaths 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 315 6.83 1.00   
Deciles 3–4 366 7.17 1.05 0.90–1.22 
Deciles 5–6 412 7.04 1.03 0.89–1.19 
Deciles 7–8 513 7.33 1.07 0.93–1.24 
Deciles 9–10 791 8.51 1.25 1.09–1.42 
Prioritised ethnicity  
Māori 732 7.83 1.14 1.04–1.25 
Pacific 319 8.86 1.29 1.14–1.46 
Asian/Indian 301 8.09 1.18 1.03–1.34 
European/Other 1,053 6.88 1.00   
Maternal age group 
<20 years 222 9.90 1.48 1.27–1.72 
20–24 years 456 7.74 1.16 1.02–1.31 
25–29 years 525 6.61 0.99 0.88–1.11 
30–34 years 596 6.69 1.00   
35+ years 609 8.68 1.30 1.16–1.45 
Gender 
Female 1,164 7.48 1.00   
Male 1,219 7.42 0.99 0.92–1.08 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; Rates are 
per 1,000 births; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
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Table 6. Distribution of fetal deaths, by type and demographic factor, New Zealand 2008–2012 
Variable Number Rate per 1,000 births Rate ratio 95% CI 
Intermediate fetal deaths* 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 186 4.03 1.00   
Deciles 3–4 232 4.54 1.13 0.93–1.37 
Deciles 5–6 244 4.17 1.03 0.86–1.25 
Deciles 7–8 293 4.19 1.04 0.86–1.25 
Deciles 9–10 383 4.12 1.02 0.86–1.22 
Prioritised ethnicity  
Māori 395 4.22 1.05 0.92–1.19 
Pacific 154 4.28 1.06 0.89–1.27 
Asian/Indian 179 4.81 1.20 1.01–1.41 
European/Other 616 4.03 1.00   
Maternal age group 
<20 years 129 5.75 1.51 1.23–1.84 
20–24 years 235 3.99 1.04 0.88–1.23 
25–29 years 286 3.60 0.94 0.81–1.10 
30–34 years 340 3.82 1.00   
35+ years 356 5.08 1.33 1.15–1.54 
Gender 
Female 645 4.14 1.00   
Male 684 4.17 1.01 0.90–1.12 
Late fetal deaths† 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 127 2.76 1.00   
Deciles 3–4 133 2.62 0.95 0.74–1.21 
Deciles 5–6 166 2.85 1.03 0.82–1.30 
Deciles 7–8 217 3.12 1.13 0.91–1.40 
Deciles 9–10 398 4.30 1.56 1.27–1.90 
Prioritised ethnicity  
Māori 330 3.54 1.25 1.08–1.44 
Pacific 159 4.43 1.56 1.30–1.88 
Asian/Indian 122 3.30 1.16 0.95–1.42 
European/Other 432 2.83 1.00   
Maternal age group 
<20 years 89 3.99 1.39 1.09–1.77 
20–24 years 217 3.70 1.29 1.07–1.54 
25–29 years 235 2.97 1.03 0.87–1.23 
30–34 years 255 2.88 1.00   
35+ years 248 3.55 1.24 1.04–1.47 
Gender 
Female 514 3.32 1.00   
Male 523 3.20 0.96 0.85–1.09 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; * Rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); † Rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more); Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
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Distribution by region 
Between 2008 and 2012 total fetal death rates were significantly higher than the national rate in Whanganui, 
Counties Manukau, MidCentral, Lakes, Hutt Valley and Auckland DHBs. Total fetal death rates were 
significantly lower than the national rate in West Coast, Bay of Plenty, Nelson Marlborough, South Canterbury, 
Capital & Coast, Taranaki, Hawke’s Bay, Wairarapa and Southern DHBs (Table 7).  
Table 7. Fetal deaths, by district health board, New Zealand 2008–2012 
DHB 
No. of deaths: 
2008–2012 




Rate ratio 95% CI 
Fetal deaths 
Northland 91 18 7.71 1.02 0.98–1.07 
Waitemata 299 60 7.50 1.00 0.96–1.04 
Auckland 262 52 7.85 1.04 1.00–1.09 
Counties Manukau 389 78 8.79 1.17 1.12–1.22 
Waikato 211 42 7.49 0.99 0.95–1.04 
Bay of Plenty 84 17 5.61 0.75 0.71–0.78 
Lakes 68 14 8.32 1.11 1.06–1.16 
Tairawhiti 28 6 7.15 0.95 0.90–1.00 
Taranaki 54 11 6.75 0.90 0.86–0.94 
Hawke's Bay 82 16 6.96 0.92 0.89–0.97 
MidCentral 98 20 8.39 1.11 1.07–1.16 
Whanganui 42 8 9.33 1.24 1.18–1.30 
Hutt Valley 89 18 8.25 1.10 1.05–1.15 
Capital & Coast 131 26 6.56 0.87 0.84–0.91 
Wairarapa 19 4 7.04 0.93 0.89–0.99 
Nelson Marlborough 49 10 5.85 0.78 0.74–0.81 
South Canterbury 20 4 6.34 0.84 0.80–0.89 
Canterbury 237 47 7.35 0.98 0.94–1.02 
West Coast 12 2 5.50 0.73 0.69–0.77 
Southern 132 26 7.05 0.94 0.90–0.98 
New Zealand 2,408 482 7.53 1.00   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; * Rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); † Rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more); Rate ratios are unadjusted 
Intermediate fetal death rates were significantly higher than the national rate in the Wairarapa, MidCentral, 
Whanganui, Auckland, Hutt Valley, Lakes, and Waitemata DHBs. Intermediate fetal death rates were 
significantly lower than the national rate in the Bay of Plenty, South Canterbury, Tairawhiti, Taranaki, 
Northland, and Nelson Marlborough DHBs (Table 8).  
Late fetal death rates were significantly higher than the national rate in Counties Manukau, Whanganui, 
Northland, Tairawhiti, Lakes and West Coast DHBs. Late fetal death rates were significantly lower than the 
national rate in the Nelson Marlborough, Capital & Coast, Hawke’s Bay, Southern, Bay of Plenty, Waitemata, 
Auckland and Canterbury DHBs (Table 9).  
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Table 8. Intermediate fetal deaths, by district health board, New Zealand 2008–2012 
DHB 
No. of deaths: 
2008–2012 
No. of deaths: 
annual average 
Rate per 1,000 
births* 
Rate ratio 95% CI 
Intermediate fetal deaths 
Northland 40 8 3.39 0.81 0.76–0.85 
Waitemata 179 36 4.49 1.07 1.01–1.13 
Auckland 161 32 4.83 1.15 1.09–1.21 
Counties Manukau 187 37 4.23 1.00 0.95–1.06 
Waikato 115 23 4.08 0.97 0.92–1.02 
Bay of Plenty 39 8 2.61 0.62 0.59–0.65 
Lakes 38 8 4.65 1.11 1.04–1.17 
Tairawhiti 12 2 3.06 0.73 0.68–0.77 
Taranaki 27 5 3.37 0.80 0.76–0.85 
Hawke's Bay 52 10 4.41 1.05 0.99–1.11 
MidCentral 58 12 4.97 1.18 1.12–1.25 
Whanganui 22 4 4.89 1.16 1.09–1.23 
Hutt Valley 52 10 4.82 1.15 1.08–1.21 
Capital & Coast 81 16 4.06 0.96 0.91–1.02 
Wairarapa 16 3 5.93 1.41 1.32–1.50 
Nelson Marlborough 31 6 3.70 0.88 0.83–0.93 
South Canterbury 9 2 2.85 0.68 0.64–0.72 
Canterbury 137 27 4.25 1.01 0.96–1.07 
West Coast <5 s s s s 
Southern 78 16 4.17 0.99 0.94–1.05 
New Zealand 1,346 269 4.21 1.00   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; * Rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); Rate ratios are unadjusted 
Table 9. Late fetal deaths, by district health board, New Zealand 2008–2012 
DHB 
No. of deaths: 
2008–2012 
No. of deaths: 
annual average 
Rate per 1,000 
births† 
Rate ratio 95% CI 
Late fetal deaths 
Northland 48 10 4.08 1.25 1.17–1.33 
Waitemata 119 24 3.00 0.91 0.86–0.97 
Auckland 100 20 3.01 0.92 0.86–0.98 
Counties Manukau 199 40 4.52 1.38 1.30–1.47 
Waikato 95 19 3.38 1.03 0.97–1.10 
Bay of Plenty 44 9 2.95 0.90 0.84–0.96 
Lakes 30 6 3.69 1.13 1.06–1.20 
Tairawhiti 15 3 3.84 1.17 1.09–1.25 
Taranaki 26 5 3.26 0.99 0.93–1.06 
Hawke's Bay 30 6 2.56 0.78 0.73–0.83 
MidCentral 39 8 3.36 1.02 0.96–1.09 
Whanganui 20 4 4.46 1.36 1.27–1.46 
Hutt Valley 35 7 3.26 1.00 0.93–1.06 
Capital & Coast 49 10 2.47 0.75 0.71–0.80 
Wairarapa <5 s s s s 
Nelson Marlborough 18 4 2.16 0.66 0.62–0.70 
South Canterbury 11 2 3.50 1.07 0.99–1.14 
Canterbury 98 20 3.05 0.93 0.88–0.99 
West Coast 8 2 3.67 1.12 1.04–1.21 
Southern 54 11 2.90 0.88 0.83–0.94 
New Zealand 1,044 209 3.28 1.00   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset and National Mortality Collection; † Rate per 
1,000 births (live births and fetal deaths of 28 weeks gestation or more); Rate ratios are unadjusted 
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2008 and 2012 fetal death rates in the Lakes DHB were significantly higher than the national rate, 
significantly lower in the Bay of Plenty and Taranaki DHBs. There was no significant difference in the Waikato 
and Tairawhiti DHBs.  
Intermediate fetal death rates were significantly higher than the national rate in Lakes DHB and significantly 
lower in Bay of Plenty, Tairawhiti and Taranaki with no significant difference in Waikato. In the Lakes and 
Tairawhiti DHBs, the late fetal death rates were significantly higher than the national rate, significantly lower in 
the Bay of Plenty, while rates in Waikato and Taranaki DHBs were not significantly different (Table 10). 






Rate per 1,000 
births 
Rate ratio 95% CI 
Fetal deaths 
Waikato 211 42 7.49 0.99 0.95–1.04 
Bay of Plenty 84 17 5.61 0.75 0.71–0.78 
Lakes 68 14 8.32 1.11 1.06–1.16 
Tairawhiti 28 6 7.15 0.95 0.90–1.00 
Taranaki 54 11 6.75 0.90 0.86–0.94 
New Zealand 2,408 482 7.53 1.00   
Intermediate fetal deaths* 
Waikato 115 23 4.08 0.97 0.92–1.02 
Bay of Plenty 39 8 2.61 0.62 0.59–0.65 
Lakes 38 8 4.65 1.11 1.04–1.17 
Tairawhiti 12 2 3.06 0.73 0.68–0.77 
Taranaki 27 5 3.37 0.80 0.76–0.85 
New Zealand 1,346 269 4.21 1.00   
Late fetal deaths† 
Waikato 95 19 3.38 1.03 0.97–1.10 
Bay of Plenty 44 9 2.95 0.90 0.84–0.96 
Lakes 30 6 3.69 1.13 1.06–1.20 
Tairawhiti 15 3 3.84 1.17 1.09–1.25 
Taranaki 26 5 3.26 0.99 0.93–1.06 
New Zealand 1,044 209 3.28 1.00   
Numerator: National Mortality Collection; Denominators: Birth Registration Dataset and National Mortality Collection; * Rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); † Rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more) 
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Regional trends 
Fetal death rates increased from 2000 to 2012 in Waikato and Lakes, while rates in Bay of Plenty, Tairawhiti 
and Taranaki varied from year to year. Intermediate fetal death rates  and those for late fetal deaths varied in all 
DHBs from year to year (Figure 11, Figure 12). 


























































































































































































































Numerator: National Mortality Collection; Denominators: Birth Registration Dataset and National Mortality Collection; * Rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); † Rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more); 2012‡ is a single year of data; Rates for Bay of Plenty and Lakes DHBs based on numbers less 
than 20  











































































































































































Numerator: National Mortality Collection; Denominators: Birth Registration Dataset and National Mortality Collection; * Rate per 
1,000 births (live births and fetal deaths of 20 weeks gestation or more); † Rate per 1,000 births (live births and fetal deaths of 
28 weeks gestation or more); 2012‡ is a single year of data; Rates based on numbers less than 20 
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Regional distribution by cause 
In the Midland region, congenital anomalies, prematurity or low birth weight, and malnutrition or slow fetal 
growth were the predominant causes of fetal deaths between 2008 and 2012 (Table 11). Of the fetal deaths with 
a maternal cause listed, placenta praevia or placental separation and haemorrhage were the predominant causes 
(Table 12).  
Table 11. Fetal deaths, by main cause of fetal death, Midland DHBs 2008−2012 








95% CI Per cent 
Fetal deaths 
Waikato 
Congenital anomalies 59 11.8 2.09 1.62–2.70 28.0 
Malnutrition or slow fetal growth 22 4.4 0.78 0.52–1.18 10.4 
Prematurity or low birth weight 15 3.0 0.53 0.32–0.88 7.1 
Intrauterine hypoxia 7 1.4 0.25 0.12–0.51 3.3 
Fetal blood loss 7 1.4 0.25 0.12–0.51 3.3 
Other causes 12 2.4 0.43 0.24–0.74 5.7 
Unspecified cause of fetal death 89 17.8 3.16 2.57–3.88 42.2 
Waikato total 211 42.2 7.49 6.54–8.56 100.0 
Bay of Plenty 
Congenital anomalies 18 3.6 1.20 0.76–1.90 21.4 
Prematurity or low birth weight 8 1.6 0.53 0.27–1.05 9.5 
Malnutrition or slow fetal growth 5 1.0 0.33 0.14–0.78 6.0 
Other causes 10 2.0 0.67 0.36–1.23 11.9 
Unspecified cause of fetal death 43 8.6 2.87 2.13–3.87 51.2 
Bay of Plenty total 84 16.8 5.61 4.53–6.94 100.0 
Lakes DHB 
Congenital anomalies 9 1.8 1.10 0.58–2.09 13.2 
Prematurity or low birth weight 9 1.8 1.10 0.58–2.09 13.2 
Intrauterine hypoxia <5 s s s s 
Malnutrition or slow fetal growth <5 s s s s 
Other causes 8 1.6 0.98 0.50–1.93 11.8 
Unspecified cause of fetal death 36 7.2 4.41 3.18–6.09 52.9 
Lakes DHB total 68 13.6 8.32 6.57–10.5 100.0 
Tairawhiti 
Congenital anomalies 9 1.8 2.30 1.21–4.36 32.1 
Other causes 5 1.0 1.28 0.55–2.98 17.9 
Unspecified cause of fetal death 14 2.8 3.57 2.13–5.99 50.0 
Tairawhiti total 28 5.6 7.15 4.95–10.3 100.0 
Taranaki 
Congenital anomalies 11 2.2 1.37 0.77–2.46 20.4 
Prematurity or low birth weight 7 1.4 0.87 0.42–1.80 13.0 
Malnutrition or slow fetal growth <5 s s s s 
Other causes <5 s s s s 
Unspecified cause of fetal death 28 5.6 3.50 2.42–5.05 51.9 
Taranaki total 54 10.8 6.75 5.17–8.79 100.0 
Numerator: National Mortality Collection; Denominators: Birth Registration Dataset and National Mortality Collection 
 
Issues in infancy: Fetal deaths 
28 
Table 12. Fetal deaths, by maternal cause of fetal death, Midland DHBs 2008−2012 









95% CI Per cent 
Fetal deaths 
Waikato 
Placenta praevia/placental separation and haemorrhage 20 4.0 0.71 0.46–1.10 9.5 
Other abnormalities of placenta 13 2.6 0.46 0.27–0.79 6.2 
Compression of umbilical cord 12 2.4 0.43 0.24–0.74 5.7 
Incompetent cervix/premature rupture of membranes 11 2.2 0.39 0.22–0.70 5.2 
Chorioamnionitis 7 1.4 0.25 0.12–0.51 3.3 
Multiple pregnancy 5 1.0 0.18 0.08–0.42 2.4 
Placental transfusion syndromes 5 1.0 0.18 0.08–0.42 2.4 
Maternal hypertensive disorders <5 s s s s 
Oligohydramnios <5 s s s s 
Other causes 34 6.8 1.21 0.86–1.69 16.1 
No listed maternal cause 96 19.2 3.41 2.79–4.16 45.5 
Waikato total 211 42.2 7.49 6.54–8.56 100.0 
Bay of Plenty 
Placenta praevia/placental separation and haemorrhage 13 2.6 0.87 0.51–1.49 15.5 
Chorioamnionitis 7 1.4 0.47 0.23–0.96 8.3 
Compression of umbilical cord 7 1.4 0.47 0.23–0.96 8.3 
Incompetent cervix/premature rupture of membranes 5 1.0 0.33 0.14–0.78 6.0 
Other abnormalities of placenta <5 s s s s 
Maternal hypertensive disorders <5 s s s s 
Other causes 13 2.6 0.87 0.51–1.49 15.5 
No listed maternal cause 32 6.4 2.14 1.51–3.02 38.1 
Bay of Plenty total 84 16.8 5.61 4.53–6.94 100.0 
Lakes DHB 
Incompetent cervix/premature rupture of membranes 8 1.6 0.98 0.50–1.93 11.8 
Compression of umbilical cord 5 1.0 0.61 0.26–1.43 7.4 
Placenta praevia/placental separation and haemorrhage <5 s s s s 
Multiple pregnancy <5 s s s s 
Oligohydramnios <5 s s s s 
Other causes 21 4.2 2.57 1.68–3.93 30.9 
No listed maternal cause 22 4.4 2.69 1.78–4.07 32.4 
Lakes DHB total 68 13.6 8.32 6.57–10.53 100.0 
Tairawhiti 
Placenta praevia/placental separation and haemorrhage <5 s s s s 
Other abnormalities of placenta <5 s s s s 
Other causes 9 1.8 2.30 1.21–4.36 32.1 
No listed maternal cause 12 2.4 3.06 1.75–5.35 42.9 
Tairawhiti total 28 5.6 7.15 4.95–10.3 100.0 
Taranaki 
Placenta praevia/placental separation and haemorrhage 5 1.0 0.62 0.27–1.46 9.3 
Multiple pregnancy 5 1.0 0.62 0.27–1.46 9.3 
Incompetent cervix/premature rupture of membranes <5 s s s s 
Compression of umbilical cord <5 s s s s 
Other causes 15 3.0 1.87 1.14–3.09 27.8 
No listed maternal cause 25 5.0 3.12 2.12–4.61 46.3 
Taranaki total 54 10.8 6.75 5.17–8.79 100.0 
Numerator: National Mortality Collection; Denominators: Birth Registration Dataset and National Mortality Collection 
 
Issues in infancy: Fetal deaths 
29 
Evidence for good practice for the prevention of fetal deaths 
Ministry of Health publications 
Ministry of Health. 2013. Guidelines for Consultation with Obstetric and Related Medical Services (Referral Guidelines). 
Wellington: Ministry of Health. http://www.health.govt.nz/publication/guidelines-consultation-obstetric-and-related-medical-
services-referral-guidelines 
These guidelines are intended for lead maternity carers. They outline criteria and processes for referral to primary care, referral for specialist 
consultation, referral for the transfer of clinical responsibility for care, transfer of clinical responsibility for care in an emergency, and emergency 
transport. 
Ministry of Health. 2011. New Zealand Maternity Standards: A set of standards to guide the planning, funding and 
monitoring of maternity services by the Ministry of Health and District Health Boards. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/new-zealand-maternity-standards  
These standards provide guidance for the provision of safe, equitable and high quality maternity services throughout New Zealand. They consist of 
three high level strategic statements to guide the funding, planning, provision and monitoring of maternity services by the Ministry of Health, DHBs, 
service providers and health practitioners. The standards underpin the DHB maternity service specifications, the Primary Maternity Services Notice 
2007, the Maternal Referral Guidelines, and other high-level guidelines and requirements. 
International guidelines  
Royal College of Obstetricians and Gynaecologists (RCOG). 2011. Reduced fetal movements (Green-top guideline; no. 57). 
London (U.K.): Royal College of Obstetricians and Gynaecologists (RCOG). 
https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_57.pdf 
The purpose of this guideline is to provide advice to clinicians, based on the best available evidence, on the management of women presenting with 
reduced fetal movements in pregnancy (excluding those with multiple pregnancy). The guidelines are structured as a series of clinical questions. The 
authors note that the available evidence is limited and that this is reflected in the low grading of some of the recommendations. Appendix 1 provides 
a care algorithm (flowchart) and Appendix 2 explains the grading scheme used for the evidence and recommendations. There is a comprehensive list 
of references. 
National Collaborating Centre for Women's and Children's Health. 2010. Pregnancy and complex social factors. A model for 
service provision for pregnant women with complex social factors. London (UK): National Institute for Health and Clinical 
Excellence (NICE). https://www.nice.org.uk/guidance/cg110 
This very comprehensive 300+ page guideline, which is complementary to the NICE guideline ‘Antenatal care: routine care for the healthy pregnant 
woman’ (NICE clinical guideline 62, https://www.nice.org.uk/guidance/cg62 ), applies to pregnant women with complex social factors, in particular 
women who misuse substances (alcohol and/or drugs); women who are recent migrants, asylum seekers or refugees, or who have difficulty speaking 
English; young women aged under 20 years; and women who experience domestic violence. It is intended for health professionals caring for pregnant 
women, those responsible for commissioning and planning health services and it may be of relevance to those working in social services and 
education. It is based on, and reports on, systematic reviews of the literature aiming to determine which interventions lead to improved pregnancy 
outcomes. 
National Institute for Health and Clinical Excellence. 2010. Weight management before, during and after pregnancy. London: 
National Institute for Health and Clinical Excellence. https://www.nice.org.uk/guidance/ph27 
Obese women who become pregnant are at increased risk of complications during pregnancy and childbirth and babies born to obese women face 
higher risks of a number of adverse outcomes: fetal death, stillbirth, congenital abnormality, shoulder dystocia, macrosomia (large body size) and 
subsequent obesity. Pregnant women are not encouraged to diet but they can be encouraged to take regular exercise and not to “eat for two”. This 
guideline on dietary and physical activity interventions for weight management before, during and after pregnancy are intended for NHS and other 
commissioners, health service managers and health professionals. The evidence reviews on which the guideline was based, and some other relevant 
background publications can be found at: https://www.nice.org.uk/guidance/ph27/evidence  
International guidelines relevant to induction of labour 
Royal College of Obstetricians and Gynaecologists. 2013. Induction of labour at term in older mothers. London: Royal College of 
Obstetricians and Gynaecologists. https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip_34.pdf 
This scientific impact paper states that epidemiological studies show that women aged 40+ years have a stillbirth risk at 39 weeks of pregnancy equal 
to the risk for 25–29 year old women at 41 weeks, and therefore is reasonable to question whether older mothers should be offered induction of 
labour. It also states that the impacts of offering induction on emergency caesarean rates needs to be considered as well as whether any reduction 
in pre-birth stillbirths would be obtained at the cost of an increase in intrapartum (during birth) and neonatal deaths. This paper considers the 
evidence and concludes that the evidence suggests that offering induction at 39–40 weeks to women ≥ 40 years would reduce late antenatal stillbirths 
and maternal risks of an on-going pregnancy such as pre-eclampsia, particularly in cases where there are concurrent medical co-morbidities, 
nulliparity or Afro Caribbean ethnicity. It also concludes that there is growing evidence that such a practice would not increase the number of operative 
vaginal deliveries or caesarean sections but insufficient evidence to assess the effect on surgical deliveries and perinatal mortality specifically in older 
mothers. The authors note that older mothers, particularly first time mothers, may request elective caesarean delivery rather than induction of labour 
and that, in such cases, a discussion comparing the risks and benefits of the two options is appropriate. They also noted that there is currently an on-
going multicentre RCT comparing induction of labour at 39 weeks of gestation with expectant management in nulliparous women aged over 35 years 
of age (details can be found here: http://www.35-39trial.org/ ). 
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Leduc D, Biringer A, Lee L, et al. 2013. Induction of labour. J Obstet Gynaecol Can, 35(9), 840-60. 
http://sogc.org/guidelines/induction-labour-replaces-107-aug-2001/ 
This guideline was produced by the Society of Obstetricians and Gynaecologists of Canada. The literature search for published evidence used to 
produce the guideline concluded at the end of 2010. Recommendations in the guideline are accompanied by evidence statements regarding the 
quality of the evidence, and by a classification, according to criteria adapted from those of the Canadian Taskforce on Preventive Health Care. 
National Guideline Clearinghouse. 2010 (revised 2014). Guideline synthesis: induction of labour. Rockville (MD): Agency for 
Healthcare Research and Quality (AHRQ). 
http://www.guideline.gov/syntheses/synthesis.aspx?id=47799&search=induction+of+labour 
This website provides a comparison of the 2011 WHO guideline and the 2008 NICE guideline highlighting areas of agreement and difference. 
Compared guidelines can be found at http://whqlibdoc.who.int/publications/2011/9789241501156_eng.pdf and 
https://www.nice.org.uk/guidance/cg70 
International guidelines relevant to the management of stillbirth 
Queensland Maternity and Neonatal Clinical Guidelines Program. 2010. Stillbirth Care. Brisbane: Queensland Government. 
http://www.health.qld.gov.au/qcg/documents/g_still5-0.pdf 
These guidelines are intended for health professionals in Queensland maternity services and they are consistent with the Perinatal Society of Australia 
and New Zealand (PSANZ) Clinical Practice Guideline for Perinatal Mortality. They cover clinical standards, diagnosis and birth, investigations, autopsy 
and subsequent pregnancy care. They are concise and well referenced but do not discuss the research evidence. 
Royal College of Obstetricians and Gynaecologists (RCOG). 2010. Late intrauterine fetal death and stillbirth. London, U.K.: Royal 
College of Obstetricians and Gynaecologists (RCOG). https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg55/ 
The purpose of this guideline, which is primarily for obstetricians and midwives, is to identify evidence-based options for women (and their families) 
who have a late intra-uterine death (after 24 weeks) and to provide guidance on general care before, during and after birth, and care in subsequent 
pregnancies. The levels of evidence and the grades of recommendations in this guideline follow the system used by the Scottish Intercollegiate 
Guidelines Network (SIGN). They cover diagnosis, investigations, labour and birth, the puerperium, psychological and social aspects of care, follow-
up, pregnancy following unexplained stillbirth, clinical governance and recommendations for further research. 
Flenady V, King J, Charles A, et al. 2009. PSANZ Clinical Practice Guideline for Perinatal Mortality. Version 2.2. Perinatal Society 
of Australia and New Zealand (PSANZ). http://www.stillbirthalliance.org.au/guideline1.htm 
The purpose of this guideline is to assist clinicians in the audit of perinatal deaths, to enable a systematic approach to perinatal audit in Australia and 
New Zealand, and also to provide guidance on dealing with the psychological and social aspects of perinatal bereavement, peri-natal post-mortem 
examination, investigation of stillbirths and neonatal deaths and the use of perinatal mortality classifications. 
Evidence-based medicine reviews 
Alfirevic Z, Stampalija T, Medley N. 2015. Fetal and umbilical Doppler ultrasound in normal pregnancy. Cochrane Database of 
Systematic Reviews (4). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001450.pub4/abstract 
A key aim of routine antenatal care is to identify babies who are not thriving in the womb so that outcomes for these babies can be improved through 
medical intervention. This review aimed to assess the effect of routine fetal and umbilical Doppler ultrasound on pregnancy outcomes and obstetric 
practice in unselected and low risk pregnancies. The review authors identified five RCTs or quasi-RCTs of Doppler ultrasound vs. no Doppler 
ultrasound, all undertaken in the 1990s, with data from 14,185 women. There were no differences between the intervention and control groups for 
perinatal death (average risk ratio (RR) 0.80, 95% CI 0.35 to 1.83; four studies, 11,183 participants) or serious neonatal morbidity (RR 0.99, 95% CI 0.06 
to 15.75; one study, 2016 participants). One trial compared a single Doppler assessment with no Doppler and found evidence for group differences 
in perinatal death: (RR 0.36, 95% CI 0.13 to 0.99; one study, 3891 participants). The review authors recommended caution in interpreting this finding. 
There was no evidence of differences between groups for the outcomes of caesarean section, neonatal intensive care admissions or preterm birth 
less than 37 weeks. The review authors used GRADE software to assess the quality of evidence for the main comparison of “All Doppler vs. no Doppler” 
and found that for the outcome of stillbirth the quality of evidence differed by regimen subgroups. The evidence for Doppler using fetal/umbilical 
vessels only was of moderate quality while the evidence for Doppler using fetal/umbilical vessels plus uterine artery vessels was of low quality. The 
review authors concluded that there was no conclusive evidence that the use of routine umbilical artery Doppler ultrasound, or combination of 
umbilical and uterine artery Doppler ultrasound, in low-risk or unselected populations benefits either mother or baby. They stated that future research 
should be designed to address small changes in perinatal outcome, and should focus on potentially preventable deaths. 
Conde-Agudelo A, Bird S, Kennedy SH, et al. 2015. First- and second-trimester tests to predict stillbirth in unselected pregnant 
women: a systematic review and meta-analysis. BJOG, 122(1), 41-55 
The aim of this review was to determine the accuracy of tests performed during the first and/or second trimester of pregnancy to predict stillbirth in 
unselected women with structurally and chromosomally normal singleton fetuses. The review did not include genetic markers or ante-partum 
surveillance tests such as assessment of fetal heart rate patterns, fetal and umbilical artery Doppler ultrasonography, and biophysical profile, which 
are routinely used to assess fetal wellbeing in pregnancies complicated by fetal or maternal conditions. The review included 71 studies (50 cohort 
and 21 case-control) of variable methodological quality assessing a total of 16 single and five combined tests. The pooled evidence indicated that 
there is no clinically useful first or second trimester test to predict stillbirth as a sole category, but a uterine artery pulsatility index greater than the 
90th centile during the second trimester and low levels of pregnancy-associated plasma protein (PAPP-A) during the first trimester had a moderate 
to high predictive accuracy for stillbirth related to placental abruption, small-for-gestational-age or pre-eclampsia (positive and negative likelihood 
ratios from 6.3 to 14.1, and from 0.1 to 0.4, respectively). 
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Aune D, Saugstad OD, Henriksen T, et al. 2014. Maternal body mass index and the risk of fetal death, stillbirth, and infant 
death: a systematic review and meta-analysis. JAMA, 311(15), 1536-46 
The aim of this systematic review and meta-analysis of cohort studies was to quantify the association between maternal body mass index (BMI) and 
the risk of fetal death, stillbirth, and infant death. Eighteen cohort studies were included in the analysis of maternal BMI and stillbirth risk. Stillbirth 
definitions varied between studies from 20 or more to 28 or more completed weeks of gestation. The 18 studies included more than 16,274 stillbirths 
among 3,288,688 participants. The summary relative risk per 5 BMI units was 1.24 (95% CI, 1.18 to 1.30). For BMI levels of 20, 25 and 30, the absolute 
risks per 10,000 pregnancies were 40 (reference standard), 48 (95% CI 46 to 61), and 59 (95% CI 55 to 63), respectively. The association was almost 
linear. Analysis of results from studies that reported antepartum and intrapartum stillbirths separately indicated summary RRs of 1.28 (95% CI 1.15 to 
1.43) and 0.90 (95% CI 0.76 to 1.06) per 5 BMI units, respectively. There was some evidence of publication bias, but once one very large US study that 
contributed more than 51% of the total number of stillbirths was excluded there was no evidence of publication bias. This US study found a weaker 
association than the overall summary estimate. 
Peters M, Riitano D, Lisy K, et al. 2014. Providing care for families who have experienced stillbirth: a comprehensive 
systematic review. Adelaide: The Joanna Briggs Institute (for the Stillbirth Foundation of Australia). 
http://www.stillbirthfoundation.org.au/wp-content/uploads/2014/03/Stillbirth-systematic-review-report.pdf 
The aim of this review was to identify effective, meaningful and/or appropriate non-pharmacological, psychosocial supportive care interventions to 
improve the psychological well-being of families following stillbirth. The review included one quantitative study and 22 qualitative studies. It suggests 
numerous implications for practice. The review authors stated that the evidence indicates that parents need sensitive and supportive preparation 
from healthcare professionals to know what to expect at all stages of the stillbirth experience. 
Likis F E, Andrews J C, Fonnesbeck C J, et al. 2014. Smoking Cessation Interventions in Pregnancy and Postpartum Care. 
Evidence Report/Technology Assessment No.214. (Prepared by the Vanderbilt Evidence-based Practice Center under 
Contract No. 290-2007-10065-I.) AHRQ Publication No. 14-E001-EF. Rockville, MD: Agency for Healthcare Research and 
Quality. http://effectivehealthcare.ahrq.gov/ehc/products/517/1871/smoking-pregnancy-infants-report-140226.pdf  
This systematic review included 59 unique studies. Three were prospective cohort studies and 56 were RCTS. The review authors considered that 13 
of the RCTs were good, 15 fair and 28 poor quality. The studies evaluated educational materials, counselling-based interventions, peer support, 
nicotine replacement therapy (NRT), multi component interventions, and other unique interventions. Overall, the reviewers considered that the 
strength of evidence regarding interventions for smoking cessation and relapse prevention in pregnant women was low. When assessed by meta-
analysis, the strength of evidence was moderate for the effectiveness of incentives (odds ratio 3.23, 95% CI 1.98–4.59) and low for all other intervention 
components (odds ratios ranged from 1.32 down to 1.05 and all the associated confidence intervals all included 1, the value associated with no effect. 
The evidence for counselling was not assessed by meta-analysis as in most studies both the intervention and control arms included counselling (so 
it was not possible to compare counselling vs. no counselling). The reviewers found insufficient evidence to determine the effect of smoking cessation 
interventions on gestational age, birth weight, neonatal deaths, or long term or child outcomes, or to assess the harms of smoking interventions. 
They stated that their review indicated that approaches combining multiple components are most likely to be successful and that incentives were the 
component with the highest probability of success. Other components with a high probability of success were information, quit guides, feedback 
about biologic measures, NRT and personal follow up. The components that added little to the success of multi-component interventions were peer 
support, clinic reinforcement and prescriptions to quit. 
Further publications on smoking cessation interventions for pregnant women can be found in the Smoking in Pregnancy chapter of the 2014 NZCYES 
report in this series, on determinants of health. 
Nieuwenhuijsen MJ, Dadvand P, Grellier J, et al. 2013. Environmental risk factors of pregnancy outcomes: a summary of recent 
meta-analyses of epidemiological studies. Environ Health, 12, 6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582445/ 
The authors of this review aimed to describe the methodologies used in recent meta-analyses of environmental exposures and pregnancy outcomes, 
including stillbirth, and to report the main findings. They identified 16 meta-analyses, only a few of which reported having followed meta-analysis 
guidelines or having used a quality rating system, although most tested for heterogeneity and publication bias. One meta-analysis identified and 
increase in stillbirth risk associated with environmental tobacco smoke (OR 1.23, 95% CI 1.09 to 1.38, 4 studies) and another identified an increased 
risk associated with indoor air pollution from solid fuel use vs. cleaner fuel (OR 1.51, 95% CI 1.23 to 1.85, 4 studies). One meta-analysis considered 
the effects of disinfection by-products in drinking water and found a summary odds ratio for stillbirth of 1.09 (95% CI 1.02 to 1.17, number of studies 
not reported) when comparing the highest exposure group to the lowest. 
Koopmans L, Wilson T, Cacciatore J, et al. 2013. Support for mothers, fathers and families after perinatal death. Cochrane 
Database of Systematic Reviews (6). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000452.pub3/abstract 
The authors of this review did not identify any RCTs of any form of support aimed at encouraging acceptance of loss, bereavement counselling, or 
specialised psychotherapy or counselling for mothers, fathers and families who have experienced perinatal death. They stated that therefore the true 
benefits of such interventions is unclear and that there was no evidence regarding the possible detrimental effects of some interventions such as 
seeing and holding the deceased baby. They noted, however, that some well-designed descriptive studies have shown that parents’ experiences of 
seeing and holding their deceased baby can be very positive if they are supported by compassionate, sensitive and experienced staff. They also 
highlighted a variety of other interventions described in the literature that may be helpful to families. 
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Horey D, Flenady V, Heazell Alexander EP, et al. 2013. Interventions for supporting parents' decisions about autopsy after 
stillbirth. Cochrane Database of Systematic Reviews (2). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009932.pub2/abstract 
The authors of this review did not find any RCTs assessing interventions specifically designed to support parents of stillborn babies to make decisions 
about consenting to autopsy or other post-mortem investigations. They stated that those offering support to bereaved parents must rely on their 
own knowledge and experience. 
Furber CM, McGowan L, Bower P, et al. 2013. Antenatal interventions for reducing weight in obese women for improving 
pregnancy outcome. Cochrane Database of Systematic Reviews (1). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009334.pub2/abstract 
Obese women are at increased risk of a number of adverse pregnancy outcomes including congenital anomalies, stillbirth, gestational diabetes, 
hypertension, pre-eclampsia, and pre-term birth, macrosomia and caesarean birth. Some observational studies have indicated that some obese 
women gain little weight in pregnancy and even lose weight whereas it is very unusual for non-obese women to do this. There is conflicting evidence 
from observational studies regarding whether weight loss during pregnancy in obese women is beneficial or harmful to the fetus but it appears that 
in heavier women (body mass index > 40 kg/m2) weight loss can be beneficial. The authors of this review did not identify any RCTs designed to reduce 
maternal weight in obese pregnant women. They stated that it is unlikely that it would be considered ethical to conduct such a RCT given the current 
observational evidence. 
Alfirevic Z, Stampalija T, Gyte MLG. 2013. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database 
of Systematic Reviews (11). http://onlinelibrary.wiley.com/enhanced/doi/10.1002/14651858.CD007529.pub3 
Doppler ultrasound may be used to detect abnormal blood flow patterns in fetal circulation that may indicate poor fetal prognosis. This review aimed 
to assess the effects of Doppler ultrasound vs. no Doppler ultrasound in high-risk pregnancies. It included 18 RCTs and quasi RCTs involving a total 
of just over 10,000 women. The quality of the trials was unclear and there was some evidence of possible publication bias. Meta-analysis indicated 
that the use of Doppler ultrasound in high-risk pregnancy was associated with a reduction in perinatal deaths: Risk ratio (RR) 0.71, 95% CI 0.52 to 
0.98, 6 studies, 10,225 babies, 1.2% versus 1.7%, number needed to treat (NNT) = 203; 95% CI 103 to 4352. It was also associated with fewer inductions 
of labour (average RR 0.89, 95% CI 0.80 to 0.99, 10 studies, 5633 women, random effects) and fewer caesarean sections (RR 0.90, 95% CI 0.84 to 0.97, 
14 studies, 7918 women). It made no difference to the probability of operative vaginal birth (RR 0.95, 95% CI 0.80 to 1.14, four studies, 2813 women), 
nor to Apgar scores less than seven at five minutes (RR 0.92, 95% CI 0.69 to 1.24, seven studies, 6321 babies). The review authors concluded that 
current evidence suggests that the use of Doppler ultrasound in high-risk pregnancies leads to fewer perinatal deaths and obstetric interventions 
but, given that the evidence is not of high quality, the results of their review should be interpreted with caution. 
Tan Kelvin H, Smyth Rebecca MD, Wei X. 2013. Fetal vibroacoustic stimulation for facilitation of tests of fetal wellbeing. 
Cochrane Database of Systematic Reviews(12) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002963.pub2/abstract 
It has been suggested that acoustic stimulation of the fetus (using an electronic device to send brief sounds through the mother’s abdomen to her 
baby) improves the efficiency of pre-labour fetal heart rate testing by reducing the number of non-reactive cartiotocographs that are due to the baby 
being asleep (as opposed to being in distress). This review included 12 trials with a total of 6822 participants. Fetal vibroacoustic stimulation reduced 
the proportion of antenatal cardiotocography tests that were non-reactive (nine trials; average risk ratio (RR) 0.62, 95% confidence interval (CI) 0.48 
to 0.81). Vibroacoustic stimulation compared with mock stimulation evoked significantly more fetal movements when used with fetal heart rate testing 
(one trial, RR 0.23, 95% CI 0.18 to 0.29). The review authors concluded that vibroacoustic stimulation is useful since it decreases the incidence of non-
reactive cardiotocography and reduces the testing time. 
Muktabhant B, Lumbiganon P, Ngamjarus C, et al. 2012. Interventions for preventing excessive weight gain during pregnancy. 
Cochrane Database of Systematic Reviews (4). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007145.pub2/abstract 
Excessive weight gain during pregnancy increases the risk of complications for both mother and baby. Some of these complications, including the 
development of diabetes and hypertension, increase the risk of stillbirth. This review aimed to evaluate the effectiveness of interventions for 
preventing excessive weight gain in pregnancy and associated pregnancy complications. It included 28 RCTs and quasi RCTs involving 3976 women; 
27 of these studies (3964 women) contributed data to the analyses. The studies considered a broad range of interventions. For most of the outcomes 
it was not possible to combine data in a meta-analysis, and, where meta-analysis was possible, no more than two or three studies could be combined 
for a particular intervention and outcome measure. Most of the results from the review were not statistically significant, and where there did seem to 
be differences between the intervention and control groups, the results were not consistent. For women in a general clinic population, one of three 
interventions examined (behavioural counselling vs. standard care) was associated with a reduction in the rate of excessive weight gain (RR 0.72, 95% 
CI 0.54 to 0.95), but for women in high-risk groups, none of the interventions appeared to reduce excess weight gain. All but one of the included 
studies reported mean weight gain and the results were inconsistent. The review authors found a statistically significant effect on mean weight gain 
for five interventions in the general population and two interventions in high-risk groups. No study reported significant effects on adverse neonatal 
outcomes and most studies did not show statistically significant effects on maternal complications. The review authors concluded that there is 
insufficient evidence to recommend any intervention for preventing excessive weight gain in pregnancy. 
Hofmeyr JG, Novikova N. 2012. Management of reported decreased fetal movements for improving pregnancy outcomes. 
Cochrane Database of Systematic Reviews (4). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009148.pub2/abstract 
Mothers who have a stillbirth commonly report perceiving a reduction in, or absence of, their baby’s movements in the days preceding their baby’s 
death. For this reason, monitoring of babies’ movements is often advised by caregivers, and used by mothers to assess their baby’s wellbeing. This 
review aimed to determine the effectiveness of various management strategies for decreased fetal movements (DFM). The review authors did not 
identify any RCTs of management of DFM. They did identify 13 randomised trials of management strategies for women whose babies are at risk of 
poor outcomes for various reasons, including DFM, but data on DFM sub-groups was only able to be provided by the authors of one trial and the 
numbers of cases of DFM (28) was too small for meaningful analysis. They concluded that there were insufficient data from RCTs to provide guidance 
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on the management of DFM in clinical practice, but that, based on the findings from other systematic reviews, the following strategies show promise 
and should be prioritised for further research: Doppler ultrasound studies, computerised cardiotocography, and fetal arousal to facilitate 
cardiotocography. 
Gulmezoglu MA, Crowther CA, Middleton P, et al. 2012. Induction of labour for improving birth outcomes for women at or 
beyond term. Cochrane Database of Systematic Reviews (6). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004945.pub3/abstract 
A pregnancy is considered to be “at term” at 37 weeks and “post-term” at 42 weeks. There is an increase in the risk of a baby dying in utero as 
pregnancy continues beyond term. Induction of labour is widely practiced to try to prevent stillbirth and other adverse outcomes for mother and 
baby. This review aimed to assess the benefits and harms of a policy of inducing labour at term compared with awaiting spontaneous onset of labour 
or later induction. It included 22 RCTs reporting on 9,382 women. The review authors considered them to be generally at moderate risk of bias. 
Compared with a policy of expectant management, a policy of induction of labour was associated with fewer all-cause perinatal deaths: risk ratio (RR) 
0.31, 95% CI 0.12 to 0.88; 17 trials, 7407 women. (Perinatal deaths are stillbirths and deaths within the first week of life.) There was one perinatal death 
in the induction policy group, but 13 in the expectant management group. The number needed to treat to benefit with induction of labour to prevent 
one perinatal death was 410 (95% CI 322 to 1492). There was no difference between timing of induction subgroups for the primary outcome of 
perinatal death and for most other outcomes; the majority of trials had a policy of induction at 41 completed weeks (287 days) or more. There were 
fewer babies in the induction group (compared to the expectant management group) with meconium aspiration syndrome (RR 0.50, 95% CI 0.34 to 
0.73; eight trials, 2371 infants), and fewer caesarean sections (RR 0.89, 95% CI 0.81 to 0.97, 21 trials 8749 women). Rates of neonatal intensive care 
unit (NICU) admission were not significantly different for induction compared to expectant management (RR 0.90, 95% CI 0.78 to 1.04; 10 trials, 6161 
infants). The review authors concluded that a policy of labour induction compared with expectant management is associated with fewer perinatal 
deaths and caesarean sections, and fewer babies with meconium aspiration syndrome, but no significant difference in the rate of NICU admission. 
The Cochrane library has a large number of reviews relating to induction of labour, which can be found at: 
http://www.cochranelibrary.com/app/content/browse/page/?context=topic/Pregnancy%20%26%20childbirth&paginationVal=1 . (Select “induction 
of labour” from the topic menu.) 
Grivell Rosalie M, Wong L, Bhatia V. 2012. Regimens of fetal surveillance for impaired fetal growth. Cochrane Database of 
Systematic Reviews doi:10.1002/14651858.CD007113.pub3 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007113.pub3/abstract 
There is wide variation in policies and protocols for surveillance of pregnancies where impaired fetal growth is suspected. This review aimed to assess 
the effects of antenatal fetal surveillance on maternal and perinatal outcomes (including stillbirth). The review authors identified only one RCT 
(involving 167 women and their babies in Auckland) which compared a twice-weekly surveillance regimen (biophysical profile, nonstress tests, 
umbilical artery and middle cerebral artery Doppler and uterine artery Doppler) with the same regimen applied fortnightly (both groups had fetal 
growth assessed fortnightly). There was not sufficient data to assess the review’s primary infant outcome (composite perinatal mortality and serious 
morbidity). There were no perinatal deaths in either group. There was no difference between the groups in the primary maternal outcome of 
emergency caesarean section for fetal distress (risk ratio (RR) 0.96; 95% CI 0.35 to 2.63). The babies in the twice-weekly surveillance group had a mean 
gestational age at birth that was four days less than the babies in the fortnightly surveillance group (mean difference (MD) −4.00; 95% CI −7.79 to 
−0.21). Compared to women in the fortnightly surveillance group, women in the twice-weekly surveillance group were 25% more likely to have 
induction of labour (RR 1.25; 95% CI 1.04 to 1.50). The review authors concluded that the evidence to inform best practice for fetal surveillance 
regimens for use when caring for women whose pregnancies had evidence of impaired fetal growth is limited and that more research is needed to 
evaluate the effects of currently used fetal surveillance regimens where there is impaired fetal growth. 
Grivell RM, Alfirevic Z, Gyte GML, et al. 2012. Antenatal cardiotocography for fetal assessment. Cochrane Database of Systematic 
Reviews (12) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007863.pub3/full 
Cardiotocography (CTG) is widely used in pregnancy to assess fetal wellbeing, especially in pregnancies at increased risk of complications. It involves 
continuous recording of the fetal heart rate via an ultrasound transducer placed on the mother’s abdomen. This review aimed to assess the 
effectiveness of antenatal CTG (both traditional and computerised) in improving outcomes for mothers and babies. The review authors searched for 
RCTs and quasi-RCTs that compared traditional antenatal CTG with no CTG or CTG with results concealed; computerised CTG with no CTG or CTG 
with results concealed; and computerised CTG with traditional CTG. They included six trials involving 2,105 women, the most recent of which was 
published in 1997. All of the trials include only women at increased risk of complications, and overall they were not of high quality. Comparison of 
traditional CTG versus no CTG showed no significant difference identified in perinatal mortality (risk ratio (RR) 2.05, 95% CI 0.95 to 4.42, 2.3% versus 
1.1%, four studies, N = 1627) or potentially preventable deaths (RR 2.46, 95% CI 0.96 to 6.30, four studies, N = 1627), though the meta-analysis was 
underpowered for assessing this outcome. There was no significant difference identified in caesarean sections (RR 1.06, 95% CI 0.88 to 1.28, 19.7% 
versus 18.5%, three trials, N = 1279) nor in the secondary outcomes that were assessed. There were no eligible studies comparing computerised CTG 
with no CTG. Comparison of computerised CTG versus traditional CTG showed a significant reduction in perinatal mortality with computerised CTG 
(RR 0.20, 95% CI 0.04 to 0.88, two studies, 0.9% versus 4.2%, 469 women) but no significant difference in potentially preventable deaths (RR 0.23, 95% 
CI 0.04 to 1.29, two studies, N = 469), though the meta-analysis was underpowered to assess this outcome. There was no significant difference 
identified in caesarean sections (RR 0.87, 95% CI 0.61 to 1.24, 63% versus 72%, one study, N = 59) or in secondary outcomes. The review authors 
concluded that there is no clear evidence that antenatal CTG improves perinatal outcomes, but that additional studies focussing on the use of 
computerised CTG in specific populations of women at high risk of complications are warranted. 
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Flenady V, Middleton P, Smith GC, et al. 2011. Stillbirths: the way forward in high-income countries. The Lancet, 377(9778), 
1703-17. 
This paper, which is one of six in the Lancet’s 2011 Stillbirth Series, notes that in developed countries, disparities in stillbirth rates between different 
population groups indicate that there is scope for further reductions in stillbirth rates. Overweight, obesity and smoking are important modifiable risk 
factors. Advanced maternal age is also a risk factor. A substantial proportion of stillbirths are linked to placental pathologies and infection associated 
with preterm birth. National perinatal mortality audit programmes aimed at improving the quality of care could reduce stillbirth rates and an 
international consensus on definitions and classifications related to stillbirth is necessary. All parents should be offered a thorough investigation 
including a high-quality autopsy and placental histopathology. Future research should focus on screening and interventions to reduce antepartum 
stillbirth as a result of placental dysfunction. 
The other papers in the Lancet stillbirth series, which provide a global perspective on the issue of stillbirth, are: 
Frøen JF, Cacciatore J, McClure EM, et al. 2011. Stillbirths: why they matter. The Lancet, 377(9774), 1353-66. 
Lawn JE, Blencowe H, Pattinson R, et al. 2011. Stillbirths: Where? When? Why? How to make the data count? The Lancet, 
377(9775), 1448-63. 
Bhutta ZA, Yakoob MY, Lawn JE, et al. 2011. Stillbirths: what difference can we make and at what cost? The Lancet, 377(9776), 
1523-38. 
Pattinson R, Kerber K, Buchmann E, et al. Stillbirths: how can health systems deliver for mothers and babies? The Lancet, 
377(9777), 1610-23. 
Goldenberg RL, McClure EM, Bhutta ZA, et al. 2011. Stillbirths: the vision for 2020. Lancet, 377(9779), 1798-805. 
Flenady V, Koopmans L, Middleton P, et al. 2011. Major risk factors for stillbirth in high-income countries: a systematic review 
and meta-analysis. Lancet, 377(9774), 1331-40. 
This systematic review included 96 population-based studies. The highest ranking modifiable risk factor for stillbirth was found to be maternal obesity 
with a population attributable risk (PAR) calculated to be 8 -18% across five countries (Australia, Canada, Netherlands, UK, and USA). Advanced 
maternal age (>35 years) had a PAR of 7–11% and maternal smoking had a PAR of 4–7%. In disadvantaged populations the PAR for smoking could 
be as high as 20%. Primiparity contributes to about 15% of stillbirths. Placental pathology has an important role in stillbirth, as indicated by the PARs 
for small-for-gestational-age (23%) and placental abruption (15%). Pre-existing maternal diabetes and hypertension still contribute to stillbirth in 
high income countries. Priority areas for stillbirth prevention are raising awareness and implementing interventions to address obesity, maternal age 
and smoking. 
Other relevant publications 
PMMRC. 2014. Eighth Annual Report of the Perinatal and Maternal Mortality Review Committee: Reporting mortality 2012. 
Wellington: Health Quality & Safety Commission. http://www.hqsc.govt.nz/assets/PMMRC/Publications/eighth-PMMRC-report-
June-2014.pdf 
The Perinatal and Maternal Mortality Review Committee (PMMRC) reviews all perinatal and maternal deaths in New Zealand with the aim of identifying 
areas for improvement in maternal and newborn care. This report is based on the data collected by the Mortality Review Data Group. A perinatal 
death is defined as one occurring after 20 weeks gestation (or of a baby weighing at least 400g if gestation is unknown) and up to and including the 
28th day of life. Besides reporting statistics, the report also makes recommendations for future work by the PMMRC, the Ministry of Health, lead 
maternity cares, DHBs and others. Key findings regarding stillbirth were: 
 There was a significant reduction in stillbirth rates from 2007 to 2012, which was independent of demographic changes. The rates (per 
1,000 total babies born at 20 weeks or beyond, or weighing at least 400g if gestation was unknown) were 5.6, 5.8, 6.1, 5.3, 5.3 and 5.1 in 
2007–2012 respectively 
 There was a significant reduction in unexplained antepartum stillbirth and hypoxic peripartum stillbirth, which contributed to the observed 
reduction 
Multivariate analysis of data for women booked with a lead maternity carer indicated that the following women are at increased risk of stillbirth: 
women with a high body mass index (the risk increase as the BMI increases beyond 25 kg/m2), women who smoke during pregnancy, women of 
Indian ethnicity, and women having their first birth. Each of these risk factors is independent of the others and of age and socio-economic deprivation. 
The most commonly reported classification of fetal deaths was unexplained (27% of all stillbirths and 37% of stillbirths at term) and other classifications 
which each accounted for 10–15% of stillbirths were congenital abnormalities, antepartum haemorrhage, specific perinatal conditions, fetal growth 
restriction and spontaneous preterm birth. 
Redshaw M, Rowe R, Henderson J. 2014. Listening to Parents after stillbirth or the death of their baby after birth. Oxford, UK: 
National Perinatal Epidemiology Unit, University of Oxford. 
https://www.npeu.ox.ac.uk/downloads/files/listeningtoparents/report/Listening%20to%20Parents%20Report%20-
%20March%202014%20-%20FINAL%20-%20PROTECTED.pdf 
This is the report of national survey of women who registered a stillbirth or a neonatal death in two three-month periods in 2012–2013 in England. 
In all, 720 women were included, a response rate of 30%. The questions addressed in this report were focussed on the recent experiences of the 
parents, their maternity care and key areas of concern. The findings are presented separately for women who had a stillborn baby and those who had 
a baby who died in the neonatal period. Just over half the women who had a stillbirth had problems in their pregnancies and most of these women 
had additional specialist care. These women were most positive about their care in labour and most critical of their care in pregnancy. Around two 
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thirds of women whose babies were stillborn before labour felt that something was wrong, mostly commonly because of decreased fetal movements 
(72%). 
Edmunds SF, Silver RM. 2013. Stillbirth reduction efforts and impact on early births. Clin Perinatol, 40(4), 611-28 
This article discusses the pros and cons of intentional delivery before 39 weeks gestation in order to reduce the risk of stillbirth. Infants born before 
39 weeks are at increased risk for neonatal death and morbidity due to complications of prematurity, therefore it is critical to identify in which 
circumstances the fetus is at high enough risk for stillbirth to justify late preterm or early term birth. Examples of conditions where early delivery may 
be justified are hypertensive disorders of pregnancy, diabetes, intra-uterine growth restriction, placental abnormalities, some birth defects, multiple 
gestation, and abnormal fetal testing. It is stated that the optimal gestational age for delivery in many of these conditions is uncertain. It is also stated 
that there is no evidence that delivery before 39 weeks gestation reduces the risk of recurrent stillbirth but acknowledges that obstetricians caring 
for women who have had a previous stillbirth, and the women themselves, tend to desire early delivery. This paper summarises the guidance regarding 
timing of delivery for particular conditions complicating pregnancy contained in the following paper: 
Spong CY, Mercer BM, D'Alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecolol 2011;118:326–
7. 
Moewaka Barnes H, Moewaka Barnes A, Baxter J, et al. 2013. Hapū Ora: Wellbeing in the Early Stages of Life. Auckland: Whāriki 
Research Group, Massey University. http://www.massey.ac.nz/massey/learning/departments/centres-research/shore/projects/hapu-
ora.cfm 
This is the report of a project funded by the partnership programme of the Health Research Council of New Zealand and the Ministry of Health. The 
project aimed to identify Māori life course research priorities, with a specific focus on wellbeing at the early stage of life, hapū ora (the fetal/gestational 
and neonatal periods). While the report does not specifically consider the prevention of fetal death, it does contain much information relevant to 
those who are involved in providing maternity care for Māori, particularly in Chapter 4, which reviews literature on antenatal, labour and delivery care 
for Māori, and in Chapter 5, which outlines views from the health sector gathered from both individuals and groups. 
Stacey T, Thompson JM, Mitchell EA, et al. 2012. Antenatal care, identification of suboptimal fetal growth and risk of late 
stillbirth: findings from the Auckland Stillbirth Study. Australian & New Zealand Journal of Obstetrics & Gynaecology, 52(3), 
242-7. http://onlinelibrary.wiley.com/doi/10.1111/j.1479-828X.2011.01406.x/abstract 
This paper reports findings from the Auckland Stillbirth Study, a case control study which included 155 cases (out of 215 invited) cases and 310 
controls (out of 429 invited). Increased risk of late stillbirth was found to be associated with accessing <50% of recommended antenatal visits 
compared to accessing the recommended number of visits (adjusted odds ratio, aOR, 2.68; 95% CI, 1.04–6.90) and with having a small-for-gestational-
age (SGA) baby that had not been identified as being SGA prior to birth (aOR, 9.46; 95% CI, 1.98–45.13), compared to having a SGA baby that was 
identified as such antenatally. There was no association found between the type or model of maternity care provider at booking and late stillbirth 
risk. The authors stated that their findings reinforced the importance of regular antenatal care attendance, which may identify babies that are SGA 
and thus reduce the chances of them being stillborn. 
Peat AM, Stacey T, Cronin R, et al. 2012. Maternal knowledge of fetal movements in late pregnancy. Australian & New Zealand 
Journal of Obstetrics & Gynaecology, 52(5), 445-9 
This paper reports on a study which involved interviewing a convenience sample of 100 women attending two antenatal clinics in Auckland in 
November and December 2011 to determine what information women in their third trimester of pregnancy receive about fetal movements, both 
from their lead maternity carer and from other sources. The study results indicated that 97% of women reported that their lead maternity carer 
regularly asked about fetal movements. Sixty-two percent recalled receiving information from their LMC about what to expect regarding fetal 
movements in the last three months of pregnancy. Thirty-three percent reported that the information they received from their LMC was that their 
baby’s movements should increase or stay the same, and 20% that their baby’s movements may decrease in late pregnancy. Forty per cent were 
advised to contact their LMC if they had any concerns about their baby's movements, and one-quarter were told to seek advice if they had fewer 
than 10 movements in a day. The study authors concluded that their results suggested that some pregnant women in Auckland lack optimum 
information about fetal movements. They stated that strategies to enhance maternal knowledge, such as pamphlet provision, could be helpful. 
Websites 
Ministry of Health. 2014. Fetal and Infant Deaths 2011. http://www.health.govt.nz/publication/fetal-and-infant-deaths-2011 
This website presents key findings regarding fetal and infant deaths in 2011. It has downloadable tables which present a summary of fetal and infant 
deaths with a focus on deaths and stillbirths registered in 2011 with the Births, Deaths, Marriages and Citizenship Registry (BDM). The tables include 
information on demographic characteristics (such as ethnicity and sex), cause of death, gestation and birthweight, and also information on deaths 
classified as sudden infant death syndrome (SIDS) and sudden unexpected death in infancy (SUDI). 
 




A preterm birth is defined by the World Health Organization as a baby born alive before 37 completed weeks of 
pregnancy.7 Spontaneous preterm birth is the leading cause of neonatal death worldwide (death occurring before 
28 days of age).7 The risk of death is inversely proportional to gestational age. In New Zealand in 2012, 32 
percent of all neonatal deaths were reported to be due to spontaneous preterm birth.5 Rates of preterm birth are 
increasing in almost all countries with reliable data.7 There are three main reasons given for this elsewhere.8 
Firstly, rates of multiple pregnancy are increasing due to increasing average maternal age and the use of fertility 
treatments. (Multiple pregnancy is associated with a much higher likelihood of preterm birth and older mothers 
are more likely to have twins than younger mothers.) Secondly, the numbers of planned early deliveries has 
increased because, as outcomes for preterm infants have improved due to advances in medical care, the risk 
associated with iatrogenic early delivery has become lower than the risk associated with the baby remaining in 
utero in cases of pregnancy complications such as placenta praevia, hypertension and diabetes.9 Thirdly, a 
number of risk factors for preterm birth have become more common, including in-vitro fertilisation, older 
maternal age, and high body mass index. However, this is not so in New Zealand where rates have stayed fairly 
constant for the last fifteen years. In New Zealand in 2012, 7.6% of babies were born preterm: 1.3% at less than 
32 weeks gestation and 6.3% at 32–36 weeks gestation.10 
Babies born prematurely, especially those born very prematurely, are at risk of severe morbidity in their early 
life from conditions including bronchopulmonary dysplasia, respiratory distress syndrome, necrotising 
enterocolitis, intraventricular haemorrhage, retinopathy of prematurity, and sepsis.8 They are also at risk of 
lifelong neurodevelopmental problems including cerebral palsy and learning disorders.8 The causes of 
spontaneous preterm birth are currently not well understood and the available interventions are of limited 
effectiveness.11 An important function of antenatal care is to identify women at risk of preterm birth. The most 
significant risk factor by far is a previous history of preterm delivery.8 At the population level, interventions to 
reduce smoking and intimate partner violence, improve access to family planning to reduce the number of 
closely spaced pregnancies, and provide support to socially disadvantaged women could help reduce preterm 
birth rates.12 
The following section reports on preterm birth rates using information from the Birth Registration Dataset. 
Data sources and methods 
Indicator 
Proportion of live babies born prematurely 
Data sources 
Birth registration dataset 
Numerator:  Live births between 20–36 weeks gestation 
Denominator:  Live births 
National Minimum Dataset 
Numerator:  In-hospital live births between 20–36 weeks gestation 
Denominator: In-hospital live births 
Definition 
Preterm birth per 100 live births 
Notes on interpretation 
Note 1: Year is year of registration, rather than year of birth. 
Note 2: In this analysis, stillborn infants have been excluded due to advice from the Ministry of Health that the Birth Registration 
dataset provides less reliable information on stillborn infants than the National Mortality Collection. Stillbirth rates, however, are 
reviewed in the Fetal Deaths section. 
Note 3: Preterm births were classified according to the criteria of WHO into groups of 20–27, 28–31, and 32–36 completed 
weeks (http://www.who.int/mediacentre/factsheets/fs363/en/) 
Note 4: In the length of stay analyses (LOS), the set is limited to babies born in-hospital as identified by an event type code of 
'BT'. Plurality was assigned using the 'Z38' code. 
Note 5: An overview of the Birth Registration and National Minimum Datasets are provided in Appendix 3. 
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National trends and distribution 
From 2000 to 2014 the pre-term birth rate in New Zealand was stable at around 7.4% of live births. Over the 
same time period around 0.5% of all live births occurred at 20–27 weeks gestation, 0.8% at 28–31 weeks and 
around 6.1% at 32–36 weeks.  
This stable pattern over time was observed for all ethnic groups, with Māori pre-term birth rates generally 
higher than rates for other ethnic groups. Since 2010 the pre-term birth rates for Asian/Indian infants have been 
generally lower than for other ethnic groups (Figure 13). 
Figure 13. Preterm live births, by ethnicity, New Zealand 2000–2014 
 
Birth Registration Dataset; Numerator: live births between 20–36 weeks gestation. Denominator: live births; Preterm live birth 
rate is per 100 live births; Ethnicity is level 1 prioritised 
Distribution by demographic factors 
Between 2010 and 2014 there were small but significant disparities in pre-term birth rates by NZDep2013 score, 
ethnicity, maternal age, and infant sex. The greatest disparity was observed with plurality which is also 
discussed on page 39. Rates of pre-term birth were significantly higher for infants living in areas with higher 
scores on NZDep2013 (deciles 7–10) compared with deciles 1–6 and for Māori infants compared with Pacific, 
MELAA and European/Other infants. Pre-term birth rates were significantly lower for Asian/Indian infants than 
for other ethnic groups. There was an association with maternal age with significantly higher pre-term birth rates 
for infants born to mothers aged under 20 years and aged over 35 years, compared with mothers aged 25–34 
years. Pre-term birth rates were significantly higher for male compared with female infants. There was a strong 
association between plurality and pre-term birth with significantly higher rates for multiple compared with 
singleton pregnancies. Pre-term birth was over nine times more likely for twins compared with singletons, and 
over 16 times more likely for other multiple births (Table 13). Between 2010 and 2014 most live births occurred 
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Figure 14. Distribution of live births, by gestational age at delivery, New Zealand 2010–2014 
 
Birth Registration Dataset. Numerator: All live births (annual average); Gestational age is in weeks 






Rate per 100 
live births 
Rate ratio 95% CI 
Preterm births 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 3,233 647 7.17 1.00   
Deciles 3–4 3,552 710 7.17 1.00 0.96–1.05 
Deciles 5–6 4,096 819 7.27 1.01 0.97–1.06 
Deciles 7–8 5,133 1,027 7.61 1.06 1.02–1.11 
Deciles 9–10 6,892 1,378 7.89 1.10 1.06–1.14 
Prioritised ethnicity  
Māori 7,085 1,417 8.01 1.08 1.05–1.11 
Pacific 2,523 505 7.42 1.00 0.96–1.05 
Asian/Indian 2,869 574 6.90 0.93 0.90–0.97 
MELAA 362 72 6.67 0.90 0.81–1.00 
European/Other 10,159 2,032 7.40 1.00   
Maternal age 
<20 years 1,570 314 8.43 1.19 1.13–1.26 
20–24 years 4,108 822 7.31 1.03 0.99–1.07 
25–29 years 5,491 1,098 7.00 0.99 0.95–1.02 
30–34 years 6,182 1,236 7.08 1.00   
35+ years 5,655 1,131 8.53 1.20 1.16–1.25 
Gender 
Female 10,568 2,114 7.08 1.00   
Male 12,438 2,488 7.89 1.11 1.09–1.14 
Plurality 
Singleton 17,954 3,591 6.02 1.00   
Twins 4,847 969 57.17 9.50 9.28–9.72 
Multiple 205 41 97.16 16.14 15.7–16.6 
Birth Registration Dataset; Numerator: live births between 20–36 weeks gestation; Denominator: live births; Preterm live birth 
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Plurality and gestational age 
Between 2010 and 2014 there were 17,954 live pre-term births of singleton infants, 4,847 twins and 205 other 
multiple births. The distribution by gestational age differed by plurality, with pre-term birth rates of 6.0% of live 
singleton births, 57.2% of live twin births and 97.2% of other live multiple births (Table 14). The peak 
gestational age at birth for singleton infants was 40 weeks, for twins 37 weeks and for other multiple births 33–
34 weeks (Figure 15).   

















20–27 1,440 0.47 0.45–0.49 20–27 1,140 0.38 0.36–0.41 
28–31 2,358 0.77 0.74–0.80 28–31 1,793 0.60 0.57–0.63 
32–36 19,208 6.26 6.17–6.35 32–36 15,021 5.04 4.96–5.12 
37+ weeks 283,745 92.46 92.4–92.6 37+ weeks 280,114 93.93 93.9–94.0 
20–36 23,006 7.50 7.40–7.59 20–36 17,954 6.02 5.94–6.11 
Twins Other multiple birth 
20–27 276 3.26 2.90–3.65 20–27 24 11.37 7.76–16.4 
28–31 530 6.25 5.76–6.79 28–31 35 16.59 12.2–22.2 
32–36 4,041 47.66 46.6–48.7 32–36 146 69.19 62.7–75.0 
37+ weeks 3,625 42.76 41.7–43.8 37+ weeks 6 2.84 1.31–6.06 
20–36 4,847 57.17 56.1–58.2 20–36 205 97.16 93.9–98.7 
Birth Registration Dataset. Numerator: live births between 20–36 weeks gestation; Denominator: live births by plurality; Preterm 
live birth rate is per 100 live births; Rate ratios are unadjusted 
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Figure 15. Distribution of live births, by plurality and gestational age at delivery, New Zealand 2010–2014 
 
Birth Registration Dataset; Rate is per 100 live births. Note that the numbers are very different at each level of plurality and 
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Plurality: Distribution by demographic factors 
Between 2010 and 2014 there was no significant difference in the pre-term birth rates of twins by NZDep2013 
score or infant sex. Pre-term birth rates were slightly but significantly lower for Māori twins compared with 
European/Other and slightly but significantly higher for Asian/Indian compared with European/Other. Pre-term 
birth rates were significantly higher for twins born to mothers aged under 20 years and aged 25–29 years 
compared with mothers aged 30–34 years (Table 16).  
In the same time period pre-term birth rates were significantly higher for other multiple births of infants in areas 
with mid-range to high NZDep2013 scores (deciles 3–10) compared with multiple birth infants in areas with the 
lowest NZDep2013 scores (deciles 1–2). There were no pre-term other multiple births to mothers aged under 20 
years. Pre-term birth rates were significantly higher for infants born to mothers aged 20–29 and over 35 years 
compared with mothers aged 30–34 years and for male multiple birth infants compared with female infants. 






Rate per 100 
live births 
Rate ratio 95% CI 
Preterm births 
Twins 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 828 166 58.4 1.00   
Deciles 3–4 853 171 60.5 1.04 0.97–1.10 
Deciles 5–6 928 186 57.4 0.98 0.92–1.04 
Deciles 7–8 1,008 202 56.2 0.96 0.91–1.02 
Deciles 9–10 1,220 244 55.2 0.95 0.89–1.00 
Prioritised ethnicity  
Māori 1,346 269 55.1 0.95 0.91–0.99 
Pacific 484 97 54.9 0.95 0.89–1.01 
Asian/Indian 500 100 63.2 1.09 1.03–1.16 
MELAA 88 18 52.1 0.90 0.78–1.04 
European/Other 2,429 486 57.9 1.00   
Maternal age 
<20 years 191 38 64.1 1.16 1.06–1.27 
20–24 years 669 134 55.8 1.01 0.95–1.07 
25–29 years 1,120 224 59.1 1.07 1.02–1.13 
30–34 years 1,414 283 55.2 1.00   
35+ years 1,453 291 57.5 1.04 0.99–1.09 
Gender 
Female 2,467 493 57.8 1.00   
Male 2,380 476 56.5 0.98 0.94–1.01 
Birth Registration Dataset; Numerator: live births between 20–36 weeks gestation; Denominator: live births; Preterm live birth 
rate is per 100 live births; Rate ratios are unadjusted; Infant ethnicity is level 1 prioritised; Decile is NZDep2013 
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 Rate per 100 
live births  
 Rate ratio   95% CI  
Preterm births 
Multiple births 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 32 6 91.4 1.00   
Deciles 3–4 42 8 97.7 1.07 0.96–1.19 
Deciles 5–6 18 4 100.0 1.09 0.99–1.21 
Deciles 7–8 62 12 100.0 1.09 0.99–1.21 
Deciles 9–10 48 10 96.0 1.05 0.93–1.18 
Prioritised ethnicity  
Māori 48 10 100.0 1.03 1.00–1.07 
Pacific 24 5 92.3 0.95 0.85–1.07 
Asian/Indian 18 4 94.7 0.98 0.87–1.09 
MELAA 15 3 100.0 1.03 1.00–1.07 
European/Other 100 20 97.1 1.00   
Maternal age 
<20 years 0 .. .. .. .. 
20–24 years 27 5 100.0 1.06 0.99–1.14 
25–29 years 51 10 96.2 1.02 0.94–1.12 
30–34 years 47 9 94.0 1.00   
35+ years 80 16 98.8 1.05 0.98–1.13 
Gender 
Female 117 23 98.3 1.00   
Male 88 18 95.7 0.97 0.93–1.02 
Birth Registration Dataset. Numerator: live births between 20–36 weeks gestation; Denominator: live births; Preterm live birth 
rate is per 100 live births; Rate ratios are unadjusted; Infant ethnicity is level 1 prioritised; Decile is NZDep2013 
Length of stay by plurality and gestational age 
The mean and median length of stay for pre-term twins were longer than for singleton infants, and were higher 
still for other multiple births (Table 17). The increased length of stay was more noticeable for twins and other 
multiple births at less than 32 weeks gestational age compared with 32–36 weeks gestational age (Figure 16).  
Table 17. Length of hospital stay of preterm babies, by plurality, New Zealand 2010–2014 
Variable  Number: total 2010−2014  
 Length of hospital stay (days)  
 Mean   Median  
Preterm births 
Singleton 16,184 12 7 
Twins 4,473 16 11 
Multiple 184 23 18 
National Minimum Dataset (hospital live births between 20–36 weeks gestation) 
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Figure 16. Length of hospital stay of preterm babies, by plurality and gestation, New Zealand 2010–2014 
 
National Minimum Dataset (hospital live births between 20–36 weeks gestation) 
Distribution by region 
 Pre-term birth rates were close to the New Zealand rate in all DHBs but were significantly higher in Counties 
Manukau, Taranaki, Hawke’s Bay, Hutt Valley, Capital & Coast, Canterbury, West Coast, and Southern DHBs, 
and significantly lower in Northland, Auckland, Waitemata, Whanganui, Wairarapa, Nelson Marlborough and 
South Canterbury DHBs (Figure 17, Table 18).  
Figure 17. Preterm live births, by district health board, New Zealand 2010–2014 
 
Birth Registration Dataset; Numerator: live births between 20–36 weeks gestation; Denominator: live births; Preterm live birth 
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Rate per 100 live 
births 
Rate ratio 95% CI 
Preterm births 
Northland 773 155 6.76 0.90 0.84–0.97 
Waitemata 2,837 567 7.21 0.96 0.93–1.00 
Auckland 2,224 445 6.94 0.93 0.89–0.96 
Counties Manukau 3,278 656 7.69 1.03 0.99–1.06 
Waikato 1,995 399 7.36 0.98 0.94–1.03 
Bay of Plenty 1,071 214 7.42 0.99 0.93–1.05 
Lakes 551 110 7.31 0.98 0.90–1.06 
Tairawhiti 274 55 7.47 1.00 0.89–1.12 
Taranaki 604 121 7.76 1.04 0.96–1.12 
Hawke's Bay 941 188 8.40 1.12 1.05–1.19 
MidCentral 824 165 7.39 0.99 0.92–1.05 
Whanganui 307 61 7.22 0.96 0.86–1.07 
Hutt Valley 782 156 7.85 1.05 0.98–1.12 
Capital & Coast 1,502 300 7.94 1.06 1.01–1.11 
Wairarapa 164 33 6.34 0.85 0.73–0.98 
Nelson Marlborough 532 106 6.72 0.90 0.82–0.97 
South Canterbury 205 41 6.63 0.88 0.77–1.01 
Canterbury 2,437 487 7.92 1.06 1.02–1.10 
West Coast 172 34 8.35 1.11 0.97–1.29 
Southern 1,433 287 8.03 1.07 1.02–1.13 
New Zealand 23,006 4,601 7.50 1.00 0.00 
Birth Registration Dataset; Numerator: live births between 20–36 weeks gestation; Denominator: live births; Preterm live birth 
rate is per 100 live births 
Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 the preterm birth rates in the Midland region were not significantly different from the 
national rate (Table 19). 






Rate per 100 live 
births 
Rate ratio 95% CI 
Preterm births 
Waikato 1,995 399 7.36 0.98 0.94–1.03 
Bay of Plenty 1,071 214 7.42 0.99 0.93–1.05 
Lakes 551 110 7.31 0.98 0.90–1.06 
Tairawhiti 274 55 7.47 1.00 0.89–1.12 
Taranaki 604 121 7.76 1.04 0.96–1.12 
New Zealand 23,006 4,601 7.50 1.00   
Birth Registration Dataset. Numerator: live births between 20–36 weeks gestation; Denominator: live births. Preterm live birth 
rate is per 100 live births 
Regional trends 
The preterm birth rate in all five Midland DHBs has fluctuated since 2000. In Waikato, Bay of Plenty, and 
Lakes DHBs the preterm birth rates has generally been similar to the national rate, while rates in Taranaki have 
decreased since 2000 (Figure 18). In Waikato and Bay of Plenty DHBs from 2000 to 2014 preterm birth rates 
were generally higher for Māori than for European/Other infants, although in Lakes, Tairawhiti, Taranaki DHBs 
differences were less consistent between ethnic groups (Figure 19).  
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Birth Registration Dataset. Numerator: live births between 20–36 weeks gestation; Denominator: live births 
Figure 19. Preterm live births, by ethnicity, Midland DHBs 2000–2014 
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Evidence for good practice for the prevention of spontaneous 
preterm birth 
International guidelines 
Roelens K, Roberfroid D, Ahmadzai N, et al. 2014. Prevention of preterm birth in women at risk: Selected topics. Brussels: 
Belgian Health Care Knowledge Centre (KCE). 
http://kce.fgov.be/sites/default/files/page_documents/KCE_228_Preterm%20birth_Report.pdf 
This Belgian guideline provides recommendations based on current scientific evidence for the secondary and tertiary prevention of spontaneous 
preterm birth. Secondary prevention applies to asymptomatic women at risk with: a history of preterm birth or surgery to the uterine cervix; short 
cervix measured by ultrasound; asymptomatic changes of cervix (e.g. funnelling, effacement or dilation). Tertiary prevention applies to women in 
preterm labour. Recommendations in the guideline are graded according to the GRADE approach. 
National Collaborating Centre for Women’s and Children’s Health. 2011. Multiple pregnancy: the management of twin and 
triplet pregnancies in the antenatal period. London: National Institute for Health and Clinical Excellence. 
https://www.nice.org.uk/guidance/cg129  
Women with twin and triplet pregnancies have a higher risk of preterm birth. This guideline is complementary to the NICE guideline ‘Antenatal 
care: routine care for the healthy pregnant woman’ (NICE clinical guideline 62) and it specifies the additional or different care that women with 
twin or triplet pregnancies should receive. Chapter 8 deals specifically with preterm birth. Following discussion of the research evidence, the 
following recommendations are made regarding the prevention of preterm birth and its associated risks: 
 Be aware that women who have had a previous premature singleton birth are at increased risk 
 Do not use fibronectin testing alone, home uterine activity monitoring, or routine cervical length measuring (with or without fetal 
fibronectin) to predict the risk of spontaneous preterm birth in twin and triplet pregnancies. 
 Do not use the following interventions (either alone or in combination) routinely to prevent spontaneous preterm birth in twin and 
triplet pregnancies: bed rest (either at home or in hospital), intramuscular or vaginal progesterone, cervical cerclage or oral tocolytics 
 Inform women with twin and triplet pregnancies about the benefits of targeted (when birth is imminent) corticosteroids 
 Do not use single or multiple untargeted (routine) courses of corticosteroids and inform women that there is no benefit from using 
untargeted corticosteroids. 
The full guideline, a 2012 evidence update, and the guideline appendices which include the details of the evidence review on which the guidance 
is based (including the evidence tables) can be found at: https://www.nice.org.uk/guidance/cg129/evidence  
Systematic and other reviews from the international literature  
The reviews in this section deal with interventions that may prevent preterm births in general, not interventions for treating women in preterm 
labour or with preterm rupture of membranes. The Cochrane library now contains a large number of reviews relevant to the treatment of such 
women. It is suggested that readers interested in these reviews consult the Cochrane library’s pregnancy and childbirth reviews that are listed 
under the headings: Pre-labour rupture of membranes, and Preterm labour, at: 
http://www.cochranelibrary.com/app/content/browse/page/?context=topic/Pregnancy%20%26%20childbirth  
In addition, the following review, which provides an overview and summary of Cochrane reviews relevant to reducing the risk of preterm birth, 
may be useful. 
Piso B, Zechmeister-Koss I, Winkler R. 2014. Antenatal interventions to reduce preterm birth: an overview of Cochrane 
Systematic Reviews. BMC Res Notes 7 265 http://www.ncbi.nlm.nih.gov/pubmed/24758148 
 This review of Cochrane reviews includes 56 Cochrane reviews. Three interventions have been shown in Cochrane reviews to increase the 
incidence of preterm birth (PTB): metronidazole treatment in pregnant women with asymptomatic trichomoniasis, vitamin C, and oestrogen 
supplementation. The latter is no longer in use due to its other negative effects. Regarding interventions shown to have positive effects in 
preventing PTB, the strongest evidence is for smoking cessation programmes, which have been shown to reduce low birthweight as well as PTB, 
and the treatment of clinical hypothyroidism in pregnancy with levothyroxine, which is standard practice. Cervical cerclage has been shown to 
reduce PTBs in women at high risk of PTB and progestogen reduces PTB in women with a previous history of PTB, but not in women with multiple 
pregnancies or at risk of PTB for other reasons. For women with a high risk of developing pre-eclampsia, two interventions reduced PTB risk, and 
also had a positive effect on other pregnancy outcomes: low dose aspirin after 12 weeks’ gestation and calcium supplementation, although the 
latter also led to a small increase in the risk of HELLP syndrome. Calcium supplementation also seems to be beneficial for women with low dietary 
calcium intake, but not for the general population of pregnant women. For women in developing countries and undernourished women, rates of 
PTB could be reduced through advice to increase protein and energy intake and zinc supplementation. 
Sosa Claudio G, Althabe F, Belizán José M, et al. 2015. Bed rest in singleton pregnancies for preventing preterm birth. 
Cochrane Database of Systematic Reviews (3) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003581.pub3/abstract 
It is common for bed rest, either at home or in hospital, to be recommended for the prevention of preterm birth in women at high risk (for 
example because of a previous preterm birth or because of a short cervical length as measured by ultrasound). This review aimed to evaluate the 
effectiveness of prescription of bed rest for preventing preterm birth, using data from randomised, cluster-randomised, and quasi-randomised 
controlled trials that assessed clinical outcomes for women and their babies. There were two studies that met the review’s inclusion criteria. One 
was unsuitable or meta-analysis as its data combined single and multiple pregnancies. This study, considered to be at low risk of selection, 
performance, detection and attrition bias, reported no differences in any maternal or perinatal outcomes. The other study, which provided the 
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data that were included in the meta-analysis, involved 1266 women. There were 432 women who were prescribed bed rest at home and 834 
women who received either a placebo (412 women) or no intervention (422 women). There was little difference between the intervention and 
control groups in preterm birth before 37 weeks: 7.9% in the intervention group vs. 8.5% in the control group; risk ratio 0.92, 95% CI 0.62 to 1.37. 
There were no other results reported for any of the other primary or secondary outcomes. The review authors concluded that there is no evidence 
to either support or refute the use of bed rest, at home or in hospital, to prevent preterm birth. They stated that bed rest could have adverse 
effects on women and their families (such as deep vein thrombosis or the cost of care for other children) and increase health system costs so 
clinicians need to discuss the pros and cons of bed rest with women at increased risk of preterm birth. 
Sangkomkamhang Ussanee S, Lumbiganon P, Prasertcharoensuk W, et al. 2015. Antenatal lower genital tract infection 
screening and treatment programs for preventing preterm delivery. Cochrane Database of Systematic Reviews (2). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006178.pub3/abstract 
Genital tract infection is associated with preterm birth; therefore it is possible that screening women for infection during pregnancy and treating 
identified infections could reduce the numbers of babies born prematurely. The authors of this review searched for all published and unpublished 
RCTs in any language that compared methods of antenatal lower genital tract infection screening with no screening, to assess the effectiveness 
of antenatal lower genital tract infection screening and treatment programs for reducing preterm birth and subsequent morbidity. They identified 
one study meeting their inclusion criteria (4155 women at <20 weeks’ gestation). The 2058 women in the intervention group received infection 
screening and treatment for bacterial vaginosis, trichomonas vaginalis and candidiasis while the 2097 women in the control group also received 
screening but were not informed of the results and received only routine antenatal care. The women in the intervention group had a significantly 
lower rate of preterm birth: 3% vs. 5%, risk ratio (RR) of 0.55, 95% CI 0.41 to 0.75. The evidence for this outcome was graded as of moderate 
quality. There was a significantly lower incidence of preterm low birthweight (≤ 2500g) infants, and very low birthweight (≤ 1500g) infants, in the 
intervention group compared to the control group: RR 0.48, 95% CI 0.34 to 0.66 and RR 0.34; 95% CI 0.15 to 0.75, respectively; both graded as 
moderate quality evidence. The authors of this study reported that, based on a subset of costs for preterm births <1900g, for each of those 
preterm births prevented, EUR 60,262 would be saved. The review authors concluded that there was evidence from one trial that infection 
screening and treatment programs for pregnant women at <20 weeks’ gestation reduce rates of preterm birth and preterm low birthweight and 
that such programs are cost saving when used to prevent preterm birth. They stated that future trials should evaluate the effects of different 
types of infection screening programs. 
Urquhart C, Currell R, Harlow F, et al. 2015. Home uterine monitoring for detecting preterm labour. Cochrane Database of 
Systematic Reviews (1) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006172.pub3/abstract 
Home uterine activity monitoring (HUAM) is intended to permit early detection of increased contraction frequency, and early intervention with 
tocolytic drugs to inhibit labour and prolong pregnancy. This review aimed to assess the effectiveness of HUAM for improving outcomes for 
women at high risk of preterm birth, and their babies. It included 15 RCTs, 13 of which contributed data. Women using HUAM were less likely to 
experience preterm birth at less than 34 weeks (risk ratio (RR) 0.78; 95% CI 0.62 to 0.99; three studies, n = 1596, fixed-effect analysis, GRADE high) 
but a significant difference was not evident in a sensitivity analysis which restricted analysis to studies at low risk of bias based on study quality 
(RR 0.75, 95% CI 0.57 to 1.00, one study, 1292 women). There was no significant difference in the rate of perinatal mortality (RR 1.22, 95% CI 0.86 
to 1.72, two studies, n = 2589, quality of evidence GRADE low). There was no significant difference in the number of preterm births at less than 
37 weeks (average RR 0.85, CI 0.72 to 1.01, eight studies, n = 4834, random-effects, T² = 0.03, I² = 68%, GRADE very low). Infants born to women 
using HUAM were less likely to be admitted to neonatal intensive care unit. Women using HUAM made more unscheduled antenatal visits and 
were more likely to have prophylactic tocolytic drug therapy (low to moderate evidence). The review authors concluded that HUAM has no impact 
on maternal and perinatal outcomes such as incidence of preterm birth or perinatal mortality but it may result in fewer admissions to neonatal 
intensive care, more unscheduled antenatal visits and more tocolytic treatment. 
Rafael Timothy J, Berghella V, Alfirevic Z. 2014. Cervical stitch (cerclage) for preventing preterm birth in multiple 
pregnancy. Cochrane Database of Systematic Reviews (9) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009166.pub2/abstract 
Cervical cerclage is a surgical procedure involving placing a stitch round the uterine cervix with the aim of preventing cervical shortening and 
opening thereby reducing the risk of preterm birth. This review included five RCTs comparing cervical cerclage with other preventive therapy 
(such as progesterone) in both single and multiple pregnancies (1577 women in total). The final analysis included 128 women (122 with twins and 
six with triplets). Two trials (73 women) assessed history-indicated cerclage and three assessed ultrasound-indicated cerclage. These five trials 
were considered to be of average to above-average quality. Three of them were at unclear risk regarding selection and detection biases. When 
outcomes for cerclage were pooled together for all indications and compared with no cerclage, there was no statistically significant differences 
in perinatal deaths (19.2% versus 9.5%, risk ratio (RR) 1.74, 95% CI 0.92 to 3.28, five trials, n = 262), serious neonatal morbidity (15.8% versus 
13.6%; average RR 0.96, 95% CI 0.13 to 7.10, three trials, n = 116), or composite perinatal death and neonatal morbidity (40.4% versus 20.3%; 
average RR 1.54, 95% CI 0.58 to 4.11, three trials, n = 116). There were also no significant differences between the cerclage and no cerclage groups 
for preterm birth <34 weeks (average RR 1.16, 95% CI 0.44 to 3.06, four trials, n = 83), preterm birth <35 weeks (average RR 1.11, 95% CI 0.58 to 
2.14, four trials, n = 83), low birthweight < 2500 g (average RR 1.10, 95% CI 0.82 to 1.48, four trials, n = 172), very low birthweight <1500 g 
(average RR 1.42, 95% CI 0.52 to 3.85, four trials, n = 172), and respiratory distress syndrome (average RR 1.70, 95% CI 0.15 to 18.77, three trials, 
n = 116), caesarean section (elective and emergency) (RR 1.24, 95% CI 0.65 to 2.35, three trials, n = 77) and maternal side-effects (RR 3.92, 95% 
CI 0.17 to 88.67, one trial, n = 28). The review authors concluded that there is no evidence that cervical cerclage in women with multiple gestations 
is effective for preventing preterm birth, reducing perinatal deaths or reducing neonatal morbidity.  
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Dodd Jodie M, Jones L, Flenady V, et al. 2013. Prenatal administration of progesterone for preventing preterm birth in 
women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews (7) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004947.pub3/abstract 
This review aimed to assess the benefits and harms of progesterone for the prevention of preterm birth in women considered to be at increased 
risk, and their infants. It included 36 RCTs (8523 women and 12,515 infants). 
Progesterone versus placebo for women with a past history of spontaneous preterm birth 
Progesterone was associated with a statistically significant reduction in the risk of perinatal mortality (six studies; 1453 women; risk ratio (RR) 0.50, 
95% CI 0.33 to 0.75), preterm birth <34 weeks (five studies; 602 women; average RR 0.31, 95% CI 0.14 to 0.69), infant birthweight <2500 g (four 
studies; 692 infants; RR 0.58, 95% CI 0.42 to 0.79), use of assisted ventilation (three studies; 633 women; RR 0.40, 95% CI 0.18 to 0.90), necrotising 
enterocolitis (three studies; 1170 women; RR 0.30, 95% CI 0.10 to 0.89), neonatal death (six studies; 1453 women; RR 0.45, 95% CI 0.27 to 0.76), 
admission to neonatal intensive care unit (three studies; 389 women; RR 0.24, 95% CI 0.14 to 0.40), preterm birth < 37 weeks (10 studies; 1750 
women; average RR 0.55, 95% CI 0.42 to 0.74) and a statistically significant increase in pregnancy prolongation in weeks (one study; 148 women; 
mean difference (MD) 4.47, 95% CI 2.15 to 6.79). For most of the outcomes examined there were no differential effects seen in terms of route of 
administration, time of commencing therapy and dose of progesterone. 
Progesterone versus placebo for women with a short cervix identified on ultrasound 
Progesterone was associated with a statistically significant reduction in the risk of preterm birth <34 weeks (two studies; 438 women; RR 0.64, 
95% CI 0.45 to 0.90), preterm birth <28 weeks' gestation (two studies; 1115 women; RR 0.59, 95% CI 0.37 to 0.93) and increased risk of urticaria 
in women when compared with placebo (one study; 654 women; RR 5.03, 95% CI 1.11 to 22.78). It was not possible to assess the effect of route 
of progesterone administration, gestational age at commencing therapy, or total cumulative dose of medication. 
Progesterone versus placebo for women with a multiple pregnancy 
Progesterone was associated with no statistically significant differences for any of the reported outcomes. 
Progesterone versus no treatment/placebo for women following presentation with threatened preterm labour 
Progesterone, was associated with a statistically significant reduction in the risk of infant birthweight <2500 g (one study; 70 infants; RR 0.52, 95% 
CI 0.28 to 0.98). 
Progesterone versus placebo for women with 'other' risk factors for preterm birth 
Progesterone, was associated with a statistically significant reduction in the risk of infant birthweight <2500 g (three studies; 482 infants; RR 0.48, 
95% CI 0.25 to 0.91). 
The review authors concluded that the use of progesterone is associated with infant health benefits when it is administered to women considered 
to be at increased risk of preterm birth because of either a previous preterm delivery or a short cervix identified on ultrasound, but there is little 
information available on longer-term infant and child outcomes, the assessment of which is continues to be a priority. They stated that further 
trials are needed to determine the optimal timing, mode of administration and dose of progesterone for women at increased risk of preterm 
birth. 
Abdel-Aleem H, Shaaban OM, Abdel-Aleem MA. 2013. Cervical pessary for preventing preterm birth. Cochrane Database of 
Systematic Reviews 5 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007873.pub3/abstract 
Among the risk factors for preterm birth are cervical incompetence and multiple pregnancy. The use of a cervical pessary has been tried as a 
simple non-invasive alternative to cervical cerclage (an invasive cervical stitch procedure necessitating anaesthesia). This review included one RCT 
of cervical pessary vs. expectant management in women with a short cervix (≤ 25mm) who were between 18 to 22 weeks of pregnancy. This trial 
involved a total of 385 women. The use of cervical pessary (192 women) was associated with a statistically significantly decrease in the incidence 
of spontaneous preterm birth <37 weeks' gestation compared with expectant management (22% versus 59%; respectively, risk ratio (RR) 0.36, 
95% CI 0.27 to 0.49) and <34 weeks’ gestation (6% and 27% respectively, RR 0.24; 95% CI 0.13 to 0.43). Mean gestational age at delivery was 
37.7±2 weeks in the pessary group and 34.9±4 weeks in the expectant group. Women in the pessary group used less tocolytics (RR 0.63; 95% CI 
0.50 to 0.81) and corticosteroids (RR 0.66; 95% CI 0.54 to 0.81) than the expectant group. Vaginal discharge was more common in the pessary 
group (RR 2.18; 95% CI 1.87 to 2.54). Among the pessary group, 27 women needed pessary repositioning without removal and there was one 
case of pessary removal. Ninety-five per cent of women in the pessary group would recommend this intervention to other people. Neonatal 
paediatric care admission was reduced in the pessary group compared to the expectant group (RR 0.17; 95% CI 0.07 to 0.42). The review authors 
concluded that one well-designed RCT had showed a beneficial effect of cervical pessary in reducing preterm birth in women with a short cervix, 
but that more research in women with different risk factors (e.g. multiple pregnancy) and in different settings is needed. 
Brocklehurst P, Gordon A, Heatley E, et al. 2013. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane 
Database of Systematic Reviews 1 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000262.pub4/abstract 
Bacterial vaginosis is an overgrowth of anaerobic bacteria in the vagina and a lack of the normal lactobacillary flora. Having this condition in 
pregnancy has been associated with adverse perinatal outcomes, particularly preterm birth (PTB). This review sought to assess the effects of 
antibiotic treatment of bacterial vaginosis in pregnancy. It included 21 good quality trials involving 7847 women diagnosed with bacterial 
vaginosis or intermediate vaginal flora. Antibiotic treatment given to women with bacterial vaginosis in pregnancy was found to be effective at 
eradicating bacterial vaginosis (average risk ratio (RR) 0.42; 95% CI 0.31 to 0.56; 10 trials, 4403 women; random-effects, T² = 0.19, I² = 91%) and 
it also reduced the risk of late miscarriage (RR 0.20; 95% CI 0.05 to 0.76; two trials, 1270 women, fixed-effect, I² = 0%). It did not reduce the risk 
of PTB at <37 weeks (average RR 0.88; 95% CI 0.71 to 1.09; 13 trials, 6491 women; random-effects, T² = 0.06, I² = 48%), or the risk of preterm pre 
labour rupture of membranes (RR 0.74; 95% CI 0.30 to 1.84; two trials, 493 women). It did increase the risk of side-effects sufficient to stop or 
change treatment (RR 1.66; 95% CI 1.02 to 2.68; four trials, 2323 women, fixed-effect, I² = 0%). New evidence for this updated review indicated 
that treatment before 20 weeks' gestation did not reduce the risk of PTB at <37 weeks (average RR 0.85; 95% CI 0.62 to 1.17; five trials, 4088 
women; random-effects, T² = 0.06, I² = 49%). In women with previous PTB, treatment did not change the risk of PTB in the current pregnancy 
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(average RR 0.78; 95% CI 0.42 to 1.48; three trials, 421 women; random-effects, T² = 0.19, I² = 72%). In women with abnormal vaginal flora 
(intermediate flora or bacterial vaginosis) evidence from two trials (894 women) suggested that treatment may reduce the risk of PTB at < 37 
weeks (RR 0.53; 95% CI 0.34 to 0.84). A few trials compared different antibiotics, different routes of administration, or different antibiotic doses. 
The differences found were either not statistically significant, or statistically significant but not clinically significant. The review authors concluded 
that while antibiotic treatment can eradicate bacterial vaginosis in pregnancy, there is little evidence that screening and treating all pregnant 
women with bacterial vaginosis will prevent PTB or its consequences. They noted that limited evidence from two studies indicated that treatment 
of women with abnormal flora was associated with a 47% reduction in preterm births. 
Berghella V, Baxter JK, Hendrix NW. 2013. Cervical assessment by ultrasound for preventing preterm delivery. Cochrane 
Database of Systematic Reviews 1 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007235.pub3/abstract 
This review aimed to assess the effectiveness of antenatal management based on transvaginal ultrasound measurement of cervical length (TVU 
CL) screening. A short cervical length is associated with a higher risk of preterm birth. There were five RCTs deemed eligible for inclusion in the 
review (507 women). There were three including singleton gestations with preterm labor (PTL); one including singleton gestations with preterm 
premature rupture of membranes (PPROM); and one including twin gestations with or without PTL. The three trials of singleton gestations with 
PTL included 290 women, randomised to either knowledge of TVU CL results (147 women) or no knowledge (143 women). Knowledge of TVU CL 
results was associated with a non-significant decrease in PTB at <37 weeks (22.3% vs. 34.7%, respectively; average risk ratio 0.59, 95% CI 0.26 to 
1.32; two trials, 242 women) and at <34 weeks (6.9% vs. 12.6%; RR 0.55, 95% CI 0.25 to 1.20; three trials, 256 women). Delivery occurred at a later 
gestational age in the knowledge versus no knowledge groups (mean difference (MD) 0.64 weeks, 95% CI 0.03 to 1.25; three trials, 290 women). 
For all other outcomes with available data (PTB at <34 or <28 weeks; birthweight <2500 grams; perinatal death; maternal hospitalization; tocolysis; 
and steroids for fetal lung maturity), there was no evidence of a difference between groups. The trial of singleton gestations with PPROM (n = 
92) had as its primary outcome measure TVU CL safety in this population, rather than its effect on management. There was no evidence of a 
difference between the TVU CL and no TVU CL groups in incidence of maternal and neonatal infections. In the trial of twin gestations with or 
without PTL (n = 125), there was no evidence of a difference in PTB at less than 36, 34, or 30 weeks, gestational age at delivery, and other perinatal 
and maternal outcomes between the TVU CL and the no TVU CL groups. Life-table analysis showed significantly less PTB at <35 weeks in the TVU 
CL group compared with the no TVU CL group (P = 0.02). the review authors concluded that there is insufficient evidence to recommend routine 
screening of either symptomatic or asymptomatic pregnant women with TVU CL. They offered some suggestions for further research. 
Likis FE, Andrews JC, Woodworth AL, et al. 2012. Progestogens for prevention of preterm birth. Comparative effectiveness 
review No. 74. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract no. 290-2007-10065-I). 
AHRQ Publication No. 12-EHC105-EF. Rockville MD: Agency for Healthcare Research and Quality. 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068098/ 
This comprehensive systematic review addressed six key questions related to the use of progestogens for the prevention of preterm birth. The 
review included 70 publications published from January 1996 to October 2010, plus eight RCTs published through to October 2011. Sixteen RCTs 
contributed data for meta-analyses. Results from meta-analyses are presented as odds ratios from Bayesian models. In women with a previous 
preterm birth and a singleton pregnancy, progestogen treatment decreased the risk of preterm birth: 4 RCTs, odds ratio (OR) 0.66, Bayesian 
credible interval (BCI) 0.53 to 0.82, corresponding to an absolute risk reduction of between 0 and 26% across studies. In this population, 
progestogen also reduced rates of neonatal death: OR 0.52, 95% BCI 0.25 to 0.96. Results of two trials of progestogen administration in women 
with short cervical length indicated an absolute risk reduction for preterm birth of between 8.8 and 15.2%. There was inconsistent, or absence of, 
evidence for the benefit of progestogen for other maternal, fetal or neonatal outcomes. For multiple gestations, there was no evidence that 
progestogen prevents prematurity (preterm birth OR 1.18, 95% BCI 0.79 to 1.39), enhances birthweight, or improves other outcomes. There was 
no definitive evidence that maternal factors, such as number or severity of previous preterm births, modify the effects of progestogen treatment. 
No reducing the effects of preterm birth, but no RCTs directly compared routes of administration or doses, but across 15 RCTs, all formulations 
were effective at reducing the risk of preterm birth, but not the risk of neonatal mortality. There was insufficient evidence to assess whether time 
of initiation or adherence to treatment affected outcomes. Research has not assessed factors associated with adherence to treatment, nor long 
term maternal and infant effects. The main conclusions of this review were that progestogens prevent preterm birth when used in singleton 
pregnancy where the mother has had a previous preterm birth or has a short cervical length (moderate to low quality evidence), but that there is 
insufficient evidence to determine whether this intervention has the ultimately desired outcome of preventing morbidity and promoting normal 
childhood development. There was moderate quality evidence suggesting that progestogens are not effective for preventing preterm birth in 
multiple gestations. 
Khanprakob T, Laopaiboon M, Lumbiganon P, et al. 2012. Cyclo-oxygenase (COX) inhibitors for preventing preterm labour. 
Cochrane Database of Systematic Reviews (10) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007748.pub2/abstract 
Prostaglandins are believed to play an important role in the birth process through their action on the smooth muscle of the uterus. Cyclo-
oxygenase (COX) is an enzyme in the pathway of prostaglandin synthesis. COX inhibitors hinder prostaglandin production by inhibiting the action 
of COX. This review aimed to assess the effectiveness and safety of COX inhibitors for preventing preterm labour in high risk pregnant women. It 
included one small RCT evaluating Rofecoxib, involving 98 women. This trial did not report on the outcome of preterm labour. Rofecoxib use was 
associated with an increased risk of preterm birth and preterm premature rupture of membranes. It was associated with a greater risk of 
oligohydramnios (deficiency of amniotic fluid) and low fetal urine production but these effects were reversible with cessation of treatment. There 
were no differences between the intervention and control groups in the number of women who discontinued treatment before 32 weeks’ 
gestation and no differences in neonatal morbidities or admission to a neonatal intensive care unit. There were no perinatal deaths or maternal 
adverse effects in either group. The review authors concluded that there was little evidence regarding the use of COX inhibitors to prevent preterm 
labour and stated that the existing data was insufficient to make any recommendations about the use of COX inhibitors in practice for the 
prevention of preterm labour, and that further research is needed. 
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Khianman B, Pattanittum P, Thinkhamrop J, et al. 2012. Relaxation therapy for preventing and treating preterm labour. 
Cochrane Database of Systematic Reviews (8) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007426.pub2/abstract 
Maternal psychological stress is associated with adverse pregnancy outcomes and may play a role in causing preterm labour (PTL). This review 
aimed to assess the effectiveness of relaxation therapies for preventing or treating PTL and preventing preterm birth (PTB). The review authors 
identified 11 RCTs with a total of 833 women, but the results of the review are based on single studies with small numbers of participants. Most 
of the studies were of limited quality and did not report adequately on sequence generation, allocation concealment or blinding. No studies 
assessed PTL or PTB as the primary outcome. For women not in PTL, one study found benefits of relaxation for maternal stress (Anxiety Stress 
Scale) at 26 to 29 weeks gestation (mean difference (MD) −7.04; 95% CI −13.91 to −0.17).There were also other beneficial effects of relaxation 
including baby birthweight (MD 285.00 g; 95% CI 76.94 to 493.06); type of delivery; (vaginal delivery; risk ratio (RR) 1.52; 95% CI 1.13 to 2.04), 
(caesarean section; RR 0.38; 95% CI 0.19 to 0.78); maternal anxiety (MD −15.79; 95% CI −18.33 to −13.25); and stress (MD −13.08; 95% CI −15.29 
to −10.87) when relaxation therapy was used together with standard treatment. For women not in PTL, a single study found no difference between 
the intervention and control groups in the main outcome of PTB (RR 0.95; 95% CI 0.57 to 1.59). A fixed-effect model from two included studies 
found a non-significant mean difference in birthweight in grams: MD −5.68; (95% CI −174.09 to 162.74). The review authors concluded that there 
was some evidence that relaxation during pregnancy reduces anxiety and stress but no evidence that it reduces PTL or PTB. They stated that the 
results of the review should be interpreted with caution due to the limited quality of the studies included.  
Alfirevic Z, Stampalija T, Roberts D, et al. 2012. Cervical stitch (cerclage) for preventing preterm birth in singleton 
pregnancy. Cochrane Database of Systematic Reviews 4 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008991.pub2/abstract 
Cervical cerclage involves placing a suture (stitch) around the neck of the womb (the cervix) to provide mechanical support to the cervix and keep 
it closed, thereby reducing the risk of preterm birth. This review aimed to determine whether the use of cervical stitch in singleton pregnancy at 
high risk of pregnancy loss because of a woman’s history and/or a finding of a short cervix on ultrasound and/or physical examination improves 
subsequent obstetric care and fetal outcome. Trials were eligible for inclusion in the review if they compared cerclage with either no treatment 
or an alternative intervention. Twelve trials, involving 3328 women, were included. When cerclage was compared to no treatment, there was a 
significant difference in preterm births (average RR 0.80; 95% CI 0.69 to 0.95; nine trials, 2898 women) but no statistically significant difference in 
perinatal deaths (8.4% versus 10.7%) (risk ratio (RR) 0.78; 95% CI 0.61 to 1.00; eight trials, 2391 women) or neonatal morbidity (9.6% versus 10.2%) 
(RR 0.95; 95% CI 0.63 to 1.43; four trials, 818 women). Cervical cerclage was associated with higher rates of maternal side effects (vaginal discharge 
and bleeding, pyrexia) (average RR 2.25; 95% CI 0.89 to 5.69; three trials, 953 women) and significantly higher caesarean section rates (RR 1.19; 
95% CI 1.01 to 1.40; 8 trials, 2817 women). There were no important differences seen across all pre-specified clinical subgroups (history-indicated, 
ultrasound indicated). One study that compared cerclage with weekly intramuscular injections of 17 α-hydroxyprogesterone caproate in women 
with a short cervix (detected via ultrasound) didn’t find any differences in obstetrical and neonatal outcomes between the two strategies. Two 
studies comparing cerclage based on previous history with cerclage only if the cervix was found to be short on transvaginal ultrasound found no 
differences in any of the primary or secondary outcomes. The authors concluded that, compared to no treatment, cervical cerclage reduces the 
incidence of preterm birth in women at risk of recurrent preterm birth but doesn’t produce statistically significant reductions in perinatal mortality 
or neonatal morbidity and does increase the likelihood of caesarean section. They stated that decisions on how best to minimise recurrent preterm 
birth should be personalised based on the clinical team’s skill and expertise and the woman’s informed choice. 
Davey M, Watson L, Rayner J, et al. 2011. Risk scoring systems for predicting preterm birth with the aim of reducing 
associated adverse outcomes. Cochrane Database of Systematic Reviews (11) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004902.pub4/abstract 
A fundamental aim of antenatal care is to identify pregnancies at higher than average risk of adverse outcomes. Many scoring systems have been 
devised to try and classify the risk of poor pregnancy outcomes, including preterm birth. Preterm birth risk assessment tools have included items 
such as maternal age, weight, height, marital status, smoking, plurality, previous low birthweight baby, threatened miscarriage and previous 
stillbirth. This review aimed to determine whether the use of a risk screening tool designed to predict preterm birth (together with appropriate 
interventions as indicated) reduces the incidence of preterm birth and very preterm birth, and the associated adverse outcomes. Despite extensive 
searching the review authors did not identify any trials of risk scoring systems to prevent preterm birth so they concluded that the role of scoring 
systems in the prevention of preterm birth is unknown. 
Whitworth M, Quenby S, Cockerill R, et al. 2011. Specialised antenatal clinics for women with a pregnancy at high risk of 
preterm birth (excluding multiple pregnancy) to improve maternal and infant outcomes. 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006760.pub2/abstract 
Having had a previous preterm delivery is a strong predictor of preterm birth. For this reason, specialised clinics for pregnant women with a 
history of previous preterm birth have been advocated as means of improving outcomes for these women and their babies. This review aimed to 
assess the evidence regarding the value of such clinics compared to standard antenatal clinics for pregnant women at high risk of preterm delivery. 
It included three trials involving 3400 women, all carried out in the US. All of them were focussed on specialised clinics for high-risk women and 
had primary outcomes of gestational age at delivery, preterm delivery, or both, but the interventions offered differed between the trials. There 
was little data on the pre-specified outcomes for the review. For most outcomes only a single study provided data and there was insufficient 
statistical power to detect differences between groups. Therefore there was no clear evidence that specialised antenatal clinics reduce rates of 
preterm births. The review authors noted that specialised clinics are now an accepted part of care in many settings and so it may not now be 
possible to carry out further RCTs. They suggested that future research should include psychological outcomes and aim to determine which 
aspects of service provision women prefer. 
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INFANT MORTALITY AND SUDDEN UNEXPECTED DEATH 
IN INFANCY 
Introduction 
Infant mortality, the number of deaths of infants aged less than 365 days per 1,000 live births, is often used as a 
barometer of the social wellbeing of a country.13 New Zealand’s infant mortality rates are higher than the OECD 
average and in 2011 New Zealand’s rate was ranked fifth highest out of 36 OECD countries.14 Mortality rates in 
the first year of life are much higher than at any other time during childhood or adolescence.15 During 2012, a 
total of 256 New Zealand infants were registered as having died prior to their first birthday, which equates to an 
infant mortality rate of 4.2 per 1,000 the lowest ever recorded in New Zealand.16  
New Zealand’s infant mortality rates have declined during the past 40 years, although the rate of decline has 
been slower in more recent years, with rates falling from 28.4 per 1,000 in 1952, to 15.6 in 1972, 7.2 in 1992, 
5.5 in 2002 and 4.2 in 2012.16 Infant mortality rates are generally higher for Pacific and Māori than 
European/Other, for males, for babies of very young mothers, and for babies from the most deprived areas.17 
However total infant mortality rates are of limited utility in guiding population health interventions, as the most 
common causes of mortality differ markedly according to the age of the infant. Interventions aimed at reducing 
New Zealand’s infant mortality rates therefore need to be based on an understanding of these component causes. 
It is noteworthy that the number of deaths from sudden unexpected death in infancy (SUDI) has fallen from 
2009 (n= 60) to 2013 (n= 38). The following section uses information from the National Mortality Collection to 
review neonatal, post neonatal and total infant mortality, as well as SUDI rates since 1990. The latest year for 
which data are available from the Ministry of Health’s Mortality Collection is 2012. 
Data source and methods 
Indicators    
 Infant mortality   
 Neonatal mortality   
 Post neonatal mortality   
 Sudden Unexpected Death in Infancy (SUDI)  
Data sources    
Numerator:  National Mortality Collection  
Denominator:  Birth Registration Dataset (live births only) 
Definition 
All deaths in the first year of life. Cause of death was the main underlying cause of death. Refer to Appendix 6 for the 
corresponding codes. 
Infant mortality  Death of a live born infant prior to 365 days of life per 1,000 live births  
Neonatal mortality:   Death of a live-born infant before 28 completed days after birth per 1,000 live births 
Post neonatal mortality:  Death of a live-born infant from 28 completed days and before the first year of life is completed 
per 1,000 live births 
Sudden Unexpected Death in Infancy (SUDI): Death of a live born infant before the first year of life is completed (<365 days of 
life) where the cause of death is Sudden Infant Death Syndrome (SIDS), accidental suffocation or 
strangulation in bed, inhalation of gastric contents or food, or ill-defined or unspecified causes. 
Rate is per 1,000 live births 
Notes on interpretation 
Note 1: SUDI and SIDS: SIDS is defined as “the sudden unexpected death of an infant <1 year of age, with onset of the fatal 
episode apparently occurring during sleep, and that remains unexplained after a thorough investigation, including performance 
of a complete autopsy and review of the circumstances of death and the clinical history”.18 Issues have emerged with defining 
SIDS, possibly as the result of pathologists and coroners becoming increasingly reluctant to label a death as SIDS in the context 
of equivocal death scene findings (e.g. death of an infant who had been co-sleeping with a parent who had recently consumed 
alcohol.18 This has resulted in a fall in the number of SIDS deaths, and a rise in the number of deaths attributed to 
“suffocation/strangulation in bed” or “unspecified causes”. 
Note 2: Two additional codes were added to the SUDI indicator in 2013 (W78: Inhalation of gastric contents; and W79: 
Inhalation and ingestion of food causing obstruction of the respiratory tract) to ensure consistency with the Child and Youth 
Mortality Review Committee’s SUDI reporting. As a result, the rates in this section are not directly comparable with those 
presented in NZCYES reports prior to 2013.  
Note 3: See Appendix 3 for an overview of the National Mortality Collection. 
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National trends and distribution  
The number of infant deaths in New Zealand declined from 507 in 1990 to 294 deaths in 2012. From 1990 to 
2012 there was an overall fall in infant mortality rates from 8.43 deaths per 1,000 live births in 1990 to 4.74 
deaths per 1,000 live births in 2012 (the lowest recorded rate). Most of the fall in infant mortality rates occurred 
between 1990 and 1998, with a further slight fall to 2005, and there has been no significant difference in rates 
from year to year since 2005. From 1996 this fall was more marked for post-neonatal than for neonatal mortality 
rates (Figure 20).  
The fall in infant mortality rates was observed in all ethnic groups and was more marked for Māori, Pacific and 
Asian/Indian infants than for European/Other. Infant mortality rates remain higher for Māori and Pacific infants 
compared with European/Other and Asian/Indian infants, however the disparity in rates has lessened over time. 
The fall in rates in all ethnic groups was more marked for post-neonatal than for neonatal mortality (Figure 21). 
Figure 20. Infant deaths, by type, New Zealand 1990–2012 
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; * 2012 is a single year of data 
Figure 21. Total infant, neonatal, and post neonatal mortality, by ethnicity, New Zealand 1996–2012 
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Distribution by cause 
Between 2008 and 2012 most infant deaths and most neonatal deaths were the result of congenital anomalies, 
extreme prematurity and other perinatal conditions including intrauterine or birth asphyxia. The most common 
underlying cause of post-neonatal death was sudden unexpected death in infancy (SUDI) which is discussed 
further on page 60 (Table 20, Table 21).  
Table 20. Infant mortality, by main underlying cause of death, New Zealand 2008−2012  










Congenital anomalies 373 75 1.17 22.8 
Extreme prematurity 264 53 0.83 16.2 
Intrauterine hypoxia or birth asphyxia 26 5 0.08 1.6 
Other perinatal conditions 464 93 1.46 28.4 
SUDI: SIDS 140 28 0.44 8.6 
SUDI: suffocation or strangulation in bed 125 25 0.39 7.7 
SUDI: all other types 17 3 0.05 1.0 
Injury or poisoning 32 6 0.10 2.0 
Other causes 192 38 0.60 11.8 
Total 1,633 327 5.14 100.0 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset 
Table 21. Neonatal and post neonatal mortality by main underlying cause of death, New Zealand 2008−2012 










Extreme prematurity 264 53 0.83 26.1 
Congenital anomalies: chromosomal 39 8 0.12 3.9 
Congenital anomalies: CNS 50 10 0.16 5.0 
Congenital anomalies: CVS 60 12 0.19 5.9 
Congenital anomalies: other 110 22 0.35 10.9 
Intrauterine hypoxia or birth asphyxia 26 5 0.08 2.6 
Other perinatal conditions 388 78 1.22 38.4 
SUDI: SIDS 10 2 0.03 1.0 
SUDI: All other types 20 4 0.06 2.0 
Injury or poisoning 5 1 0.02 0.5 
Other causes 38 8 0.12 3.8 
Total 1,010 202 3.18 100.0 
Post neonatal mortality 
SUDI: SIDS 130 26 0.41 20.9 
SUDI: suffocation or strangulation in bed 106 21 0.33 17.0 
SUDI: All other types 16 3 0.05 2.6 
Congenital anomalies: chromosomal 26 5 0.08 4.2 
Congenital anomalies: CNS 7 1 0.02 1.1 
Congenital anomalies: CVS 47 9 0.15 7.5 
Congenital anomalies: other 34 7 0.11 5.5 
Other perinatal conditions 76 15 0.24 12.2 
Injury or poisoning 27 5 0.09 4.3 
Other causes 154 31 0.48 24.7 
Total 623 125 1.96 100.0 
Infant mortality total  1,633 327 5.14   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset 
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Distribution by demographic factors 
There were disparities in infant mortality rates by NZDep2013 score, ethnicity, maternal age, infant gender and 
gestational age at birth. Between 2008 and 2012 there was a clear social gradient in infant mortality rates, with 
significantly higher rates in areas with higher NZDep2013 scores (deciles 5–10) compared with the lowest 
NZDep scores (deciles 1–2). Mortality rates were significantly higher for Māori and Pacific infants, and 
significantly lower for Asian/Indian infants, compared with European/Other infants. Mortality rates for infants 
born to mothers aged under 30 years and over 35 years were significantly higher than for infants born to mothers 
aged 30–34 years. The highest difference was observed for mothers aged under 20 years. Mortality rates were 
significantly higher for male compared with female infants. The greatest disparity was observed by gestational 
age. The mortality rate for infants born before 37 weeks gestation was 18 times higher than the rate for infants 
born at or after 37 weeks and this difference was statistically significant (Table 22). Similar disparities were 
observed for neonatal mortality rates, although the higher rate for mothers aged 20–24 years and the lower rate 
for Asian/Indian infants were not significant. The significance of disparities in post-neonatal infant mortality 
rates by NZDep2013 score, ethnicity, infant gender and gestational age at birth were the same as for overall 
infant mortality. Post-neonatal mortality rates for infants born to mothers aged under 30 years were significantly 
higher than for infants born to mothers aged 30–34 years but were not significantly different for mothers aged 
over 35 years (Table 23). 









Rate ratio 95% CI 
Infant mortality 
NZDep2013 Index of deprivation quintile Prioritised ethnicity  
Deciles 1–2 2.77 1.00   Māori 6.96 1.68 1.51–1.87 
Deciles 3–4 3.35 1.21 0.96–1.52 Pacific 6.72 1.62 1.40–1.88 
Deciles 5–6 4.25 1.53 1.24–1.90 Asian/Indian 3.04 0.73 0.60–0.89 
Deciles 7–8 5.00 1.80 1.47–2.21 European/Other 4.15 1.00   
Deciles 9–10 7.93 2.86 2.37–3.45 Gender 
Maternal age group Female 4.54 1.00   
<20 years 10.2 2.88 2.43–3.42 Male 5.72 1.26 1.14–1.39 
20–24 years 7.06 2.00 1.73–2.32 Gestation at birth 
25–29 years 4.44 1.26 1.08–1.47 20–36 weeks 37.94 18.08 16.3–20.0 
30–34 years 3.53 1.00   37+ weeks 2.10 1.00   
35+ years 4.34 1.23 1.05–1.44   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; Rates are per 1,000 live births; Rate ratios are 
unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
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Rate ratio 95% CI 
Neonatal mortality  
NZDep2013 Index of deprivation quintile Prioritised ethnicity  
Deciles 1–2 1.79 1.00   Māori 3.65 1.30 1.13–1.50 
Deciles 3–4 2.27 1.27 0.96–1.68 Pacific 4.20 1.50 1.24–1.80 
Deciles 5–6 2.77 1.55 1.19–2.02 Asian/Indian 2.41 0.86 0.68–1.08 
Deciles 7–8 3.36 1.87 1.46–2.41 European/Other 2.81 1.00   
Deciles 9–10 4.50 2.52 1.99–3.19 Gender 
Maternal age group Female 2.87 1.00   
<20 years 5.76 2.46 1.98–3.07 Male 3.48 1.21 1.07–1.37 
20–24 years 3.81 1.63 1.35–1.97 Gestation at birth 
25–29 years 2.79 1.19 0.99–1.44 20–36 weeks 29.92 37.71 32.5–43.7 
30–34 years 2.34 1.00   37+ weeks 0.79 1.00   
35+ years 3.18 1.36 1.12–1.64   
Post neonatal mortality 
NZDep2013 Index of deprivation quintile Prioritised ethnicity  
Deciles 1–2 0.98 1.00   Māori 3.31 2.48 1.13–1.50 
Deciles 3–4 1.08 1.10 0.75–1.64 Pacific 2.52 1.89 1.47–2.42 
Deciles 5–6 1.48 1.51 1.05–2.16 Asian/Indian 0.62 0.47 0.30–0.72 
Deciles 7–8 1.64 1.67 1.18–2.36 European/Other 1.34 1.00   
Deciles 9–10 3.43 3.49 2.55–4.77 Gender 
Maternal age group Female 1.67 1.00   
<20 years 4.41 3.72 2.82–4.89 Male 2.24 1.34 1.14–1.57 
20–24 years 3.25 2.74 2.16–3.47 Gestation at birth 
25–29 years 1.65 1.39 1.07–1.80 20–36 weeks 8.02 6.15 5.17–7.31 
30–34 years 1.19 1.00   37+ weeks 1.30 1.00   
35+ years 1.16 0.98 0.73–1.31   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; Rates are per 1,000 live births; Rate ratios are 
unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
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Distribution by region 
Between 2008 and 2012 infant mortality rates were significantly higher than the national rate in the Northland, 
Counties Manukau, Waikato, Lakes and Whanganui DHBs and significantly lower than the national rate in the 
Waitemata, Capital & Coast, Nelson Marlborough and Southern DHBs. In the remaining district health boards 
there were no significant differences from the national rate (Figure 22, Table 24).  
Figure 22. Infant mortality, by district health board, New Zealand 2008–2012 
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset 






Rate per 1,000 
live births 
Rate ratio 95% CI 
Infant mortality 
Northland 86 17 7.35 1.43 1.15–1.77 
Waitemata 125 25 3.16 0.61 0.51–0.74 
Auckland 155 31 4.68 0.91 0.77–1.07 
Counties Manukau 293 59 6.68 1.30 1.15–1.47 
Waikato 179 36 6.40 1.24 1.07–1.45 
Bay of Plenty 94 19 6.31 1.23 1.00–1.51 
Lakes 56 11 6.91 1.34 1.03–1.75 
Tairawhiti 23 5 5.91 1.15 0.76–1.73 
Taranaki 43 9 5.41 1.05 0.78–1.42 
Hawke's Bay 69 14 5.90 1.15 0.90–1.46 
MidCentral 59 12 5.09 0.99 0.76–1.28 
Whanganui 36 7 8.07 1.57 1.13–2.18 
Hutt Valley 52 10 4.86 0.95 0.72–1.25 
Capital & Coast 75 15 3.78 0.74 0.58–0.93 
Wairarapa 12 2 4.48 0.87 0.49–1.53 
Nelson Marlborough 20 4 2.40 0.47 0.30–0.73 
South Canterbury 19 4 6.06 1.18 0.75–1.85 
Canterbury 144 29 4.50 0.87 0.74–1.04 
West Coast 10 2 4.61 0.90 0.48–1.67 
Southern 72 14 3.87 0.75 0.60–0.95 
New Zealand 1,633 327 5.14 1.00   
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2008 and 2012 infant mortality rates were significantly higher than the national rate in Waikato and 
Lakes DHBs, while rates were not significantly different in Bay of Plenty, Tairawhiti and Taranaki DHBs.  
For neonatal mortality, rates in Bay of Plenty were significantly higher than the national rate, and the rates in the 
other Midland DHBs were not significantly different. For post neonatal mortality, rates were significantly higher 
than the national rate in Waikato DHB, while rates in the other Midland DHBs were not significantly different 
(Table 25). 






Rate per 1,000 
live births 
Rate ratio 95% CI 
Infant mortality 
Waikato 179 36 6.40 1.24 1.07–1.45 
Bay of Plenty 94 19 6.31 1.23 1.00–1.51 
Lakes 56 11 6.91 1.34 1.03–1.75 
Tairawhiti 23 5 5.91 1.15 0.76–1.73 
Taranaki 43 9 5.41 1.05 0.78–1.42 
New Zealand 1,633 327 5.14 1.00   
Neonatal mortality 
Waikato 107 21 3.82 1.20 0.99–1.47 
Bay of Plenty 63 13 4.23 1.33 1.03–1.72 
Lakes 33 7 4.07 1.28 0.91–1.81 
Tairawhiti 16 3 4.11 1.29 0.79–2.12 
Taranaki 25 5 3.14 0.99 0.67–1.47 
New Zealand 1,010 202 3.18 1.00   
Post neonatal mortality 
Waikato 72 14 2.57 1.31 1.03–1.67 
Bay of Plenty 31 6 2.08 1.06 0.74–1.52 
Lakes 23 5 2.84 1.45 0.95–2.19 
Tairawhiti 7 1 1.80 0.92 0.44–1.93 
Taranaki 18 4 2.26 1.15 0.72–1.84 
New Zealand 623 125 1.96 1.00   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset 
Regional trends 
In the Midland DHBs there was an overall fall in infant mortality rates from 1990 to 2012 (Figure 23). Falling 
rates of post neonatal mortality were observed during this period, and a fall in neonatal mortality rate was 
observed in Lakes and Taranaki DHBs while neonatal mortality rates were more variable for the other DHBs 
(Figure 24).  
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Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; *2012 is a single year of data 






















































































































































































































































































































































































































































Infant mortality DHB: neonatal mortality
NZ: neonatal mortality
DHB: post neonatal mortality
NZ: post neonatal mortality
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; *2012 is a single year of data 
 
Issues in infancy: Infant mortality and SUDI 
59 
Regional distribution by cause 
In the Midland DHBs, other perinatal conditions, and congenital anomalies were the most frequent causes of 
infant mortality between 2008 and 2012 for all except Tairawhiti DHB, where other perinatal conditions, and 
extreme prematurity were the most frequent (Table 26). 
Table 26. Infant mortality by cause, Waikato, Bay of Plenty, and Lakes DHBs 2008−2012 










Congenital anomalies 37 7 1.32 20.7 
Extreme prematurity 25 5 0.89 14.0 
Intrauterine hypoxia or birth asphyxia <5 s s s 
Other perinatal conditions 50 10 1.79 27.9 
SUDI: SIDS 16 3 0.57 8.9 
SUDI: suffocation or strangulation in bed 6 1 0.21 3.4 
SUDI: All other types <5 s s s 
Injury or poisoning 6 1 0.21 3.4 
Other causes 35 7 1.25 19.6 
Waikato total 179 36 6.40 100.0 
Bay of Plenty 
Congenital anomalies 21 4 1.41 22.3 
Extreme prematurity 14 3 0.94 14.9 
Intrauterine hypoxia or birth asphyxia <5 s s s 
Other perinatal conditions 34 7 2.28 36.2 
SUDI: SIDS 10 2 0.67 10.6 
SUDI: suffocation or strangulation in bed 6 1 0.40 6.4 
Injury or poisoning <5 s s s 
Other causes 5 1 0.34 5.3 
Bay of Plenty total 94 19 6.31 100.0 
Lakes DHB 
Congenital anomalies 12 2 1.48 21.4 
Extreme prematurity 10 2 1.23 17.9 
Intrauterine hypoxia or birth asphyxia <5 s s s 
Other perinatal conditions 11 2 1.36 19.6 
SUDI: SIDS 6 1 0.74 10.7 
SUDI: suffocation or strangulation in bed 8 2 0.99 14.3 
SUDI: All other types <5 s s s 
Injury or poisoning <5 s s s 
Other causes 5 1 0.62 8.9 
Lakes DHB total 56 11 6.91 100.0 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; SUDI = Sudden Unexpected Death in 
Infancy; SIDS = Sudden Infant Death Syndrome 
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Table 27. Infant mortality by cause, Tairawhiti and Taranaki DHBs 2008−2012 










Extreme prematurity 7 1 1.80 30.4 
Congenital anomalies <5 s s s 
Other perinatal conditions 7 1 1.80 30.4 
SUDI: SIDS <5 s s s 
SUDI: suffocation or strangulation in bed 6 1 1.54 26.1 
Tairawhiti total  23 5 5.91 100.0 
Taranaki 
Congenital anomalies 13 3 1.64 30.2 
Extreme prematurity 7 1 0.88 16.3 
Other perinatal conditions 8 2 1.01 18.6 
SUDI: SIDS <5 s s s 
SUDI: suffocation or strangulation in bed <5 s s s 
SUDI: All other types <5 s s s 
Injury or poisoning <5 s s s 
Other causes 6 1 0.75 14.0 
Taranaki total 43 9 5.41 100.0 
Taranaki total         
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; SUDI = Sudden Unexpected Death in 
Infancy; SIDS = Sudden Infant Death Syndrome 
Sudden unexpected death in infancy (SUDI) 
From 1996 to 2012 there was an overall significant fall in SUDI rates from 1.88 to 0.6 deaths per 1,000 live 
births (Figure 25). The fall in SUDI rates from 1996–2012 was greatest for Māori infants, with lesser falls for 
Pacific and European/Other ethnic groups. Asian/Indian analyses were suppressed due to small numbers. Māori 
rates were consistently highest and European/Other consistently lowest, however, the gap between ethnic groups 
was closing by 2012 (Figure 26).  
































Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; * 2012 is a single year of data 
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Figure 26. Sudden unexpected death in infancy (SUDI), by ethnicity, New Zealand 1996–2012 
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; Ethnicity is level 1 prioritised; * 2012 is a 
single year of data 
Distribution by cause 
From 1996–97 to 2012 the rate of sudden infant death syndrome (SIDS) deaths fell consistently. The diagnosis 
of unspecified SUDI was used from 2000–01 for between 0.05 and 0.20 deaths per 1,000 live births. Between 
2002–03 and 2008–09 there was a rise in the death rate for suffocation or strangulation in bed which has since 
fallen. Death rates from inhalation of food or gastric contents have been relatively stable since 1998–99 with 
some year to year variation. These changes occurred in the context of falling SUDI rates overall and will have 
been influenced by changes in coding.  
Distribution by demographic factors 
Between 2008 and 2012 SUDI was most common from 4–15 weeks of age, with the highest numbers from 4 to 
15 weeks of age, followed by deaths in the first three weeks and at 16–23 weeks. Numbers reduced with 
increasing age from 24–47 weeks and there were no deaths from 48–52 weeks. Suffocation or strangulation in 
bed was the predominant cause of death for 0–3 week olds and remained a common diagnosis until 23 weeks, 
while SIDS was the most common diagnosis for 4 to 11 weeks and again after 24 weeks of age. Inhalation of 
food or gastric contents was not noted as an underlying cause of death after age 11 weeks (Figure 27). 
There were disparities in SUDI rates by NZDep2013 index of deprivation score, ethnicity, gender, gestational 
age at birth and maternal age between 2008 and 2012. In areas with the highest NZDep2013 scores (deciles 7–
10) SUDI rates were significantly higher compared with areas with lower scores (deciles 1–6) where there was 
no significant difference between deciles. Māori and Pacific SUDI rates were significantly higher compared 
with Asian/Indian and European/Other ethnic groups. Male rates were significantly higher than female rates. 
Infants born at 20–26 weeks gestation had significantly higher SUDI rates than infants born at more than 37 
weeks gestation. SUDI rates were significantly higher for infants born to mothers aged under 30 years compared 
with infants born to mothers aged 30 years or older, with the increasing risk of SUDI with decreasing maternal 
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Figure 27. Sudden unexpected death in infancy (SUDI), by type and age in weeks, New Zealand 2008–2012 
 
National Mortality Collection; Numbers are annual average 









Rate ratio 95% CI 
Sudden unexpected death in infancy (SUDI) 
NZDep2013 Index of deprivation quintile Prioritised ethnicity  
Deciles 1–2 0.31 1.00   Māori 2.14 4.13 3.18–5.35 
Deciles 3–4 0.49 1.61 0.84–3.10 Pacific 0.84 1.62 1.06–2.46 
Deciles 5–6 0.57 1.86 1.00–3.47 Asian/Indian 0.33 0.63 0.34–1.15 
Deciles 7–8 1.11 3.63 2.05–6.41 European/Other 0.52 1.00   
Deciles 9–10 1.84 6.04 3.50–10.4 Gender 
Maternal age group Female 0.79 1.00   
<20 years 2.75 7.36 4.82–11.2 Male 1.21 1.54 1.23–1.93 
20–24 years 1.73 4.63 3.12–6.86 Gestation at birth 
25–29 years 0.71 1.90 1.24–2.93 20–36 weeks 2.24 3.17 2.35–4.29 
30–34 years 0.37 1.00   37+ weeks 0.70 1.00   
35+ years 0.35 0.93 0.55–1.56   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; Rates are per 1,000 live births, Rate ratios are 
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Distribution by region 
Between 2008 and 2012 SUDI rates were significantly higher than the national rate in the Northland, Lakes, 
Tairawhiti, Hawke's Bay, Whanganui and Hutt Valley DHBs and significantly lower in the Waitemata DHB. In 
remaining district health boards there was no significant difference from the national rate (Figure 28, Table 29).  
Figure 28. Sudden unexpected death in infancy (SUDI), by district health board, New Zealand 2008–2012 
 
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; Rates suppressed for Nelson Marlborough, 
South Canterbury, and West Coast DHBs due to numbers less than five 






Rate per 1,000 
live births 
Rate ratio 95% CI 
Sudden unexpected death in infancy 
Northland 26 5 2.22 2.20 1.48–3.29 
Waitemata 17 3 0.43 0.43 0.26–0.69 
Auckland 28 6 0.85 0.84 0.57–1.23 
Counties Manukau 47 9 1.07 1.06 0.78–1.44 
Waikato 25 5 0.89 0.89 0.59–1.33 
Bay of Plenty 17 3 1.14 1.13 0.70–1.84 
Lakes 15 3 1.85 1.84 1.09–3.08 
Tairawhiti 8 2 2.06 2.04 1.01–4.11 
Taranaki 9 2 1.13 1.12 0.58–2.18 
Hawke's Bay 19 4 1.62 1.61 1.01–2.56 
MidCentral 14 3 1.21 1.20 0.70–2.05 
Whanganui 11 2 2.47 2.45 1.34–4.46 
Hutt Valley 20 4 1.87 1.86 1.18–2.91 
Capital & Coast 15 3 0.76 0.75 0.45–1.26 
Wairarapa 5 1 1.86 1.85 0.77–4.47 
Nelson Marlborough <5 s s s s 
South Canterbury <5 s s s s 
Canterbury 24 5 0.75 0.74 0.49–1.13 
West Coast <5 s s s s 
Southern 11 2 0.59 0.59 0.32–1.07 
New Zealand 320 64 1.01 1.00   
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Midland region distribution and trends 
Comparison with New Zealand  
Between 2008 and 2012 SUDI rates were significantly higher than the national rate in Lakes and Tairawhiti 
DHBs, and not significantly different in the other Midland DHBs (Table 30).  






Rate per 1,000 
live births 
Rate ratio 95% CI 
Sudden unexpected death in infancy 
Waikato 25 5 0.89 0.89 0.59–1.33 
Bay of Plenty 17 3 1.14 1.13 0.70–1.84 
Lakes 15 3 1.85 1.84 1.09–3.08 
Tairawhiti 8 2 2.06 2.04 1.01–4.11 
Taranaki 9 2 1.13 1.12 0.58–2.18 
New Zealand 320 64 1.01 1.00   
Numerator: National Mortality Collection; Denominator: Birth Registration Dataset 
Regional trends 
In general, in the Midland DHBs the rate of SUDI fell from 1996–97 to 2012. Care should be applied when 
interpreting these rates, however, due to the small numbers of SUDI deaths in each DHB (Figure 29). 





















































































































































































































































































































































Numerator: National Mortality Collection; Denominator: Birth Registration Dataset; * 2012 is a single year of data; Care should 
be taken when interpreting these data as rates are based on small numbers 
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Evidence for good practice relevant to infant mortality and SUDI 
prevention 
Ministry of Health web pages 
Ministry of Health. 2014. Keeping baby safe and warm in bed. http://www.health.govt.nz/your-health/healthy-
living/babies-and-toddlers/keeping-baby-safe-and-warm-bed 
This web page contains advice for parents on putting their baby to sleep in a safe place to reduce the risk of suffocation during sleep. A 
pamphlet containing this information can be ordered or downloaded from the webpage. 
New Zealand guidelines 
Ministry of Health. 2012. Observation of mother and baby in the immediate postnatal period: consensus 
statements guiding practice. Wellington: Ministry of Health 
http://www.health.govt.nz/system/files/documents/publications/observation-mother-baby-immediate-postnatal-period-
consensus-statements.pdf  
This guidance is intended to address the prevention of sudden unexpected early neonatal death, risk factors for which include 
unsupervised skin-to-skin contact, inexperienced mothers, and mothers being left unsupervised in the immediate postnatal period. The 
guidance was developed by members of the New Zealand College of Midwives and the Royal Australian and New Zealand College of 
Obstetricians and Gynaecologists – New Zealand Committee, with the support of the Ministry of Health. It is endorsed by the Ministry of 
Health and it is expected that all practitioners supporting mothers and babies in the immediate postnatal period will use this document 
to guide their practice. 
International guidelines 
National Institute for Health and Care Excellence. 2014. Addendum to Clinical Guideline 37, Postnatal Care. London: 
National Institute for Health and Care Excellence. http://www.nice.org.uk/guidance/cg37/evidence/cg37-postnatal-care-
full-guideline-addendum2  
This addendum to the NICE guideline on routine postnatal care updates the guideline section on reducing the risk of sudden infant death 
syndrome (SIDS). The update was considered necessary because of the publication of new information on the association between co-
sleeping and SIDS. Unlike the original guideline which only reviewed evidence for the first 6–8 weeks after birth, this update considered 
evidence relevant to the first year of life. The review on which the recommendations were based included 11 individual studies and two 
individual patient data meta-analysis studies. All of the studies were observational (case control) rather than experimental therefore 
observed relationships between co-sleeping and SIDS could not definitively confirm that co-sleeping is a risk factor for SIDS. In summary, 
the new recommendations made are:  
1. Recognise that co-sleeping can be intentional or unintentional. Discuss this with parents and carers and inform them that there is an 
association between co-sleeping (parents or carers sleeping on a bed or sofa or chair with an infant) and SIDS. 
2. Inform parents and carers that the association between co-sleeping (sleeping on a bed or sofa or chair with an infant) and SIDS is likely 
to be greater when they, or their partner, smoke.  
3. Inform parents and carers that the association between co-sleeping (sleeping on a bed or sofa or chair with an infant) and SIDS may 
be greater with: parental or carer recent alcohol consumption, or parental or carer drug use, or low birthweight or premature infants. 
Task Force on Sudden Infant Death Syndrome. 2011. SIDS and Other Sleep-Related Infant Deaths: Expansion of SIDS 
and Other Sleep-Related Infant Deaths. Pediatrics, 128(5), 1030-39. 
http://pediatrics.aappublications.org/content/128/5/1030  
This policy statement from the American Academy of Pediatrics is an expansion of previous AAP recommendations. It was reaffirmed in 
October 2014. The new recommendations not only focus on SIDS prevention but also on safe sleep environments that can reduce the 
risk of all sleep-related infant deaths including suffocation, asphyxia and entrapment. The recommendations described in this publication 
include placing the baby in a supine position to sleep, using a firm sleeping surface, breastfeeding, sharing a room (but not a bed), routine 
immunisations, considering the use of a pacifier, and avoiding soft bedding, overheating and exposure to tobacco smoke, alcohol and 
illicit drugs. The evidence base for these recommendations is published as:  
Task Force on Sudden Infant Death Syndrome. 2011. Technical Report: SIDS and Other Sleep-Related Infant Deaths: 
Expansion of Recommendations for a Safe Infant Sleeping Environment. Pediatrics, 128(5), e1341-e67. 
Evidence-based medicine reviews 
Horne RSC, Hauck FR, Moon RY, et al. 2014. Dummy (pacifier) use and sudden infant death syndrome: Potential 
advantages and disadvantages. Journal of Paediatrics and Child Health 50(3) 170-74. 
http://dx.doi.org/10.1111/jpc.12402  
There has been some controversy over whether parents should be advised that the use of a pacifier (dummy) may reduce the risk of 
sudden infant death syndrome (SIDS). Several systematic reviews have shown a strong association between the lack of pacifier use in the 
final sleep and SIDS, but it is uncertain by what mechanism pacifier use is protective and whether pacifier use is a marker for some other 
factor that influences SIDS risk. This article describes the evidence, discussion and conclusions from the Epidemiology and Physiology 
Working Groups of the International Society for the Study and Prevention of Perinatal and Infant Death (ISPID) on this issue. It discusses 
potential disadvantages of dummy use and states that, while the current evidence regarding the effect of dummy use on breastfeeding 
duration and frequency has some methodological limitations, it reinforces the importance of introducing a dummy to breastfed infants 
only after breastfeeding has become well established, generally after 3–4 weeks. It also states that the evidence suggests that there is an 
association between otitis media and dummy use, although this has largely been observed in later infancy rather than in early infancy 
when most SIDS deaths occur. The ISPID found itself unable to provide a definitive recommendation regarding the use of dummies 
(pacifiers) for reducing SIDS risk, but members were agreed that parents of newborns should be educated about the evidence and 
potential benefits and risks to using dummies, so that they can make informed choices regarding their own infants. 
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Ball HL, Volpe LE. 2013. Sudden Infant Death Syndrome (SIDS) risk reduction and infant sleep location – Moving 
the discussion forward. Social Science & Medicine 79(0) 84-91.  
The authors of this paper argue that SIDS reduction campaigns have assumed that parents who are appropriately instructed will choose 
to place their baby to sleep in an approved location such as a crib, but that public health practitioners have failed to recognise the 
importance of infant sleep location to ethnic and sub-cultural identity and therefore their messages advising parents not to bed share 
with their baby have been rejected by target populations. They argue that more detailed research about bed sharing is needed so that 
more sophisticated and focussed infant sleep safety measures that are culturally embedded can be developed. 
Strehle E-M, Gray WK, Gopisetti S, et al. 2012. Can home monitoring reduce mortality in infants at increased risk of 
sudden infant death syndrome? A systematic review. Acta Paediatrica 101(1) 8-13. http://dx.doi.org/10.1111/j.1651-
2227.2011.02464.x 
This systematic review aimed to evaluate the effectiveness of home monitoring devices for the prevention of sudden infant death 
syndrome (SIDS). The review authors identified 11 relevant studies meeting their inclusion criteria: 10 cohort studies and one RCT. The 
RCT was a small study (100 infants in total) designed to assess the feasibility of a larger scale RCT. Across all 11 studies, 2210 infants were 
monitored for a total of 12,160 months, fiving a mean monitoring time of 5.5 months. During monitoring there were 11 deaths described 
as SIDS deaths, a rate of 5.9 per 1,000 (95% CI 1.4 to 11.0). Several studies reported deaths in infants who were not monitored or for 
whom monitoring had ceased. The review authors concluded that there is no high level evidence that home monitoring may be useful 
for preventing SIDS and that the wide variety of monitoring devices used makes comparisons between studies difficult. They noted that 
a methodologically rigorous controlled study to provide a more definitive evaluation of home monitoring may not be possible due to 
ethical concerns. 
Mitchell EA, Freemantle J, Young J, et al. 2012. Scientific consensus forum to review the evidence underpinning the 
recommendations of the Australian SIDS and Kids Safe Sleeping Health Promotion Programme--October 2010. 
Journal of Paediatrics & Child Health 48(8) 626-33. http://onlinelibrary.wiley.com/doi/10.1111/j.1440-
1754.2011.02215.x/abstract  
This paper is a summary from a 1-day scientific consensus forum that reviewed the evidence underpinning the Australian SIDS and Safe 
Sleeping Health Promotion Programme. The Consensus forum recommended that future “Reducing the Risk” campaigns should focus 
on back to sleep, face uncovered, avoidance of cigarette smoking both before and after birth, safe sleeping environment (avoiding letting 
babies sleep on sofas, in strollers etc.), and sleeping baby in own cot in parents’ room. 
Hauck FR, Thompson JMD, Tanabe KO, et al. 2011. Breastfeeding and Reduced Risk of Sudden Infant Death 
Syndrome: A Meta-analysis. Pediatrics 128(1) 103-10. http://pediatrics.aappublications.org/content/128/1/103.abstract  
The authors of this review identified 24 original case-control studies that provided data on the relationship between breastfeeding and 
SIDS risk. Eighteen studies met the review’s quality criteria and contribute data to the meta-analyses. The number of cases in each study 
ranged from 23 to 591. For infants who received any amount of breast milk for any duration, the univariable summary odds ratio (SOR) 
was 0.40 (95% CI 0.35–0.44), and the multivariable SOR was 0.55 (95% CI 0.44–0.69). For any breastfeeding at two months of age or older, 
the univariable SOR was 0.38 (95% CI 0.27–0.54). The univariable SOR for exclusive breastfeeding of any duration was 0.27 (95% CI 0.24–
0.31). The review authors concluded that breastfeeding is protective against SIDS, more so when breastfeeding is exclusive. They stated 
that breastfeeding recommendations should be included with other SIDS prevention messages, both to reduce the risk of SIDS and also 
for the many other child and maternal health benefits breastfeeding provides. 
Other relevant publications 
Horne RSC, Hauck FR, Moon RY. 2015. Sudden infant death syndrome and advice for safe sleeping. BMJ 350: h1989 
http://www.bmj.com/content/350/bmj.h1989  
This recent clinical review aims to provide healthcare professionals with the most up to date information for parents and caregivers about 
SIDS and infant safety while sleeping. It discusses the major risk factors for SIDS: prone sleeping position, smoking in pregnancy, being 
born preterm and using bedding which may cover the baby’s head. It states that breastfeeding, sharing a room with parents and use of 
a dummy (pacifier) are protective. There is a detailed discussion of the risk associated with bed sharing and it is noted that although 
earlier studies found a risk associated with bed sharing only if the mother smoked, more recent studies have found an increased risk for 
infants <3 months even if neither parent is a smoker. While apnoea monitors are popular with parents who have lost a previous baby to 
SIDS, there is a lack of evidence for their efficacy. 
Fleming P J, Blair P S, Pease A. 2015. Sudden unexpected death in infancy: aetiology, pathophysiology, 
epidemiology and prevention in 2015. Archives of Disease in Childhood. Published online first February 19, 2015. DOI: 
10.1136/archdischild-2014-306424 http://adc.bmj.com/content/early/2015/02/19/archdischild-2014-
306424.full.pdf+html  
This paper notes that changes in the way sudden infant deaths are classified by pathologists and coroners, and a reluctance to use the 
term ‘sudden infant death syndrome’ have made it difficult to assess and compare national and international data on incidence. It reviews 
current understanding of the epidemiology and aetiology of SUDI, and current hypotheses regarding the pathophysiology of the 
processes which may lead to death. It also reviews interventions to reduce SUDI, and their variable effectiveness, before discussing new 
approaches that may offer the possibility of prevention in the future. 
Hutchison L.B, Thompson JMD, Mitchell, EA. 2015. Infant care practices related to sudden unexpected death in 
infancy: a 2013 survey. NZMJ, Volume 128, Number 1408 
This paper reports on a postal survey of women recently delivered at National Women’s Health which aimed to evaluate mothers’ 
knowledge of, and practices related to, risk factors for sudden unexpected death in infancy (SUDI) and to compare results with a similar 
survey conducted in 2005. Compared to the earlier survey, significantly more mothers in the 2013 survey cited advice to avoid bed sharing, 
keep the face clear, use a firm sleep surface, avoid soft bedding, and sleep in the same room as the parent. There was a marked increase 
in reported sources of this information. Significantly more mothers than previously reported that their babies were usually placed to sleep 
on their backs, and that their baby slept in their own bed in the parents’ room. Fewer reported bed sharing and smoking in pregnancy. 
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Abel S, Stockdale-Frost A, Rolls R, Tipene-Leach D. 2015. The wahakura: a qualitative study of the flax bassinet as a 
sleep location for New Zealand Māori infants. NZMJ Volume 128 Number 1413 
This paper reports on a qualitative study in which 12 Māori mothers in the Hawke’s Bay and Tairawhiti were interviewed about their 
impressions and experience of the wahakura (a hand woven flax basket which allows a baby to sleep in their own space in the parents’ 
bed). The study also interviewed 10 key informants from the same region who were selected because of their knowledge and expertise 
about various aspects of wahakura production or use. The mothers were participants in the Kahungunu Infant Safe Sleep (KISS) study, a 
three-year RCT using a standard bassinette as a control which is currently underway. The mothers appreciated the practical advantages 
of the wahakura, especially its portability and convenience, and its cultural and spiritual values. The health professional key informants 
reported that the wahakura facilitated engaging with Māori women to impart safe sleep messages. 
Child and Youth Mortality Review Committee, Te Rōpū Arotake Auau Mate o te Hunga Tamariki, Taiohi. 2013. Special 
Report: Unintentional suffocation, foreign body inhalation and strangulation. Wellington. 
http://www.hqsc.govt.nz/assets/CYMRC/Publications/CMYRC-special-report-March-2013.pdf 
This report points out that suffocation in the place of sleep is increasingly being recognised as an important cause of SUDI and that some 
of these deaths occur when there has been a break from normal sleep routine, for example because of a social gathering or being away 
from home. In 2002–2009 48 infants under the age of 12 months died from suffocation in the place of sleep. Of the 50 children of all 
ages who died from suffocation in the place of sleep, 30 (60%) died due to overlaying by a parent or sibling, and 20 (30%) due to wedging 
(e.g. becoming trapped between a sleeping surface and bedding, or between cushions and the couch). The report includes issues 
identified and recommendations made by guest authors, by local Mortality Review Groups and by the CYMRC, and also national policy 
and practice recommendations, best practice for DHBs, PHOs and NGOs, and best practice in community messaging. 
Abel S, Tipene-Leach D. 2013. SUDI prevention: a review of Māori safe sleep innovations for infants. New Zealand 
Medical Journal 126(1379) 86-94. https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2013/vol-126-
no-1379/view-abel  
Māori have disproportionately high rates of SUDI and of smoking in pregnancy. Māori health workers have found it difficult to reduce 
smoking in pregnancy among Māori women so attention has been focussed on how to improve the safety of infant sleeping situations 
without necessarily banning bed sharing which is both a culturally valued behaviour and a practice that is common in resource-poor 
homes. This paper describes the wahakura project which involved the distribution of 85 wahakura to vulnerable Māori mothers through 
a Māori midwifery service in the Gisborne area. A wahakura is a woven flax bassinet-like basket which can be placed in the parents’ bed 
for the baby to sleep in (at the head of the bed). A second project was later initiated in the Hawke’s Bay. The high degree of weaving skill 
and the time required to make wahakura led to a search for a cheaper alternative. The pepi-pod is based on a plastic box and has been 
found to be acceptable to parents. It is the subject of randomised controlled trial comparing outcomes from an enhanced safe sleep 
education programme that uses pēpi-pods with those from a standard safe sleep education programme. 
Cowan S, Pease A, Bennett S. 2013. Usage and impact of an online education tool for preventing sudden 
unexpected death in infancy. Journal of Paediatrics & Child Health 49(3) 228-32.  
This paper reports on the evaluation of an online educational tool for mainstream health professionals, and the wider community, 
intended to equip them with the knowledge, attitudes and actions needed for providing developmentally appropriate sleeping conditions 
for babies in New Zealand. The 24 slide presentation, with voiceover, cost $3000 to develop. There were 3286 completed online sessions 
between 18 November 2009 and 31 December 2011. Users had diverse locations, ethnicities and roles. On completing the course, 69% 
gave a high rating to their “increased confidence” to discuss infant sleep safety with others. The study authors stated that the online tool 
achieved its aims of high usage and broad participation and had a cost-effective impact on increasing people’s confidence to discuss 
infant sleep safety with others. 
Mitchell EA, Blair PS. 2012. SIDS prevention: 3000 lives saved but we can do better. New Zealand Medical Journal 
125(1359) 50-7. https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2012/vol-125-no-1359/view-
mitchell  
This viewpoint article outlines the history of SIDS research and the success of subsequent SIDS prevention efforts involving the promotion 
of supine (on the back) sleeping in dramatically reducing rates of SIDS, both in New Zealand and elsewhere. It notes that there is 
considerable ongoing effort by the Ministry of Health, and many other organisations, to discourage maternal smoking and promote 
breastfeeding, to reduce SIDS risk. It highlights the fact that bed sharing is a significant risk factor, and that many parents are unaware of 
this. It lists the ISPID recommendations for reducing the risk of Sudden Infant Death Syndrome. 
International Society for the Study and Prevention of Perinatal and Infant Death (ISPID). 2012. To swaddle or not to 
swaddle? http://www.ispid.org/swaddling.html 
This brief article on the ISPID website discusses the evidence regarding swaddling (firmly wrapping a baby before putting it down to 
sleep) and SIDS. It makes the following recommendations: Parents should be aware of the potential risks of swaddling their infant, 
particularly of the use of heavy materials for swaddling; Infants must NEVER be placed prone (on their stomach) when swaddled; Current 
research suggests that it is safest to swaddle infants from birth and not to change infant care practices by beginning to swaddle their 
infant at 3 months of age when SIDS risk is greatest; Secondary caregivers should be made aware of their infant's usual sleeping 
environment and practices. 
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Tipene-Leach D, Hutchison L, Tangiora A, et al. 2010. SIDS-related knowledge and infant care practices among Māori 
mothers. New Zealand Medical Journal 123(1326) 88-96. https://www.nzma.org.nz/journal/read-the-journal/all-
issues/2010-2019/2010/vol-123-no-1326/article-tipene-leach  
This paper reports on a survey of Māori mothers who had given Counties Manukau DHB area from 21 July to 31 December 2008. There 
were 299 mothers who participated, out of 734 who were eligible. Mothers were asked to list all the factors they thought might help 
reduce the risk of SIDS, and from where and from whom they had received their information. They were also asked about current practices 
of maternal smoking, breastfeeding and both ‘last night’ and ‘usual practice’ infant sleep position and bed sharing, room sharing, pacifier 
use, plastic mattress wrapping, head shape concerns and positioning devices, and their reasons for using these practices (or not). The 
survey indicated that there was a high prevalence of Māori infant co-sleeping where there had been smoking in pregnancy (21%), which 
is an extremely high-risk practice, and that 13% of infants habitually slept prone and 36% with soft objects present in their sleeping 
environment. The authors concluded that their research had highlighted important information regarding the current state of Māori 
mothers’ knowledge and usage of child care practices and they stated that the challenge now is to develop appropriate health promotion 
tools for use in this community that might improve knowledge and so change behaviour, especially in regard to smoking cessation, safe 
sleeping environments, safe sleeping position and duration of breastfeeding. 
New Zealand College of Midwives. 2010. Consensus Statement: Safe sleeping for Baby. Christchurch: New Zealand 
College of Midwives. http://www.midwife.org.nz/pdf/resources/20%20Safe%20Sleeping%20for%20Baby.pdf 
This consensus statement sets out the recommendations on safe sleeping for babies that midwives should inform 
mothers/families/whānau about. 
McManus V, Abel S, McCreanor T, et al. 2010. Narratives of deprivation: Women's life stories around Māori sudden 
infant death syndrome. Social Science & Medicine, 71(3), 643-9. 
This paper reports on life story interviews conducted between 2002 and 2004 with nineteen Māori mothers whose infants died of SIDS. 
These mothers’ stories have common themes of alienation, marginalisation and exclusion and lives lived with serious deprivation within 
an affluent society. The authors state that is unhelpful to view some risk factors as non-modifiable and argue that new approaches that 
build on the WHO Social determinants of health framework are needed to stem the tide of deaths of Māori babies from SIDS. 
Child and Youth Mortality Review Committee, Te Rōpū Arotake Auau Mate o te Hunga Tamariki, Taiohi. 2009. Fifth 
Report to the Minister of Health: Reporting mortality 2002–2008. Wellington: Child and Youth Mortality Review 
Committee. http://www.hqsc.govt.nz/assets/CYMRC/Publications/cymrc-5th-report-chp1-sudi.pdf  
Chapter one of this report provides quantitative data on mortality from SUDI during 2002–2008, and qualitative information obtained 
from local mortality review. It also contains recommendations from the CYMRC on reducing the incidence of SUDI in New Zealand. 
A full page quick reference guide on SUDI prevention, from the CYMRC, can be found here: 
http://www.hqsc.govt.nz/assets/CYMRC/Publications/Protecting-Infants-from-SUDI.pdf  
Websites 
Child and Youth Mortality Review Committee. SUDI. http://www.hqsc.govt.nz/our-programmes/mrc/cymrc/publications-
and-resources/sudi/  
This web page, by the Child and Youth Mortality Review Committee, has a range of resources and links related to SUDI. 
Safe sleep videos from the Northland DHB http://www.hqsc.govt.nz/our-programmes/mrc/cymrc/publications-and-
resources/publication/1907/  
In conjunction with the regional Child Health Network and Whakawhetu, the Northland DHB produced four television commercials to 
promote SUDI prevention. The videos were launched for Safe Sleep Day in December 2013. The four videos, entitled: PLACE baby in his 
or her own baby bed; ELIMINATE smoking in pregnancy, in the whānau and the home; POSITION baby on his or her back to sleep; and 
ENCOURGE and support mum, so baby is breastfed, can be viewed on YouTube by following the links on the webpage. 
Whakawhetu: National SUDI Prevention for Māori http://www.whakawhetu.co.nz/  
Whakawhetū National SUDI Prevention for Māori is a national kaupapa Māori programme dedicated to reducing the rate of SUDI (Sudden 
Unexpected Death in Infancy) for Māori. They provide policy advice, disseminate evidence-based information, resources, training and 
education to the health sector and Māori communities, facilitate an annual Safe Sleep Day in December of every year, work with 
communities to develop local solution, and work with DHBs to support their work to reduce SUDI. 
TAHA Well Pacific Mother and Infant Service (www.taha.co.nz) 
The Pacific Health Programme, in the Department of Māori and Pacific Health at the University of Auckland, has developed a SUDI 
prevention programme for Pacific families in Auckland. 
Change for Our Children (www.changeforourchildren.co.nz) 
Change for our Children is on a mission to build a strong culture of respect for children that is visible in our country’s systems and services, 
conversations and communities, hearts and homes. This site contains, among other useful resources, information on the pepi-pod project 
which provides a means of enabling babies to be close to a parent but have their own safe sleeping space, and some useful publications 
both from the organisation and elsewhere. There is a link to The Pepi Shop which is an initiative allowing parents to buy their own Pepi-
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CAUSES OF DEATH AND HOSPITALISATION 
Introduction 
This section provides a brief review of the causes of death and hospitalisation for New Zealand children and 
young people for the last five years thereby giving the context for the subsequent sections of this report where 
the descriptions are of specific conditions. Infant mortality has been considered in the previous section and is 
not repeated here. The following sections use the National Mortality Collection and the National Minimum 
Dataset to describe the most common causes of death for children aged 1–14 years and young people aged 15–
24 years, and for hospitalisation of children aged 0–14 years and young people aged 15–24 years.  
Data source and methods  
Indicators 
Causes of deaths in 1–24 year olds  
Causes of hospitalisations in 0–24 year olds 
Data sources 
Numerator:  
Deaths:  National Mortality Collection 
Hospitalisations:  National Minimum Dataset 
Denominator:   Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Definition 
Numerator:  
Deaths:  Deaths in 1–24 year olds by the main underlying cause of death (deaths per 100,000 population) 
Hospitalisations:  Hospitalisations for 0–24 year olds by primary diagnosis (acute and arranged admissions; excluding  
 neonates) or primary procedure (waiting list admissions; hospitalisations per 1,000 population).  
   Refer to Appendix 6 for the codes included. 
Denominator:  1–14 DHB age range was calculated using Estimated Resident Population extrapolations for 0–14 range 
and subtracting the number of live births in that period. 
Notes on interpretation 
Note 1: Because hospitalisations during the neonatal period are likely to be heavily influenced by perinatal factors and/or result 
from preterm infants transitioning through different levels of neonatal care (e.g. from neonatal intensive care, to Level 1–3 
special care baby units), neonatal hospitalisations have been excluded from this analysis. Similarly, infant mortality is also likely 
to be heavily influenced by perinatal factors, and thus this section is restricted to an analysis of mortality aged 1–24 years (see 
Infant mortality and sudden unexpected death in infancy section beginning on page 51 for a review of the causes of mortality in 
those aged less than one year). 
Note 2: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
(sometimes referred to as semi-acute) is a non-acute hospitalisation with an admission date less than seven days after the date 
the decision was made that the hospitalisation was necessary. A waiting list admission is a planned hospitalisation, where the 
admission date is seven or more days after the date the decision was made that the hospitalisation was necessary. 
Note 3: In order to maintain consistency with the injury section, all injury hospitalisations with an Emergency Medicine Specialty 
Code on discharge have been excluded (see Appendix 3 for rationale). 
Note 4: Appendix 3 outlines the limitations of the data utilised from the National Minimum Dataset. The reader is advised to 
review this information before interpreting any trends. 
National distribution 
Causes of death  
Between 2008 and 2012 there were 718 deaths of children aged 1–14 years, an average of 144 deaths per year. 
The most common underlying causes of death were cancers (neoplasms), congenital anomalies, transport-related 
injuries, and other injuries including self-harm (Table 31). From 2008–2012 there were 1,965 deaths of young 
people aged 15–24 years, an average of 393 deaths per year. Suicide (intentional self-harm) was the most 
common cause of death in this age group followed by transport-related injury (Table 32). 
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Table 31. Deaths in 1–14 year olds, by main underlying cause, New Zealand 2008–2012 









95% CI Per cent 
New Zealand 
1–14 year olds 
Unintentional injury 227 45 5.43 4.77–6.18 31.6 
Neoplasm 112 22 2.68 2.23–3.22 15.6 
Congenital anomalies 65 13 1.55 1.22–1.98 9.1 
Suicide 39 8 0.93 0.68–1.27 5.4 
Metabolic disorders 25 5 0.60 0.40–0.88 3.5 
Assault 24 5 0.57 0.39–0.85 3.3 
Pneumonia 18 4 0.43 0.27–0.68 2.5 
Meningococcal disease 13 3 0.31 0.18–0.53 1.8 
SUDI: SIDS & unspecified 12 2 0.29 0.16–0.50 1.7 
Other medical 173 35 4.14 3.56–4.80 24.1 
Undetermined intent 5 1 0.12 0.05–0.28 0.7 
Other causes 5 1 0.12 0.05–0.28 0.7 
New Zealand total 718 144 17.17 15.96–18.47 100.0 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Excludes infants (age less 
than one year) 
Table 32. Deaths in 15–24 year olds, by main underlying cause, New Zealand 2008–2012 









95% CI Per cent 
New Zealand 
15–24 year olds 
Unintentional injury 773 155 25.03 23.32–26.86 39.3 
Suicide 625 125 20.24 18.71–21.89 31.8 
Neoplasm 141 28 4.57 3.87–5.38 7.2 
Assault 54 11 1.75 1.34–2.28 2.7 
Congenital anomalies 48 10 1.55 1.17–2.06 2.4 
Metabolic disorders 22 4 0.71 0.47–1.08 1.1 
Other medical 266 53 8.61 7.64–9.71 13.5 
Unspecified 12 2 0.39 0.22–0.68 0.6 
Undetermined intent of injury 14 3 0.45 0.27–0.76 0.7 
Other causes 10 2 0.32 0.18–0.60 0.5 
New Zealand total 1,965 393 63.62 60.87–66.50 100.0 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
Causes of hospitalisation  
0–14 year olds 
Between 2010 and 2014 there were 380,650 acute hospitalisations of children aged 0–14 years, 60,000 arranged 
admissions and 140,860 waiting list admissions. In total there were 581,510 hospitalisations of children in this 
age group. The most common reasons for acute hospitalisation in this age group were injury or poisoning, 
bronchiolitis, acute upper respiratory tract infections and gastroenteritis. The most common reasons for arranged 
admissions were cancer or cancer treatment (neoplasm, chemotherapy or radiotherapy), injury or poisoning and 
congenital anomalies. The most common procedures for waiting list admissions were gastrointestinal 
procedures, grommets and tonsillectomy (Table 33).  
15–24 year olds 
Between 2010 and 2014 there were 265,498 acute hospitalisations of young people aged 15–24 years, 54,140 
arranged hospitalisations, 139,389 reproductive admissions and 59,390 waiting list admissions. In total there 
were 518,417 hospitalisations of young people in this age group, an average of 103,683 hospitalisations per 
year. The most common reasons for acute hospitalisation in this age group were injury or poisoning, pregnancy, 
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delivery or postnatal-related conditions, mental health, and abdominal or pelvic pain. The most common reasons 
for arranged admissions were injury or poisoning, cancer or cancer treatment (neoplasm, chemotherapy or 
radiotherapy), mental health and dialysis. Most of the reproductive admissions (79.5%) were for pregnancy, 
delivery or postnatal-related conditions with smaller numbers for termination of pregnancy and spontaneous or 
other early pregnancy loss. The most common procedures for waiting list admissions were gastrointestinal 
procedures, dental procedures and tonsillectomy (Table 34). 










95% CI Per cent 
New Zealand 0–14 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 46,537 9,307 10.27 10.18–10.37 12.2 
Asthma and wheeze 31,260 6,252 6.90 6.83–6.98 8.2 
Bronchiolitis 28,377 5,675 6.27 6.19–6.34 7.5 
Acute upper respiratory tract infection 28,060 5,612 6.20 6.12–6.27 7.4 
Gastroenteritis 27,033 5,407 5.97 5.90–6.04 7.1 
Viral infection NOS 20,915 4,183 4.62 4.56–4.68 5.5 
Skin infections 15,375 3,075 3.39 3.34–3.45 4.0 
Pneumonia 14,712 2,942 3.25 3.20–3.30 3.9 
Abdominal or pelvic pain 10,461 2,092 2.31 2.27–2.35 2.7 
Urinary tract infection 7,171 1,434 1.58 1.55–1.62 1.9 
Appendicitis 5,242 1,048 1.16 1.13–1.19 1.4 
Constipation 4,378 876 0.97 0.94–1.00 1.2 
Other diagnoses 141,129 28,226 31.16 31.00–31.32 37.1 
Total 380,650 76,130 84.04 83.79–84.30 100.0 
Arranged admissions by primary diagnosis 
Neoplasm, chemotherapy, or radiotherapy 13,371 2,674 2.95 2.90–3.00 22.3 
Injury or poisoning 4,767 953 1.05 1.02–1.08 7.9 
Congenital anomalies 3,109 622 0.69 0.66–0.71 5.2 
Metabolic disorders 1,362 272 0.30 0.29–0.32 2.3 
Perinatal-related conditions 1,117 223 0.25 0.23–0.26 1.9 
Haemolytic anaemias 853 171 0.19 0.18–0.20 1.4 
Constipation 828 166 0.18 0.17–0.20 1.4 
Mental health 771 154 0.17 0.16–0.18 1.3 
Dialysis 701 140 0.15 0.14–0.17 1.2 
Removal of internal fixation device 700 140 0.15 0.14–0.17 1.2 
Dental conditions 700 140 0.15 0.14–0.17 1.2 
Other diagnoses 31,721 6,344 7.00 6.93–7.08 52.9 
Total 60,000 12,000 13.25 13.14–13.35 100.0 
Waiting list admissions by primary procedure 
Dental procedures 36,014 7,203 7.95 7.87–8.03 24.0 
Grommets 22,743 4,549 5.02 4.96–5.09 15.1 
Tonsillectomy ± adenoidectomy 15,653 3,131 3.46 3.40–3.51 10.4 
Musculoskeletal procedures 13,448 2,690 2.97 2.92–3.02 9.0 
Gastrointestinal procedures 7,381 1,476 1.63 1.59–1.67 4.9 
Procedures on skin or subcutaneous tissue 4,767 953 1.05 1.02–1.08 3.2 
Inguinal hernia repair 3,300 660 0.73 0.70–0.75 2.2 
Adenoidectomy without tonsillectomy 2,999 600 0.66 0.64–0.69 2.0 
Other procedures 37,072 7,414 8.19 8.10–8.27 24.7 
No procedure listed 6,751 1,350 1.49 1.46–1.53 4.5 
Total 150,128 30,026 33.15 32.98–33.31 100.0 
New Zealand total  590,778 118,156 130.44 130.13–130.75   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; NOS = not otherwise 
specified 
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New Zealand 15–24 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 42,049 8,410 13.47 13.35–13.60 15.9 
Mental health 21,475 4,295 6.88 6.79–6.97 8.1 
Abdominal or pelvic pain 20,981 4,196 6.72 6.63–6.81 7.9 
Skin infections 11,100 2,220 3.56 3.49–3.62 4.2 
Gastroenteritis 8,745 1,749 2.80 2.74–2.86 3.3 
Appendicitis 7,994 1,599 2.56 2.51–2.62 3.0 
Urinary tract infection 6,932 1,386 2.22 2.17–2.27 2.6 
Acute upper respiratory tract infection 5,206 1,041 1.67 1.62–1.71 2.0 
Asthma and wheeze 4,071 814 1.30 1.26–1.35 1.5 
Viral infection NOS 3,975 795 1.27 1.23–1.31 1.5 
STI or pelvic inflammatory disease 3,936 787 1.26 1.22–1.30 1.5 
Other diagnoses 127,663 25,533 40.91 40.69–41.13 48.3 
Acute total 264,127 52,825 84.63 84.32–84.94 100.0 
Arranged admissions by primary diagnosis 
Injury or poisoning 5,575 1,115 1.79 1.74–1.83 10.3 
Neoplasm, chemotherapy, or radiotherapy 3,668 734 1.18 1.14–1.21 6.8 
Mental health 2,448 490 0.78 0.75–0.82 4.5 
Dialysis 2,167 433 0.69 0.67–0.72 4.0 
Immune disorders 1,552 310 0.50 0.47–0.52 2.9 
Metabolic disorders 891 178 0.29 0.27–0.30 1.6 
Removal of internal fixation device 833 167 0.27 0.25–0.29 1.5 
Other diagnoses 37,006 7,401 11.86 11.74–11.98 68.4 
Arranged total 54,140 10,828 17.35 17.20–17.49 100.0 
Reproductive hospitalisations by primary diagnosis 
Pregnancy, delivery, or postnatal-related conditions 112,923 22,585 73.60 73.19–74.02 78.7 
Termination of pregnancy: therapeutic, other, or unspecified* 22,915 4,583 14.94 14.75–15.13 16.0 
Spontaneous or other early pregnancy loss 7,687 1,537 5.01 4.90–5.12 5.4 
reproductive total 143,525 28,705 93.55 93.09–94.01 100.0 
Waiting list admissions by primary procedure 
Musculoskeletal procedures 9,395 1,879 3.01 2.95–3.07 16.6 
Gastrointestinal procedures 8,688 1,738 2.78 2.73–2.84 15.3 
Dental procedures 4,911 982 1.57 1.53–1.62 8.7 
Procedures on skin or subcutaneous tissue 4,650 930 1.49 1.45–1.53 8.2 
Tonsillectomy ± adenoidectomy 4,585 917 1.47 1.43–1.51 8.1 
Other procedures 21,841 4,368 7.00 6.91–7.09 38.6 
no procedure listed 2,555 511 0.82 0.79–0.85 4.5 
Waiting list total 56,625 11,325 18.14 18.00–18.29 100.0 
New Zealand total  518,417 103,683       
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Injury ED cases excluded; 
NOS = not otherwise specified; reproductive hospitalisations are presented as rates per 1,000 females aged 15–24 years; 
* Termination of pregnancy includes therapeutic, other, or unspecified terminations performed in hospital, and may be an 
underestimate; overall rate not provided due to use of gender-specific denominator for reproductive hospitalisations 
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Midland region distribution 
Causes of death 
Between 2008 and 2012 the most common underlying causes of death for 1–14 year olds in the Midland DHBs 
were transport-related injuries and medical conditions, particularly cancer. The order of these diagnoses varied 
between DHBs and in the smaller DHBs numbers were too small to report by specific cause. In Bay of Plenty 
DHB there was an average of one death from suicide each year in this age group (Table 35). For 15–24 year 
olds the most common causes of death were transport-related injuries and suicide in Midland DHBs (Table 36).  
Table 35. Deaths in 1−14 year olds, by main underlying cause, Midland DHBs 2008−2012 









95% CI Per cent 
1–14 year olds 
Waikato 
Unintentional injury 27 5 7.19 4.94–10.47 42.2 
Neoplasm 7 1 1.86 0.90–3.85 10.9 
Other causes 30 6 7.99 5.60–11.41 46.9 
Waikato total 64 13 17.05 13.35–21.77 100.0 
Bay of Plenty 
Unintentional injury 21 4 9.98 6.53–15.26 44.7 
Suicide 5 1 2.38 1.02–5.57 10.6 
Other causes 21 4 9.98 6.53–15.26 44.7 
Bay of Plenty total 47 9 22.35 16.81–29.71 100.0 
Lakes DHB 
Unintentional injury 9 2 8.12 4.27–15.44 42.9 
Other causes 12 2 10.83 6.20–18.93 57.1 
Lakes total 21 4 18.95 12.40–28.97 100.0 
Tairawhiti 
All causes 12 2 21.84 1.02–5.57 100.0 
Tairawhiti total 12 2 21.84 12.49–38.17 100.0 
Taranaki 
Neoplasm 5 1 4.53 1.93–10.60 31.3 
Other causes 11 2 9.97 5.56–17.85 68.8 
Taranaki total 16 3 14.49 8.92–23.55 100.0 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population;  
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Table 36. Deaths in 15−24 year olds, by main underlying cause, Midland DHBs 2008−2012 









95% CI Per cent 
15–24 year olds 
Waikato 
Unintentional injury 78 16 29.36 23.52–36.63 40.6 
Suicide 52 10 19.57 14.93–25.66 27.1 
Neoplasm 14 3 5.27 3.14–8.84 7.3 
Congenital anomalies 5 1 1.88 0.80–4.41 2.6 
Other medical 37 7 13.93 10.10–19.19 19.3 
Other causes 6 1 2.26 1.03–4.93 3.1 
Waikato total 192 38 72.26 62.74–83.22 100.0 
Bay of Plenty 
Unintentional injury 42 8 33.98 25.14–45.93 35.9 
Suicide 37 7 29.94 21.72–41.26 31.6 
Neoplasm 13 3 10.52 6.15–18.00 11.1 
Other medical 19 4 15.37 9.84–24.01 16.2 
Other causes 6 1 4.85 2.22–10.59 5.1 
Bay of Plenty total 117 23 94.67 79.00–113.43 100.0 
Lakes DHB 
Unintentional injury 26 5 39.15 26.72–57.36 44.1 
Suicide 19 4 28.61 18.32–44.69 32.2 
Neoplasm 5 1 7.53 3.22–17.63 8.5 
Other causes 9 2 13.55 7.13–25.76 15.3 
Lakes total 59 12 88.85 68.89–114.58 100.0 
Tairawhiti 
Suicide 13 3 41.41 24.20–70.84 38.2 
Unintentional injury 7 1 22.30 10.80–46.02 20.6 
Other causes 14 3 44.60 26.57–74.85 41.2 
Tairawhiti total 34 7 108.30 77.52–151.30 100.0 
Taranaki 
Unintentional injury 17 3 24.72 15.43–39.58 40.5 
Suicide 11 2 15.99 8.93–28.64 26.2 
Neoplasm 6 1 8.72 4.00–19.03 14.3 
Other causes 8 2 11.63 5.89–22.95 19.0 
Taranaki total 42 8 61.07 45.18–82.53 100.0 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
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Causes of hospitalisation 
In the Midland DHBs between 2010 and 2014 the most frequent cause of acute hospitalisation for 1–14 year 
olds was injury or poisoning. Other common causes were bronchiolitis, upper respiratory tract infections and 
gastroenteritis. Cancer (neoplasms), congenital anomalies and injury or poisoning were common reasons for 
arranged admissions in all Midland DHBs, with constipation in Tairawhiti. The most frequent causes for waiting 
list admissions were gastrointestional procedures, insertion of grommets, and tonsillectomy +/− adenoidectomy. 
For all admission types the order of common diagnoses varied between DHBs (Table 37–Table 41).  










95% CI Per cent 
Waikato 0–14 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 3,976 795 9.75 9.45–10.05 11.4 
Bronchiolitis 3,246 649 7.96 7.69–8.23 9.3 
Acute upper respiratory tract infection 2,724 545 6.68 6.43–6.93 7.8 
Asthma and wheeze 2,521 504 6.18 5.94–6.42 7.2 
Gastroenteritis 2,471 494 6.06 5.82–6.30 7.1 
Other diagnoses 19,855 3,971 48.67 48.01–49.33 57.1 
Acute total 34,793 6,959 85.28 84.43–86.14 100.0 
Arranged admissions by primary diagnosis 
Neoplasm, chemotherapy, or radiotherapy 1,047 209 2.57 2.42–2.73 23.1 
Injury or poisoning 347 69 0.85 0.77–0.94 7.7 
Other diagnoses 3,130 626 7.67 7.41–7.94 69.2 
Arranged total 4,524 905 11.09 10.77–11.41 100.0 
Waiting list admissions by primary procedure 
Dental procedures 4,189 838 10.27 9.96–10.58 26.8 
Grommets 2,192 438 5.37 5.15–5.60 14.0 
Tonsillectomy ± adenoidectomy 1,717 343 4.21 4.01–4.41 11.0 
Musculoskeletal procedures 939 188 2.30 2.16–2.45 6.0 
Other procedures 5,265 1,053 12.91 12.56–13.26 33.7 
No procedure listed 1,310 262 3.21 3.04–3.39 8.4 
Waiting list total 15,612 3,122 38.27 37.68–38.86 100.0 
Waikato total 54,929 10,986 134.64 133.59–135.69   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; excludes neonates; NOS = 
not otherwise specified 
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95% CI Per cent 
Bay of Plenty 0–14 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 2,858 572 12.59 12.14–13.06 12.7 
Acute upper respiratory tract infection 2,006 401 8.84 8.46–9.23 8.9 
Bronchiolitis 1,857 371 8.18 7.82–8.56 8.2 
Asthma and wheeze 1,775 355 7.82 7.47–8.19 7.9 
Gastroenteritis 1,668 334 7.35 7.01–7.71 7.4 
Other diagnoses 12,409 2,482 54.68 53.75–55.62 55.0 
Acute total 22,573 4,515 99.47 98.24–100.71 100.0 
Arranged admissions by primary diagnosis 
Neoplasm, chemotherapy, or radiotherapy 1,004 201 4.42 4.16–4.71 20.9 
Congenital anomalies 292 58 1.29 1.15–1.44 6.1 
Other diagnoses 3,505 701 15.44 14.95–15.96 73.0 
Arranged total 4,801 960 21.16 20.57–21.76 100.0 
Waiting list admissions by primary procedure 
Dental procedures 1,687 337 7.43 7.09–7.80 22.4 
Grommets 1,126 225 4.96 4.68–5.26 14.9 
Tonsillectomy ± adenoidectomy 850 170 3.75 3.50–4.01 11.3 
Musculoskeletal procedures 676 135 2.98 2.76–3.21 9.0 
Other procedures 2,783 557 12.26 11.82–12.72 36.9 
No procedure listed 419 84 1.85 1.68–2.03 5.6 
Waiting list total 7,541 1,508 33.23 32.50–33.98 100.0 
Bay of Plenty total 34,915 6,983 153.85 152.38–155.34   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; excludes neonates; NOS = 
not otherwise specified 






Rate per 1,000  




Lakes DHB 0–14 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 1,384 277 11.77 11.17–12.40 13.2 
Bronchiolitis 965 193 8.21 7.71–8.74 9.2 
Asthma and wheeze 806 161 6.86 6.40–7.34 7.7 
Acute upper respiratory tract infection 735 147 6.25 5.82–6.72 7.0 
Viral infection NOS 661 132 5.62 5.21–6.07 6.3 
Other diagnoses 5,913 1,183 50.29 49.06–51.56 56.5 
Acute total 10,464 2,093 89.00 87.39–90.64 100.0 
Arranged admissions by primary diagnosis 
Neoplasm, chemotherapy, or radiotherapy 348 70 2.96 2.67–3.29 21.1 
Congenital anomalies 117 23 1.00 0.83–1.19 7.1 
Injury or poisoning 103 21 0.88 0.72–1.06 6.2 
Other diagnoses 1,085 217 9.23 8.70–9.79 65.6 
Arranged total 1,653 331 14.06 13.40–14.75 100.0 
Waiting list admissions by primary procedure 
Dental procedures 1,097 219 9.33 8.80–9.90 25.4 
Grommets 732 146 6.23 5.79–6.69 16.9 
Tonsillectomy ± adenoidectomy 425 85 3.61 3.29–3.97 9.8 
Musculoskeletal procedures 293 59 2.49 2.22–2.79 6.8 
Other procedures 1,455 291 12.38 11.76–13.02 33.6 
No procedure listed 324 65 2.76 2.47–3.07 7.5 
Waiting list total 4,326 865 36.79 35.73–37.89 100.0 
Lakes DHB total 16,443 3,289 139.86 137.88–141.85   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; excludes neonates; NOS = 
not otherwise specified 
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Rate per 1,000 




Tairawhiti 0–14 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 770 154 13.14 12.25–14.10 14.0 
Bronchiolitis 538 108 9.18 8.44–9.99 9.8 
Acute upper respiratory tract infection 524 105 8.95 8.21–9.74 9.5 
Viral infection NOS 451 90 7.70 7.02–8.44 8.2 
Asthma and wheeze 445 89 7.60 6.93–8.33 8.1 
Other diagnoses 2,761 552 47.13 45.45–48.88 50.3 
Acute total 5,489 1,098 93.70 91.37–96.09 100.0 
Arranged admissions by primary diagnosis 
Injury or poisoning 94 19 1.60 1.31–1.96 11.0 
Constipation 68 14 1.16 0.92–1.47 8.0 
Neoplasm, chemotherapy, or radiotherapy 66 13 1.13 0.89–1.43 7.7 
Congenital anomalies 44 9 0.75 0.56–1.01 5.2 
Other diagnoses 580 116 9.90 9.13–10.74 68.1 
Arranged total 852 170 14.54 13.61–15.55 100.0 
Waiting list admissions by primary procedure 
Dental procedures 552 110 9.42 8.67–10.24 28.9 
Grommets 295 59 5.04 4.49–5.64 15.4 
Tonsillectomy ± adenoidectomy 188 38 3.21 2.78–3.70 9.8 
Musculoskeletal procedures 164 33 2.80 2.40–3.26 8.6 
Other procedures 659 132 11.25 10.43–12.14 34.5 
No procedure listed 52 10 0.89 0.68–1.16 2.7 
Waiting list total 1,910 382 32.61 31.20–34.07 100.0 
Tairawhiti total 8,251 1,650 140.85 138.06–143.69   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; excludes neonates; NOS = 
not otherwise specified 
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95% CI Per cent 
Taranaki 0–14 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 1,055 211 8.82 8.30–9.36 13.6 
Asthma and wheeze 755 151 6.31 5.88–6.77 9.7 
Acute upper respiratory tract infection 527 105 4.40 4.04–4.79 6.8 
Bronchiolitis 504 101 4.21 3.86–4.59 6.5 
Gastroenteritis 493 99 4.12 3.77–4.50 6.3 
Other diagnoses 4,431 886 37.02 35.97–38.11 57.1 
Acute total 7,765 1,553 64.88 63.50–66.29 100.0 
Arranged admissions by primary diagnosis 
Neoplasm, chemotherapy, or radiotherapy 321 64 2.68 2.40–2.99 23.0 
Congenital anomalies 108 22 0.90 0.75–1.09 7.7 
Injury or poisoning 80 16 0.67 0.54–0.83 5.7 
Other diagnoses 887 177 7.41 6.94–7.91 63.5 
Arranged total 1,396 279 11.66 11.07–12.29 100.0 
Waiting list admissions by primary procedure 
Dental procedures 884 177 7.39 6.92–7.89 23.0 
Grommets 731 146 6.11 5.68–6.57 19.0 
Tonsillectomy ± adenoidectomy 383 77 3.20 2.90–3.54 10.0 
Musculoskeletal procedures 256 51 2.14 1.89–2.42 6.7 
Other procedures 1,410 282 11.78 11.19–12.41 36.7 
No procedure listed 176 35 1.47 1.27–1.70 4.6 
Waiting list total 3,840 768 32.09 31.10–33.10 100.0 
Taranaki total 13,001 2,600 108.63 106.88–110.41   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; excludes neonates; NOS = 
not otherwise specified 
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In all Midland DHBs from 2010 to 2014 the most frequent causes of acute hospitalisations in 15–24 year olds 
were injury or poisoning, mental health conditions, and abdominal or pelvic pain with the addition of skin 
infections in Tairawhiti. Frequent causes of arranged hospitalisations in this age group were injury or poisoning 
and cancer or cancer treatment with the addition of immune disorders in Lakes DHB. Dental procedures, 
tonsillectomy +/− adenoidectomy and gastrointestinal procedures were the most frequent causes of waiting list 
admissions. For all admission types the order of the diagnoses varied between DHBs. All Midland DHBs had a 
substantial number of reproductive hospitalisations; the majority were for pregnancy, delivery, or postnatal-
related conditions (Table 42–Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident 
Population; * Rate per 1,000 15–24 year olds; URTI = upper respiratory tract infection; NOS = not otherwise specified; Injury ED 
cases excluded; Reproductive rates are per 1,000 females thus overall DHB rate not provided due to use of gender-specific 
denominator for reproductive admissions; †NMDS coverage of therapeutic abortions is incomplete, and thus may 
underestimate regional totals 
Table 46). 







Rate* 95% CI 
Per 
cent 
Waikato 15–24 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 3,340 668 12.38 11.97–12.81 13.7 
Abdominal or pelvic pain 2,551 510 9.46 9.10–9.83 10.5 
Mental health 1,996 399 7.40 7.08–7.73 8.2 
Other diagnoses 16,451 3,290 60.99 60.09–61.90 67.6 
Acute total 24,338 4,868 90.23 89.15–91.32 100.0 
Arranged admissions by primary diagnosis 
Injury or poisoning 621 124 2.30 2.13–2.49 10.4 
Neoplasm, chemotherapy, or radiotherapy 465 93 1.72 1.57–1.89 7.8 
Other diagnoses 4,914 983 18.22 17.72–18.73 81.9 
Arranged total 6,000 1,200 22.24 21.69–22.81 100.0 
Reproductive hospitalisations by primary diagnosis 
Pregnancy, delivery, or postnatal-related conditions 11,013 2,203 83.19 81.71–84.69 76.3 
Termination of pregnancy: therapeutic, other, or unspecified† 2,763 553 20.87 20.11–21.65 19.2 
Spontaneous or other early pregnancy loss 652 130 4.93 4.56–5.32 4.5 
Reproductive total 14,428 2,886 108.98 107.32–110.67 100.0 
Waiting list admissions by primary procedure 
Gastrointestinal procedures 940 188 3.48 3.27–3.71 19.9 
Musculoskeletal procedures 503 101 1.86 1.71–2.03 10.6 
Procedures on skin or subcutaneous tissue 430 86 1.59 1.45–1.75 9.1 
Other procedures 2,454 491 9.10 8.75–9.46 51.8 
No procedure listed 406 81 1.51 1.37–1.66 8.6 
Waiting list total 4,733 947 17.55 17.06–18.05 100.0 
Waikato total 49,499 9,900       
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Rate per 1,000 15–24 year 
olds; URTI = upper respiratory tract infection; NOS = not otherwise specified; Injury ED cases excluded; Reproductive rates are 
per 1,000 females thus overall DHB rate not provided due to use of gender-specific denominator for reproductive admissions; 
†NMDS coverage of therapeutic abortions is incomplete, and thus may underestimate regional totals 
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Rate* 95% CI 
Per 
cent 
Bay of Plenty 15–24 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 2,228 446 17.76 17.04–18.50 18.1 
Mental health 1,088 218 8.67 8.17–9.20 8.8 
Abdominal or pelvic pain 889 178 7.09 6.64–7.57 7.2 
Other diagnoses 8,113 1,623 64.66 63.32–66.04 65.9 
Acute total 12,318 2,464 98.18 96.55–99.84 100.0 
Arranged admissions by primary diagnosis 
Injury or poisoning 208 42 1.66 1.45–1.90 11.3 
Neoplasm, chemotherapy, or radiotherapy 183 37 1.46 1.26–1.69 9.9 
Mental health 161 32 1.28 1.10–1.50 8.7 
Other diagnoses 1,293 259 10.31 9.76–10.88 70.1 
Arranged total 1,845 369 14.71 14.05–15.39 100.0 
Reproductive hospitalisations by primary diagnosis 
Pregnancy, delivery, or postnatal-related conditions 5,651 1,130 92.26 89.99–94.58 78.1 
Termination of pregnancy: therapeutic, other, or unspecified† 1,219 244 19.90 18.83–21.04 16.8 
Spontaneous or other early pregnancy loss 365 73 5.96 5.38–6.60 5.0 
Reproductive total 7,235 1,447 118.12 115.59–120.70 100.0 
Waiting list admissions by primary procedure 
Gastrointestinal procedures 610 122 4.86 4.49–5.26 23.1 
Musculoskeletal procedures 413 83 3.29 2.99–3.62 15.7 
Dental procedures 240 48 1.91 1.69–2.17 9.1 
Other procedures 1,242 248 9.90 9.37–10.46 47.1 
No procedure listed 131 26 1.04 0.88–1.24 5.0 
Waiting list total 2,636 527 21.01 20.23–21.82 100.0 
Bay of Plenty total 24,034 4,807       
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Rate per 1,000 15–24 year 
olds; URTI = upper respiratory tract infection; NOS = not otherwise specified; Injury ED cases excluded; Reproductive rates are 
per 1,000 females thus overall DHB rate not provided due to use of gender-specific denominator for reproductive admissions; 
†NMDS coverage of therapeutic abortions is incomplete, and thus may underestimate regional totals 
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Rate* 95% CI 
Per 
cent 
Lakes DHB 15–24 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 1,245 249 18.68 17.68–19.74 17.8 
Mental health 500 100 7.50 6.88–8.19 7.1 
Abdominal or pelvic pain 490 98 7.35 6.73–8.03 7.0 
Other diagnoses 4,772 954 71.61 69.68–73.60 68.1 
Acute total 7,007 1,401 105.15 102.85–107.51 100.0 
Arranged admissions by primary diagnosis 
Mental health 112 22 1.68 1.40–2.02 9.9 
Injury or poisoning 106 21 1.59 1.32–1.92 9.4 
Immune disorders 60 12 0.90 0.70–1.16 5.3 
Other diagnoses 852 170 12.79 11.96–13.67 75.4 
Arranged total 1,130 226 16.96 16.01–17.97 100.0 
Reproductive hospitalisations by primary diagnosis 
Pregnancy, delivery, or postnatal-related conditions 3,880 776 119.12 115.65–122.69 79.7 
Termination of pregnancy: therapeutic, other, or unspecified† 753 151 23.12 21.54–24.81 15.5 
Spontaneous or other early pregnancy loss 236 47 7.25 6.38–8.23 4.8 
Reproductive total 4,869 974 149.49 145.66–153.40 100.0 
Waiting list admissions by primary procedure 
Musculoskeletal procedures 251 50 3.77 3.33–4.26 16.5 
Gastrointestinal procedures 250 50 3.75 3.32–4.25 16.4 
Tonsillectomy ± adenoidectomy 148 30 2.22 1.89–2.61 9.7 
Other procedures 771 154 11.57 10.79–12.41 50.7 
No procedure listed 102 20 1.53 1.26–1.86 6.7 
Waiting list total 1,522 304 22.84 21.73–24.00 100.0 
Lakes DHB total 14,528 2,906       
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Rate per 1,000 15–24 year 
olds; URTI = upper respiratory tract infection; NOS = not otherwise specified; Injury ED cases excluded; Reproductive rates are 
per 1,000 females thus overall DHB rate not provided due to use of gender-specific denominator for reproductive admissions; 
†NMDS coverage of therapeutic abortions is incomplete, and thus may underestimate regional totals 
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Rate* 95% CI 
Per 
cent 
Tairawhiti 15–24 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 596 119 18.82 17.38–20.38 22.0 
Mental health 354 71 11.18 10.08–12.40 13.1 
Skin infections 153 31 4.83 4.13–5.66 5.6 
Abdominal or pelvic pain 150 30 4.74 4.04–5.56 5.5 
Other Diagnoses 1,457 291 46.01 43.76–48.38 53.8 
Acute Total 2,710 542 85.59 82.55–88.72 100.0 
Arranged admissions by primary diagnosis 
Injury or poisoning 94 19 2.97 2.43–3.63 19.9 
Mental health 78 16 2.46 1.97–3.07 16.5 
Neoplasm, chemotherapy, or radiotherapy 25 5 0.79 0.53–1.17 5.3 
Other Diagnoses 275 55 8.68 7.72–9.77 58.3 
Arranged Total 472 94 14.91 13.63–16.30 100.0 
Reproductive hospitalisations by primary diagnosis 
Pregnancy, delivery, or postnatal-related conditions 1,660 332 106.31 101.57–111.24 91.6 
Spontaneous or other early pregnancy loss 99 20 6.34 5.21–7.71 5.5 
Termination of pregnancy: therapeutic, other, or unspecified† 54 11 3.46 2.65–4.51 3.0 
Reproductive Total 1,813 363 116.11 111.18–121.23 100.0 
Waiting list admissions by primary procedure 
Musculoskeletal Procedures 119 24 3.76 3.14–4.49 17.2 
Gastrointestinal procedures 103 21 3.25 2.68–3.94 14.9 
Procedures on skin or subcutaneous tissue 72 14 2.27 1.81–2.86 10.4 
Tonsillectomy +/- adenoidectomy 69 14 2.18 1.72–2.76 10.0 
Other procedures 296 59 9.35 8.35–10.47 42.8 
No procedure listed 33 7 1.04 0.74–1.46 4.8 
Waiting list Total 692 138 21.85 20.30–23.52 100.0 
Tairawhiti total 5,687 1,137       
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Rate per 1,000 15–24 year 
olds; URTI = upper respiratory tract infection; NOS = not otherwise specified; Injury ED cases excluded; Reproductive rates are 
per 1,000 females thus overall DHB rate not provided due to use of gender-specific denominator for reproductive admissions; 
†NMDS coverage of therapeutic abortions is incomplete, and thus may underestimate regional totals 
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Rate* 95% CI 
Per 
cent 
Taranaki 15–24 year olds 
Acute admissions by primary diagnosis 
Injury or poisoning 978 196 14.22 13.36–15.13 14.3 
Mental health 683 137 9.93 9.21–10.70 10.0 
Abdominal or pelvic pain 599 120 8.71 8.04–9.43 8.7 
Other diagnoses 4,595 919 66.79 64.95–68.68 67.0 
Acute total 6,855 1,371 99.65 97.43–101.91 100.0 
Arranged admissions by primary diagnosis 
Injury or poisoning 69 14 1.00 0.79–1.27 4.1 
Immune disorders 54 11 0.78 0.60–1.02 3.2 
Removal of internal fixation device 53 11 0.77 0.59–1.01 3.2 
Other diagnoses 1,493 299 21.70 20.64–22.82 89.5 
Arranged total 1,669 334 24.26 23.14–25.44 100.0 
Reproductive hospitalisations by primary diagnosis 
Pregnancy, delivery, or postnatal-related conditions 3,000 600 90.85 87.80–94.00 73.3 
Termination of pregnancy: therapeutic, other, or unspecified† 891 178 26.98 25.29–28.79 21.8 
Spontaneous or other early pregnancy loss 203 41 6.15 5.36–7.05 5.0 
Reproductive total 4,094 819 123.98 120.47–127.58 100.0 
Waiting list admissions by primary procedure  
Gastrointestinal procedures 388 78 5.64 5.11–6.23 20.4 
Dental procedures 356 71 5.17 4.67–5.74 18.8 
Musculoskeletal procedures 177 35 2.57 2.22–2.98 9.3 
Procedures on skin or subcutaneous tissue 153 31 2.22 1.90–2.60 8.1 
Tonsillectomy ± adenoidectomy 141 28 2.05 1.74–2.42 7.4 
Other procedures 556 111 8.08 7.44–8.78 29.3 
No procedure listed 127 25 1.85 1.55–2.20 6.7 
Waiting list total 1,898 380 27.59 26.39–28.84 100.0 
Taranaki total 14,516 2,903       
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Rate per 1,000 15–24 year 
olds; URTI = upper respiratory tract infection; NOS = not otherwise specified; Injury ED cases excluded; Reproductive rates are 
per 1,000 females thus overall DHB rate not provided due to use of gender-specific denominator for reproductive admissions; 
†NMDS coverage of therapeutic abortions is incomplete, and thus may underestimate regional totals 
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AMBULATORY SENSITIVE HOSPITALISATIONS 
Introduction 
Ambulatory sensitive hospitalisations (ASH) are a range of conditions for which hospitalisation could 
potentially be avoided.19 At a community level, high ASH rates may indicate difficulty in accessing primary 
care in a timely fashion, poor care coordination or care continuity, or structural constraints such as limited 
supply of primary care workers. However ASH rates are also determined by other factors including hospital 
size and service configuration, capacity for emergency department management, admission policies and 
practices, as well as health literacy and overall social determinants of health in the community. It is important 
to note the deliberate use of the word ‘sensitive’ in the title of ASH. Not all these hospitalisations would be 
avoidable even in a perfect health system; for example, children who are found to have relatively minor ASH 
conditions may have come in to hospital for investigations to exclude more serious illness such as 
meningococcal disease.20  
There are currently two different ASH algorithms in use in New Zealand: the NZCYES uses paediatric ASH 
codes developed by Anderson et al21 with analysis restricted to age 0–4 years and a population-based 
denominator. The Health Quality and Safety Commission use a similar but not identical list in 0–14 year olds 
with a PHO enrolment denominator.20 Both provide analyses including and excluding ED cases.  
In New Zealand children, ASH accounts for approximately 30% of all acute and arranged medical and 
surgical discharges each year.20 Pathways to prevent ASH will vary by condition. For asthma it may be the 
use of preventative medicine, whilst for gastroenteritis it may be about access to early oral rehydration 
fluids.20 Vaccine-preventable disease can be prevented almost entirely with good immunisation coverage and 
diseases or conditions that can lead to rapid onset of problems, such as dehydration and gastroenteritis, can be 
treated in primary care.19 
The following section reports on ambulatory sensitive hospitalisations for children aged 0–4 years using the 
ASH conditions, as defined by NZCYES, applied to information from the National Mortality Collection and 
the National Minimum Dataset. Guidelines and reviews of literature which consider the most effective 
interventions for preventing or managing the specific conditions included in ASH can be found in the relevant 
indicator chapter. 
Data sources and methods 
Indicator 
Ambulatory sensitive hospitalisations (ASH) in 0–4 year olds 
Data sources 
Numerator:  National Minimum Dataset 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Definition 
Acute and arranged hospitalisations for ambulatory sensitive conditions in 0–4 year olds  
The conditions in this section are based on primary diagnosis, and include: 
Asthma and wheeze, bronchiectasis, skin infections, constipation, dental caries and other dental conditions, dermatitis and 
eczema, gastroenteritis, gastro-oesophageal reflux, nutritional deficiency, bacterial or non-viral pneumonia, rheumatic 
fever/rheumatic heart disease, otitis media, acute upper respiratory tract infections (excluding croup), vaccine preventable 
diseases: (neonatal/other tetanus, congenital rubella; pertussis age ≥6 months, diphtheria, hepatitis B, measles, mumps, 
rubella age ≥16 months, urinary tract infections age >4 years). 
Notes on interpretation 
Note 1: Age filters: The 0–4 year age group has been selected for this analysis as it aligns with the Ministry of Health’s 
previous paediatric ASH Target (0–4 years). Neonatal hospitalisations (0–27 days) have been excluded on the basis that issues 
arising in the neonatal period are likely to be heavily influenced by antenatal/perinatal factors, and as a consequence are 
likely to require different care pathways from conditions arising in the community (e.g. pneumonia in a very preterm infant). 
The only exceptions are neonatal tetanus and congenital rubella, which are potentially preventable by timely (maternal) 
access to immunisation. Further, age filters have also been applied to some vaccine preventable diseases (e.g. measles ≥16 
months) on the basis that these conditions may not be (primary care) preventable, prior to the age at which immunisation for 
the relevant condition is due. Similarly, a >4 year age criteria has been applied to urinary tract infections, on the basis that 
younger children may require hospitalisation for further investigation.  
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Note 2: Admission type filters: An acute hospitalisation is an unplanned hospitalisation occurring on the day of presentation, 
while an arranged admission is a non-acute hospitalisation with an admission date less than seven days after the decision 
was made that the admission was required. A waiting list admission is a planned hospitalisation, where the admission date is 
equal to or greater than seven days after the decision was made that the admission was necessary. In this section, all analyses 
include acute and arranged admissions only, with the exception of dental conditions, which also include waiting list 
admissions (as some DHBs routinely admit dental conditions from the waiting list, while others admit the majority as 
arranged admissions, potentially creating artefactual DHB differences if the entire burden of dental morbidity is not 
captured). This restriction was applied in order to eliminate the large number of cases where the primary diagnosis was, for 
example, otitis media, but where the main reason for admission was for the insertion of grommets. It was considered that the 
role primary care played in preventing acute admissions (e.g. for acute otitis media), was likely to differ from the one it played 
in ensuring children had access to waiting list procedures (e.g. for the insertion of grommets).  
Note 3: Emergency Department Filters: In order to deal with the issue of inconsistent uploading of Emergency Department 
(ED) cases to the National Minimum Dataset (see Appendix 3), the Ministry of Health has traditionally applied a number of 
filters to its ASH analyses.22,23 These filters exclude Accident and Emergency cases which meet the following criteria:  
• The admission and discharge dates are the same AND, 
• The patient was not discharged dead (i.e., discharge type not in ‘DD’) AND, 
• The health specialty code is in (‘M05’, ‘M06’, ‘M07’, or ‘M08’). 
While the NZ Child and Youth Epidemiology service does not recommend the use of such filters in the paediatric population, 
in order to allow DHBs to assess the impact ED cases have on their ASH rates, all the analyses in this section are presented 
with both ED cases included and excluded. In contrast to the Ministry of Health filters described above however, all ED cases 
have either been totally included or excluded, not just those admitted and discharged on the same day (as in the paediatric 
population many presentations occur late in the evening, with children then being discharged in the early hours of the 
following day, potentially making their total length of stay similar to that of ED day cases). 
For those DHBs without a dedicated paediatric emergency department, who assess the majority of their cases in a Paediatric 
Assessment Unit or on the Paediatric Ward, the ED included and excluded analyses may be identical. Local variations in the 
way health specialty codes are assigned to such cases may seriously influence the differences seen between the ED included 
and excluded rates.  
As shown in Figure 30, ASH rates were highest for children aged under two years and declined rapidly with 
increasing age from age five years whether ED cases were included or excluded. The remainder of this section 
is restricted to 0–4 year olds (Figure 30). 
Figure 30. Ambulatory sensitive hospitalisations in 0–14 year olds, by age New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions, neonates excluded); Denominator: Statistics NZ 
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Causes of ambulatory sensitive hospitalisations 
Between 2010 and 2014 there were 102,454 ASH when ED cases were included and 88,831 ASH when ED 
cases were excluded. The most frequent ASH diagnoses with ED cases included were gastroenteritis and 
asthma and wheeze. With ED cases excluded the most common ASH diagnosis was asthma and wheeze, 
followed by dental conditions and gastroenteritis (Table 47).  











95% CI Per cent 
Ambulatory sensitive hospitalisations in 0–4 year olds 
Emergency Department cases included 
Gastroenteritis 21,691 4,338 14.07 13.89–14.26 21.2 
Asthma and wheeze 21,603 4,321 14.02 13.83–14.20 21.1 
Acute upper respiratory infections (excl croup) 17,937 3,587 11.64 11.47–11.81 17.5 
Dental 14,629 2,926 9.49 9.34–9.65 14.3 
Pneumonia: bacterial, non-viral 9,162 1,832 5.94 5.82–6.07 8.9 
Skin infections 8,219 1,644 5.33 5.22–5.45 8.0 
Dermatitis and eczema 2,681 536 1.74 1.68–1.81 2.6 
Otitis media 2,480 496 1.61 1.55–1.67 2.4 
Constipation 2,030 406 1.32 1.26–1.38 2.0 
Gastro-oesophageal reflux 1,353 271 0.88 0.83–0.93 1.3 
Bronchiectasis 263 53 0.17 0.15–0.19 0.3 
Nutritional deficiencies or anaemias 211 42 0.14 0.12–0.16 0.2 
VPD ≥ 6 months: DTP, Polio, HepB 156 31 0.10 0.09–0.12 0.2 
VPD ≥ 16 months: MMR 28 6 0.02 0.01–0.03 0.0 
Rheumatic fever or rheumatic heart disease 11 2 0.01 s 0.0 
Total 102,454 20,491 66.48 66.09–66.87 100.0 
Emergency Department cases excluded 
Asthma and wheeze 16,230 3,246 10.53 10.37–10.69 20.1 
Dental 14,596 2,919 9.47 9.32–9.62 18.1 
Gastroenteritis 14,580 2,916 9.46 9.31–9.61 18.0 
Acute upper respiratory infections (excl croup) 12,598 2,520 8.17 8.03–8.32 15.6 
Skin infections 7,686 1,537 4.99 4.88–5.10 9.5 
Pneumonia: bacterial, non-viral 7,677 1,535 4.98 4.87–5.09 9.5 
Dermatitis and eczema 2,457 491 1.59 1.53–1.66 3.0 
Otitis media 1,713 343 1.11 1.06–1.17 2.1 
Constipation 1,493 299 0.97 0.92–1.02 1.8 
Gastro-oesophageal reflux 1,185 237 0.77 0.73–0.81 1.5 
Bronchiectasis 257 51 0.17 0.15–0.19 0.3 
Nutritional deficiencies or anaemias 198 40 0.13 0.11–0.15 0.2 
VPD ≥ 6 months: DTP, Polio, HepB 133 27 0.09 0.07–0.10 0.2 
VPD ≥ 16 months: MMR 17 3 0.01 0.01–0.02 0.0 
Rheumatic fever or rheumatic heart disease 11 2 0.01 s 0.0 
Total 80,831 16,166 52.45 52.10–52.80 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions, neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population; * Acute upper respiratory tract infections excludes croup; s: suppressed due to small numbers; 
VPD: Vaccine preventable diseases; DTP: diphtheria, tetanus, pertussis; HepB: hepatitis B; MMR: measles, mumps, rubella 
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National trends and distribution 
From 2000 to 2014 the hospitalisation rate for ambulatory-care sensitive conditions rose when ED cases were 
included and fell when ED cases were excluded (Figure 31).  
When considered by primary diagnosis ASH rates rose from 2000 to 2014 for asthma and wheeze and dental 
conditions and fell for pneumonia with ED cases included or excluded. Hospitalisation rates for URTI and 
gastroenteritis and skin infections were more variable over time (Figure 32).  
Figure 31. Ambulatory sensitive hospitalisations in 0–4 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions, neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population  
Figure 32. Ambulatory sensitive hospitalisations in 0–4 year olds, by primary diagnosis, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions, neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population; * Acute URTI = Acute upper respiratory infections (excl croup); Pneumonia† = Bacterial and 
non-viral pneumonia 
From 2000 to 2014 hospitalisation rates for ambulatory-care sensitive conditions were stable for 
European/Other 0–4 year olds and increased for other ethnic groups when ED cases were included. When ED 
cases were excluded ASH rates rose for Asian/Indian children, fell for European/Other children and were 
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without ED cases, were consistently highest for Pacific children, followed by Māori, European/Other and 
Asian/Indian children. Data for MELAA children were available from 2006; the MELAA rate rose when ED 
cases were included and was stable with year-to-year variability with ED cases excluded (Figure 33). 
Figure 33. Ambulatory sensitive hospitalisations in 0–4 year olds, by ethnicity, New Zealand, 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions, neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population 
Distribution by demographic factors 
From 2010 to 2014 for children aged 0–4 years there were disparities in ASH rates by NZDep2013 decile, 
ethnicity and gender. With ED cases included a social gradient was evident with a significant increase in ASH 
rates between each quintile of NZDep2013 scores compared with the quintile below. ASH rates for Māori, 
Pacific, Asian/Indian and MELAA were significantly higher than rates for European/Other children. Male 
ASH rates were significantly higher than female rates. Similar relationships with demographic factors were 
observed when ED cases were excluded except that rates for Asian/Indian 0–14 years olds were significantly 
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Table 48. Ambulatory sensitive hospitalisations in 0–4 year olds (ED cases included), by demographic variables 
New Zealand 2010–2014 
Variable Number: 2010−2014 
Rate per 1,000 0–4 
year olds 
Rate ratio 95% CI 
Ambulatory sensitive hospitalisations in 0–4 year olds 
Emergency Department cases included 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 10,977 42.16 1.00   
Deciles 3–4 12,717 48.56 1.15 1.12–1.18 
Deciles 5–6 15,981 54.24 1.29 1.26–1.32 
Deciles 7–8 23,417 68.13 1.62 1.58–1.65 
Deciles 9–10 38,901 102.24 2.42 2.38–2.48 
Prioritised ethnicity 
Māori 31,438 76.24 1.49 1.47–1.51 
Pacific 18,322 120.54 2.36 2.32–2.40 
Asian/Indian 10,750 60.89 1.19 1.17–1.22 
MELAA 1,977 93.10 1.82 1.74–1.90 
European/Other 39,820 51.12 1.00   
Gender 
Female 45,443 60.56 1.00   
Male 57,009 72.09 1.19 1.18–1.20 
Numerator: National Minimum Dataset (acute and arranged admissions, neonates excluded, ED included); Denominator: 
Statistics NZ Estimated Resident Population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013  
Table 49. Ambulatory sensitive hospitalisations in 0–4 year olds (ED cases excluded), demographic variables 




Rate per 1,000  
0–4 year olds 
Rate ratio 95% CI 
Ambulatory sensitive hospitalisations in 0–4 year olds 
Emergency Department cases excluded 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 8,614 33.09 1.00   
Deciles 3–4 9,777 37.34 1.13 1.10–1.16 
Deciles 5–6 12,221 41.48 1.25 1.22–1.29 
Deciles 7–8 18,996 55.27 1.67 1.63–1.71 
Deciles 9–10 30,896 81.20 2.45 2.40–2.51 
Prioritised ethnicity 
Māori 26,274 63.72 1.52 1.50–1.55 
Pacific 13,528 89.00 2.13 2.09–2.17 
Asian/Indian 7,035 39.85 0.95 0.93–0.98 
MELAA 1,303 61.36 1.47 1.39–1.55 
European/Other 32,560 41.80 1.00   
Gender 
Female 35,839 47.76 1.00   
Male 44,990 56.89 1.19 1.18–1.21 
Numerator: National Minimum Dataset (acute and arranged admissions, neonates excluded, ED included); Denominator: 
Statistics NZ Estimated Resident Population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013  
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Distribution by region 
Hospitalisation rates for ambulatory-sensitive conditions, with ED cases included were significantly higher 
than the New Zealand rate in the Northland, Auckland, Counties Manukau, Waikato, Bay of Plenty, Lakes, 
Tairawhiti, Whanganui and Hutt Valley DHBs between 2010 and 2014. In contrast rates were significantly 
lower than the New Zealand rate in the Waitemata, Taranaki, Hawke’s Bay, MidCentral, Capital & Coast, 
Wairarapa, Nelson Marlborough, South Canterbury, Canterbury and West Coast DHBs. Excluding ED cases 
made a difference for the Canterbury and Southern DHBs were rates became significantly higher and the 
Auckland and Waikato DHBs where rates became significantly lower than the New Zealand rate (Figure 34, 
Table 50). 



















































































































































































































Ambulatory sensitive hospitalisations DHB rate (ED cases included)
DHB rate (ED cases excluded)
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population 
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Rate per 1,000 
0–4 year olds 
Rate ratio 95% CI 
Ambulatory sensitive hospitalisations in 0–4 year olds 
Emergency Department cases included 
Northland 4,289 858 71.74 1.08 1.05–1.11 
Waitemata 11,720 2,344 60.20 0.91 0.89–0.92 
Auckland 11,124 2,225 74.67 1.12 1.10–1.14 
Counties Manukau 14,527 2,905 71.14 1.07 1.05–1.09 
Waikato 9,723 1,945 70.01 1.05 1.03–1.07 
Bay of Plenty 5,931 1,186 80.30 1.21 1.18–1.24 
Lakes 2,795 559 71.18 1.07 1.03–1.11 
Tairawhiti 1,524 305 79.11 1.19 1.13–1.25 
Taranaki 1,921 384 47.24 0.71 0.68–0.74 
Hawke's Bay 3,216 643 55.90 0.84 0.81–0.87 
MidCentral 3,154 631 55.28 0.83 0.80–0.86 
Whanganui 1,829 366 83.30 1.25 1.20–1.31 
Hutt Valley 4,556 911 88.48 1.33 1.29–1.37 
Capital & Coast 5,976 1,195 62.61 0.94 0.92–0.97 
Wairarapa 824 165 60.68 0.91 0.85–0.98 
Nelson Marlborough 1,935 387 45.16 0.68 0.65–0.71 
South Canterbury 635 127 37.37 0.56 0.52–0.61 
Canterbury 9,764 1,953 61.19 0.92 0.90–0.94 
West Coast 495 99 45.95 0.69 0.63–0.75 
Southern 6,093 1,219 64.57 0.97 0.95–1.00 
New Zealand 102,454 20,491 66.48 1.00   
Emergency Department cases excluded 
Northland 3,742 748 62.59 1.19 1.16–1.23 
Waitemata 7,866 1,573 40.40 0.77 0.75–0.79 
Auckland 5,335 1,067 35.81 0.68 0.66–0.70 
Counties Manukau 10,936 2,187 53.55 1.02 1.00–1.04 
Waikato 6,265 1,253 45.11 0.86 0.84–0.88 
Bay of Plenty 5,349 1,070 72.42 1.38 1.34–1.42 
Lakes 2,453 491 62.47 1.19 1.15–1.24 
Tairawhiti 1,500 300 77.86 1.48 1.41–1.56 
Taranaki 1,660 332 40.82 0.78 0.74–0.82 
Hawke's Bay 2,947 589 51.23 0.98 0.94–1.01 
MidCentral 2,765 553 48.47 0.92 0.89–0.96 
Whanganui 1,598 320 72.78 1.39 1.32–1.46 
Hutt Valley 4,153 831 80.65 1.54 1.49–1.58 
Capital & Coast 4,814 963 50.43 0.96 0.93–0.99 
Wairarapa 733 147 53.98 1.03 0.96–1.10 
Nelson Marlborough 1,860 372 43.41 0.83 0.79–0.87 
South Canterbury 630 126 37.07 0.71 0.65–0.76 
Canterbury 9,727 1,945 60.96 1.16 1.14–1.19 
West Coast 485 97 45.03 0.86 0.79–0.94 
Southern 5,719 1,144 60.61 1.16 1.13–1.19 
New Zealand 80,831 16,166 52.45 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions, neonates excluded, ED excluded); Denominator: 
Statistics NZ Estimated Resident Population 
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 hospitalisation rates for ambulatory sensitive conditions with ED cases included were 
significantly higher than the national rate in Waikato, Bay of Plenty, Lakes and Tairawhiti DHBs and 
significantly lower in Taranaki. When ED cases were excluded ASH rates in Bay of Plenty, Lakes and 
Tairawhiti DHBs were significantly higher than the national rate, and ASH rates were significantly lower in 
Waikato and Taranaki (Table 51). 







Rate per 1,000 
0–4 year olds 
Rate ratio 95% CI 
Ambulatory sensitive hospitalisations in 0–4 year olds 
Emergency Department cases included 
Waikato 9,723 1,945 70.01 1.05 1.03–1.07 
Bay of Plenty 5,931 1,186 80.30 1.21 1.18–1.24 
Lakes 2,795 559 71.18 1.07 1.03–1.11 
Tairawhiti 1,524 305 79.11 1.19 1.13–1.25 
Taranaki 1,921 384 47.24 0.71 0.68–0.74 
New Zealand 102,454 20,491 66.48 1.00   
Emergency Department cases excluded 
Waikato 6,265 1,253 45.11 0.86 0.84–0.88 
Bay of Plenty 5,349 1,070 72.42 1.38 1.34–1.42 
Lakes 2,453 491 62.47 1.19 1.15–1.24 
Tairawhiti 1,500 300 77.86 1.48 1.41–1.56 
Taranaki 1,660 332 40.82 0.78 0.74–0.82 
New Zealand 80,831 16,166 52.45 1.00 0.0 
Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population 
Regional trends 
Hospitalisation rates of 0–4 year olds for ambulatory sensitive conditions declined between 2000 and 2014 in 
Bay of Plenty and Taranaki. Hospitalisation rates including ED cases increased in Waikato and remained 
relatively stable in Lakes DHB during this period; when ED cases were excluded rates remained relatively 
stable in both these DHBs. Tairawhiti showed an increase in ASH rates from 2000 to 2007 and then declined 
so that 2014 ASH rates were very similar to rates in 2000 (Figure 35, Figure 36). 
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Figure 35. Ambulatory sensitive hospitalisations in children aged 0−4 years, by ED status, Waikato, Bay of Plenty 






































































































































s Ambulatory sensitive hospitalisations DHB: ED cases included
New Zealand: ED cases included
DHB: ED cases excluded
New Zealand: ED cases excluded
 
Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population 
Figure 36. Ambulatory sensitive hospitalisations in children aged 0−4 years, by ED status, Tairawhiti and 








































































































DHB: ED cases included
New Zealand: ED cases included
DHB: ED cases excluded
New Zealand: ED cases excluded
 
Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population 
The hospitalisation rates of Pacific and Māori 0–4 year olds for ambulatory sensitive conditions were 
generally higher than Asian and European/Other rates in Waikato, Bay of Plenty and Lakes DHBs from 2000 
to 2014 and in Bay of Plenty Pacific rates have been much higher than other ethnic groups since 2007. In 
Tairawhiti Māori ASH rates rose more steeply than European/Other rates from 2000 to 2007, and then fell 
steeply so that by 2014 there was little difference in ASH rates by ethnicity. In Taranaki Māori ASH rates 
were consistently somewhat higher than European/Other rates (Figure 37).
 
Issues for all ages: Ambulatory sensitive hospitalisations 
96 
Figure 37. Ambulatory sensitive hospitalisations in 0−4 year olds, by ED status and ethnicity, Midland DHBs 2000−2014. Ambulatory sensitive hospitalisations in 0−4 year olds, by ED 





























































































































































































































































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ Estimated Resident Population; Ethnicity is level 1 prioritised 
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Regional distribution by cause 
Between 2010 and 2014 0–4 year olds hospitalised with ambulatory sensitive conditions in the Midland DHBs 
were most frequently diagnosed with gastroenteritis, asthma and wheeze, upper respiratory tract infections 
(excluding croup) or dental conditions although the order of these diagnoses varied between DHBs and with 
inclusion or exclusion of ED cases (Table 52–Table 56). 











95% CI Per cent 
Ambulatory sensitive hospitalisations in Waikato 0–4 year olds 
Emergency Department cases included 
Gastroenteritis 2,065 413 14.87 14.25–15.52 21.2 
Dental 1,890 378 13.61 13.01–14.23 19.4 
Asthma and wheeze 1,837 367 13.23 12.64–13.84 18.9 
Acute upper respiratory infections (excluding croup) 1,809 362 13.03 12.44–13.64 18.6 
Skin infections 613 123 4.41 4.08–4.78 6.3 
Pneumonia: bacterial, non-viral 611 122 4.40 4.06–4.76 6.3 
Otitis media 319 64 2.30 2.06–2.56 3.3 
Constipation 223 45 1.61 1.41–1.83 2.3 
Dermatitis and eczema 151 30 1.09 0.93–1.27 1.6 
Gastro-oesophageal reflux 143 29 1.03 0.87–1.21 1.5 
Bronchiectasis 28 6 0.20 0.14–0.29 0.3 
VPD ≥6 months: DTP, Polio, HepB 19 4 0.14 0.09–0.21 0.2 
Nutritional deficiencies or anaemias 10 2 0.07 0.04–0.13 0.1 
VPD ≥16 months: MMR <5 s s s s 
Rheumatic fever or rheumatic heart disease <5 s s s s 
Total 9,723 1,945 70.01 68.68–71.36 100.0 
Emergency Department cases excluded 
Dental 1,884 377 13.57 12.97–14.19 30.1 
Asthma and wheeze 1,170 234 8.42 7.96–8.92 18.7 
Gastroenteritis 1,004 201 7.23 6.80–7.69 16.0 
Acute upper respiratory infections (excluding croup) 660 132 4.75 4.40–5.13 10.5 
Skin infections 548 110 3.95 3.63–4.29 8.7 
Pneumonia: bacterial, non-viral 478 96 3.44 3.15–3.76 7.6 
Otitis media 132 26 0.95 0.80–1.13 2.1 
Constipation 130 26 0.94 0.79–1.11 2.1 
Dermatitis and eczema 111 22 0.80 0.66–0.96 1.8 
Gastro-oesophageal reflux 100 20 0.72 0.59–0.88 1.6 
Bronchiectasis 27 5 0.19 0.13–0.28 0.4 
VPD ≥6 months: DTP, Polio, HepB 13 3 0.09 0.05–0.16 0.2 
Nutritional deficiencies or anaemias 7 1 0.05 0.02–0.10 0.1 
Rheumatic fever or rheumatic heart disease <5 s s s s 
VPD ≥16 months: MMR 0 .. .. .. .. 
Total 6,265 1,253 45.11 44.03–46.21 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population; s= suppressed due to small numbers; VPD: Vaccine preventable diseases; DTP: diphtheria, 
tetanus, pertussis; HepB: hepatitis B; MMR: measles, mumps, rubella 
 
Issues for all ages: Ambulatory sensitive hospitalisations 
98 











95% CI Per cent 
Ambulatory sensitive hospitalisations in Bay of Plenty 0–4 year olds 
Emergency Department cases included 
Acute upper respiratory infections (excluding croup) 1,323 265 17.91 16.98–18.89 22.3 
Gastroenteritis 1,290 258 17.47 16.55–18.44 21.8 
Asthma and wheeze 1,138 228 15.41 14.54–16.32 19.2 
Dental 648 130 8.77 8.13–9.47 10.9 
Pneumonia: bacterial, non-viral 470 94 6.36 5.82–6.96 7.9 
Skin infections 432 86 5.85 5.32–6.43 7.3 
Dermatitis and eczema 201 40 2.72 2.37–3.12 3.4 
Otitis media 192 38 2.60 2.26–2.99 3.2 
Constipation 97 19 1.31 1.08–1.60 1.6 
Gastro-oesophageal reflux 96 19 1.30 1.06–1.59 1.6 
Nutritional deficiencies or anaemias 18 4 0.24 0.15–0.39 0.3 
VPD ≥6 months: DTP, Polio, HepB 13 3 0.18 0.10–0.30 0.2 
Bronchiectasis 9 2 0.12 0.06–0.23 0.2 
Rheumatic fever or rheumatic heart disease <5 s s s s 
VPD ≥16 months: MMR 0 .. .. .. .. 
Total 5,931 1,186 80.30 78.37–82.29 100.0 
Emergency Department cases excluded 
Acute upper respiratory infections (excluding croup) 1,130 226 15.30 14.44–16.21 21.1 
Gastroenteritis 1,096 219 14.84 13.99–15.74 20.5 
Asthma and wheeze 1,033 207 13.99 13.16–14.86 19.3 
Dental 648 130 8.77 8.13–9.47 12.1 
Pneumonia: bacterial, non-viral 455 91 6.16 5.62–6.75 8.5 
Skin infections 415 83 5.62 5.10–6.18 7.8 
Dermatitis and eczema 195 39 2.64 2.30–3.04 3.6 
Otitis media 158 32 2.14 1.83–2.50 3.0 
Gastro-oesophageal reflux 91 18 1.23 1.00–1.51 1.7 
Constipation 84 17 1.14 0.92–1.41 1.6 
Nutritional deficiencies or anaemias 18 4 0.24 0.15–0.39 0.3 
VPD ≥6 months: DTP, Polio, HepB 13 3 0.18 0.10–0.30 0.2 
Bronchiectasis 9 2 0.12 0.06–0.23 0.2 
Rheumatic fever or rheumatic heart disease <5 s s s s 
VPD ≥16 months: MMR 0 .. .. .. .. 
Total 5,349 1,070 72.42 70.58–74.32 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population; VPD: Vaccine preventable diseases; DTP: diphtheria, tetanus, pertussis; HepB: hepatitis B; MMR: 
measles, mumps, rubella  
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95% CI Per cent 
Ambulatory sensitive hospitalisations in Lakes DHB 0–4 year olds 
Emergency Department cases included 
Asthma and wheeze 524 105 13.35 12.26–14.53 18.7 
Dental 502 100 12.79 11.72–13.95 18.0 
Acute upper respiratory infections (excluding croup) 486 97 12.38 11.33–13.52 17.4 
Gastroenteritis 480 96 12.22 11.18–13.36 17.2 
Pneumonia: bacterial, non-viral 267 53 6.80 6.03–7.66 9.6 
Skin infections 222 44 5.65 4.96–6.45 7.9 
Otitis media 99 20 2.52 2.07–3.07 3.5 
Dermatitis and eczema 96 19 2.44 2.00–2.98 3.4 
Constipation 56 11 1.43 1.10–1.85 2.0 
Gastro-oesophageal reflux 42 8 1.07 0.79–1.45 1.5 
Nutritional deficiencies or anaemias 7 1 0.18 0.09–0.37 0.3 
Bronchiectasis 6 1 0.15 0.07–0.33 0.2 
VPD ≥6 months: DTP, Polio, HepB 6 1 0.15 0.07–0.33 0.2 
VPD ≥16 months: MMR <5 s s s s 
Rheumatic fever or rheumatic heart disease 0 .. .. .. .. 
Total 2,795 559 71.18 68.68–73.77 100.0 
Emergency Department cases excluded 
Dental 501 100 12.76 11.70–13.92 20.4 
Asthma and wheeze 447 89 11.38 10.38–12.48 18.2 
Gastroenteritis 388 78 9.88 8.95–10.91 15.8 
Acute upper respiratory infections (excluding croup) 380 76 9.68 8.76–10.70 15.5 
Pneumonia: bacterial, non-viral 251 50 6.39 5.65–7.23 10.2 
Skin infections 215 43 5.48 4.79–6.26 8.8 
Dermatitis and eczema 90 18 2.29 1.87–2.82 3.7 
Otitis media 70 14 1.78 1.41–2.25 2.9 
Constipation 50 10 1.27 0.97–1.68 2.0 
Gastro-oesophageal reflux 40 8 1.02 0.75–1.39 1.6 
Nutritional deficiencies or anaemias 7 1 0.18 0.09–0.37 0.3 
Bronchiectasis 6 1 0.15 0.07–0.33 0.2 
VPD ≥6 months: DTP, Polio, HepB 6 1 0.15 0.07–0.33 0.2 
VPD ≥16 months: MMR <5 s s s s 
Rheumatic fever or rheumatic heart disease 0 .. .. .. .. 
Total 2,453 491 62.47 60.12–64.91 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population; VPD: Vaccine preventable diseases; DTP: diphtheria, tetanus, pertussis; HepB: hepatitis B; MMR: 
measles, mumps, rubella 
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95% CI Per cent 
Ambulatory sensitive hospitalisations in Tairawhiti 0–4 year olds 
Emergency Department cases included 
Acute upper respiratory infections (excluding croup) 317 63 16.46 14.75–18.35 20.8 
Gastroenteritis 271 54 14.07 12.50–15.83 17.8 
Dental 263 53 13.65 12.11–15.39 17.3 
Asthma and wheeze 237 47 12.30 10.84–13.96 15.6 
Pneumonia: bacterial, non-viral 142 28 7.37 6.26–8.68 9.3 
Skin infections 134 27 6.96 5.88–8.23 8.8 
Dermatitis and eczema 88 18 4.57 3.71–5.62 5.8 
Constipation 33 7 1.71 1.22–2.40 2.2 
Otitis media 27 5 1.40 0.96–2.04 1.8 
Gastro-oesophageal reflux 6 1 0.31 0.14–0.68 0.4 
VPD ≥6 months: DTP, Polio, HepB <5 s s s s 
Bronchiectasis <5 s s s s 
Nutritional deficiencies or anaemias <5 s s s s 
Rheumatic fever or rheumatic heart disease 0 .. .. .. .. 
VPD ≥16 months: MMR 0 .. .. .. .. 
Total 1,524 305 79.11 75.38–83.01 100.0 
Emergency Department cases excluded 
Acute upper respiratory infections (excluding croup) 311 62 16.14 14.46–18.02 20.7 
Dental 263 53 13.65 12.11–15.39 17.5 
Gastroenteritis 260 52 13.50 11.96–15.23 17.3 
Asthma and wheeze 232 46 12.04 10.60–13.68 15.5 
Pneumonia: bacterial, non-viral 142 28 7.37 6.26–8.68 9.5 
Skin infections 133 27 6.90 5.83–8.18 8.9 
Dermatitis and eczema 88 18 4.57 3.71–5.62 5.9 
Constipation 32 6 1.66 1.18–2.34 2.1 
Otitis media 27 5 1.40 0.96–2.04 1.8 
Gastro-oesophageal reflux 6 1 0.31 0.14–0.68 0.4 
VPD ≥6 months: DTP, Polio, HepB <5 s s s s 
Bronchiectasis <5 s s s s 
Nutritional deficiencies or anaemias <5 s s s s 
Rheumatic fever or rheumatic heart disease 0 .. .. .. .. 
VPD ≥16 months: MMR 0 .. .. .. .. 
Total 1,500 300 77.86 74.16–81.73 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population; VPD: Vaccine preventable diseases; DTP: diphtheria, tetanus, pertussis; HepB: hepatitis B; MMR: 
measles, mumps, rubella 
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95% CI Per cent 
Ambulatory sensitive hospitalisations in Taranaki 0–4 year olds 
Emergency Department cases included 
Asthma and wheeze 504 101 12.39 11.36–13.52 26.2 
Gastroenteritis 355 71 8.73 7.87–9.68 18.5 
Dental 308 62 7.57 6.78–8.46 16.0 
Acute upper respiratory infections (excluding croup) 288 58 7.08 6.31–7.95 15.0 
Pneumonia: bacterial, non-viral 194 39 4.77 4.15–5.49 10.1 
Skin infections 128 26 3.15 2.65–3.74 6.7 
Dermatitis and eczema 49 10 1.20 0.91–1.59 2.6 
Otitis media 37 7 0.91 0.66–1.25 1.9 
Constipation 31 6 0.76 0.54–1.08 1.6 
Gastro-oesophageal reflux 18 4 0.44 0.28–0.70 0.9 
Nutritional deficiencies or anaemias <5 s s s s 
Bronchiectasis <5 s s s s 
VPD ≥16 months: MMR <5 s s s s 
VPD ≥6 months: DTP, Polio, HepB <5 s s s s 
Rheumatic fever or rheumatic heart disease 0 .. .. .. .. 
Total 1,921 384 47.24 45.22–49.35 100.0 
Emergency Department cases excluded 
Asthma and wheeze 418 84 10.28 9.34–11.31 25.2 
Dental 308 62 7.57 6.78–8.46 18.6 
Gastroenteritis 274 55 6.74 5.99–7.58 16.5 
Acute upper respiratory infections (excluding croup) 229 46 5.63 4.95–6.41 13.8 
Pneumonia: bacterial, non-viral 181 36 4.45 3.85–5.15 10.9 
Skin infections 120 24 2.95 2.47–3.53 7.2 
Dermatitis and eczema 46 9 1.13 0.85–1.51 2.8 
Otitis media 30 6 0.74 0.52–1.05 1.8 
Constipation 28 6 0.69 0.48–1.00 1.7 
Gastro-oesophageal reflux 18 4 0.44 0.28–0.70 1.1 
Nutritional deficiencies or anaemias <5 s s s s 
Bronchiectasis <5 s s s s 
VPD ≥6 months: DTP, Polio, HepB <5 s s s s 
Rheumatic fever or rheumatic heart disease 0 .. .. .. .. 
VPD ≥16 months: MMR 0 .. .. .. .. 
Total 1,660 332 40.82 38.94–42.79 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; neonates excluded); Denominator: Statistics NZ 
Estimated Resident Population; VPD: Vaccine preventable diseases; DTP: diphtheria, tetanus, pertussis; HepB: hepatitis B; MMR: 
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UPPER RESPIRATORY TRACT INFECTIONS  
Introduction 
Acute upper respiratory tract infections (URTIs) are a common cause of illness in childhood and responsible for 
a considerable proportion of children’s visits to primary care each year.24 Although URTIs are generally of short 
duration and limited severity, they place a significant burden on secondary care services.25 In New Zealand, a 
number of acute URTIs are considered to be ambulatory sensitive on the basis that early and appropriate 
management of these conditions in primary care can significantly reduce the need for hospitalisation.25 
Upper respiratory conditions particularly relevant for children are non-specific URTIs, acute pharyngitis and 
tonsillitis. Non-specific URTIs, including the common cold, produce a variety of symptoms including cough, 
sore throat, runny nose, fever and malaise. They are usually of viral origin.26 The available evidence indicates 
that antibiotic treatment does not alter the course of these illnesses26 which are self-limiting in the vast majority 
of cases, nor is it an effective strategy for preventing complications such as lower respiratory conditions like 
pneumonia.27 A minority of cases of pharyngitis and tonsillitis are due to group A streptococci and may, if 
untreated, result in acute rheumatic fever.28 Given their multi-factorial aetiology (for example, exposure to 
infectious agents, cigarette smoke, poor nutrition, sub-standard housing, overcrowding), approaches to the 
prevention of respiratory and infectious diseases take a variety of forms. Poverty is linked to higher rates of 
respiratory and infectious disease through its associations with poor housing, poor nutrition, smoking, air 
pollution, and difficulties with accessing healthcare.29 
The following section uses data from the National Minimum Dataset to review acute and arranged admissions 
for acute upper respiratory infections in 0–14 year olds. Guidelines and evidence-based reviews, which consider 
how these conditions might best be prevented or managed, are summarised at the end of the section.  
Data sources and methods 
Indicator 
Hospitalisations for acute upper respiratory tract infections in 0–14 year olds  
Data sources 
Numerator:  National Minimum Dataset 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years) 
Definition 
Acute and arranged hospitalisations for 0–14 year olds with a primary diagnosis of acute upper respiratory tract infection (URTI). 
Acute URTIs comprise: acute nasopharyngitis (common cold); acute sinusitis; acute pharyngitis; acute tonsillitis; croup, acute 
laryngitis, or tracheitis; acute URTI multiple or unspecified sites; epiglottitis. Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: All of the acute upper respiratory tract infections listed above are considered ambulatory sensitive, with the exception of 
croup/acute laryngitis/tracheitis, where early access to primary care may not prevent a hospitalisation (e.g. children with croup 
may require hospitalisation for the management of respiratory distress). 
Note 2: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
(also referred to as a arranged admission) is a non-acute hospitalisation with an admission date less than seven days after the 
date the decision was made that hospitalisation was necessary. Because arranged hospitalisations comprise a mix of patients 
being admitted semi-acutely for the management of medical conditions, and semi-urgently for operative procedures, in this 
section, arranged hospitalisations have been included. 
Note 4: Appendix 3 outlines the limitations of the data utilised from the National Minimum Dataset. The reader is advised to 
review this appendix before interpreting any trends.  
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National trends and distribution 
From 2000 to 2014 there were 80,273 hospitalisations of 0–14 year olds with acute URTI, an average of 5352 
hospitalisations per year. The hospitalisation rate for acute URTI was stable with year-to-year fluctuations from 
2000 to 2009 and then rose significantly from 2009 to 2014 (Figure 38). The rise in hospitalisation rates for 
acute URTI was particularly marked for Pacific, MELAA and Asian/Indian ethnic groups, whereas rates for 
Māori and European/Other were more stable over time. Hospitalisation rates for Pacific, MELAA and Māori 
were consistently higher than European/Other rates; Asian/Indian rates were lower than European/Other rates 
until 2013 when they rose to become similar to European/Other (Figure 39). 
Figure 38. Hospitalisations for acute upper respiratory tract infections in 0–14 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Figure 39. Hospitalisations for acute upper respiratory tract infections (URTIs) in 0–14 year olds, by ethnicity, New 
Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
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Distribution by primary diagnosis 
Between 2010 and 2014 the primary diagnosis for the majority of acute URTI hospitalisations was unspecified 
or involved multiple acute URTI sites. Of the remainder, the most frequent diagnoses were croup, acute 
laryngitis or tracheitis and acute tonsillitis (Table 57). 
Table 57. Hospitalisations for acute upper respiratory tract infections in 0–14 year olds, by primary diagnosis, 










95% CI Per cent 
Acute upper respiratory tract infections in 0–14 year olds 
New Zealand  
Croup, acute laryngitis, or tracheitis 6,628 1,326 1.46 1.43–1.50 22.54 
Acute tonsillitis 3,657 731 0.81 0.78–0.83 12.44 
Acute pharyngitis 1,579 316 0.35 0.33–0.37 5.37 
Acute nasopharyngitis (common cold) 191 38 0.04 0.04–0.05 0.65 
Acute sinusitis 102 20 0.02 0.02–0.03 0.35 
Epiglottitis 9 2 <0.01 … <0.1 
Acute URTI multiple or unspecified sites 17,242 3,448 3.81 3.75–3.86 58.63 
Total 29,408 5,882 6.49 6.42–6.57 100.00 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Distribution by demographic factors 
For 0–14 year olds between 2010 and 2014 acute URTI hospitalisation rates were highest for 0–2 year olds and 
then decreased rapidly with increasing age. Male hospitalisation rates were higher than female children to age 
eight years (Figure 40). A similar age pattern was seen in all ethnic groups with Pacific rates higher than other 
ethnic groups for 0–2 year olds. 
Figure 40. Hospitalisations for acute upper respiratory tract infections (URTIs) in 0–14 year olds, by age and sex, 
New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Between 2010 and 2014 there was disparity in rates of acute URTI by NZDep2013 index of deprivation score, 
ethnicity and gender. There was an evident social gradient with a significant increase in acute URTI rates 
between each quintile (using the NZDep2013 scores) compared with the quintile below, significantly higher 
rates for Māori, Pacific and MELAA ethnic groups and significantly lower rates for Asian/Indian compared with 
European/Other (Table 58). 
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Table 58. Hospitalisations for acute upper respiratory tract infections in 0–14 year olds, by demographic factor, 




Rate per 1,000  
0–14 year olds 
Rate ratio 95% CI 
Acute upper respiratory tract infections in 0–14 year olds 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 3,646 4.18 1.00   
Deciles 3–4 4,009 4.97 1.19 1.14–1.24 
Deciles 5–6 4,889 5.72 1.37 1.31–1.43 
Deciles 7–8 6,641 7.07 1.69 1.62–1.76 
Deciles 9–10 10,076 9.55 2.28 2.20–2.37 
Prioritised ethnicity 
Māori 7,806 6.77 1.14 1.11–1.17 
Pacific 4,085 9.39 1.58 1.52–1.63 
Asian/Indian 2,534 5.32 0.89 0.86–0.93 
MELAA 575 10.33 1.73 1.60–1.88 
European/Other 14,359 5.96 1.00   
Gender 
Female 12,511 5.67 1.00   
Male 16,897 7.28 1.28 1.25–1.31 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rates are per 1,000 0–14 year olds; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013. 
Distribution by season 
There was seasonal variation in acute URTI hospitalisations. The highest numbers of hospitalisations were in 
June to September and the lowest numbers in December to February (Figure 41). 
Figure 41. Hospitalisations for acute upper respiratory tract infections (URTIs) in 0–14 year olds, by month, New 
Zealand 2010–2014 
 
National Minimum Dataset (acute and arranged admissions) 
Distribution by region 
Between 2010 and 2014 the hospitalisation rates for acute URTI were significantly higher than the national rate 
in the Waikato, Bay of Plenty, Tairawhiti, Whanganui, Hutt Valley, Canterbury and Southern DHBs. Total acute 
URTI hospitalisation rates were significantly lower than the national rate in the Northland, Waitemata, 
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In remaining district health boards there was no significant difference from the national rate (Figure 42, Table 
59).  
Figure 42. Hospitalisations for acute upper respiratory tract infections in 0–14 year olds, by district health board, 
New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Table 59. Hospitalisations for acute upper respiratory tract infections in 0–14 year olds, by district health board, 






Rate per 1,000 
0–14 year olds 
Rate ratio 95% CI 
Acute upper respiratory tract infections in 0–14 year olds 
Northland 970 194 5.35 0.82 0.77–0.88 
Waitemata 2,743 549 4.88 0.75 0.72–0.78 
Auckland 2,424 485 5.88 0.91 0.87–0.94 
Counties Manukau 3,836 767 6.46 1.00 0.96–1.03 
Waikato 2,811 562 6.89 1.06 1.02–1.10 
Bay of Plenty 2,082 416 9.17 1.41 1.35–1.48 
Lakes 772 154 6.57 1.01 0.94–1.09 
Tairawhiti 553 111 9.44 1.45 1.34–1.58 
Taranaki 544 109 4.55 0.70 0.64–0.76 
Hawke's Bay 896 179 5.17 0.80 0.75–0.85 
MidCentral 868 174 5.06 0.78 0.73–0.83 
Whanganui 701 140 10.71 1.65 1.53–1.78 
Hutt Valley 1,225 245 8.11 1.25 1.18–1.32 
Capital & Coast 1,744 349 6.37 0.98 0.94–1.03 
Wairarapa 296 59 7.04 1.08 0.97–1.22 
Nelson Marlborough 690 138 5.14 0.79 0.73–0.85 
South Canterbury 226 45 4.27 0.66 0.58–0.75 
Canterbury 3,714 743 7.85 1.21 1.17–1.25 
West Coast 163 33 5.16 0.80 0.68–0.93 
Southern 2,016 403 7.20 1.11 1.06–1.16 
New Zealand 29,408 5,882 6.49 1.00   
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Midland region distribution and trends 
Between 2010 and 2014, acute URTI hospitalisation rates were significantly higher than the national rate in 
Waikato, Bay of Plenty, and Tairawhiti, significantly lower in Taranaki and were not significantly different in 
Lakes DHB (Table 60). 







 Rate per 1,000 
0–14 year olds  
Rate ratio  95% CI  
Acute upper respiratory tract infections in 0–14 year olds  
Waikato 2811 562 6.89  1.06  1.02–1.10  
Bay of Plenty 2082 416 9.17  1.41  1.35–1.48  
Lakes 772 154 6.57  1.01  0.94–1.09  
Tairawhiti 553 111 9.44  1.45  1.34–1.58  
Taranaki 544 109 4.55  0.70  0.64–0.76  
New Zealand 29408 5882 6.49  1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Regional trends 
Acute URTI hospitalisations were stable from 2000 and 2014 in Waikato, Bay of Plenty and Lakes DHB with 
some variability from year to year. Hospitalisation rates rose in Tairawhiti from 2000 to 2004 and then fell again 
from 2006 to 2007 and have been stable since. There was an overall fall in hospitalisation rates in Taranaki 
(Figure 43). Hospitalisation rates for Pacific rose in Bay of Plenty from 2000 to 2014 and otherwise there was 
little difference between the rates for different ethnic groups in the Midland DHBs (Figure 44).  
Regional distribution by primary diagnosis 
In all Midland DHBs, at least half of the acute URTI hospitalisations had a primary diagnosis of multiple or 
unspecified acute URTI sites. The most common specific diagnosis were croup, acute laryngitis or tracheitis and 
acute tonsillitis (Table 61). 
Regional distribution by season 
There was seasonal variation in acute URTI hospitalisations in all Midland DHBs. The highest numbers of 
hospitalisations were typically between June and September and the lowest numbers from December to 
February (Figure 45). 
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Acute upper respiratory tract infections DHB
New Zealand
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident Population; Rate per 1,000 0–14 year olds 



































































































































































































































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident Population; Rate per 1,000 0–14 year olds 
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Table 61. Hospitalisations for acute upper respiratory tract infections in 0−14 year olds, by primary diagnosis, 










Per cent of 
category 
Acute upper respiratory tract infections in 0–14 year olds 
Waikato 
Croup, acute laryngitis, or tracheitis 511 102 1.25 2.58–3.07 18.2 
Acute tonsillitis 510 102 1.25 1.15–1.36 18.1 
Acute pharyngitis 177 35 0.43 0.37–0.50 6.3 
Acute nasopharyngitis (common cold) 42 8 0.10 0.08–0.14 1.5 
Acute sinusitis 7 1 0.02 0.01–0.04 0.2 
Epiglottitis <5 s s s s 
Acute URTI multiple or unspecified sites 1,563 313 3.83 3.65–4.03 55.6 
Total 2,811 562 6.89 6.64–7.15 100.0 
Bay of Plenty 
Croup, acute laryngitis, or tracheitis 395 79 1.74 1.97–2.40 19.0 
Acute tonsillitis 281 56 1.24 1.10–1.39 13.5 
Acute pharyngitis 128 26 0.56 0.47–0.67 6.1 
Acute nasopharyngitis (common cold) 16 3 0.07 0.04–0.11 0.8 
Acute sinusitis 5 1 0.02 0.01–0.05 0.2 
Epiglottitis 0 .. .. .. .. 
Acute URTI multiple or unspecified sites 1,257 251 5.54 5.24–5.85 60.4 
Total 2,082 416 9.17 8.79–9.58 100.0 
Lakes DHB 
Croup, acute laryngitis, or tracheitis 155 31 1.32 0.73–1.00 20.1 
Acute tonsillitis 127 25 1.08 0.91–1.28 16.5 
Acute pharyngitis 70 14 0.60 0.47–0.75 9.1 
Acute nasopharyngitis (common cold) <5 s s s s 
Acute sinusitis <5 s s s s 
Epiglottitis 0 .. .. .. .. 
Acute URTI multiple or unspecified sites 415 83 3.53 3.21–3.89 53.8 
Total 772 154 6.57 6.12–7.04 100.0 
Tairawhiti 
Croup, acute laryngitis, or tracheitis 158 32 2.70 0.75–1.02 28.6 
Acute tonsillitis 44 9 0.75 0.56–1.01 8.0 
Acute pharyngitis 23 5 0.39 0.26–0.59 4.2 
Acute nasopharyngitis (common cold) <5 s s s s 
Acute sinusitis 0 .. .. .. .. 
Epiglottitis 0 .. .. .. .. 
Acute URTI multiple or unspecified sites 325 65 5.55 4.98–6.18 58.8 
Total 553 111 9.44 8.69–10.3 100.0 
Taranaki 
Croup, acute laryngitis, or tracheitis 176 35 1.47 0.84–1.12 32.4 
Acute tonsillitis 56 11 0.47 0.36–0.61 10.3 
Acute pharyngitis 25 5 0.21 0.14–0.31 4.6 
Acute nasopharyngitis (common cold) 10 2 0.08 0.05–0.15 1.8 
Acute sinusitis <5 s s s s 
Epiglottitis <5 s s s s 
Acute URTI multiple or unspecified sites 273 55 2.28 2.03–2.57 50.2 
Total 544 109 4.55 4.18–4.94 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
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Evidence for good practice for the prevention of infectious and 
respiratory diseases 
Ministry of Health publications 
Medsafe 2015. Changes to the use of bromhexine or codeine-containing cough and cold medicines in children. 
http://www.medsafe.govt.nz/safety/EWS/2015/BromhexineOrCodeine.asp accessed June 2015. 
This web page outlines concerns regarding the use of bromhexine (a mucolytic used to break up thick phlegm associated with a chesty cough) 
and codeine (a pain reliever) in cough and cold medicines used by children. Bromhexine is metabolised to ambroxol, to which there have 
been a number of allergic reaction (including anaphylaxis) and codeine is metabolised to morphine which induces respiratory depression in 
overdoses. Due to these concerns, Medsafe and the Medicines Adverse Reactions Committee (MARC) reviewed the use of cough and cold 
medicines containing these ingredients. MARC concluded that there was insufficient evidence to support the use of such medicines in younger 
age groups and recommended that their use should be restricted as follows: to adults and children six years of age and over for medicines 
containing bromhexine; and to adults and children 12 years of age and over for medicines containing codeine. 
Ministry of Health. 2004. National health emergency plan: Infectious diseases. Wellington: Ministry of Health. 
http://www.health.govt.nz/system/files/documents/publications/nationalhealthemergencyplan.pdf 
This publication deals with responding to high-impact rapidly progressive infectious diseases that have the potential to create a national 
health-related emergency, such as severe acute respiratory syndrome (SARS) or influenza. The Plan is intended for use by all agencies and 
individuals in the health and disability sector.  
Ministry of Health. 1997. Nga Kupu Oranga Healthy Messages: A health and safety resource for early childhood 
services. Wellington: Ministry of Health. 
http://www.health.govt.nz/system/files/documents/publications/ngakupuorangahealthymessages.pdf 
This publication provides guidance for early childhood services on common childhood illnesses, how to prevent them, the care of children 
with on-going conditions, and safety issues likely to occur in any early childhood service. Section B deals with preventing infectious illnesses 
under the headings exclusion, immunisation, personal hygiene and cleaning.  
International guidelines 
National Health and Medical Research Council. 2012. Staying Healthy: Preventing infectious diseases in early childhood 
education and care services. Canberra: National Health and Medical Research Council. 
https://www.nhmrc.gov.au/guidelines-publications/ch55  
This comprehensive publication is intended to provide staff working in education and care services with simple and effective ways to minimise 
the spread of disease and to meet the requirements of the Australian National Quality Framework for Early Childhood Education and Care. 
The advice is presented in six sections, covering: concepts of infection control; monitoring illness in children; procedures; issues for employers, 
educators and other staff; fact sheets on diseases common to education and care services; and forms, useful contacts and websites. In addition 
to the Staying Healthy guideline, the website has a range of posters and pamphlets relevant to infection control. 
Zeng L, Zhang L, Hu Z, et al. 2014. Systematic review of evidence-based guidelines on medication therapy for upper 
respiratory tract infection in children with AGREE instrument. PLoS One 9(2) e87711. 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087711 
The review aimed to summarize the recommendations of existing guidelines on the treatment of upper respiratory tract infections in children, 
and to assess the methodological quality of these guidelines. The authors identified 13 evidence-based guidelines meeting their criteria: one 
on pharyngitis, four on rhinosinusitis, four on influenza, three on otitis media, and one on upper respiratory infections. They used the AGREE 
II tool (http://www.agreetrust.org/ ) to assess the quality of these guidelines. They stated that there were huge differences between the 
guidelines regarding the categorisation of evidence and recommendations and that nearly all of the guidelines lacked sufficient involvement 
of the stakeholders. Penicillin and amoxicillin were suggested for group A streptococcal pharyngitis. Amoxicillin and amoxicillin-clavulanate 
were recommended for acute bacterial rhinosinusitis. For mild otitis media, an observation period of 2–3 days prior to initiation of antibiotic 
therapy was recommended, with amoxicillin suggested as the first choice antibiotic. There was a lack of direct evidence to support strong 
recommendations for influenza. There was a lack of agreement on antimicrobial durations for pharyngitis and on the initiation and duration 
of antimicrobials for acute bacterial rhinosinusitis. The review authors recommended that future guidelines should use a consistent grading 
system for the quality of evidence and strength of recommendations. 
Snellman L, Adams W, Anderson G, et al. 2013. Diagnosis and treatment of respiratory illness in children and adults. 
Bloomington (MN): Institute for Clinical Systems Improvement (ICSI). 
https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_respiratory_guidelines/resp
iratory_illness/  
This guideline has three goals: education to assist patients to be competent and comfortable with home care of respiratory illness; to assist 
medical personnel to differentiate respiratory illness from more severe illness; to improve the appropriateness of care and reduce unnecessary 
antibiotic use for respiratory illness while decreasing the cost of that care. It covers acute conditions in infants aged >3 months, children, 
adolescents and adults, who are in good health. A summary of the guideline can be found at the National Guideline Clearinghouse website: 
National Guideline Clearinghouse. Diagnosis and treatment of respiratory illness in children and adults 
http://www.guideline.gov/content.aspx?id=43792&search=upper+respiratory+children  
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Vodicka TA, Thompson M, Lucas P, et al. 2013. Reducing antibiotic prescribing for children with respiratory tract 
infections in primary care: a systematic review. The British Journal of General Practice, 63(612), e445-e54. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693801/ 
Doctors frequently prescribe antibiotics for respiratory tract infections (RTIs), despite knowing that these infections are mostly self-limiting 
and that antibiotics are of uncertain value for RTIs. Overuse of antibiotics is of concern because it is associated with the development of 
antibiotic resistance, adverse effects, and increased healthcare seeking behaviour. This review aimed to assess the effectiveness of primary 
care based interventions to reduce antibiotic prescribing for children with RTIs. The review authors searched for randomised, cluster 
randomised and non-randomised studies testing educational and/or behavioural interventions to change antibiotics prescribing for children 
(<18 years) with RTIs. They identified 17 studies. One study included three different interventions, so in total there were 19 interventions 
studied: 10 directed at both clinicians and parents, six towards clinicians only, and three to parents only. Eight of the interventions targeting 
both parents and clinicians reported significant decreases in prescribing rates, ranging from 6% to 21% at follow-up from one week to two 
years. Of the six interventions aimed at clinicians only, one reported a significant reduction in antibiotic prescribing, a further two reported 
significant reductions in inappropriate antibiotic prescribing, and the other three reported either no significant reduction or an increase in 
antibiotic prescribing. None of the interventions targeting parents only, for example the provision of information pamphlets in waiting rooms, 
significantly reduced antibiotics prescriptions. The most effective interventions involved targeting both clinicians and parents during 
consultations, providing automatic computer prompts for evidence-based prescribing, and promoting clinician leadership or participation in 
the design of treatment guidelines and/or peer education. 
Andrews T, Thompson M, Buckley DI, et al. 2012. Interventions to influence consulting and antibiotic use for acute 
respiratory tract infections in children: a systematic review and meta-analysis. PLoS One, 7(1), e30334. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267713/ 
This review aimed to assess the effect of interventions directed at parents or caregivers that were designed to influence consulting and 
antibiotic use for children with respiratory tract infections (RTIs) in primary care. It included studies that used randomised, cluster randomised, 
or non-randomised controlled designs, or one group pre/post-test designs, to assess the effect of educational or behavioural interventions 
directed at caregivers in influencing consulting or antibiotic use for acute RTIs in children (birth to 18 years), in developed countries. There 
were 23 studies (representing 20 interventions) identified meeting these criteria. Materials designed to engage children as well as parents 
were effective in modifying parental knowledge and behaviour, resulting in reductions in consulting rates ranging from 13% to 40% (moderate 
level of evidence). Providing parents with delayed prescriptions significantly decreased reported antibiotic use (Risk Ratio 0.46, 95% CI 0.40 
to 0.54); and a delayed or no prescribing approach did not lessen parental satisfaction (strong evidence). 
Shulman ST, Bisno AL, Clegg HW, et al. 2012. Clinical practice guideline for the diagnosis and management of group A 
streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 
55(10), e86-102. http://cid.oxfordjournals.org/content/55/10/e86.long (Erratum in Clin Infect Dis. 2014 May;58(10):1496. 
Dosage error in article text.) 
This guideline is intended for healthcare providers who care for child and adult patients with group A streptococcal (GAS) pharyngitis (sore 
throat). GAS is the most common cause of bacterial pharyngitis, responsible for 20–30% of sore throat visits in children. Streptococcal 
pharyngitis is important because it can lead to the post infectious disorders of acute rheumatic fever and post-streptococcal 
glomerulonephritis. Strength of recommendations and quality of evidence are rated using the GRADE system. The guideline covers: 
establishing the diagnosis of GAS pharyngitis; who should undergo testing for GAS pharyngitis; treatment recommendations (antibiotics); 
adjunctive therapy; and chronic pharyngeal carriage of GAS. It states that penicillin or amoxicillin (for 10 days) remain the treatments of choice, 
except in penicillin allergic patients, who should be treated with first generation cephalosporin (for those not anaphylactically sensitive) for 
10 days, clindamycin or clarithromycin for 10 days, or azithromycin for 5 days. Additional publications on the treatment of streptococcal 
pharyngitis, with an emphasis on the prevention of subsequent rheumatic fever can be found in the chapter on rheumatic fever, on page 
226. 
National Institute for Health and Clinical Excellence. 2008. Prescribing of antibiotics for self-limiting respiratory tract 
infections in adults and children in primary care. London: National Institute for Health and Clinical Excellence. 
https://www.nice.org.uk/guidance/cg69  
Acute respiratory infections are common and usually self-limiting. Overuse of antibiotics in primary care increases rates of antibiotic resistance 
which could become a major public health problem. This guideline is intended to provide evidence-based best practice advice on the care of 
adults and children over three months of age for whom immediate prescribing of antibiotics is not warranted. The guidelines state that a no 
antibiotic or delayed antibiotic prescribing strategy is appropriate for patients with the following conditions: acute otitis media, acute sore 
throat/acute pharyngitis/acute tonsillitis, common cold, acute rhinosinusitis, acute cough/acute bronchitis but that an immediate antibiotic 
prescribing strategy can be considered for bilateral acute otitis media in children younger than two years, acute otitis media in children with 
otorrhoea and acute sore throat/acute pharyngitis/acute tonsillitis when three or more Centor criteria are present. The guidelines also cover 
advice to patients and identifying patients at risk of developing complications who require immediate antibiotics and/or further investigations. 
The full guideline, and the supporting evidence, can be downloaded here: http://www.nice.org.uk/guidance/cg69/evidence . 
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Jefferson T, Del Mar C, Dooley L, et al. 2011. Physical interventions to interrupt or reduce the spread of respiratory 
viruses. Cochrane Database of Systematic Reviews, 2011(7). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006207.pub4/abstract  
This review considers the effectiveness of physical interventions such as isolation, quarantine, hand washing and wearing masks, gloves and 
gowns in preventing the spread of respiratory viruses, particularly during epidemics. It includes 66 papers from 67 studies of various types 
(RCTs, cluster-RCTs, case-control studies, cohort studies and before-and-after studies). The five included RCTs, and most cluster RCTs, were 
judged to be at high risk of bias. The reviewers concluded that hand washing interventions are effective, particularly when directed at younger 
children. This may be because young children are less capable of managing their own hygiene and because they have longer-lived infections 
and more social contact (thus being more likely to make other people ill). Barrier methods such as gowns, gloves and masks are also effective, 
as is isolation of suspected cases. These interventions are even more effective when used in combination. The benefits of adding virucidals or 
antiseptics to normal hand washing are uncertain. There was limited evidence of the superior effectiveness of N95 respirators over simple 
surgical masks however the respirators were more expensive and more uncomfortable to wear. The authors state that N95 respirators may 
be useful in very high risk situations but that further research is needed to define these situations. 
Lee KM, Shukla VK, Clark M, et al. 2011. Physical Interventions to Interrupt or Reduce the Spread of Respiratory Viruses 
- Resource Use Implications: A Systematic Review. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 
https://www.cadth.ca/media/pdf/M0024_respiratory_viruses_tr_e.pdf  
This systematic review, prepared by the CADTH in partnership with the WHO, assesses the resource use implications associated with physical 
interventions for interrupting or reducing the spread of respiratory viruses. It is complementary to the Cochrane review above. Seven studies 
were identified as meeting the reviews inclusion criteria i.e. they reported information on resource use of physical interventions or assessed 
the cost-effectiveness of physical interventions. They were all observational in nature and provided only low quality evidence. The review 
authors noted that the Cochrane review indicated that the use of physical interventions to interrupt or reduce the spread of respiratory viruses 
during epidemics and pandemics is effective, and they stated that, given the generally low cost of these interventions, the reviewed economic 
studies showed that the use of personal protective equipment was economically attractive, more so when transmission and fatality rates are 
high. 
The following publication provides a brief summary of the review: https://www.cadth.ca/media/pdf/cadth-2-3-02.pdf . 
Alves Galvão Márcia G, Rocha Crispino Santos Marilene A, Alves da Cunha Antonio JL. 2014. Antibiotics for preventing 
suppurative complications from undifferentiated acute respiratory infections in children under five years of age. 
Cochrane Database of Systematic Reviews http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007880.pub2/abstract 
One possible reason why antibiotics may be prescribed for undifferentiated acute upper respiratory infections (those not confined to one 
specific part of the respiratory tract) is the belief that they may prevent bacterial complications such as otitis media, mastoiditis, quinsy 
(tonsillar abscess) or pneumonia. This review aimed to assess the efficacy and safety of antibiotics for preventing complications in children 
aged two to 59 months who have undifferentiated acute respiratory infections (ARIs). Studies were deemed eligible for inclusion in the review 
if they were RCTs or quasi-RCTs comparing antibiotic prescriptions with placebo or non-treatment in children up to 59 months with an 
undifferentiated ARI for up to seven days. Four such studies were identified, involving 1,314 children. Three trials investigated the use of 
amoxicillin/clavulanic acid to prevent otitis, and one investigated ampicillin to prevent pneumonia. Data from the three amoxicillin/clavulanic 
acid trials (414 children in total) indicated that the antibiotic was associated with a non-significant reduction in risk of otitis media: risk ratio 
0.70, 95% CI 0.45 to 1.11, moderate quality evidence. Data from the one trial (889 children) that compared ampicillin trial to supportive care 
(continuation of breastfeeding, clearing of the nose and paracetamol for fever control) indicated that ampicillin did not significantly affect 
the risk developing pneumonia: risk ratio 1.05, 95% CI 0.74 to 1.49, moderate quality evidence. It was not possible to analyse harm outcomes 
as these were reported only as percentages. There were no studies found that assessed mastoiditis, quinsy, abscess, meningitis, hospital 
admission or death. The review authors concluded that the quality of evidence currently available does not provide strong support for the 
use of antibiotics to reduce the risk of otitis or pneumonia in children aged up to five years of age with undifferentiated ARIs and that further 
high quality research is needed to provide more definitive evidence of the effectiveness of antibiotics in this population. 
Spurling Geoffrey KP, Del Mar Chris B, Dooley L, et al. 2013. Delayed antibiotics for respiratory infections. Cochrane 
Database of Systematic Reviews (4) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004417.pub4/abstract 
One strategy to reduce antibiotics prescribing for infections that are likely to be viral and/or self-limiting is to provide prescriptions but advise 
patients to delay getting them filled in the hope that symptoms will resolve first. This review sought to evaluate delayed antibiotics vs. 
immediate antibiotics as a prescribing strategy for acute respiratory infections. The review authors identified ten relevant RCTs with a total of 
3,157 participants. For most outcomes, other than patient satisfaction, the heterogeneity of the trials precluded meta-analysis. For the clinical 
outcomes evaluated in cough and common cold there was no difference between delayed, immediate and no prescribed antibiotics. In patients 
with sore throat and otitis media, immediate antibiotics were more effective than delayed antibiotics for fever, pain and malaise in some 
studies. There were no significant differences in complication rates and only minor differences in adverse effects. Compared to immediate 
antibiotics, delayed antibiotics resulted in a significant reduction in antibiotic use, and the strategy of no antibiotics use led to the least 
antibiotic use. Patients were slightly less satisfied with delayed antibiotics than immediate antibiotics: 87% vs. 92%, odds ratio (OR) 0.52; 95% 
CI 0.35 to 0.76. Delayed and no antibiotics had similar satisfaction rates: 87% vs. 83%, OR 1.44; 95% CI 0.99 to 2.10, with both strategies 
achieving over 80% satisfaction. There was no difference between the immediate and delayed antibiotics groups in re-consultation rates. No 
studies evaluated antibiotic resistance. The review authors concluded that in patients with respiratory infections, where clinicians believe it is 
safe not to give antibiotics immediately, giving no antibiotics with advice to return if symptoms don’t resolve is likely to result in the least 
antibiotics use, with similar clinical outcomes and patient satisfaction to delayed antibiotics. 
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Jefferson T, Rivetti A, Di Pietrantonj C, et al. 2012. Vaccines for preventing influenza in healthy children. Cochrane 
Database of Systematic Reviews (8) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004879.pub4/abstract 
The aim of this review was to appraise all comparative studies evaluating the effects of influenza vaccines in healthy children, assess vaccine 
efficacy (prevention of confirmed influenza) and effectiveness (prevention of influenza-like illness (ILI)) and document adverse events 
associated with influenza vaccines. The review included 75 studies with around 300,000 observations. Seventeen RCTs, 19 cohort studies and 
11 case-control studies were included in the analysis of vaccine efficacy and effectiveness. Evidence from RCTs of live attenuated vaccine 
(administered via nasal spray) indicated that six children under the age of six need to be vaccinated to prevent one case of influenza (infection 
and symptoms). There was no usable data on live attenuated vaccine use in children aged ≤ two years. Inactivated vaccines (administered via 
injection) were not significantly more efficacious than placebo in children aged ≤ two years. Twenty-eight children over the age of six needed 
to be vaccinated to prevent one case of influenza (infection and symptoms), and eight need to be vaccinated to prevent one case of influenza-
like illness (ILI). There was no evidence found regarding an effect on secondary cases, lower respiratory disease, drug prescriptions, otitis 
media and its consequences and socioeconomic impact. There was weak single-study evidence of an effect on children’s school absenteeism, 
and caring parents’ work absenteeism. Due to variability in study design and presentation of data, a meta-analysis of safety outcome data 
was unfeasible. Extensive evidence of reporting bias of safety outcomes from trials of live-attenuated vaccines inhibited meaningful analysis. 
One specific brand of monovalent pandemic vaccine is associated with cataplexy and narcolepsy in children and there is sparse evidence of 
serious harms (such as febrile convulsions) in specific situations. The review authors concluded that influenza vaccine are efficacious in 
preventing cases of influenza in children > two years of age, but there is little evidence available for younger children. They noted that 
vaccination of healthy children is recommended from six months of age in the US, Canada, parts of Europe and Australia despite there being 
only one study of inactivated vaccine in children < two years of age. They also noted that many published trials are funded by industry and 
there is widespread evidence of manipulation of conclusions and spurious notoriety of studies. They stated that the review content and 
findings should be interpreted with this in mind.  
Wang K, Shun-Shin M, Gill P, et al. 2012. Neuraminidase inhibitors for preventing and treating influenza in children 
(published trials only). Cochrane Database of Systematic Reviews (4) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002744.pub4/abstract 
During influenza epidemics, more than 40% of children may become ill. Options for prevention include the neuraminidase inhibitors zanamivir 
(Relenza) and oseltamivir (Tamiflu). Laninamivir octanoate, the prodrug of laninamivir, is under development. This review aimed to assess the 
efficacy, safety and tolerability of neuraminidase inhibitors in treating and preventing influenza in children. The review authors identified six 
double-blind RCTs involving 1,906 children with clinical influenza and 450 children with influenza diagnosed on rapid near-patient influenza 
testing. Of these 2,356 children, 1,255 had laboratory-confirmed influenza. The review also included three prophylaxis trials involving 863 
children exposed to influenza. In children with laboratory-confirmed influenza oseltamivir reduced median duration of illness by 36 hours 
(26%, p < 0.001). One trial of oseltamivir in children with asthma who had laboratory-confirmed influenza showed only a small reduction in 
illness duration (10.4 hours, 8%), which was not statistically significant (p = 0.542). Laninamivir octanoate 20 mg reduced symptom duration 
by 2.8 days (60%, p < 0.001) in children with oseltamivir-resistant influenza A/H1N1. Zanamivir reduced median duration of illness by 1.3 days 
(24%, p < 0.001). Oseltamivir significantly reduced acute otitis media in children aged one to five years with laboratory-confirmed influenza 
(risk difference (RD) −0.14, 95% CI −0.24 to −0.04). Prophylaxis with either zanamivir or oseltamivir was associated with an 8% absolute 
reduction in developing influenza after a case came into the household (RD −0.08, 95% CI −0.12 to −0.05, p < 0.001). The adverse event 
profile of zanamivir was no worse than placebo but vomiting was more common with oseltamivir than placebo (number needed to harm = 
17, 95% CI 10 to 34). Laninamivir octanoate and oseltamivir had similar adverse event profiles. The review authors concluded that oseltamivir 
and zanamivir appear to have modest benefit in reducing duration of illness in children with influenza. They noted that their analysis was 
limited by small sample sizes and being unable to pool data from different studies, and that using data from only published studies may have 
resulted in significant publication bias. They concluded that: based on published trial data, ostelamivir reduces the incidence of otitis media 
in children aged one to five years, but is associated with a significant risk of vomiting; one study indicated that laninamivir octanoate was 
more effective than oseltamivir in reducing duration of illness in children with oseltamivir-resistant influenza A/H1N1; there is weak evidence 
that oseltamivir and zanamivir have modest benefits in preventing the transmission of influenza in households. They stated that the clinical 
efficacy of neuraminidase inhibitors in 'at risk' children, such as those with chronic medical conditions, is still uncertain and that larger high-
quality trials are needed to determine the efficacy of neuraminadase inhibitors in preventing serious complications of influenza, such as 
hospital admission or pneumonia, especially in “at-risk” groups. 
Immunisation Advisory Centre. 2014. Influenza vaccine (Fluarix® or Influvac®) http://www.immune.org.nz/node/604 
accessed June 2015. 
This webpage provides information about influenza vaccination. The section “Who should get the vaccine” states that the vaccine is available 
for anyone aged 6 months or more, and free for children aged four and under who have been hospitalised for respiratory illness or have a 
history of a significant respiratory illness, children and adults with a medical condition that increases their risk of acquiring influenza or 
developing complications from influenza, and Children and young people aged 6 months to 18 years living within the Canterbury District 
Health Board area 
MacDonald N E, McDonald J C, Canadian Paediatric Society Infectious Diseases and Immunization Committee. 2014. The 
benefits of influenza vaccine in pregnancy for the fetus and the infant younger than six months of age 
http://www.cps.ca/en/documents/position/influenza-vaccine-in-pregnancy accessed June 2015. 
This practice point (with references) explains that influenza is a serious problem for infants aged <6 months, who have hospitalisation rates 
comparable with those of the elderly. Because influenza vaccination is ineffective in this age group, the optimal evidence-based strategy is to 
administer trivalent inactivated influenza vaccines during pregnancy. Immunizing with trivalent inactivated influenza vaccines in the second 
and third trimester is stated to be well studied and safe, not only providing protection for the pregnant woman and her infant <6 months of 
age, but also for the fetus by decreasing the risk for low birth weight. 
 




In New Zealand, there are large number of waiting list admissions for tonsillectomy each year.30 While some 
tonsillectomies are performed for the management of upper airway obstruction and/or obstructive sleep apnoea, 
most are for the management of recurrent tonsillitis.30 There has been considerable controversy regarding the 
benefits of tonsillectomy for recurrent throat infections, and internationally tonsillectomy is now a much less 
frequently performed procedure than it was in the past.31-33 Several national guidelines and an Australasian 
position paper recommend the use of the “Paradise Criteria” when determining the indications for 
tonsillectomy.31,34,35 These are: seven or more well-documented, adequately treated disabling sore throats due to 
tonsillitis in the preceding year; OR five or more such episodes in each of the previous two years; OR three or 
more such episodes in the previous three years.36 
A recent Cochrane review of this issue found that for children with chronic or recurrent acute tonsillitis, having 
a tonsillectomy or adenotonsillectomy resulted in having, on average, 0.6 fewer episodes of sore throat of any 
severity in the first post-operative year (including as one episode the period post-surgery).37 In the sub-group of 
severely affected patients, there was low quality evidence that having tonsillectomy resulted in 0.1 fewer 
episodes of moderate/severe sore throat, while in the sub-group of moderately affected patients, there was 
moderate quality evidence that having tonsillectomy resulted in 0.8 more episodes of moderate/severe sore 
throat, including the period post-surgery in both sub-group analyses. 
The most significant complication of tonsillectomy is haemorrhage which has been reported as occurring in 2–
3% of cases and which has, on rare occasions, proved fatal.31,38 
The following section uses data from the National Minimum Dataset to review waiting list admissions for 
tonsillectomy with or without adenoidectomy. Guidelines and evidence-based reviews, which consider how 
these conditions might best be prevented or managed, are summarised at the end of the section.  
Data sources and methods 
Indicator 
Hospitalisations for tonsillectomy +/− adenoidectomy in 0–14 year olds  
Data sources 
Numerator:  National Minimum Dataset  
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years) 
Definition   
Arranged or waiting list hospitalisations of 0–14 year olds for tonsillectomy +/− adenoidectomy (hospitalisations per 1,000 
population) 
Primary diagnoses associated with tonsillectomy and/or adenoidectomy procedures include: Chronic tonsillitis; hypertrophy of 
the tonsils/adenoids; sleep apnoea, and other or unspecified chronic diseases of tonsils/adenoids. Refer to Appendix 6 for the 
codes included. 
Notes on interpretation 
Note 1: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
(also referred to as an arranged admission) is a non-acute hospitalisation with an admission date less than seven days after the 
date the decision was made that the hospitalisation was necessary. A waiting list admission is a planned hospitalisation, where 
the admission date is seven or more days after the date the decision was made that the hospitalisation was necessary. Because 
arranged admissions comprise a mix of patients being admitted semi-acutely for the management of medical conditions, and 
semi-urgently for operative procedures, in this section arranged admissions have been included.  
While in a small number of cases a single child may have appeared in both the tonsillectomy and acute URTI analyses, in reality 
the majority of hospitalisations for tonsillectomy were for chronic upper respiratory conditions (e.g. chronic tonsillitis, 
obstructive sleep apnoea) and are not included in the acute URTI section.  
Note 2: The term "tonsillectomy +/- adenoidectomy" has been used as adenoidectomy is often performed simultaneously with 
tonsillectomy and it is difficult to exclude those receiving both procedures without excluding a large number of cases of 
tonsillectomy. 
Note 3: Appendix 3 outlines the limitations of the data utilised from the National Minimum Dataset. The reader is advised to 
review this appendix before interpreting any trends. 
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National trends and distribution 
From 2000 to 2005 the hospitalisation rate for tonsillectomy +/- adenoidectomy (tonsillectomy) fell, and then 
increased from 2005 until 2014.The rate was not significantly different in 2014 to that in 2000 (Figure 46). The 
highest tonsillectomy hospitalisation rates were in European/Other, and it was in this ethnic group that the fall in 
rates to 2005 and later rise in rates was evident. Rates for Māori, Pacific and Asian/Indian were fairly stable 
until 2005–2006. Since 2006 rates for Māori have increased steadily, while rates for Pacific and Asian/Indian 
increased between 2005 and 2007 and have been fairly stable since (Figure 47). 
Figure 46. Hospitalisations for tonsillectomy +/‒ adenoidectomy in 0–14 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Figure 47. Hospitalisations for tonsillectomy +/‒ adenoidectomy in 0–14 year olds, by ethnicity, New Zealand 
2000–2014 
 
Numerator: National Minimum Dataset (arranged and waiting list admissions only); Denominator: Statistics NZ Estimated 
Resident Population; Ethnicity is level 1 prioritised 
Distribution by primary diagnosis 
Between 2010 and 2014 the most common primary diagnosis associated with hospitalisation for tonsillectomy 
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95% CI Per cent 
Tonsillectomy +/‒ adenoidectomy in 0–14 year olds 
New Zealand  
Chronic tonsillitis 8,732 1,746 1.93 1.89–1.97 55.40 
Hypertrophy tonsils/adenoids 3,532 706 0.78 0.75–0.81 22.40 
Sleep apnoea 2,866 573 0.63 0.61–0.66 18.20 
Acute tonsillitis 34 7 0.01 <0.01–0.01 0.20 
Otitis media 145 29 0.03 0.03–0.04 0.90 
Perforation or other disorders tympanic membrane 5 1 <0.01 s <0.1 
Peritonsillar abscess <5 s s s s 
Other or unspecified chronic diseases of the tonsils 
or adenoids 
23 5 <0.01 s 0.10 
Other diagnoses 421 84 0.09 0.08–0.10 2.67 
Total 15,761 3,152 3.48 3.43–3.53 100.00 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Distribution by demographic factors 
Male tonsillectomy rates were higher than female to age seven, and female rates higher from age eight. The 
peak age for tonsillectomy hospitalisation in all ethnic groups was four years after which rates decreased with 
increasing age to age 13 (Figure 48). The peak age for tonsillectomy hospitalisation was four years for 
European/Other and Asian/Indian and six years for Māori and Pacific, otherwise the age pattern was similar 
across ethnic groups. 
Figure 48. Hospitalisations for tonsillectomy +/‒ adenoidectomy in 0–14 year olds, by age and sex, New Zealand 
2010–2014 
 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Distribution by region 
Between 2010 and 2014 hospitalisation rates for tonsillectomy were significantly higher than the national rate in 
the Northland, Waikato, Bay of Plenty, Hawke's Bay, MidCentral, Whanganui, South Canterbury, West Coast 
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Capital & Coast DHBs. In remaining district health boards there was no significant difference from the national 
rate (Figure 49, Table 63).  
Figure 49. Hospitalisations for tonsillectomy +/‒ adenoidectomy in 0–14 year olds, by district health board, New 
Zealand 2010–2014 
 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Table 63. Hospitalisations for tonsillectomy +/‒ adenoidectomy in 0–14 year olds, by district health board, 






Rate per 1,000 
0–14 year olds 
Rate ratio 95% CI 
Tonsillectomy +/‒ adenoidectomy in 0–14 year olds 
Northland 717 143 3.95 1.14 1.05–1.22 
Waitemata 1,482 296 2.64 0.76 0.72–0.80 
Auckland 1,113 223 2.70 0.78 0.73–0.82 
Counties Manukau 1,717 343 2.89 0.83 0.79–0.87 
Waikato 1,731 346 4.24 1.22 1.16–1.28 
Bay of Plenty 851 170 3.75 1.08 1.01–1.15 
Lakes 426 85 3.62 1.04 0.95–1.15 
Tairawhiti 192 38 3.28 0.94 0.82–1.09 
Taranaki 386 77 3.23 0.93 0.84–1.03 
Hawke's Bay 752 150 4.34 1.25 1.16–1.34 
MidCentral 857 171 5.00 1.44 1.34–1.54 
Whanganui 373 75 5.70 1.64 1.48–1.81 
Hutt Valley 481 96 3.18 0.92 0.84–1.00 
Capital & Coast 628 126 2.29 0.66 0.61–0.71 
Wairarapa 149 30 3.55 1.02 0.87–1.20 
Nelson Marlborough 429 86 3.19 0.92 0.83–1.01 
South Canterbury 380 76 7.18 2.06 1.86–2.28 
Canterbury 1,597 319 3.37 0.97 0.92–1.02 
West Coast 163 33 5.16 1.48 1.27–1.73 
Southern 1,327 265 4.74 1.36 1.29–1.44 
New Zealand 15,761 3,152 3.48 1.00   
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 hospitalisation rates for tonsillectomy +/- adenoidectomy (tonsillectomy) were 
significantly higher than the national rate in Waikato and Bay of Plenty DHBs, and not significantly different in 
the other Midland DHBs (Table 64).  







Rate per 1,000 
0–14 year olds 
Rate ratio 95% CI 
Tonsillectomy +/‒ adenoidectomy in 0–14 year olds 
Waikato 1,731 346 4.24 1.22 1.16–1.28 
Bay of Plenty 851 170 3.75 1.08 1.01–1.15 
Lakes 426 85 3.62 1.04 0.95–1.15 
Tairawhiti 192 38 3.28 0.94 0.82–1.09 
Taranaki 386 77 3.23 0.93 0.84–1.03 
New Zealand 15,761 3,152 3.48 1.00   
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Regional trends 
Between 2000 and 2014 there has been year-on-year variability in the tonsillectomy hospitalisation rates in the 
Midland DHBs. The rate of hospitalisations has generally decreased in Bay of Plenty, while rates gradually 
increased in the other Midland DHBs (Figure 50). 
Between 2000 and 2014 the tonsillectomy hospitalisation rates were higher for European/Other 0–14 year olds 
than for the other ethnic groups in all Midland DHBs (Figure 51). 
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Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident Population 





















































































































































































































































































































































































































Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident Population; Ethnicity is level 1 prioritised 
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Regional distribution by primary diagnosis 
Between 2010 and 2014 the most frequent primary diagnosis associated with hospitalisation for tonsillectomy in 
all five Midland DHBs was chronic tonsillitis. Hypertrophy of tonsils and/or adenoids and sleep apnoea were 
also common (Table 65).  
Table 65. Hospitalisations for tonsillectomy +/− adenoidectomy in 0−14 year olds, by primary diagnosis, 






Rate per 1,000 
0–14 year olds 
95% CI Per cent 
Tonsillectomy +/‒ adenoidectomy in 0–14 year olds 
Waikato 
Chronic tonsillitis 1,171 234 2.87 2.71–3.04 67.6 
Hypertrophic tonsils and/or adenoids 392 78 0.96 0.87–1.06 22.6 
Sleep apnoea 125 25 0.31 0.26–0.37 7.2 
Acute tonsillitis <5 s s s s 
Otitis media 10 2 0.02 0.01–0.05 0.6 
Other tonsil or adenoid diseases* <5 s s s s 
Other diagnoses 31 6 0.08 0.05–0.11 1.8 
Total 1,731 346 4.24 4.05–4.45 100.0 
Bay of Plenty 
Chronic tonsillitis 529 106 2.33 2.14–2.54 62.2 
Hypertrophic tonsils and/or adenoids 130 26 0.57 0.48–0.68 15.3 
Sleep apnoea 158 32 0.70 0.6–0.81 18.6 
Acute tonsillitis <5 s s s s 
Otitis media 11 2 0.05 0.03–0.09 1.3 
Other tonsil or adenoid diseases* <5 s s s s 
Other diagnoses 20 4 0.09 0.06–0.14 2.4 
Total 851 170 3.75 3.51–4.01 100.0 
Lakes DHB 
Chronic tonsillitis 253 51 2.15 1.90–2.43 59.4 
Hypertrophic tonsils and/or adenoids 143 29 1.22 1.03–1.43 33.6 
Sleep apnoea 22 4 0.19 0.12–0.28 5.2 
Acute tonsillitis <5 s s s s 
Otitis media <5 s s s s 
Other diagnoses 5 1 0.04 0.02–0.10 1.2 
Total 426 85 3.62 3.3–3.98 100.0 
Tairawhiti 
Chronic tonsillitis 133 27 2.27 1.92–2.69 69.3 
Hypertrophic tonsils and/or adenoids 51 10 0.87 0.66–1.14 26.6 
Sleep apnoea 5 1 0.09 0.04–0.20 2.6 
Acute tonsillitis <5 s s s s 
Other diagnoses 2 0 0.03 0.01–0.12 1.0 
Total 192 38 3.28 2.85–3.77 100.0 
Taranaki 
Chronic tonsillitis 227 45 1.90 1.67–2.16 58.8 
Hypertrophic tonsils and/or adenoids 22 4 0.18 0.12–0.28 5.7 
Sleep apnoea 93 19 0.78 0.63–0.95 24.1 
Other tonsil or adenoid diseases* <5 s s s s 
Peritonsillar abscess <5 s s s s 
Other diagnoses 41 8 0.34 0.25–0.46 10.6 
Total 386 77 3.23 2.92–3.56 100.0 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population; * Other tonsil or adenoid diseases = Other or unspecified chronic diseases of the tonsils or adenoids 
 
Conditions of the respiratory system: Tonsillectomy 
125 
Evidence for good practice for the prevention and treatment of 
tonsillitis  
International guidelines on the indications for tonsillectomy 
Marcus CL, Brooks LJ, Draper KA, et al. 2012. Diagnosis and management of childhood obstructive sleep apnea 
syndrome. Pediatrics. http://pediatrics.aappublications.org/content/early/2012/08/22/peds.2012-1671.abstract 
This clinical practice guideline, from the American Academy of Pediatrics, provides recommendations for the diagnosis and management of 
obstructive sleep apnoea syndrome (OSAS) in children and adolescents. It focusses on uncomplicated childhood OSAS associated with 
adenotonsillar hypertrophy and/or obesity in an otherwise healthy child who is being treated in primary care. The recommendations and 
strength of evidence are graded according to the AAP policy statement, “Classifying Recommendations for Clinical Practice Guidelines”. The 
recommendations are: (1) All children/adolescents should be screened for snoring. (2) Polysomnography should be performed in 
children/adolescents with snoring and symptoms/signs of OSAS and, if polysomnography is not available, then alternative diagnostic tests 
or specialist referral for more extensive evaluation may be considered. (3) Adenotonsillectomy is the recommended first-line treatment for 
patients with adenotonsillar hypertrophy. (4) High-risk patients should have postoperative monitoring as inpatients. (5) Patients should be 
re-evaluated postoperatively to determine whether further treatment is required, and objective testing should be performed in patients who 
are high risk or have persistent symptoms/signs of OSAS after therapy. (6) Continuous positive airway pressure is recommended for treatment 
of OSAS if adenotonsillectomy is not performed or if OSAS persists postoperatively. (7) Weight loss is recommended in addition to other 
therapy for patients who are overweight or obese. (8) Intranasal corticosteroids are an option for children with mild OSAS in whom 
adenotonsillectomy is contraindicated or for children with mild postoperative OSAS. 
Marcus CL, Brooks LJ, Ward SD, et al. 2012. Diagnosis and management of childhood obstructive sleep apnea 
syndrome. Pediatrics, 130(3), e714-e55. http://pediatrics.aappublications.org/content/130/3/e714.abstract 
This technical report describes the procedures involved in developing the AAP’s recommendations on the management of childhood 
obstructive sleep apnoea syndrome (OSAS), see above. The authors evaluated literature from 1999 through 2011 and identified 350 articles 
which provided relevant data. Most studies (76%) were given an evidence grading of level III or IV, and did not include a control group. The 
authors stated that there was a clear need for randomised clinical trials with blinding. The literature indicated that the prevalence of OSAS in 
children ranged from 0% to 5.7% and that obesity is an independent risk factor. Most diagnostic tests for OSAS had low sensitivity and 
specificity. Treatment of OSAS (with adenotonsillectomy) leads to improvements in behaviour and attention, and probably improvement in 
cognitive abilities, but a proportion of patients have residual OSAS post-operatively, ranging from 13% to 29% in low risk groups to 73% 
when obese children were included and stricter polysomnographic criteria for initial diagnosis were used. A significant proportion of obese 
patients needed intubation or continuous positive airway pressure (CPAP) postoperatively, which reinforces the need for inpatient 
observation. CPAP was found to be an effective treatment for OSAS but adherence is a major barrier and therefore CPAP is not recommended 
as a first-line therapy for OSAS where adenotonsillectomy is an option. Mild OSAS may be ameliorated by intranasal steroids but follow-up 
is required. 
Baugh R, Archer S, Mitchell R, et al. 2011. Clinical practice guideline: Tonsillectomy in children. American Academy of 
Otolaryngology–Head and Neck Surgery. http://oto.sagepub.com/content/144/1_suppl/S1.full.pdf+html 
This guideline provides evidence-based guidance for identifying the children (1–18 years) who are the best candidates for tonsillectomy; 
optimising perioperative management; and improving communication with parents about management options. Each evidence-based 
statement is followed by an indication of the strength of the recommendation based on the quality of the evidence. It recommends watchful 
waiting for recurrent throat infections if there have been <7 episodes in the past year, <5 episodes per year in the past 2 years, or <3 episodes 
per year in the past 3 years. These criteria form part of the “Paradise Criteria”, which are used in what the guidelines call the most frequently 
cited and meticulous RCTs investigating the efficacy of tonsillectomy. Table 9 compares three major guidelines: those of the US, Scotland and 
Italy. The Scottish and US guidelines recommend the Paradise criteria for assessing the need for tonsillectomy. The Italian guidelines state 
the that tonsillectomy is indicated in patients with at least one year of recurrent tonsillitis (5+ episodes per year) that is disabling and interferes 
with normal activities, but only after an additional six months of watchful waiting during which a diary documenting clinical symptoms is kept. 
The guidelines also cover indications for tonsillectomy in children with sleep disordered breathing (the common indication for tonsillectomy 
other than recurrent sore throat). 
Roland PS, Rosenfeld RM, Brooks LJ, et al. 2011. Clinical practice guideline: Polysomnography for sleep-disordered 
breathing prior to tonsillectomy in children. Otolaryngol Head Neck Surg, 145(1 Suppl), S1-15 
Polysomnography (PSG) is the electrographic recording of simultaneous physiologic variables during sleep, in a dedicated sleep laboratory. 
It is considered to be the best method for objectively assessing sleep disorders. The purpose of this guideline is to provide evidence-based 
recommendations for PSG prior to tonsillectomy in children aged 2–18 years for whom sleep disordered breathing (SDB) is the primary 
indication for surgery. It does not apply to children having adenoidectomy alone, or to children who are being considered for continuous 
positive airway pressure (CPAP) or other surgery for SDB. The guideline makes following recommendations based on observational studies 
with a preponderance of benefit over harm: children with obesity, Down syndrome, craniofacial abnormalities, neuromuscular disorders, sickle 
cell disease or mucopolysaccaridoses and SDB should be referred for PSG; for children without any of the previous conditions but for whom 
the need for surgery is uncertain or for whom there is discordance between observed tonsillar size and the reported severity of SDB, clinicians 
should advocate for PSG; clinicians should communicate PSG results to the anaesthetist; clinicians should admit children with OSA 
documented via PSG for inpatient, overnight monitoring after tonsillectomy if they are aged < 3 years or have severe OSA (apnoea-hypopnea 
index of 10 or more obstructive events/hour, oxygen saturation nadir less than 80%, or both). Based on diagnostic studies with limitations, 
and a preponderance of benefit over harm, the guideline recommends laboratory-based PSG over unattended monitoring at home with a 
portable device, when possible. 
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Evidence-based Medicine reviews 
Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, et al. 2015. Pneumococcal vaccination during pregnancy 
for preventing infant infection. Cochrane Database of Systematic Reviews (1) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004903.pub4/abstract 
The bacterium Streptococcus pneumoniae can cause serious illnesses including bacteraemia, meningitis and pneumonia, as well as other lower 
and upper respiratory tract infections such as otitis media and sinusitis. Pneumococcal vaccination is ineffective in infants less than three 
months of age. Vaccination of pregnant women may offer their infants protection from pneumococcal disease in their early months of life. 
The authors of this review identified seven RCTs of pneumococcal vaccination in pregnant women. Six of these (919 participants) contributed 
data for meta-analysis. There was no evidence that pneumococcal vaccination during pregnancy reduces the risk of neonatal infection (risk 
ratio (RR) 0.66; 95% CI 0.30 to 1.46; two trials, 241 pregnancies, low quality evidence). For the other outcomes of interest (maternal and 
neonatal antibody levels, percentage of women with seroprotection) there were mostly wide confidence intervals crossing one (indicating no 
significant effect). Most of the trials had small numbers of participants and few events so the quality of the evidence they provided was low. 
The review authors concluded that there is insufficient evidence to determine whether pneumococcal vaccination during pregnancy could 
reduce infant infection. 
Sauni R, Verbeek Jos H, Uitti J, et al. 2015. Remediating buildings damaged by dampness and mould for preventing or 
reducing respiratory tract symptoms, infections and asthma. Cochrane Database of Systematic Reviews (2) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007897.pub3/abstract 
Moisture damage is a common problem in homes, workplaces and public buildings such as schools. The resulting dampness and mould has 
been associated with respiratory symptoms, asthma and respiratory infections in the buildings’ occupants. This review aimed to determine 
the effectiveness of repairing buildings damaged by dampness and mould in reducing or preventing respiratory symptoms, asthma and 
respiratory infections. It included 12 studies with a total of 8,028 participants: two RCTs (294 participants), one cluster RCT (4,407 participants), 
and nine controlled before and after (CBA) studies (3,327 participants). Interventions varied from thorough renovation to cleaning only. There 
was moderate to low quality evidence that repairing houses decreased asthma-related symptoms and respiratory infections in adults. For 
children, there was no difference between those whose houses were repaired and those who received information only in the number of 
asthma days or asthma-related emergency department visits (one study, moderate quality evidence). One CBA study provided very low quality 
evidence that asthma-related and other respiratory symptoms decreased after repairing a mould-damaged office building, and another CBA 
study found no difference between full and partial repair of houses. For children in schools, the evidence regarding an effect of mould 
remediation on respiratory symptoms was inconsistent. Out of many symptom measures only respiratory infections might have decreased 
after the intervention. For staff in schools, there was very low quality evidence that asthma-related and other respiratory symptoms were 
similar in staff in mould-damaged schools and staff in undamaged schools, both before and after intervention. The review authors stated that 
better research is needed, preferably with a cluster-RCT design and more validated outcome measures. 
Hao Q, Dong Bi R, Wu T. 2015. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of 
Systematic Reviews (2) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006895.pub3/abstract 
Probiotics are live bacteria believed to confer health benefits (such as improved immune system function) when consumed in foods such as 
yoghurt, or as dietary supplements. This review aimed to assess the effectiveness and safety of probiotics, compared to placebo, in preventing 
upper respiratory infections (URTIs) in people of all ages, at risk of URTIs. The review authors identified 13 relevant RCTs, but could extract 
data for meta-analysis from only 12 of them (3,720 participants including children, adults, and older people). They found that probiotics were 
better than placebo when measuring the number of participants experiencing episodes of acute URTI as follows: at least one episode (odds 
ratio (OR) 0.53; 95% CI 0.37 to 0.76, p < 0.001, low quality evidence); at least three episodes (OR 0.53; 95% CI 0.36 to 0.80, p = 0.002, low 
quality evidence); the mean duration of an episode of acute URTI (mean difference −1.89 days; 95% CI −2.03 to −1.75 days, p < 0.001, low 
quality evidence); reduced antibiotic prescription rates for acute URTIs (OR 0.65; 95% CI 0.45 to 0.94, moderate quality evidence), and cold-
related school absence (OR 0.10; 95% CI 0.02 to 0.47, very low quality evidence). Probiotics and placebo were similar when measuring the 
rate ratio of episodes of acute URTI (rate ratio 0.83; 95% CI 0.66 to 1.05, p = 0.12, very low quality evidence) and adverse events (OR 0.88; 
95% CI 0.65 to 1.19, p = 0.40, low quality evidence). Probiotics were associated with minor side effects, most commonly gastrointestinal 
symptoms. The review authors found that some subgroups had a high level of heterogeneity when they conducted pooled analyses and the 
evidence level was low or very low quality. They concluded that probiotics were better than placebo in reducing the number of participants 
experiencing episodes of acute URTI, the mean duration of an episode of acute URTI, antibiotic use and cold-related school absence. They 
stated that these findings indicate that probiotics may be better than placebo for preventing acute URTIs but that the quality of the evidence 
was low or very low. 
Burton Martin J, Glasziou Paul P, Chong Lee Y, et al. 2014. Tonsillectomy or adenotonsillectomy versus non-surgical 
treatment for chronic/recurrent acute tonsillitis. Cochrane Database of Systematic Reviews (11) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001802.pub3/abstract 
There is some controversy about the indications for tonsillectomy. This updated review aimed to assess the effectiveness of tonsillectomy 
(with or without adenoidectomy) in children and adults with chronic/recurrent tonsillitis in reducing the number and severity of episodes of 
sore throat or tonsillitis. It included seven RCTs, judged to have low to moderate risk of bias, comparing tonsillectomy (with or without 
adenoidectomy) with non-surgical treatment in adults and children with chronic/recurrent acute tonsillitis. Five trials involved children (987 
participants) and two, adults (156 participants). There was good information about the effectiveness of adeno-tonsillectomy only for the first 
year after surgery in children (due to the high numbers of children lost to follow up after that time) and only for the first six months after 
surgery in adults.  
Combined data from five trials in children, involving both severely affected and less severely affected children, indicated that children who 
had an adeno-/tonsillectomy had an average of three episodes of sore throats (of any severity) in the first postoperative year, compared to 
3.6 episodes in the control group; a difference of 0.6 episodes (95% confidence interval (CI) −1 to −0.1; moderate quality evidence). One of 
the three episodes in the surgical group was the 'predictable' one in the immediate postoperative period. Analysis of only episodes of 
moderate or severe sore throat indicated that children who had been more severely affected and had adeno-/tonsillectomy had on average 
1.1 episodes of sore throat in the first postoperative year, compared with 1.2 episodes in the control group (low quality evidence). This 
difference was not significant, but it must be remembered that one episode in the surgical group was the one occurring immediately following 
surgery. Less severely affected children had more episodes of moderate/severe sore throat after surgery (1.2 episodes) than in the control 
group (0.4 episodes: difference 0.8, 95% CI 0.7 to 0.9), but again one episode was the predictable postoperative episode (moderate quality 
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evidence). There was data on the number of sore throat days only for moderately affected children. In the first year after surgery children 
undergoing surgery had an average of 18 days of sore throat (of which some – between five and seven on average – would have been in the 
immediate postoperative period), compared with 23 days in the control group (difference 5.1 days, 95% CI 2.2 to 8.1; moderate quality 
evidence). 
Two studies in children reported on quality of life outcomes. These found no statistically significant differences between the surgery and non-
surgery groups. One study reported no difference in consumption of analgesics. No studies provided evidence regarding the prescription of 
antibiotics. There was limited data available for quantifying the important risks of primary and secondary haemorrhage after surgery. 
The review authors stated that there was insufficient information to draw firm conclusions about the effectiveness of adenotonsillectomy vs. 
non-surgical treatment in adults. They stated that for children the impact of surgery is modest and many children improve spontaneously 
without surgery. They also stated that the potential benefit of surgery needs to be weighed against the risks of the procedure, particularly 
primary and secondary haemorrhage, and that, even with good analgesia, adults tend to find the procedure particularly uncomfortable. 
McCallum Gabrielle B, Bailey Emily J, Morris Peter S, et al. 2014. Clinical pathways for chronic cough in children. Cochrane 
Database of Systematic Reviews (9) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006595.pub3/abstract 
Chronic cough, defined as a cough lasting for more than four weeks is a common problem in children internationally. Evidence-based clinical 
guidelines (pathways) for the management of chronic cough in children have been developed. This review aimed to evaluate the effectiveness 
of using a clinical pathway in the management of children with chronic cough. It included one RCT, a multi-centre trial based in five Australian 
hospitals which recruited 272 children. Children were randomly assigned to early (two weeks) and delayed (six weeks) referral to respiratory 
specialists who used a cough management pathway. An intention-to-treat analysis indicated that clinical failure at six weeks post-
randomisation was significantly less in the early pathway arm compared to the control arm: odds ratio 0.35, 95% CI 0.21 to 0.58. (Clinical 
failure was defined as < 75% improvement in cough score, or total resolution of cough for less than three consecutive days.) These results 
indicate that one extra child will be cured for every five treated via the cough pathway: number needed to treat for additional benefit = 5, 
95% CI 3 to 9, at six weeks. Cough-specific parent-reported quality of life scores were significantly better in the early-pathway group; the 
mean difference (MD) between groups was 0.60 (95% CI 0.19 to 1.01, possible scores ranged from 0–7). Duration of cough post randomisation 
was significantly shorter in the intervention group (early-pathway arm) compared with the control group (delayed-pathway arm): MD −2.70 
weeks, 95% CI −4.26 to −1.14. The review authors concluded that using a clinical algorithm for the management of children with chronic 
cough in hospital outpatient settings is more effective than providing waiting list care and that further high quality RCTs are needed to 
evaluate cough management pathway in GP and other primary care settings. 
Teoh L, Hurwitz M, Acworth Jason P, et al. 2011. Treatment of obstructive sleep apnoea for chronic cough in children. 
Cochrane Database of Systematic Reviews (4) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008182.pub2/abstract 
Obstructive sleep apnoea (OSA) in children is characterised by repeated episodes of partial or complete upper airway obstruction during 
sleep that result in disruption of normal ventilation and sleep patterns. It has been reported that OSA is a cause of chronic cough in adults, 
but there is little data available for children, despite both chronic cough and OSA being relatively common. Because OSA and chronic cough 
are common, the probability of a child having both symptoms by chance alone is high and any observed association between the two 
conditions may not reflect causality. This review aimed to investigate the efficacy of treatment of OSA in the management of children with 
chronic cough. The review authors did not find any RCTs comparing an intervention for OSA to a control group (placebo or usual treatment) 
in children with chronic cough and therefore they concluded that there is currently no evidence that therapies directed at OSA are useful for 
the management of chronic cough in children. They stated that that the presence or absence of cough should not be a factor in clinicians’ 
decisions regarding management of OSA. 
In addition to the reviews above, the Cochrane Collection: http://www.thecochranelibrary.com/view/0/index.html contains 
a very large number of other reviews relevant to upper respiratory conditions. Review topics include: 
 Adenoidectomy: adenoidectomy for otitis media, intranasal steroids for adenoidal hypertrophy, curettage vs. other methods 
 Tonsillectomy: antibiotics to reduce post tonsillectomy morbidity, coblation vs. other techniques, dissection vs. diathermy, oral 
rinses, mouthwashes and sprays post tonsillectomy, perioperative local anaesthesia, steroids for improving post-tonsillectomy 
recovery, tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis, & cervical adenitis syndrome (PFAPA), non-steroidal 
anti-inflammatory drugs and post tonsillectomy bleeding, adenoidectomy for obstructive sleep apnoea 
 Sore throat/pharyngitis: corticosteroids (as stand-alone or add-on treatment), antibiotics, different antibiotics for group A 
streptococcal pharyngitis, short-term late-generation antibiotics vs. longer term penicillin for acute streptococcal pharyngitis in 
children, Chinese medicinal herbs, tonsillectomy/adenoidectomy vs. non-surgical treatment, rapid antigen testing for group A 
streptococcus 
Other relevant publications 
Paradise JL, Bluestone CD, Bachman RZ, et al. 1984. Efficacy of tonsillectomy for recurrent throat infection in severely 
affected children. Results of parallel randomized and nonrandomized clinical trials. New England Journal of Medicine 
310(11) 674-83. 
This paper reports on two studies comparing the efficacy of tonsillectomy with non-surgical treatment in children meeting strict criteria for 
recurrent tonsillitis in the following categories: frequency of episodes of throat infection (7+ episodes in the preceding year, or 5+ in each of 
the preceding 2 years, or 3+ in each of the preceding 3 years), clinical features, treatment and documentation. There was a non-randomised 
study of 96 children whose parents did not consent to being part of the randomised study and a RCT involving 91 children. In both studies 
the incidence of throat infections was significantly lower in the surgical group (p ≤0.05) in the first two years of follow up but not in the third 
year, however many in the non-surgical group had only 1–2 if any episodes of infection and most episodes were mild. The authors say their 
results support choosing tonsillectomy. 
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MIDDLE EAR CONDITIONS: OTITIS MEDIA AND 
GROMMETS 
Introduction 
Otitis media is the clinical term for any inflammation of the middle ear.39 It is a very common condition in 
children and one of the most common reasons for children to visit a general practitioner and to be prescribed 
antibiotics.40 The two main types of otitis media are acute otitis media (AOM) and otitis media with effusion 
(OME). 
Acute otitis media is a condition of rapid onset which often follows an upper respiratory infection. Symptoms 
include ear pain, irritability, and fever. If there is perforation of the tympanic membrane (ear drum) there may be 
otorrhoea (discharge from the ear).39 Examination of the ear via an otoscope may reveal bulging and redness of 
the tympanic membrane.40 Risk factors for AOM include exposure to secondhand smoke, bottle feeding and 
attendance at childcare.39 Antibiotics are commonly prescribed for AOM but international guidelines emphasise 
that in children aged two years or over with uncomplicated AOM antibiotics are of little benefit and treatment 
should comprise adequate analgesia and watchful waiting.40-42 Serious complications from AOM are rare. They 
include mastoiditis, cholesteatoma, labyrinthitis, facial paralysis, and, very rarely, intracranial infection such as 
meningitis, lateral sinus thrombosis brain abscess.41 
Otitis media with effusion is defined as an accumulation of non-purulent fluid behind an intact eardrum 
without signs of acute infection.41 It is a common condition in early childhood and it causes hearing loss which 
is usually transient and self-limiting but which may be persistent and associated with educational, language and 
behavioural problems.43 For children with long-standing (lasting for more than 3–6 months) bilateral OME, or 
recurrent AOM, and for children particularly susceptible to OME such as children with Down syndrome or cleft 
palate, grommets (ventilation or tympanostomy tubes) are often considered as a means of restoring normal 
hearing. The procedure improves ventilation and pressure regulation in the middle ear. It involves making a 
small incision in the eardrum (with or without the aspiration of middle ear fluid) and inserting a small 
ventilation tube. On average, grommets remain in the eardrum for 6–12 months before falling out.44 Little is 
known about the long term effects of grommets on children’s language, speech or development as very little 
research has been done in this area.45 The following section uses data from the National Minimum Dataset to 
explore acute hospital admission for otitis media in children, as well as arranged and waiting list admissions for 
the insertion of grommets. 
Data sources and methods 
Indicator 
Hospitalisations of 0–14 year olds for otitis media or for insertion of grommets 
Data sources 
Numerator:  National Minimum Dataset  
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years). 
Definition 
Hospitalisations: Acute hospitalisations of 0–14 year olds for otitis media or for other conditions of the middle ear and 
mastoid.  
Arranged and waiting list hospitalisations of 0–14 year olds for the insertion of grommets 
Indications for Otitis media and grommets include: chronic tonsillitis; hypertrophy of the tonsils/adenoids; sleep apnoea; and 
other or unspecified chronic diseases of tonsils/adenoids. Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
(also referred to as a semi-acute admission) is a non-acute hospitalisation with an admission date less than seven days after the 
date the decision was made that the admission was necessary. A waiting list admission is a planned hospitalisation, where the 
admission date is 7+ days after the date the decision was made that the hospitalisation was necessary. 
While the majority of children admitted acutely with a primary diagnosis of otitis media do not receive a surgical intervention, 
the majority of children admitted from the waiting list with the same primary diagnosis do, with the most common operative 
procedure being the insertion of grommets. For arranged admissions the picture is more mixed, with some patients being 
admitted semi-acutely for the non-surgical management of otitis media, and others for an operative intervention such as 
grommets. On balance however, more arranged admissions with a primary diagnosis of otitis media are for surgical 
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interventions, and thus in this section arranged admissions have been grouped with the waiting list category (in contrast to 
other sections where acute and arranged admission are considered together).  
Note 2: Appendix 3 describes the National Minimum Dataset and outlines the limitations of the data utilised from this data 
collection. The reader is advised to review this appendix before interpreting any trends. 
Note 3: 95% confidence intervals have been provided for the rate ratios in this section and where appropriate, the terms 
significant or not significant have been used to communicate the significance of the observed associations. Tests of statistical 
significance have not been applied to other data in this section, and thus (unless the terms significant or non-significant are 
specifically used) the associations described do not imply statistical significance or non-significance (see Appendices for further 
discussion of this issue).  
National trends and distribution 
From 2000 to 2004 the hospitalisation rate of 0–14 year olds for otitis media (otitis media hospitalisation rate) 
fell slightly and then remained stable with minor year-to-year fluctuations. From 2000 to 2014 the 
hospitalisation rate for insertion of grommets (grommet hospitalisation rate) fell significantly (Figure 52). 
Different patterns over time were observed by ethnicity. From 2000 to 2014 the fall in otitis media 
hospitalisation rate was more marked for European/Other and Māori than for Pacific, and the rate was stable 
with year-to-year fluctuations for Asian/Indian. The grommet hospitalisation rate for Asian/Indian has been 
fairly stable over time and consistently much lower than the rates for other ethnic groups. The decrease in 
grommet hospitalisation rates has been more marked for Māori and Pacific compared with European/Other and 
although rates for Māori and Pacific were higher until 2013, in 2014 rates were similar for Māori, Pacific and 
European/Other (Figure 53). 
Figure 52. Hospitalisations for otitis media and grommets in 0–14 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (Otitis media: acute admissions; Grommets: arranged and waiting list admissions); 
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Figure 53. Hospitalisations for otitis media and grommets in 0–14 year olds, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (Otitis media: acute admissions; Grommets: arranged and waiting list admissions); 
Denominator: Statistics NZ Estimated Resident Population; Ethnicity is level 1 prioritised 
Distribution by primary diagnosis 
Between 2010 and 2014 otitis media was by far the most common primary diagnosis in this category accounting 
for 92.9% of hospitalisations for conditions of the middle ear and mastoid and 95.4% of grommet 
hospitalisations (Table 66, Table 67). 
Table 66. Hospitalisations for conditions of the middle ear and mastoid in 0–14 year olds, by primary diagnosis, 










95% CI Per cent 
Conditions of middle ear and mastoid in 0–14 year olds 
New Zealand  
Otitis media 2,637 527 0.58 0.56–0.60 92.9 
Mastoiditis and related disorders 164 33 0.04 0.03–0.04 5.8 
Perforation or other disorders of the tympanic membrane 27 5 <0.01 s 1.0 
Cholesteatoma of the Middle Ear 8 2 <0.01 s 0.3 
Other disorders of the Middle Ear or Mastoid <5 s s s s 
Eustachian tube disorders 0  .. .. .. .. 
Total 2,838 568 0.63 0.60–0.65 100.0 
Numerator: National Minimum Dataset (acute admissions); Denominator: Statistics NZ Estimated Resident Population; s: 
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95% CI Per cent 
Insertion of grommets in 0–14 year olds 
New Zealand  
Otitis media 21,935 4,387 4.84 4.78–4.91 95.4 
Perforation or other disorders of tympanic 
membrane 
465 93 0.10 0.09–0.11 2.0 
Eustachian tube disorders 140 28 0.03 0.03–0.04 0.6 
Other disorders of middle ear or mastoid 90 18 0.02 0.02–0.02 0.4 
Sleep apnoea 33 7 0.01 s 0.1 
Hypertrophic tonsils and/or adenoids 27 5 <0.01 s 0.1 
Chronic tonsillitis 19 4 <0.01 s 0.1 
Cholesteatoma of the middle ear 11 2 <0.01 s <0.1 
Other diagnoses 274 54 0.06 0.05–0.07 1.2 
Total  22,994 4,599 5.08 5.01–5.14 100.0 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population; s: suppressed due to small numbers 
Distribution by demographic factors 
Otitis media hospitalisation rates were highest for 0–1 year olds and then decreased significantly to age 3 years 
followed by a steady decrease with increasing age. Grommet hospitalisations were uncommon in the first year 
of life; the highest rate was for 1 year olds and a second peak at age 4–5 years after which they decreased with 
increasing age (Figure 54). The otitis media pattern by age was similar for all ethnic groups, with consistently 
higher hospitalisation rates for Māori to age 13 years, for Pacific to age 10 years and consistently lower rates for 
Asian/Indian, compared with European/Other. The peak of grommet hospitalisation rates for European/Other 
and Māori was at age 1 year with a secondary peak at ages 4–6 years, however for Pacific the peak was at age 
5–6 years with a lower peak at age 1 year and for Asian/Indian there was a sustained peak for 1–5 year olds. 
Grommet hospitalisation rates were consistently lower for Asian/Indian than for other ethnic groups, and 
European/Other rates were higher than Māori and Pacific for 0–4 year olds and lower for 5–14 year olds 
(Figure 55).  
Between 2010 and 2014 there was disparity in otitis media and in grommet hospitalisation rates by NZDep2013 
index of deprivation score, ethnicity and gender. 
Figure 54. Hospitalisations for otitis media and grommets in 0–14 year olds, by age, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (Otitis media: acute admissions; Grommets: arranged and waiting list admissions); 
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Figure 55. Hospitalisations for otitis media and grommets in 0–14 year olds, by age and ethnicity, New Zealand 
2010–2014 
 
Numerator: National Minimum Dataset (Otitis media: acute admissions; Grommets: arranged and waiting list admissions); 
Denominator: Statistics NZ Estimated Resident Population; Ethnicity is level 1 prioritised 
Otitis media hospitalisation rates were significantly lower in areas with the lowest deprivation scores 
(NZDep2013 deciles 1–2) compared with higher deprivation scores (deciles 3–10) and for the highest 
deprivation areas (deciles 5–10) there was a significant increase in otitis media hospitalisation rates between 
each quintile of NZDep2013 scores compared with the quintile below. Compared with European/Other, rates 
were significantly higher for Māori, Pacific, and MELAA and not significantly different for Asian/Indian. Male 
rates were significantly higher than female rates (Table 68).  
There was a significant increase in grommet hospitalisation rates between each quintile of NZDep2013 scores 
compared with the quintile below. Compared with European/Other, rates were significantly higher for Māori 
and Pacific and significantly lower for Asian/Indian and MELAA. Male rates were significantly higher than 
female rates (Table 69). 




Rate per 1,000  
0–14 year olds 
Rate ratio 95% CI 
Otitis media in 0–14 year olds 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 311 0.36 1.00   
Deciles 3–4 338 0.42 1.17 1.01–1.37 
Deciles 5–6 394 0.46 1.29 1.11–1.50 
Deciles 7–8 602 0.64 1.79 1.57–2.06 
Deciles 9–10 975 0.92 2.59 2.28–2.94 
Prioritised ethnicity 
Māori 806 0.70 1.46 1.33–1.59 
Pacific 406 0.93 1.94 1.74–2.18 
Asian/Indian 221 0.46 0.97 0.84–1.12 
MELAA 44 0.79 1.65 1.22–2.22 
European/Other 1,157 0.48 1.00   
Gender 
Female 1,124 0.51 1.00   
Male 1,513 0.65 1.28 1.18–1.38 
Numerator: National Minimum Dataset (acute admissions); Denominator: Statistics NZ Estimated Resident Population; Rates are 















































































Conditions of the respiratory system: Middle ear conditions 
133 




Rate per 1,000  
0–14 year olds 
Rate ratio 95% CI 
Insertion of grommets in 0–14 year olds 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 2,993 3.43 1.00   
Deciles 3–4 3,394 4.20 1.22 1.17–1.29 
Deciles 5–6 4,326 5.06 1.47 1.41–1.54 
Deciles 7–8 5,320 5.66 1.65 1.58–1.72 
Deciles 9–10 6,947 6.58 1.92 1.84–2.00 
Prioritised ethnicity 
Māori 6,604 5.73 1.09 1.06–1.12 
Pacific 2,608 5.99 1.14 1.09–1.19 
Asian/Indian 825 1.73 0.33 0.31–0.35 
MELAA 201 3.61 0.69 0.60–0.79 
European/Other 12,691 5.27 1.00   
Gender 
Female 9,156 4.15 1.00   
Male 13,838 5.96 1.44 1.40–1.48 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rates are per 1,000 0–14 year olds; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
Distribution by season 
There was seasonal variation in otitis media hospitalisation rates. The highest rates were observed in June–
September and the lowest rates in January-February. There was no seasonal variation in grommet 
hospitalisations (Figure 56). 
Figure 56. Hospitalisations for otitis media and grommets in 0–14 year olds, by month, New Zealand 2010–2014 
 
National Minimum Dataset (Otitis media: acute admissions; Grommets: arranged and waiting list admissions); Number is annual 
average, Month is based on hospitalisation admission date 
Distribution by region 
Otitis media 
Between 2010 and 2014 hospitalisation rates for otitis media were significantly higher in the Northland, 
Waikato, Bay of Plenty, Lakes, Whanganui, Hutt Valley, and Southern DHBs than the national rate, and 
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West Coast DHBs. In remaining district health boards there was no significant difference from the national rate 
(Table 70, Figure 57). 
Figure 57. Hospitalisations for otitis media in 0–14 year olds, by district health board, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute admissions); Denominator: Statistics NZ Estimated Resident Population 






Rate per 1,000 
0–14 year olds 
Rate ratio 95% CI 
Otitis media in 0–14 year olds 
Northland 145 29 0.80 1.37 1.16–1.62 
Waitemata 253 51 0.45 0.77 0.68–0.88 
Auckland 196 39 0.48 0.82 0.71–0.94 
Counties Manukau 270 54 0.45 0.78 0.69–0.89 
Waikato 353 71 0.87 1.49 1.33–1.66 
Bay of Plenty 209 42 0.92 1.58 1.37–1.82 
Lakes 111 22 0.94 1.62 1.34–1.96 
Tairawhiti 31 6 0.53 0.91 0.64–1.30 
Taranaki 42 8 0.35 0.60 0.44–0.82 
Hawke's Bay 50 10 0.29 0.50 0.37–0.66 
MidCentral 59 12 0.34 0.59 0.46–0.76 
Whanganui 65 13 0.99 1.71 1.33–2.18 
Hutt Valley 142 28 0.94 1.61 1.36–1.91 
Capital & Coast 166 33 0.61 1.04 0.89–1.22 
Wairarapa 29 6 0.69 1.19 0.82–1.71 
Nelson Marlborough 40 8 0.30 0.51 0.37–0.70 
South Canterbury 25 5 0.47 0.81 0.55–1.20 
Canterbury 224 45 0.47 0.81 0.71–0.93 
West Coast 7 1 0.22 0.38 0.18–0.80 
Southern 204 41 0.73 1.25 1.08–1.44 
New Zealand 2,637 527 0.58 1.00   
Numerator: National Minimum Dataset (acute admissions); Denominator: Statistics NZ Estimated Resident Population 
Grommets 
Between 2010 and 2014 hospitalisation rates for insertion of grommets were significantly higher in the 
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significantly lower in the Northland, Counties Manukau, Hawke's Bay, MidCentral, Whanganui, Hutt Valley, 
Capital & Coast, and West Coast DHBs. In remaining district health boards there was no significant difference 
from the national rate (Table 71, Figure 58). 
Figure 58. Hospitalisations for grommet insertion in 0–14 year olds, by district health board, New Zealand 2010–
2014 
 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population 







Rate per 1,000 
0–14 year olds 
Rate ratio 95% CI 
Insertion of grommets in 0–14 year olds 
Northland 780 156 4.30 0.85 0.79–0.91 
Waitemata 3,277 655 5.84 1.15 1.11–1.19 
Auckland 2,162 432 5.24 1.03 0.99–1.08 
Counties Manukau 2,645 529 4.45 0.88 0.84–0.91 
Waikato 2,206 441 5.41 1.07 1.02–1.11 
Bay of Plenty 1,130 226 4.98 0.98 0.92–1.04 
Lakes 733 147 6.23 1.23 1.14–1.32 
Tairawhiti 299 60 5.10 1.01 0.90–1.13 
Taranaki 735 147 6.14 1.21 1.12–1.30 
Hawke's Bay 418 84 2.41 0.48 0.43–0.52 
MidCentral 645 129 3.76 0.74 0.68–0.80 
Whanganui 209 42 3.19 0.63 0.55–0.72 
Hutt Valley 685 137 4.54 0.89 0.83–0.96 
Capital & Coast 1,187 237 4.34 0.85 0.81–0.91 
Wairarapa 185 37 4.40 0.87 0.75–1.00 
Nelson Marlborough 722 144 5.38 1.06 0.98–1.14 
South Canterbury 453 91 8.56 1.69 1.54–1.85 
Canterbury 2,341 468 4.94 0.97 0.93–1.02 
West Coast 113 23 3.58 0.71 0.59–0.85 
Southern 2,063 413 7.36 1.45 1.39–1.52 
New Zealand 22,994 4,599 5.08 1.00   
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 hospitalisation rates for otitis media were significantly higher than the national rate in 
Waikato, Bay of Plenty, and Lakes DHBs, significantly lower in Taranaki DHB, and not significantly different 
in Tairawhiti DHB (Table 72).  
Regional distribution by primary diagnosis 
Between 2010 and 2014 otitis media was the most common primary diagnosis among hospitalisations for 
conditions of the middle ear and mastoid in all the Midland DHBs, and also accounted for over 90% of grommet 
hospitalisations (Table 73, Table 74).  






annual average  
Rate per 1,000 
0–14 year olds  
Rate ratio  95% CI  




Waikato 353 71 0.87 1.49 1.33–1.66 
Bay of Plenty 209 42 0.92 1.58 1.37–1.82 
Lakes 111 22 0.94 1.62 1.34–1.96 
Tairawhiti 31 6 0.53 0.91 0.64–1.30 
Taranaki 42 8 0.35 0.60 0.44–0.82 
New Zealand 2,637 527 0.58 1.00   




Waikato 2,206 441 5.41 1.07 1.02–1.11 
Bay of Plenty 1,130 226 4.98 0.98 0.92–1.04 
Lakes 733 147 6.23 1.23 1.14–1.32 
Tairawhiti 299 60 5.10 1.01 0.90–1.13 
Taranaki 735 147 6.14 1.21 1.12–1.30 
New Zealand 22,994 4,599 5.08 1.00   
Numerator: National Minimum Dataset (Otitis media: acute admissions; Grommets: arranged and waiting list admissions); 
Denominator: Statistics NZ Estimated Resident Population 
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Table 73. Hospitalisations for conditions of the middle ear and mastoid in 0−14 year olds, by primary diagnosis, 










95% CI Per cent 












Otitis media 353 71 0.87 0.78–0.96 94.13 
Mastoiditis and related disorders 12 2 0.03 0.02–0.05 3.20 
Perforation or other disorders of the 
Tympanic Membrane 
7 1 0.02 0.01–0.04 1.87 
Cholesteatoma of the Middle Ear <5 s s s s 
Total 375 75 0.92 0.83–1.02 100.00 






Otitis media 209 42 0.92 0.80–1.05 95.87 
Mastoiditis and related disorders 6 1 0.03 0.01–0.06 2.75 
Perforation or other disorders of the 
Tympanic Membrane 
<5 s s s s 







Otitis media 111 22 0.94 0.78–1.14 99.11 
Mastoiditis and related disorders <5 s s s s 







Otitis media 31 6 0.53 0.37–0.75 86.11 
Mastoiditis and related disorders 5 1 0.09 0.04–0.20 13.89 







Otitis media 42 8 0.35 0.26–0.47 95.45 
Mastoiditis and related disorders <5 s s s s 
Total 44 9 0.37 0.27–0.49 100.00 
Numerator: National Minimum Dataset (acute admissions); Denominator: Statistics NZ Estimated Resident Population; s: 
suppressed due to small numbers 
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95% CI Per cent 












Otitis media 2,032 406 4.98 4.77–5.20 92.11 
Perforation or other disorders of tympanic 
membrane 
73 15 0.18 0.14–0.22 3.31 
Eustachian tube disorders 34 7 0.08 0.06–0.12 1.54 
Other disorders of Middle Ear or Mastoid 10 2 0.02 0.01–0.05 0.45 
Hypertrophic tonsils and/or adenoids 5 1 0.01 0.01–0.03 0.23 
Cholesteatoma of the Middle Ear <5 s s s s 
Chronic tonsillitis <5 s s s s 
Sleep apnoea <5 s s s s 
Other diagnoses 46 9 0.11 0.08–0.15 2.09 
Total 2,206 441 5.41 5.19–5.64 100.00 






Otitis media 1,065 213 4.69 4.42–4.98 94.25 
Perforation or other disorders of tympanic 
membrane 
32 6 0.14 0.10–0.20 2.83 
Other disorders of Middle Ear or Mastoid 8 2 0.04 0.02–0.07 0.71 
Eustachian tube disorders 5 1 0.02 0.01–0.05 0.44 
Sleep apnoea <5 s s s S 
Hypertrophic tonsils and/or adenoids <5 s s s S 
Chronic tonsillitis <5 s s s S 
Other diagnoses 13 3 0.06 0.03–0.1 1.15 







Otitis media 705 141 6.00 5.57–6.45 96.18 
Perforation or other disorders of tympanic 
membrane 
9 2 0.08 0.04–0.15 1.23 
Eustachian tube disorders 5 1 0.04 0.02–0.10 0.68 
Other disorders of Middle Ear or Mastoid 5 1 0.04 0.02–0.10 0.68 
Sleep apnoea <5 s s s S 
Hypertrophic tonsils and/or adenoids <5 s s s S 
Other diagnoses 7 1 0.06 0.03–0.12 0.95 







Otitis media 284 57 4.85 4.32–5.44 94.98 
Eustachian tube disorders 9 2 0.15 0.08–0.29 3.01 
Perforation or other disorders of tympanic 
membrane 
5 1 0.09 0.04–0.20 1.67 
Cholesteatoma of the Middle Ear <5 s s s S 







Otitis media 723 145 6.04 5.62–6.50 98.37 
Perforation or other disorders of tympanic 
membrane 
<5 s s s S 
Other disorders of Middle Ear or Mastoid <5 s s s S 
Hypertrophic tonsils and/or adenoids <5 s s s S 
Other diagnoses 9 2 0.08 0.04–0.14 1.22 
Total 735 147 6.14 5.71–6.60 100.00 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident 
Population; s: suppressed due to small numbers 
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Regional trends 
Hospitalisation rates for otitis media in 0–14 year olds fluctuated between 2000 and 2014 in all the Midland 
DHBs, although rates generally decreased in Bay of Plenty, Tairawhiti and Taranaki DHBs. Hospitalisation 
rates for insertion of grommets fell in all the Midland DHBs (Figure 59). 
Regional distribution by ethnicity 
There were few differences between Māori and European/Other hospitalisation rates for insertion of grommets 
in 0–14 year olds in any of the Midland DHBs in 2000–2014, although rates for the Asian/Indian ethnic group 
were considerably lower than those of any other ethnic groups in Waikato DHB. Rates declined for both Māori 
and European/Other 0–14 year olds in Waikato and Tairawhiti DHBs while rates fluctuated without any clear 
pattern for either Māori or European/Other ethnic groups in Bay of Plenty, Lakes and Taranaki DHBs (Figure 
60). Small numbers prevent a review of differences in otitis media hospitalisations by ethnicity. 
Regional distribution by season 
There was seasonal variation in otitis media hospitalisation rates in all the Midland DHBs. Rates tended to be 
highest in the cooler months. There was no seasonal variation in grommet hospitalisations (Figure 61). 
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Figure 59. Hospitalisations for otitis media and insertion of grommets in 0−14 years, MIdland DHBs vs New Zealand 2000−2014 
 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident Population; Rate per 1,000 0–14 year olds 
Figure 60. Hospitalisations for insertion of grommets in 0−14 year olds, by ethnicity, Midland DHBs vs New Zealand 2000−2014 
 
Numerator: National Minimum Dataset (arranged and waiting list admissions); Denominator: Statistics NZ Estimated Resident Population; Rate per 1,000 0–14 year olds; Ethnicity is level 1 prioritised; Rates for 
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Figure 61. Hospitalisations for otitis media and grommets in 0–14 year olds, by month, Midland DHBs 2010−2014 
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Evidence for good practice for the prevention and management of 
otitis media and grommets 
Ministry of Health Publications 
Ministry of Health. 2014. National vision and hearing screening protocols: revised 2014. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/national-vision-and-hearing-screening-protocols 
This document describes the best practice for Vision Hearing Technicians (VHTs) who deliver the National Vision and Hearing screening 
programme. The programme involves hearing and vision screening of all four year olds (as part of the B4 school check), and vision screen for all 
11 year olds (year 7 students). Hearing screening for four year olds is by audiometry, with additional tympanometry if audiometry results are 
abnormal. Individual DHBs may choose to offer targeted tympanometry screening at three years of age to groups at high-risk of harm from glue 
ear, at their discretion. The web page has a training video which demonstrates best practice for VHTs delivering vision and hearing screening. 
Ministry of Health. 2014. Well Child / Tamariki Ora Programme Practitioner Handbook: Supporting families and whānau 
to promote their child’s health and development. Revised 2014. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/well-child-tamariki-ora-programme-practitioner-handbook-2013 
This handbook was produced to assist and support all providers who deliver Well Child/Tamariki Ora (WCTO) services in accordance with the 
WCTO Schedule. It includes information from the National vision and hearing screening protocols (above) and The B4 School Check: A handbook 
for practitioners (below). Additional information for the health sector on the B4 School Check can be found here: http://www.health.govt.nz/our-
work/life-stages/child-health/b4-school-check/b4-school-check-information-health-sector 
Ministry of Health. 2008. The B4 School Check: A handbook for practitioners. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/b4-school-check-handbook-practitioners  
The B4 School Check includes vision and hearing screening. Section 4 of this publication provides brief information on childhood hearing 
impairment and provides guidance for practitioners on audiometry screening of four, five and six year old children using the sweep test and, if 
the sweep test is equivocal or abnormal, tympanometry. 
International Guidelines 
Guidelines and Protocols Advisory Committee, Medical Services Commission. 2010. Otitis media: acute otitis media (AOM) 
and otitis media with effusion (OME). Victoria, BC: Government of British Columbia. 
http://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/otitis.pdf 
This concise Canadian guideline applies to otherwise healthy children over the age of six months, presenting with either acute otitis media (AOM) 
or otitis media with effusion (OME). It is well-referenced but recommendations in the guideline are not accompanied by evidence grades or an 
indication of strength of recommendation. There is a summary of this guideline at the National Guideline Clearinghouse website: 
http://www.guideline.gov/content.aspx?id=38906. 
Lieberthal AS, Carroll AE, Chonmaitree T, et al. 2013. The diagnosis and management of acute otitis media. Pediatrics, 131(3), 
e964-99. (Erratum in Pediatrics. 2014 Feb;133(2):346. Dosage error in article text.) 
http://pediatrics.aappublications.org/content/131/3/e964.long  
This evidence-based guideline from the American Academy of Pediatrics provides recommendations for primary care clinicians on the diagnosis 
and management of children (aged from six months through 12 years) with uncomplicated acute otitis media (AOM). It covers pain management, 
initial observation versus antibiotic treatment, appropriate choices of antibiotic agents, and preventive measures. It also addresses recurrent AOM. 
Recommendations in the guideline are accompanied by indications of the strength of recommendation and the quality of the evidence on which 
the recommendation is based. A summary of this guideline can be found on the National Guideline Clearinghouse website: 
http://www.guideline.gov/content.aspx?id=43892&search=otitis+media  
University of Michigan Health System. 2013. Otitis media. Ann Arbor (MI): University of Michigan Health System. 
http://www.med.umich.edu/1info/FHP/practiceguides/om/OM.pdf 
This guideline covers diagnosis and management of acute otitis media and otitis media with effusion in children (older than two months) and 
adults. Recommendations in the guideline are accompanied by an indication of the strength of recommendation (from I to III) and the quality of 
the supporting evidence (from A to D). A summary of this guideline can be found on the National Guideline Clearinghouse website: 
http://www.guideline.gov/content.aspx?id=46420&search=otitis+media  
Rosenfeld RM, Schwartz SR, Pynnonen MA, et al. 2013. Clinical practice guideline: Tympanostomy tubes in children. 
Otolaryngol Head Neck Surg, 149(1 Suppl), S1-35 
The main purpose of this guideline from the American Academy of Otolaryngology - Head and Neck Surgery is to provide US clinicians with 
evidence-based recommendations on the indications for, and management of, tympanostomy tubes in children aged six months to 12 years. The 
guidelines are structured as a series of key action statements, each followed by a strength of recommendation and an “action statement profile” 
indicating aggregate evidence quality, level of confidence in the evidence, benefit-harm assessment, statement of costs, value judgments, the 
role of patient and caregiver preferences, clarification of any intentional vagueness by the guideline panel, exceptions to the statement, and any 
differences of opinion among the panel. After each action statement profile there is a discussion of the evidence base supporting the statement. 
Statement 3 is: “Clinicians should offer tympanostomy bilateral tube insertion to children with bilateral otitis media with effusion (OME) for 3 
months or longer AND documented hearing difficulties.” Other statements deal with children with an isolated single short-term episode of OME, 
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when hearing tests are indicated, symptoms associated with OME that may be indications for tympanostomy, surveillance of chronic OME, 
recurrent acute otitis media in the absence of middle ear effusion, bilateral vs. unilateral tympanostomy, OME and tympanostomy tubes in at-risk 
children (such as children with developmental delays and children with Down syndrome), perioperative education, acute tympanostomy tube 
otorrhoea, and water precautions for children with tympanostomy tubes. 
National Institute for Health and Care Excellence. 2008. Surgical management of otitis media with effusion in children. 
London: National Institute for Health and Care Excellence. http://www.nice.org.uk/guidance/cg60 
This evidence-based guideline covers the surgical management of OME in children aged less than 12 years and it includes specific 
recommendations for children with Down syndrome and cleft palate. It provides information on assessment, diagnosis and indications for 
specialist referral, indications for surgical intervention, the effectiveness of surgical and non-surgical interventions, information for parents and 
carers and recommendations for research. It states that children with persistent bilateral OME documented over a period of three months with a 
hearing level in the better ear of 25–30 dBHL or worse should be considered for surgery. The following treatments are not recommended as non-
surgical interventions: antibiotics, topical/systemic antihistamines, decongestants or steroids, homeopathy, cranial osteopathy, acupuncture, 
dietary modifications, probiotics, immunostimulants or massage. Hearing aids should be offered to children with persistent bilateral hearing loss 
for whom surgery is contraindicated or unacceptable and autoinflation (forced exhalation with closed mouth and nose to reopen the Eustachian 
tube) may be considered during the observation period for cooperative children. The full guideline, which includes a review of the evidence and 
an evidence summary for each section, is:  
National Collaborating Centre for Women’s and Children’s Health. 2008. Surgical management of children with otitis media 
with effusion (OME). London: RCOG Press. http://www.nice.org.uk/guidance/cg60/evidence/cg60-surgical-management-of-
ome-full-guideline 
Appendix C of the full guideline provides an economic evaluation of alternative management strategies for OME in children. The evidence 
tables on which the guidelines were based can be found at: http://www.nice.org.uk/guidance/CG60/documents/cg60-surgical-management-of-
ome-evidence-tables2  
National Institute for Health and Clinical Excellence. 2008. Prescribing of antibiotics for self-limiting respiratory tract 
infections in adults and children in primary care. London: National Institute for Health and Clinical Excellence. 
https://www.nice.org.uk/guidance/cg69  
This guidelines states that a no antibiotic or delayed antibiotic prescribing strategy is appropriate for patients with acute otitis media but that an 
immediate antibiotic prescribing strategy can be considered for bilateral acute otitis media in children younger than two years and acute otitis 
media in children with otorrhoea (discharge from the ear). The full guideline, and the supporting evidence, can be downloaded here: 
http://www.nice.org.uk/guidance/cg69/evidence . 
Evidence-based medicine reviews 
Venekamp RP, Sanders S, Glasziou PP, et al. 2015. Antibiotics for acute otitis media in children. Cochrane Database 
Systematic Reviews (6). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000219.pub4/abstract 
This review assessed the effects of antibiotics for acute otitis media (AOM) through a review of RCTs comparing (1) antibiotics with placebo and 
(2) antibiotics with expectant observation (including delayed antibiotics prescribing) in children with AOM. Thirteen RCTs generally at low risk of 
bias (3,401 children and 3,938 AOM episodes in high income countries) compared antibiotics with placebo. The combined results of these trials 
indicated that, 24 hours from the start of treatment, 60% of children had recovered whether or not they had received antibiotics. Pain was not 
reduced by antibiotics at 24 hours (risk ratio (RR) 0.89, 95% CI 0.78 to 1.01) but almost a third fewer had residual pain at two to three days (RR 
0.70, 95% CI 0.57 to 0.86; number needed to treat for an additional beneficial outcome (NNTB) 20). Antibiotics did reduce the number of children 
with abnormal tympanostomy findings at 2–4 weeks and 6–8 weeks, and the number of children with tympanic membrane perforations, and 
halved the number of contralateral otitis episodes compared to placebo. There was no difference between the antibiotics and placebo groups in 
rates of severe complications, which were rare, but children taking antibiotics had more adverse events such as vomiting and diarrhoea. Individual 
patient data meta-analysis of a subset of included trials indicated that antibiotics are most beneficial in children aged less than two years with 
bilateral AOM, or with both AOM and otorrhoea. For the comparison of immediate antibiotics vs. expectant observation, four RCTs (1,007 children) 
provided usable data for meta-analysis. Data from 959 children indicated no detectable difference in pain at three to seven days (RR 0.75, 95% 
CI 0.50 to 1.12). There were also no differences between groups in number of children with abnormal tympanometry findings at four weeks, 
tympanic membrane perforations and AOM recurrence. No serious complications occurred in either group but there was a substantially increased 
risk of vomiting, diarrhoea or rash in the antibiotics group. Results from an individual patient data meta-analysis including data from six high-
quality trials (1,643 children) that were also included as individual trials in the review indicated that antibiotics appear to be most beneficial in 
children younger than two years of age with bilateral AOM (NNTB 4) and in children with both AOM and otorrhoea (NNTB 3). The review authors 
concluded that clinical management of AOM should emphasise advice about adequate analgesia and the limited role for antibiotics. They stated 
that antibiotics are most beneficial in children under two years of age with bilateral AOM, or with both AOM and otorrhoea, and that for most 
other children with mild disease in high-income countries, an expectant observational approach seems justified.  
Norhayati Mohd N, Ho Jacqueline J, Azman Mohd Y. 2015. Influenza vaccines for preventing acute otitis media in infants 
and children. Cochrane Database of Systematic Reviews (3). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010089.pub2/abstract 
Although most cases of acute otitis media (AOM) in children are due to bacterial infection, episodes of AOM are often triggered by a viral 
infection. This review aimed to evaluate the effectiveness of influenza vaccine in reducing the occurrence of AOM in infants and children. Ten 
placebo RCTs involving16,707 children aged six months to six years were included. Nine trials, and all five trials that contributed to the primary 
outcome (reduction in AOM), were funded by vaccine manufacturers. Trials assessing the primary outcome showed a small reduction in at least 
one episode of AOM over at least six months of follow-up (five trials, 4,736 participants: risk ratio 0.80, 95% CI 0.67 to 0.96; risk difference −0.04, 
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95% CI −0.07 to −0.02; number needed to treat to benefit 25, 95% CI 15 to 50). There was a reduction in the use of antibiotics in vaccinated 
children (two trials, 1223 participants: RR 0.70, 95% CI 0.59 to 0.83; RD −0.15, 95% CI −0.30 to −0.00). The review authors concluded that influenza 
vaccination results in a small reduction in AOM but the benefits may not justify the use of influenza vaccine without taking into account vaccine 
efficacy in reducing influenza and safety data. They stated that the quality of the evidence was high to moderate and that further research is 
needed. 
Wallace IF, Berkman ND, Lohr KN, et al. 2014. Surgical treatments for otitis media with effusion: a systematic review. 
Pediatrics, 133(2), 296-311. http://pediatrics.aappublications.org/content/133/2/296.long 
This review aimed to compare the effectiveness of surgical strategies currently used in the management of otitis media with effusion (OME). The 
review authors identified three recent systematic reviews and 41 unique studies. The studies included RCTs, non-randomised trials and cohort 
studies that compared myringotomy (incision of the eardrum to release fluid from the middle ear), adenoidectomy, tympanostomy tubes (tubes, 
grommets) and watchful waiting. In comparison with watchful waiting or myringotomy, tubes decreased time with OME and improved hearing 
in the short term (12 RCTs); no specific tube type was superior (8 RCTs). Adenoidectomy alone, as an adjunct to myringotomy, or combined with 
tubes, (8 RCTs in total), reduced OME and improved hearing in comparison with either myringotomy or watchful waiting. Tubes and watchful 
waiting did not differ in language (4 trials), or cognitive or academic outcomes (2 trials). Otorrhoea (discharge from the ear) and tympanosclerosis 
(scarring of the eardrum) were more common in ears with tubes. Adenoidectomy increased the risk of postsurgical haemorrhage. The review 
authors concluded that tubes and adenoidectomy reduce time with OME and improve hearing in the short-term (up to 1–2 years). They noted 
that both treatments have associated harms. They stated that large, well-controlled studies could help resolve the risk-benefit ratio by measuring 
acute otitis media recurrence, functional outcomes, quality of life, and long-term outcomes and that research is needed to support treatment 
decisions in subpopulations, especially in patients with comorbidities. 
Boonacker CW, Rovers MM, Browning GG, et al. 2014. Adenoidectomy with or without grommets for children with otitis 
media: an individual patient data meta-analysis. Health Technol Assess, 18(5), 1-118. 
http://www.ncbi.nlm.nih.gov/books/NBK261525/ 
Children with persistent otitis media with effusion (OME) or recurrent acute otitis media (AOM) may be offered insertion of grommets, 
adenoidectomy, or a combination of the two. This study aimed to: (1) Develop a model to predict the risk of children referred for adenoidectomy 
having prolonged duration of their OM, and then (2a) evaluate the overall effect of adenoidectomy, with or without grommets, on OM by 
evaluating individual patient data, and (2b) identify those sub-groups of children who are most likely to benefit from adenoidectomy with or 
without grommets. Studies were deemed eligible for inclusion in the meta-analysis if they were RCTs in children aged up to 12 years of age 
diagnosed with recurrent AOM and/or persistent OME in which adenoidectomy (with or without grommets) was compared with non-surgical 
treatment or grommets alone. Ten trials (1,761 children) were included in the meta-analysis: eight were considered to be at low risk of bias and 
two at moderate risk. The primary outcome measure was failure at 12 months, defined by a set of persisting symptoms and signs. The prognostic 
analyses indicated that, of the 342 children who were referred for adenoidectomy but were randomised to non-surgical groups, 193 (56%) failed 
to improve at 12 months. Indication was an independent predictor of failure. The absolute risk of failing to improve for children with an indication 
of persistent OME was 89%, and for children with an indication of recurrent AOM it was 38%. 
The proportion of children who failed at 12 months in the adenoidectomy group (adenoidectomy with or without grommets) was 32% while the 
proportion of children who failed at 12 months in the no adenoidectomy (non-surgical or grommets alone) group was 45%. The unadjusted risk 
difference for failure at 12 months was –13% [95% confidence interval (CI) –17% to –8%], resulting in a number needed to treat (NNT) of eight 
children to prevent one failure. The adjusted RR was 0.76 (95% CI 0.69 to 0.85), which was similar to the unadjusted RR (0.72, 95% CI 0.63 to 0.81). 
For all secondary outcomes, other than presence of effusion for ≥ 50% of the time in the first 12 months, results for children in the adenoidectomy 
group were also statistically significantly better than results for those in the no adenoidectomy group. Two sub-groups of children were found to 
be most likely to benefit from adenoidectomy: (1) children aged < 2 years with recurrent AOM, where 16% of those who had adenoidectomy 
failed at 12 months compared to 27% of those who did not [rate difference (RD) 12%, 95% CI 6% to 18%; number needed to treat (NNT) = 9]; (2) 
children aged ≥4 years with persistent OME, where 51% of those who had adenoidectomy failed at 12 months compared to 70% of those who 
did not (RD 19%, 95% Cl 12% to 26%; NNT = 6). There was found to be no significant benefit of adenoidectomy in children aged ≥2 years with 
recurrent AOM and children aged <4 years with persistent OME. The review authors concluded that adenoidectomy is most beneficial in children 
with persistent OME aged ≥4 years. 
Mohiuddin S, Schilder A, Bruce I. 2014. Economic evaluation of surgical insertion of ventilation tubes for the management 
of persistent bilateral otitis media with effusion in children. BMC Health Serv Res, 14, 253. 
http://www.biomedcentral.com/1472-6963/14/253 
The commonest surgical treatment for otitis media with effusion (OME) is the insertion of ventilation tubes (VTs), also known as grommets or 
tympanostomy tubes. The use of VTs to treat OME is somewhat contentious, because OME tends to resolve spontaneously with increasing age 
in the majority of children. An alternative to insertion of VTs is to fit a child with hearing aids (HAs) to compensate for the hearing loss associated 
with OME, and await the natural resolution of the condition. The aim of this study as to evaluate the cost-effectiveness of VTs insertion for the 
management of persistent bilateral OME in children, compared with HAs alone and HAs plus VTs strategies. The study authors employed a 
decision-tree model, using data from published sources, and assuming a 2-year time horizon and a UK NHS perspective for costs. They found 
that the VTs strategy was more effective and less costly than the HAs plus VTs strategy, and that the incremental cost-effectiveness ratio for the 
VTs strategy compared to the HAs alone strategy was £5,086 per quality-adjusted life year (QALY) gained. At a willingness-to-pay threshold of 
£20,000 per QALY, the probability that the VTs strategy is likely to be more cost-effective was 0.58. The authors stated that the expected value of 
perfect information (EVPI) value at population level of around £9.5 million at the willingness-to-pay threshold of £20,000 indicated that future 
research in this area is potentially worthwhile, while the partial EVPI analysis indicated considerable uncertainty surrounding the parameters used 
for computing the QALYs for which more precise estimates would be most valuable. They concluded that The VTs strategy is a cost-effective 
option when compared with the HAs alone and HAs plus VTs strategies, but that further research is needed and that future studies of surgical 
and non-surgical treatment of OME in children should evaluate the economic impact of interventions. 
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Gisselsson-Solen M. 2014. The importance of being specific–a meta-analysis evaluating the effect of antibiotics in acute 
otitis media. International Journal of Pediatric Otorhinolaryngology, 78(8), 1221-27. 
http://www.sciencedirect.com/science/article/pii/S0165587614003139 
Making a diagnosis of acute otitis media in clinical practice is often difficult and physicians may be uncertain of the diagnosis in a substantial 
minority of cases. This paper points out that many trials assessing the effect of antibiotics in acute otitis media (AOM) in children have used 
symptomatic outcome measures, such as pain, and found that antibiotics have only modest effects on AOM but two recent trials which used 
treatment failure as an outcome measure found more substantial effects. The aim of this study was to perform a meta-analysis to calculate the 
composite risk ratio for treatment failure in AOM (indicated by diagnostic findings such as bulging and immobility of the tympanic membrane 
on otoscopy, as well as symptoms) and to investigate whether the specificity of treatment failure as an outcome measure is different from that 
of other symptomatic outcomes, such as pain. The authors identified trials evaluating the effects of antibiotics in AOM and reporting the number 
of treatment failures and performed a fixed-effects meta-analysis. They also searched the literature for articles providing direct or indirect figures 
on the specificity of different outcome measures in AOM trials and designed a hypothetical study to show how differences in the 
sensitivity/specificity of inclusion/outcome criteria affect the results of a trial. The meta-analysis yielded a composite risk ratio of 0.4 (95% CI 0.35 
to 0.48, p < 0.001) for the effect of antibiotics on treatment failure. Based on data from the literature, the specificity of treatment failure was 
estimated to be 92–100%. The hypothetical study showed how using a non-specific outcome measure biases the effect estimate towards the null, 
whereas other kinds of misclassification only decrease precision. The authors concluded that future trials should improve diagnostic criteria to 
increase precision but primarily, they should focus on choosing a specific outcome measure so as to avoid getting a biased effect estimate. 
Mikals SJ, Brigger MT. 2014. Adenoidectomy as an adjuvant to primary tympanostomy tube placement: a systematic 
review and meta-analysis. JAMA Otolaryngol Head Neck Surg, 140(2), 95-101 
Adenoidectomy (Ad) done in conjunction with tympanostomy tube (grommet) placement (TT) may reduce the likelihood of a child needing repeat 
surgery for tube placement (r-TT) because of otitis media. This review aimed to assess the effectiveness of primary adenoidectomy as an adjuvant 
to TT (Ad + TT) compared with TT alone. It included 15 prospective and retrospective studies comparing outcomes for children (aged ≤ 18 years) 
who underwent primary Ad+TT with children who had undergone TT only for middle ear disease. To be included studies had to have (1) 
extractable data regarding indications, procedures, and outcomes for each group; (2) an adequately described study design, and (3) documented 
follow-up. Ten studies (71,353 children) reported that primary Ad + TT decreased the risk of r-TT or risk of recurrent acute otitis media (RAOM), 
otitis media with effusion (OME), or otorrhea compared with TT alone. Four studies (n = 538) reported no difference between Ad + TT groups and 
TT-only groups in the prevention of r-TT or of RAOM, OME, or otorrhea. Despite significant heterogeneity, limited meta-analysis and pooling of 
data indicated that the children undergoing primary Ad + TT had an estimated rate of r-TT of 17.2% (95% CI, 12.2% to 22.2%) vs 31.8% (95% CI, 
23.9%-39.8%) for children undergoing TT only. When stratified by age, the protective effects of adenoidectomy were diminished in children 
younger than 4 years. The review authors concluded that the current evidence suggests that primary Ad + TT may be superior to TT only in 
decreasing the risk of r-TT and the risk of RAOM, OME, or otorrhea in children older than four years but this benefit needs to be weighed against 
the additional morbidity of an adenoidectomy and the cost effectiveness of Ad + TT given the modest improvement in outcomes. They noted 
limitations of the evidence including heterogeneity of the source data, with the predominance of retrospective data. 
Perera R, Glasziou Paul P, Heneghan Carl J, et al. 2013. Autoinflation for hearing loss associated with otitis media with 
effusion. Cochrane Database of Systematic Reviews (5). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006285.pub2/abstract 
This review aimed to assess the effectiveness of autoinflation compared to no treatment in children and adults with otitis media with effusion 
(OME, ‘glue ear’). Autoinflation is the opening of, and fording air through, the Eustachian tube by raising intranasal pressure. The can be achieved 
by forced exhalation with closed mouth and nose, blowing up a small balloon attached to a nose piece through each nostril in turn, use of an 
anaesthetic mask or a Politzer device. The review included eight studies (702 participants in total) comparing a form of autoinflation to no 
autoinflation in individuals with glue ear. All of the studies were small, of limited duration and had short follow-up. The review authors combined 
data from seven studies using a composite outcome measure which included any outcome signifying improvement (as defined in the individual 
studies, either by tympanogram or audiometry) and assessed outcomes at two time points: ≤ one month and > one month. Only the > one 
month analysis indicated a significant improvement: relative risk of improvement 1.74, 95% CI 1.22 to 2.50. Sub-group analysis based on the type 
of intervention indicated a significant effect for using a Politzer device both at ≤ one month (RRI 7.07, 95% CI 3.70 to 13.51) and > one month 
(RRI 2.25, 95% CI 1.67 to 3.04). The review authors concluded that, because of autoinflation’s low cost and the absence of associated adverse 
effects, it is reasonable to consider its use while awaiting natural resolution of OME. They suggested that primary care could be a suitable place 
to evaluate this intervention further. They stated that further research should also consider the duration of treatment, long term impacts on 
developmental outcomes in children, and additional quality of life outcome measures for children and families. 
Syed Mohammed I, Suller S, Browning George G, et al. 2013. Interventions for the prevention of postoperative ear 
discharge after insertion of ventilation tubes (grommets) in children. Cochrane Database of Systematic Reviews (4). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008512.pub2/abstract 
This review aimed to assess the effectiveness of prophylactic interventions in reducing the incidence of otorrhoea (ear discharge) after the 
insertion of grommets in children. The review authors identified 15 relevant RCTs (2,476 children, aged from four months to 17 years). Seven trials 
(936 children) were considered to be at low risk of bias, as were two arms of another RCT. The other seven were deemed to be at high risk of 
bias. For a single application at surgery, two low risk trial provided evidence that the risk of otorrhoea at two weeks post-surgery provided was 
reduced by: multiple saline washouts (from 30% to 16%; relative risk (RR) 0.52, 95% CI 0.27 to 1.00; number needed to treat to benefit (NNTB) 7, 
one RCT with 140 children); and by antibiotic/steroid ear drops (from 9% to 1%; RR 0.13, 95% CI 0.03 to 0.57; NNTB 13; one RCT; 322 ears). A 
meta-analysis of two trials at low risk of bias (222 ears) did not find any effect at four to six weeks postoperatively from single application of 
antibiotic/steroid ear drops. For prolonged application of an intervention, four trials at low risk of bias provided evidence that the risk of otorrhoea 
was reduced at two weeks post-surgery by antibiotic ear drops (from 15% to 8%; RR 0.54, 95% CI 0.30 to 0.97; NNTB 15; one RCT; 372 children), 
antibiotic/steroid ear drops (from 39% to 5%; RR 0.13, 95% CI 0.05 to 0.31; NNTB 3; one RCT; 200 children), aminoglycoside/steroid ear drops 
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(from 15% to 5%; RR 0.37, 95% CI 0.18 to 0.74; NNTB 11; one RCT; 356 children) or oral antibacterial agents/steroids (from 39% to 5%; RR 0.13, 
95% CI 0.03 to 0.51; NNTB 3; one RCT; 77 children). Only one trial assessed the secondary outcome of ototoxicity: it found no effect. No trials 
assessed quality of life. The review authors noted the wide variation between trials in rates of otorrhoea, and that the higher the rate of otorrhoea 
within a RCT, the lower the NNTB for therapy. They concluded that if surgeon has a high rate of postoperative otorrhoea in children then either 
saline irrigation or antibiotic ear drops at the time of surgery would significantly reduce that rate. They suggested that, if topical drops are chosen, 
then to reduce the cost and the potential for ototoxic damage, a single application at the time of surgery should be used rather than prolonged 
application. 
Berkman ND, Wallace IF, Steiner MJ, et al. 2013. AHRQ Comparative Effectiveness Reviews: Otitis Media With Effusion: 
Comparative Effectiveness of Treatments. Rockville (MD): Agency for Healthcare Research and Quality (US). 
http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1485 
This comparative effectiveness review for the AHRQ addressed five key questions relating to the treatment of otitis media with effusion (OME): 
 KQ 1. What is the comparative effectiveness of the following treatment options (active treatments and watchful waiting) in affecting 
clinical outcomes or health care utilisation in patients with OME? Treatment options include: tympanostomy tubes (grommets), 
myringotomy, oral or topical nasal steroids, autoinflation, complementary and alternative medical procedures, watchful waiting, and 
variations in surgical technique or procedures. 
 KQ 2. What is the comparative effectiveness of the different treatment options listed in KQ 1 (active treatments, watchful waiting, and 
variations in surgical procedures) in improving functional and health-related quality of life outcomes in patients with OME? 
 KQ 3. What are the harms or tolerability among the different treatment options? 
 KQ 4. What are the comparative benefits and harms of treatment options in subgroups of patients with OME? 
 KQ 5. Is the comparative effectiveness of treatment options related to factors affecting health care delivery or the receipt of 
pneumococcal vaccine inoculation? 
In total, the review included 59 studies: 49 RCTs, six non-randomised studies, and four cohort studies. Forty-two of these were included in five 
systematic reviews, and of the other 17, 15 were considered to be at medium risk of bias, one at high risk and one at low risk. Of the five systematic 
reviews, four were assessed as being at low risk of bias (they included only RCTs) and one at medium risk. The findings relating to the key 
questions are summarised in tables which give numbers of studies and sample sizes, outcomes and results and strength of evidence for each 
intervention vs. comparator combination. Overall, the reviewers found an uneven body of evidence across treatment comparisons and outcomes. 
They found strong and consistent evidence that, compared to watchful waiting or myringotomy, tympanostomy tubes decreased effusion and 
improved hearing over the short term but did not affect longer-term speech, language or other functional outcomes. There was, however, weaker 
evidence that tube placement was associated with increased rates of side effects such as otorrhoea and tympanosclerosis. Although 
adenoidectomy results in fewer children having OME in the short term compared to watchful waiting, less is known about its long term effects, 
particularly with regard to functional outcomes. Steroids were found not to be of benefit. The reviewers stated that additional research and better 
methods are needed to develop a comprehensive evidence base to support decision making about the various treatment options, especially in 
sub-populations defined by age and co-existing conditions. 
Levi JR, Brody RM, McKee-Cole K, et al. 2013. Complementary and alternative medicine for pediatric otitis media. 
International Journal of Pediatric Otorhinolaryngology, 77(6), 926-31. 
This review discusses complementary and alternative medicine for otitis media in children. Thirty-six unique publications were reviewed. These 
included case reports, case series, RCTs, and basic science research. The review authors noted that, of all therapies in complementary and 
alternative medicine, only xylitol has been studied in well-designed, randomized, blinded trials. (Xylitol is a natural sugar found in many fruits and 
used as a sweetener in chewing gum.) They stated that xylitol is probably effective in preventing acute otitis media, but compliance limits its 
applicability. They identified breastfeeding and avoidance of secondhand smoke as effective preventive measures. 
van Zon A, van der Heijden Geert J, van Dongen Thijs MA, et al. 2012. Antibiotics for otitis media with effusion in children. 
Cochrane Database of Systematic Reviews (9). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009163.pub2/abstract 
Otitis media with effusion (OME) is characterised by an accumulation of fluid in the middle ear behind the tympanic membrane (ear drum), 
without symptoms signs of acute infection. Despite the absence of evidence of acute infection, in around one in three children with OME a 
bacterial pathogen can be identified in the middle ear fluid. This review therefore aimed to assess the effects of antibiotics in children with OME 
(aged up to 18 years). The review included 23 RCTs (3,207 children) covering a range of antibiotics, participants, outcome measures and time 
points of evaluation. The reviewers considered the trials to be generally at low risk of bias. The outcome of primary interest was complete 
resolution of OME at two to three months. Five individual studies provided data on this outcome. The differences (improvement) in the proportion 
of children having such resolution (risk difference (RD)) ranged from 1% (RD 0.01, 95% CI −0.11 to 0.12; not significant) to 45% (RD 0.45, 95% CI 
0.25 to 0.65). Results from these studies could not be pooled because of clinical and statistical heterogeneity. It was possible to pool results from 
studies assessing complete resolution at more than six months: antibiotics were associated with an increase in resolution of 13% (RD 0.13, 95% 
CI 0.06 to 0.19). Pooled analysis was also possible for complete resolution at the end of treatment, with the following increases in resolution rates: 
17% (RD 0.17, 95% CI 0.09 to 0.24) for treatment for 10 days to two weeks, 34% (RD 0.34, 95% CI 0.19 to 0.50) for treatment for four weeks, 32% 
(RD 0.32, 95% CI 0.17 to 0.47) for treatment for three months, and 14% (RD 0.14, 95% CI 0.03 to 0.24) for treatment continuously for at least six 
months. The review authors found no evidence of a substantial improvement in hearing as a result of antibiotics, nor did they find an effect on 
the rate of ventilation tube insertion. No trials examined speech, language, cognitive development or quality of life. Six studies reported on 
adverse effects but their results could not be pooled due to high heterogeneity. Increases in the rates of adverse events ranged from 3% (RD 
0.03, 95% CI −0.01 to 0.07; not significant) to 33% (RD 0.33, 95% CI 0.22 to 0.44) in the individual studies. The review authors concluded that the 
evidence did not support routine use of antibiotics in children with OME. They noted that the greatest effects of antibiotics were found in children 
treated continuously for four weeks and three months. The stated that, even when benefits of antibiotics are apparent, these must be weighed 
against potential adverse events, both for the individual (e.g. diarrhoea) and society (e.g. emergence of antibiotic resistance). 
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El-Makhzangy AM, Ismail NM, Galal SB, et al. 2012. Can vaccination against pneumococci prevent otitis media with 
effusion? Eur Arch Otorhinolaryngol, 269(9), 2021-6 
This review aimed to determine, according to the best available published evidence, whether vaccination against pneumococci effectively prevents 
otitis media with effusion. Three relevant studies were identified: one RCT (161 children with OME aged 2–8 years), and two secondary analyses 
of previously conducted RCTs (1,662 children aged 2−12 months and 383 children aged 1−7 years). Meta-analysis indicated that anti-
pneumococcal vaccination conferred no significant preventive advantage for OME. The review authors concluded that analysis of the best 
available published evidence does not show a significant value for anti-pneumococcal vaccination in preventing OME, but given the very small 
number of RCTs directly addressing the disease in question, research is still open to resolve this issue. 
Shekelle PG, Takata G, Newberry SJ, et al. 2010. Management of Acute Otitis Media: Update. Evidence Report/Technology 
Assessment No. 198. (Prepared by the RAND Evidence-Based Practice Center under Contract No. 290 2007 10056 I). 
Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/research/findings/evidence-based-
reports/otitisup-evidence-report.pdf 
This review is an update of a previous AHRQ review (2001). It updates findings on the diagnosis and treatment of uncomplicated acute otitis 
media (AOM), assesses the evidence for the treatment of recurrent AOM, and assesses the impact of the heptavalent pneumococcal conjugate 
vaccine (PCV-7) on the microbiology of AOM. (Since the publication of this report the US has introduced a 13-valent PCV vaccine.) The review 
authors found few studies that had examined the accuracy and precision of diagnosis of AOM. Following the introduction of PCV-7, Streptococcus 
pneumoniae became less commonly identified in AOM microbiology while Haemophilus influenzae became more prominent. Pooled analysis of 
RCT results from seven trials indicated that for uncomplicated AOM, nine children (95% CI 6 to 20) would need to be treated with ampicillin or 
amoxicillin rather than placebo to note a difference in the rate of clinical success. Of four studies of delayed antibiotic treatment for uncomplicated 
AOM, two found that immediate antibiotic treatment had a higher rate of clinical success while two did not. Three studies found a marked 
decrease in antibiotic utilisation. The review authors could not determine the comparative effectiveness of different antibiotics for AOM in children 
with recurrent otitis media (ROM), or the comparative effectiveness of different treatments in subgroups of children with AOM. For children with 
ROM, long term treatment with antibiotics decreased AOM episodes from 3 to 1.5 per 12 months of treatment for each AOM-prone child (95% 
CI 1.2 to 2.1), but this benefit needs to be weighed against the potential consequences of long term treatment (such as diarrhoea). Amoxicillin-
clavulanate was generally associated with more frequent adverse events than cefdinir, ceftriaxone, or azithromycin. The review authors stated 
that higher quality studies and improved reporting of quality-related study characteristics are needed to provide definitive conclusions about 
treatment for AOM and ROM. 
Other relevant publications 
Gribben B, Salkeld LJ, Hoare S, et al. 2012. The incidence of acute otitis media in New Zealand children under five years of 
age in the primary care setting. Journal of Primary Health Care 4(3) 205-12  
This paper reports on a cohort study of children aged less than five years enrolled in a sample of GP practices (63 in total) in New Zealand from 
1 November 2008 to 31 October 2009. The aim of the study was to estimate the incidence of acute otitis media (AOM). There were 19,146 children 
included in the sample. The raw incidence of AOM was 273 per 1,000 children (27.3%; 95% CI 216 to 330). Of the 3,885 children, 2888 (74%) had 
one episode of AOM and 152 (4%) of these children developed recurrent AOM. Incidence declined with age. There was no difference in incidence 
between Māori, Pacific and ‘Other’ ethnicities. Antibiotics were used to treat 2653 (51%) AOM episodes and 113 (4.3%) of these children re-
presented within three days of antibiotic therapy for persistent symptoms. The only complication noted was tympanic membrane perforation, 
which was observed in 62 (1%) episodes. The authors believed this figure was likely to be an underestimate of the true incidence of this 
complication. They stated that their data indicate that AOM is an important and frequent childhood infection in New Zealand. They also stated 
that their data show a significant decline in the use of antibiotics to manage AOM in concordance with accepted best practice. 
 
 




Bronchiolitis occurs predominantly in infants aged under one year and is a leading cause of hospital admission 
in this age group.46 Around one in three infants will develop bronchiolitis in their first year of life and 2–3% will 
require hospitalisation.46 Bronchiolitis is due to viral infection, most commonly with respiratory syncytial virus 
(RSV), although many other respiratory viruses can cause the illness.46 In temperate climates such as New 
Zealand’s, bronchiolitis tends to occur in seasonal epidemics peaking in late winter.47 
Affected infants appear initially to have a simple upper respiratory infection with a mild fever, a runny nose and 
a cough but after a few days this progresses to wheezing and respiratory distress, with rapid breathing, nasal 
flaring and the use of accessory muscles. Feeding and sleeping may be impaired, and very young infants may 
also have episodes of apnoea. Severely affected infants require hospital care, which consists of supportive 
therapy with nasal suction to facilitate oral feeding, support for hydration by nasogastric or intravenous fluids, 
and supplemental oxygen.46 Recovery from the acute illness normally takes 5–7 days, although around 50% of 
children have a persistent cough for more than two weeks.46 Deaths from bronchiolitis are rare, with reported 
rates in the US and the UK of around 2 per 100,000 live births.47 
Risk factors for severe illness requiring intensive care include young age (<6 weeks), premature birth, chronic 
lung disease of prematurity, congenital heart disease and immunodeficiency.47-49 More common risk factors that 
are associated with hospitalisation for less severe bronchiolitis include male sex, age less than six months, birth 
during the first half of the RSV season, overcrowding, socio-economic disadvantage, older siblings, attendance 
at day care, lack of breast feeding and maternal smoking.50,51 Hospital admissions for RSV bronchiolitis can be 
prevented by the use of a monthly-injected monoclonal antibody (Palivizumab), but this therapy is very 
expensive so its use is considered only in very high-risk infants.52 
The following section reviews bronchiolitis in infants aged less than one year using information from the 
National Minimum Dataset and Mortality Collection. The section concludes with a brief overview of evidence-
based guidelines and reviews on interventions to prevent or manage bronchiolitis in infants. 
Data sources and methods 
Indicator 
1. Infant deaths from bronchiolitis 
2. Infants hospitalised for bronchiolitis 
Data sources 
Numerator:  
Deaths:  National Mortality Collection 
Hospitalisations: National Minimum Dataset 
Denominator:  Birth Registration Dataset 
Definition 
Deaths:   Deaths of infants (aged less than one year) where the main underlying cause of death was bronchiolitis 
Hospitalisations:  Acute and arranged hospitalisations for infants (aged less than one year) with a primary diagnosis of 
bronchiolitis (per 1,000 livebirths). Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
is a non-acute hospitalisation with an admission date less than seven days after the date the decision was made that 
hospitalisation was necessary. 
Note 2: Appendix 3 describes the National Minimum Dataset and outlines the limitations of the data utilised from this data 
collection. The reader is advised to review this appendix before interpreting any trends. 
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National trends and distribution 
There were three deaths of infants aged less than one year with bronchiolitis as the underlying cause from 2008 
to 2012. From 2000 to 2014 the bronchiolitis hospitalisation rate of infants aged less than one year rose with 
most of this increase occurring from 2007 to 2009 (Figure 62). Bronchiolitis hospitalisation rates for Māori and 
Pacific rose from 2000–2014 with noticeable periods of rising and falling rates within the time frame. The rise 
in rates was less marked for European/Other and Asian/Indian infants. Hospitalisation rates were consistently 
highest for Pacific, followed by Māori, European/Other and Asian/Indian. From 2006 to 2014 MELAA rates 
showed a slight rise at rates similar to those for European/Other (Figure 63). 
Figure 62. Hospitalisations for bronchiolitis in infants, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset 
Figure 63. Infants hospitalised for bronchiolitis, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset; Ethnicity is 
level 1 prioritised 
Distribution by demographic factors 
Between 2010 and 2014 bronchiolitis the highest hospitalisation rates were at ages 2–7 months and then 
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Between 2010 and 2014 there was disparity in bronchiolitis hospitalisation rates by NZDep2013 index of 
deprivation score, ethnicity and gender. There was a strong social gradient in bronchiolitis hospitalisation rates 
with a significant increase between each quintile of NZDep2013 scores compared with the quintile below. 
Compared with European/Other, rates were significantly higher for Māori and Pacific, significantly lower for 
Asian/Indian and not significantly different for MELAA. Male rates were significantly higher than female rate 
(Table 75). 









































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset 




 Rate per 1,000 
livebirths  
 Rate ratio  95% CI 
Bronchiolitis in under 1 year olds 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 1,673 37.1 1.00   
Deciles 3–4 2,221 44.9 1.21 1.14–1.29 
Deciles 5–6 3,221 57.1 1.54 1.45–1.63 
Deciles 7–8 5,592 82.9 2.23 2.12–2.36 
Deciles 9–10 13,156 150.6 4.06 3.86–4.26 
Prioritised ethnicity 
Māori 11,625 131.4 2.69 2.61–2.76 
Pacific 6,360 187.1 3.83 3.70–3.95 
Asian/Indian 952 22.9 0.47 0.44–0.50 
MELAA 274 50.5 1.03 0.92–1.16 
European/Other 6,715 48.9 1.00   
Gender 
Female 9,853 66.0 1.00   
Male 16,103 102.1 1.55 1.51–1.58 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset; Rates are per 
1,000 livebirths; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
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Distribution by season 
There was seasonal variation in bronchiolitis hospitalisation rates. The highest rates were observed in July to 
September and the lowest rates in January to March (Figure 65).  
Figure 65. Hospitalisations for bronchiolitis in infants, by month, New Zealand 2010–2014 
 
National Minimum Dataset (acute and arranged admissions); Number is annual average, Month is based on hospitalisation 
admission date 
Distribution by region 
Between 2010 and 2014 hospitalisation rates for bronchiolitis were significantly higher than the national rate in 
the Northland, Counties Manukau, Waikato, Bay of Plenty, Lakes, Tairawhiti, Hawke's Bay, Whanganui and 
Hutt Valley DHBs and significantly lower in the remaining DHBs (Figure 66, Table 76). 
Figure 66. Infants hospitalised for bronchiolitis, by district health board, New Zealand 2010–2014 
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annual average  
 Rate per 1,000 
livebirths  
 Rate ratio   95% CI  
Bronchiolitis in infants 
Northland 1,345 269 117.7 1.39 1.32–1.47 
Waitemata 2,459 492 62.5 0.74 0.71–0.77 
Auckland 2,371 474 73.9 0.87 0.84–0.91 
Counties Manukau 4,993 999 117.1 1.38 1.35–1.42 
Waikato 2,975 595 109.8 1.30 1.25–1.35 
Bay of Plenty 1,594 319 110.4 1.31 1.24–1.37 
Lakes 905 181 120.1 1.42 1.33–1.51 
Tairawhiti 480 96 130.8 1.55 1.42–1.68 
Taranaki 483 97 62.1 0.73 0.67–0.80 
Hawke's Bay 1,244 249 111.1 1.31 1.24–1.39 
MidCentral 737 147 66.1 0.78 0.73–0.84 
Whanganui 474 95 111.5 1.32 1.21–1.44 
Hutt Valley 927 185 93.1 1.10 1.03–1.17 
Capital & Coast 1,257 251 66.5 0.79 0.74–0.83 
Wairarapa 179 36 69.2 0.82 0.71–0.94 
Nelson Marlborough 337 67 42.6 0.50 0.45–0.56 
South Canterbury 139 28 45.0 0.53 0.45–0.63 
Canterbury 1,720 344 55.9 0.66 0.63–0.69 
West Coast 78 16 37.9 0.45 0.36–0.56 
Southern 1,176 235 65.9 0.78 0.74–0.82 
New Zealand 25,956 5,191 84.6 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 hospitalisation rates for bronchiolitis were significantly higher than the national rate in 
Waikato, Bay of Plenty, Lakes DHB and Tairawhiti DHBs and significantly lower in Taranaki DHB (Table 77). 






Rate per 1,000 
livebirths  
Rate ratio  95% CI  
Bronchiolitis in infants 
Waikato 2,975 595 109.76 1.30 1.25–1.35 
Bay of Plenty 1,594 319 110.43 1.31 1.24–1.37 
Lakes 905 181 120.07 1.42 1.33–1.51 
Tairawhiti 480 96 130.83 1.55 1.42–1.68 
Taranaki 483 97 62.06 0.73 0.67–0.80 
New Zealand 25,956 5,191 84.58 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset  
Regional trends 
In 2000–2014 the bronchiolitis hospitalisation rate of infants aged less than one year generally increased in 
Waikato but fluctuated from year-to-year in the other Midland DHBs (Figure 67). Over the same period, 
hospitalisation rates were consistently higher for Māori (and Pacific in Waikato DHB) than European/Other in 
all the Midland DHBs, although trends over time were similar in all ethnic groups for each DHB, except in 
Waikato DHB where Māori and Pacific rates rose higher than those of other ethnic groups from around 2006. 
Asian/Indian hospitalisation rates in Waikato DHB were consistently lower than those of other ethnic groups 
and increased slightly over the period 2009–2014 (Figure 68). 
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Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset  



















































































































































































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset; Ethnicity is level 1 prioritised; European/Other rates for Tairawhiti are affected by small 
numbers; Pacific and Asian/Indian rates are suppressed for some DHBs due to large fluctuations caused by small numbers 
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Regional distribution by season 
There was seasonal variation in bronchiolitis hospitalisation rates in the Midland DHBs. The highest rates were 
observed in June–September and the lowest rates in January–March (Figure 69, Figure 70). 







































































































































National Minimum Dataset (acute and arranged admissions); Number is annual average, Month is based on hospitalisation 
admission date 
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Evidence for good practice for the prevention and management of 
bronchiolitis 
International guidelines 
National Institute for Health and Care Excellence. 2015. Bronchiolitis in children. London: National Institute for Health and 
Care Excellence. https://www.nice.org.uk/guidance/ng9 
This clinical guideline provides best practice advice on the care of children with bronchiolitis. It contains ‘key priorities for implementation’, the 
most important points for practitioners to be aware of, followed by more detailed recommendations covering assessment and diagnosis, when 
to refer, when to admit, management of bronchiolitis, when to discharge, and key safety information for looking after a child at home. It also 
contains recommendations for further research from the Guideline Development Group. This version of the guideline does not contain details of 
the evidence used to develop the guideline. This information is contained in the full guideline: 
National Collaborating Centre for Women's and Children's Health. 2015. Bronchiolitis: diagnosis and management of 
bronchiolitis in children. London: National Collaborating Centre for Women's and Children's Health. 
http://www.nice.org.uk/guidance/ng9/evidence/full-guideline-60851053 
This is the full guideline (301 Pages) which contains the evidence used to develop the clinical guideline. It addresses 19 review questions relating 
to the description of the condition, diagnosis, prognosis and interventions. Evidence from published studies was reviewed and synthesised 
according to the GRADE approach. Where it was thought to be relevant, economic evidence was also reviewed. For each question there is a 
description of the evidence, tables which summarise the GRADE profile for all the reviewed studies, a series of evidence statement summarising 
the evidence, a discussion of the evidence, and recommendations for practice along with recommendations for research with brief explanations 
of why the research questions are important. The appendices to the full guideline, which include more detailed evidence tables (in Appendix I), 
can be found here: http://www.nice.org.uk/guidance/ng9/evidence/appendices-aj-60851054. 
Ralston SL, Lieberthal AS, Meissner HC, et al. 2014. Clinical Practice Guideline: The Diagnosis, Management, and Prevention 
of Bronchiolitis. Pediatrics:1 34:e1474–e1502 http://pediatrics.aappublications.org/content/early/2014/10/21/peds.2014-
2742.abstract 
This guideline from the American Academy of Pediatrics is a revision of the 2006 guideline. It applies to children aged from one through 23 
months of age. It is structured as a series of ‘key action statements’ under the headings: diagnosis, treatment and prevention. Each key action 
statement indicates level of evidence, benefit-harm relationship, and level of recommendation. 
National Guideline Clearinghouse. 2007 Sep (revised 2014 Jun). Guideline synthesis: Prevention, diagnosis and management 
of pediatric bronchiolitis. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ). 
http://www.guideline.gov/syntheses/synthesis.aspx?id=48172&search=bronchiolitis 
This webpage at the National Guideline Clearinghouse provides a guideline synthesis of the two guidelines below, including a direct comparison 
of the recommendations in the guidelines, noting areas of similarity and difference. 
Working Group of the Clinical Practice Guideline on Acute Bronchiolitis, Fundació Sant Joan de Déu. 2010. Clinical Practice 
Guideline on Acute Bronchiolitis. Barcelona, Spain: Catalan Agency for Health Technology Assessment and Research (CAHTA). 
http://www.guiasalud.es/GPC/GPC_475_Bronchiolitis_AIAQS_compl_en.pdf 
This Spanish guideline addresses a total of 46 clinical questions (formulated using the PICO method) under the headings: diagnosis, additional 
examinations, treatment, monitoring, prevention, and progression. For each question there is a review of previously published clinical practice 
guidelines from around the world and relevant published studies. Recommendations are presented, graded A to D according to the quality of 
the evidence, or as good clinical practice if the recommendation is based only on the consensus of the working group. A summary of the guideline 
can be found on the National Guideline Clearinghouse website: http://www.guideline.gov/content.aspx?id=38414. 
Bronchiolitis Guideline Team, Cincinnati Children's Hospital Medical Center. 2010. Evidence-based care guideline for the 
management of bronchiolitis in infants 1 year or less with a first time episode. Cincinnati (OH): Cincinnati Children's 
Hospital Medical Center. http://www.cincinnatichildrens.org/WorkArea/DownloadAsset.aspx?id=87885 
These concise guidelines are intended primarily for use in children with bronchiolitis typical in presentation and clinical course. They are not 
intended for use in children with cystic fibrosis, a history of bronchopulmonary dysplasia, or immunodeficiencies, children admitted to intensive 
care, children requiring ventilator care, or children with other severe comorbid conditions complicating care. They cover prevention (in the 
community and in hospitals), emergency department and inpatient management, admission and discharge criteria, therapies not routinely 
recommended, and questions for further research. There are brief notes on relevant research and references for each recommendation, and an 
indication of evidence quality and strength of recommendation. There is an algorithm (flowchart) summarising medical management. A summary 
of the guideline can be found on the National Guideline Clearinghouse website: http://www.guideline.gov/content.aspx?id=34411. 
Evidence-based medicine reviews 
Jat Kana R, Mathew Joseph L. 2015. Continuous positive airway pressure (CPAP) for acute bronchiolitis in children. 
Cochrane Database of Systematic Reviews (1) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010473.pub2/abstract 
There is no specific treatment for bronchiolitis, only supportive therapy. Continuous positive airway pressure (CPAP) is supposed to be helpful in 
bronchiolitis through widening peripheral airways in the lung allowing the deflation of over-distended lungs and through preventing the collapse 
of poorly supported peripheral small airways during expiration. Observational studies have described benefits from CPAP. The authors of this 
review could find only two small RCTS (50 participants in total) evaluating the effect of CPAP in children aged < three years with bronchiolitis. 
They concluded that the effect of CPAP is uncertain due to the limited evidence and that larger adequately powered RCTs are needed. 
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Liu F, Ouyang J, Sharma Atul N, et al. 2015. Leukotriene inhibitors for bronchiolitis in infants and young children. Cochrane 
Database of Systematic Reviews (3) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010636.pub2/abstract 
Leucotriene inhibitors are thought to reduce airway inflammation and so they might be of benefit to patients with bronchiolitis (inflammation of 
the small airways). The authors of this review identified five RCTs (1,296 participants aged < two years) comparing monteleukast (a leukotriene 
inhibitor) with placebo. Two studies at low risk of bias assessed its impact on length of hospital stay and provided low quality evidence of a non-
significant effect on length of stay: mean difference (MD) −0.95 days, 95% CI −3.08 to 1.19, P value = 0.38, and on clinical severity scores on day 
two and day three. Individual analysis of the data from the other three studies, which assessed the effects of several weeks of monteleukast in 
preventing post-bronchiolitis symptoms, did not find significant differences between the leukotriene inhibitors group and the control group in 
symptom-free days and incidence of recurrent wheezing. The review authors concluded that the quality of the evidence was low and did not 
allow definitive conclusions to be made regarding the effects of leukotriene inhibitors on length of hospital stay and clinical severity score in 
infants and young children with bronchiolitis. They stated that further research is needed and they noted one on-going study which may be 
helpful. 
McNally JD, Sampson M, Matheson LA, et al. 2014. Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: 
A systematic review and meta-analysis. Pediatric Pulmonology, 49(8), 790-99.  
A small number of studies have suggested a relationship between vitamin D status and severe acute lower respiratory infection, including 
bronchiolitis. This study aimed to evaluate the relationship between vitamin D receptor (VDR) polymorphism and severe RSV-bronchiolitis through 
a systemic literature review and meta-analysis. The authors identified three case-control studies meeting their criteria. Two VDR polymorphisms 
were included in more than one study: TaqI (rs731236) and FokI (rs2228570). All three studies reported a positive relationship between the FokI 
minor allele and disease with random effects meta-analyses indicating a statistically significant relationship (OR 1.52, 95% CI 1.12 to 2.05). 
Genotype analysis was highly suggestive of a dominant or incomplete dominance model with combined odds ratios for fF (OR 1.73, 95% CI: 0.92 
to 3.36) and ff (OR 2.24, 95% CI: 0.98 to 5.14) compared to the FF genotype. No association between TaqI and severe RSV-bronchiolitis was 
evident at the allele or genotype level. The authors concluded that the available literature supports an association between the FokI polymorphism 
and severe RSV disease. They stated that determination of VDR receptor polymorphism status could help predict high risk infants who might 
benefit from preventive measures (such as administration of monthly RSV antibody, which is well known to reduce hospital admissions in high-
risk subpopulations, including infants born extremely prematurely or with congenital heart disease, although it is very expensive). 
Farley R, Spurling Geoffrey KP, Eriksson L, et al. 2014. Antibiotics for bronchiolitis in children under two years of age. 
Cochrane Database of Systematic Reviews (10) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005189.pub4/abstract 
Bronchiolitis is most commonly caused by respiratory syncytial virus (RSV) but babies with the condition are often prescribed antibiotics, because 
doctors may be concerned about secondary bacterial infection or be expecting benefits from anti-inflammatory effects attributed to some 
antibiotics. This updated review sought to evaluate the effectiveness of antibiotics for bronchiolitis in children < two years of age compared to 
placebo or other interventions. It included seven placebo RCTs with a total of 824 participants. Due to heterogeneity between the studies, pooling 
of results for meta-analysis was only possible for the outcomes length of supplemental oxygen use, length of hospital admission, and death. Two 
studies (281 participants) had been published since the previous review, both comparing azithromycin with placebo. Data from three studies with 
adequate data on days of supplementary oxygen indicated no difference between antibiotics and placebo: pooled mean difference (MD) −0.20 
days; 95% CI −0.72 to 0.33. Similarly, data from three studies indicated no difference in length of hospital stay between antibiotics (azithromycin) 
and placebo: pooled MD −0.58 days; 95% CI −1.18 to 0.02). Two studies randomised children to intravenous ampicillin, oral erythromycin and 
control and found no difference for most symptom measures. None of the seven studies reported any deaths and no other adverse effects were 
reported. The review authors concluded that there was not sufficient evidence to support the use of antibiotics for bronchiolitis, but that further 
research may be justified to identify a subgroup of patients who may benefit from antibiotics, to determine why clinicians prescribe antibiotics, 
and to determine how to decrease their anxiety about not doing so. 
Gadomski Anne M, Scribani Melissa B. 2014. Bronchodilators for bronchiolitis. Cochrane Database of Systematic Reviews (6) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001266.pub4/abstract 
This review aimed to assess the effect of bronchodilators on clinical outcomes in infants aged 0–12 months with acute bronchiolitis. The review 
authors identified 30 RCTs comparing bronchodilators (other than epinephrine) with placebo, representing 1,192 infants. In 11 inpatient and 10 
outpatient studies, bronchodilators did not improve oxygen saturation (mean difference (MD) −0.43, 95% CI −0.92 to 0.06, n = 1242). (Oxygen 
saturation is measured as %, normal saturation is in the range 95–100%) Outpatient bronchodilator treatment did not reduce the rate of 
hospitalization (11.9% in bronchodilator group versus 15.9% in placebo group, odds ratio (OR) 0.75, 95% CI 0.46 to 1.21, n = 710). Inpatient 
bronchodilator treatment did not reduce the duration of hospitalization (MD 0.06, 95% CI −0.27 to 0.39, n = 349). Adverse effects of 
bronchodilators included tachycardia, oxygen desaturation and tremors. The review authors concluded that bronchodilators such as albuterol or 
salbutamol do not improve oxygen saturation, do not reduce hospital admission after outpatient treatment, do not shorten the duration of 
hospitalization and do not reduce the time to resolution of illness at home. They stated that, given the adverse side effects and the expense of 
these treatments, bronchodilators are not useful in the routine management of bronchiolitis. They also stated that their ability to draw conclusions 
was limited by the small sample sizes and the lack of standardized study design and validated outcomes across the studies, and that further trials 
with large sample sizes, standardized methodology across clinical sites and consistent assessment methods are needed to answer completely the 
question of efficacy. 
Beggs S, Wong Zee H, Kaul S, et al. 2014. High-flow nasal cannula therapy for infants with bronchiolitis. Cochrane Database 
of Systematic Reviews (1) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009609.pub2/abstract 
Conventional treatment for bronchiolitis consists of supportive therapy with fluids, supplemental oxygen and respiratory support. The usual way 
oxygen is delivered is as a dry gas at 100% concentration via low-flow nasal prongs. An alternative is the use of heated, humidified, high-flow 
nasal cannula (HFNC) therapy which enables delivery of higher inspired gas flows of an air/oxygen blend, up to 12 L/min in infants and 30 L/min 
in children. This provides a degree of continuous positive airway pressure in a minimally invasive manner, and may reduce the need for invasive 
respiratory support with its added costs and associated adverse effects. This review aimed to effects of HFNC therapy compared with conventional 
respiratory support in the treatment of infants with bronchiolitis. Because only one small pilot RCT was identified the review authors concluded 
 
Conditions of the respiratory system: Bronchiolitis 
157 
that there was insufficient evidence to determine the effectiveness of HFNC in this situation. The trial had 19 participants and compared HFNC 
with conventional treatment in infants aged < 24 months with a clinical diagnosis of bronchiolitis. 
Ralston S, Comick A, Nichols E, et al. 2014. Effectiveness of Quality Improvement in Hospitalization for Bronchiolitis: A 
Systematic Review. Pediatrics 134(3) 571-81  
This review looked at 14 studies (involving > 12,000 children) describing any active quality improvement (QI) intervention vs. usual care in 
hospitalised children < two years of age with acute viral bronchiolitis. Studies were deemed eligible for inclusion if their design was one of the 
following: cluster RCT, before-and-after study, cohort study, or QI report. The review authors extracted data from the studies and pooled it using 
a random effects model. Quality improvement interventions resulted in 16 fewer patients exposed to repeated doses of bronchodilators per 100 
hospitalized (7 studies) (risk difference: 0.16, 95% CI 0.11 to 0.21) and resulted in 5.3 fewer doses of bronchodilator given per patient (95% CI 2.1 
to 8.4). Interventions resulted in fewer hospitalized children exposed to steroids (5 per 100), chest radiography (9 per 100), and antibiotics (4 per 
100). There were no significant harms reported. Benchmarks derived from the reported data were: repeated bronchodilator use, 16%; steroid use, 
1%; chest radiography use, 42%; and antibiotic use, 17%. The studies’ heterogeneity limited the reviewers’ ability to classify specific characteristics 
of effective QI interventions. The reviewers concluded that the use of QI interventions results in lower rates of unnecessary care in children 
hospitalised with viral bronchiolitis. 
Chen Y-J, Lee W-L, Wang C-M, et al. 2014. Nebulized Hypertonic Saline Treatment Reduces Both Rate and Duration of 
Hospitalization for Acute Bronchiolitis in Infants: An Updated Meta-analysis. Pediatrics & Neonatology, 55(6), 431-38. 
http://www.sciencedirect.com/science/article/pii/S1875957213002295 
This systematic review included 11 studies, 10 of which were included in the Cochrane review below. There are minor numerical differences 
between the results of this review and the Cochrane review but the conclusions are similar except that this review, unlike the Cochrane review, 
found that nebulised hypertonic saline did significantly decrease the rate of hospitalisation: risk ratio 0.59, 95% CI 0.37 to 0.93, p = 0.02. 
Zhang L, Mendoza-Sassi Raúl A, Wainwright C, et al. 2013. Nebulised hypertonic saline solution for acute bronchiolitis in 
infants. Cochrane Database of Systematic Reviews (7) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006458.pub3/abstract 
Nebulised hypertonic saline given to babies with bronchiolitis may reduce airway oedema and mucus plugging. This review aimed to assess the 
effects of nebulised hypertonic (≥ 3%) saline solution in infants up to 24 months of age with acute viral bronchiolitis, as indicated by RCTs or 
quasi-RCTs which used nebulised hypertonic saline alone or in conjunction with bronchodilators as an active intervention and nebulised 0.9% 
saline as a comparator. Eleven trials were included. These involved 1,090 infants with mild to moderate bronchiolitis, around half of whom were 
inpatients and half outpatients or emergency department patients. Patients treated with nebulised 3% saline had a significantly shorter mean 
length of hospital stay compared to those treated with nebulised 0.9% saline: mean difference (MD) −1.15 days, 95% CI −1.49 to −0.82, P < 
0.00001). The hypertonic saline group also had a significantly lower post-inhalation clinical score than the 0.9% saline group in the first three days 
of treatment (day 1: MD −0.88, 95% CI −1.36 to −0.39, P = 0.0004; day 2: MD −1.32, 95% CI −2.00 to −0.64, P = 0.001; day 3: MD −1.51, 95% CI 
−1.88 to −1.14, P < 0.00001). The effects of improving clinical score were seen in both outpatients and inpatients. Four emergency department-
based trials did not show any significant short-term effects (30 to 120 minutes) of up to three doses of nebulised 3% saline in improving clinical 
score and oxygen saturation. No trials reported significant adverse events related to hypertonic saline inhalation. The review authors concluded 
that nebulised hypertonic saline may significantly reduce the length of hospital stay among infants hospitalised with non-severe acute viral 
bronchiolitis and improve the clinical severity score in both outpatient and inpatient populations. 
Fernandes Ricardo M, Bialy Liza M, Vandermeer B, et al. 2013. Glucocorticoids for acute viral bronchiolitis in infants and 
young children. Cochrane Database of Systematic Reviews (6) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004878.pub4/abstract 
Glucocorticoids (such as prednisolone or dexamethasone) have been used to treat bronchiolitis, based on the apparent similarities between 
bronchiolitis and asthma. Previous systematic reviews have not shown glucocorticoids to be clearly beneficial in acute viral bronchiolitis but recent 
large trials have added to the evidence base and suggested novel treatment approaches that` include glucocorticoids. Trials were eligible for 
inclusion in this review if they were RCTs comparing short-term systemic or inhaled glucocorticoids vs. placebo or another intervention in children 
< 24 months with acute bronchiolitis (first episode with wheezing). The review authors identified 17 eligible trials with a total of 2,596 participants. 
Three trials had low overall risk of bias. Compared to placebo, glucocorticoids did not significantly reduce outpatient admissions by days 1 and 
7: pooled risk ratios (RRs) 0.92, 95% CI 0.78 to 1.08 and 0.86, 95% CI 0.7 to 1.06, respectively. They did not reduce length of stay for inpatients 
(mean difference −0.18 days; 95% CI −0.39 to 0.04). Unadjusted results from a large factorial low risk of bias RCT found combined high-dose 
systemic dexamethasone and inhaled epinephrine reduced admissions by Day 7 (baseline risk of admission 26%; RR 0.65; 95% CI 0.44 to 0.95; 
number needed to treat 11; 95% CI 7 to 76), with no differences in short-term adverse effects. No other comparisons showed relevant differences 
in primary outcomes. The review authors concluded that current evidence does not support a clinically relevant effect of systemic or inhaled 
glucocorticoids on admissions or length of hospitalisation, but combined dexamethasone and epinephrine may reduce outpatient admissions 
(although results are exploratory and safety data limited). They stated that future research should further assess the efficacy, harms and 
applicability of combined therapy. 
Anderson-James S, Marchant Julie M, Acworth Jason P, et al. 2013. Inhaled corticosteroids for subacute cough in children. 
Cochrane Database of Systematic Reviews (2) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008888.pub2/abstract 
The aim of this review was to evaluate the efficacy of inhaled corticosteroids (ICS) in reducing the severity of cough in children with subacute 
cough. The only two relevant RCTs identified by the authors were conducted in infants with post acute bronchiolitis illness. Meta-analysis of data 
on 98 children indicated no significant difference between groups in the proportion of children 'not cured' at follow-up (primary outcome 
measure), with a pooled odds ratio of 0.61 (95% CI 0.24 to 1.55). The review authors concluded that there is currently no evidence to support the 
use of ICS for treatment of subacute cough in children. They noted that their ability to draw conclusions was limited by the small number of 
studies available for analysis and the size, quality and design of these studies. They stated that additional well-designed RCTs are needed. 
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Roqué i Figuls M, Giné-Garriga M, Granados Rugeles C, et al. 2012. Chest physiotherapy for acute bronchiolitis in paediatric 
patients between 0 and 24 months old. Cochrane Database of Systematic Reviews (2) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004873.pub4/abstract 
This updated review’s main aim was to determine the efficacy of chest physiotherapy in infants aged less than 24 months with acute bronchiolitis. 
A secondary aim was to determine the efficacy of different techniques of chest physiotherapy (for example, vibration and percussion and passive 
forced exhalation). The review included nine RCTs (891 participants), all comparing physiotherapy with no intervention. Five trials (246 participants) 
evaluated vibration and percussion techniques and four trials (645 participants) evaluated passive expiratory techniques. The review authors found 
no significant differences between intervention and control groups in the severity of disease (eight trials, 867 participants). Results were negative 
for both types of physiotherapy. They found no differences between groups in respiratory parameters (two trials, 118 participants), oxygen 
requirements (one trial, 50 participants), length of stay (five trials, 222 participants) or severe side effects (two trials, 595 participants). One trial 
(496 participants) showed differences in mild transient adverse effects (vomiting and respiratory instability). The review authors concluded that 
chest physiotherapy doesn’t improve the severity of disease, respiratory parameters, or reduce length of hospital stay or oxygen requirements in 
hospitalised infants with acute bronchiolitis who are not on mechanical ventilation. Different chest physiotherapy modalities (vibration and 
percussion or passive expiratory techniques) have shown equally negative results. 
Enriquez A, Chu IW, Mellis C, et al. 2012. Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 
months. Cochrane Database of Systematic Reviews (11) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008395.pub2/abstract 
The sputum of infants with bronchiolitis has increased deoxyribonucleic acid (DNA) content, leading to mucous plugging and airway obstruction. 
This review aimed to evaluate the efficacy of nebulised recombinant human deoxyribonuclease (rhDNase), an enzyme that digests extracellular 
DNA, on the severity and duration of viral bronchiolitis in children aged < 24 months in the hospital setting. The review authors identified three 
RCTs (333 participants), all of which used 2.5 mL (1 mg/mL) of nebulised rhDNase compared with placebo either as a daily or a twice daily dose. 
Adjunctive therapy included nebulised salbutamol, steroids, supplemental oxygen, intravenous fluids or tube feeding, nasal washing, nasal 
decongestants and antibiotics. Two trials were multicentre trials in which all the participants had tested positive for respiratory syncytial virus. The 
other trial enrolled participants clinically diagnosed with bronchiolitis from a hospital in Italy. Overall, this review found no benefit from nebulised 
rhDNase in regard to clinically meaningful outcomes. Meta-analysis indicated that patients in the control group had a shorter duration of hospital 
stay (MD 0.50 days; 95% CI 0.10 to 0.90, P = 0.01) and better clinical score improvement (SMD −0.24; 95% CI -0.50 to 0.01, P = 0.06). The largest 
trial showed no difference in supplemental oxygen use or intensive care unit (ICU) admission. In one RCT, four out of 11 patients had atelectasis, 
a severe complication of bronchiolitis wherein the lung does not expand completely. Two of the four patients improved significantly after 
nebulised rhDNase. Trials found no differences between intervention and control groups in adverse events. In total 11 patients from both 
treatment groups suffered adverse effects, including temporary oxygen desaturation, temporary coughing, increased coughing, facial rash, 
hoarseness, dyspnoea and bad taste. The review authors concluded that the evidence did not support the use of nebulised rhDNase in children 
< 24 months of age hospitalised with acute bronchiolitis. They stated that it might have a role in severe bronchiolitis complicated by atelectasis 
but further clinical studies would need to be performed to confirm or refute this. 
McCallum Gabrielle B, Morris Peter S, Chang Anne B. 2012. Antibiotics for persistent cough or wheeze following acute 
bronchiolitis in children. Cochrane Database of Systematic Reviews (12). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009834.pub2/abstract 
Acute bronchiolitis is usually a self-limiting condition. Some children may have persistent symptoms such as cough and wheezing and present or 
re-present to secondary care. This review aimed to determine the effectiveness of antibiotics compared to a control (no treatment or placebo) 
for persistent respiratory symptoms (within six months) following acute bronchiolitis. Only one small study, with a high attrition rate, met the 
review’s inclusion criteria. Thirty infants with respiratory syncytial virus-confirmed bronchiolitis were randomised to receive either a daily dose of 
oral clarithromycin 15 mg/kg or placebo for three weeks. Using an intention-to-treat analysis, there was no significant difference between groups 
for the proportion of children who had persistent symptoms (odds ratio (OR) 0.20; 95% CI 0.02 to 2.02) or re-hospitalisation within six months 
(OR 0.11; 95% CI 0.01 to 1.29). There were no treatment studies of later commencement of antibiotics. The review authors concluded that there 
was insufficient evidence to indicate whether antibiotics should be used to treat or prevent persistent respiratory symptoms in the post-acute 
bronchiolitis phase. They stated that further RCTs are needed, particularly in areas where both acute and post-bronchiolitis morbidity is high such 
as in Indigenous communities in the US, New Zealand and Australia. 
Jat Kana R, Chawla D. 2012. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database of Systematic 
Reviews (9). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009194.pub2/abstract 
Bronchiolitis is one of the most common causes of respiratory failure in infants and some infants require intensive care and mechanical ventilation. 
There is no evidence for any effective treatment for bronchiolitis beyond supportive care. Abnormalities of surfactant quantity or quality (or both) 
have been observed in severe cases of bronchiolitis. Exogenous surfactant administration appears to improve the haemodynamics of the lungs 
and could be a potentially promising therapy for severe bronchiolitis. This review aimed to evaluate the efficacy of exogenous surfactant, 
compared to placebo, no intervention or standard care in reducing mortality and the duration of ventilation in infants and children with 
bronchiolitis requiring mechanical ventilation. Three small RCTs, with 79 participants, were included. Two trials had no placebo in the control arms 
and the third trial used air placebo. Two studies reported no mortality and the third did not mention it. The reviewers judged some of the included 
studies to have an unclear risk of bias but stated that none had a high risk of bias. Pooled analysis of data from the three trials indicated that 
duration of mechanical ventilation was not different between the groups (mean difference (MD) −63.04 hours, 95% CI −130.43 to 4.35 hours) but 
duration of intensive care unit (ICU) stay was less in the surfactant group than in the control group: MD −3.31 days, 95% CI −6.38 to −0.25 days). 
After excluding one trial which produced significant heterogeneity, the duration of mechanical ventilation and duration of ICU stay were found 
to be significantly lower in the surfactant group compared to the control group: MD −28.99 (95% CI −40.10 to −17.87 hours) and MD −1.81 (95% 
CI −2.42 to −1.19 days), respectively. Use of surfactant had favourable effects on oxygenation and CO2 elimination. No adverse effects and no 
complications were seen in any of the three included studies. The review authors concluded that the available evidence was not sufficient to 
establish the effectiveness of surfactant therapy for critically ill infants with bronchiolitis who require mechanical ventilation. 
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Umoren R, Odey F, Meremikwu Martin M. 2011. Steam inhalation or humidified oxygen for acute bronchiolitis in children 
up to three years of age. Cochrane Database of Systematic Reviews (1) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006435.pub2/abstract  
Steam inhalation (or cool mist therapy) is commonly used to treat acute bronchiolitis in resource-constrained settings. This review aimed to 
evaluate the effect of steam inhalation or humidified oxygen in relieving respiratory distress, and any adverse effects it might have, in children up 
to three years old with acute bronchiolitis. Only one RCT eligible for inclusion was identified (156 children aged between seven weeks and 24 
months with signs and symptoms of bronchiolitis). Participants were randomised into three groups: nebulised salbutamol, nebulised saline and 
mist in a tent. The results indicated a significant decrease in respiratory distress symptom (RDS) score in the nebulised salbutamol group but no 
significant decrease in RDS score in the mist in a tent group or in the nebulised saline group. The study did not report on adverse effects of the 
interventions. The review authors stated that, as only one RCT was analysed, it would be misleading to conclude that mist therapy is ineffective 
in children with bronchiolitis. They concluded that there is insufficient evidence to inform practice regarding using steam inhalation or mist 
therapy for acute bronchiolitis in children up to three years old. 
Hartling L, Bialy Liza M, Vandermeer B, et al. 2011. Epinephrine for bronchiolitis. Cochrane Database of Systematic Reviews (6) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003123.pub3/abstract 
This review aimed to examine the efficacy of epinephrine (a bronchodilator that is often used to treat asthma) in the treatment of children aged 
< two years with acute viral bronchiolitis. It included 19 RCTs with a total of 2,256 participants. Epinephrine vs. placebo in outpatients showed a 
significant reduction in admissions at Day 1 (risk ratio (RR) 0.67; 95% CI 0.50 to 0.89) but not at Day 7 post-emergency department visit. There 
was no difference in length of stay (LOS) for inpatients. Epinephrine vs. salbutamol showed no differences in outpatients for admissions at Day 1 
or Day 7. Inpatients receiving epinephrine had a significantly shorter LOS compared to salbutamol: mean difference −0.28 days, 95% CI −0.46 to 
−0.09). One large RCT showed a significantly shorter admission rate at Day 7 for epinephrine and steroid combined vs. placebo: RR 0.65, 95% CI 
0.44 to 0.95). There were no important differences in adverse events. The review authors concluded that epinephrine is superior to placebo for 
short-term outcomes for outpatients, particularly in the first 24 hours of care. They stated that exploratory evidence from a single study suggests 
benefits of epinephrine and steroid combined for later time points, but that further research is required to confirm this finding. They found no 
evidence of effectiveness for repeated doses or prolonged use of epinephrine with or without dexamethasone in inpatients. 
Harris KC, Anis AH, Crosby MC, et al. 2011. Economic evaluation of palivizumab in children with congenital heart disease: a 
Canadian perspective. Can J Cardiol, 27(4), 523.e11-5 
In children with congenital heart disease (CHD), bronchiolitis due to respiratory syncytial virus (RSV) is associated with significant morbidity and 
mortality. Palivizumab is a monoclonal antibody that reduces the number of RSV-associated hospitalizations in children with CHD. This study 
aimed to assess cost savings and cost-effectiveness of palivizumab in children < two years old with hemodynamically significant CHD in a 
provincially administered RSV prophylaxis program. The study involved comparing a cohort of children who received palivizumab (N = 292) from 
2003-2007 to a historical cohort of children (N = 412) from 1998-2003 who met the eligibility criteria for palivizumab prior to initiation of the 
prophylaxis program. Direct and indirect costs and benefits were determined. It was found that the direct and indirect costs in the historical cohort 
were $838 per patient season compared to $9130 per patient season in the palivizumab cohort. Risk of admission was reduced by 42%, and days 
in hospital were reduced by 83%. The incremental cost of the RSV prophylaxis program was $8292 per patient for one RSV season. The incremental 
cost to prevent one day of hospitalization was $15,514. The cost of palivizumab accounted for 87.9% of the cost of prophylaxis. The study authors 
concluded that palivizumab is clinically effective but that the cost was exceptionally high relative to the outcomes in this population. They stated 
that, given the financial constraints in a public health care setting, more strict criteria for patient selection or reduced drug costs would improve 
the cost-effectiveness of RSV prophylaxis. 
Wang D, Bayliss S, Meads C. 2011. Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in 
high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. 
Health Technology Assessment (Winchester, England), 15(5). http://www.journalslibrary.nihr.ac.uk/hta/volume-15/issue-5  
This report is based on an analysis of thirteen studies, most of which were small and inadequately powered for the outcomes of interest. The aim 
was to use evidence from a systematic review of prognostic and hospitalisation studies to estimate the cost-effectiveness of palivizumab for RSV 
prophylaxis in different groups of children at high risk from RSV infection including children with and without chronic lung disease (CLD) or 
congenital heart disease (CHD). The authors concluded that, at a willingness-to-pay threshold of £30,000 per quality-adjusted life year, prophylaxis 
with palivizumab may be cost-effective for some sub groups. According to this criterion children without either CLD or CHD would need at least 
two additional risk factors apart from gestational age and birth age to justify prophylaxis but children with CHD or CLD would not necessarily 
need any apart from gestational age and birth age. 
Other relevant publications 
Oakley E, Borland M, Neutze J, et al. 2013. Nasogastric hydration versus intravenous hydration for infants with 
bronchiolitis: a randomised trial. The Lancet Respiratory Medicine, 1(2), 113-20 
Hydration is one of the mainstays of treatment for bronchiolitis. This study aimed to determine whether intravenous hydration or nasogastric 
hydration is better for infants hospitalised with bronchiolitis. It was a multi-centre open RCT which enrolled infants aged 2–12 months admitted 
to hospitals in Australia and New Zealand with a clinical diagnosis of bronchiolitis. The mean length of stay for 381 infants assigned nasogastric 
hydration was 86·6 hours (SD 58·9) compared with 82·2 hours (SD 58·8) for 378 infants assigned intravenous hydration (absolute difference 4·5 
hours, 95% CI −3·9 to 12·9, p=0·30). Rates of admission to intensive-care units, need for ventilatory support, and adverse events did not differ 
between groups. At randomisation, seven infants assigned nasogastric hydration were switched to intravenous hydration and 56 infants assigned 
intravenous hydration were switched to nasogastric hydration because the study-assigned method was unable to be inserted. For those infants 
who had data available for successful insertion, 275 (85%) of 323 infants in the nasogastric hydration group and 165 (56%) of 294 infants in the 
intravenous hydration group required only one attempt for successful insertion. The study authors concluded that both intravenous hydration 
and nasogastric hydration are appropriate means to hydrate infants with bronchiolitis. They noted that nasogastric insertion might require fewer 
attempts and have a higher success rate of insertion than intravenous hydration. 
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Trenholme AA, Byrnes CA, McBride C, et al. 2013. Respiratory health outcomes 1 year after admission with severe lower 
respiratory tract infection. Pediatric Pulmonology, 48(8), 772-9 
Severe lower respiratory infection (LRI), such as severe bronchiolitis or pneumonia, is considered to be one precursor of protracted bronchitis, 
chronic moist cough (CMC), and chronic suppurative lung disease. The aim of this study was to determine and to describe the presence of 
respiratory morbidity in young children one year after being hospitalized with a severe LRI at Kidz First Children’s Hospital in Counties Manukau. 
The children selected for inclusion in this study (n = 237) were chosen from 394 children aged < two years admitted from August 1, 2007 to 
December 23, 2007 and already enrolled in a prospective epidemiological study. They were included in this second study only if they had a 
diagnosis of severe bronchiolitis or of pneumonia with no comorbidities. Funding permitted 164 to be identified chronologically, of whom 131 
were able to be contacted, and 94 agreed to be assessed by a paediatrician one year after their index admission. For each child, demographic 
information, medical history and responses to a respiratory questionnaire were recorded, and examination, pulse oximetry, and chest X-ray (CXR) 
were performed. The predetermined primary endpoints were; (i) history of CMC for at least 3 months, (ii) the presence of moist cough and/or 
crackles on examination in clinic, and (iii) an abnormal CXR when seen at a time of stability. Each CXR was read by two paediatric radiologists 
blind to the individuals' current health. Results indicated that 30% had a history of CMC, 32% had a moist cough and/or crackles on examination 
in clinic, and in 62% of those with a CXR it was abnormal. Of the 81 children with a readable follow-up X-ray, 11% had all three abnormal outcomes, 
and 74% had one or more abnormal outcomes. Three children had developed bronchiectasis on high resolution CT. (CT was not part of the study, 
but some children were noted to have had CT for clinical indications at some time during the year.) In summary, the majority of children with a 
hospital admission at < two years of age for severe bronchiolitis or pneumonia continued to have respiratory morbidity one year later when seen 
at a time of stability, and a small number had already sustained significant lung disease. 
Trenholme A, Vogel A, Lennon D, et al. 2012. Household characteristics of children under 2 years admitted with lower 
respiratory tract infection in Counties Manukau, South Auckland. NZMJ, 125(1367)15-23. 
The aim of this study was to describe the household characteristics of admissions for lower respiratory tract infection (LRI) in children aged < two 
years in Counties Manukau. The study involved prospective recruitment of all children aged < two years admitted with a primary diagnosis of LRI 
from August to December 2007 using a caregiver questionnaire. There were 580 admissions involving 465 children, 394 of whom had completed 
questionnaires (85% response rate). Sixty-four percent of admissions had a diagnosis of bronchiolitis and 26% of pneumonia. Relative risk of 
admission was 4.4 (95% CI 3.2 to 6.2) for Māori and 5.8 (95% CI 4.4–7.9) for Pacific peoples compared with European/others and 3.1 (95% CI 2.4–
3.9) for the most deprived quintile compared with other quintiles. Longer total stay was more likely in children who were of younger age, 
premature, or of Māori or Pacific ethnicity. Household characteristics showed that 25% lived with seven or more other people, 33% lived with four 
or more children, 65% of children were exposed to cigarette smoke and 27% used no form of heating. The conclusions of this study were that 
among young children admitted to hospital with LRI there is a high rate of exposure to known avoidable risk factors such as smoking, lack of 
heating and large households in overcrowded conditions. 
  
 




Pneumonia is inflammation of the lungs, usually as the result of a bacterial or viral infection. It often follows an 
upper respiratory infection. Children with community-acquired pneumonia may present with fever, tachypnoea 
(rapid breathing), breathlessness or difficulty breathing, cough, wheeze or chest pain. They may also have 
abdominal pain and/or vomiting and headache.53 Severely affected children with pneumonia are admitted to 
hospital but less severely affected children can be safely managed at home. While a significant proportion of 
cases of pneumonia in children are due to viruses, in clinical practice there is no reliable way of distinguishing 
viral from bacterial pneumonia, and mixed infections are common, so guidelines recommend that all children 
with clinical signs of pneumonia should be given antibiotics.53,54 Microbiological investigations are normally 
done only in patients with more severe disease and/or complications (such as lung abscess). 
Streptococcus pneumoniae (S. pneumoniae) is the most common bacterial cause of pneumonia in children53 and 
the organism is also a common cause of otitis media, bacterial meningitis and bacteraemia.55 New Zealand 
introduced a pneumococcal conjugate vaccine (Prevenar, PCV7) in to the childhood immunisation schedule in 
June 2008.56 The current schedule includes a 13-valent vaccine, Prevenar 13 (PCV13).57 Invasive pneumococcal 
disease (IPV), where S. pneumoniae has been isolated from a usually sterile site (blood, pleural fluid or 
cerebrospinal fluid), has been a notifiable disease in New Zealand since October 2008.56 There has been a 
dramatic fall in the rate of IPD in infants aged under two years since the introduction of PCV7 from 104.8 per 
100,000 in 2006 to 20.0 per 100,000 in 2013 and there has also been a significant reduction in the two to four 
years age group over the same period, from 18.3 to 8.5 per 100,000.56  
While hospitalisations for pneumonia in young children in New Zealand have decreased since the introduction 
of PCV7, there are significant ethnic and socio-economic disparities.58 Research done in Counties Manukau 
found that Māori and Pacific children were 4–5 times more likely to be admitted to hospital with lower 
respiratory infections (LRIs), including pneumonia, than European children and that children living in the most 
socioeconomically deprived deciles (deciles 9 and 10) were 1.4 times more likely to be admitted than children 
from other deciles.58 Household characteristics of Counties Manukau children aged less than two years admitted 
to hospital with LRIs in 2007 indicated that 25% lived with seven or more other people, 33% lived with four or 
more children, 65% of children were exposed to cigarette smoke and 27% were in households that used no form 
of heating.59 
Data sources and methods 
Indicator 
Deaths from pneumonia in 0–24 year olds  
Hospitalisations for pneumonia in 0–24 year olds 
Data sources 
Numerator:  
Deaths:  National Mortality Collection 
Hospitalisations:  National Minimum Dataset 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Definition 
Deaths: Deaths in 0–24 year olds where the main underlying cause of death was pneumonia (deaths per 100,000 
population) 
Hospitalisations: Acute and arranged hospitalisations for 0–24 year olds with a primary diagnosis of pneumonia 
(hospitalisations per 1,000 population). Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: An acute hospitalisation is an unplanned hospitalisation occurring on the day of presentation, while an arranged 
hospitalisation (referred to elsewhere in this report as a arranged hospitalisation) is a non-acute hospitalisation with an 
admission date less than seven days after the date the decision was made that the hospitalisation was necessary. A waiting list 
hospitalisation is a planned hospitalisation, where the admission date is seven or more days after the date the decision was 
made that the hospitalisation was necessary.  
Note 2: Appendix 3 outlines the limitations of the hospitalisation data used. The reader is advised to review this appendix 
before interpreting any trends based on hospitalisation data. 
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National trends and distribution 
From 2000 to 2012 there were 148 deaths of 0–24 year olds with pneumonia as the underlying cause; there was 
year-to year variation and an overall significant rise in death rate (Figure 71). The age-specific pneumonia 
death rate was highest in the first year of life (38 deaths per 100,000 infants aged under 1 year) and fell rapidly 
with increasing age to 0–2 deaths per 100,000 for each year of age from age three. District health boards in the 
Northern region and Waikato DHB had the highest pneumonia death rates per 100,000 0–24 year olds. Other 
DHBs had fewer than five pneumonia deaths over the five-year period. 
From 2000 to 2014 the pneumonia hospitalisation rate fell significantly from 2.81 to 2.42 hospitalisations per 
1,000 0–24 year olds with some year-to-year fluctuations. The fall in rates was specific to 0–14 year olds; there 
was a small but significant rise in pneumonia hospitalisation rate for 15–24 year olds. Hospitalisation rates for 
0–14 year olds were consistently much higher than rates for the older age group (Figure 72). 






























































Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Numbers of deaths are per 
two year period, with the exception of 2012; 2012* is a single year  
Figure 72. Hospitalisations for pneumonia in 0–24 year olds, by age group, New Zealand 2000–2014 
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The fall in pneumonia hospitalisation rates from 2000 to 2014 was more marked for Māori and Pacific ethnic 
groups than for European/Other.For MELAA and Asian/Indian the rates rose slightly. Hospitalisation rates were 
consistently highest for Pacific, followed by Māori and MELAA with the lowest rates for Asian/Indian and 
European/Other (Figure 73). 













































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Distribution by primary diagnosis 
Between 2010 and 2014 79.4% of hospitalisations had a primary diagnosis that was unspecified. The remaining 
pneumonia hospitalisations were attributed to specific and non-specific viruses or bacteria (Table 78). 










95% CI Per cent 
Pneumonia in 0–24 year olds 
New Zealand  
Viral pneumonia, not elsewhere classified 2,236 447 0.29 0.28–0.30 12.6 
Bacterial pneumonia, not elsewhere classified 801 160 0.10 0.10–0.11 4.5 
Pneumonia due to Streptococcus pneumoniae 272 54 0.04 0.03–0.04 1.5 
Influenza with pneumonia: other influenza virus 192 38 0.03 0.02–0.03 1.1 
Pneumonia due to Haemophilus influenzae 110 22 0.01 0.01–0.02 0.6 
Influenza with pneumonia: virus not identified 24 5 <0.01 … 0.1 
Pneumonia due to other infectious organisms NEC 13 3 <0.01 … 0.1 
Pneumonia, organism unspecified 14,084 2,817 1.84 1.81–1.87 79.4 
Total 17,732 3,546 2.32 2.28–2.35 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; NEC = not elsewhere classified 
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Distribution by demographic factors 
Between 2010 and 2014 pneumonia hospitalisation rates were highest for one year olds and decreased rapidly 
with increasing age. The lowest rates were in 11–24 year olds. Male rates were higher than female at ages 0–1 
years but there was little difference between genders from age two years (Figure 74). 
Figure 74. Hospitalisations for pneumonia in 0–24 year olds, by age and gender, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Between 2010 and 2014 there was disparity in pneumonia hospitalisation rates by NZDep2013 index of 
deprivation score, ethnicity, gender, and age group. Rates were significantly higher in areas with higher 
deprivation scores (NZDep deciles 3–10) compared with the lowest deprivation score areas (deciles 1–2). There 
was a strong gradient in pneumonia hospitalisation rates with increasing deprivation scores; rates were 
significantly higher in NZDep2103 deciles 9–10 compared with deciles 7–8, and in deciles 7–8 compared with 
deciles 5–6. Compared with European/Other, hospitalisation rates were significantly higher for Māori, Pacific 
and MELAA and this difference was greatest for Pacific; rates were not significantly different for Asian/Indian. 
Male rates were significantly higher than female rates. Hospitalisation rates were significantly higher for 0–4 
year olds and 5–14 year olds compared with 15–24 year olds, and this difference was greatest for 0–4 year olds 
(Table 79). 
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Rate per 1,000  
0–24 year olds 
Rate ratio 95% CI 
Pneumonia in 0–24 year olds 
New Zealand 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 1,930 1.38 1.00   
Deciles 3–4 2,128 1.60 1.16 1.09–1.24 
Deciles 5–6 2,518 1.75 1.27 1.20–1.35 
Deciles 7–8 3,683 2.27 1.65 1.56–1.75 
Deciles 9–10 7,404 3.98 2.89 2.75–3.04 
Prioritised ethnicity 
Māori 5,172 2.90 1.91 1.84–1.98 
Pacific 4,437 6.33 4.16 4.00–4.32 
Asian/Indian 1,512 1.61 1.06 1.00–1.12 
MELAA 280 2.85 1.88 1.66–2.11 
European/Other 6,284 1.52 1.00   
Gender 
Female 8,393 2.24 1.00   
Male 9,339 2.39 1.07 1.03–1.10 
Age 
0–4 years 11,402 7.40 9.44 9.03–9.86 
5–14 years 3,883 1.30 1.66 1.58–1.74 
15–24 years 2,447 0.78 1.00   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Rate ratios are unadjusted; 
Ethnicity is level 1 prioritised; Decile is NZDep2013 
Distribution by season 
There was seasonal variation in pneumonia hospitalisation rates, particularly for 0–14 year olds. The highest 
rates were observed in July–September and the lowest rates in January–February (Figure 75).  
Figure 75. Hospitalisations for pneumonia in 0–24 year olds, by age group and month of admission, New Zealand 
2010–2014 
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Regional distribution 
Between 2010 and 2014 pneumonia hospitalisation rates were significantly higher than the national rate in the 
Northland, Waitemata, Auckland, Counties Manukau, Bay of Plenty, Lakes, Tairawhiti and Hutt Valley DHBs 
and significantly lower in the Waikato, Taranaki, Hawke's Bay, MidCentral, Capital & Coast, Nelson 
Marlborough, South Canterbury, Canterbury, West Coast and Southern DHBs. In the remaining district health 
boards there was no significant difference from the national rate (Figure 76, Table 80).  
Figure 76. Hospitalisations for pneumonia in 0–24 year olds, by district health board, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 





annual average  
Rate per 1,000 
0–24 year olds  
Rate ratio  95% CI  
Pneumonia 
0–24 year olds 
Northland 852 170 3.07 1.32 1.24–1.42 
Waitemata 2,779 556 2.94 1.27 1.22–1.32 
Auckland 2,380 476 3.04 1.31 1.26–1.37 
Counties Manukau 3,252 650 3.35 1.44 1.39–1.50 
Waikato 1,288 258 1.90 0.82 0.77–0.87 
Bay of Plenty 886 177 2.51 1.08 1.01–1.16 
Lakes 542 108 2.94 1.27 1.17–1.38 
Tairawhiti 272 54 3.01 1.30 1.15–1.47 
Taranaki 357 71 1.89 0.82 0.74–0.91 
Hawke's Bay 478 96 1.76 0.76 0.70–0.83 
MidCentral 548 110 1.84 0.79 0.73–0.86 
Whanganui 239 48 2.28 0.98 0.87–1.12 
Hutt Valley 746 149 3.04 1.31 1.22–1.41 
Capital & Coast 823 165 1.63 0.70 0.66–0.75 
Wairarapa 130 26 1.98 0.85 0.72–1.01 
Nelson Marlborough 240 48 1.14 0.49 0.43–0.56 
South Canterbury 85 17 1.00 0.43 0.35–0.53 
Canterbury 1,010 202 1.22 0.53 0.49–0.56 
West Coast 86 17 1.72 0.74 0.60–0.92 
Southern 673 135 1.30 0.56 0.52–0.61 
New Zealand 17,732 3,546 2.32 1.00   
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 pneumonia hospitalisation rates in 0–24 year olds were significantly higher than the 
national rate in Bay of Plenty, Lakes and Tairawhiti DHBs and significantly lower in Waikato and Taranaki 
DHBs. Rates for 0–14 year olds were significantly higher than the national rate in Lakes and Tairawhiti DHBs, 
significantly lower in Waikato and Taranaki DHBs, and not significantly different in Bay of Plenty DHB. Rates 
for 15–24 year olds were significantly higher than the national rate in Lakes and Tairawhiti DHBs, significantly 
lower in, and not significantly different in Waikato, Bay of Plenty and Taranaki DHBs (Table 81). 
Table 81. Hospitalisations for pneumonia in 0−24 year olds, Midland DHBs vs New Zealand 2010−2014 
DHB 
Number: 
2010−2014   
Number: annual 
average  
Rate  Rate ratio  95% CI  
Pneumonia 
0–24 year olds 
Waikato 1,288 258 1.90 0.82 0.77–0.87 
Bay of Plenty 886 177 2.51 1.08 1.01–1.16 
Lakes 542 108 2.94 1.27 1.17–1.38 
Tairawhiti 272 54 3.01 1.30 1.15–1.47 
Taranaki 357 71 1.89 0.82 0.74–0.91 
New Zealand 17,732 3,546 2.32 1.00   
0–14 year olds 
Waikato 1102 220 2.70 0.80 0.75–0.85 
Bay of Plenty 777 155 3.42 1.01 0.94–1.09 
Lakes 456 91 3.88 1.15 1.05–1.26 
Tairawhiti 237 47 4.05 1.20 1.05–1.36 
Taranaki 309 62 2.58 0.77 0.68–0.86 
New Zealand 15285 3057 3.37 1.00   
15–24 year olds 
Waikato 186 37 0.69 0.88 0.76–1.02 
Bay of Plenty 109 22 0.87 1.11 0.91–1.34 
Lakes 86 17 1.29 1.65 1.33–2.04 
Tairawhiti 35 7 1.11 1.41 1.01–1.97 
Taranaki 48 10 0.70 0.89 0.67–1.18 
New Zealand 2447 489 0.78 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Regional trends 
From 2000 to 2014 pneumonia hospitalisation rates for 0–24 year olds fell overall in Bay of Plenty and Lakes 
DHBs, fell from 2001–2007 then rose from 2007–2014  in Waikato DHB, and fluctuated from year to year in 
Tairawhiti and Taranaki DHBs (Figure 77).  
In all the Midland DHBs hospitalisation rates were mostly higher for Māori than for European/Other. Pacific 
rates in Waikato were similar to Māori rates from 2000–2010 but higher in than Māori rates in subsequent years. 
Asian/Indian rates in Waikato DHB were similar to European/Other rates. Pacific rates in Lake DHB were often 
much higher than those of other ethnic groups. In most Midland DHBs, Māori and European rates followed 
similar trends to the total rates (Figure 78).  
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Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident Population 






















































































































































































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident Population; Ethnicity is level 1 prioritised 
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Regional distribution by season 
There was seasonal variation in pneumonia hospitalisation rates in all the Midland DHBs. Rates were mostly 
highest in in June–September (Figure 79, Figure 80). 
Figure 79. Average number of hospitalisations for pneumonia in 0−24 year olds, by month, Waikato, Bay of 

































































































































National Minimum Dataset (acute and arranged admissions); Number is annual average; Month is based on hospitalisation 
admission date 
Figure 80. Average number of hospitalisations for pneumonia in 0−24 year olds, by month, Tairawhiti and 
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Evidence for good practice for the prevention and management of 
pneumonia  
Ministry of Health publications 
 Ministry of Health. 2014. Immunisation Handbook 2014. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/immunisation-handbook-2014 
Chapter 15 of this handbook covers pneumococcal disease. It provides a summary of key information and more detailed information on 
bacteriology, clinical features, epidemiology, vaccines, the recommended immunisation schedule, contraindications and precautions, 
expected responses and adverse events following immunisation, and public health measures. The current immunisation schedule is for a 13-
valent protein conjugate vaccine, PCV-13 (Prevenar 13) for healthy children aged under 5 years, at ages 6 weeks, 3, 5, and 15 months. High-
risk children and adults (those who are immunocompromised e.g. due to chemotherapy, asplenia or having had an organ transplant) are 
entitled to receive additional doses of a 23-valent polysaccharide vaccine (Pneumonvax 23). 
International guidelines 
World Health Organization. 2014. Revised WHO classification and treatment of childhood pneumonia at health 
facilities: evidence summaries. Geneva: World Health Organization. 
http://apps.who.int/iris/bitstream/10665/137319/1/9789241507813_eng.pdf 
These guidelines set out a pneumonia control strategy suitable for use in countries with limited healthcare resources. They include a summary 
of WHO-approved recommendations and the evidence supporting them. 
World Health Organization, The United Nations Children's Fund (UNICEF). 2013. End preventable deaths: Global Action 
Plan for Prevention and Control of Pneumonia and Diarrhoea. Geneva: World Health Organization, The United Nations 
Children's Fund (UNICEF). 
http://www.who.int/maternal_child_adolescent/documents/global_action_plan_pneumonia_diarrhoea/en/ 
This Action Plan offers a global perspective on the prevention of pneumonia and diarrhoea in children. It notes that worldwide these two 
diseases account for 29% of all deaths of children younger than five years of age. It states that effective measures for prevention of pneumonia 
are: exclusive breastfeeding for six months and continued breastfeeding with appropriate complementary feeding from six months; 
vaccination against the two most common bacterial causes of childhood pneumonia, Streptococcus pneumoniae and Haemophilus influenzae 
type b; vaccination against pertussis and measles (conditions in which pneumonia may be a complication); the use of standardised guidelines 
for identification and treatment of pneumonia, innovative demand creation activities to achieve behaviour change and sustain long-term 
preventive practices; water, sanitation and hygiene interventions, and reduction of household air pollution. 
Harris M, Clark J, Coote N, et al. 2011. British Thoracic Society guidelines for the management of community acquired 
pneumonia in children: update 2011. Thorax, 66 Suppl 2, ii1-23. https://www.brit-thoracic.org.uk/document-
library/clinical-information/pneumonia/paediatric-pneumonia/bts-guidelines-for-the-management-of-community-
acquired-pneumonia-in-children-update-2011/ 
These guidelines from the British Thoracic society are an updated version of the 2002 guideline, incorporating new evidence. 
Recommendations in the guideline cover clinical features, investigations, severity assessment, general management, antibiotic management, 
complications, and follow-up. Each is accompanied by an evidence level (Ia to IVb) and a grade of recommendation (A to D). A summary of 
this guideline can be found on the National Guideline Clearinghouse website: 
http://www.guideline.gov/content.aspx?id=37287&search=pneumonia . 
Bradley JS, Byington CL, Shah SS, et al. 2011. The Management of Community-Acquired Pneumonia in Infants and 
Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and 
the Infectious Diseases Society of America. Clinical Infectious Diseases, 53(7), 617-30. 
http://cid.oxfordjournals.org/content/53/7/e25.long#sec-145  
These guidelines are intended for primary care and subspecialty providers caring for otherwise healthy infants ≥ 3 months and children 
with community-acquired pneumonia in both outpatient and inpatient settings. They cover site-of-care management, diagnosis, 
antimicrobial and adjunctive surgical therapy, and prevention. Recommendations are accompanied by an indication of the strength of 
recommendation and of the quality of the evidence. A summary of this Guideline can be found on the National Guideline Clearinghouse 
website: 
http://www.guideline.gov/content.aspx?id=34433&search=pneumonia+children . 
Evidence-based medicine reviews 
Lassi Zohra S, Imdad A, Bhutta Zulfiqar A. 2015. Short-course versus long-course intravenous therapy with the same 
antibiotic for severe community-acquired pneumonia in children aged two months to 59 months. Cochrane Database 
of Systematic Reviews (6). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008032.pub2/abstract 
Hospital care for children with severe pneumonia places a significant burden on healthcare systems and families, particularly in low income 
countries where most deaths from pneumonia occur. The World Health Organization’s 2014 recommendations for the treatment of childhood 
pneumonia (see above) recommend intravenous antibiotics for five days as a first-line treatment for severe childhood pneumonia. This review 
aimed to evaluate the efficacy of short-course (two to three days) vs. long-course (five days) intravenous therapy with the same antibiotic for 
severe community-acquired pneumonia in children aged two months to 59 months. The review authors did not identify any RCTs addressing 
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this issue and they recommended that physicians should continue to treat severe childhood pneumonia according to the WHO 
recommendations until further evidence becomes available. 
Laopaiboon M, Panpanich R, Swa Mya K. 2015. Azithromycin for acute lower respiratory tract infections. Cochrane 
Database of Systematic Reviews (3). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001954.pub4/abstract 
Acute lower respiratory infections (LRIs) include acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia. Azithromycin is 
a macrolide antibiotic, structurally modified from erythromycin. It is noted for its activity against some gram-negative organisms associated 
with respiratory tract infections, particularly Haemophilus influenzae. This review aimed to compare the effectiveness of azithromycin to 
amoxicillin or amoxicillin/clavulanic acid (amoxiclav) in the treatment of LRTI, in terms of clinical failure, incidence of adverse events and 
microbial eradication. It included 16 RCTs or quasi-RCTs involving 2,648 participants (adults and children). It was possible to analyse data 
from 15 trials with 2,496 participants. Pooled analysis indicated no significant difference between antibiotic groups in the incidence of clinical 
failure on about days 10 to 14 risk ratio (RR), random-effects 1.09; 95% CI 0.64 to 1.85). A subgroup analysis in trials with acute bronchitis 
participants showed significantly lower clinical failure in the azithromycin group compared to the amoxicillin or amoxiclav group (RR random-
effects 0.63; 95% CI 0.45 to 0.88). A sensitivity analysis showed that, in three adequately concealed studies, there was a non-significant 
reduction in clinical failure in azithromycin-treated participants (RR 0.55; 95% CI 0.25 to 1.21), compared to RR 1.32; 95% CI 0.70 to 2.49 in 12 
studies with inadequate concealment. Twelve trials reported the incidence of microbial eradication and there was no significant difference 
between the two groups (RR 0.95; 95% CI 0.87 to 1.03). There were fewer adverse events in the azithromycin group: RR 0.76 (95% CI 0.57 to 
1.00). The review authors concluded that it was unclear whether azithromycin is superior to amoxicillin or amoxiclav in treating acute LRTI but 
that, in patients with acute bronchitis with suspected bacterial cause, azithromycin tends to be more effective in terms of lower incidence of 
treatment failure and adverse events than amoxicillin or amoxiclav. They stated that most studies were of unclear methodological quality and 
had small sample sizes so further trials with adequate sample sizes and high methodological quality are needed. 
Gardiner Samantha J, Gavranich John B, Chang Anne B. 2015. Antibiotics for community-acquired lower respiratory 
tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database of Systematic Reviews (1). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004875.pub5/abstract 
Mycoplasma pneumoniae (M. pneumoniae) is widely recognised as an important cause of community-acquired lower respiratory tract infection 
(LRTI) in children, accounting for 14% to 34% of cases. Pulmonary manifestations are typically tracheobronchitis or pneumonia but the 
organism is also implicated in wheezing episodes in both asthmatic and non-asthmatic individuals. Major paediatric textbooks offer 
conflicting advice regarding the use of antibiotics in children with M. pneumoniae infection. This review aimed to determine whether 
antibiotics are effective for treating LRTIs in children that are secondary to M. pneumoniae infection acquired in the community. Studies were 
eligible for inclusion in the review if they were RCTs comparing antibiotics commonly used for treating M. pneumoniae (i.e. macrolide, 
tetracycline or quinolone classes) vs. placebo, or antibiotics from any other class, in the treatment of children < 18 years of age with 
community-acquired LRTI secondary to M. pneumoniae. The review authors identified seven studies enrolling a total of 1,912 children. Data 
interpretation was significantly limited by the inability to extract data that specifically referred to children with LRTI caused by M. pneumoniae. 
There was only one study which compared antibiotics vs. placebo, funded by a drug company. This study did not distinguish between upper 
and lower respiratory infections in the analysis of results, although it did provide details on the number of M. pneumoniae infections. It found 
that significantly more children in the azithromycin group had ‘clinical success’ on follow up than the placebo group (100% vs. 77%). In the 
other studies, in the sub-group of children with M. pneumoniae infection (38 children in total), the comparison was a macrolide antibiotic vs. 
a non-macrolide antibiotic, usually amoxicillin clavulanate. There was insufficient data to analyse the efficacy of macrolide antibiotics in this 
group, but adverse effects were reported in 11% to 67% of children. The review authors concluded that the evidence was insufficient to draw 
any specific conclusions about the efficacy of antibiotics for community-acquired LRTIs secondary to M. pneumoniae in children, although 
they noted that one trial suggested that macrolides may be efficacious in some children. They stated that the use of antibiotics has to be 
balanced with possible adverse effects and that high-quality double-blinded RCTs are needed to assess the efficacy and safety of antibiotics 
for LRTI secondary to M. pneumoniae in children. 
Lassi Zohra S, Kumar R, Das Jai K, et al. 2014. Antibiotic therapy versus no antibiotic therapy for children aged two to 
59 months with WHO-defined non-severe pneumonia and wheeze. Cochrane Database of Systematic Reviews (5). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009576.pub2/abstract 
The World Health Organization (WHO) has developed case management guidelines based on simple clinical signs to help clinicians decide 
on the appropriate pneumonia treatment. These guidelines are designed to be useful in resource-poor settings where pulse oximetry, x-rays 
or laboratory tests may be unavailable. The WHO guidelines do not distinguish viral and bacterial pneumonia and recommend that children 
and infants who exhibit rapid breathing ( > 50 breaths per minute or more in infants aged 2–12 months and > 40 in children aged 12 months 
to five years) and cough should be presumed to have non-severe pneumonia and treated with antibiotics. This review aimed to evaluate the 
efficacy of antibiotic therapy vs. no antibiotic therapy for children aged two to 59 months with WHO-defined non-severe pneumonia and 
wheeze. The review authors did not identify any relevant RCTs. They stated that there is a clear need for RCTs to address this question and 
that there is currently no evidence to support or challenge the WHO guidelines. 
Chang Christina C, Cheng Allen C, Chang Anne B. 2014. Over-the-counter (OTC) medications to reduce cough as an 
adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database of Systematic Reviews (3). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006088.pub4/abstract 
Patients with pneumonia frequently find coughing distressing and so they may use over the counter (OTC) cough medications (mucolytics or 
cough suppressants). Although these may reduce cough severity, cough suppression might reduce airway clearance and cause harm. This 
aim of this updated review was to evaluate the efficacy of OTC cough medications as an adjunct to antibiotics in children and adults with 
pneumonia. The review authors identified no new RCTs published since the previous review. Previously, four RCTs with a total of 224 
participants had been included. One involved children only and the other three involved adolescents or adults. The one study assessing an 
anti-tussive (cough suppressant) had no extractable pneumonia-specific data. The other studies assessed three different mucolytics; only two 
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of these studies had extractable data. They indicated no significant difference between intervention and control groups for the primary 
outcome of ‘not cured or improved’. A secondary outcome of 'not cured' was reduced for children: odds ratio (OR) 0.36, 95% CI 0.16 to 0.77; 
number needed to treat to benefit (NNTB) at day 10 = 5 (95% CI 3 to 16), and for adults: OR 0.32 (95% CI 0.13 to 0.75); NNTB at day 10 = 5 
(95% CI 3 to 19). In a post hoc analysis combining data for children and adults, there was again no difference in the primary outcome of 'not 
cured or not improved' (OR 0.85, 95% CI 0.40 to 1.80) although mucolytics reduced the secondary outcome 'not cured' (OR 0.34, 95% CI 0.19 
to 0.60; NNTB 4, 95% CI 3 to 8). The risk of bias was low or unclear. The review authors concluded that there was insufficient evidence to 
determine whether OTC medications for cough are beneficial for patients with pneumonia but that mucolytics may be beneficial. They stated 
that it is currently recommended that young children should not be given OTC cough medications containing codeine derivatives and 
antihistamines because of the known adverse events associated with these agents. 
Hu Q-J, Shen Y-C, Jia L-Q, et al. 2014. Diagnostic performance of lung ultrasound in the diagnosis of pneumonia: a 
bivariate meta-analysis. International Journal of Clinical and Experimental Medicine 7(1) 115-21 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902248/ 
Making a diagnosis of pneumonia is clinically challenging. Ultrasound examination can be performed with a portable device, and is user 
friendly, non-invasive and inexpensive. This review was to evaluate the overall diagnostic accuracy of chest ultrasound for pneumonia. It 
included nine prospective studies with 1080 subjects in total (44 with pneumonia and 436 controls). Most studies used chest x-ray or CT as a 
reference standard to diagnose pneumonia. The summary estimates for lung ultrasound in the diagnosis of pneumonia in the studies included 
were as follows: sensitivity, 0.97 (95% CI 0.93 to 0.99); specificity, 0.94 (95% CI 0.85 to 0.98); diagnostic odds ratio 507.99 (95% CI 128.11 to 
2014.34); positive likelihood ratio, 15.62 (95% CI 6.31 to 38.68); negative likelihood ratio, 0.03 (95% CI 0.01 to 0.08); The area under the 
summary receiver operating characteristic curve was 0.99 (95% CI 0.98 to 1.00). Based on these results, the study authors concluded that lung 
ultrasound is capable of diagnosing pneumonia with a high degree of accuracy and is a promising attractive alternative to chest radiography 
and thoracic CT scan. 
Loo JD, Conklin L, Fleming-Dutra KE, et al. 2014. Systematic review of the effect of pneumococcal conjugate vaccine 
dosing schedules on prevention of pneumonia. Pediatr Infect Dis J 33 Suppl 2 S140-51 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944478/  
Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; but there is 
uncertainty regarding the optimum PCV dosing schedule. This review looked at studies published from 1994 to 2010 (supplemented post 
hoc with studies from 2011) documenting the effect of PCV dosing schedules on clinical and radiologically confirmed pneumonia, 
pneumococcal pneumonia and empyema among children of ages targeted to receive the vaccine. Data on 2- and 3-dose schedules were 
included. The review authors identified 42 primary citations that evaluated PCV schedules and pneumonia. Thirty-seven (88%) were from 
North America, Europe or Australia; 37 (88%) evaluated PCV7 and 1 (2%) PCV10. Two studies (both observational) compared multiple 
schedules within the study. They found evidence of reduced clinical and radiologically confirmed pneumonia incidence for all schedules, 
including 2 primary doses plus 1 booster (2 + 1, one nonrandomized trial, 5 observational studies), 3 primary doses (3+0, 5 randomized trials, 
2 observational studies) and 3 primary doses plus 1 booster (3+1, 5 clinical trials, 24 observational studies) schedules. The magnitude of 
disease impact did not differ among schedules. Evidence for impact on pneumococcal pneumonia and empyema varied. The authors 
concluded that all schedules (2+1, 3+0 and 3+1) reduced clinical and radiologically confirmed pneumonia. Quantifying differences in 
pneumonia disease impact between schedules was difficult due to heterogeneity among studies in design, case definition and population. 
The authors stated that their findings support World Health Organization recommendations for 3-dose schedules administered as either 3+0 
or 2+1 regimens. They also stated that pneumonia impact data are still needed on expanded serotype PCV products, developing country 
settings and the role for a booster dose. 
Biondi E, McCulloh R, Alverson B, et al. 2014. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics 
133(6) 1081-90 http://pediatrics.aappublications.org/content/133/6/1081.long 
Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP) and other community-acquired lower respiratory 
tract infections (CA-LRTIs), particularly in school-aged children and adolescents. Children with CA-LRTIs are commonly given antibiotics for 
M. pneumonia. This review aimed to evaluate the effect of treating M. pneumoniae in children with CA-LRTI. Studies were deemed eligible for 
inclusion in this review if they were RCTs or observational studies of children ≤17 years old with confirmed M. pneumonia and a diagnosis of 
CA-LRTI; and they had compared treatment regimens with and without a spectrum of activity against M. pneumonia. Sixteen articles detailing 
17 studies were included. The most commonly selected primary outcome was symptomatic improvement. Nine studies examined M. 
pneumonia treatment in CA-LRTI secondary to M. pneumoniae, and 5 RCTs met criteria for meta-analysis. The pooled risk difference was not 
significant and demonstrated significant heterogeneity: risk difference 0.12 favouring treatment (95% confidence interval, −0.04 to 0.20). 
Limitations included substantial bias and subjective outcomes within the individual studies, difficulty interpreting testing modalities, and the 
inability to correct for mixed infections or timing of intervention. The review authors concluded that there was insufficient evidence to support 
or refute treatment of M. pneumoniae in CA-LRTI. They stated that there is a need for well-designed, prospective RCTs assessing the effect of 
treating M. pneumoniae in CA-LRTI. 
Conklin L, Loo JD, Kirk J, et al. 2014. Systematic review of the effect of pneumococcal conjugate vaccine dosing 
schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 33 Suppl 2 S109-
18 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944481/ 
Many countries have introduced pneumococcal conjugate vaccines (PCV) in recent years, using a variety of different schedules. This review 
aimed to assess the relative benefit of various PCV dosing schedules in preventing vaccine-type invasive pneumococcal disease (VT-IPD) in 
children, but it also provides an overview of studies on PCV effectiveness against VT-IPD. It included studies published in English from 1994 
to 2010 (supplemented post hoc with studies from 2011) on PCV effectiveness against VT-IPD among children targeted to receive vaccine. 
Data on 2-dose and 3-dose primary series, both with and without a booster (“2+0,” “2+1,” “3+0” and “3+1”), were included. For observational 
studies using surveillance data or case counts, the study authors calculated percentage reduction in VT-IPD before and after PCV introduction. 
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There were four RCTs and 31 observational studies reporting VT-IPD among young children. None evaluated a 2+0 complete series, seven 
(19%) evaluated 2+1, four (11%) 3+0 and 27 (75%) 3+1. Most (86%) studies were from North America or Europe. All but two studies evaluated 
PCV7; these two evaluated a 9-valent vaccine (PCV9). No studies evaluated PCV10 or PCV13. Only one study (observational) directly compared 
2 schedules (3+0 vs. 3+1); results supported the use of a booster dose. In clinical trials, vaccine efficacy ranged from 65% to 71% with 3+0 
and 83% to 94% with 3+1. Surveillance data and case counts demonstrated reductions in VT-IPD of up to 100% with 2+1 (6 studies) or 3+1 
(17 studies) schedules and up to 90% with 3+0 (2 studies). Reductions were observed as early as one year after PCV introduction. The review 
authors concluded that the available data support the use of 2+1, 3+0 and 3+1 schedules, although most data regarding PCV impact on VT-
IPD among young children are from high-income countries using 3+1. They stated that it is difficult to discern differences between schedules 
for impact on VT-IPD based on available data. 
Chaves Gabriela SS, Fregonezi Guilherme AF, Dias Fernando AL, et al. 2013. Chest physiotherapy for pneumonia in 
children. Cochrane Database of Systematic Reviews (9). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010277.pub2/abstract 
Chest physiotherapy is commonly used in the treatment of pneumonia to help eliminate mucus and secretions, remove airway obstructions, 
reduce airway resistance, enhance gas exchange and reduce the work of breathing. This review aimed to assess the effectiveness of chest 
physiotherapy, in relation to time until clinical resolution, in children (from birth up to 18 years old) of either gender with any type of 
pneumonia. It included three RCTs (involving 255 child inpatients) comparing chest physiotherapy of various types (conventional chest 
physiotherapy, positive expiratory pressure and continuous positive airway pressure) with no chest physiotherapy. Outcomes measured were: 
duration of hospital stay, time to clinical resolution, change in adventitious sounds, change in chest X-ray and duration of cough in days. Two 
studies found a significant improvement in respiratory rate and oxygen saturation but the third failed to show that standardised respiratory 
physiotherapy and positive expiratory pressure decreased the time to clinical resolution and the duration of hospital stay. No adverse effects 
of the interventions were reported. The review authors could not pool data from the studies because of the different characteristics of the 
trials, such as the duration of treatment, levels of severity, types of pneumonia and the techniques used, as well as differences in their statistical 
presentation. They considered that two of the included studies had a low risk of bias and the other had an overall unclear risk of bias. They 
concluded that their review did not provide conclusive evidence to justify the use of chest physiotherapy in children with pneumonia owing 
to lack of data as a result of the small number of studies and differences in statistical presentation between studies. 
Hemilä H, Louhiala P. 2013. Vitamin C for preventing and treating pneumonia. Cochrane Database of Systematic Reviews 
(8) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005532.pub3/abstract 
This review aimed to assess the prophylactic (preventive) and therapeutic effects of vitamin C on pneumonia. Selection criteria were placebo 
controlled trials (to assess therapeutic effect) and controlled trails with or without a placebo (to assess prophylactic effect). The review authors 
identified three prophylactic trials in which 37 cases of community-acquired pneumonia were recorded in 2,335 people. Only one of these 
was satisfactorily randomised, double-blind and placebo controlled. Two trials involved military recruits and the third, boys at boarding school 
in the UK during WW2. All three trials found a statistically significant (80% or greater) reduction in pneumonia incidence in the vitamin C 
group. The authors identified two therapeutic trials involving 197 patients with community-acquired pneumonia. One of these was 
satisfactorily randomised, double-blind and placebo-controlled. It involved elderly people in the UK and it found lower mortality and reduced 
severity in the vitamin C group although the benefit was restricted to the most ill patients. The other therapeutic trial, which involved adult 
patients with a wide age range in the former Soviet Union, found a dose-dependent reduction in the duration of pneumonia with two vitamin 
C doses. The authors identified one prophylactic trial in severely burned hospital patients. Thirteen out of 37 patients developed hospital-
acquired pneumonia and one-day administration of vitamin C did not affect pneumonia incidence. None of the studies included in the review 
found adverse effects of vitamin C. The review authors concluded that further research should investigate the prophylactic use of vitamin C 
in populations which have a high incidence of pneumonia and low dietary vitamin C intakes, and the therapeutic use of vitamin C in 
pneumonia patients with low plasma vitamin C levels. They stated that the current evidence is too weak to support prophylactic vitamin C to 
prevent pneumonia in the general population but that it may be reasonable to consider therapeutic vitamin C supplementation in pneumonia 
patients with low plasma vitamin C levels because the costs and risks of such therapy are low. 
Lodha R, Kabra Sushil K, Pandey Ravindra M. 2013. Antibiotics for community-acquired pneumonia in children. 
Cochrane Database of Systematic Reviews (6) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004874.pub4/abstract  
Although studies have suggested that many cases of pneumonia in children are caused by viruses, it can be impractical to undertake 
investigations to try to determine whether a child with clinical diagnosis of pneumonia does or does not have a bacterial infection before 
prescribing antibiotics, especially in low-income countries where mortality from pneumonia in children is high. The World Health Organization 
(WHO) recommends that, in countries with high rates of pneumonia fatalities, children with clinically-diagnosed pneumonia should be given 
empirical treatment with antibiotics. The aim of this review was to identify effective antibiotic drug therapies for community-acquired 
pneumonia (CAP) of varying severity in children by comparing various antibiotics. Twenty-nine RCTs involving 14,188 children were included 
in this review. All compared multiple antibiotics: none compared antibiotic to placebo. Seventeen studies were of good quality with adequate 
allocation concealment, including five which were double blind and 12 which were unblinded. More than one study compared co-trimoxazole 
with amoxicillin, oral amoxicillin with injectable penicillin/ampicillin and chloramphenicol with ampicillin/penicillin and the studies were of 
good quality, suggesting the evidence for these comparisons was of high quality compared to other comparisons. In ambulatory settings, for 
treatment of WHO defined non-severe CAP, amoxicillin compared with co-trimoxazole had similar failure rates (odds ratio (OR) 1.18, 95% CI 
0.91 to 1.51) and cure rates (OR 1.03, 95% CI 0.56 to 1.89). These figures were derived from three studies involving 3,952 children. 
In children with severe pneumonia without hypoxaemia, oral antibiotics (amoxicillin/co-trimoxazole) compared with injectable penicillin had 
similar failure rates (OR 0.84, 95% CI 0.56 to 1.24), hospitalisation rates (OR 1.13, 95% CI 0.38 to 3.34) and relapse rates (OR 1.28, 95% CI 0.34 
to 4.82). Six studies involved 4331 children < 18 years of age. 
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In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving penicillin plus gentamicin (OR 
1.25, 95% CI 0.76 to 2.07, one study involving 1116 children) and compared to those receiving ampicillin plus gentamicin (OR 1.65, 95% CI 
0.99 to 2.77, one study with 958 participants). 
The review authors’ conclusions were as follows. For outpatient treatment of pneumonia, amoxicillin is an alternative to co-trimoxazole and, 
based on limited data, co-amoxyclavulanic acid and cefpodoxime may be alternative second-line drugs. Children with severe pneumonia but 
without hypoxaemia can be treated as outpatients with amoxicillin. For children hospitalised with severe and very severe CAP, 
penicillin/ampicillin plus gentamycin is superior to chloramphenicol. The other alternative drugs for such patients are co-amoxyclavulanic 
acid and cefuroxime. Until more studies are available, these drugs can be used as second-line therapies. These recommendations apply to 
countries with high case fatalities due to pneumonia in children without underlying morbidities and where point of care tests for identification 
of causative agents for pneumonia are not available. The review authors stated that there is a need for more studies with radiographically 
confirmed pneumonia in larger patient populations and similar methodologies to compare newer antibiotics. 
Lamberti LM, Zakarija-Grkovic I, Fischer Walker CL, et al. 2013. Breastfeeding for reducing the risk of pneumonia 
morbidity and mortality in children under two: a systematic literature review and meta-analysis. BMC Public Health 
13 Suppl 3 S18 http://www.biomedcentral.com/1471-2458/13/S3/S18 
Suboptimal breastfeeding of infants and young children (< two years of age) is associated with a higher risk of pneumonia morbidity and 
mortality. The aim of this systematic review and meta-analysis was to quantify the protective effects of breastfeeding exposure against 
pneumonia incidence, prevalence, hospitalizations and mortality. The review authors used random effects meta-analyses to generate pooled 
effect estimates by outcome, age and exposure level. There were 10 studies included in the analysis, seven prospective cohort studies and 
three case control studies. By WHO region, the included studies were conducted in Latin America (n=5), South Asia (n=4), Africa (n=2) and 
the Western Pacific (n=1), with one study located in three different locations. Suboptimal breastfeeding elevated the risk of pneumonia 
morbidity and mortality outcomes across age groups. In particular, pneumonia mortality was higher among not breastfed compared to 
exclusively breastfed infants 0–5 months of age (relative risk (RR): 14.97; 95% CI: 0.67 to 332.74) and among not breastfed compared to 
breastfed infants and young children 6–23 months of age (RR: 1.92; 95% CI: 0.79 to 4.68). The review authors stated that their results highlight 
the importance of breastfeeding during the first 23 months of life as a key intervention for reducing pneumonia morbidity and mortality. 
Das RR, Singh M, Panigrahi I, et al. 2013. Vitamin D supplementation for the treatment of acute childhood pneumonia: 
a systematic review. ISRN Pediatr 2013 Article ID 459160 http://www.hindawi.com/journals/isrn/2013/459160/  
Studies have found an increased incidence of vitamin D deficiency in children with pneumonia. This review reports that there have been only 
two RCTs comparing vitamin D3 with placebo in children ≤ five years with pneumonia. One trial, involving 503 outpatient children in 
Afghanistan, used a single 100,000 unit of oral vitamin D3 at the onset of pneumonia. There was no significant difference in the mean (±SD) 
number of days to recovery between the vitamin D3 and placebo arms (4.74 ± 2.22 vs. 4.98 ± 2.89, P = 0.17). Another trial, involving 200 child 
inpatients in India, used oral vitamin D3 (1000 IU for children aged <one year and 2000 IU for >one year) for five days in children with severe 
pneumonia. Median duration of resolution of severe pneumonia was similar in the two groups (intervention, 72 hours, 95% CI 64.7 to 79.3; 
placebo, 64 hours, 95% CI 55.2 to 72.8). Duration of hospitalization and time to resolution of tachypnea, chest retractions, and inability to 
feed were also comparable between the two groups. The review authors concluded that oral vitamin D supplementation does not help 
children aged < five years with acute pneumonia. 
Wang K, Gill P, Perera R, et al. 2012. Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in 
children and adolescents with community-acquired pneumonia. Cochrane Database of Systematic Reviews (10) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009175.pub2/abstract 
Mycoplasma pneumoniae (M. pneumoniae) is a significant cause of community-acquired pneumonia (CAP) in children and adolescents. 
Treatment with macrolide antibiotics is recommended. It is difficult to diagnose M. pneumoniae based on clinical symptoms and signs. 
Diagnostic uncertainty can result in inappropriate antibiotic prescribing, which may worsen clinical prognosis and increase antibiotic 
resistance. This review had two aims: (i) to assess the diagnostic accuracy of symptoms and signs in the clinical recognition of M. pneumoniae 
in children and adolescents with CAP; and (ii) to assess the influence of potential sources of heterogeneity on the diagnostic accuracy of 
symptoms and signs in the clinical recognition of M. pneumoniae. The seven studies included in the review (1491 hospitalised children in 
total) were selected because they were peer-reviewed published studies which prospectively and consecutively recruited children with CAP 
from any healthcare setting, confirmed the presence of M. pneumoniae using serology with or without other laboratory methods and reported 
data on clinical symptoms and signs in sufficient detail to construct 2 x 2 tables. Overall, the reviewers considered these studies to be of 
moderate quality. In two studies the presence of chest pain more than doubled the probability of M. pneumoniae. Wheeze was 12% more 
likely to be absent in children with M. pneumoniae (pooled positive likelihood ratio (LR+) 0.76, 95% CI 0.60 to 0.97; pooled negative likelihood 
ratio (LR−) 1.12, 95% CI 1.02 to 1.23). Sensitivity analysis showed that the presence of crepitations was associated with M. pneumoniae, but 
this finding was of borderline statistical significance (pooled LR+ 1.10, 95% CI 0.99 to 1.23; pooled LR− 0.66, 95% CI 0.46 to 0.96). The reviewers 
concluded that M. pneumoniae cannot be reliably diagnosed in children and adolescents with CAP on the basis of clinical symptoms and 
signs and that further high quality large scale research in primary care settings is needed to help develop prediction rules based on 
epidemiological data as well as clinical and baseline patient characteristics. 
Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 30(32) 4717-8 
This article presents the World Health Organization (WHO) recommendations on the use of pneumococcal vaccines excerpted from the 
Pneumococcal vaccines WHO position paper - 2012 published in the Weekly Epidemiological Record. It focusses on the currently available 
10-valent and 13-valent conjugate vaccines and their introduction and use in national immunization programmes. It also deals with the 23-
valent polysaccharide vaccine, though in less detail than is provided in the April 2008 position paper which remains valid. Footnotes to this 
paper provide a number of core references including references to grading tables that assess the quality of scientific evidence for a few key 
conclusions. WHO recommends PCV be included in childhood immunisation programmes worldwide, using either 3 primary doses (3p+0 
schedule) or, as an alternative, 2 primary doses plus a booster (2p+1 schedule) for infants from as early as six weeks of age. All the WHO 
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vaccine position papers, including the full position paper on pneumococcal vaccines, a summary, key points and references can be found on 
the following web page: http://www.who.int/immunization/documents/positionpapers/en/  
Tan K, Lai Nai M, Sharma A. 2012. Surfactant for bacterial pneumonia in late preterm and term infants. Cochrane 
Database of Systematic Reviews (2) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008155.pub2/abstract 
 Pulmonary surfactant is a lipoprotein complex secreted by type II pneumocytes in the lungs. Its lowers the surface tension of the air water 
interface and is an important part of the host defences against respiratory infections. Bacterial pneumonia in late preterm or term newborn 
infants often results in surfactant deficiency or dysfunction. This review sought to assess the effect of exogenous surfactant treatment on 
mortality and pulmonary complications in infants with bacterial pneumonia. The review authors did not identify any relevant RCTs and so 
they concluded that there is no evidence from RCTs to support or refute the efficacy of surfactant in near-term and term infants with proven 
or suspected bacterial pneumonia. They stated that RCTs are still required to answer this question. 
Haider Batool A, Lassi Zohra S, Ahmed A, et al. 2011. Zinc supplementation as an adjunct to antibiotics in the treatment 
of pneumonia in children 2 to 59 months of age. Cochrane Database of Systematic Reviews (10) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007368.pub2/abstract 
Zinc deficiency is associated with decreased immunocompetence and it may be an underlying cause of increased infant mortality in 
malnourished children in low-income countries. This review aimed to evaluate the effect of zinc supplementation, as an adjunct to antibiotics, 
in the treatment of pneumonia (indicated by clinical recovery) in children aged two to 59 months. It included four RCTs involving 3,267 
children aged two to 35 months. Analysis showed that zinc supplementation in addition to antibiotic therapy in children with severe and non-
severe pneumonia was not associated with a statistically significant effect on time-to-clinical recovery (hazard ratio 1.02; 95% CI 0.93 to 1.11). 
In children with severe pneumonia, zinc supplementation as an adjunct to antibiotic therapy was not associated with a significant effect on 
time-to-recovery from tachypnoea (respiratory rate > 50 breaths per minute) (hazard ratio 1.13; 95% CI 0.82 to 1.57) and time-to-recovery 
from chest in-drawing (hazard ratio 1.08; 95% CI 0.88 to 1.31) as compared to the control group. Zinc supplementation in children with severe 
pneumonia also had no significant effect on time-to-hospital discharge as compared to the control group (hazard ratio 1.04; 95% CI 0.89 to 
1.22). The review authors concluded that the available evidence was insufficient to recommend the use of zinc as an adjunct to standard 
antibiotic therapy for pneumonia in children aged two to 35 months. 
Weir K, McMahon S, Chang AB. 2012. Restriction of oral intake of water for aspiration lung disease in children. 
Cochrane Database Systematic Reviews (9) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005303.pub3/abstract 
Children who have difficulty with feeding and swallowing due to a variety of complex medical conditions, such as neurological conditions and 
abnormal anatomy, may be at risk of aspirating food and liquid into their lungs. This may result in respiratory problems, including pneumonia. 
To prevent aspiration, food and fluids may be restricted, and children may be given texture-modified diets and thickened fluids. Young 
children often refuse thickened fluids, thus causing a management dilemma for parents and health professionals. This review aimed to 
evaluate the efficacy of restriction of oral water ingestion on the pulmonary status of children with thin fluid aspiration demonstrated on a 
modified barium swallow study. The review authors were unable to identify any RCTs addressing this issue. They therefore concluded that 
there is currently no evidence to support a strict approach of full restriction of oral water intake or to support a more liberal approach of 
allowing oral water ingestion in children with primary aspiration of thin fluids. 
Rozenbaum MH, van Hoek AJ, Fleming D, et al. 2012. Vaccination of risk groups in England using the 13 valent 
pneumococcal conjugate vaccine: economic analysis. BMJ 345 e6879 http://www.bmj.com/content/345/bmj.e6879.long 
The aim of this economic evaluation was to estimate the cost effectiveness of vaccinating people with high risk conditions in England against 
invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine. The population considered were people aged ≥ two 
years at increased risk of invasive pneumococcal disease due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised 
immune system; chronic heart, liver, or respiratory disease; or diabetes. Outcome measures for the analysis were costs, gains in life years and 
quality adjusted life years (QALYs), and incremental cost effectiveness ratios. The study authors noted that, due to increasing indirect 
protection resulting from the vaccination of infants with the 13-valent pneumococcal vaccine, the burden of disease preventable by 
vaccinating high risk people aged > two years will diminish over time. They stated that, under base case assumptions (no overall impact on 
non-bacteraemic pneumonia* and assuming the high-risk vaccination programme would be launched two to three years after the infant 
programme) the incremental cost effectiveness ratio was estimated to be more than £30,000 per QALY gained for most risk groups. If, 
however, the vaccine does offer protection against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced at the same 
time as the infant 13 valent pneumococcal conjugate vaccination programme then vaccinating high risk people would (more) likely be cost 
effective. Sensitivity analyses indicated that the cost effectiveness was particularly sensitive to vaccine efficacy estimates and assumed herd 
benefits. The study authors concluded that under base case assumptions it is unlikely that a programme to vaccinate high risk individuals 
against pneumococcal disease could be considered cost effective. They stated that uncertainty could be substantially reduced by ascertaining 
the effectiveness of the 13 valent pneumococcal conjugate vaccine against non-bacteraemic pneumococcal pneumonia, particularly in at risk 
groups. 
*Bacteraemic pneumonia (where pneumococcal bacteria have spread to the bloodstream) has a much higher mortality than non-bacteraemic 
pneumonia (where the infection is confined to the respiratory system). 
Chen Y, Li K, Pu H, et al. 2011. Corticosteroids for pneumonia. Cochrane Database of Systematic Reviews (3) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007720.pub2/abstract 
Corticosteroids can affect immune regulation, carbohydrate metabolism, protein catabolism, electrolyte balance and stress response. They 
are used to treat a variety of inflammatory diseases but it is unclear whether they are beneficial for patients with pneumonia. This review 
aimed to assess the efficacy and safety of corticosteroids in the treatment of pneumonia. It included six RCTs involving 437 participants. 
Methodological quality was high in two studies and poor in three. All studies had small numbers of participants. Two small studies provided 
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weak evidence that corticosteroids did not significantly reduce mortality (Peto odds ratio (OR) 0.26, 95% CI 0.05 to 1.37), but did accelerate 
the resolution of symptoms and time to clinical stability, and decrease the relapse rate for the disease. Steroids can improve oxygenation and 
reduce the need for mechanical ventilation in patients with severe pneumonia. There was no significant difference between treatment groups 
in the time to discharge from the intensive care unit (ICU). There were insufficient data to report the time to pneumonia resolution and rate 
of admission to ICU. Serious adverse events were rare. In total from the 437 participants, three patients had adverse events. These were 
arrhythmia, upper gastrointestinal bleeding and malignant hypertension. The review authors concluded that, in most patients with 
pneumonia, corticosteroids are generally beneficial for accelerating the time to resolution of symptoms but that the evidence from the 
included studies was not strong enough to make any recommendations. They did, however recommend steroids for children with pneumonia 
due to M. pneumoniae because corticosteroids can significantly relieve clinical symptoms and prevent relapse of the disease. 
A number of recent Cochrane reviews deal with the prevention or treatment of pneumonia in particular situations (such in association with 
ventilator use) or in particular patient groups (such as patients with AIDS or cystic fibrosis). The titles and links of these reviews are listed 
below. 
Ewald H, Raatz H, Boscacci R, et al. 2015. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients 
with HIV infection. Cochrane Database of Systematic Reviews (4). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006150.pub2/abstract 
Berton Danilo C, Kalil Andre C, Teixeira Paulo José Z. 2014. Quantitative versus qualitative cultures of respiratory 
secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database of Systematic 
Reviews (10). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006482.pub4/abstract 
Bo L, Li J, Tao T, et al. 2014. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database of 
Systematic Reviews (10). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009066.pub2/abstract 
Regan Kate H, Bhatt J. 2014. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. 
Cochrane Database of Systematic Reviews (10). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009876.pub2/abstract 
Stern A, Green H, Paul M, et al. 2014. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV 
immunocompromised patients. Cochrane Database of Systematic Reviews (10). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005590.pub3/abstract 
Burgess L, Southern Kevin W. 2014. Pneumococcal vaccines for cystic fibrosis. Cochrane Database of Systematic Reviews 
(8). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008865.pub3/abstract 
Amin R, Waters V. 2014. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. 
Cochrane Database of Systematic Reviews (4). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009249.pub3/abstract 
Kabra Sushil K, Lodha R. 2013. Antibiotics for preventing complications in children with measles. Cochrane Database of 
Systematic Reviews (8). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001477.pub4/abstract 
Shi Z, Xie H, Wang P, et al. 2013. Oral hygiene care for critically ill patients to prevent ventilator-associated 
pneumonia. Cochrane Database of Systematic Reviews (8) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008367.pub2/abstract 
Horsley A, Jones Andrew M. 2012. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis 
experiencing a pulmonary exacerbation. Cochrane Database of Systematic Reviews (10) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009529.pub2/abstract 
Other relevant publications 
Vogel AM, Trenholme AA, Stewart JM, et al. 2013. Impact of pneumococcal vaccine on hospital admission with lower 
respiratory infection in children resident in South Auckland, New Zealand. N Z Med J 126(1378) 26-35 
This study aimed to assess the change in admission rates for all lower respiratory infection (LRIs), including pneumonia, for children residing 
in the Counties Manukau DHB, following the introduction of the 7-valent pneumococcal conjugate vaccine (PCV-7) in June 2008. It found 
that pneumonia, but not bronchiolitis, admissions have been declining since 2001. There was a significant decrease in pneumonia admissions 
after PCV7 introduction (incidence risk ratio pre vs. post PCV7 (IRR) 1.51, 95% CI 1.08 to 1.77), additional to the gradual decline since 2001. 
Post PCV introduction, there was a significant decline for Pacific children (IRR 1.70, 95% CI 1.39 to 2.07) but not for Māori children (IRR 1.05, 
95% CI 0.78 to 1.40). Māori and Pacific children were found to be at increased risk of admission with LRI compared to European children 
(relative risk (RR) 4.6, 95% CI 4.3 to 5.0 and 5.0, 95% CI 3.7 to 5.3, respectively) as were those living in Decile 9, 10 compared with those from 
other deciles (RR 1.43, 95% CI 1.36 to 1.50). The study authors concluded that admissions for pneumonia in young children had declined 
following the introduction of PCV7 but there had been less impact for Māori children in Counties Manukau DHB. 
  
 




Asthma is the most common non-communicable disease in children.60 The diagnosis is a clinical one, based on 
recurrent episodes of asthma symptoms (more than one of breathlessness, wheezing, chest tightness and 
cough).61 It is important to understand that there are many different causes of wheezing in children and that, 
especially in pre-school children and infants, the commonest clinical pattern is episodes of wheezing, cough and 
difficulty breathing in association with viral upper respiratory infections.61 Most of these children will stop 
having recurrent chest symptoms by school age61 and so clinicians have become increasingly reluctant to 
diagnose very young children with asthma. Nevertheless, a high proportion of children diagnosed with chronic 
asthma in later childhood had their first symptoms and signs of the disorder in their preschool years.62 
The causes of asthma are not well understood.60 The strongest risk factors for developing asthma are a genetic 
predisposition (family history of asthma and/or other allergic diseases such as eczema and allergic rhinitis) 
together with environmental exposure to inhaled substances and particles that may provoke allergic reactions or 
irritate the airways, such as house dust mites, pet dander, pollen, mould, and tobacco smoke.60 Asthma can also 
be triggered by cold air, exercise and psychological distress.60 The prevalence of asthma in New Zealand is one 
of the highest in the world.63 There are ethnic disparities in asthma prevalence64 and hospitalisation rates.65 
Although primary prevention of asthma will not be possible until the causes of asthma are better understood, 
better treatment through improved access to primary care, and educational interventions for parents, children 
and healthcare providers, has the potential to reduce asthma morbidity and hospitalisation rates.61 
The following section reports on deaths due to asthma and hospitalisations for asthma and wheeze in children 
and young people, using information from the National Minimum Dataset and the National Mortality 
Collection. It concludes with a brief overview of evidence-based reviews and guidelines which consider the 
most effective interventions for preventing or managing asthma in children and young people.  
Data sources and methods 
Indicators 
 Deaths from asthma or wheeze in 0–24 year olds  
 Hospitalisations for asthma or wheeze in 0–24 year olds  
Data sources 
Numerator:  Deaths:  National Mortality Collection 
  Hospitalisations: National Minimum Dataset 
Denominator:  Statistics NZ estimated resident population (with linear extrapolation being used to calculate denominators 
between Census years) 
Definition 
Deaths: Deaths of 0–24 year olds with where the main underlying cause of death was asthma or wheeze (per 100,000 age-
specific population)  
Hospitalisations: Acute and arranged hospitalisations of 0–24 year olds with a primary diagnosis of asthma or wheeze (per 
1,000 age-specific population). Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: In 2013, a number of changes were made to the ICD-10-AM codes included in this indicator. The changes included 
broadening asthma to include wheeze to take into account a shift in the way paediatricians were diagnosing asthma in 
preschool children. As a result, the rates in this section are not directly comparable with those presented in NZCYES reports 
prior to 2013.  
Note 2: An acute hospitalisation is an unplanned hospitalisation occurring on the day of presentation, while an arranged 
hospitalisation (referred to elsewhere in this report as an arranged hospitalisation) is a non-acute hospitalisation with an 
admission date less than seven days after the date the decision was made that the hospitalisation was necessary.  
Note 3: Appendix 3 describes the National Minimum Dataset and outlines the limitations of the data utilised from this data 
collection. The reader is advised to review this appendix before interpreting any patterns. 
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National trends and distribution 
There were 24 deaths of 0–24 year olds from 2008 to 2012 with asthma as the underlying cause, an average of 
4.8 deaths per year. The number of hospitalisations for asthma increased from 5,020 in 2000 to 6,982 in 2014. 
There was a significant rise in rate from 3.60 hospitalisations per 1,000 0–24 year olds in 2000 to 4.71 
hospitalisations per 1,000 0–24 year olds in 2010 with fairly stable rates since then (Figure 81). From 2000 to 
2014 the rise in hospitalisation rates was specific to 0–14 year olds (4.67 to 6.86 hospitalisations per 1,000) 
whereas there was a significant fall in hospitalisation rates for 15–24 year olds from 1.81 to 1.15 hospitalisations 
per 1,000 (Figure 82).  
The rise in asthma hospitalisation rates over time was seen in all ethnic groups. Hospitalisation rates were 
consistently highest for Pacific; Māori and MELAA rates were consistently higher than European/Other and 
Asian/Indian rates (Figure 83). 
Figure 81.Hospitalisations for asthma in 0–24 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Figure 82. Hospitalisations for asthma in 0–24 year olds, by age group, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
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Figure 83. Hospitalisations for asthma in 0–24 year olds, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Primary diagnosis 
Between 2010 and 2014 the most common primary diagnoses for hospitalisations in the section were asthma 
and wheeze. The diagnosis of wheeze occurred mainly in 0–14 year olds, where it accounted for 31.5% of 
hospitalisations. In 15–24 year olds asthma was the diagnosis in 94.8% of hospitalisations (Table 82). 






Rate per 1,000 
0–24 year olds 
95% CI Per cent 
Asthma and wheeze 
0–24 year olds 
Asthma 24,752 4,950 3.24 3.20–3.28 69.1 
Status asthmaticus 1,047 209 0.14 0.13–0.15 2.9 
Wheeze 10,003 2,001 1.31 1.28–1.33 27.9 
Total 35,802 7,160 4.68 4.63–4.73 100.0 
0–14 year olds 
Asthma 20,853 4,171 4.60 4.54–4.67 65.8 
Status asthmaticus 864 173 0.19 0.18–0.20 2.7 
Wheeze 9,973 1,995 2.20 2.16–2.25 31.5 
Total 31,690 6,338 7.00 6.92–7.07 100.0 
15–24 year olds 
Asthma 3,899 780 1.25 1.21–1.29 94.8 
Status asthmaticus 183 37 0.06 0.05–0.07 4.5 
Wheeze 30 6 0.01 0.01–0.01 0.7 
Total 4,112 822 1.32 1.28–1.36 100.0 
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Distribution by demographic factors 
Between 2010 and 2014 the asthma hospitalisation rate was highest for one year olds, fell significantly with 
increasing age to age 13 years after which rates remained similar with increasing age (Figure 84).  There was 
disparity in asthma hospitalisation rates by age, with the highest rate in 0–4 year olds (14 hospitalisations per 
1,000 1–4 year olds) which was 10.64 (95% CI 10.30–11.00) times higher than the rate for 15–24 year olds; the 
rate of 3.37 per 1,000 5–14 year olds was 2.56 (95% CI 2.47–2.66) times higher than the rate for 15–24 year 
olds.  
For 0–14 year olds there was disparity in asthma hospitalisation rates by NZDep2013 index of deprivation score, 
ethnicity and gender. There was a consistent social gradient with a significant increase in rate between each 
quintile of NZDep2013 scores compared with the quintile below. Compared with European/Other, rates were 
significantly higher for Māori, Pacific, Asian/Indian and MELAA. Male rates were significantly higher than 
female rates (Table 83).  
For 15–24 year olds there was similar disparity by NZDep2013 index of deprivation score. Compared with 
European/Other, asthma hospitalisation rates were significantly higher for Māori, Pacific and MELAA and 
significantly lower for Asian/Indian. There was no significant difference between male and female rates in this 
older age group (Table 83).  
Figure 84. Hospitalisations for asthma in 0–24 year olds, by age, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
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Rate per 1,000  
0–24 year olds 
Rate ratio 95% CI 
Asthma 
0–14 year olds 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 3,599 4.13 1.00   
Deciles 3–4 4,245 5.26 1.27 1.22–1.33 
Deciles 5–6 5,201 6.08 1.47 1.41–1.54 
Deciles 7–8 7,282 7.75 1.88 1.80–1.95 
Deciles 9–10 11,209 10.62 2.57 2.48–2.67 
Prioritised ethnicity 
Māori 10,728 9.31 1.98 1.93–2.04 
Pacific 5,860 13.47 2.87 2.78–2.96 
Asian/Indian 3,225 6.77 1.44 1.39–1.50 
MELAA 528 9.49 2.02 1.85–2.20 
European/Other 11,308 4.69 1.00   
Gender 
Female 12,380 5.61 1.00   
Male 19,309 8.32 1.48 1.45–1.52 
15–24 year olds 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 355 0.67 1.00   
Deciles 3–4 431 0.83 1.24 1.07–1.42 
Deciles 5–6 650 1.12 1.67 1.47–1.90 
Deciles 7–8 1,012 1.49 2.23 1.97–2.51 
Deciles 9–10 1,639 2.04 3.05 2.72–3.42 
Prioritised ethnicity 
Māori 1,571 2.49 2.60 2.43–2.79 
Pacific 628 2.36 2.47 2.25–2.71 
Asian/Indian 181 0.39 0.41 0.35–0.48 
MELAA 71 1.67 1.75 1.38–2.22 
European/Other 1,647 0.96 1.00   
Gender 
Female 2,800 1.83 1.00   
Male 1,312 0.83 0.45 0.42–0.48 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rates are per 1,000 age-specific population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is 
NZDep2013 
Distribution by season 
The lowest rates of asthma hospitalisation were in January with no clear seasonal variation through the rest of 
the year.  
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Distribution by region 
Between 2010 and 2014 asthma hospitalisation rates for 0–24 year olds were significantly higher than the 
national rate in the Auckland, Counties Manukau, Bay of Plenty, Lakes, Tairawhiti, Whanganui and Hutt Valley 
DHBs and significantly lower in the Waikato, Hawke's Bay, MidCentral, Nelson Marlborough, South 
Canterbury, West Coast and Southern DHBs. In the remaining district health boards there was no significant 
difference from the national rate (Figure 85, Table 84). 
Figure 85. Hospitalisations for asthma in 0–24 year olds, by district health board, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged hospitalisations); Denominator: Statistics NZ Estimated Resident 
Population 




 Number:  
annual average 
Rate per 1,000  
0–24 year olds 
Rate ratio 95% CI 
Asthma 
0–24 year olds 
Northland 1,329 266 4.78 1.02 0.97–1.08 
Waitemata 4,281 856 4.53 0.97 0.94–1.00 
Auckland 4,848 970 6.19 1.32 1.28–1.36 
Counties Manukau 4,844 969 4.99 1.07 1.03–1.10 
Waikato 2,908 582 4.29 0.92 0.88–0.95 
Bay of Plenty 1,975 395 5.60 1.20 1.14–1.25 
Lakes 946 189 5.14 1.10 1.03–1.17 
Tairawhiti 506 101 5.61 1.20 1.10–1.31 
Taranaki 855 171 4.54 0.97 0.91–1.04 
Hawke's Bay 982 196 3.63 0.77 0.73–0.83 
MidCentral 1,043 209 3.50 0.75 0.70–0.80 
Whanganui 538 108 5.14 1.10 1.01–1.20 
Hutt Valley 1,399 280 5.70 1.22 1.15–1.28 
Capital & Coast 2,225 445 4.41 0.94 0.90–0.98 
Wairarapa 275 55 4.18 0.89 0.79–1.01 
Nelson Marlborough 555 111 2.65 0.57 0.52–0.62 
South Canterbury 165 33 1.94 0.41 0.36–0.48 
Canterbury 3,946 789 4.76 1.02 0.99–1.05 
West Coast 156 31 3.13 0.67 0.57–0.78 
Southern 1,859 372 3.60 0.77 0.73–0.81 
New Zealand 35,802 7,160 4.68 1.00   
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 asthma hospitalisation rates for 0–24 year olds were significantly higher than the 
national rate in Bay of Plenty, Lakes, and Tairawhiti DHBs, significantly lower in Waikato DHB, and not 
significantly different in Taranaki DHB. Rates for 0–14 year olds were significantly higher in Bay of Plenty 
DHB and significantly lower in Waikato and Taranaki DHBs. Rates for 15–24 year olds were significantly 
higher in Bay of Plenty, and Lakes DHBs. The following rates were not significantly different from the national 
rate: 0–14 year olds in Lakes DHB, and 15–24 year olds in Waikato, Tairawhiti, and Taranaki DHBs (Table 
85). 






Rate per 1,000 
population 
Rate ratio 95% CI 
Asthma 
0–24 year olds 
Waikato 2,908 582 4.29 0.92 0.88–0.95 
Bay of Plenty 1,975 395 5.60 1.20 1.14–1.25 
Lakes 946 189 5.14 1.10 1.03–1.17 
Tairawhiti 506 101 5.61 1.20 1.10–1.31 
Taranaki 855 171 4.54 0.97 0.91–1.04 
New Zealand 35,802 7,160 4.68 1.00   
0–14 year olds 
Waikato 2,544 509 6.24 0.89 0.86–0.93 
Bay of Plenty 1,781 356 7.85 1.12 1.07–1.18 
Lakes 810 162 6.89 0.98 0.92–1.06 
Tairawhiti 466 93 7.96 1.14 1.04–1.25 
Taranaki 762 152 6.37 0.91 0.85–0.98 
New Zealand 31,690 6,338 7.00 1.00   
15–24 year olds 
Waikato 364 73 1.35 1.02 0.92–1.14 
Bay of Plenty 194 39 1.55 1.17 1.02–1.36 
Lakes 136 27 2.04 1.55 1.31–1.84 
Tairawhiti 40 8 1.26 0.96 0.70–1.31 
Taranaki 93 19 1.35 1.03 0.84–1.26 
New Zealand 4,112 822 1.32 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Regional trends 
From 2000 to 2014 the asthma hospitalisation rates for 0–24 year olds varied from year to year, rates generally 
rose in the five Midland DHBs (Figure 86).  
In Waikato DHB from 2000 to 2014, asthma hospitalisation rates for 0–24 year olds were consistently highest 
for Pacific and Māori, and lowest for European/Other and Asian/Indian (these last two groups had similar rates). 
In Bay of Plenty and Lakes DHBs, Māori hospitalisation rates were consistently higher than European/Other 
rates while Pacific rates were highly variable (due to small numbers) (Figure 87). 
During the time period, the hospitalisation rates for Māori and Pacific rose in the Midland DHBs, with the 
exception of Lakes DHB, while the rates were steady in European/Other. In Lakes DHB, the Māori 
hospitalisation rate remained stable and rose for European/Other ethnic group (Figure 87). 
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Numerator: National Minimum Dataset (acute and arranged admissions), Denominator: Statistics NZ Estimated Resident Population 























































































































































































































































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident Population; Pacific rates in Bay of Plenty and Lakes DHBs and Asian/Indian rates in Bay 
of Plenty DHB are affected by small numbers for earlier years  
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Regional distribution by season 
In the Midland DHBs, while no consistent seasonal variations in asthma hospitalisations in 0–14 year olds were 
evident, the number of hospitalisations was generally lower in December and January (Figure 88, Figure 89). 
Figure 88. Average number of hospitalisations for asthma in 0–24 year olds, by month and age group, Waikato, 
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Numerator: National Minimum Dataset (acute and arranged admissions) 
Figure 89. Average number of hospitalisations for asthma in 0–24 year olds, by month and age group, Tairawhiti 








































Numerator: National Minimum Dataset (acute and arranged admissions) 
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Evidence for good practice for the prevention and management of 
asthma 
International guidelines 
Global Initiative for Asthma. 2015. Global Strategy for Asthma Management and Prevention. 
http://www.ginasthma.org/documents/4 
This report is intended as a guide for health professionals and policymakers. It is based on current best evidence and medical knowledge. 
Report chapters cover definition, description and diagnosis of asthma, assessment, treatment, asthma exacerbations, asthma-COPD overlap 
syndrome, asthma in children five years and younger, primary prevention of asthma, and implementing asthma management strategies into 
health systems. Treatment recommendations are accompanied by evidence grades and references. Regarding primary prevention in children 
five years and younger, the report suggests that parents enquiring about how to reduce the risk of their child developing asthma can be 
advised that: children should not be exposed to environmental tobacco smoke before or after birth, vaginal delivery is preferred if possible 
(to expose the infant to the mother’s vaginal microflora), breastfeeding is advised (for reasons other than prevention of allergy and asthma) 
and the use of broad-spectrum antibiotics in the first year of life should be discouraged. The GINA website has a number of other useful 
resources, including pocket guides for asthma management and prevention, and the appendix to the Global Strategy. These can be found 
here: http://www.ginasthma.org/documents/1. It is necessary to download and save the documents to be able to navigate them more easily. 
British Thoracic Society, Scottish Intercollegiate Guidelines Network. 2014. British guideline on the management of 
asthma: A national clinical guideline. London, Edinburgh: British Thoracic Society, Scottish Intercollegiate Guidelines 
Network. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/ 
This guideline provides best practice recommendations, based on current evidence, for the management of asthma in adults (including 
pregnant women), adolescents and children. Recommendations in the guideline cover diagnosis and monitoring, supported self-
management, non-pharmacological management, pharmacological management, inhaler devices, acute asthma, difficult asthma, asthma in 
pregnancy, occupational asthma and organisation and delivery of care. Recommendations are accompanied by a grade indicating the 
strength of the supporting evidence. A quick reference version of the guideline can be found here: https://www.brit-
thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-quick-reference-guide-2014/ Supporting material 
for the guideline, and patient information resources, can be found on the SIGN website: 
http://www.sign.ac.uk/guidelines/fulltext/141/index.html . 
Chung KF, Wenzel SE, Brozek JL, et al. 2014. International ERS/ATS guidelines on definition, evaluation and treatment 
of severe asthma. Eur Respir J, 43(2), 343-73. http://erj.ersjournals.com/content/43/2/343.long 
This guideline defines severe asthma as asthma that requires treatment with high dose inhaled corticosteroids plus a second controller and/or 
systemic corticosteroids to prevent it becoming ”uncontrolled” or that remains “uncontrolled” despite this therapy. A Task force supported 
by the American Thoracic Society and the European Respiratory Society performed a literature review and then held an expert committee 
discussion which used the GRADE approach to develop specific clinical recommendations on the evaluation and treatment of severe asthma 
in children and adults. The Task Force stated that severe asthma is a heterogenous condition with various phenotypes. They made specific 
recommendations on the use of sputum eosinophil count and exhaled nitric oxide to guide therapy as well as treatment with anti IgE antibody, 
methotrexate, macrolide antibiotics, antifungal agents and bronchial thermoplasty. These are set out in a table which gives, for each 
recommendation, the strength of recommendation, the quality of evidence and also brief discussion of values and preferences and 
explanatory remarks. 
Lougheed MD, Lemiere C, Ducharme FM, et al. 2012. Canadian Thoracic Society 2012 guideline update: diagnosis and 
management of asthma in preschoolers, children and adults. Can Respir J, 19(2), 127-64. 
http://www.pulsus.com/journals/abstract.jsp?sCurrPg=journal&jnlKy=4&atlKy=10569&isuKy=1021&isArt=t 
This guideline update from the Canadian Thoracic Society addresses four clinical questions: the role of non-invasive measurements of airway 
inflammation for the adjustment of anti-inflammatory therapy; the initiation of adjunct therapy to corticosteroids (ICS) for uncontrolled 
asthma; the role of a single inhaler of an ICS/long-acting beta-agonist combination as a reliever, and as a reliever and a controller; and the 
escalation of controller medication for acute loss of asthma control as part of a self-management action plan. The guideline panel formally 
assessed and graded the evidence and made 34 recommendations.  
Sveum R, Bergstrom J, Brottman G, et al. 2012. Diagnosis and Management of Asthma. Bloomington, MN: Institute for 
Clinical Systems Improvement. 
https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_respiratory_guidelines/asth
ma/ 
This guideline covers asthma diagnosis, and emergent, inpatient and outpatient management of acute and chronic asthma, in all patients 
over five years of age who present with asthma-like symptoms or have been diagnosed with asthma. The guideline presents two algorithms, 
one for general asthma management and one for emergency department or inpatient management, accompanied by annotations which 
explain and provide supporting information for the steps in the algorithms. Recommendations are accompanied by references and indications 
of evidence quality. 
The Cincinnati Children’s Hospital Medical Center has produced a number of Best Evidence Statements relating to asthma. 
Recommendations are accompanied by an indication of level of evidence and a strength of recommendation, and a discussion/summary of 
the evidence related to the recommendation. Links to these Best Evidence Statements are given below. 
Use of a clinical pathway in decreasing albuterol frequency in all patients up to 18 years of age admitted to the hospital with a diagnosis of 
asthma or reactive airway disease. (2011) 
Pediatric Patients with Wheezing: Oxygen versus Air Nebulization (2011) 
Management of acute exacerbation of asthma in children: (2010) Care Guideline | Highlights | Inpatient Order Set 
Using formal communication to collaborate with schools to decreased patient admissions/Emergency Department visits and missed school 
days and improve ACT scores for children with asthma (2012) 
Culturally Sensitive Asthma Education (2013) 
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Evidence-based medicine reviews 
There are now hundreds of Cochrane reviews relating to asthma in children, therefore it has not been possible to summarise them all here. 
The recent Cochrane reviews that have been included deal mostly with more general non-pharmacological interventions. 
Sauni R, Verbeek Jos H, Uitti J, et al. 2015. Remediating buildings damaged by dampness and mould for preventing or 
reducing respiratory tract symptoms, infections and asthma. Cochrane Database of Systematic Reviews (2) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007897.pub3/abstract 
Moisture damage is a common problem in homes, workplaces and public buildings such as schools. The resulting dampness and mould has 
been associated with respiratory symptoms, asthma and respiratory infections in the buildings’ occupants. This review aimed to determine 
the effectiveness of repairing buildings damaged by dampness and mould in reducing or preventing respiratory symptoms, asthma and 
respiratory infections. It included 12 studies with a total of 8,028 participants: two RCTs (294 participants), one cluster RCT (4,407 participants), 
and nine controlled before and after (CBA) studies (3,327 participants). Interventions varied from thorough renovation to cleaning only. There 
was moderate to low quality evidence that repairing houses decreased asthma-related symptoms and respiratory infections in adults. For 
children, there was no difference between those whose houses were repaired and those who received information only in the number of 
asthma days or asthma-related emergency department visits (one study, moderate quality evidence). One CBA study provided very low quality 
evidence that asthma-related and other respiratory symptoms decreased after repairing a mould-damaged office building, and another CBA 
study found no difference between full and partial repair of houses. For children in schools, the evidence regarding an effect of mould 
remediation on respiratory symptoms was inconsistent. Out of many symptom measures only respiratory infections might have decreased 
after intervention. For staff in schools, there was very low quality evidence that asthma-related and other respiratory symptoms were similar 
in staff in mould-damaged schools and staff in undamaged schools, both before and after intervention. The review authors stated that better 
research is needed, preferably with a cluster-RCT design and more validated outcome measures. 
National Institute for Health and Care Excellence (NICE). 2014. Measuring fractional exhaled nitric oxide concentration 
in asthma: NIOX MINO, NIOX VERO and NObreath. London: National Institute for health and Care Excellence. 
http://www.nice.org.uk/guidance/dg12 
Nitric oxide is produced in the lungs and is present in exhaled air. It has been shown to act as a vasodilator, bronchodilator, neurotransmitter 
and inflammatory mediator in the lungs and airways. Fractional exhaled nitric oxide (FeNO) has been proposed as non-invasive marker of 
airway inflammation in people with asthma. FeNO levels are raised in people with asthma and can be lowered with corticosteroid treatment. 
The purpose of this evaluation was to evaluate the clinical and cost effectiveness of measuring FeNO in the diagnosis and management of 
asthma. Three devices for measuring FeNO were evaluated: NIOX MINO, NIOX VERO and NObreath. A systematic review was carried out to 
identify evidence on the equivalence of FeNO devices (analytical validity), evidence of the diagnostic accuracy of FeNO testing for asthma 
diagnosis and evidence for the efficacy of FeNO-guided asthma management. A decision analytical model and a Markov model were 
developed to assess the cost effectiveness of measuring FeNO in the diagnosis and management of asthma. The review identified 27 studies 
comparing NIOX MINO, NIOX VERO and NObreath with other devices, 24 studies relevant to the diagnostic accuracy of FeNO devices, four 
studies on FeNO-guided asthma management in adults and five studies on FeNO-guided asthma management in children. 
The NICE recommendations are: 
(1) FeNO testing is recommended as an option to help diagnose asthma in adults and children: who, after initial clinical examination, 
are considered to have an intermediate probability of having asthma (as defined in the British guideline on the management of 
asthma 2012) and when FeNO testing is intended to be done in combination with other diagnostic options according to the British 
guideline on the management of asthma (2012). Further investigation is recommended for people whose FeNO test result is 
negative because a negative result does not exclude asthma. 
(2)  FeNO measurement is recommended as an option to support asthma management (in conjunction with the British guideline on 
the management of asthma 2012) in people who are symptomatic despite using inhaled corticosteroids.  
National Institute for Health and Care Excellence. 2013. Omalizumab for treating severe persistent allergic asthma 
(review of technology appraisal guidance 133 and 201). London: National Institute for Health and Care Excellence. 
http://www.nice.org.uk/guidance/ta278 
Omalizumab (Xolair, Novartis) is a monoclonal antibody that binds to IgE. It is used as an add-on therapy in children over six years of age, 
adolescents and adults with severe persistent allergic asthma that is not well controlled despite high dose inhaled corticosteroid plus long-
acting beta-2 agonist therapy. The NICE assessment group identified 11 RCTs, comparing omalizumab with placebo, in its efficacy review. 
Nine included only adolescents and adults, one children only, and one people between the ages of six and 20 years. The trials were considered 
to be generally of high quality. The assessment group also reviewed data from observational studies to support evidence from the trials, 
particularly data on longer-term response to omalizumab and corticosteroid sparing. They also reviewed six published cost-effectiveness 
studies and developed their own economic model from the perspective of the UK NHS. The assessment group’s model indicated that, for 
both children and adults, omalizumab add-on treatment was both more costly and more effective than standard care alone. The Assessment 
Group calculated that the annual average cost of omalizumab for children was £8455 plus administration costs of £268 in the first year and 
£151 in subsequent years, and the cost for adults and adolescents was £8056 plus administration costs of £260 in the first year and £146 in 
subsequent years. The Appraisal Committee considered the data on the clinical and cost-effectiveness of omalizumab, the value placed on 
this therapy by patients and clinicians, and the cost to the NHS. The key conclusion of the Appraisal Committee was that omalizumab be 
recommended as a treatment option for severe persistent confirmed allergic IgE-mediated asthma as an add-on to optimised standard 
therapy in people aged six years and older who need continuous or frequent oral corticosteroid treatment (defined as four or more courses 
in the previous year), only if the manufacturer makes omalizumab available with the discount agreed in the patient access scheme. 
Omalizumab was added to the pharmaceutical schedule in New Zealand in October 2014 (requiring special authority). 
 
Conditions of the respiratory system: Asthma 
188 
Okelo SO, Butz AM, Sharma R, et al. 2013. Interventions to modify health care provider adherence to asthma 
guidelines. Comparative effectiveness review No. 95. (Prepared by Johns Hopkins University Evidence-based 
Practice Center under Contract No. 290-2007-10061-I.) AHRQ Publication No. 13-EHC022-EF. Rockville, MD: Agency 
for Healthcare Research and Quality. http://www.ncbi.nlm.nih.gov/books/NBK144097/ 
This review was designed to synthesise the published literature on the effects of interventions designed to improve health care providers' 
adherence to asthma guidelines on: (1) health care process outcomes; (2) clinical outcomes; and (3) health care processes that subsequently 
impact clinical outcomes. Seventy-three studies were eligible for inclusion. Thirty-four were RCTs, 29 were pre-post, and the other 10 were of 
various non-randomised designs. All took place in primary care settings. The studies assessed eight types of intervention: decision support, 
organizational change, feedback and audit, clinical pharmacy support, education only, quality improvement (QI)/pay-for-performance, 
multicomponent, and information only. Health care process outcomes included prescription of asthma controller medication (n=41), provision 
of an asthma action plan (n=18), prescription of a peak flow meter (n=17), and self-management education (n=12). Clinical outcomes included 
emergency department (ED) visits (n=30) and hospitalizations (n=27), use of short-acting β2 agonists (n=9), missed school days (n=8), lung 
function tests (n=6), symptom days (n=6), quality of life (n=5), and urgent doctor visits (n=5).  
The review authors identified four critical outcomes for which 68 studies provided information. They reported the following results: there was 
moderate evidence for increased prescriptions of asthma controller medications following decision support, feedback and audit, and clinical 
pharmacy support interventions and low grade evidence for organizational change and multicomponent interventions. Moderate evidence 
supported the use of decision support and clinical pharmacy interventions to increase provision of patient self-education/asthma action 
plans; for the same outcome, low grade evidence supported the use of organizational change, feedback and audit, education only, quality 
improvement, and multicomponent interventions. Moderate grade evidence supported the use of decision support tools to reduce ED 
visits/hospitalizations while low grade evidence suggested there is no benefit associated with organizational change, education only, and 
QI/pay-for-performance. Organizational change interventions provided no benefit for lost days of work/school. The evidence for the 
remainder of interventions was insufficient or low in strength. 
The review authors concluded that there was low-to moderate evidence to support to support the use of decision support tools, feedback 
and audit, and clinical pharmacy support to improve the adherence of health care providers to asthma guidelines, as measured through 
health care process outcomes, and to improve clinical outcomes. They stated that health care provider-targeted interventions need to be 
further evaluated with a focus on standardized measures of outcomes and more rigorous study designs. 
Azad MB, Coneys JG, Kozyrskyj AL, et al. 2013. Probiotic supplementation during pregnancy or infancy for the 
prevention of asthma and wheeze: systematic review and meta-analysis. BMJ, 347, f6471. 
http://www.bmj.com/content/347/bmj.f6471.long 
Commensal gut bacteria stimulate the development of the neonatal immune system. Disruption of the gut biota due to factors such as 
caesarean delivery, lack of breastfeeding and antibiotic use is thought to play a role in the development of allergic disorders, including 
asthma. Probiotics are live micro-organisms ingested either in fermented foods such as yoghurt, or as dietary supplements. This review aimed 
to evaluate the association between probiotic supplementation during pregnancy or infancy with childhood asthma and wheeze. The review 
authors identified 20 eligible RCTs involving 4866 children. The trials varied in type and duration of probiotic supplement used, and duration 
of follow up. Only five trials had follow up of participants beyond age six years (median 24 months), and none were powered to detect asthma 
as the primary outcome. Most were at high (10 trials) or unclear (nine trials) risk of bias, mainly due to attrition. Overall, 10.7% of participants 
had doctor-diagnosed asthma, 33.3% had incident wheeze and 13.9% respiratory tract infection. Among 3257 infants enrolled in nine trials 
contributing asthma data, the risk ratio of doctor diagnosed asthma in participants randomised to receive probiotics was 0.99 (95% CI 0.81 
to 1.21, I2=0%). The risk ratio of incident wheeze was 0.97 (95% CI 0.87 to 1.09, I2=0%, 9 trials, 1949 infants). Among 1364 infants enrolled in 
six trials, the risk ratio of lower respiratory tract infection after probiotic supplementation was 1.26 (0.99 to 1.61, I2=0%). The review authors 
concluded that there was no evidence to support a protective association between perinatal use of probiotics and doctor diagnosed asthma 
or childhood wheeze, and that further research is needed to determine the role of probiotics in preventing asthma. 
Cates Christopher J, Rowe Brian H. 2013. Vaccines for preventing influenza in people with asthma. Cochrane Database of 
Systematic Reviews (2) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000364.pub4/abstract 
In many countries influenza vaccination is recommended for people with asthma as observational studies have indicated that influenza 
infection can be associated with asthma exacerbations. This review aimed to assess the efficacy and safety of influenza vaccination in children 
and adults with asthma. It included 18 RCTs. Most trials studied injected inactivated virus vaccines, but four studied intranasal live vaccines. 
All the studies included some outcome measures for asthma exacerbation in the early post-vaccination period, but only six looked for late 
outcomes to assess the vaccines’ efficacy in protecting against asthma exacerbations related to influenza infection. One parallel group trial, 
involving 696 children, was able to assess the protective effects of influenza vaccination. It found no significant reduction in the number, 
duration or severity of influenza-related asthma exacerbations over the influenza season. Two cross-over trials, involving 1526 adults and 712 
children measured adverse effects of inactivated influenza vaccination in the first two weeks after vaccination. There was no clinically important 
increase in asthma exacerbations among those who had received the vaccine compared to those who had received a placebo (risk difference 
0.014; 95% CI −0.010 to 0.037). Two small studies (17 adults and 48 children) compared live attenuated (intranasal) vaccination vs. placebo 
and found no significant differences in asthma exacerbations or measures of lung function. One study on 2229 children over six years of age 
compared live attenuated vaccine (intranasal) vs. trivalent inactivated vaccine (intramuscular) and found no significant differences in asthma 
exacerbations. The review authors concluded that there is still uncertainty about the degree of protection vaccination provides against 
influenza-related asthma exacerbations but evidence from more recently published RCTs of inactivated split-virus vaccines indicates that 
there is no significant increase in asthma exacerbations immediately after vaccination in adults or children over three years of age. They stated 
that they were unable to address concerns regarding possible increased wheezing and hospital admissions in infants given live intranasal 
vaccination. 
Carson Kristin V, Chandratilleke Madhu G, Picot J, et al. 2013. Physical training for asthma. Cochrane Database of 
Systematic Reviews (9). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001116.pub4/abstract 
This review aimed to use evidence from RCTs (involving people over the age of eight years) to obtain a better understanding of the effects 
of physical training on the respiratory and general health of people with asthma. Twenty-one studies (772 participants) were included in the 
review. Physical training was found to be well tolerated with no adverse effects reported. No studies reported worsening of asthma symptoms 
after physical training. Physical training was associated with marked improvement in cardiovascular fitness, as indicated by a statistically and 
clinically significant increase in maximum oxygen uptake (mean difference (MD) 4.92 mL/kg/min; 95% CI 3.98 to 5.87; P < 0.00001; eight 
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studies, 267 participants), but there were no statistically significant effects on forced expiratory volume in one second (FEV1), forced vital 
capacity (FVC), minute ventilation at maximal exercise (VEmax) or peak expiratory flow rate (PEFR). Meta-analysis of data from four studies 
indicated a statistically significant increase in maximum heart rate, which was still significant after a sensitivity analysis and removal of two 
studies (MD 3.67 bpm; 95% CI 0.90 to 3.44; P = 0.01). Due to diverse reporting measures, it was not possible to pool studies’ results for quality 
of life, but there was some evidence to suggest that physical training may have positive effects on quality of life with four studies reporting 
a statistically and clinically significant benefit. The review authors concluded that physical training produced significant improvement in 
maximum oxygen uptake, but not in other measures of pulmonary function. They stated that it was well tolerated by study participants and 
therefore people with asthma should be encouraged to participate in physical activity without fear of exacerbating their asthma symptoms. 
They stated that more research is need to understand how physical activity impacts asthma management. 
Beggs S, Foong Yi C, Le Hong Cecilia T, et al. 2013. Swimming training for asthma in children and adolescents aged 18 
years and under. Cochrane Database of Systematic Reviews (4). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009607.pub2/abstract 
Observational studies have suggested that swimming is an ideal form of physical activity to improve fitness and decrease the burden of 
disease in asthma. This review aimed determine the effectiveness and safety of swimming training as an intervention for asthma in children 
and adolescents aged 18 years and under. Studies were eligible for inclusion if they were RCTs or quasi-RCTs of children and adolescents 
comparing swimming training with usual care, a non-physical activity, or physical activity other than swimming. There were eight such trials 
(all RCTs), involving 262 participants aged between five and 18 years. In seven studies swimming training varied from 30 to 90 minutes, two 
to three times a week, over six to 12 weeks and in one study swimming training was 30 minutes six times per week. The comparison was usual 
care in seven studies and golf in one. There were no statistically significant effects seen in studies comparing swimming training with usual 
care or another physical activity for the primary outcomes: quality of life, asthma control, asthma exacerbations or use of corticosteroids for 
asthma. Compared to usual care, swimming training had a clinically meaningful effect on exercise capacity as measured by maximal oxygen 
consumption during a maximum effort exercise test (VO2 max) (two studies, n = 32), with a mean increase of 9.67 mL/kg/min; 95% CI 5.84 
to 13.51. A difference of equivalent magnitude was found when other measures of exercise capacity were also pooled (four studies, n = 74), 
giving a standardised mean difference (SMD) 1.34; 95% CI 0.82 to 1.86. Swimming training was associated with small increases in resting lung 
function parameters of varying statistical significance; mean difference (MD) for FEV1 % predicted 8.07; 95% CI 3.59 to 12.54. In sensitivity 
analyses, by risk of attrition bias or use of imputed standard deviations, there were no important changes in effect sizes. Unknown chlorination 
status of pools limited subgroup analyses. Based on limited data, there were no adverse effects on asthma control or occurrence of 
exacerbations. The review authors stated that their review indicated that swimming training is well-tolerated in children and adolescents with 
stable asthma, and it increases lung function (moderate strength evidence) and cardio-pulmonary fitness (high strength evidence). They 
stated that there was no evidence that swimming training is associated with adverse effects in young people under eighteen years with stable 
asthma of any severity. They also stated that they could not determine whether swimming is better than any other form of physical activity, 
and that further adequately powered trials with longer follow-up periods are needed to better assess the long-term benefits of swimming. 
The following non-pharmacological interventions have been the subject of Cochrane reviews (date in brackets) which found that there was 
insufficient evidence to determine whether or not the intervention was beneficial for asthma: 
 Vitamins C and E for asthma and exercise-induced bronchoconstriction. (2014). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010749.pub2/abstract 
 Written emotional disclosure for asthma (2014) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007676.pub2/abstract 
 Vitamin C for asthma and exercise-induced bronchoconstriction. 
(2013)http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010391.pub2/abstract 
 Smartphone and tablet self management apps for asthma. (2013) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010013.pub2/abstract 
 Breathing exercises for adults with asthma. (2013) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001277.pub3/abstract 
 Prebiotics in infants for prevention of allergy. (2013) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006474.pub3/abstract (two studies, 226 infants) 
 Monosodium glutamate avoidance for chronic asthma in adults and children.(2012) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004357.pub4/abstract 
 Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in 
the child. (2012) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000133.pub3/abstract 
 Alexander technique for chronic asthma. (2012) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000995.pub2/abstract 
 Weight loss interventions for chronic asthma. (2012) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009339.pub2/abstract 
The following non-pharmacological interventions have been the subject of Cochrane reviews (date in brackets) which found that the available 
evidence either did not clearly indicate that an intervention was beneficial or harmful, or did not clearly indicate that one intervention was 
better than another (for asthma outcomes): 
 Interventions for managing asthma in pregnancy. (2014) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010660.pub2/abstract 
 Dehumidifiers for chronic asthma.(2013) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003563.pub2/abstract 
 Inspiratory muscle training for asthma. (2013) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003792.pub2/abstract 
 Nurse versus physician-led care for the management of asthma. (2013) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009296.pub2/abstract 
 Optimal duration of exclusive breastfeeding. (2012) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003517.pub2/abstract This review found that exclusive breastfeeding for 
six months did not reduce the risk of atopic eczema, asthma or allergies. Pooled data from three observational studies in 
developed countries indicated a risk ratio for asthma at 5–7 years in children exclusively breastfed for six months vs. 3–4 months 
(with mixed breastfeeding thereafter) of 1.02, 95% CI 0.72 to 1.44. 
 
Conditions of the respiratory system: Asthma 
190 
 Ionisers for chronic asthma. (2012) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002986.pub2/abstract 
 Primary care based clinics for asthma.(2012) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003533.pub2/abstract 
(three RCTs, 466 participants) 
 Home-based educational interventions for children with asthma.(2011) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008469.pub2/abstract 
Other relevant publications 
Jones B, Ingham TR, Reid S, et al. 2015. He māramatanga huangō: Asthma health literacy for Māori children in New 
Zealand. Wellington: University of Otago. http://asthmafoundation.org.nz/Māori-health/he-maramatanga-huango-report/ 
This report, prepared for the Ministry of Health and the Asthma Foundation, was the result of a project intended to inform health policy, 
service delivery and resource development by: (1) examining the health literacy demands on both whānau (family) and health providers 
regarding asthma management, (2) investigating and identifying health literacy barriers and facilitators, (3) identifying gaps in and issues with 
asthma health literacy skills and knowledge and (4) making recommendations to improve health literacy, in order to improve asthma 
outcomes for Māori children. The project used a kaupapa Māori research methodology with a mixed methods approach. The study found 
that the health literacy demands of managing a child with asthma are complex and multi-faceted. The study authors concluded that the 
predominant barriers to optimal health literacy for Māori children with asthma are structural, endemic to the acute care model of health care 
delivery that currently predominates. They presented their recommendations under four headings: Mātauranga (Knowledge), Whakaakoako 
(Teaching Strategies), Whakawhanake (Workforce development) and Te Anga (Model of care). Under each heading there is an overarching 
recommendation and recommended actions, according to a three-level hierarchy: Health Systems (macro level), Health Organisations (meso 
level), and Health Professionals (micro level). 
The following paper describes the research with Māori families that informed the above report. 
Jones B, Ingham TR, Cram F, et al. 2013. An indigenous approach to explore health-related experiences among Māori parents: the 
Pukapuka Hauora asthma study. BMC Public Health, 13, 228. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608319/?report=classic.  
Mogasale V, Vos T. 2013. Cost-effectiveness of asthma clinic approach in the management of chronic asthma in 
Australia. Aust N Z J Public Health, 37(3), 205-10 
Asthma control is less than ideal in Australia, despite the availability of effective drugs. One of the strategies recommended to improve asthma 
management is effective self-management. Self-management has four components: asthma education, self-monitoring of symptoms, regular 
review of asthma severity and treatment by a medical practitioner, and a written asthma plan. This study aimed to compare cost-effectiveness 
of an asthma clinic that would provide education, promotion of self-monitoring of symptoms, regular review of treatment by a medical 
practitioner and a written asthma action plan, to current practice in Australia. The researchers used a decision tree model to evaluate the 
benefits of asthma clinics under three scenarios: 1) the intervention reduces only emergency department visits; 2) in addition, it leads to a 
reduction in days out of role (e.g. absences from school or work); and 3) it also reduces unplanned general practitioner visits and 
hospitalisations. They used evidence from existing published studies for asthma incidence, duration, treatment practices, and health-seeking 
behaviours. Costs for one year were estimated based on an Australian asthma clinic trial. The results of the model indicated that the estimated 
$274 million annual cost of asthma clinics was much greater than the potential cost savings of $11 million resulting from reduced emergency 
department visits, and an overall potential cost saving of $85 million resulting from decreased GP visits and hospitalisations. The incremental 
cost-effective ratio (ICER) was $24,000 if a reduction in days out of role was quantified as a health benefit in estimating disability-adjusted 
life years (DALY). If a potential $85 million in cost-savings from decreased emergency department visits, GP visits and hospitalisation was 
taken into account, the ICER dropped to $17,000 per DALY averted. The study authors concluded that an asthma clinic as an intervention for 
improving self-management might be cost-effective in Australia if multiple benefits could be achieved. 
Gillies TD, Tomlin AM, Dovey SM, et al. 2013. Ethnic disparities in asthma treatment and outcomes in children aged 
under 15 years in New Zealand: analysis of national databases. Primary Care Respiratory Journal, 22(3), 312–8. 
Previous research has indicated that Māori and Pacific children are more likely to be hospitalised for asthma than children of other ethnicities 
and that Māori children are less likely to be prescribed preventive medicines. This study aimed to determine whether the poorer asthma 
outcomes for Māori and Pacific children are associated with less optimal asthma treatment and lower adherence to guidelines. The study 
authors used the pharmaceutical claims database to identify children aged <15 years who were dispensed ≥ two asthma medicines during 
2011 (80,514 children). They measured the number of children dispensed oral steroids ≥ two times and hospital admissions with a primary 
diagnosis of asthma and compared asthma treatment steps and hospitalisation by age and ethnicity. The results were as follows: 16.0% of 
children were dispensed asthma medicines, 9.2% were dispensed medicine ≥ two times, 3.6% of children were hospitalised at least once for 
asthma and 98.9% of admissions were acute. Māori (OR 1.46, 95% CI 1.41 to 1.51) and Pacific children (OR 2.38, 95% CI 2.28 to 2.47) were 
more likely to remain on the lowest step of treatment (and not be given inhaled corticosteroids or long-acting β2-agonists). At all steps of 
treatment, Māori and Pacific children had higher rates of oral steroid use. In all age groups, more Māori children (5.1%, OR 1.88, 95% CI 1.73 
to 2.04) and Pacific children (5.6%, OR 2.05, 95% CI 1.84 to 2.29) were hospitalised for asthma than children of other ethnicities (2.8%). The 
study authors suggested that these results may indicate less frequent use of GP services by Māori and Pacific children until symptoms become 
severe (possibly because of cost), and that a lack of understanding of medicines, ineffective communication with healthcare providers, and 
other cultural issues can lead to a lack of adherence to prescribed treatment in Māori and Pacific peoples which may result in a failure to pick 
up prescribed medicines or not receiving the correct number of repeat dispensings. 
Silvers KM, Frampton CM, Wickens K, et al. 2012. Breastfeeding protects against current asthma up to 6 years of age. 
Journal of Pediatrics, 160(6), 991-6.e1. 
This paper reports on the association between breastfeeding and wheezing and current asthma in children aged 2–6 years in the New Zealand 
Asthma and Allergy Cohort Study. This study enrolled 1105 infants at birth. Detailed information about infant feeding was collected via 
questionnaires at birth, and at 3, 6 and 15 months. This was used to calculated duration of any and exclusive breastfeeding. Information about 
wheezing and current asthma was collected at 2, 3, 4, 5, and 6 years. Logistic regression was used to model associations between breastfeeding 
and outcomes, with and without adjustment for confounders. After adjustment for confounders, each month of exclusive breastfeeding was 
associated with significant reductions in current asthma from 2 to 6 years (all, P < .03). Current asthma at 2, 3, and 4 years was also reduced 
by each month of any breastfeeding (all, P < .005). In atopic children, exclusive breastfeeding for ≥3 months reduced current asthma at ages 
4, 5, and 6 by 62%, 55%, and 59%, respectively. The study authors concluded that breastfeeding, particularly exclusive breastfeeding, protects 
 
Conditions of the respiratory system: Asthma 
191 
against current asthma up to six years. They noted that, while exclusive breastfeeding reduced risk of current asthma in all children to age 
six, the degree of protection beyond three years was greater in atopic children. 
Kristiansen J, Hetutu E, Manukia M, et al. 2012. An evaluation of a pictorial asthma medication plan for Pacific children. 
New Zealand Medical Journal, 125(1354), 42-50. http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-
2019/2012/vol-125-no-1354/article-kristiansen  
Pacific children are disproportionately affected by asthma. They have a higher asthma prevalence, more severe acute symptoms and more 
frequent hospitalisations. The precise reasons for these disparities are uncertain but evidence suggests that Pacific families lack understanding 
of asthma medicines and how to recognise worsening asthma. The authors of this study developed a web-based tool, www.pamp.co.nz which 
health professionals can use to produce personalised pictorial asthma resources in English and three Pacific languages. In this study, resources 
were provided to families with face-to-face education at a general practice or inpatient setting in West Auckland. A questionnaire about the 
resources was completed after six weeks, and an audit regarding use after six months. Data from 48 children were analysed (Samoan, n=31). 
Forty-five English and 22 first language versions (Samoan, Tongan, Tuvaluan) of the resources were used. The median time to questionnaire 
completion was 48 days. The pictorial asthma medication plan was acceptable to families, effective at reinforcing the importance of ‘everyday’ 
inhalers, and a reminder for regular use; the signs and symptoms sheets were informative and improved self-efficacy; 93% of families were 
using the resources after six months. An increase in ‘everyday’ inhaler use was observed after education. The study authors concluded that 
the resources were effective at improving inhaler knowledge and supporting symptom recognition. They stated that the characteristics of 
their resources, in particular their ‘less-is–more’ approach, pictorial format, and first language availability, may benefit children of other 
ethnicities. 
Crengle S, Robinson E, Grant C, et al. 2011. Pharmacological management of children's asthma in general practice: 
findings from a community-based cross-sectional survey in Auckland, New Zealand. New Zealand Medical Journal, 
124(1346), 44-56. https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2011/vol-124-no-1346/article-
crengle  
While there is some evidence that the prevalence of asthma symptoms is higher in Māori and Pacific children than in European children, 
ethnic differences in prevalence are not believed to be the sole reason for the significantly higher asthma hospitalisation rates of Māori 
children. The aim of this study was to describe the pharmacological management of asthma in New Zealand children and assess whether 
there were ethnic differences in pharmacological management. The study involved a cross-sectional survey of caregivers of asthmatic children 
in Auckland. Children were eligible for the survey if they were aged two to 14 years, and had experienced asthma symptoms in the 12 months 
prior to interview; and they had a doctor diagnosis of asthma or had experienced wheeze or whistling in the chest. The survey sample (n = 
583) included the caregivers of 221 Māori, 173 Pacific, and 189 European/other children. Interviewers collected data on socio-demographic 
variables, and on medications received and medication delivery devices used in the 12 months prior to interview. Descriptive and logistic 
regression analyses were undertaken to investigate ethnic differences in pharmacologic management. There were no ethnic differences in 
spacer use. Eighty per cent of children under seven years of age and 34% of children seven years or over used spacers. Māori (58%) and 
Pacific (65%) were significantly (p<0.0001) more likely to have been given a nebuliser than European/other children (34%). Most children 
(96%) received inhaled beta-agonists and there were no ethnic differences for these medications. Overall, 69% of children had received 
inhaled corticosteroids (ICS) and there were no significant ethnic differences in receipt of these medications, but only 68–78% of children in 
the moderate, severe, and very severe morbidity groups reported inhaled corticosteroids use in the previous 12 months, suggesting that this 
group is being under-treated. Analyses stratified by morbidity suggested that Māori and Pacific children who had experienced severe 
morbidity in the previous 12 months were less likely to have received ICS. The study authors concluded that some aspects of the 
pharmacological management of asthma are more consistent with recommendations in evidence-based guidelines than previously reported 
in NZ, but that there is still room for improvement, particularly with respect to the use of inhaled corticosteroids among children who 
experience significant morbidity, the use of nebulisers, and the use of spacer devices. They stated that asthma outcomes could be further 
improved by implementing clinical quality assurance activities that support PHOs and providers to monitor and improve the delivery of 
evidence-based asthma care. 
Websites 
PHARMAC. 2010. Space to breathe. http://www.spacetobreathe.co.nz/  
This website provides information about asthma and its management for people with asthma, their families and carers, and health 
practitioners. 
The Asthma Foundation http://asthmafoundation.org.nz/ 
The Asthma Foundation website provides information and downloadable resources related to asthma and other respiratory conditions. These 
included booklets, fact sheets, posters and management plans. There is guidance for schools on asthma policy (under the education tab). 
  
 




Bronchiectasis is a lung condition in which the bronchi are distended and often thick-walled. These bronchial 
changes are associated with accumulation of mucus and frequent bacterial infections which can lead to further 
inflammatory destruction of the bronchial tree. Although in adults these changes are permanent there is at least 
the potential for the condition to be reversible in children. Many children with bronchiectasis have a clinical 
history of repeated lower respiratory tract infections.66 The main symptom of bronchiectasis is a persistent wet 
cough lasting for 4 weeks or more that does not respond to antibiotics. Other symptoms that may be present 
include shortness of breath with exercise, recurrent chest infections (even if these do respond to antibiotic 
treatment), growth failure, or abnormalities of the shape of the chest wall of or the fingertips (the clinical sign of 
‘clubbing’).67  
Children with bronchiectasis typically have a preceding history of recurrent chest infections and the condition is 
strongly associated with socioeconomic disadvantage.68 The number of New Zealand children known to have 
bronchiectasis increased almost threefold between 2000 and 2008, and is much higher than the reported 
incidence rates in Finland and the UK. Pacific and Māori children are disproportionately affected by 
bronchiectasis compared with European and other children.69 Prevention of bronchiectasis includes reducing the 
risk of respiratory infections, and also ensuring follow up a few weeks after acute chest infections to enable 
early detection of ongoing disease.70  
The following section reports on deaths and hospitalisations for bronchiectasis in children and young people 
using information from the National Mortality Collection and the National Minimum Dataset. It concludes with 
a brief overview of evidence-based reviews and guidelines which consider the most effective interventions for 
preventing or managing bronchiectasis in children and young people. 
Data sources and methods 
Indicator   
 Deaths from (non-cystic fibrosis) bronchiectasis in 0–24 year olds  
 Hospitalisations for (non-cystic fibrosis) bronchiectasis in 0–24 year olds   
Data sources 
Numerator:  Deaths: National Mortality Collection 
  Hospitalisations: National Minimum Dataset 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years) 
Definition  
Deaths: Deaths of 0–24 year olds where the main underlying cause of death was bronchiectasis (deaths per 100,000 
age-specific population) and excludes records where cystic fibrosis is listed as a contributory cause 
Hospitalisations: Acute and arranged hospitalisations of 0–24 year olds with a primary diagnosis of bronchiectasis 
(hospitalisations per 100,000 age-specific population) and excludes records where cystic fibrosis is listed in 
any of the first 15 diagnoses 
 Acute and arranged hospitalisations of 0–24 year olds with a diagnosis of bronchiectasis (hospitalisations 
per 100,000 age-specific population) in any of the first 15 diagnoses and excludes records where cystic 
fibrosis is listed in any of the first 15 diagnoses. Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: Unless otherwise specified, this analysis focuses on hospitalisations of 0–24 year olds with bronchiectasis listed in any of 
the first 15 diagnoses (rather than on the subset of hospitalisations where bronchiectasis was listed only as the primary 
diagnosis). The rationale for this wider focus is that many 0–24 year olds with bronchiectasis will not be hospitalised for 
bronchiectasis per se, but rather for one of its predisposing conditions or resulting complications. 
Note 2. The rationale for excluding bronchiectasis cases where cystic fibrosis is also documented arises from the differing 
aetiology of cystic fibrosis and non-cystic fibrosis bronchiectasis and also that bronchiectasis typically develops over time in 
people with cystic fibrosis. 
Note 3. An acute hospitalisation is an unplanned hospitalisation occurring on the day of presentation, while an arranged 
hospitalisation (referred to elsewhere in this report as an arranged hospitalisation) is a non-acute hospitalisation with an 
admission date less than seven days after the date the decision was made that the hospitalisation was necessary.  
Note 4. Appendix 3 describes the National Minimum Dataset and outlines the limitations of the data utilised from this data 
collection. The reader is advised to review this before interpreting any trends.  
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National trends and distribution 
In New Zealand from 2008 to 2012 there were six deaths of 0–24 year olds where bronchiectasis was the main 
underlying cause. From 2000 to 2014 the number of hospitalisations of 0–24 year olds with bronchiectasis as a 
primary diagnosis increased from 104 to 262, and for any diagnosis from 296 to 402. There was an overall 
significant rise in hospitalisation rates for bronchiectasis which was more marked for bronchiectasis as a 
primary diagnosis than any diagnosis (Figure 90). Bronchiectasis hospitalisation rates (any diagnosis) increased 
for all ethnic groups from 2000–2014 and this increase was most marked for Māori and Pacific. Rates were 
generally highest for Pacific, and Pacific and Māori rates were consistently higher than Asian/Indian and 
European/Other (Figure 91).  
Figure 90. Hospitalisations for bronchiectasis in 0–24 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions, cystic fibrosis cases excluded); Denominator: Statistics 
NZ Estimated Resident Population; All cases include bronchiectasis listed in any of first 15 diagnoses 
Figure 91. Hospitalisations for bronchiectasis in 0–24 year olds, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions, cystic fibrosis cases excluded); Denominator: Statistics 
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Distribution by demographic factors 
Between 2010 and 2014 bronchiectasis hospitalisation rates were highest for 1–2 year olds and then tended to 
fall slowly with increasing age with the lowest rates in 16–24 year olds (Figure 92). There was disparity in 
bronchiectasis hospitalisation rates (any diagnosis) by NZDep2013 index of deprivation score, ethnicity and age 
between 2010 and 2014. Rates were significantly lower in areas with the lowest deprivation scores (NZDep2013 
deciles 1–2) compared with higher deprivation scores (deciles 3–10). There was a strong gradient in 
bronchiectasis hospitalisation rates with increasing deprivation scores; rates were significantly higher in 
NZDep2013 deciles 9–10 compared with deciles 7–8, and in deciles 7–8 compared with deciles 5–6. Compared 
with European/Other, rates were significantly higher for Māori, Pacific and MELAA with no significant 
difference for Asian/Indian. Bronchiectasis rates in the 0–4 and 5–14 age groups were significantly higher than 
in the 15–24 age group. There was no significant difference between male and female bronchiectasis 
hospitalisation rates (Table 86). Disparities were the same for bronchiectasis as primary diagnosis. 
Figure 92. Hospitalisations for bronchiectasis in 0–24 year olds, by age at discharge, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions, cystic fibrosis cases excluded); Denominator: Statistics 
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Table 86. Hospitalisations for bronchiectasis in 0–24 year olds, New Zealand 2010–2014 
Variable Number: 2010−2014 
Rate per 100,000  
0–24 year olds 
Rate ratio 95% CI 
Bronchiectasis in 0–24 year olds 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 98 6.99 1.00   
Deciles 3–4 122 9.18 1.31 1.01–1.71 
Deciles 5–6 153 10.65 1.52 1.18–1.96 
Deciles 7–8 294 18.15 2.60 2.07–3.26 
Deciles 9–10 938 50.43 7.22 5.86–8.89 
Prioritised ethnicity 
Māori 847 47.51 7.94 6.89–9.15 
Pacific 431 61.50 10.28 8.79–12.0 
Asian/Indian 61 6.50 1.09 0.82–1.44 
MELAA 17 17.33 2.90 1.77–4.74 
European/Other 247 5.98 1.00   
Gender 
Female 746 19.94 1.00   
Male 860 22.00 1.10 1.00–1.22 
Age group (years) 
0–4 433 28.10 2.19 1.91–2.50 
5–14 772 25.84 2.01 1.78–2.27 
15–24 401 12.85 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions, diagnosis listed within the first 15 diagnoses; cystic 
fibrosis cases excluded); Denominator: Statistics NZ Estimated Resident Population; Rates are per 100,000 0–24 year olds; Rate 
ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013  
Distribution by season 
Between 2010 and 2014 bronchiectasis hospitalisation rates were lowest from December to February with no 
other seasonal variation.  
Distribution by region 
Between 2010 and 2014 bronchiectasis hospitalisation rates were significantly higher than the national rate in 
the Northland, Counties Manukau and Lakes DHBs, not significantly different in the Auckland, Waikato, 
Tairawhiti, Hawke's Bay and Whanganui DHBs, and significantly lower in the remaining district health boards 
(Figure 93).  
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Figure 93. Hospitalisations for bronchiectasis in 0–24 year olds, by district health board, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions; diagnosis listed within the first 15 diagnoses); 
Denominator: Statistics NZ Estimated Resident Population; Rates are per 100,000 0–24 year olds  






Rate per 100,000 
0–24 year olds 
Rate ratio 95% CI 
Bronchiectasis in 0–24 year olds 
Northland 158 32 56.87 2.71 2.30–3.19 
Waitemata 199 40 21.06 1.00 0.87–1.16 
Auckland 171 34 21.83 1.04 0.89–1.22 
Counties Manukau 384 77 39.53 1.88 1.68–2.10 
Waikato 163 33 24.05 1.15 0.98–1.35 
Bay of Plenty 53 11 15.04 0.72 0.54–0.94 
Lakes 69 14 37.46 1.78 1.40–2.27 
Tairawhiti 19 4 21.05 1.00 0.64–1.58 
Taranaki 15 3 7.96 0.38 0.23–0.63 
Hawke's Bay 59 12 21.78 1.04 0.80–1.35 
MidCentral 22 4 7.39 0.35 0.23–0.54 
Whanganui 20 4 19.10 0.91 0.59–1.41 
Hutt Valley 43 9 17.51 0.83 0.62–1.13 
Capital & Coast 72 14 14.27 0.68 0.54–0.86 
Wairarapa 5 1 7.60 0.36 0.15–0.87 
Nelson Marlborough 25 5 11.92 0.57 0.38–0.84 
South Canterbury 0 .. .. .. .. 
Canterbury 80 16 9.66 0.46 0.37–0.58 
West Coast 5 1 10.03 0.48 0.20–1.15 
Southern 44 9 8.52 0.41 0.30–0.55 
New Zealand 1,606 321 20.99 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions; diagnosis listed within the first 15 diagnoses); 
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 hospitalisation rates for bronchiectasis were significantly higher than the national rate 
in Lakes DHB, significantly lower in Bay of Plenty and Taranaki DHBs, and not significantly different from the 
national rate in Waikato and Tairawhiti DHBs (Table 88). 






Rate per 100,000 
0–24 year olds 
Rate ratio 95% CI 
Bronchiectasis in 0–24 year olds 
Waikato 163 33 24.05 1.15 0.98–1.35 
Bay of Plenty 53 11 15.04 0.72 0.54–0.94 
Lakes 69 14 37.46 1.78 1.40–2.27 
Tairawhiti 19 4 21.05 1.00 0.64–1.58 
Taranaki 15 3 7.96 0.38 0.23–0.63 
New Zealand 1,606 321 20.99 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions, cystic fibrosis cases excluded); Denominator: Statistics 
NZ Estimated Resident Population; Rates are per 100,000 0–24 year olds; All cases encompasses a diagnosis listed within the 
first 15 diagnoses 
Regional trends 
From 2000 to 2014 bronchiectasis hospitalisations in 0–24 year olds generally fluctuated from year-to-year in 
Waikato, Bay of Plenty, Lakes, Tairawhiti, and Taranaki DHBs. Rates were consistently higher than the national 
rate in Lakes DHB (Figure 94, Figure 95). 




































































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions, cystic fibrosis cases excluded); Denominator: Statistics 
NZ Estimated Resident Population; All cases encompasses bronchiectasis listed in any of first 15 diagnoses 
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Numerator: National Minimum Dataset (acute and arranged admissions, cystic fibrosis cases excluded); Denominator: Statistics 
NZ Estimated Resident Population; All cases encompasses bronchiectasis listed in any of first 15 diagnoses 
Evidence for good practice for the prevention and management of 
bronchiectasis 
New Zealand guidelines 
Edwards E. 2008. Starship Children's Health clinical guideline: Cough - Investigation of chronic cough &/or 
confirmed bronchiectasis. http://www.adhb.govt.nz/starshipclinicalguidelines/_Documents/Cough%20-
%20Investigation%20of%20Chronic.pdf accessed 13 October 2015. 
This clinical guideline lists the important questions to include in the clinical history of a child with chronic cough and algorithms for initial 
and secondary investigations. The electronic version of the guideline is dated 2008, and is the version currently in use. It is a very practical 
and clinically focussed guideline. 
Chang AB, et al. 2015. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and 
New Zealand Thoracic Society of Australia and New Zealand guidelines. 
http://www.thoracic.org.au/imagesDB/wysiwyg/BEposstatement_2014_revised_TSANZ_website_v3_wrFINAL.pdf accessed 
13 October 2015. 
These guidelines cover both bronchiectasis and chronic suppurative lung disease (CSLD) which are overlapping clinical syndromes. The 
recommendations were based on a comprehensive review of evidence available in 2013 and a table summarising the levels of evidence 
is provided (pages 17–21). Chest high-resolution computed tomography scan (c-HRCT) remains the diagnostic gold standard, preferably 
reconstructed from a multi-detector (MDCT) scan as this is substantially more likely to detect bronchiectasis if present. Specialist advice 
should be sought before ordering c-HRCT for children, for whom specific protocols are required to ensure the lowest possible radiation 
exposure to obtain adequate assessment. Recommended baseline investigations include a sweat test in all children to see if cystic fibrosis 
is an underlying cause. Antibiotic treatment to reduce bacterial load has a central role in management of bronchiectasis and CSLD, and 
choice of antibiotic should be based on outcomes of investigations together with knowledge about local patterns of antimicrobial 
sensitivity and resistance. Long-term antibiotics should not be prescribed routinely, but may be indicated in selected patients. Regular 
exercise, optimal nutrition and eliminating exposure to environmental tobacco smoke are all important in management, together with 
vaccinations according to the National Immunisation Schedule as well as timely annual influenza vaccine. The aim of management is to 
optimise general wellbeing, maintain good symptom control, optimise lung function and quality of life, reduce the frequency of 
exacerbations and prevent excessive decline in lung function.  
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International guidelines 
M C Pasteur, et al. 2010. British Thoracic Society guideline for non-CF bronchiectasis. Thorax, 65(Supplement 1), i1-
i58. 
The British Thoracic Society guideline for non-CF bronchiectasis has been accredited by the National Institute for Health and Care 
Excellence (NICE) in the UK. The purpose of the guideline is to identify relevant studies in non-cystic fibrosis bronchiectasis and provide 
management guidelines based on published studies where possible or a consensus view, as well as to identify gaps in knowledge and 
identify areas for future study. The guideline covers all ages, and has specific reference to children including the importance of 
investigating chronic cough in children, considering an underlying immune deficiency when bronchiectasis is diagnosed, indications for 
bronchoscopy (when bronchiectasis affects a single lobe of the lung to exclude a foreign body), clinical features suggesting possible 
underlying cystic fibrosis or allergic bronchopulmonary aspergillosis (persistent isolation of Staphylococcus aureus and/or Pseudomonas 
aeruginosa), the importance of normal growth and development as management goals for children with bronchiectasis, recommendation 
for all children with bronchiectasis to be followed up by secondary care services, and specific antibiotic regimes for children with 
Pseudomonas aeruginosa or MRSA infection or infection with pathogens with multiple resistant patterns.  
Hill AT, et al. 2011. Primary care summary of the British Thoracic Society Guideline on the management of non-
cystic fibrosis bronchiectasis. Primary Care Respiratory Journal, 20, 135. 
This paper summarises the key recommendations from the British Thoracic Society (BTS) guideline for non-cystic fibrosis bronchiectasis 
that are relevant to primary care. In particular the possibility of bronchiectasis in children who present with a chronic, productive cough 
or with asthma which responds poorly to treatment, incomplete resolution of a severe pneumonia, or recurrent pneumonia, pertussis-
like illness failing to resolve after six months, persistent and unexplained respiratory clinical signs or symptoms especially in children with 
structural or functional disorders of the oesophagus and upper respiratory tract or unexplained haemoptysis. The paper also highlights 
specific advice from the BTS about antibiotic use in primary care and criteria for admission to hospital. 
Evidence-Based Medicine Reviews 
Al Subie H & Fitzgerald DA. 2012. Non-cystic fibrosis bronchiectasis. Journal of Paediatrics and Child Health, 48(5), 
382-88. 
The authors provide a detailed summary of the definition, epidemiology, aetiology, clinical presentation, investigation and treatment of 
bronchiectasis in children with reference to their clinical experience in Australia. A recurrent chest infection was the most common reason 
that children found to have bronchiectasis were referred to a specialist service (77% of children with bronchiectasis); other common 
reasons for referral were chronic cough (35%) and recurrent wheeze (10%). The key practice points in this article are that chronic or 
recurrent wet cough must not be ignored, that chest radiograph is not sensitive in diagnosing early bronchiectasis and high-resolution 
CT scan is required, that it is worthwhile to distinguish between generalised suppurative lung disease (SLD), which may indicate an 
underlying abnormality such as primary ciliary dyskinesia or cystic fibrosis, and localised SLD which is more suggestive of an inhaled 
foreign body or congenital malformation of the airway, and the importance of looking for the clinical sign of clubbing of the fingers which 
is a frequent early sign of SLD.  
Welsh Emma J, et al. 2015. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane 
Database of Systematic Reviews doi:10.1002/14651858.CD010337.pub2 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010337.pub2/pdf 
A review of Cochrane reviews to provide an overview of evidence about interventions for adults and children with non-cystic fibrosis 
bronchiectasis. Data were extracted from nine reviews, which covered 40 trials. Only three trials included children. All reviews were high 
quality, but the trials themselves were often small and not of high quality. The authors looked at all interventions and categorised them 
as pharmacological or non-pharmacological. Primary outcomes were frequency or duration of exacerbations, measured lung function 
and quality of life using validated measures, with a range of secondary outcomes. Airway clearance techniques showed a statistically 
significant benefit in forced expiratory volume for children. Long-term antibiotics were associated with significantly lower sputum 
leukocyte and purulence scores and with significantly reduced sputum volume in small paediatric trials. Macrolide maintenance therapy 
was effective and safe in reducing bronchiectasis exacerbations for children and adults, but did not reduce the need for hospitalisation 
when exacerbations occurred. There were no studies on the effectiveness of mucolytics for children with bronchiectasis. Long-term 
antibiotics, inhaled corticosteroids and mucolytics are priority clinical areas for research to improve outcomes for people, particularly for 
children, with bronchiectasis. It is important that standardised endpoints are used in future research including measurement of 
exacerbations, quality of life and lung function.  
Other relevant publications 
Munro KA, et al. 2011. Do New Zealand children with non-cystic fibrosis bronchiectasis show disease progression? 
Pediatr Pulmonol, 46(2), 131-8. 
This case series reviewed the electronic clinical records of 91 children on the bronchiectasis database at Starship Children’s Health, 
Auckland, who had been followed for at least five years since diagnosis. Six of the children died either from bronchiectasis (2) or co-
morbidities (4). There was a ‘did not attend’ rate of 28% for the cohort. The main finding was that almost half (45%) had declining lung 
function over time despite follow-up in a tertiary level hospital respiratory clinic. Rapid decline in lung function was associated with female 
gender, Māori ethnicity, living in an area with a high NZDep score, and physical deformities of the fingers (clubbing) or chest wall. 
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Singleton RJ, et al. 2014. Indigenous children from three countries with non-cystic fibrosis chronic suppurative 
lung disease/bronchiectasis. Pediatr Pulmonol, 49(2), 189-200. 
180 Australian Aboriginal and Torres Strait Islander, Alaska Native, NZ Māori and NZ Pacific children aged 0.5–8 years with CSLD or 
bronchiectasis were recruited to a case series observational study with up to five years of follow-up. Household crowding and high levels 
of exposure to environmental tobacco smoke were evident in all groups. A high proportion of study children were born at less than 36 
weeks gestation and all children had at least one previous acute lower respiratory infection (ALRI) (91% had been hospitalised) with a 
median of 10 previous infections and some children with more than 40. The children were very young at the time of their ALRI (median 
age 3.7 months) and had a median of four ALRIs in the first year of life. The authors conclude that measures to prevent premature birth 
and to reduce ALRIs are important equity issues to reduce bronchiectasis in indigenous children.  
Valery PC, et al. 2013. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or 
chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised 
controlled trial. Lancet Respir Med, 1(8), 610-20. 
Between 2008 and 2010 the researchers enrolled 89 Indigenous Australian, Māori and Pacific children aged 1–8 years with either 
bronchiectasis or chronic suppurative lung disease into a multi-centre, double-blind, randomised, parallel group, placebo-controlled 
comparing azithromycin (30 mg/kg) or placebo once a week for 12-24 months (mean treatment duration 20.7 months standard deviation 
5.7 months). Children receiving azithromycin had significantly lower exacerbation rates (incidence rate ratio 0·50; 95% CI 0·35–0·71; 
p<0·0001) and the study drugs were well tolerated with no serious adverse events being attributed to the intervention. There needs to 
be further investigation to determine the clinical consequences of the observation that children in the azithromycin group developed 
significantly higher carriage of azithromycin-resistant bacteria (19 of 41, 46%) than those receiving placebo (four of 37, 11%; p=0·002).  
Websites 
Ministry of Health. 2015. Bronchiectasis. http://www.health.govt.nz/your-health/conditions-and-treatments/diseases-
and-illnesses/bronchiectasis accessed 13 October 2015.  
This website provides patient- and family-centred information about bronchiectasis. Key points are the importance of seeking medical 
attention for coughs that won’t go away, having a management plan for bronchiectasis, eligibility for free influenza vaccination and the 
importance of a smokefree home and regular exercise for children with bronchiectasis. Actions tō prevent bronchiectasis include smoking 
cessation during pregnancy, breastfeeding, healthy balanced diet, warm and dry housing and childhood immunisation. 
Kidshealth. 2014. Bronchiectasis. http://www.kidshealth.org.nz/bronchiectasis-bx accessed 13 October 2015. 
This website provides information about bronchiectasis and detail about commonly-used diagnostic tests, types of treatment, and what 
to expect at outpatient appointments and if a child is admitted to hospital with bronchiectasis. 
Health Navigator New Zealand. 2015. Bronchiectasis. http://www.healthnavigator.org.nz/health-topics/bronchiectasis/ 
accessed 13 October 2015. 
The Health Navigator NZ website helps patients and parents find reliable health information and self-help resources. There are also links 

















Pertussis (whooping cough) is a highly contagious acute respiratory tract infection caused by the bacterium 
Bordetella pertussis. It is spread by aerosol droplets. “Classic” pertussis follows an incubation period of a few 
days to a few weeks and is recognised as having three stages: a catarrhal stage with a runny nose and sneezing 
(1–2 weeks), a paroxysmal stage (2–6 weeks) in which prolonged bursts of uninterrupted coughing are followed 
by a characteristic inspiratory whoop, and a convalescent stage (≥ 2 weeks). Young infants in their first few 
months of life, who make up more than 90% of the fatalities from pertussis, do not display the classic stages and 
initially apnoea and cyanosis may be the only signs of the disease. Young infants suspected of having pertussis 
need hospitalisation and the most severely affected can require intubation, drug-induced paralysis and 
ventilation.71 
Routine pertussis vaccination began in New Zealand in 1960 and the current schedule recommends vaccination 
at six weeks, three months, and five months of age with booster doses at four years and 11 years, and during 
pregnancy at 28 to 38 weeks’ gestation.57 Neither vaccination nor natural disease provides complete or lifelong 
immunity.71 Immunity wanes over time, and Bordetella pertussis is endemic in the older child and adult 
population so there is always the potential for an incompletely vaccinated infant to be infected by an older 
person who may not have any symptoms other than a persistent cough and may not be especially unwell.57 The 
fact that neither natural infection nor vaccination provides long term immunity is the reason why pertussis 
epidemics continue to recur in two to five-yearly epidemic cycles, just as they did before routine immunisation. 
Now, despite these recurrences, there are much lower rates of disease. New Zealand had a pertussis epidemic 
from 2011 to 2014 with several hundred infant hospitalisations and three deaths.72 
Besides improving coverage and timeliness of infant vaccination, which is the most important strategy, the 
Global Pertussis Initiative recommends universal preschool booster doses, universal adolescent immunisation, 
universal adult immunisation, selective immunisation of new mothers, family, and close contacts of newborns 
(the “cocoon strategy”), selective immunisation of healthcare workers, and selective immunisation of childcare 
workers.73,74 
The following section reviews pertussis rates in infants aged less than one year using information from the 
National Minimum Dataset and Mortality Collection. The section concludes with a brief overview of policy and 
evidence-based review documents which consider interventions to reduce pertussis at the population level.  
Data sources and methods 
Indicators 
 Deaths from pertussis in infants 
Hospitalisations for pertussis in infants 
Data sources 
Numerator:  Deaths:  National Mortality Collection 
Hospitalisations: National Minimum Dataset  
Denominator:  Birth Registration Dataset 
Definition 
Pertussis or whooping cough was used to identify hospitalisations and deaths. This includes: 
 Whooping cough due to Bordetella pertussis 
 Whooping cough due to Bordetella parapertussis 
 Whooping cough due to other Bordetella species 
 Whooping cough, unspecified 
Deaths: Deaths of infants (up to one year old) where the main underlying cause of death was pertussis (per 100,000 
age-specific population) 
Hospitalisations: Acute and arranged hospitalisations of infants (up to one year old) with a primary diagnosis of pertussis 
(per 1,000 age-specific population). Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: An acute hospitalisation is an unplanned hospitalisation occurring on the day of presentation, while an arranged 
hospitalisation (also referred to as aN arranged hospitalisation) is a non-acute hospitalisation with an admission date less than 
seven days after the date the decision was made that the hospitalisation was necessary.  
Note 2: Appendix 3 describes the National Minimum Dataset and outlines the limitations of the data utilised from this 
collection. The reader is advised to review this appendix before interpreting any trends. 
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National trends and distribution 
Between 2000 and 2014, hospitalisations for pertussis in infants fluctuated, with peaks occurring in 2000, 2004 
and 2012. Rates reached their lowest point in 2007, after which rates rose gradually until 2011, increased 
sharply in 2012 and then fell sharply in each of the following two years (Figure 96). During this period 
hospitalisations for pertussis were consistently higher for Pacific and Māori than European/Other (Figure 97). 
Figure 96. Hospitalisations for pertussis in under 1 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset 
Figure 97. Hospitalisations for pertussis in under 1 year olds, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset; Rates are per 
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Distribution by demographic factors 
Between 2010 and 2014 hospitalisation rates for pertussis were highest in infants aged one and two months. 
Rates then declined rapidly with increasing age (Figure 98). 
During the same period, hospitalisation rates for pertussis were significantly lower for infants in areas with the 
lowest NZDep2013 scores (NZDep2013 deciles 1–2) compared with areas with higher scores (deciles 3–10). 
Rates were significantly higher for Pacific and Māori and significantly lower for Asian/Indian compared with 
European/Other, whereas rates for MELAA were not significantly different. There was no significant difference 
by gender (Table 89).  
Figure 98. Hospitalisations for pertussis in 0–24 year olds, by age, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominators: under 1 year: Birth registration Dataset; 
1–24 years: Statistics NZ Estimated Resident Population 




Rate per 1,000 under 
one year olds 
Rate ratio 95% CI 
Pertussis in under 1 year olds 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 37 0.82 1.00   
Deciles 3–4 72 1.45 1.77 1.19–2.63 
Deciles 5–6 107 1.90 2.31 1.59–3.36 
Deciles 7–8 169 2.51 3.05 2.14–4.36 
Deciles 9–10 352 4.03 4.91 3.50–6.88 
Prioritised ethnicity 
Māori 318 3.59 2.09 1.77–2.47 
Pacific 151 4.44 2.58 2.11–3.17 
Asian/Indian 23 0.55 0.32 0.21–0.49 
MELAA 10 1.84 1.07 0.57–2.02 
European/Other 236 1.72 1.00   
Gender 
Female 379 2.54 1.00   
Male 359 2.28 0.90 0.78–1.04 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset; Rates are per 


































































Common communicable diseases: Pertussis 
206 
Distribution by season 
Between 2010 and 2014 there were slightly more hospitalisations for pertussis in infants aged under one year 
during the last four months of the year (Figure 99). 
Figure 99. Average number of hospitalisations for pertussis in under 1 year olds, by month, New Zealand 2010–
2014 
 
National Minimum Dataset (acute and arranged admissions); Number is annual average 
Distribution by region 
In Counties Manukau, Tairawhiti, Hawke’s Bay, and Whanganui during 2010–2014, hospitalisations for 
pertussis in infants were significantly higher than the national rate, while in Waitemata, Auckland, and Taranaki, 
rates were significantly lower. While rates in a number of other DHBs also differed from the national rate, in no 
other cases did these differences reach statistical significance (Figure 100, Table 90). 
Figure 100. Under one year olds hospitalised for pertussis, by district health board, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset; Rates 
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Rate per 1,000 
under one year 
olds 
Rate ratio 95% CI 
Pertussis in under one year olds 
Northland 29 6 2.54 1.06 0.73–1.53 
Waitemata 60 12 1.52 0.63 0.49–0.82 
Auckland 53 11 1.65 0.69 0.52–0.91 
Counties Manukau 159 32 3.73 1.55 1.31–1.84 
Waikato 53 11 1.96 0.81 0.62–1.07 
Bay of Plenty 42 8 2.91 1.21 0.89–1.65 
Lakes 24 5 3.18 1.32 0.88–1.99 
Tairawhiti 27 5 7.36 3.06 2.09–4.49 
Taranaki 7 1 0.90 0.37 0.18–0.79 
Hawke's Bay 38 8 3.39 1.41 1.02–1.95 
MidCentral 22 4 1.97 0.82 0.54–1.25 
Whanganui 28 6 6.59 2.74 1.88–3.99 
Hutt Valley 19 4 1.91 0.79 0.50–1.25 
Capital & Coast 34 7 1.80 0.75 0.53–1.05 
Wairarapa <5 s s s s 
Nelson Marlborough 18 4 2.27 0.95 0.59–1.51 
South Canterbury <5 s s s s 
Canterbury 77 15 2.50 1.04 0.82–1.32 
West Coast <5 s s s s 
Southern 40 8 2.24 0.93 0.68–1.28 
New Zealand 738 148 2.40 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset; s: suppressed 
due to small numbers 
Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 hospitalisation rates for pertussis in infants less than one year old were significantly 
higher than the national rate in the Tairawhiti DHB and not significantly different from the national rate in 
Waikato, Bay of Plenty, Lakes DHB, and Taranaki DHBs (Table 91). 






Rate per 1,000 
under 1 year olds 
Rate ratio 95% CI 
Pertussis in under 1 year olds 
Waikato 53 11 1.96 0.81 0.62–1.07 
Bay of Plenty 42 8 2.91 1.21 0.89–1.65 
Lakes 24 5 3.18 1.32 0.88–1.99 
Tairawhiti 27 5 7.36 3.06 2.09–4.49 
Taranaki 7 1 0.90 0.37 0.18–0.79 
New Zealand 738 148 2.40 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset 
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Regional trends 
In the Midland DHBs, from 2000 to 2014 the pattern of hospitalisation for pertussis in infants aged less than one 
year was similar to that of the national rates, with peaks in 2000, 2003–2004 and 2012–2013. There was 
considerable year-to-year variation in hospitalisation rates (Figure 101, Figure 102). 
























































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset 




























































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Birth Registration Dataset 
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Evidence for good practice for the prevention and management of 
pertussis 
Ministry of Health documents 
Ministry of Health. 2014. Immunisation Handbook 2014. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/immunisation-handbook-2014 
Chapter 14 of this handbook provides key information on pertussis, its clinical features and epidemiology, the available vaccines, the 
immunisation schedule, contraindications and precautions, expected responses and adverse events, and public health measures. The 
immunisation schedule specifies a primary course of pertussis vaccine given as DTaP-IPV-HepB/Hib (Infanrix-hexa) at ages 6 weeks, 3 months 
and 5 months, followed by a dose of DTaP-IPV (Infanrix-IPV) at age 4 years. A further booster is given at age 11 years (school year 7) as Tdap 
(Boostrix). Pregnant women should receive a dose of Tdap (funded) from 28 to 38 weeks’ gestation. This should be given during each pregnancy. 
Combined tetanus, diphtheria and pertussis immunisation is recommended, but not funded for lead maternity carers and other health care 
workers who work in neonatal units or are exposed to infants, household contacts of newborns including older siblings (for whom update 
vaccines are funded) and mothers shortly after delivery, and early childhood workers. A ten yearly booster dose is recommended for those with 
on-going contact with infants. 
Ministry of Health. 2012. Communicable Disease Control Manual. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/communicable-disease-control-manual-2012 
Pertussis is a notifiable disease. This manual sets out the standard practice that public health services would normally follow in regard to the 
prevention and control of notifiable diseases. The chapter on pertussis covers epidemiology, case definition, laboratory testing, notification, 
management of cases and contacts, other control measures, and reporting. The references include guidelines from other countries, including 
the US, the UK and Australia. 
Ministry of Health. 2007. Direct Laboratory Notification of Communicable Diseases National Guidelines. Wellington: 
Ministry of Health. http://www.health.govt.nz/publication/direct-laboratory-notification-communicable-diseases-national-
guidelines  
The purpose of these guidelines is to inform those working in the health sector, so that they can fulfil their legislative requirements under 
Section 74AA of the Health Act 1956 with respect to notifying a Medical Officer of Health (and a territorial authority for some conditions) when 
a notifiable disease case is suspected and when it is confirmed by laboratory testing. Many of the infectious diseases covered in this report are 
notifiable diseases including acute gastroenteritis (in some situations only), meningitis, vaccine preventable diseases (including pertussis), 
tuberculosis and rheumatic fever. 
Evidence-based medicine reviews 
Zhang L, Prietsch Sílvio OM, Axelsson I, et al. 2014. Acellular vaccines for preventing whooping cough in children. 
Cochrane Database of Systematic Reviews (9) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001478.pub6/abstract  
The first pertussis vaccines were made from killed whole pertussis bacteria. Concerns about the possible association of these vaccines with 
neurological disorders led to the development of acellular vaccines which contain up to five Bordetella pertussis antigens. These vaccines were 
developed in the 1970s and widely used and tested in Japan in the 1980s.This updated review included six efficacy trials (46,283 participants) 
and 52 safety trials (136,541 participants) of acellular pertussis vaccines. Multi-component vaccines (≥ 3 antigens) had efficacy ranging from 
84% to 85% in preventing typical whooping cough and 71% to 78% in preventing mild pertussis disease. One and two-component vaccines 
had efficacy ranging from 59% to 75% against typical whooping cough and 41% to 58% against mild pertussis disease. The review authors 
concluded that multi-component acellular vaccines are more effective than low-efficacy whole cell vaccines but may be less effective than high 
efficacy whole cell vaccines. However acellular vaccines were followed by significantly fewer local and systemic adverse events than whole cell 
vaccines both for the primary series and the booster doses. 
Wang K, Bettiol S, Thompson Matthew J, et al. 2014. Symptomatic treatment of the cough in whooping cough. Cochrane 
Database of Systematic Reviews (9) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003257.pub5/abstract 
A characteristic feature of whooping cough is coughing paroxysms that may last for over a minute and be followed by gasping for air that 
produces the classic inspiratory whoop. Much of the morbidity associated with pertussis is due to the effects of the paroxysmal cough. This 
review aimed to assess the efficacy and safety of interventions to reduce the severity of paroxysmal cough in whooping cough in children and 
adults. Studies were eligible for inclusion if they were RCTs or quasi-RCTs of any intervention (excluding antibiotics and vaccines) for cough 
suppression. Twelve trials were included, with a total of 578 participants. Trial sample sizes ranged from nine to 135. Ten trials (448 participants) 
involved children and two (130 participants) adolescents and adults. Only three trials were considered to be of high methodological quality 
(one trial each of diphenhydramine, pertussis immunoglobulin and montelukast). The trials in the review did not show a statistically significant 
benefit for any of the interventions. The review authors concluded that there was insufficient evidence to draw any conclusions about the 
effectiveness of interventions for the cough in whooping cough. They stated that more high quality trials are needed. 
Bar-On Edna S, Goldberg E, Hellmann S, et al. 2012. Combined DTP-HBV-HIB vaccine versus separately administered 
DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus 
influenzae B (HIB). Cochrane Database of Systematic Reviews (4) 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005530.pub3/abstract 
Combining childhood vaccines reduces the number of visits and injections, and patient discomfort, thus increasing compliance and optimising 
disease prevention. This review compared the effectiveness of combined DTP-HBV-HIV vaccines with separate DTP-HBV and HIB vaccinations. 
The reviewers did not identify any studies providing data on the prevention of disease i.e. the incidence of diphtheria, tetanus, pertussis and H. 
influenzae type B after vaccination. The 20 included RCTs or quasi-randomised clinical trials compared vaccination with combined DTP-HBV-
HIB vaccine (with or without polio vaccine) with separate DTP-HBV and HIB vaccinations and assessed the outcomes immunogenicity (5874 
participants) and reactogenicity (adverse events, 5232 participants). There were no significant differences found in immunogenicity for pertussis, 
diphtheria, polio and tetanus but two studies found less immunologic response for HBV and HIB after the combined vaccines. Serious adverse 
events were comparable (mainly hospitalisation and acute bronchiolitis). Minor adverse events were more common after the combined vaccine. 
The authors stated that the studies’ results were inconclusive due to uncertain risk of bias and studies not using intention-to-treat analysis and 
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therefore they were unable to conclude that the responses elicited by the combined vaccines were either different from, or equivalent to, those 
elicited by the separate vaccines. They stated that studies addressing clinical end points whenever possible, using correct methodology and a 
large enough sample size, should be conducted. 
Altunaiji Sultan M, Kukuruzovic Renata H, Curtis Nigel C, et al. 2007. Antibiotics for whooping cough (pertussis). Cochrane 
Database of Systematic Reviews (3) http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004404.pub3/abstract 
It is commonly recommended that people with whooping cough and their contacts take erythromycin for 14 days but this regimen is often 
unpopular with patients due to gastrointestinal side effects. This review aimed to assess the risks and benefits of antibiotic treatment of 
whooping cough, and contact prophylaxis against whooping cough, in children and adults. Thirteen trials (RCTs and quasi-RCTs) of variable 
quality were included, with 2197 participants in total. Eleven trials investigated treatment regimens and two investigated prophylaxis regimens. 
Ten of the treatment studies compared one antibiotic with another and one compared antibiotics vs. no treatment. The two prophylaxis studies 
compared antibiotics with placebo. Results from the treatment studies indicated that, for eradicating Bordetella pertussis (B. pertussis) from the 
nasopharynx, short-term antibiotics (azithromycin for three to five days, or clarithromycin or erythromycin for seven days) were as effective as 
long-term (erythromycin for 10 to 14 days) (risk ratio (RR) 1.01; 95% CI 0.98 to 1.04), but had fewer side effects (RR 0.66; 95% CI 0.52 to 0.83). 
Trimethoprim/sulphamethoxazole for seven days was also effective. There were no differences between short and long term antibiotics in 
clinical outcomes or microbiological relapse, When used to prevent infection in contacts older than six months of age, antibiotics did not 
significantly improve clinical symptoms, nor reduce the number of people developing culture-positive B. pertussis. Antibiotics had side effects. 
These varied between antibiotics. In their conclusions, the review authors stated that, although antibiotics were effective in eliminating B. 
pertussis, they did not make any difference to the subsequent clinical course of the illness. They reported that there was insufficient evidence 
to determine the benefits of prophylactic antibiotics for pertussis contacts. They cautioned that the review’s conclusions were based on a limited 
number of trials, some of which had small numbers of participants. 
Other relevant publications 
Kiedrzynski T, Bissielo A, Suryaprakash M, et al. 2015. Whooping cough-where are we now? A review. N Z Med J 128(1416) 
21-7 https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2015/vol-128-no-1416/6559  
This paper describes the recent trends in pertussis and vaccine uptake in New Zealand, based on analysis of notifications and immunisation 
registration data since 2011. It notes that, despite having >90% immunisation coverage at 12 months, New Zealand experienced a large 
pertussis epidemic from 2011 to 2014 with several hundred infant hospitalisations and three deaths. It highlights the current risk for infants in 
the first months after birth and the crucial role a pertussis booster in pregnancy could play. It also aims to show that protection of infants by 
the current vaccine can be improved by timely immunisation even in a situation of improving overall uptake rates that are nearing the national 
target of 95%. It states that pertussis vaccination should be offered to all mothers between 28 and 38 weeks of pregnancy and that further 
improvements are still possible in coverage at 6 months, particularly in Māori and but also in Pacific populations, and in more deprived 
populations.  
Lugnér AK, van der Maas N, van Boven M, et al. 2013. Cost-effectiveness of targeted vaccination to protect new-borns 
against pertussis: Comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine 31(46) 5392-97 
Pertussis disease is a severe disease in infants aged less than six months, who are too young to have received any or all of their vaccinations. 
Strategies to protect neonates include vaccinating neonates, vaccinating their mothers directly after birth (cocooning), or vaccinating the mother 
during pregnancy (maternal vaccination). This paper reports on a study which investigated the cost-effectiveness of these three strategies in 
the Netherlands. Costs for health care utilisation and productivity losses, as well as impact on quality of life were calculated for a 10-year 
vaccination programme, assuming that vaccine-induced immunity lasts 5 years. Cocooning was the most cost-effective strategy, costing €89,000 
per QALY, followed by maternal vaccination (€126,000 per QALY) then neonatal vaccination (€318,000 per QALY); however none of these 
strategies would be cost-effective when judged by (unofficial) thresholds for cost-effectiveness of preventive health interventions in the 
Netherlands (€20,000–€50,000/QALY). 
Philipson K, Goodyear-Smith F, Grant CC, et al. 2013. When is acute persistent cough in school-age children and adults 
whooping cough? A prospective case series study. Br J Gen Pract 63(613) e573-9. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722834/ 
Most patients with pertussis infection presenting in primary care have been vaccinated, therefore their signs and symptoms are subtle and it is 
difficult for clinicians to distinguish pertussis from other causes of acute persistent cough. This paper reports on a study conducted in Auckland 
which aimed to estimate the proportion of school-aged children and adults <50 years of age identified in general practice with acute persistent 
cough who had recent infection with B. pertussis and to determine whether there are symptoms that predict B. pertussis infection. The study 
used an oral fluid-based assay (measurement of IgG antibodies to pertussis toxin) as the diagnostic test for B. pertussis infection, and so a 
secondary aim of the study was to demonstrate the applicability of this test to the primary care setting. In total 226 participants were enrolled: 
70 children aged 5–16 years (31%) and 156 adults (69%). Oral fluid samples were obtained from 225 participants. Ten per cent (23/225) had 
recent B. pertussis infection: a greater proportion of children than adults (17% versus 7%, P = 0.003). Neither cough duration nor any individual 
symptom discriminated between those with and without recent B. pertussis infection. They study authors concluded that pertussis is a common 
cause of acute persistent cough in primary care and that distinguishing pertussis from other causes of acute persistent cough is clinically 
difficult. They stated that an oral fluid based diagnostic test, which is less invasive than other diagnostic approaches (e.g. blood sampling), has 
high acceptability in primary care. 
Websites 
The Institute of Environmental Science and Research Ltd (ESR). 2015. Pertussis report. 
https://surv.esr.cri.nz/surveillance/PertussisRpt.phps  
These reports include information on the descriptive epidemiology of pertussis cases reported in New Zealand. Pertussis is a notifiable disease 
in New Zealand and these reports use data available from EpiSurv, the national notifiable disease database. 
Auckland Regional Public Health Service. Pertussis (Whooping cough) http://www.arphs.govt.nz/health-
information/communicable-disease/pertussis-whooping-cough#.VdVbcPmqpBc 
This website has a variety of useful information and resources relating to pertussis, including advice for health professionals, information for 
cases and contacts, information for schools and early childhood centres, posters, and video and audio recordings. 
 




Neisseria meningitis bacteria can cause a serious invasive disease that begins suddenly as a flu-like illness and 
rapidly progresses to potentially fatal septicaemia and in severe cases to shock and multi-organ failure. Children 
with meningococcal disease typically experience acute fever, malaise, nausea, myalgia, arthralgia and 
prostration with a rash in about two-thirds of cases. Infants present with less-specific features.75 There are 
several serogroups of meningococci; groups B and C are the important types seen in children and young adults 
in New Zealand.57  
Highest age-specific rates of meningococcal disease are seen in infants aged under one year and children aged 
one to four years with a secondary peak in notification rates at age 15–19 years. Infection rates are consistently 
higher for Māori and for Pacific people, with the highest rates of all observed in Māori infants aged under one 
year.57 About 15% of the New Zealand population carry N. meningitidis in the nasopharynx without any 
outward symptoms. The events that cause invasive meningococcal disease are poorly understood but include a 
combination of factors related to the organism, the susceptible child and the external environment. There tends 
to be a seasonal pattern with more cases in winter and spring.75 Early detection and prompt follow-up of 
contacts with antibiotics to reduce nasopharyngeal carriage of N. meningitidis are key components of control of 
meningococcal disease. Living in crowded dwellings and exposure to environmental tobacco smoke are also risk 
factors and can be addressed through social planning and effective health promotion.76 
The following section reports on deaths and hospitalisations for meningococcal disease in children and young 
people using information from the National Mortality Collection and the National Minimum Dataset. It 
concludes with a brief overview of evidence-based reviews and guidelines which consider the most effective 
interventions for preventing or managing this condition in children and young people. 
Data sources and methods 
Indicator 
Deaths from meningococcal disease in 0–24 year olds  
Hospitalisations for meningococcal disease in 0–24 year olds  
Data sources 
Numerator:  
 Deaths:   National Mortality Collection 
 Hospitalisations:  National Minimum Dataset 
Denominator:   Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years) 
Definition 
Meningococcal disease includes: meningococcal meningitis; Waterhouse-Friderichsen syndrome; acute meningococcaemia; 
chronic meningococcaemia; meningococcaemia unspecified; meningococcal heart disease; other meningococcal infections; and 
meningococcal infection unspecified 
Deaths: Deaths of 0–24 year olds with where the main underlying cause of death was meningococcal disease (deaths per 
100,000 age-specific population) 
Hospitalisations: Acute and arranged hospitalisations of 0–24 year olds with a primary diagnosis of meningococcal disease 
(hospitalisations per 100,000 age-specific population) 
Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: While in the datasets used it was not possible to break down the cases identified by strain, it was likely that a mix of 
group B and C strains predominated. The ESR review of meningococcal disease notifications during 2011 found that of the 100 
notified cases where the strain type was identified (92.6% of all notifications), 37.0% were group B:P1.7-2,4 and 27.0% were 
group C:P1.5-1,10-8.77 
Note 2: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
(also referred to as an arranged admission) is a non-acute hospitalisation with an admission date less than seven days after the 
date the decision was made that the hospitalisation was necessary. 
Note 3: Appendix 3 outlines the limitations of the data utilised from the National Minimum Dataset. The reader is advised to 
review this appendix before interpreting any trends. 
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National trends and distribution 
From 2008 to 2012 there were 28 deaths of 0–24 year olds with meningococcal disease as the underlying cause. 
The death rate varied from year to year (Figure 103). From 2000 to 2014 the hospitalisation rate for 
meningococcal disease in 0–24 year olds declined rapidly during the early-mid 2000s, and continued to decline 
overall, albeit at a much slower rate, over subsequent years (Figure 104). Rates for all ethnic groups fell over 
the period and ethnic differences reduced considerably as Pacific and Māori rates fell to a greater degree than 
European rates (Figure 105). 
Figure 103. Deaths due to meningococcal disease in 0–24 year olds, New Zealand 2000–2012 
 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Numbers of deaths are per 
two year period, with the exception of 2012; * 2012 is a single year  
Figure 104. Hospitalisations for meningococcal disease in 0–24 year olds, New Zealand 2000–2014 
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Figure 105. Hospitalisations for meningococcal disease in 0–24 year olds, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Asian/Indian rates suppressed due to small numbers 
Distribution by demographic factors 
Between 2010 and 2014 hospitalisations rates for meningococcal disease were highest in infants under one year, 
and next highest in one year olds. Rates in other age groups were much lower (Figure 106). Rates for 
meningococcal disease were significantly higher for 0–4 year olds compared with 15–24 year olds, for Pacific 
and Māori compared with European/Other, and for those living in areas with higher deprivation scores 
(NZDep2013 deciles 3–10) compared with those in deciles 1–2 (Table 92). 
Figure 106. Hospitalisations for meningococcal disease in 0–24 year olds, by age at discharge, New Zealand 2010–
2014 
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Rate per 100,000  
0–24 year olds 
Rate ratio 95% CI 
Meningococcal disease in 0–24 year olds 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 23 1.64 1.00   
Deciles 3–4 41 3.08 1.88 1.13–3.13 
Deciles 5–6 55 3.83 2.33 1.43–3.80 
Deciles 7–8 66 4.07 2.48 1.55–3.99 
Deciles 9–10 159 8.55 5.21 3.37–8.07 
Prioritised ethnicity 
Māori 160 8.97 3.04 2.40–3.85 
Pacific 54 7.71 2.61 1.89–3.59 
Asian/Indian 7 0.75 0.25 0.12–0.54 
MELAA <5 s s s 
European/Other 122 2.95 1.00   
Gender 
Female 164 4.38 1.00   
Male 182 4.66 1.06 0.86–1.31 
Age group (years) 
0–4 210 13.63 5.52 4.25–7.17 
5–14 59 1.97 0.80 0.57–1.12 
15–24 77 2.47 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rates are per 100,000 0–24 year olds; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
Distribution by season 
There was seasonal variation in meningococcal hospitalisation rates, particularly for 0–14 year olds. The highest 
rates were observed in June–September and the lowest rates in January–February (Figure 107).  
Figure 107. Average number of hospitalisations for meningococcal disease in 0–24 year olds, by admission month, 
New Zealand 2010–2014 
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Distribution by region 
Between 2010 and 2014 hospitalisation rates for meningococcal disease were significantly higher than the 
national rate in Northland DHB, while rates in the Auckland and Nelson Marlborough DHBs were significantly 
lower. In remaining district health boards there was no significant difference from the national rate (Figure 108, 
Table 93). 
Figure 108. Hospitalisations for meningococcal disease in 0–24 year olds, by district health board, New Zealand 
2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rates are per 100,000 0–24 year olds; Rates suppressed due to small numbers for Tairawhiti, Whanganui, Wairarapa, 
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Rate per 100,000 
0–24 year olds 
Rate ratio 95% CI 
Meningococcal disease in 0–24 year olds 
Northland 34 7 12.24 2.71 1.90–3.85 
Waitemata 43 9 4.55 1.01 0.73–1.38 
Auckland 22 4 2.81 0.62 0.40–0.96 
Counties Manukau 41 8 4.22 0.93 0.68–1.29 
Waikato 30 6 4.43 0.98 0.67–1.42 
Bay of Plenty 18 4 5.11 1.13 0.70–1.81 
Lakes 13 3 7.06 1.56 0.90–2.71 
Tairawhiti <5 s s s s 
Taranaki 10 2 5.31 1.17 0.63–2.20 
Hawke's Bay 12 2 4.43 0.98 0.55–1.74 
MidCentral 16 3 5.37 1.19 0.72–1.96 
Whanganui <5 s s s s 
Hutt Valley 17 3 6.92 1.53 0.94–2.49 
Capital & Coast 22 4 4.36 0.96 0.63–1.48 
Wairarapa <5 s s s s 
Nelson Marlborough <5 s s s s 
South Canterbury <5 s s s s 
Canterbury 30 6 3.62 0.80 0.55–1.16 
West Coast <5 s s s s 
Southern 21 4 4.07 0.90 0.58–1.40 
New Zealand 346 69 4.52 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rates are per 100,000 0–24 year olds 
Midland region distribution and trends 
Comparison with New Zealand 
Although the meningococcal hospitalisation rates for the five Midland DHBs were not significantly different 
from the national rate, rates for 0–24 year olds between 2010 and 2014 were higher than the national rate in Bay 
of Plenty, Lakes, and Taranaki, lower in Waikato. The small numbers in Tairawhiti have been suppressed 
(Table 94). 






Rate per 100,000 
0–24 year olds 
Rate ratio 95% CI 
Meningococcal disease in 0–24 year olds 
Waikato 30 6 4.43 0.98 0.67–1.42 
Bay of Plenty 18 4 5.11 1.13 0.70–1.81 
Lakes 13 3 7.06 1.56 0.90–2.71 
Tairawhiti <5 s s s s 
Taranaki 10 2 5.31 1.17 0.63–2.20 
New Zealand 346 69 4.52 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
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Regional trends 
From 2000 to 2014 the hospitalisation rates for meningococcal disease in 0–24 year olds fell in all five Midland 
DHBs, as they did in New Zealand as a whole (Figure 109, Figure 110). 
Figure 109. Hospitalisations for meningococcal disease in 0–24 year olds, Waikato, Bay of Plenty, and Lakes DHBs 
































































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 





































































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rates in both DHBs are based upon small numbers 
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Evidence for good practice for the prevention and management of 
meningococcal disease 
Ministry of Health publications 
Ministry of Health. 2012. Communicable Disease Control Manual 2012. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/communicable-disease-control-manual-2012 
The Communicable Disease Control Manual seeks to describe the standard practice that public health services would normally follow in 
regard to the prevention and control of notifiable diseases. It is intended to be used alongside other best practice guidelines including 
the Immunisation Handbook. Invasive meningococcal disease is a notifiable condition and attending medical practitioners or laboratories 
must immediately notify the local medical officer of health of suspected cases even before confirmation has been obtained. Key steps in 
management include administering parenteral antibiotics as soon as the diagnosis is suspected, and public health follow-up of all 
household and other close contacts who have had unprotected contact with respiratory droplets from the affected child. Cases should 
be kept isolated (droplet precautions) until 24 hours after the start of antibiotic treatment. Antibiotic prophylaxis should be provided to 
contacts as soon as possible and ideally within 24 hours.  
Ministry of Health. 2014. Immunisation Handbook 2014. Wellington: Ministry of Health. 
Details about meningococcal disease are provided on pages 313–340. There is currently no meningococcal vaccine funded in the routine 
New Zealand immunisation schedule. Polysaccharide and conjugate meningococcal vaccines (that protect against serogroups A, C, Y, and 
W135) are funded in special circumstances including children with functional asplenia or who require splenectomy, with 
immunodeficiency including HIV, complement deficiency or following solid organ transplant, and close contacts of meningococcal cases. 
Children who are travelling to high risk countries including travel to the Hajj are recommended to have a meningococcal vaccine, as are 
young adults living in communal accommodation like school or university hostels. There is no group B vaccine available in New Zealand. 
Management of organisational or community outbreaks is the responsibility of the medical officer of health and the Ministry of Health, 
and may include a funded vaccination programme for a defined population. 
Ministry of Health. 2014. Meningococcal B immunisation programme and MeNZB vaccine. 
http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/immunisation-programme-
decisions/meningococcal-b-immunisation-programme-and-menzbtm-vaccine accessed 28 October 2015. 
This webpage provides a succinct summary of the meningococcal vaccination programme offered in New Zealand between 2004 and 
2011. More than 1.1 million young New Zealanders received the MeNZB vaccine and the number of people developing meningococcal 
disease due to the then epidemic strain of serogroup B reduced from over 300 cases in 2001 to less than 30 cases in 2010, meaning that 
vaccination is no longer needed to control the epidemic. The epidemic waned faster than expected and as the MeNZB™ vaccine was 
developed specifically to curb the epidemic of this particular strain of meningococcal disease it is no longer available in New Zealand.  
International guidelines 
National Institute for Health and Care Excellence. 2015. Bacterial meningitis and meningococcal septicaemia 
overview. http://pathways.nice.org.uk/pathways/bacterial-meningitis-and-meningococcal-septicaemia accessed 28 
October 2015. 
This NICE pathway covers diagnosis and management of bacterial meningitis and meningococcal septicaemia in children and young 
people (under 16 years) in primary and secondary care. Control of meningococcal disease is both a clinical and public health priority in 
the UK where serogroup B meningococcus is now the most common cause of bacterial meningitis and septicaemia in children and young 
people aged 3 months and older. Introduction of Haemophilis influenza type b, pneumococcal, and serogroup C meningococcal vaccines 
have dramatically affected the epidemiology of these conditions in the UK over the past two decades. The paths in the pathway include 
symptoms and signs, pre-hospital management and management of meningococcal disease. There is a particularly helpful path on long-
term management and immune testing after an episode of meningococcal disease which emphasises the importance of audiological 
assessment within four to six weeks after discharge from hospital. Immune testing is not generally required except in a few specific 
circumstances. 
Evidence-based medicine reviews 
Zalmanovici Trestioreanu A, et al. 2013. Antibiotics for preventing meningococcal infections. Cochrane Database of 
Systematic Reviews doi:10.1002/14651858.CD004785.pub5 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004785.pub5/abstract  
This systematic review studied the effectiveness of different antibiotics to prevent infection and eradicate asymptomatic Neisseria 
meningitidis carriage among household contacts of people with invasive meningococcal infection. The review included 19 studies with a 
total of 2531 randomised participants, and five studies with a total of 4354 cluster-randomised participants. Most studies were of high 
quality. As there were no cases of meningococcal disease during the follow-up of all these individuals, the end point of eradication of N. 
meningitidis was used. Compared with placebo, ciprofloxacin, rifampicin and penicillin were effective at eradicating N. meningitidis at one 
to two weeks following treatment. Although ceftriaxone was not compared with placebo, it was more effective than rifampicin at one to 
two weeks following treatment. Side effects were reported for 18 of the studies, and these were all mild in nature including nausea, 
diarrhoea, headaches, dizziness and pain at the injection site. Drug-resistant isolates were seen in some contacts treated with rifampicin, 
which may mean that this antibiotic in inappropriate to use in an outbreak. All of the antibiotics recommended for prophylactic use in 
New Zealand were found to be effective in this systematic review. 
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Other relevant publications 
Sarfatti A & Nadel S. 2015. Management of meningococcal disease. Paediatrics and Child Health (United Kingdom), 
25(5), 203-09. 
This article provides an overview of the management of meningococcal disease with an international perspective. Early recognition and 
treatment is vital to improve outcome of invasive meningococcal disease which remains an important cause of childhood sickness and 
death. Introduction of serogroup C vaccine into the routine vaccination schedule in the UK and other countries has been associated with 
a dramatic reduction in the incidence of disease. The impact of a recently developed serogroup B meningococcal vaccine is yet to be 
determined. 
Websites 
Ministry of Health. 2015. Meningococcal disease. http://www.health.govt.nz/your-health/conditions-and-
treatments/diseases-and-illnesses/meningococcal-disease accessed 28 October 2015. 
This webpage provides information about meningococcal disease for New Zealand families. It includes a 3 minute video interview with 
the parents of an 18-year-old woman who died from meningococcal disease.  
Ministry of Health. 2014. Meningococcal http://www.health.govt.nz/our-work/diseases-and-conditions/meningococcal 
accessed 28 October 2015. 
This webpage provides information about meningococcal disease for health professionals and includes a link to a helpful page of 
frequently asked questions about the condition.  
HealthEd. 2013. Meningococcal disease: Information for health professionals. 
https://www.healthed.govt.nz/resource/meningococcal-disease-information-health-professionals accessed 28 October 
2015. 
This webpage provides information for health professionals about the symptoms and signs of meningococcal disease plus detailed 
information about recommended antibiotics, together with links to a patient information leaflet. Free copies of the A3 poster and the 
patient information leaflet can be ordered through the website. 
 
 




The overall rate of active tuberculosis (TB) in New Zealand is low compared with many countries, although TB 
remains one of the most common notifiable infectious diseases.57 TB is a chronic bacterial infection caused by 
Mycobacterium complex, including M .tuberculosis or M. bovis. The lung is the most common site of infection, 
but any organ can be affected. Young children with active TB may present with symptoms of fever, lassitude 
and cough, while older children and adults may present with loss of appetite, fatigue, weight loss, chills, night 
sweats, cough, blood in sputum or chest pain. The disease may be active or latent; the risk of progression from 
latent to active TB disease is much higher for children than for healthy adults.78 
Most children with TB are infected as a result of contact with an infectious adult in their family although there 
have been outbreaks of TB among New Zealand children in the past.79,80 Children aged under 15 years account 
for 7–14% of all notified cases; this proportion varies significantly by ethnicity such that children account for 
25% of TB cases in Pacific peoples, 14% of cases in Māori, 5% in Europeans and 4% in ‘Others’. The very 
youngest children appear to be most susceptible, with just over half the cases of childhood TB occurring in 
children aged under 5 years.78 In all countries TB mostly affects the poorest and most vulnerable communities 
and in Auckland the notification rates in the least affluent parts of the region are 60 times higher than 
notification rates in the most affluent.78 The most common risk factor for TB infection is contact with a known 
case of TB.78 Vaccination can protect neonates and infants at high risk from severe forms of TB disease.57 The 
mainstay of tuberculosis control in New Zealand is early identification of people with the disease and public 
health follow-up of cases and contacts.78  
As there have only been two deaths during the period 2000 to 2014, the following section reports on 
hospitalisations for TB in children and young people using information from the National Minimum Dataset. It 
concludes with a brief overview of evidence-based reviews and guidelines which consider the most effective 
interventions for preventing or managing TB in children and young people. 
Data sources and methods 
Indicator 
Hospitalisations for tuberculosis in 0–24 year olds 
Data sources 
Numerator:  National Minimum Dataset  
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years) 
Definition 
Acute and arranged hospitalisations of 0–24 year olds with a primary diagnosis of tuberculosis (hospitalisations per 100,000 0–
24 year olds). Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
(also referred to as an arranged admission) is a non-acute hospitalisation with an admission date less than seven days after the 
date the decision was made that the hospitalisation was necessary  
Note 2: Appendix 3 outlines the limitations of the data utilised from the National Minimum Dataset. The reader is advised to 
review this appendix before interpreting any trends. 
National trends and distribution 
The hospitalisation rate for tuberculosis in 0–24 year olds declined from 2003 to 2007 and remained steady from 
2007 onwards (Figure 111). While there was year to year variation, rates generally declined for all ethnic 
groups from 2003 to 2007. From 2007–2008 onwards rates rose somewhat for Pacific and Asian/Indian children 
and young people while Māori and European rates were variable (Figure 112). 
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Figure 111. Hospitalisations for tuberculosis in 0–24 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Figure 112. Hospitalisations for tuberculosis in 0–24 year olds, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Caution: rates are subject to small number effect, particularly European/Other from 2009 
Distribution by demographic factors 
Between 2010 and 2014 tuberculosis hospitalisation rates for 0–24 year olds were highest amongst those in their 
late teens and early twenties (Figure 113). There were disparities in tuberculosis hospitalisation rates by 
NZDep2013 index of deprivation score, ethnicity and age. Rates were significantly lower in areas with the 
lowest deprivation scores (NZDep2013 deciles 1−2) compared with higher deprivation scores (deciles 5−10). 
Compared with European/Other, rates were significantly higher for Māori, Pacific, Asian/Indian, and MELAA. 
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Figure 113. Hospitalisations for tuberculosis in 0–24 year olds, by age New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Table 95. Hospitalisations for tuberculosis in 0–24 year olds, by demographic factor, New Zealand 2010–2014 
Variable 
 Number:  
2010−2014  
 Rate per 100,000  
0–24 year olds  
Rate ratio 95% CI 
Tuberculosis in 0–24 year olds 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 13 0.93 1.00   
Deciles 3–4 21 1.58 1.70 0.85–3.40 
Deciles 5–6 42 2.92 3.15 1.69–5.87 
Deciles 7–8 51 3.15 3.40 1.85–6.24 
Deciles 9–10 99 5.32 5.74 3.22–10.24 
Prioritised ethnicity 
Māori 35 1.96 16.22 6.35–41.39 
Pacific 53 7.56 62.47 25.0–156.27 
Asian/Indian 124 13.22 109.16 44.65–266.89 
MELAA 10 10.20 84.21 28.78–246.37 
European/Other 5 0.12 1.00   
Gender 
Female 109 2.91 1.00   
Male 118 3.02 1.04 0.80–1.34 
Age group (years) 
0–4 23 1.49 0.26 0.17–0.40 
5–14 25 0.84 0.15 0.10–0.22 
15–24 179 5.74 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rates are per 100,000 0–24 year olds; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
Distribution by season 
There were no consistent seasonal variations in hospitalisations for tuberculosis in 0–24 year olds. 
Distribution by region 
Between 2010 and 2014 hospitalisation rates for tuberculosis in 0–24 year olds were significantly higher than 
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DHBs also differed from the national rate, in no other cases did these differences reach statistical significance 
(Figure 114). In addition it should be noted that most DHBs had very small numbers of hospitalisations per 
year. Only Auckland and Counties Manukau had an average number of hospitalisations per year of more than 
five (Table 96). 
Figure 114. Hospitalisations for tuberculosis in 0–24 year olds, by district health board, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; rates suppressed for Taranaki, Whanganui, Wairarapa, Canterbury, and Southern DHBs due to numbers less than 5 








24 year olds 
Rate ratio 95% CI 
Tuberculosis in 0–24 year olds 
Northland 6 1 2.16 0.73 0.32–1.64 
Waitemata 21 4 2.22 0.75 0.48–1.17 
Auckland 62 12 7.92 2.67 2.01–3.53 
Counties Manukau 47 9 4.84 1.63 1.19–2.23 
Waikato 13 3 1.92 0.65 0.37–1.13 
Bay of Plenty 8 2 2.27 0.77 0.38–1.55 
Lakes 5 1 2.71 0.91 0.38–2.22 
Tairawhiti 0 .. .. .. .. 
Taranaki <5 s s s s 
Hawke's Bay 8 2 2.95 1.00 0.49–2.01 
MidCentral 8 2 2.69 0.91 0.45–1.83 
Whanganui <5 s s s s 
Hutt Valley 14 3 5.70 1.92 1.12–3.30 
Capital & Coast 16 3 3.17 1.07 0.64–1.77 
Wairarapa <5 s s s s 
Nelson Marlborough 8 2 3.82 1.29 0.64–2.60 
South Canterbury 0 .. .. .. .. 
Canterbury <5 s s s s 
West Coast 0 .. .. .. .. 
Southern <5 s s s s 
New Zealand 227 45 2.97 1.00   
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 tuberculosis hospitalisation rates for 0–24 year olds were not significantly different than 
the national rate in Waikato, Bay of Plenty, and Lakes DHB, while rates are suppressed in Tairawhiti and 
Taranaki DHBs due to numbers being less than five (Table 97).  






Rate per 100,000 
0–24 year olds 
Rate ratio 95% CI 
Tuberculosis in 0–24 year olds 
Waikato 13 3 1.92 0.65 0.37–1.13 
Bay of Plenty 8 2 2.27 0.77 0.38–1.55 
Lakes 5 1 2.71 0.91 0.38–2.22 
Tairawhiti 0 .. .. .. .. 
Taranaki <5 s s s s 
New Zealand 227 45 2.97 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Evidence for good practice for the control of tuberculosis 
Ministry of Health Publications 
Ministry of Health. 2014. Immunisation Handbook 2014. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/immunisation-handbook-2014 accessed 22 October 2015 
Details about TB and Bacillus Calmette-Guérin (BCG) vaccination for TB are provided on pages 471–488. Neonatal BCG vaccine should be 
offered to infants at increased risk of TB, for example those who will be living in a house or family/whānau with a person with either current 
TB or a history of TB, who will be living for 3 months or longer in a country with a TB rate ≥40 per 100,000 before they reach age five years, 
or whose parents or caregivers have lived in such countries for six months or more in the past 5 years. Funded BCG vaccination may be 
offered to at-risk people if they are tuberculin skin test- or interferon gamma release assay (IGRA)-negative, including contacts of active TB 
cases aged under 5 years, immigrants aged under 5 years from countries with a rate ≥40 per 100,000, health care workers and laboratory 
staff depending on their risk of exposure, and people exposed to animals that are likely to be infected. BCG immunisation in New Zealand 
may legally be performed only by gazetted BCG vaccinators. 
Ministry of Health. 2012. Communicable Disease Control Manual 2012. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/communicable-disease-control-manual-2012 accessed 23 October 2015 
The Communicable Disease Control Manual seeks to describe the standard practice that public health services would normally follow in 
regard to the prevention and control of notifiable diseases. It is intended to be used alongside other best practice guidelines including the 
Immunisation Handbook and Guidelines for tuberculosis control in New Zealand. The lifetime risk of developing active TB following infection 
is 5–10% in adults although higher in children, or in those with a predisposing medical condition and immunosuppression (e.g. HIV). The 
main means of transmission of infection is by inhalation of airborne droplets; infection after drinking contaminated unpasteurised milk or 
milk products is infrequent. Index cases should be considered infectious from onset of cough or three months before diagnosis, and the 
risk of transmission usually reduces to negligible levels 2–4 weeks after commencing effective treatment. The manual outlines reporting 
responsibilities, notification procedure, and key aspects of case management including isolation precautions, management of contacts and 
counselling for all affected people.  
New Zealand guidelines 
Ministry of Health. 2010. Guidelines for tuberculosis control in New Zealand 2010. 
http://www.health.govt.nz/publication/guidelines-tuberculosis-control-new-zealand-2010 accessed 13 October 2015 
These guidelines were published in 2010 and the Ministry of Health notes that recent evidence suggests that the guidance given for 
treatment of tuberculosis, particularly in Chapter 3 needs to be revised. Any treatment concerns should be discussed with an appropriate 
clinician (respiratory / infectious diseases / paediatric) rather than relying on the guidelines. However the document still provides useful 
information about the epidemiology and surveillance of tuberculosis (TB) in New Zealand, detailed information about the clinical features, 
investigation (including laboratory methods and standards) and assessment of TB. Specific circumstances, settings and population groups 
are also considered including HIV associated TB, contact investigation, TB in correctional facilities, infection control including in hospital 
settings, and people from countries with a high incidence of TB. Chapter 5 addresses TB in children. Although optimal treatment regimens 
and dosages are not known for children, most children have good outcomes on current regimens. Most child cases of TB are the result of 
transmission of infection from a close family member, and the treatment regimen is based on drug sensitivity testing from the adult case. 
Most TB in children occurs within a year of infection, and children have a higher risk than adults of developing severe disease especially if 
the child is aged under two years or has HIV infection or other immunocompromising condition. 
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International Guidelines 
National Institute for Health and Care Excellence. 2015. Tuberculosis overview. 
http://pathways.nice.org.uk/pathways/tuberculosis accessed 23 October 2015 
This NICE pathway, designed to be interactive and used on-line, brings together guidance, quality standards and materials to support 
commissioning of TB services, preventing spread of TB, and diagnosing and managing active TB. There is also a link to the NICE pathway 
on antimicrobial stewardship. The downloadable PDF includes a helpful glossary. Hard-to-reach groups include children from any ethnic 
background whose social circumstances, language, culture or lifestyle, or those of their parents or carers, make it difficult to recognise the 
clinical onset of TB, access diagnostic and treatment services, have treatment administered by a parent or carer or attend regular clinic 
appointments. This group includes unaccompanied minors, children whose parents are hard-to-reach, children whose parents are in prison, 
and looked-after children. Within the interactive pathway there are links to guidance about screening for latent TB in children who have 
been in close contact with people with sputum-smear-positive TB several by age group from neonates through to 5 years and older and 
by BCG vaccination status. There is also guidance about immigrant screening children from high-incidence countries. This is a good place 
to quickly find guidance, particularly about prevention of spread to TB, for very specific population groups of children. 
World Health Organization. 2014. Guidance for national tuberculosis programmes on the management of 
tuberculosis in children. Geneva: World Health Organization. http://www.who.int/tb/publications/childtb_guidelines/en/ 
accessed 23 October 2015 
While designed for countries where TB is endemic at a high level, the principles of TB treatment in children (page 33) remain relevant in all 
countries: Cure the child of TB, prevent death, relapse and transmission of TB, prevent development and transmission of drug-resistant TB, 
and achieve all this with minimal toxicity. Medication dosages for children need to take into account the risk of drug-induced hepatotoxicity 
with isoniazid or pyrazinamide and optic neuritis due to ethambutol. The WHO revised dosage recommendations have an excellent safety 
profile based on systematic review of available evidence and underpin the recommendations for children in Guidelines for tuberculosis 
control in New Zealand. 
Evidence-Based Medicine Reviews 
Bose A, et al. 2014. Intermittent versus daily therapy for treating tuberculosis in children. Cochrane Database of 
Systematic Reviews doi:10.1002/14651858.CD007953.pub2 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007953.pub2/abstract 
Treatment for TB includes a combination of drugs given daily for six at least months. Although the World Health Organization currently 
recommends treatments, some national governments recommend twice- or thrice-weekly doses for children with TB as this is more 
convenient. The authors undertook a systematic literature review to compare the effectiveness and safety of intermittent compared with 
daily TB treatment. They found only four randomised trials that compared twice-weekly treatment with daily doses of anti-TB drugs 
including a total of 563 children aged five months to 15 years. The trials were small, and did not detect a difference between twice-weekly 
or daily treatment in the number of children who were cured, died, relapsed, reported taking most or all of the drugs, or had adverse effects. 
They concluded that trials conducted to date are insufficient to support or refute the use of intermittent twice- or thrice-weekly, short-
course treatment regimens over daily short-course treatment in children with TB.  
M'Imunya James M, et al. 2012. Patient education and counselling for promoting adherence to treatment for 
tuberculosis. Cochrane Database of Systematic Reviews doi:10.1002/14651858.CD006591.pub2 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006591.pub2/abstract  
Because non-adherence to treatment can lead to prolonged infectivity and increase morbidity and mortality from TB, the authors undertook 
a systematic review to evaluate the effects of patient education or counselling on treatment completion in people requiring treatment for 
active or latent TB. They identified three randomised controlled trials with a total of 1437 participants and found that educational or 
counselling interventions may improve completion of treatment. In a trial in children from Spain telephone counselling or home visits by 
nurses increased completion of treatment from 65% to 94% or 95%. Both interventions were superior to counselling by physicians at the 
TB clinic. 
Other Relevant Publications 
World Health Organization. 2014. Global tuberculosis report 2014. World Health Organization. 
http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf accessed 23 October 2015 
This comprehensive report provides an international perspective on TB, which remains one of the world’s deadliest communicable diseases 
responsible for a total of 1.5 million deaths in 2013. Estimating global TB incidence in children is technically difficult The report has a 
supplement highlighting progress in surveillance of and responses to multidrug-resistant TB. The WHO post-2015 global TB strategy was 
approved by all Member States in May 2014 and includes targets of 95% reduction in TB deaths and 90% reduction in TB incidence by 2035 
together with a target of zero catastrophic costs for TB-affected families by 2020.  
Websites 
Institute of Environmental Science and Research. 2015. Public Health Surveillance: Information for New Zealand 
public health action. https://surv.esr.cri.nz/index.php accessed 23 October 2015 
This website provides detailed surveillance data for all notifiable diseases in New Zealand, including TB. 
Ministry of Health. 2015. Tuberculosis. http://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-
illnesses/tuberculosis accessed 23 October 2015 
This website provides consumer information about TB with links to brochures about TB and BCG vaccination in English and other languages.  
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RHEUMATIC FEVER AND HEART DISEASE 
Introduction 
Acute rheumatic fever (RF) is an autoimmune reaction that occurs two to three weeks after a throat infection 
with the bacterium Streptococcus pyogenes also known as group A Streptococcus (GAS).75,81 It causes an illness 
that mainly affects the heart, joints, brain and skin. If a person experiences several attacks of RF they may 
develop rheumatic heart disease (RHD). Damage to the heart valves can cause serious health problems and may 
require cardiac surgery. The primary episode usually occurs in children aged 5–15 years and consequently 
interventions are usually targeted on this group.82 A child with RF will usually present with sore or swollen 
joints and may also have a skin rash, fever, stomach pains and jerky movements.83  
Although acute RF appears to have been virtually eradicated from most ‘developed’ countries, rates in New 
Zealand remain some of the highest reported in a developed country. Observed inequality between ethnic groups 
has increased over time with much higher rates for Pacific and for Māori compared with non-Māori non-Pacific 
children aged 5–14 years.82 Reducing the incidence of RF by two-thirds is one of the results set by the 
Government as part of the priority to support vulnerable children through delivery of better public services.84 
Effective strategies to address the multiple determinants of RF include prevention of transmission of GAS 
infections, for example, by addressing household crowding and socioeconomic factors that predispose to it, and 
early detection and treatment of GAS infections through improved community awareness and capacity, for 
example, by improving health literacy, health service access and early diagnosis and treatment. All patients 
presenting with sore throat should be assessed for the presence or absence of significant risk factors for 
rheumatic fever. Patients are considered to be at high risk if they have a personal, family or household history of 
rheumatic fever, or meet two or more of the following criteria: Māori or Pacific ethnicity, age 3-35 years or 
living in crowded circumstances or in lower socioeconomic areas of the North Island. High risk patients 
presenting in primary care or emergency departments should have a throat swab if follow-up is possible and be 
started on 10 days of empiric penicillin or amoxicillin or given a single dose of IM benzathine penicillin, while 
high risk patients identified in school sore throat clinics should have a throat swab and, only if this is positive 
for group A streptococcus (GAS), be given 10 days of antibiotics.85 Patients not considered to be at high risk 
may not require either throat swabbing or antibiotics unless they have severe symptoms or are at increased risk 
of spreading GAS.85 Early diagnosis of acute RF can reduce the risk of severe rheumatic heart disease especially 
if there is good follow-up for antibiotic prophylaxis (secondary prevention) for those with a diagnosis of acute 
RF.75 Monthly injections of long-acting benzathine penicillin G can prevent RF recurrences and must be 
continued for 10 years after diagnosis or until age 21 (whichever is the longer) or until age 30 or even life-long 
in the presence of carditis or established RHD.86 Annual influenza vaccination is recommended and funded for 
children aged over 6 months who have RHD.57 Because RF is a notifiable disease the attending medical 
practitioner is expected to notify the local medical officer of health of suspected initial or recurrent cases of 
acute RF within seven days, and not wait for a confirmed diagnosis.75 
The following section reports on deaths and hospitalisations for rheumatic fever and rheumatic heart disease in 
children and young people using information from the National Mortality Collection and the National Minimum 
Dataset. It concludes with a brief overview of evidence-based reviews and guidelines which consider the most 
effective interventions for preventing or managing these conditions in children and young people. 
Data sources and methods 
Indicator 
 Deaths of 0–24 year olds due to acute rheumatic fever or rheumatic heart disease  
 Hospitalisations of 0–24 year olds for acute rheumatic fever of rheumatic heart disease 
Data sources 
Numerator:   
Deaths  National Mortality Collection 
Hospitalisations National Minimum Dataset 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate 
denominators between Census years). 
Definition 
Deaths: Deaths of 0–24 year olds where the main underlying cause of death was acute rheumatic fever or rheumatic heart 
disease 
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Hospitalisations: Acute and arranged hospitalisations of 0–24 year olds with a diagnosis of acute rheumatic fever or chronic 
rheumatic heart disease (hospitalisations per 100,000 population). Refer to Appendix 6 for the codes included.  
Notes on interpretation 
Note 1: Unless otherwise specified, this analysis focuses on all hospitalisations of 0–24 year olds with either acute rheumatic 
fever (as primary diagnosis) or chronic rheumatic heart disease listed in any of the first 15 diagnoses. The rationale for this wider 
focus for chronic rheumatic heart disease was that many 0–24 year olds with chronic rheumatic heart disease will not be 
hospitalised for their heart disease per se, but rather for one of its resulting complications. For example, during 2005–2009 only 
39.0% of hospitalisations for 0–24 year olds with rheumatic heart disease had this listed as the primary diagnosis, with 11.8% 
being admitted for pregnancy and childbirth, and 11.0% for other cardiovascular diagnoses. These data in this section may 
differ from data reported elsewhere. 
Note 2: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
(also referred to as an arranged hospitalisation) is a non-acute hospitalisation with an admission date less than seven days after 
the date the decision was made that the hospitalisation was necessary. 
Note 3: Appendix 3 describes the National Minimum Dataset and outlines the limitations of the data utilised from this 
collection. The reader is advised to review this appendix before interpreting any trends. 
Note 4: All data presented are based on counts of hospitalisations (not individuals) and some individuals may have had multiple 
hospitalisations. 
National trends and distribution 
From 2008 to 2012 there were nine deaths of 0–24 year olds with acute rheumatic fever or rheumatic heart 
disease as the underlying cause. 
From 2000 to 2014 the hospitalisation rates for 0–24 year olds with a primary or any diagnosis of acute 
rheumatic fever and a primary or any diagnosis of rheumatic heart disease were stable with year-to-year 
fluctuations (Figure 115). Similar patterns over time were observed for all ethnic groups but rates were 
consistently highest in Pacific children and young people, and next highest in Māori (Figure 116). 
Figure 115. Hospitalisations for acute rheumatic fever and rheumatic heart disease in 0–24 year olds, New Zealand 
2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
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Figure 116. Hospitalisations for acute rheumatic fever and rheumatic heart disease in 0–24 year olds, by ethnicity, 
New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Acute rheumatic fever is primary diagnosis; Chronic rheumatic heart disease is listed in any of the first 15 diagnoses; 
Asian/Indian rates suppressed due to small numbers 
Distribution by demographic factors 
Between 2010 and 2014 acute rheumatic fever hospitalisation rates for 0–24 year olds were low in preschool 
children, rose rapidly with increasing age from 5 years to peak at 10 years, then fell until 16 years, after which 
they did not vary much with age (Figure 117). Hospitalisation rates for rheumatic heart disease followed a 
similar pattern but with a broader, less pronounced, peak over the age range 8–14 years (Figure 117).  
Pacific and Māori hospitalisation rates for acute rheumatic fever followed a similar pattern by age to the overall 
rate. Pacific rates were higher than Māori rates at all ages. Rates for European and Asian/Indian children and 
young people were so low that no clear pattern by age was apparent (Figure 118). Pacific hospitalisations for 
rheumatic heart disease peaked over the age range 8–14 years, but no clear pattern with age could be seen in 
Māori (except that hospitalisations were low in under 6 year olds). Rates for European and Asian/Indian 
children and young people were so low that no clear pattern by age was apparent (Figure 119).  
Between 2010 and 2014 there were disparities in acute rheumatic fever hospitalisation rates by NZDep2013 
index of deprivation score, ethnicity, gender and age. Rates were significantly higher in areas with the highest 
deprivation score (deciles 9–10) compared to all other areas. Rates were significantly lower in areas with the 
lowest deprivation scores (NZDep2013 deciles 1–2) compared with areas with higher deprivation scores (deciles 
3–10). Compared with European/Other, rates were significantly higher for Pacific and Māori. Male rates were 
significantly higher than female rates. Compared to rates for 15–24 year olds, rates were significantly lower in 
0–4 year olds and significantly higher in 5–14 year olds (Table 98). 
There were also disparities in rheumatic heart disease by NZDep2013 index of deprivation score, ethnicity, and 
age. Rates were significantly higher in areas with the highest deprivation score (deciles 9–10) compared to all 
other areas and in deciles 7–8 compared to deciles 1–4 and significantly lower in areas with the lowest 
deprivation scores (NZDep2013 deciles 1–2) compared with areas with higher deprivation scores (deciles 5–10). 
Compared with European/Other, rates were significantly higher for Pacific and Māori. Compared to rates for 
15–24 year olds, rates were significantly lower in 0–4 year olds and significantly higher in 5–14 year olds 
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Figure 117. Hospitalisations for acute rheumatic fever and rheumatic heart disease in 0–24 year olds, by age, New 
Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Acute rheumatic fever is primary diagnosis; Chronic rheumatic heart disease is listed in any of the first 15 diagnoses; 
Rates are per 100,000 age-specific population 










































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
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Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Chronic rheumatic heart disease in any of the first 15 diagnoses; Rates are per 100,000 population; Asian/Indian and 
European/Other rates suppressed due to small numbers 
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Table 98. Hospitalisations for acute rheumatic fever and rheumatic heart disease in 0–24 year olds, by 
demographic factor, New Zealand 2010–2014 
Variable 
 Number:  
2010−2014  
Rate per 100,000 
population  
Rate ratio  95% CI 
0–24 year olds 
Acute rheumatic fever 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 18 1.28 1.00   
Deciles 3–4 46 3.46 2.70 1.56–4.65 
Deciles 5–6 87 6.05 4.72 2.84–7.84 
Deciles 7–8 207 12.78 9.96 6.15–16.12 
Deciles 9–10 854 45.91 35.78 22.43–57.06 
Prioritised ethnicity 
Māori 636 35.68 30.78 23.02–41.16 
Pacific 521 74.35 64.15 47.86–85.98 
Asian/Indian 8 0.85 0.74 0.35–1.55 
MELAA 0 .. .. .. 
European/Other 49 1.16 1.00   
Gender 
Female 516 13.89 1.00   
Male 699 18.05 1.30 1.16–1.46 
Age 
0–4 years 6 0.40 0.04 0.02–0.09 
5–14 years 904 30.17 3.06 2.68–3.48 
15–24 years 305 9.88 1.00   
Rheumatic heart disease 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 13 0.93 1.00   
Deciles 3–4 19 1.43 1.54 0.76–3.12 
Deciles 5–6 47 3.27 3.53 1.91–6.52 
Deciles 7–8 118 7.28 7.86 4.43–13.93 
Deciles 9–10 443 23.82 25.70 14.80–44.61 
Prioritised ethnicity 
Māori 301 16.88 14.57 10.77–19.70 
Pacific 306 43.67 37.68 27.87–50.94 
Asian/Indian 5 0.53 0.46 0.18–1.15 
MELAA 0 .. .. .. 
European/Other 49 1.16 1.00   
Gender 
Female 345 9.28 1.00   
Male 318 8.21 0.88 0.76–1.03 
Age 
0–4 years 27 1.80 0.20 0.14–0.30 
5–14 years 361 12.05 1.35 1.16–1.58 
15–24 years 275 8.90 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Acute rheumatic fever is primary diagnosis; Chronic rheumatic heart disease is listed in any of the first 15 diagnoses; 
Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
  
 
Common communicable diseases: Rheumatic fever and heart disease 
232 
Distribution by season 
There was no clear seasonal pattern in hospitalisations for either acute rheumatic fever or rheumatic heart 
disease. 
Distribution by region 
Acute rheumatic fever  
Between 2010 and 2014 hospitalisations for acute rheumatic fever were significantly higher than the national 
rate in the Northland, Counties Manukau, Lakes and Tairawhiti DHBs, and significantly lower in the Waitemata, 
Auckland, Taranaki, MidCentral, Capital & Coast, Wairarapa, Nelson Marlborough, Canterbury, South 
Canterbury, West Coast and Southern DHBs. While rates in a number of other DHBs also differed from the 
New Zealand rate, in no other cases did these differences reach statistical significance (Figure 120, Table 99). 
Figure 120. Hospitalisations for acute rheumatic fever in 0–24 year olds, by district health board, New Zealand 
2010–2014 
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Rate per 100,000 
population 
Rate ratio 95% CI 
Rheumatic fever 
0–24 year olds 
Northland 123 25 44.27 3.09 2.56–3.72 
Waitemata 91 18 9.63 0.67 0.54–0.83 
Auckland 80 16 10.21 0.71 0.57–0.89 
Counties Manukau 406 81 41.80 2.91 2.60–3.27 
Waikato 99 20 14.61 1.02 0.83–1.25 
Bay of Plenty 50 10 14.19 0.99 0.75–1.31 
Lakes 41 8 22.26 1.55 1.14–2.12 
Tairawhiti 32 6 35.46 2.47 1.74–3.51 
Taranaki <5 s s s s 
Hawke's Bay 30 6 11.08 0.77 0.54–1.11 
MidCentral 15 3 5.04 0.35 0.21–0.58 
Whanganui 13 3 12.41 0.87 0.50–1.50 
Hutt Valley 38 8 15.47 1.08 0.78–1.49 
Capital & Coast 47 9 9.32 0.65 0.49–0.87 
Wairarapa <5 s s s s 
Nelson Marlborough <5 s s s s 
South Canterbury 0 .. .. .. .. 
Canterbury 17 3 2.05 0.14 0.09–0.23 
West Coast <5 s s s s 
Southern <5 s s s s 
New Zealand 1,097 219 14.34 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rate ratios are unadjusted; s: suppressed due to small numbers 
Rheumatic heart disease 
Between 2010 and 2014 hospitalisations for rheumatic heart disease were significantly higher than the national 
rate in the Counties Manukau and Tairawhiti DHBs, while rates were significantly lower in the Waitemata, 
MidCentral, Canterbury, and Southern DHBs. While rates in a number of other DHBs also differed from the 
national rate, in no other DHB did these differences reach statistical significance and some DHBs had very 
small numbers (Table 100, Figure 121).  
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Figure 121. Hospitalisations for rheumatic heart disease in 0–24 year olds, by district health board, New Zealand 
2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Chronic rheumatic heart disease is listed in any of the first 15 diagnoses; Rates suppressed if numbers less than five 







Rate per 100,000 
population 
Rate ratio 95% CI 
Rheumatic heart disease 
0–24 year olds 
Northland 22 4 7.92 0.91 0.60–1.40 
Waitemata 47 9 4.97 0.57 0.43–0.77 
Auckland 54 11 6.89 0.80 0.60–1.05 
Counties Manukau 250 50 25.74 2.97 2.57–3.43 
Waikato 45 9 6.64 0.77 0.57–1.04 
Bay of Plenty 33 7 9.36 1.08 0.76–1.53 
Lakes 24 5 13.03 1.50 1.00–2.26 
Tairawhiti 24 5 26.59 3.07 2.04–4.61 
Taranaki <5 s s s s 
Hawke's Bay 14 3 5.17 0.60 0.35–1.01 
MidCentral 15 3 5.04 0.58 0.35–0.97 
Whanganui 15 3 14.32 1.65 0.99–2.76 
Hutt Valley 18 4 7.33 0.85 0.53–1.35 
Capital & Coast 31 6 6.14 0.71 0.49–1.02 
Wairarapa <5 s s s s 
Nelson Marlborough 10 2 4.77 0.55 0.29–1.03 
South Canterbury <5 s s s s 
Canterbury 28 6 3.38 0.39 0.27–0.57 
West Coast 0 .. .. .. .. 
Southern 5 1 0.97 0.11 0.05–0.27 
New Zealand 663 133 8.67 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 hospitalisation rates for acute rheumatic fever were significantly higher than the 
national rate in the Lakes and Tairawhiti DHBs. While similar patterns were evident for rheumatic heart disease, 
only in Tairawhiti did these differences reach statistical significance (Table 101). 







Rate per 100,000 
population 
Rate ratio 95% CI 
0–24 year olds 
Rheumatic fever 
Waikato 99 20 14.61 1.02 0.83–1.25 
Bay of Plenty 50 10 14.19 0.99 0.75–1.31 
Lakes 41 8 22.26 1.55 1.14–2.12 
Tairawhiti 32 6 35.46 2.47 1.74–3.51 
Taranaki <5 s s s s 
New Zealand 1,097 219 14.34 1.00   
Rheumatic heart disease 
Waikato 45 9 6.64 0.77 0.57–1.04 
Bay of Plenty 33 7 9.36 1.08 0.76–1.53 
Lakes 24 5 13.03 1.50 1.00–2.26 
Tairawhiti 24 5 26.59 3.07 2.04–4.61 
Taranaki <5 s s s s 
New Zealand 663 133 8.67 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Acute rheumatic fever is primary diagnosis; Chronic rheumatic heart disease is listed in any of the first 15 diagnoses 
Regional trends 
While year-to-year fluctuations in the hospitalisation rates for acute rheumatic fever and for rheumatic heart 
disease were observed in the Midland DHBs, hospitalisation rates for acute rheumatic fever in Lakes DHB, and 
rates for both acute rheumatic fever and rheumatic heart disease in Tairawhiti DHB tended to be well above 
national rates (Figure 122, Figure 123). 
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Figure 122. Hospitalisations for acute rheumatic fever and rheumatic heart disease in 0–24 year olds, Waikato, Bay 






























































































































































































































DHB: Acute rheumatic fever
New Zealand: Acute rheumatic fever
DHB: Rheumatic heart disease
New Zealand: Rheumatic heart disease
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Acute rheumatic fever is primary diagnosis; Chronic rheumatic heart disease is listed in any of the first 15 diagnoses; 
Caution: some rates affected by small numbers 
Figure 123. Hospitalisations for acute rheumatic fever and rheumatic heart disease in 0–24 year olds, Tairawhiti 


































































































































































DHB: Acute rheumatic fever
New Zealand: Acute rheumatic fever
DHB: Rheumatic heart disease
New Zealand: Rheumatic heart disease
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Acute rheumatic fever is primary diagnosis; Chronic rheumatic heart disease is listed in any of the first 15 diagnoses; 
Caution: some rates affected by small numbers 
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Evidence for good practice for the prevention and management of 
rheumatic fever 
Ministry of Health publications 
Ministry of Health. 2015. Rheumatic fever. http://www.health.govt.nz/our-work/diseases-and-conditions/rheumatic-
fever accessed 30 October 2015. 
This section provides information about what is being done by the Ministry of Health through the Rheumatic Fever Prevention 
Programme (RFPP) and also by the health sector to address RF. It includes the latest media updates and provides links to information 
for health professionals. It includes links to RF resources developed in partnership with the Health Promotion Agency 
http://www.health.govt.nz/our-work/diseases-and-conditions/rheumatic-fever/rheumatic-fever-resources accessed 30 October 2015. 
From 1 July 2017, the government will invest ongoing funding of $5 million each year to continue with proven RF prevention initiatives. 
This webpage provides links to RF plans for each of the 11 DHBs in high incidence areas http://www.health.govt.nz/our-work/diseases-
and-conditions/rheumatic-fever/district-health-board-rheumatic-fever-prevention-plans  
New Zealand Guidelines Group. 2011. Rheumatic fever: a systematic review of the literature on health literacy, 
overcrowding and rheumatic fever. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/rheumatic-fever-systematic-review-literature-health-literacy-overcrowding-and-
rheumatic-fever  
The NZ Guidelines Group (NZGG) undertook systematic reviews of the literature to establish if health literacy/health education and 
interventions to reduce overcrowding and improve housing quality were effective in reducing GAS infections and rheumatic fever. The 
authors included relevant systematic reviews, meta-analyses, randomised controlled trials, cohort, case-control and cross-sectional 
studies involving children aged 5–15 years. Four NZ case studies are also included. Studies were of varying quality and not all could be 
fully appraised. Key factors in effective education and literacy programmes include multimodal approaches, collaboration between 
health and education sectors, addressing barriers to accessing health practitioners, and culturally appropriate information in local 
languages ideally coming from the local community, church and educational leaders and lay health workers. Within NZ endorsement 
by Māori and Pacific leadership is important for ensuring acceptance of RF prevention education, and Māori and Pacific networks are 
key partners in resource development and dissemination. NZGG recommend establishment of processes and structures that “allow 
programme providers and stakeholders to consolidate and share resources, innovations and key learnings” (p.44). Decreasing 
overcrowding is likely to improve health in general and as a consequence to lead to a decrease in rheumatic fever incidence. NZGG 
note that improvements in health literacy and primordial prevention in the form of decreased overcrowding and improved housing 
quality will only be effective within a wider prevention programme that includes case detection and registration and effective primary 
and secondary prophylaxis.  
New Zealand Guidelines Group. 2011. Management of Group A Streptococcal Sore Throat. Wellington: New 
Zealand Guidelines Group. 
http://www.health.govt.nz/system/files/documents/publications/12041320sore20throat20final20to20the20ministry.pdf  
The purpose of this evidence review is to provide an evidence-based summary of current New Zealand and overseas evidence to inform 
best practice in the management of people with GAS throat infection (pharyngitis) especially with the aim of preventing more acute 
RF. There are several key messages from the report: Antibiotics should be initiated as soon as possible as there is no evidence to support 
current practice of delaying treatment by up to nine days and there is no evidence to support any other recommendation about the 
timing of treatment. Children at high risk of developing rheumatic fever should continue to receive empiric (immediate) antibiotic 
treatment and the presence of GAS should continue to be confirmed by laboratory culture. Where an intervention is planned in a school 
population, all consented children should be swabbed before and after the intervention, regardless of symptoms, to allow evaluation 
of programme effectiveness. There is reliable evidence about the efficacy of rapid antigen diagnostic tests, which give a result much 
faster than swabbing and testing, however there are also concerns about the heterogeneity between studies .and the potential false 
positives if this is used as a front-line test. Once daily amoxicillin is the first choice for antibiotic treatment for a GAS throat infection. 
Amoxicillin is likely to achieve better compliance than Penicillin V because of once daily dosing and ability to be taken with food 
compared with more frequent dosing and the requirement to take it on an empty stomach.  
Ministry of Health. 2015. Using practitioner supply orders and standing orders in the rheumatic fever prevention 
programme: Guidance for sore throat management services. Wellington: Ministry of Health. 
http://www.health.govt.nz/system/files/documents/publications/using-practitioner-supply-orders-and-standing-
orders-rheumatic-fever-prevention-programme-feb15-v5.pdf 
A practitioner supply order is a written order for the supply of community pharmaceuticals. This document provides guidance for the 
dispensing and supply of antibiotics in RFPP sore throat management services including school-based programmes, rapid response 
clinics and other clinics that are part of the RFPP and will help health practitioners to meet the requirements of the Medicines Act 1981 
and Medicines Regulations 1984. In the context of the RFPP a practitioner supply order enables a practitioner to order quantities of 
certain antibiotics in excess of the usual limits set by the PHARMAC Pharmaceutical Schedule, to ensure medical supplies are available 
for patients with suspected or confirmed GAS throat infections. The document includes advice for medical practitioners, pharmacists, 
and people working under a standing order. Appendices detail the recommended antibiotics with dosages, and provide a template for 
RFPP standing orders.  
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Litmus Ltd. 2013. Implementation and Formative Evaluation of the Rheumatic Fever Prevention Programme: 
Final Report. Wellington: Litmus LTD. http://www.health.govt.nz/publication/implementation-and-formative-
evaluation-rheumatic-fever-prevention-programme  
This report was prepared for the Ministry of Health and evaluates the first 18 months of the rheumatic fever prevention programme 
(RFPP) from 1 July 2011 to 31 December 2012. The evaluation used a mixed-methods approach including: literature and documentation 
review; interviews and focus groups with RFPP providers interviews and parents/caregivers as well as a survey of parents/caregivers; 
review of monitoring data; and case studies of four RFPP sites. The report found that there had been a positive response to the RFPP 
roll-out, with enthusiastic local providers rising to the challenge of implementing school throat swabbing services and community 
awareness raising in short timeframes. The report also identified a number of aspects to be considered to maximise the effectiveness, 
consistency and sustainability of activities across the RFPP sites, including better linkage to existing DHB and local child health strategies 
and better integration with primary care and with other health and social service providers. Key informants often cautioned that the 
mix of RFPP activities would not adequately address the primordial causes of RF (poverty, crowded housing, lack of access to culturally 
competent primary care) and there were also questions raised about cost-effectiveness of the RFPP. 
Ministry of Social Development documents 
Ministry of Social Development. 2011. Delivering better public services: Supporting vulnerable children result 
action plan. Wellington: Ministry of Social Development http://www.msd.govt.nz/documents/about-msd-and-our-
work/work-programmes/better-public-services/supporting-vulerable-children/supporting-vulnerable-children-result-
action-plan.pdf  
This results action plan provides the context for the Government target to reduce the incidence of rheumatic fever to 1.4 cases per 
100,000 people by June 2017. This target is part of supporting vulnerable children, which is a component of the Government priority 
to deliver better public services within tight financial constraints. The key actions are to provide throat swabbing and treatment to 
children at high risk; raise community and health sector awareness of the disease; improve knowledge of rheumatic fever through 
surveillance and research; and work across Government agencies to address risk factors like housing conditions and hygiene in schools. 
The result action plan outlines the expected pattern of disease if the five-year goal is met, as well as ways the results will be measured 
and reported.  
New Zealand guidelines 
Heart Foundation of New Zealand. 2014. Group A Streptococcal Sore Throat Management Guideline. 2014 
Update. Auckland: Heart Foundation of New Zealand. 
http://www.heartfoundation.org.nz/uploads/sore_throat_guideline_14_10_06_FINAL-revised.pdf  
This guideline aims to maximise diagnosis and management of pharyngitis in those who are at greatest risk of developing rheumatic 
fever, while minimising investigations and antibiotic use in those who are at the lowest risk, with the overall goal of RF prevention. Both 
the sore throat management and household sore throat management algorithm have been updated. The population at high risk for RF 
is defined as those individuals who have a personal, family or household history of RF, or who have two or more of the following criteria; 
Māori or Pacific ethnicity, age 3-35 years, living in crowded circumstances or in lower socioeconomic areas of the North Island. Correct 
treatment of GAS pharyngitis will substantially reduce the occurrence of ARF in populations at high risk. Throat swabbing remains the 
gold standard for diagnosing GAS pharyngitis and rapid antigen diagnostic tests are not currently recommended. Confirmed or 
suspected GAS pharyngitis in high risk populations should be treated as soon as possible; it is not safe to wait up to nine days as 
previously recommended. Courses of oral antibiotics for GAS pharyngitis should be of 10 days duration as there is no evidence that 
shorter courses prevent the subsequent development of RF. Throat swabbing is also recommended for symptomatic contacts of a 
patient with GAS pharyngitis, particularly if they are school-aged. Some symptomatic GAS positive patients may require isolation for 
24 hours after starting antibiotics if there is a high risk of spread of infection. There are specific recommendations for outbreaks of GAS 
pharyngitis within a household or in another group setting. Given the lack of clarity in the literature on certain aspects of (GAS) 
pharyngitis the report recommends research on 14 specific research questions. An algorithms for sore throat management is available 
as a standalone document from http://www.heartfoundation.org.nz/programmes-resources/health-professionals/guidelines-and-
position-statements 
Heart Foundation of New Zealand. 2015. New Zealand Guidelines for Rheumatic Fever: Diagnosis, Management 
and Secondary Prevention of Acute Rheumatic Fever and Rheumatic Heart Disease: 2014 Update. Auckland: 
Heart Foundation of New Zealand. 
http://www.heartfoundation.org.nz/uploads/HF2227A_Rheumatic_Fever_Guideline_v3.pdf  
This guideline has been developed by the Heart Foundation of New Zealand and the Cardiac Society of Australia and New Zealand to 
identify and present the evidence for best practice in acute rheumatic fever (ARF) diagnosis, identify the standard of care that should 
be available to all people in New Zealand and areas where current management strategies may not be in line with available evidence, 
and ensure that high-risk populations receive the same standard of care as that available to other New Zealanders. It is recommended 
that the NZ criteria are used for the diagnosis of RF (a table on page 15 shows how these differ from the revised Jones criteria 1992 
and Australian high risk criteria). The guideline details initial and ongoing management of acute RF, secondary prevention including 
prophylaxis in general and in specific circumstances such as in pregnancy, on oral contraceptives and in patients on anticoagulant 
medication. The comprehensive section on rheumatic heart disease considers oral health care, pregnancy and childbirth, 
anticoagulation, prevention of infective endocarditis and indications for cardiac surgery. There is no formal screening programme for 
RHD in NZ, however the WHF guidelines (see below) can be used to diagnose RHD by echocardiogram following clinical scenarios such 
as investigation of a heart murmur, history suggestive of past acute RF, or chance finding on echocardiography for other indications. 
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Algorithms for use of echocardiography in acute RF and duration of secondary prophylaxis are available as standalone documents from 
http://www.heartfoundation.org.nz/programmes-resources/health-professionals/guidelines-and-position-statements  
International guidelines 
Remenyi B, et al. 2012. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart 
disease--an evidence-based guideline. Nature Reviews Cardiology, 9, 297-309. 
Since 2004 the WHO has recommended echocardiographic screening for RHD in high-risk populations; a global consequence has been 
the observation that prevalence of RHD is much higher than previously thought. An international advisory group of 21 experts in 
rheumatic heart disease from six continents worked together to define the minimum echocardiographic criteria for a diagnosis of RHD 
in individuals without a clear history of acute RF. The guidelines are important to overcome systematic differences in the approaches 
to diagnosis and reporting of RHD that had developed over time, based on the differing experiences and disease patterns between 
localities. The guidelines address the full spectrum of RHD from normal, to borderline to definite RHD with subcategories of the latter 
two groups, and were developed on the basis of the best available evidence. A formal consensus process was used to reach agreement 
where evidence was insufficient in itself. Criteria are provided for individuals aged 20 years or younger, and for those aged over 20 
years. Criteria are based on the type of portable echocardiographic machines that are available in relatively resource-poor and remote 
settings (2D, continuous-wave, and colour-Doppler echocardiography). The current value of applying the guidelines is to establish the 
epidemiology of RHD; further research is needed to determine whether a screening programme can reduce the burden of RHD. In 
particular there is uncertainty about the natural history of subclinical disease detected by echocardiography where there is no clinical 
heart murmur. 
Evidence-based medicine reviews 
Webb RH, et al. 2015. Acute rheumatic fever. BMJ, 351, h3443. 
The authors searched Medline and the Cochrane Database of Systematic Reviews to collate and summarise what is currently known 
about RF. The journal article summarises the diagnostic criteria, management of the various symptoms of acute RF, long term 
complications, antibiotic prophylaxis and public health implications. References are provided to educational resources for patients, 
families and health professionals. Questions for future research include improving knowledge about the pathogenesis of RF, better 
estimation of the global burden of the disease, assessing the possible role of screening high-risk populations for RHD, cost-effectiveness 
of throat swabbing programmes, and questions about potential efficacy of a GAS vaccine to prevent acute RF and RHD or for immune 
modulatory therapies to improve cardiac outcomes and prevent the need for surgery.  
Cilliers A, et al. 2015. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database of 
Systematic Reviews doi:10.1002/14651858.CD003176.pub3 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003176.pub3/pdf  
Although it is clear that antibiotic treatment can prevent the development of RF and antibiotic prophylaxis can prevent recurrence, the 
role of anti-inflammatory treatment for established active carditis is less certain. Carditis is the most serious major manifestation of RF 
which may culminate in chronic valvular disease and can lead to heart failure and, ultimately, death. This systematic review included 
eight randomised controlled trials involving 996 people; six of the trials included children. Researchers compared several steroidal 
agents versus aspirin, placebo or no treatment. There was little evidence of any benefit when corticosteroids or intravenous 
immunoglobulins were used to reduce the risk of heart valve lesions in patients with acute RF. Most of the trials were completed over 
40 years ago and there was substantial risk of bias, so results should be viewed with caution. New randomised controlled trials are 
needed in patients with acute RF to assess the effects of corticosteroids such as oral prednisone and intravenous methylprednisolone 
and the effects of other new anti-inflammatory a gents, using contemporary echocardiography techniques to provide more objective 
and precise assessments of cardiac outcomes. 
Spinks A, et al. 2013. Antibiotics for sore throat. Cochrane Database of Systematic Reviews 
doi:10.1002/14651858.CD000023.pub4 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000023.pub4/pdf 
A systematic review of 27 randomised placebo-controlled trials with a total of 12,835 cases of sore throat found that antibiotics 
shortened the duration of pain symptoms by about one day and reduced the chance of developing RF by more than two-thirds in 
communities where that complication was common. Very few of these studies included children. The studies were of moderate to high 
quality; however most were conducted more than 30 years ago when patterns of disease and of antibiotic resistance were different 
from the present time. Based on the results of this review the use of antibiotics to treat sore throats may be justified to reduce the 
incidence of RF in high-prevalence settings, but in other settings there is a balance to be made between modest symptom reduction 
and the hazards of antimicrobial resistance. More trials are needed that involve children, and in high-income countries we need better 
prognostic studies to further define which patients are most likely to develop complications of sore throat and therefore benefit from 
antibiotic treatment. 
Esposito S, et al. 2015. Geoepidemiological hints about Streptococcus pyogenes strains in relationship with acute 
rheumatic fever. Autoimmunity Reviews, 14(7), 616-21. 
Group A Streptococcus causes a wide array of syndromes, including acute RF and GAS isolates can be serotyped using serotype specific 
antisera against the M protein. Although the epidemiological relationship between peculiar GAS strains and acute RF epidemics is 
complex, types M5 and M18 are particularly associated with acute RF. Newer genotyping methods (emm-typing) allows scientists to 
distinguish between GAS strains that were identical based on M-typing. Over 200 emm genotypes have been documented so far, and 
many studies have shown variability of emm genotypes in different countries of the world. The association with RF for each strain is 
variable depending on the design of studies, year of observation, seasonal variations, country involved, patients' age and gender. This 
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area of laboratory research is important because surveillance of disease-causing emm genotypes in communities with high rates of 
acute rheumatic fever could contribute to design of a potential vaccine against GAS infections. 
Other relevant publications 
Saxena A. 2014. Increasing detection of rheumatic heart disease with echocardiography. Expert Review of Medical 
Devices, 11(5), 491-97. 
This article reviewed data on echocardiographic screening from several countries including India and summarised the current 
understanding of unresolved issues relevant to the significance and management of subclinical RHD detected by echocardiography in 
asymptomatic patients. The author notes that RHD is estimated to affect over 20 million people worldwide with the vast majority of 
these people living in developing countries. Screening for RHD has been recommended by the WHO since 2004. Conventionally, 
auscultation of the chest with a stethoscope has been used for diagnosing RHD, but this method has limitations and may not detect 
mild cases. A large number of studies have reported echocardiographic screening for RHD over the last several years. Most of these 
studies report an almost 10-fold higher prevalence of RHD by echocardiography as compared to conventional method of auscultation. 
Early diagnosis of such mild cases may be important as instituting secondary prophylaxis in such cases may reduce the burden of the 
disease. However, several concerns remain about the significance and natural history of these minor valvular changes detected by 
echocardiography. Whether secondary prophylaxis will reverse these abnormalities is also unclear. Long term follow up studies are 
required to answer some of these concerns. 
Websites 
Ministry of Health. 2015. Rheumatic fever. http://www.health.govt.nz/your-health/conditions-and-
treatments/diseases-and-illnesses/rheumatic-fever accessed 29 October 2015. 
Information for families and communities about the symptoms of RF, ways to prevent it, and important actions for children who have 
had RF (e.g. monthly penicillin injections, and precautions before dental procedures. Includes links to videos and transcripts of interviews 
of children with RF and their parents as well as to the Ministry of Health RF website http://rheumaticfever.health.govt.nz/ All of the RF 
videos are available at http://www.health.govt.nz/our-work/diseases-and-conditions/rheumatic-fever/rheumatic-fever-
resources/rheumatic-fever-campaign-online-videos  
Ministry of Health. 2015. Sore throat clinics. https://www.health.govt.nz/your-health/conditions-and-
treatments/diseases-and-illnesses/sore-throat/sore-throat-clinics accessed 29 October 2015. 
This patient information page provides details of the free clinics where Māori or Pacific children aged 4–19 years in the Northland, 
Auckland, Lakes, Waikato, Bay of Plenty, Gisborne/East Coast, Hawke’s Bay, Porirua or Hutt Valley areas can have a sore throat checked 
at no charge. 
Kidshealth. 2015. Rheumatic fever. http://www.kidshealth.org.nz/rheumatic-fever accessed 30 October 2015 
This webpage provides information for parents and caregivers of children with RF and rheumatic heart disease. It describes conditions, 
explains that a child will usually need to stay in hospital for one to two weeks, or longer if their heart is affected, and provides advice 
about caring for the child when they return home, ensuring monthly penicillin injections continue until advised to stop by a doctor 
(usually at age 21 or 30), and key points to prevent further episodes of RF.  
National Heart Foundation. Rheumatic fever. http://www.heartfoundation.org.nz/know-the-
facts/conditions/rheumatic-fever accessed 30 October 2015 
This is a further webpage with information for the public about RF and rheumatic heart disease. It includes a link to a booklet about RF, 
published in 2012 and currently under revision, which is available in English, Tongan and Samoan. 
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SERIOUS SKIN INFECTIONS 
Introduction 
Serious skin infections are bacterial infections of the skin or subcutaneous tissue which require hospitalisation 
and often require invasive treatment like surgery. Such infections may be associated with a primary disease of 
the skin (e.g. eczema) and may follow trauma to the skin (e.g. insect bites).87 
New Zealand has one of the highest rates of childhood skin infections in the western world.88 Between 1990 and 
2007 skin infection hospitalisation rates almost doubled with disproportionate increases in infection rates in 
Māori and Pacific children and children from areas with high socioeconomic deprivation scores.89 An initial 
study suggests that there may be 14 cases treated in the community (primary care/GP) for every serious skin 
infection hospitalisation90 A number of socioeconomic factors are linked to the increasing frequency of skin 
infections including affordability of hot water, washing machines and dryers, access to medical care, household 
crowding, and inadequate nutrition.91 Other reasons for the development of skin infection include lack of 
awareness or knowledge about skin infections, and community attitudes which normalise such infection or 
stigmatise it so that people keep the condition hidden.88 
The following section reports on hospitalisations for serious skin infections in children and young people using 
information from the National Minimum Dataset. It concludes with a brief overview of evidence-based reviews 
and guidelines which consider the most effective interventions for preventing or managing serious skin 
infections. 
Data sources and methods 
Indicator 
 Hospitalisations involving serious skin infections in 0–24 year olds  
Data sources 
Numerator:  National Minimum Dataset 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years). 
Definition 
Hospitalisations of 0–24 year olds with a diagnosis of a serious skin infection in any of the first 15 diagnoses (hospitalisations 
per 1,000 age-specific population) 
The following select conditions were identified as the primary diagnosis among the hospitalisations involving serious skin 
infections: impetigo, cutaneous abscess, furuncle, or carbuncle, cellulitis, acute lymphadenitis, pilonidal cyst with abscess, other 
infections of skin and subcutaneous tissue, infections of other anatomical sites, infected, unspecified, or other dermatitis, insect 
or spider bites, post traumatic or open wound infection, scabies, and varicella with other complications.  
Notes on interpretation 
Note 1: This section utilises hospitalisations with relevant codes (see Appendix 6) in ANY of the first 15 diagnoses, rather than 
the primary diagnosis. 
Note 2: This section utilises a broader set of the diagnostic codes compared to those utilised in the sections covering 
ambulatory sensitive hospitalisations (ASH) or hospitalisations with a social gradient. Select codes external to the skin infection 
codes have been incorporated, such as insect and spider bites, infected and unspecified eczema, infected open wounds, and 
infections at specific anatomical sites (e.g. the genitalia), based on review by O’Sullivan and Baker of skin infections in children.89  
Note 3: The rates presented here differ from those presented in the ambulatory sensitive hospitalisations (ASH) or 
hospitalisations with a social gradient sections. As these indicators utilise primary diagnoses and full assessment and sector 
consultation has not yet occurred regarding these sections adopting of the revised coding convention, as utilised in this section. 
Note 4: Appendix 3 outlines the limitations of the data utilised from the National Minimum Dataset. The reader is advised to 
review this appendix before interpreting any trends. 
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National trends and distribution 
The hospitalisation rate for skin infections in 0–24 year olds was stable from 2000 to 2005, rose from 2005 to 
2011 and has since been steadily falling (Figure 124). A similar pattern was seen in 0–14 year olds and 15–24 
year olds although in every year the rate was higher in the younger age group (Figure 125). 
During the same period, rates were consistently highest in Pacific 0–24 year olds, followed by Māori then 
European then Asian/Indian. Pacific rates peaked in 2011 and Māori rates in 2010. Asian/Indian rates, although 
low, rose from 2000 to 2014, while European rates rose from 2000 to 2011 and then fell. Rates for MELAA 
were variable and slightly higher than European rates in 2009–2014 (Figure 126). 
Figure 124. Hospitalisations involving skin infections in 0–24 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; skin infections in any of the 
first 15 diagnoses 
Figure 125. Hospitalisations involving skin infections in 0–24 year olds, by age group, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Rate is per 1,000 age-
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Figure 126. Hospitalisations involving skin infections in 0–24 year olds, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Rate is per 1,000 age-
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Distribution by cause 
Between 2010 and 2014 cellulitis and cutaneous abscesses/furuncles/ carbuncles were the most frequent primary 
diagnoses in 0–14 year olds and 15–24 year olds hospitalised with serious skin infections (Table 102). Pilonidal 
cyst with abscess was also a relatively common diagnosis in 15–24 year olds. 
Table 102. Hospitalisations for skin infections in 0–24 year olds, by age group and primary diagnosis, New 
Zealand 2010–2014 






Rate 95% CI Per cent 
New Zealand 
0–14 year olds 
Cellulitis 6,674 1,335 1.47 1.44–1.51 18.8 
Cutaneous abscess, furuncle, or carbuncle 6,392 1,278 1.41 1.38–1.45 18.0 
Infected, unspecified, or other dermatitis 2,823 565 0.62 0.60–0.65 8.0 
Infections of other anatomical sites 1,977 395 0.44 0.42–0.46 5.6 
Acute lymphadenitis 1,151 230 0.25 0.24–0.27 3.2 
Impetigo 825 165 0.18 0.17–0.20 2.3 
Other infections of skin and subcutaneous tissue 623 125 0.14 0.13–0.15 1.8 
Insect or spider bites 566 113 0.12 0.12–0.14 1.6 
Scabies 518 104 0.11 0.10–0.12 1.5 
Varicella with other complications 465 93 0.10 0.09–0.11 1.3 
Post traumatic or open wound infection 144 29 0.03 0.03–0.04 0.4 
Pilonidal cyst with abscess 113 23 0.02 0.02–0.03 0.3 
Other diagnoses 13,209 2,642 2.92 2.87–2.97 37.2 
Total 35,480 7,096 7.83 7.75–7.92 100.0 
15–24 year olds 
Cutaneous abscess, furuncle, or carbuncle 4,703 941 1.51 1.46–1.55 21.3 
Cellulitis 3,507 701 1.12 1.09–1.16 15.9 
Pilonidal cyst with abscess 2,750 550 0.88 0.85–0.91 12.5 
Infections of other anatomical sites 1,803 361 0.58 0.55–0.61 8.2 
Infected, unspecified, or other dermatitis 399 80 0.13 0.12–0.14 1.8 
Insect or spider bites 321 64 0.10 0.09–0.11 1.5 
Other infections of skin and subcutaneous tissue 168 34 0.05 0.05–0.06 0.8 
Post traumatic or open wound infection 121 24 0.04 0.03–0.05 0.5 
Acute lymphadenitis 119 24 0.04 0.03–0.05 0.5 
Impetigo 117 23 0.04 0.03–0.04 0.5 
Scabies 71 14 0.02 0.02–0.03 0.3 
Varicella with other complications 8 2 <0.01 s <0.1 
Other diagnoses 7,993 1,599 2.56 2.51–2.62 36.2 
Total 22,080 4,416 7.07 6.98–7.17 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; skin infections in any of the 
first 15 diagnoses 
Distribution by demographic factors 
Between 2010 and 2014 skin infection hospitalisation rates for 0–24 year olds were highest for one year olds 
and decreased sharply with increasing age from one to four years. From age 15 years, rates rose somewhat with 
increasing age before levelling off from 19 years. At every age, male rates were a little higher than female rates 
(Figure 127). Similar patterns according to age were observed for all ethnic groups. Hospitalisation rates were 
consistently highest in Pacific, followed by Māori then European/Other and then Asian/Indian (Figure 128). 
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Figure 127. Hospitalisations involving skin infections in 0–24 year olds, by age and gender, New Zealand 2010–
2014 
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Rates are per 1,000 age-
specific population; skin infections in any of the first 15 diagnoses 
Figure 128. Hospitalisations involving skin infections in 0–24 year olds, by age and ethnicity, New Zealand 2010–
2014 
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Rates are per 1,000 age-
specific population; skin infections in any of the first 15 diagnoses 
Between 2010 and 2014 in 0–14 year olds there were disparities in skin infection hospitalisation rates by 
NZDep2013 index of deprivation score, ethnicity and gender. At each level of deprivation (other than deciles 1–
2), rates were significantly higher than those of the level below. There were significant differences in rates 
between all ethnic groups. Rates were highest in Pacific, followed by (in decreasing order) Māori, MELAA, 
Asian/Indian and European. Male rates were significantly higher than female rates (Table 103). 
In 15–24 year olds there were also disparities in skin infection hospitalisation rates by NZDep2013 index of 
deprivation score, ethnicity and gender. At each level of deprivation (other than deciles 1–2), rates were 
significantly higher than those of the level below. There were significant differences in rates between most 
ethnic groups. Only the difference between MELAA and European was non-significant. Rates were highest in 
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Pacific, followed by (in decreasing order) Māori, European and MELAA. Male rates were significantly higher 
than female rates (Table 103). 





Rate per 1,000 population Rate ratio 95% CI 
Skin infections 
0–14 year olds 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 3,078 3.53 1.00   
Deciles 3–4 3,549 4.40 1.24 1.19–1.31 
Deciles 5–6 4,868 5.69 1.61 1.54–1.69 
Deciles 7–8 7,245 7.71 2.18 2.09–2.28 
Deciles 9–10 16,578 15.71 4.45 4.28–4.62 
Prioritised ethnicity 
Māori 13,629 11.83 2.74 2.67–2.81 
Pacific 8,806 20.24 4.68 4.55–4.81 
Asian/Indian 2,235 4.69 1.09 1.04–1.14 
MELAA 336 6.04 1.40 1.25–1.56 
European/Other 10,418 4.32 1.00   
Gender 
Female 15,385 6.97 1.00   
Male 20,095 8.65 1.24 1.22–1.27 
15–24 year olds 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 2,288 4.31 1.00   
Deciles 3–4 2,709 5.19 1.20 1.14–1.27 
Deciles 5–6 3,539 6.08 1.41 1.34–1.49 
Deciles 7–8 5,027 7.39 1.72 1.63–1.80 
Deciles 9–10 8,302 10.31 2.39 2.29–2.51 
Prioritised ethnicity 
Māori 6,523 10.35 1.64 1.59–1.69 
Pacific 3,326 12.52 1.99 1.91–2.06 
Asian/Indian 947 2.05 0.33 0.30–0.35 
MELAA 272 6.41 1.02 0.90–1.15 
European/Other 10,847 6.30 1.00   
Gender 
Female 9,219 6.01 1.00   
Male 12,861 8.11 1.35 1.31–1.39 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Rates are per 1,000 age-
specific population; skin infections in any of the first 15 diagnoses; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; 
Decile is NZDep2013 
Distribution by month 
There was no great variation in hospitalisation for serious skin infections by month in 0–14 year olds or 15–24 
year olds in 2010–2014 but rates tended to be somewhat higher during January–March. 
Distribution by region 
Between 2010 and 2014 hospitalisation rates for serious skin infections in 0–24 year olds were significantly 
higher than the national rate in the Northland, Waitemata, Auckland, Counties Manukau, Bay of Plenty, Lakes, 
Tairawhiti, Whanganui, and Hutt Valley DHBs, and significantly lower in Waikato, Taranaki, Hawke’s Bay, 
MidCentral, Capital & Coast, Wairarapa and all of the South Island DHBs (Figure 129, Table 104).  
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The significance for DHB hospitalisation rates for serious skin infections in 0–14 year olds was the same as for 
0–24 year olds (Table 105) while for 15–24 year olds rates were significantly higher than the national rate in the 
Northland, Counties Manukau, Bay of Plenty, Lakes, Tairawhiti, Whanganui and Hutt Valley DHBs, and 
significantly lower in Auckland, Waikato, Capital & Coast, and all of the South Island DHBs (Table 106). 
Figure 129. Hospitalisations involving skin infections in 0–24 year olds, by district health board, New Zealand 
2010–2014 
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; skin infections in any of the 
first 15 diagnoses; Rates are per 1,000 0–24 year olds 







Rate per 1,000  
0–24 year olds 
Rate ratio 95% CI 
Any skin infections 
0–24 year olds 
Northland 2,721 544 9.79 1.30 1.25–1.35 
Waitemata 7,525 1,505 7.96 1.06 1.03–1.08 
Auckland 6,161 1,232 7.87 1.05 1.02–1.07 
Counties Manukau 10,295 2,059 10.60 1.41 1.38–1.44 
Waikato 4,493 899 6.63 0.88 0.85–0.91 
Bay of Plenty 3,316 663 9.41 1.25 1.21–1.29 
Lakes 1,761 352 9.56 1.27 1.21–1.33 
Tairawhiti 1,068 214 11.83 1.57 1.48–1.67 
Taranaki 1,096 219 5.82 0.77 0.73–0.82 
Hawke's Bay 1,889 378 6.97 0.93 0.89–0.97 
MidCentral 2,023 405 6.79 0.90 0.86–0.94 
Whanganui 893 179 8.53 1.13 1.06–1.21 
Hutt Valley 2,394 479 9.75 1.30 1.24–1.35 
Capital & Coast 3,309 662 6.56 0.87 0.84–0.90 
Wairarapa 413 83 6.28 0.83 0.76–0.92 
Nelson Marlborough 792 158 3.78 0.50 0.47–0.54 
South Canterbury 330 66 3.87 0.51 0.46–0.57 
Canterbury 3,939 788 4.76 0.63 0.61–0.65 
West Coast 182 36 3.65 0.49 0.42–0.56 
Southern 2,611 522 5.05 0.67 0.65–0.70 
New Zealand 57,560 11,512 7.52 1.00   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; skin infections in any of the 
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Rate per 1,000  
0–14 year olds 
Rate ratio 95% CI 
Any skin infections 
0–14 year olds 
Northland 1,853 371 10.22 1.30 1.24–1.37 
Waitemata 4,805 961 8.56 1.09 1.06–1.13 
Auckland 3,949 790 9.57 1.22 1.18–1.26 
Counties Manukau 6,749 1,350 11.37 1.45 1.41–1.49 
Waikato 2,720 544 6.67 0.85 0.82–0.88 
Bay of Plenty 2,143 429 9.44 1.21 1.15–1.26 
Lakes 1,100 220 9.36 1.19 1.13–1.27 
Tairawhiti 738 148 12.60 1.61 1.50–1.73 
Taranaki 596 119 4.98 0.64 0.59–0.69 
Hawke's Bay 1,240 248 7.16 0.91 0.86–0.97 
MidCentral 1,098 220 6.40 0.82 0.77–0.87 
Whanganui 567 113 8.66 1.11 1.02–1.20 
Hutt Valley 1,574 315 10.42 1.33 1.27–1.40 
Capital & Coast 1,905 381 6.96 0.89 0.85–0.93 
Wairarapa 244 49 5.81 0.74 0.65–0.84 
Nelson Marlborough 473 95 3.52 0.45 0.41–0.49 
South Canterbury 197 39 3.72 0.48 0.41–0.55 
Canterbury 2,048 410 4.33 0.55 0.53–0.58 
West Coast 75 15 2.38 0.30 0.24–0.38 
Southern 1,255 251 4.48 0.57 0.54–0.60 
New Zealand 35,480 7,096 7.83 1.00   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; skin infections in any of the 
first 15 diagnoses; Rates are per 1,000 0–14 year olds; Rate ratios are unadjusted 





 Number:  
annual average 
Rate per 1,000 
15–24 year olds 
Rate ratio 95% CI 
Any skin infections 
15–24 year olds 
Northland 868 174 9.00 1.27 1.19–1.36 
Waitemata 2,720 544 7.09 1.00 0.96–1.04 
Auckland 2,212 442 5.97 0.84 0.81–0.88 
Counties Manukau 3,546 709 9.39 1.33 1.28–1.37 
Waikato 1,773 355 6.57 0.93 0.89–0.97 
Bay of Plenty 1,173 235 9.35 1.32 1.25–1.40 
Lakes 661 132 9.92 1.40 1.30–1.51 
Tairawhiti 330 66 10.42 1.47 1.32–1.64 
Taranaki 500 100 7.27 1.03 0.94–1.12 
Hawke's Bay 649 130 6.65 0.94 0.87–1.02 
MidCentral 925 185 7.33 1.04 0.97–1.11 
Whanganui 326 65 8.31 1.17 1.05–1.31 
Hutt Valley 820 164 8.67 1.23 1.14–1.31 
Capital & Coast 1,404 281 6.08 0.86 0.81–0.91 
Wairarapa 169 34 7.11 1.01 0.86–1.17 
Nelson Marlborough 319 64 4.23 0.60 0.54–0.67 
South Canterbury 133 27 4.12 0.58 0.49–0.69 
Canterbury 1,891 378 5.33 0.75 0.72–0.79 
West Coast 107 21 5.84 0.83 0.68–1.00 
Southern 1,356 271 5.74 0.81 0.77–0.86 
New Zealand 22,080 4,416 7.07 1.00   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; skin infections in any of the 
first 15 diagnoses; Rates are per 1,000 15–24 year olds; Rate ratios are unadjusted 
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014 hospitalisation rates for serious skin infections in 0–24 year olds, 0–14 year olds, and 
15–24 year olds were significantly higher than the national rate in Bay of Plenty, Lakes DHB, and Tairawhiti 
DHBs. In Taranaki DHB rates in 0–24 year olds and 0–14 year olds were significantly lower than the national 
rate, but rates were not significantly different in 15–24 year olds. Waikato DHB rates in all age groups were 
significantly lower than the corresponding national rate (Table 107). 







Rate per 1,000 
population 
Rate ratio 95% CI 
Any skin infections 
0–24 year olds 
Waikato 4,493 899 6.63 0.88 0.85–0.91 
Bay of Plenty 3,316 663 9.41 1.25 1.21–1.29 
Lakes 1,761 352 9.56 1.27 1.21–1.33 
Tairawhiti 1,068 214 11.83 1.57 1.48–1.67 
Taranaki 1,096 219 5.82 0.77 0.73–0.82 
New Zealand 57,560 11,512 7.52 1.00   
0–14 year olds 
Waikato 2,720 544 6.67 0.85 0.82–0.88 
Bay of Plenty 2,143 429 9.44 1.21 1.15–1.26 
Lakes 1,100 220 9.36 1.19 1.13–1.27 
Tairawhiti 738 148 12.60 1.61 1.50–1.73 
Taranaki 596 119 4.98 0.64 0.59–0.69 
New Zealand 35,480 7,096 7.83 1.00   
15–24 year olds 
Waikato 1,773 355 6.57 0.93 0.89–0.97 
Bay of Plenty 1,173 235 9.35 1.32 1.25–1.40 
Lakes 661 132 9.92 1.40 1.30–1.51 
Tairawhiti 330 66 10.42 1.47 1.32–1.64 
Taranaki 500 100 7.27 1.03 0.94–1.12 
New Zealand 22,080 4,416 7.07 1.00   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the 
first 15 diagnoses; Rate ratios are unadjusted 
Regional trends 
During 2000–2014, hospital admissions for serious skin infections in 0–24 year olds generally increased in all 
five Midland DHBs over most of the period but, like the national rate, have been falling over recent years 
(Figure 130). The same general trend was apparent in all the DHBs in both the 0–14 and 15–24 years age 
groups, but in Bay of Plenty, Lakes DHB, and Tairawhiti rates were consistently higher for 0–14 and 15–24 year 
olds (Figure 131).  
From 2000 to 2014, rates for Pacific and Māori 0–24 year olds hospitalised with skin infections in Waikato, Bay 
of Plenty, and Lakes DHB, and for Māori 0–24 year olds in Tairawhiti and Taranaki DHB followed the overall 
national trend rising for the earlier part of the period and falling more recently. Pacific rates were mostly higher 
than Māori rates in Bay of Plenty. Māori consistently had the highest rates in the other Midland DHBs.  
European rates remained steady in all Midland DHBs between 2000 and 2014, while Asian/Indian rates rose 
slightly in Waikato and Bay of Plenty DHBs. European rates were higher than Asian/Indian but lower than 
Māori and Pacific rates in Waikato and Bay of Plenty DHBs, and lower than Māori rates in all Midland DHBs. 
In Bay of Plenty DHB rates for Pacific and Asian/Indian 0–24 year olds were variable, which is likely to be a 
reflection of the small numbers in those ethnic groups there (Figure 132). 
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Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the first 15 diagnoses 



















































































































































































































































































































































DHB 0–14 years New Zealand 0–14 years
DHB 15–24 years New Zealand 15–24 years
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the first 15 diagnoses; Rates per 1,000 age-specific population 
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Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the first 15 diagnoses 
 
 
Common communicable diseases: Serious skin infections 
252 
Regional distribution by cause 
In all the Midland DHBs during 2010–2014, cellulitis and cutaneous abscesses, furuncles or carbuncles were the 
most frequent primary diagnoses in 0–24 year olds admitted to hospital with serious skin infections (Table 108–
Table 112). 
Table 108. Hospitalisations for serious skin infections in 0–24 year olds, by age group and primary diagnosis, 
Waikato DHB 2010–2014 









95% CI Per cent 
Waikato 
0–14 year olds 
Cutaneous abscess, furuncle, or carbuncle 518 104 1.27 1.16–1.38 19.0 
Cellulitis 462 92 1.13 1.03–1.24 17.0 
Infections of other anatomical sites 157 31 0.38 0.33–0.45 5.8 
Infected, unspecified, or other dermatitis 149 30 0.37 0.31–0.43 5.5 
Acute lymphadenitis 66 13 0.16 0.13–0.21 2.4 
Insect or spider bites 59 12 0.14 0.11–0.19 2.2 
Impetigo 52 10 0.13 0.10–0.17 1.9 
Other infections of skin and subcutaneous tissue 48 10 0.12 0.09–0.16 1.8 
Varicella with other complications 44 9 0.11 0.08–0.14 1.6 
Scabies 35 7 0.09 0.06–0.12 1.3 
Pilonidal cyst with abscess 9 2 0.02 0.01–0.04 0.3 
Post traumatic or open wound infection 7 1 0.02 0.01–0.04 0.3 
Other diagnoses 1,114 223 2.73 2.58–2.90 41.0 
Total 2,720 544 6.67 6.42–6.92 100.0 
15–24 year olds 
Cutaneous abscess, furuncle, or carbuncle 357 71 1.32 1.19–1.47 20.1 
Cellulitis 249 50 0.92 0.82–1.05 14.0 
Pilonidal cyst with abscess 240 48 0.89 0.78–1.01 13.5 
Infections of other anatomical sites 175 35 0.65 0.56–0.75 9.9 
Insect or spider bites 33 7 0.12 0.09–0.17 1.9 
Infected, unspecified, or other dermatitis 14 3 0.05 0.03–0.09 0.8 
Other infections of skin and subcutaneous tissue 13 3 0.05 0.03–0.08 0.7 
Acute lymphadenitis 8 2 0.03 0.02–0.06 0.5 
Scabies 8 2 0.03 0.02–0.06 0.5 
Impetigo <5 s s s s 
Post traumatic or open wound infection <5 s s s s 
Varicella with other complications 0  .. .. .. .. 
Other diagnoses 670 134 2.48 2.30–2.68 37.8 
Total 1,773 355 6.57 6.28–6.89 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the 
first 15 diagnoses; Rates per 1,000 age-specific population 
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Table 109. Hospitalisations for serious skin infections in 0–24 year olds, by age group and primary diagnosis, 
Bay of Plenty DHB 2010–2014 









95% CI Per cent 
Bay of Plenty 
0–14 year olds 
Cellulitis 358 72 1.58 1.42–1.75 16.7 
Cutaneous abscess, furuncle, or carbuncle 329 66 1.45 1.30–1.61 15.4 
Infected, unspecified, or other dermatitis 217 43 0.96 0.84–1.09 10.1 
Infections of other anatomical sites 108 22 0.48 0.39–0.57 5.0 
Insect or spider bites 76 15 0.33 0.27–0.42 3.5 
Impetigo 55 11 0.24 0.19–0.32 2.6 
Acute lymphadenitis 50 10 0.22 0.17–0.29 2.3 
Scabies 48 10 0.21 0.16–0.28 2.2 
Varicella with other complications 45 9 0.20 0.15–0.27 2.1 
Other infections of skin and subcutaneous tissue 38 8 0.17 0.12–0.23 1.8 
Post traumatic or open wound infection 20 4 0.09 0.06–0.14 0.9 
Pilonidal cyst with abscess 5 1 0.02 0.01–0.05 0.2 
Other diagnoses 794 159 3.50 3.26–3.75 37.1 
Total 2,143 429 9.44 9.05–9.85 100.0 
15–24 year olds 
Cutaneous abscess, furuncle, or carbuncle 231 46 1.84 1.62–2.09 19.7 
Cellulitis 191 38 1.52 1.32–1.75 16.3 
Pilonidal cyst with abscess 111 22 0.88 0.73–1.07 9.5 
Infections of other anatomical sites 59 12 0.47 0.36–0.61 5.0 
Insect or spider bites 38 8 0.30 0.22–0.42 3.2 
Infected, unspecified, or other dermatitis 27 5 0.22 0.15–0.31 2.3 
Post traumatic or open wound infection 13 3 0.10 0.06–0.18 1.1 
Impetigo 10 2 0.08 0.04–0.15 0.9 
Other infections of skin and subcutaneous tissue 10 2 0.08 0.04–0.15 0.9 
Acute lymphadenitis 5 1 0.04 0.02–0.09 0.4 
Scabies <5 s s s s 
Varicella with other complications 0 s s s s 
Other diagnoses 473 95 3.77 3.45–4.12 40.3 
Total 1,173 235 9.35 8.83–9.90 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the 
first 15 diagnoses; Rates per 1,000 age-specific population 
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Table 110. Hospitalisations for serious skin infections in 0–24 year olds, by age group and primary diagnosis, 
Lakes DHB 2010–2014 









95% CI Per cent 
Lakes DHB 
0–14 year olds 
Cellulitis 202 40 1.72 1.50–1.97 18.4 
Cutaneous abscess, furuncle, or carbuncle 141 28 1.20 1.02–1.41 12.8 
Infected, unspecified, or other dermatitis 99 20 0.84 0.69–1.02 9.0 
Infections of other anatomical sites 48 10 0.41 0.31–0.54 4.4 
Acute lymphadenitis 30 6 0.26 0.18–0.36 2.7 
Impetigo 26 5 0.22 0.15–0.32 2.4 
Varicella with other complications 24 5 0.20 0.14–0.30 2.2 
Insect or spider bites 23 5 0.20 0.13–0.29 2.1 
Other infections of skin and subcutaneous tissue 18 4 0.15 0.10–0.24 1.6 
Scabies 14 3 0.12 0.07–0.20 1.3 
Pilonidal cyst with abscess 7 1 0.06 0.03–0.12 0.6 
Post traumatic or open wound infection <5 s s s s 
Other diagnoses 465 93 3.96 3.61–4.33 42.3 
Total 1,100 220 9.36 8.82–9.92 100.0 
15–24 year olds 
Cutaneous abscess, furuncle, or carbuncle 132 26 1.98 1.67–2.35 20.0 
Cellulitis 116 23 1.74 1.45–2.09 17.5 
Pilonidal cyst with abscess 60 12 0.90 0.70–1.16 9.1 
Infections of other anatomical sites 29 6 0.44 0.30–0.62 4.4 
Insect or spider bites 16 3 0.24 0.15–0.39 2.4 
Infected, unspecified, or other dermatitis 15 3 0.23 0.14–0.37 2.3 
Other infections of skin and subcutaneous tissue <5 s s s s 
Scabies <5 s s s s 
Acute lymphadenitis <5 s s s s 
Impetigo <5 s s s s 
Post traumatic or open wound infection <5 s s s s 
Varicella with other complications 0 .. .. .. .. 
Other diagnoses 278 56 4.17 3.71–4.69 42.1 
Total 661 132 9.92 9.19–10.7 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the 
first 15 diagnoses; Rates per 1,000 age-specific population 
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Table 111. Hospitalisations for serious skin infections in 0–24 year olds, by age group and primary diagnosis, 
Tairawhiti DHB 2010–2014 









95% CI Per cent 
Tairawhiti 
0–14 year olds 
Cellulitis 109 22 1.86 1.54–2.24 14.8 
Cutaneous abscess, furuncle, or carbuncle 107 21 1.83 1.51–2.21 14.5 
Infected, unspecified, or other dermatitis 100 20 1.71 1.40–2.08 13.6 
Impetigo 27 5 0.46 0.32–0.67 3.7 
Infections of other anatomical sites 21 4 0.36 0.23–0.55 2.8 
Acute lymphadenitis 17 3 0.29 0.18–0.46 2.3 
Other infections of skin and subcutaneous tissue 17 3 0.29 0.18–0.46 2.3 
Scabies 10 2 0.17 0.09–0.31 1.4 
Insect or spider bites 7 1 0.12 0.06–0.25 0.9 
Varicella with other complications 6 1 0.10 0.05–0.22 0.8 
Pilonidal cyst with abscess <5 s s s s 
Post traumatic or open wound infection 0 .. .. .. .. 
Other diagnoses 316 63 5.39 4.83–6.02 42.8 
Total 738 148 12.60 11.7–13.5 100.0 
15–24 year olds 
Cellulitis 72 14 2.27 1.81–2.86 21.8 
Cutaneous abscess, furuncle, or carbuncle 55 11 1.74 1.33–2.26 16.7 
Pilonidal cyst with abscess 22 4 0.69 0.46–1.05 6.7 
Infections of other anatomical sites 16 3 0.51 0.31–0.82 4.8 
Infected, unspecified, or other dermatitis 5 1 0.16 0.07–0.37 1.5 
Acute lymphadenitis 5 1 0.16 0.07–0.37 1.5 
Other infections of skin and subcutaneous tissue 5 1 0.16 0.07–0.37 1.5 
Insect or spider bites <5 s s s s 
Impetigo <5 s s s s 
Varicella with other complications <5 s s s s 
Scabies 0 .. .. .. .. 
Post traumatic or open wound infection 0 .. .. .. .. 
Other diagnoses 144 29 4.55 3.86–5.35 43.6 
Total 330 66 10.42 9.36–11.6 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the 
first 15 diagnoses; Rates per 1,000 age-specific population 
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Table 112. Hospitalisations for serious skin infections in 0–24 year olds, by age group and primary diagnosis, 
Taranaki DHB 2010–2014 









95% CI Per cent 
Taranaki 
0–14 year olds 
Cellulitis 110 22 0.92 0.76–1.11 18.5 
Cutaneous abscess, furuncle, or carbuncle 104 21 0.87 0.72–1.05 17.4 
Infected, unspecified, or other dermatitis 62 12 0.52 0.4–0.66 10.4 
Impetigo 31 6 0.26 0.18–0.37 5.2 
Infections of other anatomical sites 20 4 0.17 0.11–0.26 3.4 
Other infections of skin and subcutaneous tissue 14 3 0.12 0.07–0.2 2.3 
Scabies 12 2 0.10 0.06–0.18 2.0 
Insect or spider bites 9 2 0.08 0.04–0.14 1.5 
Acute lymphadenitis 8 2 0.07 0.03–0.13 1.3 
Varicella with other complications 5 1 0.04 0.02–0.1 0.8 
Post traumatic or open wound infection <5 s s s s 
Pilonidal cyst with abscess <5 s s s s 
Other diagnoses 216 43 1.80 1.58–2.06 36.2 
Total 596 119 4.98 4.6–5.4 100.0 
15–24 year olds 
Cellulitis 105 21 1.53 1.26–1.85 21.0 
Cutaneous abscess, furuncle, or carbuncle 94 19 1.37 1.12–1.67 18.8 
Pilonidal cyst with abscess 62 12 0.90 0.7–1.16 12.4 
Infections of other anatomical sites 43 9 0.63 0.46–0.84 8.6 
Insect or spider bites 9 2 0.13 0.07–0.25 1.8 
Infected, unspecified, or other dermatitis 8 2 0.12 0.06–0.23 1.6 
Other infections of skin and subcutaneous tissue 5 1 0.07 0.03–0.17 1.0 
Impetigo <5 s s s s 
Acute lymphadenitis <5 s s s s 
Post traumatic or open wound infection <5 s s s s 
Varicella with other complications 0 .. .. .. .. 
Scabies 0 .. .. .. .. 
Other diagnoses 167 33 2.43 2.09–2.82 33.4 
Total 500 100 7.27 6.66–7.93 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; Skin infections in any of the 
first 15 diagnoses; Rates per 1,000 age-specific population 
Regional distribution by season 
In the Midland DHBs during 2010–2014, there were no consistent seasonal variations in hospitalisation rates for 
serious skin infections among 0–24 year olds. 
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Evidence for good practice relevant to serious skin infections 
Ministry of Health publications 
White C, et al. 2013. Health literacy and the prevention and management of skin infections. Workplace Education Trust. 
http://www.healthliteracy.org.nz/wp-content/uploads/2013/11/Report-skin-infections.pdf  
This report was prepared for the Ministry of Health to investigate the role of health literacy interventions in the prevention and management 
of skin infections in Māori children aged under 15 years. Identification of barriers to and facilitators of health literacy as well as interventions to 
improve health literacy led to the development and trialling of resources for parents and caregivers. These could be used by health practitioners 
and teachers to discuss the prevention and management of skin infections. The booklet and poster were well received and lesson plans 
developed for schools also received positive feedback from teachers. Appendices include the full skin infection literature review and copies of 
the booklet and poster. The latter resources can also be accessed from the Workplace Education webpage (scroll down to find skin resources) 
http://www.healthliteracy.org.nz/research-and-projects/#3726 .  
New Zealand guidelines 
DermNet New Zealand Trust. 2015. DermNet NZ: The dermatology resource. http://www.dermnetnz.org/contents.html 
accessed 16 November 2015. 
This interactive website provides detailed information about skin conditions including boils, abscesses, impetigo and cellulitis. For each type of 
skin infection there are links to clinical information including photographs, reasons for occurrence, prevention and treatment methods. Within 
the website there is also a link to an online continuing education resource for health professionals on bacterial skin infections 
http://www.dermnetnz.org/doctors/bacterial-infections/  
Evidence-based medicine reviews 
Bowen AC, et al. 2015. The global epidemiology of impetigo: A systematic review of the population prevalence of 
impetigo and pyoderma. PLoS ONE, 10(8). 
A systematic review of the global childhood population prevalence of impetigo (also known as skin sores or school sores) and bacterial skin 
infections associated with the production of pus (collectively known as pyoderma; a term that is inclusive of impetigo) using journal articles 
published between 1970 and 2014. Impetigo prevalence was highest in Oceania, in both resource-poor countries and underprivileged 
populations within high-income countries. The authors comment that as antibiotics are a mainstay of treatment for impetigo, the high disease 
burden may contribute to antibiotic resistance in the absence of evidence-based treatment algorithms.  
Koning S, et al. 2012. Interventions for impetigo. Cochrane Database of Systematic Reviews. 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003261.pub3/full  
Authors included 68 trials with 5578 participants, reporting on 50 different treatments, including placebo. Topical antibiotic treatment showed 
better cure rates than placebo (pooled risk ratio (RR) 2. 24, 95% confidence interval (CI) 1.61 to 3.13) in 6 studies with 575 participants. In 4 
studies with 440 participants the two most commonly studied topical antibiotics (mupirocin and fusidic acid) were equally effective. There was 
good evidence that topical mupirocin and topical fusidic acid are equally, or more, effective than oral treatment. There was a lack of evidence 
for the benefit of using disinfectant solutions. In 2 pooled studies with 292 participants, topical antibiotics were significantly better than 
disinfecting treatments (RR 1.15, 95% CI 1.01 to 1.32).  
Other relevant publications 
O'Sullivan CE, et al. 2011. Increasing hospitalizations for serious skin infections in New Zealand children, 1990 - 2007. 
Epidemiology and Infection, 139(11), 1794-804. 
Descriptive epidemiology of serious skin infections in New Zealand 0–14 year olds showed an increase in incidence from 1990 to 2007 in which 
time rates almost doubled. Between 1990 and 2007 there were 64,568 hospitalisations of NZ children for serious skin infections with a mean 
stay of 3.3 days. Cost of hospitalisations in 2007 alone was estimated at NZ$15 million. Hospitalisation rates were significantly higher in summer 
and autumn, and there was a rough North-South gradient with higher rates in North Island DHBs compared with South Island. Urban areas had 
higher hospitalisation rates than rural areas for skin infections. There was worsening disparity by NZ Index of Deprivation score over time.  
O'Sullivan C & Baker MG. 2012. Skin infections in children in a New Zealand primary care setting: Exploring beneath the 
tip of the iceberg. New Zealand Medical Journal, 125(1351), 70-79. https://www.nzma.org.nz/journal/read-the-journal/all-
issues/2010-2019/2012/vol-125-no-1351/article-osullivan2  
O’Sullivan et al undertook subsequent research to estimate the incidence of childhood skin infections in primary care through prospective 
observational analysis of cases seen by a cohort of general practitioners (GPs) in the Tairawhiti region. They found that the epidemiology of 
skin infections in primary care reflected that of hospitalised serious skin infections, except there was a relatively higher proportion of 5–9 year 
olds presenting to GPs whereas hospitalisations were mainly of preschool-aged children. If the observed ratio of 14 primary care cases for every 
one hospitalised case applied uniformly across NZ there may be 62,347 GP cases per year nationally, although further studies in other primary 
care populations are needed before relying on such extrapolations. 
Websites 
Kidshealth. 2014. Looking after your child's skin and treating skin infections. http://kidshealth.org.nz/looking-after-your-
childs-skin-and-treating-skin-infections accessed 18 November 2015. Kidshealth. 2014. Boils. accessed 16 November 2015. 
This webpage provides a link to a 24 page booklet that will assist parents and caregivers to keep skin healthy and recognise a number of skin 
conditions including boils, cellulitis and impetigo. From this page parents can follow links to information about a number of skin conditions 
including patient-centred information about identification and management of boils http://kidshealth.org.nz/boils and impetigo 
http://kidshealth.org.nz/impetigo-school-sores and a poster about skin problems in children http://kidshealth.org.nz/skin-problems-children. 
 
 




Acute gastroenteritis is the sudden onset of diarrhoea with three or more loose stools per day and may be 
accompanied by vomiting. It is most commonly caused by micro-organisms spread by the faecal-oral route and 
is only rarely due to chemical contamination of water or food.75 Gastroenteritis caused by rotavirus is extremely 
common, estimated to affect almost all children, and has an illness spectrum more severe than diarrhoea from 
other causes. Clinical presentation of rotavirus can vary from asymptomatic infection to severe dehydrating 
gastroenteritis; the latter occurs predominantly between the ages of three months and two years.57  
Certain categories of acute gastroenteritis are notifiable conditions including cases of infectious gastroenteritis 
where there is a suspected common source (e.g. norovirus or rotavirus outbreak); single cases in a high-risk 
category (e.g. early childhood education worker), single cases of chemical, bacterial or toxic food poisoning 
(e.g. botulism), and disease caused by toxin-producing Escherichia coli or other organisms of public health 
importance. These must all be reported to the local medical officer of health without delay.75 The most 
important factors in preventing the spread of gastroenteritis are washing hands with soap in warm running water 
and careful drying (especially after going to the toilet or changing nappies and before preparing, serving or 
eating food), and keeping children away from school until at least 48 hours after the last episode of diarrhoea or 
vomiting and from swimming in pools until two weeks after the last episode of diarrhoea.75,92 However because 
rates of rotavirus illness are similar in developed and developing countries it is likely that good hygiene and 
clean water supplies do not have a significant impact on primary prevention of rotaviral disease and 
immunisation is the primary public health measure for the reduction of rotavirus disease burden. Since July 
2014 rotavirus vaccine has been funded at ages 6 weeks, 3 and 5 months as part of the National Immunisation 
Schedule.57  
The following section reports on hospitalisations for gastroenteritis in children and young people using 
information from the National Minimum Dataset. It concludes with a brief overview of evidence-based reviews 
and guidelines which consider the most effective interventions for preventing or managing gastroenteritis in 
children and young people. 
Data sources and methods 
Indicator 
 Hospitalisations for gastroenteritis in 0–24 year olds 
Data sources 
Numerator: National Minimum Dataset 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years). 
Definition 
Hospitalisations: Acute and arranged hospitalisations for 0–24 year olds with a primary diagnosis of gastroenteritis. Refer to 
Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: An acute admission is an unplanned hospitalisation occurring on the day of presentation, while an arranged admission 
(also referred to as an arranged hospitalisation) is a non-acute hospitalisation with an admission date less than seven days after 
the date the decision was made that the hospitalisation was necessary.  
Note 2: Appendix 3 outlines the limitations of the data utilised from the National Minimum Dataset. The reader is advised to 
review this appendix before interpreting any trends. 
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National trends and distribution 
From 2000 to 2014 the gastroenteritis hospitalisation rate for 0–24 year olds rose slightly overall although there 
were year to year fluctuations (Figure 133). 
Similar patterns over time were observed for the four largest ethnic groups. Pacific rates were consistently 
higher than all other groups except MELAA. Māori, European/Other and Asian/Indian rates were similar over 
the period (with European rates generally being slightly higher), but MELAA rates were consistently higher 
than any other ethnic group and increased to a greater degree from 2007 onwards so that the gap between rates 
for MELAA and for other ethnic groups increased noticeably over time (Figure 134). The upward trend in 
gastroenteritis admission rates was evident in all age groups (Figure 135). 
Figure 133. Hospitalisations for gastroenteritis in 0–24 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Figure 134. Hospitalisations for gastroenteritis in 0–24 year olds, by ethnicity, New Zealand 2000–2014 
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Figure 135. Hospitalisations for gastroenteritis in 0–24 year olds, by age group, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Distribution by cause 
Between 2010 and 2014 most gastroenteritis hospitalisations were presumed infectious although the specific 
agent was not identified, and where identified, viral infections were most common. During this period, then the 
most frequent primary diagnoses among 0–24 year olds admitted to hospital with gastroenteritis were ‘other 
gastroenteritis and colitis of infectious origin and viral enteritis’ (Table 113). 










95% CI Per cent 
Gastroenteritis in 0–24 year olds 
New Zealand  
Bacterial 
Typhoid and paratyphoid fevers 116 23 0.02 0.01–0.02 0.3 
Other salmonella infections 202 40 0.03 0.02–0.03 0.5 
Shigellosis 42 8 0.01 0.004–0.01 0.1 
Other bacterial intestinal infections 1,150 230 0.15 0.14–0.16 3.1 
Other bacterial foodborne intoxications 106 21 0.01 0.01–0.02 0.3 
Total bacterial 1,616 323 0.21 0.20–0.22 4.4 
Parasitic 
Amoebiasis 11 2 0.00 0.001–0.003 0.0 
Other protozoal intestinal diseases 138 28 0.02 0.02–0.02 0.4 
Total parasitic 149 30 0.02 0.02–0.02 0.4 
Viral 
Rotavirus 3,557 711 0.46 0.45–0.48 9.7 
Norovirus 81 16 0.01 0.01–0.01 0.2 
Other viral 8,461 1,692 1.11 1.08–1.13 23.0 
Total viral 12,099 2,420 1.58 1.55–1.61 32.9 
Other infectious 
Other gastroenteritis and colitis of infectious origin 16,848 3,370 2.20 2.17–2.24 45.7 
Other (presumed non-infectious) 
Nausea and vomiting 5,719 1,144 0.75 0.73–0.77 15.5 
Non-infective gastroenteritis and colitis, unspecified 397 79 0.05 0.05–0.06 1.1 
Total 36,828 7,366 4.81 4.77–4.86 100.0 
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Distribution by demographic factors  
Between 2010 and 2014 gastroenteritis hospitalisation rates for 0–24 year olds were highest for babies under 
one year old and decreased steeply with increasing age from zero to five years, and then changed little with 
increasing age from age six years, although there was a small increase from age 15 to 21 years (Figure 136). 
Between 2010 and 2014 there was disparity in gastroenteritis hospitalisation rates by NZDep2013 index of 
deprivation score, ethnicity and age. Rates were significantly lower in areas with lower deprivation scores 
compared with areas with higher deprivation scores. There was a significant increase in gastroenteritis 
hospitalisation rates between each quintile of NZDep2013 scores compared with the quintile below. Compared 
with European/Other, rates were significantly lower for Māori and Asian/Indian and significantly higher for 
Pacific and MELAA. The rate for the 0–4 year olds was significantly higher than those of older age groups 
(Table 114). 
Figure 136. Hospitalisations for gastroenteritis in 0–24 year olds, by age New Zealand 2010–2014 
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Rate per 1,000 0–24 
year olds 
Rate ratio 95% CI 
Gastroenteritis in 0–24 year olds 
New Zealand  
NZ Deprivation Index quintile 
Deciles 1–2 4,807 3.43 1.00   
Deciles 3–4 5,364 4.04 1.18 1.13–1.22 
Deciles 5–6 6,463 4.50 1.31 1.26–1.36 
Deciles 7–8 8,379 5.17 1.51 1.46–1.56 
Deciles 9–10 11,501 6.18 1.80 1.74–1.87 
Prioritised ethnicity 
Māori 7,430 4.17 0.87 0.85–0.89 
Pacific 4,400 6.28 1.31 1.27–1.35 
Asian/Indian 4,148 4.42 0.92 0.89–0.95 
MELAA 965 9.84 2.06 1.93–2.19 
European/Other 19,771 4.79 1.00   
Gender 
Female 18,179 4.86 1.00   
Male 18,649 4.77 0.98 0.96–1.00 
Age group (years) 
0–4 22,037 14.30 5.03 4.91–5.15 
5–14 5,918 1.98 0.70 0.67–0.72 
15–24 8,873 2.84 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
Distribution by month 
There was seasonal variation in gastroenteritis hospitalisation rates. Between 2010 and 2014, rates were higher 
in late winter, spring and early summer (Figure 137). 







































Gastroenteritis: 0–24 year olds
 
Numerator: National Minimum Dataset (acute and arranged admissions); Number is annual average 
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Distribution by region 
Between 2010 and 2014 hospitalisation rates for gastroenteritis in 0–24 year olds were significantly higher than 
the national rate in the Waitemata, Auckland, Counties Manukau, Bay of Plenty, Whanganui and Hutt Valley 
DHBs and significantly lower in the Taranaki, Hawke's Bay, MidCentral, and Capital & Coast DHBs and all the 
South Island DHBs except for Southern DHB. In the remaining district health boards there was no significant 
difference from the national rate (Table 115, Figure 138). 
In 2010–2014 hospitalisation rates for gastroenteritis in 0–14 year olds were significantly higher than the 
national rate in the Waitemata, Auckland, Counties Manukau, Bay of Plenty and Hutt Valley DHBs and 
significantly lower in the Northland, Lakes, Taranaki, Hawke's Bay, MidCentral, and Capital & Coast DHBs 
and all the South Island DHBs except for Southern DHB. In the remaining district health boards there was no 
significant difference from the national rate (Table 116). 
In 2010–2014 hospitalisation rates for gastroenteritis in 15–24 year olds were significantly higher than the 
national rate in the Northland, Waitemata, Bay of Plenty, Taranaki, Whanganui, Wairarapa and Southern DHBs 
and significantly lower in the Counties Manukau, Tairawhiti, Hutt Valley, Capital & Coast, Canterbury and 
West Coast DHBs. In the remaining district health boards there was no significant difference from the national 
rate (Table 117).  






Rate per 1,000 
0–24 year olds 
Rate ratio 95% CI 
Gastroenteritis 
0–24 year olds 
Northland 1,278 256 4.60 0.96 0.90–1.01 
Waitemata 4,916 983 5.20 1.08 1.05–1.11 
Auckland 4,303 861 5.49 1.14 1.11–1.18 
Counties Manukau 5,046 1,009 5.19 1.08 1.05–1.11 
Waikato 3,343 669 4.93 1.02 0.99–1.06 
Bay of Plenty 2,196 439 6.23 1.29 1.24–1.35 
Lakes 838 168 4.55 0.94 0.88–1.01 
Tairawhiti 402 80 4.45 0.93 0.84–1.02 
Taranaki 782 156 4.15 0.86 0.80–0.93 
Hawke's Bay 1,163 233 4.29 0.89 0.84–0.95 
MidCentral 1,164 233 3.91 0.81 0.77–0.86 
Whanganui 584 117 5.58 1.16 1.07–1.26 
Hutt Valley 1,304 261 5.31 1.10 1.04–1.17 
Capital & Coast 2,181 436 4.32 0.90 0.86–0.94 
Wairarapa 338 68 5.14 1.07 0.96–1.19 
Nelson Marlborough 720 144 3.43 0.71 0.66–0.77 
South Canterbury 310 62 3.64 0.76 0.68–0.85 
Canterbury 2,961 592 3.57 0.74 0.72–0.77 
West Coast 159 32 3.19 0.66 0.57–0.77 
Southern 2,544 509 4.93 1.02 0.98–1.06 
New Zealand 36,828 7,366 4.81 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
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Figure 138. Hospitalisations for gastroenteritis in 0–24 year olds, by district health board, New Zealand 2010–2014 
 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 






Rate per 1,000  
0–14 year olds 
Rate ratio 95% CI 
Gastroenteritis 
0–14 year olds 
Northland 941 188 5.19 0.84 0.79–0.90 
Waitemata 3,705 741 6.60 1.07 1.03–1.11 
Auckland 3,275 655 7.94 1.29 1.24–1.33 
Counties Manukau 4,064 813 6.84 1.11 1.07–1.15 
Waikato 2,524 505 6.19 1.00 0.96–1.04 
Bay of Plenty 1,728 346 7.61 1.23 1.18–1.29 
Lakes 631 126 5.37 0.87 0.80–0.94 
Tairawhiti 334 67 5.70 0.92 0.83–1.03 
Taranaki 516 103 4.31 0.70 0.64–0.76 
Hawke's Bay 905 181 5.22 0.85 0.79–0.90 
MidCentral 813 163 4.74 0.77 0.72–0.82 
Whanganui 440 88 6.72 1.09 0.99–1.20 
Hutt Valley 1,119 224 7.41 1.20 1.13–1.27 
Capital & Coast 1,583 317 5.78 0.94 0.89–0.99 
Wairarapa 253 51 6.02 0.98 0.86–1.10 
Nelson Marlborough 507 101 3.78 0.61 0.56–0.67 
South Canterbury 222 44 4.20 0.68 0.60–0.78 
Canterbury 2,343 469 4.95 0.80 0.77–0.84 
West Coast 138 28 4.37 0.71 0.60–0.84 
Southern 1,730 346 6.17 1.00 0.95–1.05 
New Zealand 27,955 5,591 6.17 1.00   
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Rate per 1,000 
15–24 year olds 
Rate ratio 95% CI 
Gastroenteritis 
15–24 year olds 
Northland 337 67 3.49 1.23 1.10–1.37 
Waitemata 1,211 242 3.16 1.11 1.05–1.18 
Auckland 1,028 206 2.77 0.98 0.91–1.04 
Counties Manukau 982 196 2.60 0.91 0.86–0.98 
Waikato 819 164 3.04 1.07 0.99–1.15 
Bay of Plenty 468 94 3.73 1.31 1.20–1.44 
Lakes 207 41 3.11 1.09 0.95–1.25 
Tairawhiti 68 14 2.15 0.76 0.60–0.96 
Taranaki 266 53 3.87 1.36 1.20–1.54 
Hawke's Bay 258 52 2.64 0.93 0.82–1.05 
MidCentral 351 70 2.78 0.98 0.88–1.09 
Whanganui 144 29 3.67 1.29 1.10–1.52 
Hutt Valley 185 37 1.96 0.69 0.59–0.80 
Capital & Coast 598 120 2.59 0.91 0.84–0.99 
Wairarapa 85 17 3.58 1.26 1.02–1.56 
Nelson Marlborough 213 43 2.83 0.99 0.87–1.14 
South Canterbury 88 18 2.73 0.96 0.78–1.18 
Canterbury 618 124 1.74 0.61 0.56–0.66 
West Coast 21 4 1.15 0.40 0.26–0.62 
Southern 814 163 3.44 1.21 1.13–1.30 
New Zealand 8,873 1,775 2.84 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Midland region distribution and trends 
In the Midland DHBs between 2010 and 2014, hospitalisations for gastroenteritis were significantly higher than 
the national rate in Bay of Plenty DHB, significantly lower than the national rate in Taranaki DHB, and were not 
significantly different from the national rate in Waikato, Lakes, and Tairawhiti DHBs (Table 118). 






Rate per 1,000 Rate ratio 95% CI 
Gastroenteritis 
0–24 year olds 
Waikato 3343 668.6 4.93 1.02 0.99–1.06 
Bay of Plenty 2196 439.2 6.23 1.29 1.24–1.35 
Lakes 838 167.6 4.55 0.94 0.88–1.01 
Tairawhiti 402 80.4 4.45 0.93 0.84–1.02 
Taranaki 782 156.4 4.15 0.86 0.80–0.93 
New Zealand 36828 7365.6 4.81 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Regional trends 
Hospitalisations for gastroenteritis in 0–24 year olds generally rose during 2000 to 2014 in the Midland DHBs 
(Figure 139). Waikato and Taranaki DHBs had noticeable drops and rises in their rates around 2007 to 2009. As 
in New Zealand as a whole, rates were higher in 0–14 year olds in all the Midland DHBs, and rates in both 0–14 
year olds and 15–24 year olds rose over the period except in Taranaki DHB where rates in 0–14 year olds 
decreased slightly over the period to end at a similar level as the rate for 15–24 year olds (Figure 140). 
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Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident Population 

























































































































































































































































































































































DHB 0–14 years New Zealand 0–14 years
DHB 15–24 years New Zealand 15–24 years
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Evidence for good practice for the prevention and management of 
gastroenteritis 
Ministry of Health publications 
Ministry of Health. 2012. Communicable Disease Control Manual 2012. Wellington: Ministry of Health. 
http://www.health.govt.nz/publication/communicable-disease-control-manual-2012  
This manual outlines the epidemiology and clinical features of gastroenteritis, with management advice for individual cases and for 
managing contacts. In early childhood services or other institutional situations it is important to ensure satisfactory facilities and 
practices regarding hand cleaning; nappy changing; toilet use and toilet training; preparation and handling of food; and cleaning of 
sleeping areas, toys and other surfaces. Complete case information must be entered into EpiSurv and the Ministry of Health 
Communicable Diseases Team notified if an outbreak occurs. If a food premise or commercial food source is thought to be involved 
then liaison with a local authority environmental health officer or with the Ministry for Primary Industries is required. 
Ministry of Health. 2014. Immunisation Handbook 2014. Wellington: Ministry of Health.  
Since July 2014 rotavirus vaccine has been funded at ages 6 weeks, 3 and 5 months as part of the National Immunisation Schedule. The 
first dose must be given before age 15 weeks and the third dose must be given before age 8 months. The Immunisation Handbook 
provides information about the microbiology, clinical features and epidemiology of rotavirus infection in NZ as well as details of public 
health measures..  
Ministry for Primary Industries publications 
Ministry for Primary Industries. 2012. Food safety at home. Wellington: Ministry for Primary Industries. 
http://www.foodsmart.govt.nz/elibrary/consumer/food-safety-in-the-home.pdf 
A consumer-focused booklet detailing ways to avoid foodborne illness. Covers general measures and also specific advice regarding 
outdoor cooking (barbecue) and packed lunches. The Ministry for Primary Industries also has detailed information about food 
regulation and legislation safety and food handling advice for households on interactive websites http://www.foodsafety.govt.nz/ and 
http://www.foodsmart.govt.nz/  
New Zealand guidelines 
Ministry of Health. 2015. Guidelines for Drinking Water Quality Management for New Zealand 2015. Wellington: 
Ministry of Health. http://www.health.govt.nz/system/files/documents/publications/guidelines-drinking-water-quality-
management-for-new-zealand-2015-oct15.pdf  
The guidelines provide information about tools the Ministry of Health uses to promote provision of drinking water that is safe to drink 
and protects the public from pathogenic micro-organisms and toxic chemicals. There have been a number of waterborne gastroenteritis 
outbreaks in New Zealand including several involving school children. Contaminated drinking water also contributes to the endemic 
and sporadic enteric disease burden. The Guidelines bring together legislative and regulatory requirements, guidance and good 
management principles for community drinking-water supplies and technical data to assist drinking-water providers, especially in small 
communities, to comply with the standards. 
International Guidelines 
National Institute for Health and Care Excellence. 2015. Diarrhoea and vomiting in children overview. 
http://pathways.nice.org.uk/pathways/diarrhoea-and-vomiting-in-children# accessed 12 November 2015. 
This overview brings together information about the ‘red flag’ symptoms and signs of clinical dehydration and shock as well as key 
steps in the diagnosis and management of gastroenteritis and advise for parents and carers. It is presented as an interactive webpage 
and also available as a downloaded pdf file. There is a link to a detailed flow chart with guidance on fluid and nutritional management 
in children with diarrhoea and vomiting. 
http://pathways.nice.org.uk/pathways/diarrhoea-and-vomiting-in-children#path=view%3A/pathways/diarrhoea-and-vomiting-in-
children/fluid-and-nutritional-management-in-children-with-diarrhoea-and-vomiting.xml&content=view-index  
Evidence-Based Medicine Reviews 
Fedorowicz Z, et al. 2011. Antiemetics for reducing vomiting related to acute gastroenteritis in children and 
adolescents. Cochrane Database of Systematic Reviews doi:10.1002/14651858.CD005506.pub5 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005506.pub5/abstract accessed 12 November 2015 
This is a systematic review of seven trials involving 1,020 children and adolescent aged five months to 12 years who presented with 
vomiting and had a confirmed clinical diagnosis of gastroenteritis. All seven trials were randomized, double blind, and placebo-
controlled. Six of the trials were conducted in emergency departments of children’s hospitals and one enrolled children from six 
paediatric practices. Although all seven studies were classified as either ’unclear’ or ’high’ risk of bias, the authors consider that the 
body of evidence is sufficient to allow certain conclusions to be drawn about the effectiveness of the interventions used in the treatment 
of vomiting related to acute gastroenteritis in children and adolescents. Ondansetron given as a single dose (0.1 mg/kg orally, or 
intravenously) to children with mild to moderate dehydration in the emergency department appears to decrease the number of children 
who have persistent vomiting as a barrier to oral rehydration therapy (ORT) and decreases the number of children requiring intravenous 
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rehydration and hospital admission. It may not reduce the chance of a revisit or admission after departure from the emergency 
department. Oral ondansetron may be useful alongside ORT in the outpatient or home-care setting. 
Soares-Weiser K, et al. 2012. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of 
Systematic Reviews doi:10.1002/14651858.CD008521.pub3 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008521.pub3/abstract accessed 12 November 2015 
A systematic review of 41 randomised controlled trials (RCTs) in children comparing rotavirus vaccines approved for use with placebo, 
no intervention, or another vaccine. Twenty-nine trials (101,671 participants) assessed RV1, and 12 trials (84,592 participants) evaluated 
RV5 which is the vaccine funded in NZ. In countries with low-mortality rates, RV5 probably prevents 87% of severe rotavirus diarrhoea 
cases in children aged up to one year (RR 0.13, 95% CI 0.04 to 0.45; 2344 participants, three trials; moderate-quality evidence), and may 
prevent 72% of severe all-cause diarrhoea cases (RR 0.28, 95% CI 0.16 to 0.48; 1029 participants, one trial; low-quality evidence). Three 
trials reported on severe rotavirus diarrhoea cases in children aged up to two years and found that RV5 probably prevents 82% (RR 
0.18, 95% CI 0.07 to 0.50; 3190 participants, three trials; moderate-quality evidence), and may prevent 96% of severe all-cause diarrhoea 
cases (RR 0.04, 95% CI 0.00 to 0.70; 1029 participants, one trial; low-quality evidence). The trials were not powered to detect death as 
an end point. Serious adverse events were reported in 1884 out of 78,226 children (2.4%) vaccinated with RV5 with 34 cases of 
intussusception reported in 81,459 children after RV5 vaccination. No significant difference was found between children receiving RV1 
or RV5 and placebo in the number of serious adverse events, and intussusception in particular.  
Pammi M & Haque Khalid N. 2011. Oral immunoglobulin for the prevention of rotavirus infection in low birth 
weight infants. Cochrane Database of Systematic Reviews doi:10.1002/14651858.CD003740.pub2 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003740.pub2/abstract accessed 12 November 2015 
Rotavirus infection can occur and spread in a neonatal unit and oral administration of anti-rotaviral immunoglobulin preparations is a 
possible way to prevent rotaviral infections especially in low birth weight babies. A search of the literature found only one published 
study addressing the effectiveness and safety of oral immunoglobulin preparations for the prevention of rotavirus infection in 
hospitalized low birthweight infants (birthweight < 2500 g), and found no significant difference in the rates of rotavirus infection after 
oral gammaglobulin versus placebo in hospitalized low birthweight babies [RR 1.27 (95% CI 0.65 to 2.37). In the subset of infants in the 
study who became infected with rotavirus there was no significant difference in the duration of rotavirus excretion between the group 
who had gammaglobulin (mean 2 days, range 1 to 4 days) and the group who had placebo (mean 3 days, range 1 to 6 days). Therefore 
current evidence does not support the use of oral immunoglobulin preparations to prevent rotavirus infection in low birthweight infants 
and more research is needed.  
Websites 
Kidshealth. 2015. Viral gastroenteritis. http://kidshealth.org.nz/viral-gastroenteritis-gastro accessed 4 November 
2015. 
Kidshealth provides accurate and reliable information about children’s health for NZ parents, caregivers, family and whānau. Key points 
in relation to gastroenteritis include the importance of maintaining fluid intake by offering small amounts of fluid often, and taking 
children to the doctor if they become dehydrated or if aged less than six months. The page provides specific information about care at 
home and preventing spread of illness. There are links to the Ministry of Health information about rotavirus vaccination which is free 
for babies aged up to 15 weeks https://www.healthed.govt.nz/resource/immunise-against-rotavirus-protect-your-child and also to 
Ministry of Health leaflets about specific bacterial causes of gastroenteritis: https://www.healthed.govt.nz/resource/campylobacter 
https://www.healthed.govt.nz/resource/giardia and https://www.healthed.govt.nz/resource/cryptosporidium  
Ministry of Health. 2015. Rotavirus. http://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-
illnesses/rotavirus accessed 4 November 2015.  
This webpage provides consumer information about the symptoms, treatment and prevention of rotavirus and includes a link to the 
Ministry of Health information about rotavirus vaccination https://www.healthed.govt.nz/resource/immunise-against-rotavirus-
protect-your-child 
Ministry of Health. 2012. Drinking-water DVD series. http://www.health.govt.nz/publication/drinking-water-dvd-
series accessed 12 November 2015. 
A series of five DVDs owned by the Ministry of Health and licensed for reuse under a Creative Commons Licence which are intended 
















Injury is a leading cause of death in New Zealand among children and young people and unintentional injury is 
the largest contributor.93 There are two common causes of unintentional injury deaths in this age group. The rate 
of suffocation is relatively high among infants under 12 months of age and the rate for road traffic injury is high 
among those aged 15–24 years. Drowning rates are the next most common cause of death for all age groups. 
The Statistics NZ data for 2000 to 2013 indicate that the rate of traffic crash deaths has fallen over the last 
decade, and the rate for injury, as Crash Analysis System (CAS) records of injury, has been falling since 2007.94 
Further analysis shows that while the fatality rates for 0–14 year olds have remained relatively low, high rates 
continue to be seen among those aged 15–24 years. Since 2009 there has been a decrease in the rate of sudden 
unexpected death in infancy (SUDI) to which the rate of suffocation contributes.95 
There are effective interventions for both these causes of injury death and data are showing a reduction in the 
rates for both. Other causes of injury death also have effective interventions and what is needed is consistent and 
ongoing implementation. Evidence of this is seen in New Zealand with proper implementation of regulations 
and strategies for road safety being effective in reducing the road toll:96 for example, speed limits, the Graduated 
Drivers Licence, child restraint use, alcohol limits, median strips, and the changes that have been made in the 
construction of cars.  
Injury death is recognised internationally as a leading cause of death for those aged under 25 years, but it is not 
the only serious outcome as a result of injury.97,98 Increasingly attention is being paid to the well-recognised 
long term impact of the physical, cognitive and behavioural problems that can arise with serious injury, for 
example, traumatic head injury.99 Traumatic head injury, is often associated with road traffic crashes and it has 
implications for the individual and their whānau as well as for health and other services. Injury such as burns 
and near drowning can also result in high personal and resource costs. 
Internationally concern is expressed regarding the lack of sustained, strategically-planned action to reduce injury 
at the country level, and the lack of focus on unintentional injury globally, particularly when injury has been 
implicated as the leading cause of inequalities for children in the EU.100 Prevention is important because injury 
can have long term effects for individuals, whānau, and health and community services. Children and young 
people have been injured needlessly because effective interventions have not been implemented. 
The following sections review the main causes of injury for 0–24 year olds using data from the National 
Minimum Dataset and the National Mortality Collection. The section concludes with a brief overview of local 
policy documents and evidence-based reviews which consider the prevention of injuries at the population level. 
Data sources and methods 
Indicators 
Deaths of 0–24 year olds from unintentional injury 
Hospitalisations of 0–24 year olds for unintentional injury 
Data sources 
Numerators:  
Deaths: National Mortality Collection 
Hospitalisations: National Minimum Dataset 
Denominator: Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years) 
Definition 
Death of 0–24 year olds where the main underlying cause of death was an unintentional injury 
Hospitalisation of 0–24 year olds with a primary diagnosis of injury (excluding cases involving intentional injury, complications 
of drugs/medical/surgical care and late sequelae of injury or where there was an Emergency Medicine Specialty code on 
discharge). Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Appendix 3 describes the National Minimum Dataset and outlines the limitations of the data utilised from this collection. 




National trends and distribution 
Unintentional injury deaths fell consistently from 2008 to 2012. Figure 141 shows the main causes of injury 
death for 0–24 year olds which indicates the reduction is predominantly as a result of a fall in the rate of road 
traffic injury which began in 2006–07. The suffocation rate (most evident in under 1 year olds) rose from 2004–
05 to 2008–09 before falling again. (Suffocation occurred most commonly in bed and these events are included 
in Sudden Unexpected Death in Infancy (SUDI) (see page 60). 











































Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
From 2000 to 2014 the hospitalisation rate (excluding emergency department or ED discharges) for 
unintentional injury among 0–14 year olds fell steadily. For 15–24 year olds the rate remained stable in 2000–
2008 and then fell (Figure 142). The ED only discharges rose over time for 0–14 year olds, but from 2009, the 
rate of ED only discharges fell for 15–24 year olds. 














































































































































































Distribution by cause 
From 2008 to 2012 there were 373 deaths of 0–14 year olds and 773 deaths of 15–24 year olds from 
unintentional injury; a total of 1,146 deaths. Among those aged 0–14 years, 40.2% were from suffocation 
(predominantly aged under 1 year), 22.0% from road traffic injuries (RTI), 12.3% from drowning and 10.7% 
from non-traffic transport events. Among 15–24 year olds 63.8% were from RTI with 6.9% from poisoning and 
6.5% from drowning (Table 119, Figure 143).  
Table 119. Deaths due to unintentional injuries in 0–24 year olds, by age group and cause of injury, New Zealand, 
2008–2012 






Rate per 100,000 
population 
95% CI Per cent 
New Zealand  
0–14 year olds 
Suffocation 150 30 3.33 2.84–3.91 40.2 
Road traffic crashes 82 16 1.82 1.47–2.26 22.0 
Drowning or submersion 46 9 1.02 0.77–1.36 12.3 
Non-traffic transport accidents 40 8 0.89 0.65–1.21 10.7 
Inanimate mechanical forces 14 3 0.31 0.19–0.52 3.8 
Thermal  11 2 0.24 0.14–0.44 2.9 
Poisoning 9 2 0.20 0.11–0.38 2.4 
Falls 7 1 0.16 0.08–0.32 1.9 
Animate mechanical forces <5 s s s s 
Other or unspecified land transport <5 s s s s 
Other transport <5 s s s s 
Other causes 8 2 0.18 0.09–0.35 2.1 
Undetermined intent 0 s s s s 
Total 373 75 8.29 7.49–9.17 100.0 
15–24 year olds 
Road traffic crashes 493 99 15.96 14.6–17.4 63.8 
Poisoning 53 11 1.72 1.31–2.24 6.9 
Drowning or submersion 50 10 1.62 1.23–2.13 6.5 
Falls 38 8 1.23 0.90–1.69 4.9 
Non-traffic transport accidents 31 6 1.00 0.71–1.42 4.0 
Other transport 23 5 0.74 0.50–1.12 3.0 
Inanimate mechanical forces 18 4 0.58 0.37–0.92 2.3 
Suffocation 10 2 0.32 0.18–0.60 1.3 
Thermal  10 2 0.32 0.18–0.60 1.3 
Animate mechanical forces <5 s s s s 
Other or unspecified land transport <5 s s s s 
Other causes 42 8 1.36 1.01–1.84 5.4 
Undetermined intent 0 .. .. .. .. 
Total 773 155 25.03 23.32–26.86 100.0 









































Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
Between 2010 and 2014, 45.1% of unintentional injury hospitalisations for 0–14 year olds were from falls and 
23.5% were from inanimate mechanical forces (Table 120). For the 15–24 year olds, inanimate mechanical 
forces and falls comprised 26.6% and 25.6% respectively of the hospitalisations for injury (Table 121). More 
detailed discussion of hospitalisation data for specific types of injury follows later in this section. 
Table 120. Hospitalisations from unintentional injuries in 0–14 year olds, by external cause of injury, New Zealand 
2010–2014 
Hospitalisations by main external 









95% CI Per cent 
New Zealand  
0–14 year olds 
Falls 22,130 4,426 488.60 482.22–495.07 45.1 
Inanimate mechanical forces 11,560 2,312 255.23 250.63–259.92 23.5 
Animate mechanical forces 2,949 590 65.11 62.80–67.50 6.0 
Non-traffic transport accidents 2,393 479 52.83 50.76–54.99 4.9 
Road traffic crashes 2,111 422 46.61 44.66–48.64 4.3 
Other or unspecified land transport 711 142 15.70 14.59–16.89 1.4 
Other transport 63 13 1.39 1.09–1.78 0.1 
Thermal 1,965 393 43.38 41.51–45.35 4.0 
Poisoning 1,792 358 39.57 37.78–41.44 3.6 
Suffocation 441 88 9.74 8.87–10.69 0.9 
Drowning or submersion 172 34 3.80 3.27–4.41 0.4 
Other causes 2,563 513 56.59 54.44–58.82 5.2 
Undetermined intent 253 51 5.59 4.94–6.32 0.5 
Total 49,103 9,821 1,084.13 1,074.64–1,093.71 100.0 





Table 121. Hospitalisations from unintentional injuries in 15–24 year olds, by external cause of injury, New 
Zealand 2010–2014 
Hospitalisations by main external 









95% CI Per cent 
New Zealand  
15–24 year olds 
Inanimate mechanical forces 10,299 2,060 330.00 323.70–336.43 26.6 
Falls 9,913 1,983 317.63 311.45–323.94 25.6 
Road traffic crash 5,801 1,160 185.88 181.16–190.72 15.0 
Animate mechanical forces 3,360 672 107.66 104.08–111.36 8.7 
Non-traffic transport incidents 2,710 542 86.83 83.63–90.16 7.0 
Other or unspecified land transport 736 147 23.58 21.94–25.35 1.9 
Other transport 164 33 5.25 4.51–6.12 0.4 
Thermal 759 152 24.32 22.65–26.11 2.0 
Poisoning 504 101 16.15 14.80–17.62 1.3 
Suffocation 56 11 1.79 1.38–2.33 0.1 
Drowning or submersion 35 7 1.12 0.81–1.56 0.1 
Other causes 3,705 741 118.72 114.96–122.60 9.6 
Undetermined intent 677 135 21.69 20.12–23.39 1.7 
Total 38,719 7,744 1,240.64 1,228.42–1,252.98 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population 
Distribution by region 
From 2008 to 2012 deaths due to unintentional injury were significantly higher than the overall national rate in 
Northland, Bay of Plenty, Lakes, MidCentral, South Canterbury and West Coast while rates in Waitemata, 
Auckland, Counties Manukau, and Capital & Coast DHBs were significantly lower than the national rate. In the 
remaining DHBs there was no significant difference from the national rate (Figure 144). 
From 2010 to 2014 injury hospitalisation rates in Northland, Counties Manukau, Bay of Plenty, Lakes, 
Tairawhiti, Hawke’s Bay, Whanganui, Wairarapa, South Canterbury, and West Coast were significantly higher 
than the national rate. Rates for Waitemata, Auckland, Taranaki, MidCentral, Capital & Coast, and Southern 
DHBs were significantly lower than the overall national rate. In the remaining DHBs there was no significant 























































































































































































































Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 























































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population 
Distribution by demographic factors 
Certain causes of unintentional injury have noticeable age distributions. Injury hospitalisation rates for falls, 
inanimate mechanical forces (which includes struck against or by, caught between, contact with sharp items, 
machinery), thermal, and poisoning peak around ages 1 to 2 years. Inanimate mechanical forces, road traffic 
crashes, and falls are the most common causes of injury among those older than 15 years. Both non-traffic land 
transport and animate mechanical forces injury hospitalisation rates gradually increase with increasing age from 




Figure 146. Hospitalisations from selected unintentional injuries in 0–24 year olds, by age and injury type, 
















































Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population 
Road traffic injury 
Death rates from road traffic injuries rates fell steeply from 10.59 deaths per 100,000 0–24 year olds in 2000–01 
to 5.36 in 2012 and most of this fall has occurred since 2004 (Figure 141). Between 2008 and 2012 there were 
82 deaths of 0–14 year olds and 493 deaths of 15–24 year olds as a result of road traffic injury (RTI). In both 0–
14 and 15–24 age groups the deceased was most commonly a vehicle occupant or a pedestrian. For 15–24 year 
olds motorbike injury deaths were equal to pedestrian deaths (Table 119).  
From 2000 to 2014 hospitalisation rates for RTI fell and this was mainly attributable to a steep fall in 
hospitalisation rates of 15–24 year olds as a vehicle occupant in a road traffic crash, although over the whole 
time period hospitalisation rates were consistently highest for this type of RTI in this age group. Hospitalisation 
rates for pedestrian injury also fell for 15–24 year olds, whereas rates for motorbike and pedestrian injury were 
more variable. For 0–14 year olds there was a slight steady fall in all types of RTI hospitalisations as a vehicle 
occupant, cyclist, pedestrian or on a motorbike. In this age group hospitalisation rates for cyclist RTI were 




Figure 147. Hospitalisations from road traffic injuries in 0–24 year olds, by age group, year of discharge, and RTI 






































































































































































Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population 
Distribution by cause 
There were 2,111 hospitalisations of 0–14 year olds and 5,801 hospitalisations of 15–24 year olds for RTI 
between 2010 and 2014. The most common types of RTI hospitalisation for 0–14 year olds were as cyclists, 
vehicle occupants and pedestrian. The most common types of RTI for 15–24 year olds were as vehicle occupant, 
motorbike, and cyclist (Table 122). 
Table 122. Hospitalisations from road traffic injuries in 0–24 year olds, by age group, New Zealand 2010–2014 






Rate per 100,000 
population 
95% CI Per cent 
New Zealand  
0–14 year olds 
Vehicle occupant 619 124 13.67 12.63–14.79 29.3 
Motorbike 160 32 3.53 3.03–4.12 7.6 
Cyclist 805 161 17.77 16.59–19.04 38.1 
Pedestrian 504 101 11.13 10.20–12.14 23.9 
Other land transport 23 5 0.51 0.34–0.76 1.1 
Total 2,111 422 46.61 44.66–48.64 100.0 
15–24 year olds 
Vehicle occupant 3,615 723 115.83 112.12–119.67 62.3 
Motorbike 1,044 209 33.45 31.48–35.54 18.0 
Cyclist 597 119 19.13 17.66–20.73 10.3 
Pedestrian 469 94 15.03 13.73–16.45 8.1 
Other land transport 76 15 2.44 1.95–3.05 1.3 
Total 5,801 1,160 185.88 181.16–190.72 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Distribution by demographic factors 
The patterns of RTI hospitalisation varied by age group (Figure 148). Hospitalisation rates as a result of vehicle 
occupant injury were highest at ages 15–19 (115.2 per 100,000 age-specific population) and 20–24 years (116.5) 
where rates for 0–4 years was 10.7. Across the age groups, motorbike injury rates were highest at age 20–24 
years (39.4); cyclist injuries were highest at age 10–14 years although within age groups, cycling injuries were 
also the highest RTI for 5–9 years. Pedestrian was the highest cause of RTI for 0–4 year olds (Table 123).  
Table 123. Hospitalisations from road traffic crash injuries in 0–24 year olds, by 5-year age group, New Zealand 
2010–2014 






Rate per 100,000 
population 
95% CI Per cent 
New Zealand  
0–4 year olds 
Vehicle occupant 165 33 10.71 9.19–12.47 46.5 
Motorbike 7 1 0.45 0.22–0.94 2.0 
Cyclist 53 11 3.44 2.63–4.50 14.9 
Pedestrian 126 25 8.18 6.87–9.73 35.5 
Other land transport <5 s s s s 
Total 355 71 23.03 20.76–25.56 100.0 
5–9 year olds 
Vehicle occupant 204 41 13.65 11.90–15.66 28.9 
Motorbike 36 7 2.41 1.74–3.33 5.1 
Cyclist 273 55 18.27 16.22–20.57 38.7 
Pedestrian 190 38 12.71 11.03–14.65 27.0 
Other land transport <5 s s s s 
Total 705 141 47.17 43.82–50.79 100.0 
10–14 year olds 
Vehicle occupant 250 50 16.74 14.79–18.95 23.8 
Motorbike 117 23 7.83 6.54–9.39 11.1 
Cyclist 479 96 32.07 29.32–35.07 45.6 
Pedestrian 188 38 12.59 10.91–14.52 17.9 
Other land transport 17 3 1.14 0.71–1.82 1.6 
Total 1,051 210 70.37 66.24–74.75 100.0 
15–19 year olds 
Vehicle occupant 1,801 360 115.21 110.01–120.65 63.1 
Motorbike 430 86 27.51 25.03–30.23 15.1 
Cyclist 349 70 22.33 20.10–24.79 12.2 
Pedestrian 242 48 15.48 13.65–17.56 8.5 
Other land transport 34 7 2.17 1.56–3.04 1.2 
Total 2,856 571 182.70 176.12–189.52 100.0 
20–24 year olds 
Vehicle occupant 1,814 363 116.46 111.22–121.94 61.6 
Motorbike 614 123 39.42 36.42–42.66 20.8 
Cyclist 248 50 15.92 14.06–18.03 8.4 
Pedestrian 227 45 14.57 12.80–16.60 7.7 
Other land transport 42 8 2.70 1.99–3.64 1.4 
Total 2,945 589 189.07 182.37–196.01 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Between 2010 and 2014 disparities in RTI hospitalisation rates by NZDep2013 score, ethnicity and gender 
varied according to the type of RTI. The strongest social gradients were seen in vehicle occupant injuries in 0–
14 and 15–24 year olds where hospitalisation rates were significantly higher for areas with higher deprivation 
index scores (NZDep2013 deciles 3–10) compared with low deprivation score areas (deciles 1–2) (Table 124). 
Although numbers were small, motorbike injury hospitalisation rates were significantly higher for 0–14 year 
olds in areas with the highest deprivation scores (deciles 9–10) compared with lower scoring areas (deciles 1–8) 
but there was no significant difference by NZDep2013 scores for motorbike injury in 15–24 year olds (Table 
125). Cycle injury hospitalisation rates for 0–14 year olds were in significantly higher in NZDep2013 deciles 9–
10 compared with deciles 1–2, but in 0–24 year olds the gradient reversed with significantly lower rates in 
NZDep2013 deciles 7–10 compared with deciles 1–2 (Table 126). Hospitalisation rates for 0–14 year old 
pedestrian injury were significantly higher for NZDep2013 deciles 3–10 compared to those in decile 1–2 
whereas for 15–24 year olds the rate was significantly higher only in areas with the highest NZDep2013 scores 
(deciles 9–10) (Table 127). 





































































































































Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; Decile is NZDep2013 
Compared with European/Other, vehicle occupant RTI hospitalisation rates were significantly higher for Māori 
aged 0–14 years and 15–24 years and significantly lower for Pacific and Asian/Indian aged 15–24 years. 
Motorbike rates were significantly lower for Māori, Pacific and Asian/Indian aged 15–24 years. Cyclist rates 
were significantly lower for Asian/Indian aged 0–14 years and for Māori, Pacific and Asian/Indian aged 15–24 
years; and pedestrian rates were significantly higher for Māori aged 0–24 years and Pacific and MELAA aged 
0–14 years (Table 124, Table 125, Table 126, Table 127). 
Hospitalisation rates were significantly higher for males than females in the 0–14 and 15–24 years age groups 
for all types of road traffic injury except for injury as a vehicle occupant where there was no significant 
difference by gender in 0–14 year olds. The disparity by gender was most marked for motorbike injuries (Table 




Table 124. Hospitalisations for vehicle occupant-related road traffic injuries in 0–24 year olds, by age group and 




Rate per 100,000 
population 
Rate ratio 95% CI 
Road traffic injuries: vehicle occupant 
0–14 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 49 5.62 1.00   
Deciles 3–4 73 9.04 1.61 1.12–2.31 
Deciles 5–6 88 10.29 1.83 1.29–2.59 
Deciles 7–8 137 14.58 2.59 1.87–3.59 
Deciles 9–10 256 24.26 4.32 3.18–5.86 
Prioritised ethnicity 
Māori 272 23.60 2.42 2.03–2.88 
Pacific 51 11.72 1.20 0.89–1.63 
Asian/Indian 54 11.34 1.16 0.86–1.56 
MELAA <5 s s s 
European/Other 235 9.75 1.00   
Gender 
Female 311 14.09 1.00   
Male 308 13.27 0.94 0.80–1.10 
15–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 416 78.31 1.00   
Deciles 3–4 514 98.44 1.26 1.10–1.43 
Deciles 5–6 618 106.19 1.36 1.20–1.54 
Deciles 7–8 771 113.33 1.45 1.28–1.63 
Deciles 9–10 1,172 145.60 1.86 1.66–2.08 
Prioritised ethnicity 
Māori 1,021 161.96 1.40 1.30–1.51 
Pacific 266 100.15 0.87 0.76–0.99 
Asian/Indian 274 59.32 0.51 0.45–0.58 
MELAA 41 96.63 0.84 0.62–1.14 
European/Other 1,984 115.32 1.00   
Gender 
Female 1,508 98.29 1.00   
Male 2,107 132.79 1.35 1.26–1.44 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Table 125. Hospitalisations for motorbike-related road traffic injuries in 0–24 year olds, by age group and 




Rate per 100,000 
population 
Rate ratio 95% CI 
Road traffic injuries: motorbike 
0–14 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 19 2.18 1.00   
Deciles 3–4 29 3.59 1.65 0.92–2.94 
Deciles 5–6 31 3.62 1.66 0.94–2.94 
Deciles 7–8 35 3.72 1.71 0.98–2.99 
Deciles 9–10 46 4.36 2.00 1.17–3.41 
Prioritised ethnicity 
Māori 50 4.34 1.00 0.71–1.39 
Pacific <5 s s s 
Asian/Indian <5 s s s 
MELAA 0 .. .. .. 
European/Other 105 4.36 1.00   
Gender 
Female 21 0.95 1.00   
Male 139 5.99 6.29 3.98–9.96 
15–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 162 30.49 1.00   
Deciles 3–4 189 36.20 1.19 0.96–1.46 
Deciles 5–6 184 31.62 1.04 0.84–1.28 
Deciles 7–8 238 34.98 1.15 0.94–1.40 
Deciles 9–10 256 31.80 1.04 0.86–1.27 
Prioritised ethnicity 
Māori 215 34.10 0.79 0.68–0.92 
Pacific 33 12.42 0.29 0.20–0.41 
Asian/Indian 33 7.14 0.17 0.12–0.23 
MELAA 12 28.28 0.66 0.37–1.16 
European/Other 742 43.13 1.00   
Gender 
Female 133 8.67 1.00   
Male 911 57.41 6.62 5.52–7.94 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Table 126. Hospitalisations for cyclist-related road traffic injuries in 0–24 year olds, by age group and 




Rate per 100,000 
population 
Rate ratio 95% CI 
Road traffic injuries: cyclist 
0–14 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 139 15.95 1.00   
Deciles 3–4 121 14.99 0.94 0.74–1.20 
Deciles 5–6 138 16.13 1.01 0.80–1.28 
Deciles 7–8 166 17.66 1.11 0.88–1.39 
Deciles 9–10 236 22.37 1.40 1.14–1.73 
Prioritised ethnicity 
Māori 222 19.27 1.05 0.90–1.24 
Pacific 69 15.86 0.87 0.67–1.12 
Asian/Indian 61 12.80 0.70 0.54–0.91 
MELAA 10 17.97 0.98 0.52–1.84 
European/Other 441 18.30 1.00   
Gender 
Female 217 9.83 1.00   
Male 588 25.33 2.58 2.20–3.01 
15–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 120 22.59 1.00   
Deciles 3–4 92 17.62 0.78 0.59–1.02 
Deciles 5–6 119 20.45 0.91 0.70–1.17 
Deciles 7–8 114 16.76 0.74 0.57–0.96 
Deciles 9–10 138 17.14 0.76 0.59–0.97 
Prioritised ethnicity 
Māori 96 15.23 0.59 0.47–0.74 
Pacific 19 7.15 0.28 0.18–0.44 
Asian/Indian 26 5.63 0.22 0.15–0.32 
MELAA 8 18.86 0.73 0.36–1.47 
European/Other 443 25.75 1.00   
Gender 
Female 124 8.08 1.00   
Male 473 29.81 3.69 3.03–4.49 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Table 127. Hospitalisations for pedestrian-related road traffic crash injuries in 0–24 year olds, by age group and 




Rate per 100,000 
population 
Rate ratio 95% CI 
Road traffic injuries: pedestrian 
0–14 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 40 4.59 1.00   
Deciles 3–4 62 7.68 1.67 1.12–2.49 
Deciles 5–6 67 7.83 1.71 1.15–2.52 
Deciles 7–8 115 12.24 2.67 1.86–3.82 
Deciles 9–10 217 20.57 4.48 3.20–6.28 
Prioritised ethnicity 
Māori 187 16.23 2.31 1.88–2.85 
Pacific 102 23.44 3.34 2.61–4.27 
Asian/Indian 33 6.93 0.99 0.68–1.43 
MELAA 10 17.97 2.56 1.35–4.85 
European/Other 169 7.01 1.00   
Gender 
Female 164 7.43 1.00   
Male 340 14.64 1.97 1.64–2.37 
15–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 70 13.18 1.00   
Deciles 3–4 87 16.66 1.26 0.92–1.73 
Deciles 5–6 73 12.54 0.95 0.69–1.32 
Deciles 7–8 84 12.35 0.94 0.68–1.29 
Deciles 9–10 147 18.26 1.39 1.04–1.84 
Prioritised ethnicity 
Māori 132 20.94 1.55 1.25–1.91 
Pacific 47 17.70 1.31 0.96–1.79 
Asian/Indian 49 10.61 0.78 0.58–1.07 
MELAA 6 14.14 1.04 0.46–2.35 
European/Other 233 13.54 1.00   
Gender 
Female 173 11.28 1.00   
Male 296 18.65 1.65 1.37–2.00 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 





Distribution by region 
For 0–14 year olds, the RTI hospitalisation rates were significantly higher than the national rate in the 
Northland, Waikato, Bay of Plenty, Tairawhiti, Taranaki, Whanganui, South Canterbury and West Coast DHBs 
and significantly lower in the Auckland, Hutt Valley, Capital & Coast, Canterbury and Southern DHBs. In 
remaining district health boards there was no significant difference from the national rate. 
For 15–24 year olds the RTI hospitalisation rates were significantly higher than the national rate in the 
Northland, Bay of Plenty, Lakes, Tairawhiti, Hawke's Bay, Whanganui, Wairarapa, South Canterbury and West 
Coast DHBs and significantly lower in the Waitemata, Auckland, Hutt Valley, Capital & Coast, Canterbury and 
Southern DHBs. In remaining district health boards there was no significant difference from the national rate 
(Figure 149).  
Figure 149. Hospitalisations for injuries from road traffic crash, by age group and district health board, 


















































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population 
Falls 
There are few injury deaths resulting from falls among those aged 0–24 years. Between 2008 and 2012 there 
were 7 deaths of 0–14 year olds and 38 deaths of 15–24 year olds (Table 119). Falls were the most common 
reason for unintentional injury hospitalisation among 0–24 year olds and between 2010 and 2014 there were 
22,130 hospitalisations of 0–14 year olds for injury from falls, more than twice the 9,913 hospitalisations for 
15–24 year olds (Table 120, Table 121). 
Distribution by cause 
The most common types of fall resulting in hospitalisation for 0–14 year olds were falls involving playground 
equipment and falls on the same level. For 15–24 year olds the most common type was fall on same level due to 
collision with, or pushing by, another person (Table 128). Falls from playground equipment occurred most 




Table 128. Hospitalisations from fall-related injuries in 0–24 year olds, by age group and cause of injury, 
New Zealand 2010–2014 









95% CI Per cent 
New Zealand  
0–14 year olds 
Fall involving playground equipment 7,023 1,405 155.06 151.48–158.73 31.7 
Fall on same level from slipping, tripping & stumbling 2,432 486 53.70 51.60–55.87 11.0 
Fall involving ice-skates, skis, rollerskates or 
skateboards 
2,110 422 46.59 44.64–48.62 9.5 
Other fall on same level 1,581 316 34.91 33.23–36.67 7.1 
Fall from, out of or through building or structure 1,244 249 27.47 25.98–29.04 5.6 
Other fall on same level due to collision with, or 
pushing by, another person 
1,243 249 27.44 25.96–29.01 5.6 
Other fall from one level to another 1,303 261 28.77 27.25–30.37 5.9 
Fall from tree 918 184 20.27 19.00–21.62 4.1 
Fall involving chair 1,035 207 22.85 21.50–24.29 4.7 
Fall involving bed 875 175 19.32 18.08–20.64 4.0 
Fall on and from stairs and steps 621 124 13.71 12.67–14.83 2.8 
Fall while being carried or supported by other persons 402 80 8.88 8.05–9.79 1.8 
Fall involving other furniture 294 59 6.49 5.79–7.28 1.3 
Fall from cliff 119 24 2.63 2.20–3.14 0.5 
Diving or jumping into water causing injury other 
than drowning or submersion 
104 21 2.30 1.90–2.78 0.5 
Fall on and from ladder 96 19 2.12 1.74–2.59 0.4 
Other specified falls 33 7 0.73 0.52–1.02 0.1 
Unspecified fall 697 139 15.39 14.29–16.57 3.1 
Total 22,130 4,426 488.60 482.22–495.07 100.0 
15–24 year olds 
Other fall on same level due to collision with, or 
pushing by, another person 
2,021 404 64.76 62.00–67.64 20.4 
Fall on same level from slipping, tripping & stumbling 1,627 325 52.13 49.66–54.73 16.4 
Fall involving ice-skates, skis, rollerskates or 
skateboards 
1,574 315 50.43 48.00–52.99 15.9 
Other fall on same level 1,107 221 35.47 33.44–37.62 11.2 
Fall from, out of or through building or structure 826 165 26.47 24.72–28.33 8.3 
Fall on and from stairs and steps 669 134 21.44 19.87–23.12 6.7 
Other fall from one level to another 586 117 18.78 17.32–20.36 5.9 
Fall from cliff 243 49 7.79 6.87–8.83 2.5 
Fall involving playground equipment 227 45 7.27 6.39–8.28 2.3 
Diving or jumping into water causing injury* 165 33 5.29 4.54–6.16 1.7 
Fall on and from ladder 109 22 3.49 2.90–4.21 1.1 
Fall from tree 108 22 3.46 2.87–4.18 1.1 
Fall involving chair 63 13 2.02 1.58–2.58 0.6 
Fall while being carried or supported by other persons 49 10 1.57 1.19–2.08 0.5 
Fall involving bed 36 7 1.15 0.83–1.60 0.4 
Fall involving other furniture 24 5 0.77 0.52–1.14 0.2 
Other specified falls 56 11 1.79 1.38–2.33 0.6 
Unspecified fall 423 85 13.55 12.32–14.91 4.3 
Total 9,913 1,983 317.63 311.45–323.94 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Distribution by demographic factors 
Patterns of fall-related hospitalisation rates by age show a very high rate of falls involving playground 
equipment peaking at age 5–6 years and then falling steeply with increasing age. Rates for falls on same level 
due to collision with or pushing by another person began to rise from age nine years and remained at relatively 
high levels through the teenage years. Rates for falls involving skates, skis or skateboards rose until age 13 and 
then fell with increasing age. Other types of fall had highest rates at age one year and then tended to fall with 
increasing age until rising again from age 18–19 years (Figure 150).  











































Fall-related injury Fall involving playground equipment
Fall on same level from slipping, tripping and stumbling
Fall involving ice-skates, skis, rollerskates or skateboards
Other fall on same level*
All other falls
 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; Rates per 100,000 age-specific population; * Other fall on same level relates to other fall on 




Fall-related injury hospitalisation rates were highest at age 5–9 years for all ethnic groups, with rates for Pacific 
generally higher and rates for Asian/Indian consistently lower than rates for European/Other and Māori (Figure 
151). This peak in rates in 5–9 year olds is mainly due to falls involving playground equipment.  
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Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; Ethnicity is level 1 prioritised 
Between 2010 and 2014 in 0–14 year olds there was some disparity in hospitalisation rates for fall injury 
involving playground equipment by NZDep2013 index of deprivation score and ethnicity. Rates were 
significantly higher in areas with the highest deprivation scores (NZDep2013 deciles 9–10) compared with areas 
with lower deprivation scores (deciles 1–8). Rates were significantly lower for Asian/Indian than rates for 
European/Other, Māori, Pacific and MELAA. There was no significant difference between male and female 
rates (Table 129).  
In the same time period for 15–24 year olds there was similar disparity by NZDep2013 score for falls on the 
same level due to collision with or pushing by another person with significantly higher injury hospitalisation 
rates in areas with the highest deprivation scores (NZDep2013 deciles 9–10) compared with areas with lower 
deprivation scores (deciles 1–8). Compared with European/Other, rates for this form of injury were significantly 





Table 129. Hospitalisations for fall-related injuries in 0–24 year olds, by age group and demographic factor, 




Rate per 100,000 
population 
Rate ratio 95% CI 
New Zealand 
Falls among 0–14 year olds involving playground equipment  
NZ Deprivation Index quintile 
Deciles 1–2 1,217 139.65 1.00   
Deciles 3–4 1,114 138.01 0.99 0.91–1.07 
Deciles 5–6 1,149 134.34 0.96 0.89–1.04 
Deciles 7–8 1,344 143.00 1.02 0.95–1.11 
Deciles 9–10 2,135 202.36 1.45 1.35–1.55 
Prioritised ethnicity 
Māori 1,917 166.36 1.06 1.00–1.12 
Pacific 740 170.04 1.08 1.00–1.17 
Asian/Indian 452 94.88 0.60 0.55–0.66 
MELAA 82 147.33 0.93 0.75–1.16 
European/Other 3,797 157.59 1.00   
Gender 
Female 3,359 152.17 1.00   
Male 3,664 157.81 1.04 0.99–1.09 
Injuries among 15–24 year olds from other fall on same level* 
NZ Deprivation Index quintile 
Deciles 1–2 289 54.40 1.00   
Deciles 3–4 319 61.10 1.12 0.96–1.32 
Deciles 5–6 347 59.62 1.10 0.94–1.28 
Deciles 7–8 378 55.56 1.02 0.88–1.19 
Deciles 9–10 673 83.61 1.54 1.34–1.76 
Prioritised ethnicity 
Māori 483 76.62 1.45 1.29–1.61 
Pacific 534 201.05 3.79 3.41–4.22 
Asian/Indian 58 12.56 0.24 0.18–0.31 
MELAA 16 37.71 0.71 0.43–1.17 
European/Other 912 53.01 1.00   
Gender 
Female 158 10.30 1.00   
Male 1,863 117.41 11.40 9.69–13.41 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Inanimate mechanical force 
Between 2008 and 2012 injury from inanimate mechanical force resulted in 14 deaths of 0–14 year olds and 18 
deaths of 15–24 year olds (Table 119). Injury from exposure to inanimate forces was a major cause of 
hospitalisation. Over the five years 2010–2014 there were 11,560 hospitalisations of 0–14 year olds and 10,299 
of 15–24 year olds for this type of injury (Table 120, Table 121). 
Distribution by cause 
The main causes were similar for both 0–14 year olds and 15–24 year olds: caught between, foreign body 
penetrating, struck against or by some object and events involving cutting and piercing (Table 130). 
Table 130. Hospitalisations for injuries from exposure to an inanimate mechanical force in 0–24 year olds, by age 
group and cause of injury, New Zealand 2010–2014 










95% CI Per cent 
New Zealand 
0–14 year olds 
Caught, crushed, jammed or pinched in or 
between objects 
3,955 791 87.32 84.64–90.08 34.2 
Foreign body entering into or through eye, 
natural orifice or skin 
2,611 522 57.65 55.48–59.90 22.6 
Striking against or struck by sports equipment or 
other objects* 
2,567 513 56.68 54.53–58.91 22.2 
Contact with sharp glass, knife, sword or dagger 1,287 257 28.42 26.90–30.01 11.1 
Contact with other powered, other and 
unspecified machinery† 
350 70 7.73 6.96–8.58 3.0 
Contact with nonpowered hand tool 296 59 6.54 5.83–7.32 2.6 
Discharge of firework, handgun or other and 
unspecified firearms 
64 13 1.41 1.11–1.80 0.6 
Explosion and rupture of gas cylinder or other 
materials 
19 4 0.42 0.27–0.66 0.2 
Exposure to other and unspecified inanimate 
mechanical forces‡ 
411 82 9.07 8.24–10.00 3.6 
Total 11,560 2,312 255.23 250.63–259.92 100.0 
15–24 year olds 
Caught, crushed, jammed or pinched in or 
between objects 
706 141 22.62 21.01–24.35 6.9 
Foreign body entering into or through eye, 
natural orifice or skin 
750 150 24.03 22.37–25.81 7.3 
Striking against or struck by sports equipment or 
other objects* 
2,713 543 86.93 83.72–90.26 26.3 
Contact with sharp glass, knife, sword or dagger 3,608 722 115.61 111.90–119.44 35.0 
Contact with other powered, other and 
unspecified machinery† 
1,516 303 48.58 46.19–51.08 14.7 
Contact with nonpowered hand tool 334 67 10.70 9.61–11.91 3.2 
Discharge of firework, handgun or other and 
unspecified firearms 
148 30 4.74 4.04–5.57 1.4 
Explosion and rupture of gas cylinder or other 
materials 
66 13 2.11 1.66–2.69 0.6 
Exposure to other and unspecified inanimate 
mechanical forces‡ 
458 92 14.68 13.39–16.08 4.4 
Total 10,299 2,060 330.00 323.70–336.43 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; * Striking against or struck by sports equipment or other objects or thrown, projected or falling 
object; † includes contact with powered lawnmower, agricultural machinery, other and unspecified machinery, other powered 
hand tools and household machinery, and lifting and transmission devices, not elsewhere classified; ‡ includes contact with 




Distribution by demographic factors 
Children around one year of age had a high rate of hospitalisation for caught, jammed, pinched in or between 
objects. Rates for foreign bodies entering fell from about 4 years of age while rates for sports-related struck by 
injury rose from age 8 years. Injury from sharp objects increased from age 12 years and peaked around 19–20 
years (Figure 152).  
For injury caused by being caught, crushed, jammed, or pinched in or between objects there was a significant 
difference associated with NZDep2013 score: hospitalisation rates for 0–14 year olds in areas with higher 
deprivation scores (NZDep2013 deciles 9–10 were significantly higher than rates in deciles 1–2. Among 15–24 
year olds hospitalisation rates after contact with sharp glass, knife, sword or dagger were significantly higher in 
NZDep2013 deciles than in areas with the lowest deprivation scores (deciles 1–2). Compared with 
European/Other hospitalisation rates for ‘caught between’ injuries were significantly higher for Māori, Pacific 
and MELAA 0–14 year olds. Hospitalisation rates for injury from sharp objects were significantly higher for 
Māori and Pacific 15–24 year olds and significantly lower for Asian/Indian compared with European/Other and 
MELAA. Males in both age groups, 0–14 years and 15–24 years, were significantly more likely than females to 
be hospitalised from inanimate mechanical forces (Table 131, Table 132). 
Figure 152. Hospitalisations for injuries from inanimate mechanical forces in 0–24 year olds, by age and force 







































Injury from inanimate mechanical forces
Caught, crushed, jammed or pinched in or between objects
Foreign body entering into or through eye, natural orifice or skin
Striking against or struck by sports equipment or other objects*
Contact with sharp glass, knife, sword or dagger
Contact with other powered, other and unspecified machinery†
Contact with nonpowered hand tool
Exposure to other and unspecified inanimate mechanical forces‡
 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; * Striking against or struck by sports equipment or other objects or thrown, projected or falling 
object; † includes contact with powered lawnmower, agricultural machinery, other and unspecified machinery, other powered 
hand tools and household machinery, and lifting and transmission devices, not elsewhere classified; ‡ includes contact with 




Table 131. Hospitalisations for injuries from exposure to an inanimate mechanical force in 0–14 year olds, by age 




Rate per 100,000 
population 
Rate ratio 95% CI 
New Zealand 
Injuries among 0–14 year olds from being caught, crushed, jammed, or pinched in or between objects 
NZ Deprivation Index quintile 
Deciles 1–2 491 56.34 1.00   
Deciles 3–4 468 57.98 1.03 0.91–1.17 
Deciles 5–6 565 66.06 1.17 1.04–1.32 
Deciles 7–8 768 81.71 1.45 1.30–1.62 
Deciles 9–10 1,645 155.91 2.77 2.50–3.06 
Prioritised ethnicity 
Māori 1,116 96.85 1.51 1.40–1.63 
Pacific 902 207.27 3.24 2.98–3.52 
Asian/Indian 323 67.80 1.06 0.94–1.19 
MELAA 63 113.19 1.77 1.38–2.28 
European/Other 1,542 64.00 1.00   
Gender 
Female 1,787 80.95 1.00   
Male 2,168 93.38 1.15 1.08–1.23 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
Table 132. Hospitalisations for injuries from exposure to an inanimate mechanical force in 15–24 year olds, by age 




Rate per 100,000 
population 
Rate ratio 95% CI 
New Zealand 
Injuries among 15–24 year olds from contact with sharp glass, knife, sword or dagger 
NZ Deprivation Index quintile 
Deciles 1–2 348 65.51 1.00   
Deciles 3–4 451 86.38 1.32 1.15–1.52 
Deciles 5–6 531 91.24 1.39 1.22–1.59 
Deciles 7–8 856 125.82 1.92 1.70–2.18 
Deciles 9–10 1,390 172.68 2.64 2.34–2.96 
Prioritised ethnicity 
Māori 1,237 196.22 2.01 1.87–2.17 
Pacific 492 185.24 1.90 1.72–2.10 
Asian/Indian 136 29.44 0.30 0.25–0.36 
MELAA 40 94.28 0.97 0.71–1.32 
European/Other 1,676 97.42 1.00   
Gender 
Female 759 49.47 1.00   
Male 2,849 179.55 3.63 3.35–3.93 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Animate mechanical force 
Between 2008 and 2012 there were fewer than five deaths of 0–14 year olds and of 15–24 year olds as a result 
of animate mechanical force (Table 119). Between 2010 and 2014, there were 3,033 hospitalisations of 0–14 
year olds and 3,443 of 15–24 year olds for injuries resulting from animate mechanical forces (Table 120, Table 
121). 
Distribution by cause 
Causes varied by age from these injuries, however, 49.4% of these hospitalisations for 0–14 year olds and 
77.1% for 15–24 year olds were from being struck, hit, twisted, by a person or crowd (or stampede). Being 
bitten or struck by a dog accounted for 29.6% of animate force hospitalisations in 0–14 year olds and 8.6% in 
15–24 year olds (Table 133).  
Table 133. Hospitalisations for injuries from exposure to an animate mechanical force in 0–24 year olds, by age 
group and cause of injury, New Zealand 2010–2014 
Cause of injury: exposure to an animate 









95% CI Per cent 
New Zealand  
0–14 year olds 
Struck etc by another person or by crowd 
or human stampede* 
1,456 291 32.15 30.54–33.84 49.4 
Bitten or struck by dog 874 175 19.30 18.06–20.62 29.6 
Contact with plant or bitten or stung† 434 87 9.58 8.72–10.53 14.7 
Contact with, bitten or struck by marine 
animal, rat or other mammals 
174 35 3.84 3.31–4.46 5.9 
Exposure to other and unspecified animate 
mechanical forces‡ 
11 2 0.24 0.14–0.43 0.4 
Total 2,949 590 65.11 62.80–67.50 100.0 
15–24 year olds 
Struck etc by another person or by crowd 
or human stampede* 
2,592 518 83.05 79.92–86.31 77.1 
Bitten or struck by dog 289 58 9.26 8.25–10.39 8.6 
Contact with plant or bitten or stung† 185 37 5.93 5.13–6.85 5.5 
Contact with, bitten or struck by marine 
animal, rat or other mammals 
280 56 8.97 7.98–10.09 8.3 
Exposure to other and unspecified animate 
mechanical forces‡ 
14 3 0.45 0.27–0.75 0.4 
Total 3,360 672 107.66 104.08–111.36 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; * Hit, struck, kicked, twisted, bitten, scratched, striking against or bumped into by another 
person or crushed, pushed or stepped on by crowd or human stampede; † Contact with plant thorns and spines and sharp 
leaves or bitten or stung by nonvenomous insect and other nonvenomous arthropods; ‡ Exposure to other and unspecified 
animate mechanical forces also includes being bitten or struck by other animals 
Distribution by demographic factors 
Patterns of animate force injury requiring hospitalisation varied by age. Hospitalisation rates after being hit, 
struck, kicked, twisted, bitten, scratched, striking against or bumped into by another person or crushed, pushed 
or stepped on by crowd or human stampede rose with increasing age from age 8 years to a plateau from around 
14–24 years. Dog-related injury hospitalisations were highest at age 2 years and then fell with increasing age 
until a plateau from around age 13. Plant- and insect-related injuries were also most common in 2–3 year olds 
and then tended to decline with increasing age (Figure 153). 
For all ages, those living in areas with the highest deprivation scores (NZDep2013 deciles 9–10) had a 
significantly higher chance of being struck by another person or a crowd compared with deciles 1–6. Compared 
with European/Other, hospitalisation rates for this type of injury were significantly higher for Pacific 0–24 year 
olds and Māori 15–24 year olds. Males had a significantly higher rate than females of being struck by and this 




Figure 153. Hospitalisations for injuries from animate mechanical forces in 0–24 year olds, by age and force type, 








































Injury from animate mechanical forces
Struck etc by another person or by crowd or human stampede*
Bitten or struck by dog
Contact with plant, or bitten or stung†
Exposure to other and unspecified animate mechanical forces‡
 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; * Hit, struck, kicked, twisted, bitten, scratched, striking against or bumped into by another 
person or crushed, pushed or stepped on by crowd or human stampede; † Contact with plant thorns and spines and sharp 
leaves or bitten or stung by nonvenomous insect and other nonvenomous arthropods; ‡ Exposure to other and unspecified 
animate mechanical forces also includes being bitten or struck by other animals 
Table 134. Hospitalisations for injuries from exposure to an animate mechanical force in 0–14 year olds, by age 




Rate per 100,000 
population 
Rate ratio 95% CI 
Injuries from animate mechanical forces: struck etc by another person or by crowd or human stampede* 
0–14 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 252 28.92 1.00   
Deciles 3–4 237 29.36 1.02 0.85–1.21 
Deciles 5–6 223 26.07 0.90 0.75–1.08 
Deciles 7–8 295 31.39 1.09 0.92–1.28 
Deciles 9–10 444 42.08 1.46 1.25–1.70 
Prioritised ethnicity 
Māori 384 33.32 1.00 0.89–1.13 
Pacific 189 43.43 1.30 1.11–1.53 
Asian/Indian 56 11.76 0.35 0.27–0.46 
MELAA 19 34.14 1.03 0.65–1.62 
European/Other 802 33.29 1.00   
Gender 
Female 381 17.26 1.00   
Male 1,075 46.30 2.68 2.39–3.02 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; * Hit, struck, kicked, twisted, bitten, scratched, striking against or bumped into by another 
person or crushed, pushed or stepped on by crowd or human stampede; Rate ratios are unadjusted; Ethnicity is level 1 





Table 135. Hospitalisations for injuries from exposure to an animate mechanical force in 15–24 year olds, by age 
group and demographic factor, New Zealand 2010–2014 
Variable Number: 2010−2014 
Rate per 100,000 
population 
Rate ratio 95% CI 
Injuries from animate mechanical forces: struck etc by another person or by crowd or human stampede* 
15–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 384 72.28 1.00   
Deciles 3–4 337 64.54 0.89 0.77–1.03 
Deciles 5–6 424 72.85 1.01 0.88–1.16 
Deciles 7–8 563 82.75 1.14 1.01–1.30 
Deciles 9–10 858 106.59 1.47 1.31–1.66 
Prioritised ethnicity 
Māori 681 108.02 1.49 1.36–1.63 
Pacific 505 190.14 2.62 2.36–2.90 
Asian/Indian 96 20.78 0.29 0.23–0.35 
MELAA 38 89.56 1.23 0.89–1.70 
European/Other 1,249 72.60 1.00   
Gender 
Female 325 21.18 1.00   
Male 2,267 142.87 6.74 6.00–7.58 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; * Hit, struck, kicked, twisted, bitten, scratched, striking against or bumped into by another 
person or crushed, pushed or stepped on by crowd or human stampede; Rate ratios are unadjusted; Ethnicity is level 1 
prioritised; Decile is NZDep2013 
Non-traffic transport injury 
Between 2008 and 2012 there were 40 deaths as a result of injuries from non-traffic transport (i.e. events 
occurring off road) among children aged 0–14 years and 31 deaths among 15–24 year olds. The deceased was 
most commonly a pedestrian among 0–14 year olds (24 deaths) and a vehicle occupant among 15–24 year olds 
(12 deaths) (Table 119).  
The hospitalisation rate for non-traffic injuries fell from 2004 to 2014 for the 0–14 year olds and this was mainly 
driven by a fall in cyclist hospitalisations. Among 15–24 year olds the hospitalisation rate rose from 2004 to 
2007 and then declined overall; this pattern was influenced mainly by changes in motorbike-related injury 
hospitalisations. A similar rise and fall in motorbike-related injury hospitalisation over time was seen in 0–14 




Figure 154. Hospitalisations from non-traffic land transport injuries in 0–24 year olds, by age group, year of 







































































































































































Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population 
Distribution by cause 
Between 2010 and 2014 injuries arising from non-traffic transport resulted in 2,393 hospitalisations among 0–14 
year olds and 2,710 hospitalisations among those aged 15–24 years. Hospitalisations for non-traffic transport 
injury among 0–14 year olds were more commonly for cycling (46.6%) followed by motorbike (29.9%) and for 
15–24 year olds most common was motorbike injuries (48.9%) and cycling (27.0%) (Table 136).  
Table 136. Hospitalisations from unintentional non-traffic crash injuries in 0–24 year olds, by age group, 
New Zealand 2010–2014 









95% CI Per cent 
New Zealand  
0–14 year olds 
Vehicle occupant 78 16 1.72 1.38–2.15 3.3 
Motorbike 716 143 15.81 14.69–17.01 29.9 
Cyclist 1,116 223 24.64 23.24–26.13 46.6 
Pedestrian 256 51 5.65 5.00–6.39 10.7 
Other land transport 227 45 5.01 4.40–5.71 9.5 
Total 2,393 479 52.83 50.76–54.99 100.0 
15–24 year olds 
Vehicle occupant 160 32 5.13 4.39–5.99 5.9 
Motorbike 1,324 265 42.42 40.20–44.77 48.9 
Cyclist 733 147 23.49 21.85–25.25 27.0 
Pedestrian 92 18 2.95 2.40–3.61 3.4 
Other land transport 401 80 12.85 11.65–14.17 14.8 
Total 2,710 542 86.83 83.63–90.16 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Distribution by demographic factors 
Between 2010 and 2014 hospitalisation rates of 0–24 year olds for vehicle occupant non-traffic injuries were 
significantly higher in areas with the highest NZDep2013 scores (NZDep2013 deciles 9–10) compared with 
deciles 1–2. Asian/Indian ethnic groups had significantly lower rates than European/Other, and 0–4 and 5–14 
year olds had significantly lower rates than 15–24 year olds (Table 137).  
There was no clear social gradient in hospitalisation rates for non-traffic motorbike or cycle injuries with the 
highest rates in areas with NZDep2013 decile 3-4 scores (significantly higher than deciles 1–2) and the lowest 
rates in areas with the highest deprivation index scores (significantly lower than deciles 1–2) (Table 138). For 
both these type of injury Māori, Pacific and Asian/Indian had significantly lower rates than European/Other. 
Compared with 15–24 year olds non-traffic motorbike hospitalisation rates were significantly lower for 0–4 and 
5–14 year olds, whereas for non-traffic cycle injury hospitalisation rates were significantly lower for 0–4 year 
olds and significantly higher for 5–14 year olds (Table 138).  
Hospitalisation rates for pedestrian injuries were significantly higher in areas with higher deprivation index 
scores (NZDep2013 deciles 7–10) compared with deciles 1–2. Māori rates were significantly higher than 
European/Other, and rates for for 0–4 and 5–14 year olds were significantly higher than for 15–24 year olds 
(Table 139). 
Male hospitalisation rates were significantly higher than female for all specific types of non-traffic injury and 
this difference was particularly marked for motorbike injury (Table 138, Table 139). 
Table 137. Hospitalisations for vehicle occupant-related non-traffic land transport injuries in 0–24 year olds, by 




Rate per 100,000 
population 
Rate ratio 95% CI 
Non-traffic land transport injuries: vehicle occupant 
0–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 34 2.42 1.00   
Deciles 3–4 38 2.86 1.18 0.74–1.87 
Deciles 5–6 42 2.92 1.21 0.77–1.89 
Deciles 7–8 47 2.90 1.20 0.77–1.86 
Deciles 9–10 70 3.76 1.55 1.03–2.34 
Prioritised ethnicity 
Māori 62 3.48 0.98 0.73–1.31 
Pacific 20 2.85 0.80 0.50–1.28 
Asian/Indian 5 0.53 0.15 0.06–0.37 
MELAA <5 s s s 
European/Other 147 3.56 1.00   
Gender 
Female 75 2.00 1.00   
Male 163 4.17 2.08 1.58–2.73 
Age group (years) 
0–4 33 2.14 0.42 0.29–0.61 
5–14 45 1.51 0.29 0.21–0.41 
15–24 160 5.13 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population; Rate ratios are unadjusted; 




Table 138. Hospitalisations for motorbike-related and cyclist-related non-traffic land transport injuries in 0–24 




Rate per 100,000 
population 
Rate ratio 95% CI 
0–24 year olds 
Non-traffic land transport injuries: motorbike 
NZ Deprivation Index quintile 
Deciles 1–2 352 25.09 1.00   
Deciles 3–4 443 33.33 1.33 1.15–1.53 
Deciles 5–6 450 31.31 1.25 1.09–1.43 
Deciles 7–8 409 25.24 1.01 0.87–1.16 
Deciles 9–10 368 19.78 0.79 0.68–0.91 
Prioritised ethnicity 
Māori 272 15.26 0.37 0.32–0.42 
Pacific 18 2.57 0.06 0.04–0.10 
Asian/Indian 11 1.17 0.03 0.02–0.05 
MELAA <5 s s s 
European/Other 1,717 41.58 1.00   
Gender 
Female 182 4.86 1.00   
Male 1,858 47.54 9.77 8.39–11.38 
Age group (years) 
0–4 24 1.56 0.04 0.02–0.05 
5–14 692 23.16 0.55 0.50–0.60 
15–24 1,324 42.42 1.00   
Non-traffic land transport injuries: cyclist 
NZ Deprivation Index quintile 
Deciles 1–2 310 22.10 1.00   
Deciles 3–4 356 26.78 1.21 1.04–1.41 
Deciles 5–6 345 24.00 1.09 0.93–1.27 
Deciles 7–8 363 22.40 1.01 0.87–1.18 
Deciles 9–10 440 23.66 1.07 0.93–1.24 
Prioritised ethnicity 
Māori 405 22.72 0.74 0.66–0.83 
Pacific 97 13.84 0.45 0.37–0.56 
Asian/Indian 42 4.48 0.15 0.11–0.20 
MELAA 24 24.47 0.80 0.53–1.20 
European/Other 1,263 30.58 1.00   
Gender 
Female 342 9.14 1.00   
Male 1,507 38.56 4.22 3.75–4.74 
Age group (years) 
0–4 209 13.56 0.58 0.50–0.67 
5–14 907 30.35 1.29 1.17–1.42 
15–24 733 23.49 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population; Rate ratios are unadjusted; 




Table 139. Hospitalisations for pedestrian-related non-traffic land transport injuries in 0–24 year olds, by 




Rate per 100,000 
population 
Rate ratio 95% CI 
Non-traffic land transport injuries: pedestrian 
0–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 38 2.71 1.00   
Deciles 3–4 46 3.46 1.28 0.83–1.96 
Deciles 5–6 46 3.20 1.18 0.77–1.82 
Deciles 7–8 78 4.81 1.78 1.21–2.62 
Deciles 9–10 132 7.10 2.62 1.83–3.76 
Prioritised ethnicity 
Māori 126 7.07 1.90 1.50–2.40 
Pacific 37 5.28 1.42 0.99–2.03 
Asian/Indian 27 2.88 0.77 0.51–1.16 
MELAA <5 s s s 
European/Other 154 3.73 1.00   
Gender 
Female 133 3.55 1.00   
Male 215 5.50 1.55 1.25–1.92 
Age group (years) 
0–4 137 8.89 3.02 2.32–3.93 
5–14 119 3.98 1.35 1.03–1.77 
15–24 92 2.95 1.00   
Numerator: National Minimum Dataset, Denominator: Statistics NZ Estimated Resident Population; Rate ratios are unadjusted; 






Between 2008 and 2012 there were 11 deaths of 0–14 year olds and 10 deaths of 15–24 year olds as a result of 
thermal injury (Table 119). Between 2010 and 2014 thermal injury resulted in 1,965 hospitalisations for 0–14 
year olds and 759 hospitalisations of 15–24 year olds (Table 120, Table 121).  
Distribution by cause 
Over half the hospitalisations of 0–14 year olds (57.4%) were the result of contact with hot drinks, food, fats and 
other hot fluids. For 15–24 year olds the most common causes of thermal injury were exposure to smoke, flame 
and fire, and contact with hot drinks, foods; combined these two causes comprised 56.8% of all hospitalisations 
for the older age group (Table 140). 
Table 140. Hospitalisations for thermal injuries in 0–24 year olds, by age group and cause of injury, New Zealand 
2010–2014 









95% CI Per cent 
New Zealand 
0–14 year olds 
Contact with hot drinks, food, fats, cooking oils, 
other hot fluids 
1,128 226 24.90 23.49–26.40 57.4 
Contact with hot household appliances, hot 
heating appliances, radiators and pipes 
260 52 5.74 5.08–6.48 13.2 
Contact with hot tap-water 204 41 4.50 3.93–5.17 10.4 
Exposure to smoke, fire and flames 182 36 4.02 3.48–4.65 9.3 
Contact with hot substances, other hot metals, 
other and unspecified heat 
61 12 1.35 1.05–1.73 3.1 
Exposure to ignition of highly flammable material 44 9 0.97 0.72–1.30 2.2 
Contact with hot engines, machinery and tools 28 6 0.62 0.43–0.89 1.4 
Exposure to electric current 28 6 0.62 0.43–0.89 1.4 
Exposure to ignition or melting clothing or 
nightwear 
26 5 0.57 0.39–0.84 1.3 
Other thermal injury <5 s s s s 
Total 1,965 393 43.38 41.51–45.35 100.0 
15–24 year olds 
Exposure to smoke, fire and flames 222 44 7.11 6.24–8.11 29.2 
Contact with hot drinks, food, fats, cooking oils, 
other hot fluids 
209 42 6.70 5.85–7.67 27.5 
Exposure to ignition of highly flammable material 125 25 4.01 3.36–4.77 16.5 
Contact with hot substances, other hot metals, 
other and unspecified heat 
53 11 1.70 1.30–2.22 7.0 
Exposure to electric current 50 10 1.60 1.22–2.11 6.6 
Contact with hot household appliances, hot 
heating appliances, radiators and pipes 
32 6 1.03 0.73–1.45 4.2 
Contact with hot engines, machinery and tools 22 4 0.70 0.47–1.07 2.9 
Contact with hot tap-water 19 4 0.61 0.39–0.95 2.5 
Exposure to ignition or melting clothing or 
nightwear 
18 4 0.58 0.36–0.91 2.4 
Other thermal injury 9 2 0.29 0.15–0.55 1.2 
Total 759 152 24.32 22.65–26.11 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 





Distribution by demographic factors 
For 0–14 year olds there is a differential for thermal injury hospitalisation with rates for areas with NZDep2013 
decile 3–10 scores being significantly higher than those in deciles 1–2. Among 15–24 year olds rates were 
significantly higher for NZDep2013 deciles 7–10. Compared with European/Other thermal injury hospitalisation 
rates were significantly higher for Māori 0–24 year olds, Pacific, Asian/Indian and MELAA 0–14 year olds, and 
significantly lower for Pacific and Asian/Indian 15–24 year olds. Males had a significantly higher rate than 
females (Table 141, Table 142). Children aged under 5 years had much higher rates of hospitalisation than any 
other age group (Figure 155). 
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Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; Ethnicity is level 1 prioritised 




Rate per 100,000 
population 
Rate ratio 95% CI 
Thermal injuries 
0–14 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 175 20.08 1.00   
Deciles 3–4 210 26.02 1.30 1.06–1.58 
Deciles 5–6 266 31.10 1.55 1.28–1.87 
Deciles 7–8 439 46.71 2.33 1.95–2.77 
Deciles 9–10 861 81.61 4.06 3.45–4.78 
Prioritised ethnicity 
Māori 670 58.14 1.92 1.73–2.13 
Pacific 340 78.13 2.58 2.26–2.93 
Asian/Indian 172 36.11 1.19 1.01–1.41 
MELAA 45 80.85 2.66 1.97–3.60 
European/Other 731 30.34 1.00   
Gender 
Female 799 36.20 1.00   
Male 1,166 50.22 1.39 1.27–1.52 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 










Rate per 100,000 
population 
Rate ratio 95% CI 
Thermal injuries 
15–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 92 17.32 1.00   
Deciles 3–4 105 20.11 1.16 0.88–1.54 
Deciles 5–6 128 21.99 1.27 0.97–1.66 
Deciles 7–8 179 26.31 1.52 1.18–1.95 
Deciles 9–10 240 29.82 1.72 1.35–2.19 
Prioritised ethnicity 
Māori 205 32.52 1.23 1.04–1.45 
Pacific 45 16.94 0.64 0.47–0.87 
Asian/Indian 41 8.88 0.34 0.24–0.46 
MELAA <5 s s s 
European/Other 454 26.39 1.00   
Gender 
Female 208 13.56 1.00   
Male 551 34.73 2.56 2.18–3.00 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 






Between 2008 and 2012 there were nine deaths of 0–14 year olds and 53 deaths of 15–24 year olds as a result of 
unintentional poisoning (Table 119). Between 2010 and 2014 there were 1,792 hospitalisations of 0–14 year 
olds and 504 of 15–24 year olds for poisoning (Table 120, Table 121). 
Distribution by cause 
The most common causes of poisoning for both 0–14 year olds and 15–24 year olds were the two groupings: 
firstly, antiepileptic, sedative-hypnotic, anti-parkinsonism and psychotropic drugs, not elsewhere classified, and 
secondly, non-opioid analgesics, antipyretics and anti-rheumatics (Table 143). 
Table 143. Hospitalisations for poisoning in 0–24 year olds, by age group and type of poisoning, New Zealand 
2010–2014 









95% CI Per cent 
New Zealand  
0–14 year olds 
Antiepileptic, sedative-hypnotic, antiparkinsonism 
and psychotropic drugs, NEC 
340 68 7.51 6.75–8.35 19.0 
Non-opioid analgesics, antipyretics and 
antirheumatics 
333 67 7.35 6.60–8.19 18.6 
Narcotics and psychodysleptics (hallucinogens), NEC 162 32 3.58 3.07–4.17 9.0 
Other and unspecified drugs, medicaments and 
biological substances 
422 84 9.32 8.47–10.25 23.5 
Other drugs acting on the autonomic nervous 
system 
80 16 1.77 1.42–2.20 4.5 
Organic solvents and halogenated hydrocarbons and 
their vapours 
71 14 1.57 1.24–1.98 4.0 
Pesticides 40 8 0.88 0.65–1.20 2.2 
Alcohol 34 7 0.75 0.54–1.05 1.9 
Other gases and vapours 20 4 0.44 0.29–0.68 1.1 
Other and unspecified chemicals and noxious 
substances 
290 58 6.40 5.71–7.18 16.2 
Total 1,792 358 39.57 37.78–41.44 100.0 
15–24 year olds 
Antiepileptic, sedative-hypnotic, antiparkinsonism 
and psychotropic drugs, NEC 
120 24 3.85 3.22–4.60 23.8 
Non-opioid analgesics, antipyretics and 
antirheumatics 
117 23 3.75 3.13–4.49 23.2 
Narcotics and psychodysleptics (hallucinogens), NEC 52 10 1.67 1.27–2.18 10.3 
Other and unspecified drugs, medicaments and 
biological substances 
44 9 1.41 1.05–1.89 8.7 
Other drugs acting on the autonomic nervous 
system 
<5 s s s s 
Alcohol 39 8 1.25 0.91–1.71 7.7 
Other gases and vapours 19 4 0.61 0.39–0.95 3.8 
Pesticides 6 1 0.19 0.09–0.42 1.2 
Organic solvents and halogenated hydrocarbons and 
their vapours 
<5 s s s s 
Other and unspecified chemicals and noxious 
substances 
102 20 3.27 2.69–3.97 20.2 
Total 504 101 16.15 14.80–17.62 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 





Distribution by demographic factors 
The 0–14 year olds living in areas with higher deprivation index scores (NZDep2013 deciles 5–10) had 
significantly higher rates for poisoning than those living in low deprivation areas (deciles 1–2). Rates for Māori 
were significantly higher, and for Pacific and Asian/Indian significantly lower, than European/Other for those 
aged 0–14 years. There was no significant difference between males and females aged 0–14 years (Table 144).  
Among 15–24 year olds, those in NZDep2013 deciles 7–10 had significantly higher rates, and Pacific and 
Asian/Indian had significantly lower rates than European/Other. There was no significant difference between 
males and females among 15–24 year olds (Table 145). Rates for hospitalisations for unintentional poisoning 
were highest for Māori and European/Other aged 0–4 year olds (Figure 156).  
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Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised 




Rate per 100,000 
population 
Rate ratio 95% CI 
Poisoning 
0–14 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 227 26.05 1.00   
Deciles 3–4 249 30.85 1.18 0.99–1.42 
Deciles 5–6 329 38.47 1.48 1.25–1.75 
Deciles 7–8 454 48.30 1.85 1.58–2.17 
Deciles 9–10 527 49.95 1.92 1.64–2.24 
Prioritised ethnicity 
Māori 559 48.51 1.13 1.02–1.26 
Pacific 104 23.90 0.56 0.46–0.68 
Asian/Indian 70 14.69 0.34 0.27–0.44 
MELAA 25 44.92 1.05 0.71–1.56 
European/Other 1,032 42.83 1.00   
Gender 
Female 831 37.65 1.00   
Male 961 41.39 1.10 1.00–1.21 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 








Rate per 100,000 
population 
Rate ratio 95% CI 
Poisoning 
15–24 year olds 
NZ Deprivation Index quintile 
Deciles 1–2 63 11.86 1.00   
Deciles 3–4 70 13.41 1.13 0.80–1.59 
Deciles 5–6 81 13.92 1.17 0.84–1.63 
Deciles 7–8 147 21.61 1.82 1.36–2.45 
Deciles 9–10 137 17.02 1.44 1.06–1.93 
Prioritised ethnicity 
Māori 127 20.15 1.12 0.91–1.38 
Pacific 32 12.05 0.67 0.47–0.97 
Asian/Indian 25 5.41 0.30 0.20–0.45 
MELAA 8 18.86 1.05 0.52–2.12 
European/Other 309 17.96 1.00   
Gender 
Female 244 15.90 1.00   
Male 260 16.39 1.03 0.87–1.23 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 
Estimated Resident Population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013 
Midland region distribution and trends 
Comparison with New Zealand  
From 2008 to 2012 deaths due to unintentional injury for 0–24 year olds were significantly higher than the 
overall national rate in Bay of Plenty and Lakes DHBs. Rates in Waikato and Tairawhiti and Taranaki were not 
significantly different to the national rate. Rates were significantly higher in Bay of Plenty, Lakes and Tairawhiti 
DHBs for 0–14 year olds, but only significantly higher in Lakes for 15–24 year olds (Table 146).  
From 2010 to 2014 injury hospitalisation rates for 0–24 year olds were significantly higher in Bay of Plenty, 
Lakes and Tairawhiti DHBs than the overall national rate, and significantly lower in Waikato and Taranaki 










Rate per 100,000 
population 
Rate ratio 95% CI 
Unintentional injury deaths 
0–24 year olds 
Waikato 116 23 17.34 1.15 0.95–1.39 
Bay of Plenty 70 14 20.07 1.33 1.04–1.69 
Lakes 44 9 23.74 1.57 1.16–2.12 
Tairawhiti 21 4 23.27 1.54 1.00–2.37 
Taranaki 24 5 12.83 0.85 0.57–1.27 
New Zealand 1,146 229 15.10 1.00   
0–14 year olds 
Waikato 38 8 9.42 1.14 0.81–1.59 
Bay of Plenty 28 6 12.43 1.50 1.02–2.20 
Lakes 18 4 15.14 1.83 1.14–2.93 
Tairawhiti 14 3 23.80 2.87 1.68–4.89 
Taranaki 7 1 5.92 0.71 0.34–1.51 
New Zealand 373 75 8.29 1.00   
15–24 year olds 
Waikato 78 16 29.36 1.17 0.93–1.48 
Bay of Plenty 42 8 33.98 1.36 1.00–1.85 
Lakes 26 5 39.15 1.56 1.06–2.31 
Tairawhiti 7 1 22.30 0.89 0.42–1.87 
Taranaki 17 3 24.72 0.99 0.61–1.60 
New Zealand 1,146 229 15.10 1.00   
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 






Rate per 100,000 
population 
Rate ratio 95% CI 
Unintentional injury hospitalisations 
0–24 year olds 
Waikato 7,555 1,511 1,114.78 0.97 0.95–0.99 
Bay of Plenty 4,762 952 1,351.31 1.18 1.14–1.21 
Lakes 2,516 503 1,365.85 1.19 1.14–1.24 
Tairawhiti 1,360 272 1,507.04 1.31 1.24–1.38 
Taranaki 2,010 402 1,066.47 0.93 0.89–0.97 
New Zealand 87,822 17,564 1,147.98 1.00   
0–14 year olds 
Waikato 4,217 843 1,033.63 0.95 0.92–0.98 
Bay of Plenty 2,864 573 1,262.03 1.16 1.12–1.21 
Lakes 1,423 285 1,210.33 1.12 1.06–1.18 
Tairawhiti 814 163 1,389.59 1.28 1.20–1.37 
Taranaki 1,108 222 925.81 0.85 0.80–0.91 
New Zealand 49,103 9,821 1,084.13 1.00   
0–24 year olds 
Waikato 3,338 668 1,237.51 1.00 0.96–1.03 
Bay of Plenty 1,898 380 1,512.78 1.22 1.16–1.28 
Lakes 1,093 219 1,640.26 1.32 1.25–1.40 
Tairawhiti 546 109 1,724.34 1.39 1.28–1.51 
Taranaki 902 180 1,311.18 1.06 0.99–1.13 
New Zealand 87,822 17,564 1,147.98 1.00   
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 





From 2000 to 2014 the hospitalisation rate (excluding emergency department (ED) discharges) for unintentional 
injury among 0–14 year olds declined in all Midland DHBs (Figure 157).  
Injury hospitalisation rates for falls for 0–14 year olds declined from 2000 to 2014 in the Midland DHBs, while 
hospitalisations for inanimate mechanical forces remained relatively stable except in Taranaki where it declined. 
The hospitalisation rate for 15–24 year olds for RTIs declined from 2000–2014 for all but Tairawhiti where 
small numbers make patterns hard to discern. Bay of Plenty and Lakes DHBs showed consistent declines in 
hospitalisations rates for falls and inanimate mechanical forces from 2009 (Figure 158).  
Distribution by cause 
In the Midland DHBs between 2008 and 2012, the leading causes of death among 0–14 year olds were 
suffocation and road traffic injury. Among the 15–24 year olds the leading cause was road traffic injury. The 
following less commonly occurring causes were found in both age groups although not consistently: drowning, 
non-traffic transport incidents and poisoning (Table 148, Table 149).  


































































































































































































































































































































































































Numerator: National Minimum Dataset (acute and arranged admissions); Denominator: Statistics NZ Estimated Resident 
Population; ED cases are those with a health speciality code on discharge of M05–M08; ED rates suppressed where reporting 























































































































































































































































































































































Injury: 0–14 year oldsFalls Inanimate mechanical forces
Animate mechanical forces Road traffic injuries























































































































































































































































































































































Injury: 15–24 year oldsFalls Inanimate mechanical forces
Animate mechanical forces Road traffic injuries
Non-traffic transport incidents Thermal
Poisoning
 




Table 148. Unintentional injury deaths in 0–24 year olds, by age group and cause, Waikato and Bay of Plenty 
DHBs 2008–2012 










95% CI Per cent 
Waikato 
0–14 year olds 
Road traffic 12 2 2.98 1.70–5.20 31.6 
Suffocation 10 2 2.48 1.35–4.56 26.3 
Drowning or submersion 6 1 1.49 0.68–3.25 15.8 
Non-traffic transport accidents 3 1 0.74 0.25–2.19 7.9 
Inanimate mechanical forces <3 s s s s 
Poisoning <3 s s s s 
Falls <3 s s s s 
Other causes <3 s s s s 
Total 38 8 9.42 6.86–12.93 100.0 
15–24 year olds 
Road traffic 55 11 20.70 15.90–26.94 70.5 
Poisoning 8 2 3.01 1.53–5.94 10.3 
Drowning or submersion 7 1 2.63 1.28–5.44 9.0 
Non-traffic transport accidents 3 1 1.13 0.38–3.32 3.8 
Other transport <3 s s s s 
Thermal <3 s s s s 
Inanimate mechanical forces <3 s s s s 
Falls <3 s s s s 
Total 78 16 29.36 23.52–36.63 100.0 
Bay of Plenty 
0–14 year olds 
Road traffic 11 2 4.88 2.73–8.75 39.3 
Suffocation 10 2 4.44 2.41–8.17 35.7 
Non-traffic transport accidents 4 1 1.78 0.69–4.57 14.3 
Drowning or submersion <3 s s s s 
Poisoning <3 s s s s 
Total 28 6 12.43 8.60–17.97 100.0 
15–24 year olds 
Road traffic 32 6 25.89 18.34–36.55 76.2 
Non-traffic transport accidents 4 1 3.24 1.26–8.32 9.5 
Other or unspecified land transport <3 s s s s 
Inanimate mechanical forces <3 s s s s 
Drowning or submersion <3 s s s s 
Other transport <3 s s s s 
Other causes <3 s s s s 
Total 42 8 33.98 25.14–45.93 100.0 





Table 149. Deaths due to unintentional injuries in 0–24 year olds, by age group and cause of injury, Lakes, 
Tairawhiti and Taranaki DHBs 2008–2012  










95% CI Per cent 
Lakes DHB 
0–14 year olds 
Suffocation 8 2 6.73 3.41–13.28 44.4 
Road traffic 4 1 3.36 1.31–8.65 22.2 
Non-traffic transport accidents <3 s s s s 
Falls <3 s s s s 
Inanimate mechanical forces <3 s s s s 
Poisoning <3 s s s s 
Other causes <3 s s s s 
Total 18 4 15.14 9.58–23.93 100.0 
15–24 year olds 
Road traffic 22 4 33.13 21.88–50.16 84.6 
Non-traffic transport accidents <3 s s s s 
Other transport <3 s s s s 
Poisoning <3 s s s s 
Drowning or submersion <3 s s s s 
Total 26 5 39.15 26.72–57.36 100.0 
Tairawhiti 
0–14 year olds 
Suffocation 6 1 10.20 4.67–22.25 42.9 
Drowning or submersion 4 1 6.80 2.64–17.48 28.6 
Non-traffic transport accidents 3 1 5.10 1.73–14.99 21.4 
Inanimate mechanical forces <3 s s s s 
Total 14 3 23.80 14.18–39.94 100.0 
15–24 year olds 
Road traffic 6 1 19.11 8.76–41.70 85.7 
Inanimate mechanical forces <3 s s s s 
Total 7 1 22.30 10.80–46.02 100.0 
Taranaki 
0–14 year olds 
Suffocation 3 1 2.54 0.86–7.45 42.9 
Road traffic <3 s s s s 
Non-traffic transport accidents <3 s s s s 
Drowning or submersion <3 s s s s 
Total 7 1 5.92 2.87–12.21 100.0 
15–24 year olds 
Road traffic 13 3 18.90 11.05–32.34 76.5 
Drowning or submersion <3 s s s s 
Non-traffic transport accidents <3 s s s s 
Thermal <3 s s s s 
Total 17 3 24.72 15.43–39.58 100.0 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
Between 2010 and 2014, falls was the leading cause of hospitalisations among 0–14 year olds in all Midland 
DHBs with the next most common being inanimate mechanical forces. For all the Midland DHBs, the two most 
common causes of injury hospitalisations for 15–24 year olds during this time period were falls and inanimate 




Table 150. Hospitalisations from unintentional injuries in 0–24 year olds, by age group and cause of injury, 
Waikato DHB 2010–2014 
Hospitalisations by main external 









95% CI Per cent 
Waikato 
0–14 year olds 
Falls 1,830 366 448.55 428.51–469.53 43.4 
Inanimate mechanical forces 1,012 202 248.05 233.25–263.79 24.0 
Non-traffic transport incidents 304 61 74.51 66.60–83.37 7.2 
Vehicle occupant 6 1 1.47 0.67–3.21 0.1 
Motorbike 97 19 23.78 19.49–29.00 2.3 
Cyclist 141 28 34.56 29.31–40.75 3.3 
Pedestrian 32 6 7.84 5.56–11.07 0.8 
Other or unspecified 28 6 6.86 4.75–9.92 0.7 
Animate mechanical forces 248 50 60.79 53.68–68.84 5.9 
Road traffic crash 224 45 54.90 48.17–62.58 5.3 
Vehicle occupant 78 16 19.12 15.32–23.86 1.8 
Motorbike 25 5 6.13 4.15–9.05 0.6 
Cyclist 76 15 18.63 14.88–23.31 1.8 
Pedestrian 41 8 10.05 7.41–13.63 1.0 
Other or unspecified <5 s s s s 
Other or unspecified land transport 57 11 13.97 10.78–18.10 1.4 
Other transport <5 s s s s 
Thermal 153 31 37.50 32.01–43.93 3.6 
Poisoning 68 14 16.67 13.15–21.13 1.6 
Suffocation 33 7 8.09 5.76–11.36 0.8 
Drowning or submersion 15 3 3.68 2.23–6.07 0.4 
Other causes 246 49 60.30 53.22–68.31 5.8 
Undetermined intent 23 5 5.64 3.76–8.46 0.5 
Total 4,217 843 1,033.63 1,003.05–1,065.13 100.0 
15–24 year olds 
Inanimate mechanical forces 952 190 352.94 331.25–376.04 28.5 
Falls 767 153 284.35 264.95–305.17 23.0 
Road traffic crash 513 103 190.19 174.44–207.35 15.4 
Vehicle occupant 322 64 119.38 107.04–133.14 9.6 
Motorbike 101 20 37.44 30.82–45.49 3.0 
Cyclist 48 10 17.80 13.42–23.59 1.4 
Pedestrian 34 7 12.60 9.02–17.61 1.0 
Other or unspecified 8 2 2.97 1.50–5.85 0.2 
Non-traffic transport incidents 277 55 102.69 91.30–115.51 8.3 
Vehicle occupant 11 2 4.08 2.28–7.30 0.3 
Motorbike 147 29 54.50 46.37–64.05 4.4 
Cyclist 63 13 23.36 18.26–29.88 1.9 
Pedestrian 7 1 2.60 1.26–5.36 0.2 
Other or unspecified 49 10 18.17 13.74–24.01 1.5 
Other or unspecified land transport 74 15 27.43 21.86–34.44 2.2 
Other transport 11 2 4.08 2.28–7.30 0.3 
Animate mechanical forces 274 55 101.58 90.25–114.33 8.2 
Thermal 54 11 20.02 15.35–26.12 1.6 
Poisoning 29 6 10.75 7.49–15.44 0.9 
Suffocation <5 s s s s 
Drowning or submersion 0 .. .. .. .. 
Other causes 333 67 123.45 110.89–137.44 10.0 
Undetermined intent 51 10 18.91 14.38–24.86 1.5 
Total 3,338 668 1,237.51 1,196.48–1,279.93 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Table 151. Hospitalisations from unintentional injuries in 0–24 year olds, by age group and cause of injury, 
Bay of Plenty DHB 2010–2014 
Hospitalisations by main external 









95% CI Per cent 
Bay of Plenty 
0–14 year olds 
Falls 1,247 249 549.49 519.91–580.76 43.5 
Inanimate mechanical forces 537 107 236.63 217.47–257.48 18.8 
Animate mechanical forces 191 38 84.16 73.05–96.97 6.7 
Non-traffic transport incidents 189 38 83.28 72.23–96.03 6.6 
Vehicle occupant <5 s s s s 
Motorbike 72 14 31.73 25.20–39.95 2.5 
Cyclist 79 16 34.81 27.94–43.38 2.8 
Pedestrian 25 5 11.02 7.46–16.26 0.9 
Other or unspecified 10 2 4.41 2.39–8.11 0.3 
Road traffic crash 159 32 70.06 59.99–81.83 5.6 
Vehicle occupant 77 15 33.93 27.15–42.40 2.7 
Motorbike 14 3 6.17 3.67–10.36 0.5 
Cyclist 49 10 21.59 16.33–28.54 1.7 
Pedestrian 19 4 8.37 5.36–13.08 0.7 
Other or unspecified 0 .. .. .. .. 
Other or unspecified land transport 57 11 25.12 19.39–32.54 2.0 
Other transport <5 s s s s 
Poisoning 151 30 66.54 56.74–78.03 5.3 
Thermal 102 20 44.95 37.03–54.55 3.6 
Suffocation 21 4 9.25 6.05–14.15 0.7 
Drowning or submersion 15 3 6.61 4.01–10.91 0.5 
Other causes 181 36 79.76 68.96–92.25 6.3 
Undetermined intent 12 2 5.29 3.02–9.24 0.4 
Total 2,864 573 1,262.03 1,216.92–1,308.79 100.0 
15–24 year olds 
Inanimate mechanical forces 500 100 398.52 365.14–434.93 26.3 
Falls 401 80 319.61 289.86–352.40 21.1 
Road traffic crash 352 70 280.56 252.77–311.39 18.5 
Vehicle occupant 234 47 186.51 164.11–211.96 12.3 
Motorbike 75 15 59.78 47.70–74.92 4.0 
Cyclist 19 4 15.14 9.70–23.65 1.0 
Pedestrian 19 4 15.14 9.70–23.65 1.0 
Other or unspecified 5 1 3.99 1.70–9.33 0.3 
Non-traffic transport incidents 189 38 150.64 130.65–173.68 10.0 
Vehicle occupant 7 1 5.58 2.70–11.52 0.4 
Motorbike 105 21 83.69 69.14–101.29 5.5 
Cyclist 52 10 41.45 31.61–54.34 2.7 
Pedestrian 9 2 7.17 3.77–13.63 0.5 
Other or unspecified 16 3 12.75 7.85–20.72 0.8 
Other or unspecified land transport 30 6 23.91 16.75–34.13 1.6 
Other transport 14 3 11.16 6.65–18.73 0.7 
Animate mechanical forces 140 28 111.59 94.58–131.65 7.4 
Thermal 35 7 27.90 20.06–38.79 1.8 
Poisoning 26 5 20.72 14.14–30.36 1.4 
Suffocation <5 s s s s 
Drowning or submersion 0 .. .. .. .. 
Other causes 163 33 129.92 111.45–151.43 8.6 
Undetermined intent 44 9 35.07 26.13–47.07 2.3 
Total 1,898 380 1,512.78 1,446.71–1,581.82 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Table 152. Hospitalisations from unintentional injuries in 0–24 year olds, by age group and cause of injury, 
Lakes DHB 2010–2014 
Hospitalisations by main external 









95% CI Per cent 
Lakes DHB 
0–14 year olds 
Falls 665 133 565.61 524.33–610.13 46.7 
Inanimate mechanical forces 253 51 215.19 190.28–243.35 17.8 
Non-traffic transport incidents 115 23 97.81 81.50–117.39 8.1 
Vehicle occupant <5 s s s s 
Motorbike 34 7 28.92 20.70–40.41 2.4 
Cyclist 57 11 48.48 37.42–62.80 4.0 
Pedestrian 16 3 13.61 8.38–22.11 1.1 
Other or unspecified 5 1 4.25 1.82–9.96 0.4 
Animate mechanical forces 80 16 68.04 54.68–84.67 5.6 
Road traffic crash 65 13 55.29 43.38–70.45 4.6 
Vehicle occupant 22 4 18.71 12.36–28.33 1.5 
Motorbike 8 2 6.80 3.45–13.43 0.6 
Cyclist 22 4 18.71 12.36–28.33 1.5 
Pedestrian 12 2 10.21 5.84–17.84 0.8 
Other or unspecified <5 s s s s 
Other or unspecified land transport 29 6 24.67 17.18–35.42 2.0 
Other transport 0 .. .. .. .. 
Poisoning 58 12 49.33 38.17–63.76 4.1 
Thermal 50 10 42.53 32.26–56.06 3.5 
Suffocation 18 4 15.31 9.68–24.20 1.3 
Drowning or submersion <5 s s s s 
Other causes 82 16 69.74 56.20–86.55 5.8 
Undetermined intent <5 s s s s 
Total 1,423 285 1,210.33 1,149.40–1,274.45 100.0 
15–24 year olds 
Inanimate mechanical forces 242 48 363.17 320.27–411.79 22.1 
Falls 237 47 355.67 313.24–403.82 21.7 
Road traffic crash 178 36 267.12 230.70–309.28 16.3 
Vehicle occupant 124 25 186.09 156.11–221.81 11.3 
Motorbike 26 5 39.02 26.63–57.17 2.4 
Cyclist 17 3 25.51 15.93–40.86 1.6 
Pedestrian 8 2 12.01 6.08–23.69 0.7 
Other or unspecified <5 s s s s 
Non-traffic transport incidents 140 28 210.10 178.08–247.85 12.8 
Vehicle occupant <5 s s s s 
Motorbike 72 14 108.05 85.82–136.04 6.6 
Cyclist 51 10 76.54 58.22–100.61 4.7 
Pedestrian <5 s s s s 
Other or unspecified 11 2 16.51 9.22–29.56 1.0 
Other or unspecified land transport 20 4 30.01 19.43–46.36 1.8 
Other transport 8 2 12.01 6.08–23.69 0.7 
Animate mechanical forces 95 19 142.57 116.65–174.23 8.7 
Thermal 30 6 45.02 31.54–64.26 2.7 
Poisoning 14 3 21.01 12.52–35.27 1.3 
Suffocation <5 s s s s 
Drowning or submersion <5 s s s s 
Other causes 121 24 181.58 152.00–216.91 11.1 
Undetermined intent <5 s s s s 
Total 1,093 219 1,640.26 1,546.57–1,739.53 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Table 153. Hospitalisations from unintentional injuries in 0–24 year olds, by age group and cause of injury, 
Tairawhiti DHB 2010–2014 
Hospitalisations by main external 









95% CI Per cent 
Tairawhiti 
0–14 year olds 
Falls 350 70 597.49 538.24–663.22 43.0 
Inanimate mechanical forces 120 24 204.85 171.36–244.88 14.7 
Road traffic crash 50 10 85.36 64.75–112.50 6.1 
Vehicle occupant 15 3 25.61 15.52–42.25 1.8 
Motorbike 8 2 13.66 6.92–26.95 1.0 
Cyclist 14 3 23.90 14.24–40.12 1.7 
Pedestrian 13 3 22.19 12.97–37.97 1.6 
Other or unspecified 0 .. .. .. .. 
Thermal 49 10 83.65 63.28–110.56 6.0 
Animate mechanical forces 46 9 78.53 58.88–104.72 5.7 
Non-traffic transport incidents 43 9 73.41 54.50–98.85 5.3 
Vehicle occupant <5 s s s s 
Motorbike 11 2 18.78 10.49–33.63 1.4 
Cyclist 19 4 32.44 20.77–50.66 2.3 
Pedestrian 8 2 13.66 6.92–26.95 1.0 
Other or unspecified <5 s s s s 
Other or unspecified land transport 38 8 64.87 47.27–89.02 4.7 
Other transport <5 s s s s 
Poisoning 39 8 66.58 48.71–90.99 4.8 
Suffocation 14 3 23.90 14.24–40.12 1.7 
Drowning or submersion 9 2 15.36 8.08–29.20 1.1 
Other causes 44 9 75.11 55.96–100.81 5.4 
Undetermined intent 10 2 17.07 9.27–31.42 1.2 
Total 814 163 1,389.59 1,297.93–1,487.62 100.0 
15–24 year olds 
Inanimate mechanical forces 151 30 476.88 406.77–559.00 27.7 
Falls 112 22 353.71 294.07–425.40 20.5 
Road traffic crash 95 19 300.02 245.51–366.59 17.4 
Vehicle occupant 62 12 195.80 152.78–250.91 11.4 
Motorbike 11 2 34.74 19.40–62.20 2.0 
Cyclist 10 2 31.58 17.16–58.13 1.8 
Pedestrian 8 2 25.27 12.80–49.85 1.5 
Other or unspecified <5 s s s s 
Animate mechanical forces 52 10 164.22 125.26–215.27 9.5 
Non-traffic transport incidents 21 4 66.32 43.38–101.37 3.8 
Vehicle occupant 5 1 15.79 6.74–36.96 0.9 
Motorbike 10 2 31.58 17.16–58.13 1.8 
Cyclist <5 s s s s 
Pedestrian 0 .. .. .. .. 
Other or unspecified <5 s s s s 
Other or unspecified land transport 22 4 69.48 45.89–105.18 4.0 
Other transport 5 1 15.79 6.74–36.96 0.9 
Thermal 16 3 50.53 31.11–82.07 2.9 
Poisoning <5 s s s s 
Suffocation 0 .. .. .. .. 
Drowning or submersion 0 .. .. .. .. 
Other causes 56 11 176.86 136.23–229.57 10.3 
Undetermined intent 14 3 44.21 26.34–74.21 2.6 
Total 546 109 1,724.34 1,586.70–1,873.69 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 




Table 154. Hospitalisations from unintentional injuries in 0–24 year olds, by age group and cause of injury, 
Taranaki DHB 2010–2014 
Hospitalisations by main external 









95% CI Per cent 
Taranaki 
0–14 year olds 
Falls 518 104 432.83 397.19–471.64 46.8 
Inanimate mechanical forces 173 35 144.55 124.57–167.74 15.6 
Non-traffic transport incidents 84 17 70.19 56.70–86.88 7.6 
Vehicle occupant <5 s s s s 
Motorbike 37 7 30.92 22.43–42.61 3.3 
Cyclist 32 6 26.74 18.94–37.74 2.9 
Pedestrian <5 s s s s 
Other or unspecified 10 2 8.36 4.54–15.38 0.9 
Road traffic crash 73 15 61.00 48.52–76.68 6.6 
Vehicle occupant 17 3 14.20 8.87–22.75 1.5 
Motorbike 5 1 4.18 1.78–9.78 0.5 
Cyclist 39 8 32.59 23.84–44.54 3.5 
Pedestrian 12 2 10.03 5.74–17.53 1.1 
Other or unspecified 0 .. .. .. .. 
Other or unspecified land transport 23 5 19.22 12.81–28.84 2.1 
Other transport <5 s s s s 
Animate mechanical forces 63 13 52.64 41.15–67.34 5.7 
Thermal 45 9 37.60 28.10–50.30 4.1 
Poisoning 43 9 35.93 26.68–48.39 3.9 
Suffocation 14 3 11.70 6.97–19.64 1.3 
Drowning or submersion <5 s s s s 
Other causes 63 13 52.64 41.15–67.34 5.7 
Undetermined intent <5 s s s s 
Total 1,108 222 925.81 873.11–981.67 100.0 
15–24 year olds 
Inanimate mechanical forces 273 55 396.84 352.55–446.68 30.3 
Falls 176 35 255.84 220.77–296.47 19.5 
Road traffic crash 136 27 197.69 167.17–233.78 15.1 
Vehicle occupant 86 17 125.01 101.25–154.35 9.5 
Motorbike 20 4 29.07 18.82–44.90 2.2 
Cyclist 17 3 24.71 15.43–39.57 1.9 
Pedestrian 9 2 13.08 6.88–24.86 1.0 
Other or unspecified <5 s s s s 
Non-traffic transport incidents 99 20 143.91 118.23–175.16 11.0 
Vehicle occupant <5 s s s s 
Motorbike 66 13 95.94 75.42–122.03 7.3 
Cyclist 22 4 31.98 21.12–48.42 2.4 
Pedestrian <5 s s s s 
Other or unspecified 7 1 10.18 4.93–21.00 0.8 
Other or unspecified land transport 18 4 26.17 16.55–41.36 2.0 
Other transport <5 s s s s 
Animate mechanical forces 67 13 97.39 76.71–123.66 7.4 
Thermal 16 3 23.26 14.32–37.78 1.8 
Poisoning 5 1 7.27 3.10–17.02 0.6 
Suffocation <5 s s s s 
Drowning or submersion 0 .. .. .. .. 
Other causes 86 17 125.01 101.25–154.35 9.5 
Undetermined intent 22 4 31.98 21.12–48.42 2.4 
Total 902 180 1,311.18 1,228.85–1,398.95 100.0 
Numerator: National Minimum Dataset (acute and arranged admissions; excludes ED cases); Denominator: Statistics NZ 





Evidence for good practice for the prevention of injury 
New Zealand policy documents 
Ministry of Transport. Safer Journeys: New Zealand’s Road Safety Strategy 2010–2020 
http://www.transport.govt.nz/saferjourneys/Documents/SaferJourneyStrategy.pdf 
Increasing the safety of young drivers is a major priority in the Road Safety Strategy 2010–2020. The aim is to reduce road fatality rates 
for young people from 21 per 100,000 to a rate similar to Australia (13 per 100,000). Proposed strategies include multiple policy and 
practice initiatives across four key areas: safe roads and roadsides, safe speeds, safe vehicles and safe road use. The strategy reflects a 
programme designed to address some of the risk factors that research has identified but also to actively engage the community in 
acting positively to increase road safety. 
New Zealand Water Safety Sector Strategy 2020 http://www.watersafety.org.nz/our-sector/water-safety-sector-
strategy-2020/ 
The New Zealand Water Safety Sector has collectively developed and published in 2015, the Water Safety Sector Strategy 2020. In the 
face of New Zealand having the 8th highest drowning rate in the OECD, the Strategy provides describes the problem and identifies a 
set of outcomes and goals. Its goals are to reduce preventable drowning deaths by 35%, reduce drowning hospitalisations by 42%, 
halve the male drowning rate and reduce pre-school drowning to zero by 2020. These are to be reached by the sector working 
collectively so that all New Zealanders enjoy the water safely.  
Ministry of Business Industry and Enterprise Working Safer: a blueprint for health and safety at work 
http://www.mbie.govt.nz/info-services/employment-skills/workplace-health-and-safety-reform/document-and-image-
library/safety-first-blueprint.pdf 
The Working Safer Blueprint spells out the intention to reduce the unacceptably high rates of fatalities and serious injuries in the 
workplace by at least 25% by 2020. It quotes the principle included in the report of the Royal Commission on the Pike River Tragedy 
that “health and safety in New Zealand can be improved only by the combined efforts of government, employers and workers.” The 
blueprint does not specify young people within the document, however, it is relevant to young people who are in the workforce. 
International guidelines 
NICE – National Institute for Health and Care Excellence http://www.nice.org.uk/ 
Unintentional injuries among under – 15s overview  
http://pathways.nice.org.uk/pathways/unintentional-injuries-among-under-15s 
http://www.nice.org.uk/guidance/ph30, http://www.nice.org.uk/guidance/ph31 
The Pathway provides guidelines for preventing unintentional injury to children. The first of a series of three guidelines provides 
recommendations for national and local strategy, policy and development and setting specific paths for health services, local authorities, 
highway authorities, police, fire and rescue services, schools and for private and public outdoor play. Topics include off road cycling, 
home visiting, water safety, and road safety. The second and third of the set of Guidances (PH30, PH31) provide more specific 
recommendations for preventing unintentional injuries in the home and on the road. 
Head injuries quality standard (QS74) and Head injuries assessment and early management (CG176) 
https://www.nice.org.uk/guidance/conditions-and-diseases/injuries–accidents-and-wounds/head-injuries 
In addition to the injury prevention guidance, NICE is developing a set of pathways for injuries, accidents and wounds. These include 
head injuries, trauma, wound management and general injury, accidents and wounds. The head injury quality standard and assessment 
and early management guidelines have been completed while guidance or advice for others is to be published in February 2016. While 
being based in the UK system and not specifically for children, guidance is based on research evidence and therefore has relevance to 
the New Zealand setting. 
Systematic reviews: Home safety 
Kendrick D, Mulvaney C, Ye, L et al Parenting interventions for the prevention of unintentional injuries in 
childhood Cochrane Database of Systematic Reviews. (2013) (6). 
Kendrick et al examined 22 studies (including 16 RCTs) among which were 15 home visiting programmes and 2 paedediatric practice-
based interventions. The families in 19 of the studies were from families in socioeconomically disadvantaged populations and were 
considered to be at risk of adverse child outcomes. The authors’ meta-analysis (10 studies, 5074 participants) indicated that intervention 
families had a statistically significant lower risk of injury than control families. The authors concluded that “parenting programmes are 
effective in reducing unintentional injury in children and can improve home safety, particularly in families who may be considered ‘at 
risk,’ such as some teenage or single mothers. It would be worthwhile for health and social care providers to make parenting 




Kendrick D, Young B, Masonjones AJ et al Home safety education and provision of safety equipment for injury 
prevention. Cochrane Database of Systematic Reviews. (2014)(10) 
This systematic review involved examining 98 studies (2,605,044 people) of which 54 were included in the meta-analysis (812,705 
people), and of these 35 were RCTs. The criteria were for home safety education with or without the provision of safety equipment for 
those aged ≤19 years and which reported injury, safety practices or possession of safety equipment. The main conclusion was that 
home safety interventions that provide face-to-face, one-to-one education and provision of safety equipment may reduce injury rates, 
particularly if they are provided at home. The review notes conflicting findings on the provision of equipment. There was no evidence, 
however, that home safety education was less effective in those participants at greater risk of injury. Further research is required however 
to confirm these findings. 
Systematic reviews: Road safety 
Ehiri JE, Ejere ODH, Magnussen L et al. Interventions for promoting booster seat use in four to eight year olds 
travelling in motor vehicles. Cochrane Database of Systematic Reviews (2012)(11) 
It has been recommended that booster seats be used for children aged from around 4 to 8 years to reduce the potential for injury in 
the event of a crash. Various interventions have been implemented to increase the use of these booster seats. This review examines the 
effectiveness of the interventions to increase acquisition and use of the booster seats in the target audience. Five studies (3,070 
participants) were examined and all showed a positive effect. The effective interventions included incentives combined with education, 
distribution of free booster seats with education and education only. The study in which the intervention was enforcement of the law 
demonstrated no marked beneficial effect, although before and after studies that did not meet the inclusion criteria for the meta-
analysis did show some beneficial effect of legislation.  
Kardamanidis K, Martiniuk A, Ivers RQ, Stevenson MR, Thistlethwaite K. Motorcycle rider training for the prevention 
of road traffic crashes. Cochrane Database of Systematic Reviews 2010, Issue 10. Art. No.: CD005240. DOI: 
10.1002/14651858.CD005240.pub2 
This review considered evaluations of the effectiveness of motorcycle rider courses in reducing the number of traffic offences, crashes, 
injuries and death. There was a variety of content and delivery within the 23 research studies included in the review. The evidence was 
unclear as to whether training reduces any of these outcomes, and what kind of training is most effective. The authors concluded they 
could not recommend a particular type of rider training. They did note that some form of rider training was necessary for learning basic 
motorcycle handling techniques and to ride a motorcycle safely and that further research was required. 
Thompson DC, Rivara F, Thompson R. Helmets for preventing head and facial injuries in bicyclists. Cochrane 
Database of Systematic Reviews (2009) (4) 
The main conclusion from this review of cycle helmets was that helmets provide between 63 to 88% reduction in the risk of head, brain 
and severe brain injury. This is for all ages of riders. This conclusion was based on the results of five case control studies that met the 
inclusion criteria and were considered well conducted. Helmets are considered to provide protection for events involving motor vehicle 
crashes (69%) as well as other causes (68%). 
Systematic review: water safety  
Leavy JE, Crawford G, Leaversuch F, et al. A review of drowning prevention interventions for children and young people 
in high, low and middle income countries. Journal Community Health DOI 10.1007/s10900-015-0105-2 October 2015. 
The authors of this review identified 15 studies from five different countries that met PRISMA criteria. The studies examined were varied, 
with more than seven designs utilised and the age of the participants, duration, strategies and evaluation measures and outcomes 
varied between interventions. All used aspects of the International Life Saving Federation (ILSF) drowning prevention chain-control 
measures (education and information, denial of access, supervision and acquisition of survival skills): 40% of the studies depended on 
education and information. Only three studies used a multi-themed approach while supervision was a key theme in two studies. While 
the review identifies considerable limitations in all the studies, for example because of their over reliance on self-report and focus on 
short term effects, the authors provide a useful analysis for intervention studies.  
Systematic reviews: Sport and recreational injury 
Rossler R, Donath L, Verhagen E et al. Exercise-based injury prevention in child and adolescent sport: a systematic 
review and meta-analysis. Sports Med. 2014;44(12):1733-48. doi: 10.1007/s40279-014-0234-2. 
Conclusions drawn following examination of 21 trials conducted on 27,561 athletes with an age range of 10 .7 to 17.8 years were that 
there was good evidence that there were beneficial effects of exercise based injury prevention programmes for organised youth sports. 
Programmes focusing on specific injuries and injuries in general showed significant reductions and girls benefited more than boys. 
Multimodal programmes that included jumping/plyometric exercises were recommended. However, there is little data for effects of 




Brussoni MJ, Olsen LL, Pike I, Sleet DA. Risky play and children's safety: balancing priorities for optimal child 
development Int. J. Environ. Res. Public Health 2012; 9(9): 3134-3148.  
This review examines the role of injury prevention and its relationship between child development, play and concepts of risk taking. 
This is a useful review to inform discussion around the debate of whether children are over-protected. The authors suggest a 
modification to the safety paradigm to aim to create an environment for children that is “as safe as necessary” rather than “as safe as 
possible”. They discuss the options for increasing opportunities for play, the importance of play and the effects of parents curtailing 
children’s activities and the potential reactive response may be problematic for the interventions that have made a major difference to 
injury death and hospitalisations for children, such as child car restraints 
Data links – New Zealand 
Statistics New Zealand. Injury Information Portal http://search.stats.govt.nz/browse_for_stats/health/injuries.aspx 
This website provides links to various websites that provide data on New Zealand injury. 
Injury Prevention Research Unit. New Zealand Injury Query System http://ipru3.otago.ac.nz/niqs/ 
Visitors to this website can select from year range, age range, cause of injury, intent, gender, region (district health board, territorial 
local authority, all New Zealand) to create tables of for injury, either fatal or non-fatal. The data come from public hospital discharge 
data and the New Zealand Coronial Service. A customised enquiries service is also available. 
New Zealand Child and Youth Mortality Review Committee. 10th Data Report 2009-2013. 
http://www.hqsc.govt.nz/assets/CYMRC/Publications/tenth-data-report-2009-2013.pdf (2014) 
The Health Quality and Safety Commission publish an annual report from the NZ Child Mortality Review Group in which the data on 
deaths to those aged between 0 to 24 years are presented in 5-year age groups. It uses the underlying cause of death classification 
from the Ministry of Health’s Mortality Collection.  
International reports  
World Health Organization. Injuries and Violence: The Facts. 2014 
http://apps.who.int/iris/bitstream/10665/149798/1/9789241508018_eng.pdf?ua=1&ua=1 
This publication outlines the magnitude of death from injury in the global context, noting that more than 5 million people die each 
year as a result of injuries. Of these 24% are road traffic injuries and the report notes that road traffic injuries are the leading cause of 
death among 15–29 year olds worldwide. Evidence-based measures to reduce main causes of injury death are listed which are relevant 
to the New Zealand context.  
Peden M, Oyegbite K, Ozanne-Smith J et al (eds). World report on child injury prevention World Health 
Organization and Unicef 2008 http://www.unicef.org/eapro/World_report.pdf 
The World report notes that for each area of child injury, there are proven ways to reduce the likelihood and severity of injury. Much of 
the problem is a lack of awareness of the problem and the lack of political will to make a difference. While this report was published in 
2008 and includes much directed towards middle income countries, in its examination of each area of injury, it contains interventions 
that are current, known to be effective and many are relevant to New Zealand. Each chapter provides key messages, makes 
recommendations for reducing childhood injury and offers fact sheets intended for various audiences.  
European Public Health Alliance (EPHA) and TACTICS. EPHA Briefing: Mandated responsibility for intentional and 
Unintentional Child Injury Prevention in Europe focusing on road safety, water safety, home safety and intentional 
injury. http://epha.org/IMG/pdf/EPHA_Briefing_-_TACTICS-child_safety-Final.pdf (2014) 
The underlying rationale for the development of this brief is the United Nations Convention on the rights of the Child. This document 
provides a strategy for the member states of the EU to reach a set of objectives to improve the well-being of children. Included are the 
development of a framework for an evidence based review, the promotion of multisectoral action, and to identify the role of the health 
sector in developing and coordinating policies and delivering services to meet the health needs of children and young people. Safety 
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IN DEPTH TOPIC: YOUNG PEOPLE’S SEXUAL AND 
REPRODUCTIVE HEALTH 
Introduction 
Having sex for the first time is a major milestone in life that almost everyone reaches. In New Zealand, around 
37% of secondary school students have had sex by the age of 16 years and around 46% by the age of 17 or 
more.101 Becoming sexually active brings both risks and rewards. Policy makers are generally most concerned 
with the risks, particularly the risks of early unintended pregnancy and sexually transmitted infections and the 
associated costs to society. Good sexual health, however, is more than not contracting a sexually transmitted 
infection and not being involved in an unintended pregnancy. It has both individual and public health 
dimensions, as indicated by the following broad definition of sexual health, developed in the US: 
‘Sexual health is a state of well-being in relation to sexuality across the life span that involves physical, 
emotional, mental, social, and spiritual dimensions. Sexual health is an intrinsic element of human health 
and is based on a positive, equitable, and respectful approach to sexuality, relationships, and 
reproduction, that is free of coercion, fear, discrimination, stigma, shame, and violence. It includes: the 
ability to understand the benefits, risks, and responsibilities of sexual behaviour; the prevention and care 
of disease and other adverse outcomes; and the possibility of fulfilling sexual relationships. Sexual 
health is impacted by socioeconomic and cultural contexts–including policies, practices, and services–
that support healthy outcomes for individuals, families, and their communities.’102 
Supporting young people to attain sexual health as defined above is clearly not something the health system can 
accomplish on its own, nevertheless there is an important role for the health system in helping young people to 
avoid unwanted pregnancy, providing care to young pregnant women, and preventing and treating sexually 
transmitted infections. 
This in-depth topic considers ways of improving the sexual and reproductive health of New Zealand adolescents 
and young adults. It focuses on the prevention of unintended teenage pregnancy but also touches on the 
prevention of sexually transmitted infections. It does not deal with maternity services for pregnant teenagers or 
services for teenage parents because a previous in-depth topic in this series of reports (2012) was entitled 
Services and Interventions for Women Experiencing Multiple Adversities in Pregnancy and this included a 
substantial section on services for teenage parents.103 
It begins by summarising what is known about the sexual behaviour of young people in New Zealand. It then 
reviews sexuality education, sexual and reproductive health services for young people, and contraceptive 
options for young people (with a particular focus on long-acting reversible methods). It concludes with some 
recommendations for improving the sexual and reproductive health of New Zealand young people and 
preventing unintended teenage pregnancies. 
This choice of areas for review was influenced by the 2013 report of the Health Committee (one of the select 
committees of the New Zealand Parliament) Inquiry into improving child health outcomes and preventing child 
abuse with a focus from preconception until three years of age104. One of the major recommendations which 
came out of the inquiry was as follows: 
‘We recommend to the Government that it develop a co-ordinated cross-sectoral action plan with the 
objective of giving New Zealand world-leading, best-practice evidence-based sexuality and reproductive 
health education, contraception, sterilisation, termination, and sexual health services, distributed to 
cover the whole country. The plan should be developed within 12 to 18 months of this report being 
published, and be matched with appropriate, sustainable resourcing. The plan should also be monitored 
by trends in teenage pregnancy, sexually transmitted diseases, unplanned pregnancy, and terminations.’ 
It should be borne in mind that in developed countries teenage pregnancy (except in the youngest teenagers) is 
not so much a medical problem as a social problem.105 Many of the adverse medical outcomes attributed to 
teenage pregnancy, such as prematurity and low birth weight, are probably mostly due to the poor socio-
economic circumstances and associated risk-taking behaviours that predispose young women to early 
pregnancy.106,107 It should not be assumed that if women in the most deprived communities would only delay 
their first birth by five years or ten years, then that alone would inevitably improve outcomes for them and their 
children.  
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The sexual health and behaviour of New Zealand’s young people 
The only recently published surveys of the sexual health and behaviour of New Zealand young people are the 
Youth 2000 series of surveys of secondary school students, conducted in 2001108, 2007109 and 2012110, and the 
2009 Tertiary Student Health Survey.111 
Information from the Youth 2000 Survey Series 
The 2012 survey found that, out of all 8,500 participating students, 24% reported that they had ever had sex and 
19% that they were currently sexually active (these categories did not include sexual abuse).110 There were no 
significant differences between males and females. As could be expected, the proportions of students reporting 
having ever had sex and being currently sexually active increased with increasing age. Of students aged 17 years 
or older, 46% reported that they had ever had sex and 36% were currently sexually active. 
Most students (93% of males and 92% of females) were attracted only to the opposite sex, while 4% of students 
were attracted to the same-sex or to both sexes and 4% were either not sure of their sexual attractions or were 
attracted to neither sex.110 
Of the students who were sexually active, 58% reported always using contraception to prevent pregnancy. 
Forty-four percent had talked to their partner about preventing sexually transmitted infections and 46% reported 
always using a condom to protect against sexually transmitted infections. Seventeen percent of the students who 
were currently sexually active reported that they did not or only sometimes used condoms or other 
contraception. This proportion was greater among younger students and students living in high deprivation 
areas. 112 
Comparing results from the 2000, 2007 and 2012 surveys shows that the percentage of students who always use 
contraception to prevent pregnancy and the percentage who always use condoms to prevent sexually transmitted 
infections have not changed over time.110 The percentage of students who reported ever having had sex was 
lower in 2012 (24%) than in 2001 (31%) and 2007 (36%) but this may have been because the 2012 survey 
question about having ever had sex explicitly told students not to count abuse or unwanted sexual experiences, 
whereas in 2007 and 2001 this was not stated.101,110 
Information from the 2009 Tertiary Student Health Survey 
This survey involved 2,922 students aged 17 to 24 years from all eight New Zealand universities (50.6% of the 
5,770 invited to participate).111 Sixty-nine percent of both men and women reported having had sexual 
intercourse, and the median age at first sex was 16 for women and 17 for men. The median number of sexual 
partners ever was three for both men and women. The median number of partners in the last year was one 
although about 25% of students had three or more. Most students (66%) reported that the person they last had 
sex with was someone they were in a ‘steady relationship’ or were ‘living together, engaged, or married’ but 3% 
of women and 11% of men reported having ‘just met’ the person they last had sex with. Fifty-eight percent of 
men and 51% of women reported using a condom the last time they had sex. Those with a higher number of 
sexual partners in the last 12 months were less likely to report having used a condom at last sex (51% of those 
with one partner vs. 42% of those with nine or more partners).  
Overall, 32% of respondents reported that they had been drinking alcohol the last time they had sex. Adverse 
sexual experiences (unsafe sex, regretted sex, experiencing unwanted sexual advances) as a result of a 
respondent’s own or others’ drinking were common.113 
Of the women survey participants, 112 (5.8% of those who had ever had sex) reported having had an unintended 
pregnancy and 74% of these had resulted in a termination. 
Around 95% of students reported sexual attraction to the opposite sex mainly. Men were more likely than 
women to report being exclusively heterosexual (90.8% vs. 83.2%). About 2% of both men and women reported 
attraction to both sexes equally and about and 3% of men and 1% of women reported same sex attraction only or 
mainly. 
Information from official and health services statistics 
Some indirect information about the sexual health and behaviour of New Zealand’s young people can be gained 
by looking at official statistics and data collected by health services. Information on rates of sexually transmitted 
infections in young people is analysed by The Institute of Environmental Science and Research (ESR) which 
collects surveillance information on STIs from diagnostic laboratories and from sexual health and family 
planning clinics.114 The ESR has stated that laboratory information is the best indicator of disease incidence for 
chlamydia and gonorrhoea in most DHBs and that surveillance of genital herpes and genital warts is solely 
 
Reproductive health: Young people’s sexual and reproductive health 
323 
clinic based.114 The Abortion Supervisory Committee collects and analyses data on abortions performed in New 
Zealand.115 
Teenage births in New Zealand 
Information on trends in teenage births in New Zealand can be found in the ‘Births’ section beginning on page 
340 of this report. The New Zealand teenage birth rate in 2014 was 23.9 per 1,000 women aged 15–19 years.116 
New Zealand’s teenage birth rate is declining and births to teenage mothers are increasingly concentrated in 
teenagers aged 18 and 19 years.117 In 2013, almost three quarters (71.6%) of all teenage births were to 18 and 19 
year olds (up from 66.6% in 2006).117 Few teenagers have more than one birth as teenagers. Of the women who 
had a baby aged 15 years in 2008, only 2% had a second or subsequent birth before their 20 th birthday.117 
Māori have a higher rate of teenage births than the national rate (53.2 vs. 22.0 per 1,000 in 2013) but the Māori 
rate is declining at a similar rate to the national rate.117 Teenage birth rates are significantly higher than the 
national average in Northland and Gisborne, and significantly lower in metropolitan Auckland, Wellington and 
Canterbury, as well as in the rest of the South Island.117 Nationally there is a very strong correlation between the 
level of socioeconomic deprivation (NZDep score) and teenage birth rates and, in the regions with high teenage 
birth rates, a relatively large proportion of the teenage population live in high deprivation areas.118 Māori 
teenage birth rates are higher than European rates at all levels of deprivation, indicating that socioeconomic 
deprivation is not the sole reason for higher teenage birth rates among Māori, and that other factors, such as a 
cultural preference for early motherhood, may play a part.118,119 
 International comparisons in teenage birth rates 
As can be seen from Figure 159, New Zealand has a teenage birth rate that is high compared to other OECD 
countries, with the exception of the United States. Teenage birth rates have declined in all the countries shown 
in Figure 159, but not to the same degree. 
Figure 159. Teenage birth rates in selected OECD countries 2005 to 2015 
The 
World Bank. Adolescent fertility rate (births per 1,000 women ages 15-19). 2015 [cited November, 2015]; Available from: 
http://data.worldbank.org/indicator/SP.ADO.TFRT  
Sexually transmitted infections in New Zealand young people 
Chlamydia is the most commonly reported STI in New Zealand.114 This infection is often asymptomatic (in 
around 25% of male cases and 70% of female cases) but can have serious consequences if untreated, including 
pelvic inflammatory disease, ectopic pregnancy and both female and male infertility.114 In 2013, the ESR 
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reported that 68% (19,327) of positive chlamydia cases were young people aged 15–24 years.114 National 
disease rates were 3,080 per 100,000 for 15–19 year olds and 2,981 per 100,000 for 20–24 year olds. There were 
marked geographic variations in young people’s chlamydia rates. Lakes and Tairawhiti DHBs had rates around 
twice the national rate. Rates for young females, but not young males, declined from 2009 to 2013 (by 27% in 
females aged 15–19 years and by 17% in females aged 20–24). Testing rates were 205 per 1,000 for 15−19 year 
olds and 298 per 1,000 for 20–24 year olds. Young women were around five times more likely to have tests than 
young men but the men’s tests were more likely to be positive. 
Gonorrhoea is also most commonly reported in young people. In 2013, 59% of positive cases were aged 15–24 
years. National rates were 358 per 100,000 for 15–19 year olds and 277 per 100,000 for 20–24 year olds. From 
2009 to 2013, there was a 43% increase in the rate of gonorrhoea in females in the 15–19 years age group (from 
312 to 445 cases per 100,000) and a small increase in the rate for 15–19 year old males. Rates for young people 
in Tairawhiti, Lakes and Hawke’s Bay DHBs were much higher than the national rate.114 
The number of cases of genital warts in young people has been decreasing since 2009, which is likely to be 
related to the introduction of HPV vaccination onto the routine immunisation schedule for girls aged 12 years 
from late 2008, together with a catch-up programme targeting girls born on or after 1 January 1990.57,114,120 
Abortions in young New Zealand women 
In the year ended December 2014, 44% of all abortions were performed in women aged less than 25 years.121 In 
2014 1,758 women aged 15–19 years and 4,024 women aged 20–24 years had an abortion. These figures 
correspond to abortion rates of 11.5 per 1,000 for women aged 15–19 years and 25.2 per 1,000 for women aged 
20–24 years.121 Information on previous abortions and contraceptive use by age has not been reported for those 
who had abortions in 2014121 but, in 2013, 12% of the 15–19 year olds and 32% of the 20–24 year olds who had 
an abortion had previously had one or more abortions.122 In 2013, Fifty-nine percent of the 15–19 year olds and 
55% of the 20–24 year olds who had an abortion had not used contraception.122 
Since 2007, there has been a steady decline in abortion rates for young women. The fall has been especially 
dramatic for 15–19 year olds (from 27 per 1,000 in 2007 to 11.5 per 1,000 in 2014).121 The Abortion 
Supervisory Committee attributed this to the licencing and funding of a long acting subcutaneous implant in 
August 2010.122 
 Sexuality education 
Young people learn about relationships and sexuality in many ways: from parents and other family members, 
peers, their first sexual partner, teachers, health professionals, movies, television, radio, popular music, 
advertising, books, magazines and other print media, the internet, social media, video games and 
pornography.123 This section discusses only formal sexuality education, in other words, planned health 
promotion interventions intended to equip young people with the knowledge and skills that will make them 
more likely to attain physical, emotional, mental and social wellbeing in relation to their sexuality. It takes the 
standpoint that all young people have a fundamental right to the information and services necessary to maintain 
their sexual health. It has a focus on preventing sexually transmitted infections and unintended pregnancies, not 
because rates of unintended pregnancy or STIs are the only or the best indicators of a population’s sexual health 
but because these indicators are relatively easy to quantify and commonly used as outcome measures in research 
studies, for assessing trends in sexual health, and for international comparisons. 
Sexuality education in schools 
Schools are in a special position to influence the wellbeing of adolescents since almost everyone attends school. 
The World Health Organization has recognised this and, in 1995, it launched the Global School Health Initiative 
to help improve the health of students, staff, parents and community members and increase the number of 
Health-Promoting Schools. Its publication Family Life, Reproductive Health, and Population Education: Key 
elements of a Health-Promoting School124, states that: ‘When schools do not address family life, reproductive 
health, and population issues, they miss an opportunity to positively affect students’ education, quality of life 
and relationships, and ultimately the economy and productivity of nations’. It sets out a series of well-referenced 
arguments that make a case for family life, reproductive health, and population education and can be used to 
convince families, community members, and religious leaders that schools are able to address these issues in an 
appropriate and effective way that does not lead to promiscuity. It notes that adolescents who engage in one type 
of risky behaviour, such as unprotected sex, are more likely to engage in other risky behaviours such as tobacco 
and drug use or violence, and so addressing one risky behaviour may have a positive influence on other risky 
behaviours. 
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Sexuality education in New Zealand schools 
Sexuality education is one of seven key learning areas in the health and physical education section of The New 
Zealand Curriculum (the Ministry of Education’s statement of official policy relating to teaching and learning in 
New Zealand schools).125 Health education is the only part of a school’s curriculum regarding which boards of 
trustees are legally required to consult with their school’s community on how the school will implement the 
curriculum.126 Under section 25AA of the Education Act 1989 (updated in 2001), the parent of a student 
enrolled at any State school may get their child excluded from tuition in specified parts of the health curriculum 
related to sexuality education.127 All students study health and physical education from Years 1 to 10, but not all 
senior students choose to study health as one of their NCEA subjects. 
The Ministry of Education has recently (in 2015) released new guidelines on sexuality education.126 These 
suggest that in the junior primary years discussions about identity, personal health, body parts, and families are 
woven into learning throughout the year, but that in later years specific time is devoted to learning about 
sexuality. They state that the Education Review Office has found that schools with effective sexuality education 
programmes spend at least 12–15 hours per year on sexuality education, with significantly more time allocated 
for programmes for senior secondary students (in years 11 to 13)128, and they recommend that all senior students 
engage in sexuality education, not just those studying health to achieve NCEA qualifications. 
The new guidelines promote holistic and comprehensive sexuality education that not only equips students with 
the knowledge and skills to take care of their sexual and reproductive health, but also gives them opportunities 
to learn about, consider and discuss issues relating to relationships, gender, sexual identities, sexual orientation, 
sexual behaviour, consent and coercion, rights and responsibilities, societal attitudes and messages, sexual 
harassment, and pornography.126 The guidelines stress the importance of a school-wide culture where diversity 
is valued and students feel supported, visible and safe, regardless of their sexual and gender identity. 
The research literature on sexuality education for young people 
Introduction 
From a global perspective the AIDS pandemic has been the main impetus for improving sexuality education. In 
Western developed countries, however, prevention of teenage pregnancy is the main aim of sexuality education. 
There is a very substantial research literature devoted to the evaluation of educational interventions to improve 
adolescent sexual and reproductive health. 
Programme content categorises sexuality education programmes as belonging to one of three broad types:129 
 Abstinence-only programmes promote abstinence as the only way to avoid adverse sexual health 
outcomes. Some stress abstinence until marriage. They generally include messages about the 
psychological and health benefits of abstinence and the dangers of sexual activity.130 They do not 
include information on safer sex strategies or contraception. If they mention condoms and 
contraception it is only to highlight their failure rates.131 
 Abstinence-plus programmes have abstinence as their main message but also provide information on 
safer sex practices and contraception. 
 Comprehensive programmes are similar to abstinence-plus programmes but have a focus on safer sex 
practices and contraception, with the benefits of delaying sex being included in the information 
provided. Some also provide information on, or access to, contraceptive and sexual health services. 
Some are part of comprehensive youth development programmes.130 
Some background to research on sexuality education interventions 
Evaluations of sexuality education programmes have used a variety of outcome measures to assess programmes’ 
effectiveness: pregnancy rates, STI rates, self-reported behavioural outcomes (condom use, delayed sex or 
abstinence, number of sexual partners) and proxy measures (such as changes in sexual health knowledge, 
attitudes and intentions, and self-efficacy).129 A study using pregnancy, birth or STI rates as outcome measures 
needs to be large and have long term follow-up to be likely to measure statistically significant results, and will 
therefore be expensive to carry out. This is probably the main reason why there have been relatively few studies 
that have used these outcome measures and most studies have relied on participants self-reporting outcomes. 
The review Emerging Answers 2007132 explains this point in more detail (page 94): ‘At least two important 
methodological problems stand in the way of using pregnancy and STI rates as outcome measures. First, 
regardless of how they are measured, pregnancy and STI rates are a very insensitive measure of programme 
impact. If a programme reduces the annual teen pregnancy rate by 20%, from 100 pregnancies per 1,000 to 80 
per 1,000, the programme would be very successful. However, that decrease represents a difference of only 20 
pregnancies per 1,000 (or two percentage points), so a very large sample size (more than 6,000) would be 
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required to have a strong chance of finding that change to be statistically significant. The same problem applies 
to an even greater extent to birth rates, and it applies to STI rates whenever those rates are low in a 
population.’ 
Most studies of sexual health interventions for young people have been conducted in the US and a majority of 
the US studies targeted African Americans.133 A number of influential reviews have included only studies of 
prevention programmes that were conducted in the US.130-132  
It is worth remembering that health care in the US is characterised by a mix of public and private funding and 
that individual states have considerable autonomy. Teen pregnancy programmes tend to be commercial products 
(developed and researched with the help of funding from various sources including government, academic, 
charitable and faith-based organisations) that can be purchased by schools or healthcare providers.134 The US 
Department of Health and Human Services, through the Office of Adolescent Health’s Teen Pregnancy Program 
funds only evidence-based programs, that have been shown, in at least one program evaluation, to have a 
positive impact on preventing teen pregnancies, sexually transmitted infections, or sexual risk behaviours135, 
therefore there is an incentive for programme developers to undertake robust evaluations of their programmes’ 
efficacy (using RCTs or quasi-experimental methods) and publish the results of these evaluations in peer-
reviewed academic journals. 
It has been argued that evidence-based interventions tend to have a narrow focus on preventing pregnancy and 
STIs and that they do not take account of the broad context of adolescents’ lives or the psychosocial and 
structural factors that shape the ways adolescents conduct their sexual lives.136 Schalet et al.136 state that there is 
extensive social and behavioural research documenting the influence of gender inequity, ideologies and 
stereotypes; sexual orientation; school and peer culture; poverty (both at the individual and neighbourhood 
level); racism and socio-political issues on adolescent sexual health and behaviour. They point out that, in the 
most disadvantaged communities, young women may feel that their life prospects are made no worse by an 
early pregnancy and young men may view sexual activity as a pathway to social status rather than an obstacle to 
socio-economic achievement. They suggest that sexuality education needs to recognise students’ diverse life 
courses and family formations and create opportunities for them to discuss sexual agency and risk in the context 
of their broader life aspirations and the multiple factors that constrain those aspirations. 
Kirby’s 2007 review 
In his comprehensive 2007 review for the US National Campaign to Prevent Teen and Unplanned Pregnancy, 
entitled Emerging Answers 2007: Research Finding on Programs to Reduce Teen Pregnancy and Sexually 
Transmitted Diseases132, Kirby described the programmes and approaches that have reduced teen sexual risk-
taking and teen pregnancy or STIs in the US. He provided a list of programmes with strong evidence of impact 
and described the characteristics of effective sex and STI/HIV education programmes that contributed to their 
success. The review considered only primary prevention of teen pregnancy (not prevention of repeat 
pregnancies in teen mothers), and it did not consider the efficacy of the various contraceptive measures, nor 
same-sex aspects of STI and HIV prevention. Studies were eligible for inclusion in the review if they had been 
conducted in the US between 1990 and 2007; were focussed on teens aged 12 to 18 years; examined impacts on 
sexual behaviour, use of condoms or other contraceptives, combined measures of sexual risk, and pregnancy, 
birth or STI rates; had a reasonably strong experimental or quasi-experimental research design and a sample size 
of at least 100 teens; measured behaviour for a sufficient length of time; and used appropriate statistical 
analysis.  
Of the 115 studies were included in the review, 56 measured the impact of curriculum-based sex and STI/HIV 
education programmes and 59 measured the effect of other types of programmes (such as clinic programmes, 
school-based health services, welfare reforms, and early childhood or youth development programmes). Seventy 
had an experimental design (they were RCTs) while 45 had a good quasi-experimental design (they compared a 
study group with a comparison group believed to be similar to the study group although participants were not 
randomly assigned to one or the other group). Eighty-three of the 115 studies measured outcomes for one year 
or more, 40 measured outcomes for two years or more, and 26 measured outcomes for three years or more. A 
large majority of the studies were underpowered and so, while they found intervention effects, these were often 
not statistically significant. Kirby stated that this produced a conservative bias which was probably quite large 
(in other words, programmes may be more effective than study results indicated). 
The aim of educational interventions is to change the behaviour that leads to unintended pregnancy and STIs. 
Kirby stated that interventions to prevent pregnancy need to encourage both abstaining from sex (including 
delaying first sex, returning to abstinence, and avoiding unwanted, unintended and unprotected sex) and 
effective use of contraception, while interventions for reducing STIs need to encourage abstaining from sex, 
limiting the number of sexual partners (especially concurrent partners), increasing the time between sexual 
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partners, reducing the frequency of sex, using condoms, getting tested and treated for STIs, and vaccination 
against Hepatitis B and HPV. He noted that most US teen pregnancy prevention programmes address all the 
relevant behaviours (abstinence and use of contraception) but most STI prevention programmes do not as they 
tend to address only abstinence and condom use. He stated that some STI programmes place some (lesser) 
emphasis on STI testing and treatment but very few emphasise the importance of having few sexual partners and 
almost none mention avoiding concurrent partners (and having sex with people who have them), increasing the 
time between partners and the value of long-term committed and caring relationships. 
In addition to addressing the behaviours that lead to unintended pregnancy and STIs, interventions may address 
the risk factors for risky sexual behaviour. Kirby stated that research has identified more than 500 factors that 
either increase or decrease the chances that teens will engage in risky sexual behaviour and that some are easier 
to modify than others. He stated that the factors most strongly related to sexual behaviour are teens’ own sexual 
beliefs, values and attitudes, and that the risk and protective factors most easily changed by teen pregnancy/STI 
prevention programmes are the sexual ones: sexual knowledge and values, perception of peer norms, motivation 
and self-efficacy. He suggested that identifying groups of teens at high risk because of factors such as 
community and/or family disorganisation and disadvantage is useful (even though these risk factors may not be 
changeable in the short term) because high-risk teens can be targeted with more intensive and effective 
interventions. 
Curriculum-based educational programmes 
Kirby’s review reported on studies of 56 curriculum-based programmes. Eight focussed on reducing teen 
pregnancy, 24 on preventing STIs/HIV, and 24 on both. Eight were abstinence programmes and the remaining 
48 were comprehensive programmes which encouraged both abstinence and contraceptive use.  
A substantial proportion of programmes significantly reduced one or more types of risky sexual behaviour and 
they did not increase sexual behaviour among young people, as has been feared. Most of the studies that 
measured pregnancy, birth rates or STI rates did not find statistically significant effects. As explained earlier, 
this may reflect the difficulties and expense of conducting studies that are adequately powered to detect 
statistically significant results. Twelve studies measured programme impact on self-reported pregnancy rates: 
nine found no significant results while two found a significant decrease, and one a significant increase. Four 
studies measured impact on birth rates: one found a significant decrease and three found no significant impact. 
Ten studies measured effects on STI rates: seven found no significant results; one found a significant increase in 
self-reported STIs, which may have been because the programme encouraged young people to be tested and 
treated; and two found significant decreases in STI rates based on laboratory tests. 
The review examined abstinence and comprehensive programmes separately, although the author noted that 
programmes fell on a continuum and were not easy to categorise. The main findings were as follows: 
 A number of abstinence programmes, including abstinence-until-marriage programmes, have been 
rigorously evaluated and found not to have any effect on delaying initiation of sex, age at first sex, 
return to abstinence, contraceptive or condom use or number of sexual partners. Abstinence 
programmes do not seem to have any negative effects and they do not appear to hasten or increase 
sexual activity or reduce condom or contraceptive use. 
 In contrast, comprehensive programmes have shown strong evidence of positive effects on behaviour 
and no significant negative effects. Two-thirds of comprehensive programmes delayed initiation of sex, 
reduced frequency of sex, reduced number of sexual partners, increased condom use, increased 
contraceptive use, or reduced risky sexual behaviour. None hastened sexual initiation or increased the 
frequency of sex. Almost all had a positive impact on one or more factors affecting behaviour. They 
improved factors such as knowledge about the risks and consequences of pregnancy and STIs; attitudes 
and values related to having sex and using condoms or contraception; perceptions of peer norms about 
sex and contraception; confidence in ability to refuse unwanted sex, insist on condom or contraceptive 
use, or actually use condoms or contraception; intentions to avoid sex or use contraception; and 
communication with parents and other adults about sexual matters. 
 Among the weaknesses of the research studies were: few described programmes adequately; none dealt 
with students engaging in same-sex behaviour; some had implementation problems; an unknown 
number had measurement problems; and many were inadequately powered and did not adjust for 
multiple tests of significance or clustering. There may have been publication bias because studies with 
positive results are more likely to be published. 
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The characteristics of effective education programmes 
Kirby identified 17 characteristics of effective sex and STI/HIV education programmes. He stated that most of 
the programmes with these 17 characteristics were effective; most effective programmes had most of the 17 
characteristics; and programmes with these characteristics were more effective than those without. The 17 
characteristics fell into three categories: those related to the process of developing the curriculum; those related 
to the overall design and teaching strategies of the curriculum itself; and those related to the process of 
implementing the curriculum. They are presented in Table 155. Kirby suggested that the first 13 characteristics 
can be used to select programmes likely to be effective, to adapt selected programmes to make them more 
effective, or to develop new programme curricula from scratch, and that the final four characteristics can be 
used as a guide for implementing effective curricula. 
Table 155. The characteristics of effective curriculum-based programmes 
The process of developing the curriculum 
1. Involved multiple people with expertise in theory, research, and STI/HIV education to develop the curriculum 
2. Assessed relevant needs and assets of the target group 
3. Used a logic model approach that specified the health goals, the types of behaviour affecting those goals, the risk and 
protective factors affecting those types of behaviour, and activities to change those risk and protective factors 
4. Designed activities consistent with community values and available resources (e.g. staff time, staff skills, facility space and 
supplies) 
5. Pilot-tested the programme 
The contents of the curriculum itself* 
Curriculum goals and objectives 
6. Focussed on clear health goals–the prevention of STI/HIV, pregnancy or both 
7. Focussed narrowly on specific types of behaviour leading to those health goals (e.g. abstaining from sex or using condoms 
or other contraceptives), gave clear messages about these types of behaviour, and discussed situations that might lead to 
unwanted and/or unprotected sex and how to avoid them 
8. Addressed sexual psychosocial risk and protective factors that affect sexual behaviour (e.g. knowledge, perceived risks, 
values, attitudes, perceived norms, and self-efficacy) and changed them 
 
Activities and teaching methods 
9. Created a safe social environment for young people to participate 
10. Included multiple activities to change each of the targeted risk and protective factors 
11. Employed instructionally sound teaching methods that actively involved participants, that helped them personalise the 
information, and that were designed to change the targeted risk and protective factors 
12. Employed activities, instructional methods, and behavioural messages that were appropriate to the teens’ culture, 
developmental age and sexual experience 
13. Covered topics in a logical sequence 
The process of implementing the curriculum 
14. Secured at least minimal support from appropriate authorities, such as departments of health, school districts, or 
community organisations 
15. Selected educators with desired characteristics (whenever possible), trained them, and provided monitoring supervision 
and support 
16. If needed, implemented activities to recruit and retain teens and overcome barriers to their involvement (e.g. publicised 
the programme, offered food or obtained consent) 
17. Implemented virtually all activities with reasonable fidelity 
Kirby D. 2007. Emerging answers 2007132 https://thenationalcampaign.org/sites/default/files/resource-primary-
download/EA2007_full_0.pdf . * This section is based on a review of the curricula for 19 effective programmes, five of which 
were from outside the US. 
Gender and power issues as part of sexuality education 
To be able to protect their own sexual health, young women need to be empowered to see themselves as equal 
partners in their relationships, and as individuals capable of being active participants in society. In their 2014 
review of sexuality education in the global context, Haberland and Rogow137 stated that relatively few 
comprehensive sexuality education (CSE) programmes have historically emphasised gender and rights but that 
there is increasing evidence that an empowerment approach to CSE is particularly effective. 
Comprehensive sex education that takes an empowerment approach uses curricula encompassing feminist 
theory – either explicitly or implicitly – which help students to understand how gender inequality is socially 
constructed and to reflect on and critique prevailing social norms (such as social expectations for boys to ‘score’ 
and the ‘double standard’).137 The aim is that, as students develop more egalitarian attitudes and relationships, 
they will adopt different behaviour and, among other positive outcomes, have better sexual health outcomes.137 
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Haberland and Rogow reviewed sexual risk reduction programmes that had been evaluated using pregnancy and 
STI rates and they stated that programmes that addressed issues of gender and power were more likely to show 
significant positive effects on health outcomes than those that did not.138 Examples of successful gender-and-
empowerment orientated programmes included HORIZONS, an HIV prevention intervention for young African-
American women which reduced rates of chlamydial infection139, and Stepping Stones, an HIV prevention 
programme which was associated with a 33% reduction in the incidence of Herpes simplex type 2 in a cluster-
RCT conducted in South Africa.140 The Stepping Stones trial found that the intervention also significantly 
reduced the proportions of men reporting intimate partner violence, transactional sex and problem drinking at 12 
months. 
The publication It’s All One Curriculum: Guidelines and Activities for a Unified Approach to Sexuality, Gender, 
HIV, and Human Rights Education141 provides valuable information on sexuality education that emphasises 
gender equality and human rights, and critical-thinking teaching methods. It was developed by a working group 
comprised of three international NGOs (Population Council, IPPF, and International Women's Health 
Coalition); one regional NGO (IPPF/Western Hemisphere Region); and three country-based NGOs (Girls Power 
Initiative/Nigeria, CREA/India, and Mexfam/Mexico). 
The 2012 systematic reviews by Chin et al. 
Chin et al. conducted systematic reviews for the US Guide to Community Preventive Services on two strategies 
for group-based behavioural interventions for adolescents to prevent or reduce the risk of adolescent pregnancy, 
HIV and STIs; one on comprehensive risk reduction interventions and one on abstinence education.130,131 (In the 
US until 2010, states could receive federal funding to implement only abstinence programmes that followed 
federal A-H guidelines. These guidelines stated that abstinence from sexual activity outside marriage is the 
expected standard for all school age children and that a mutually faithful monogamous relationship in context of 
marriage is the expected standard of human sexual activity.142) 
The reviews assessed the effectiveness of the two strategies by determining how much they reduced sexual risk 
behaviours, pregnancy, HIV and other STIs, and increased protective sexual behaviours. To be eligible for 
inclusion in the review studies had to be published in English during 1988–2007 and evaluate an intervention 
delivered in US schools, community settings or both. Interventions for teen parents or HIV-infected adolescents 
were excluded. 
For each strategy the reviewers conducted meta-analyses on seven key outcomes: current sexual activity; 
number of sex partners; frequency of unprotected sexual activity; use of protection (condoms and/or hormonal 
contraception); pregnancy; and STIs. 
The effectiveness of comprehensive risk-reduction interventions 
Chin et al.’s review of comprehensive risk reduction interventions included 66 studies, 62 of which provided 
data for the analyses. Twelve were considered to have good quality of execution and 50 to have fair quality. 
Sixty-one percent were RCTs and the rest were controlled before-and-after studies. Interventions were almost 
evenly split between school and community settings and between targeted and untargeted approaches. 
Percentages of recipients by school level were 35% middle school (10−14 years) and 65% high school (15−19 
years). Intervention contact hours ranged from one to fifty-four, with a mean of 14.5 hours. Most interventions 
(80%) were delivered by an adult only, but 20% were delivered by an adult together with a peer. Most outcomes 
were self-reported although STIs were sometimes confirmed by laboratory testing.  
All of the outcomes measured in the comprehensive risk reduction interventions showed effectiveness (Table 
156). All the effects estimates, except for pregnancy rates, were statistically significant. (The risk ratio can be 
interpreted as the ratio of the risk of an outcome in the intervention group to the risk of the same outcome in the 
control group. A risk ratio of 0.75 indicates that those in the intervention group had 75% of the risk of those in 
the control group.143) 
The economic efficiency of comprehensive risk-reduction interventions 
Chin et al.’s review identified ten comprehensive risk-reduction studies that included economic information. In 
six of the eight economic evaluations of individual interventions studies, costs per participant per year (in 2008 
US dollars) ranged from $66144 to $10,024145 per person per year. The review authors stated that the wide 
variation was due to variability in programme content, number of participants and programme duration. The 
lowest cost was for a school-based programme involving curriculum-based education144 while the most 
expensive programme was a multi-faceted youth development intervention that included family life, sex and 
health education; career support; academic support; artistic expression; recreation; and physical and mental 
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health referrals.145 Six studies reported on economic benefits from intervention: six estimated healthcare costs 
averted and four estimated productivity costs.  
Table 156. Effectiveness of comprehensive risk-reduction interventions, as indicated by meta-analysis results 
Outcomes1 Number of studies 
Number of study 
arms 
Odds ratio (95% CI) 
Estimated Risk 
Ratio 
Sexual activity 38 54 0.84 (0.75–0.95) 0.88 
Frequency of sexual activity 13 14 0.81 (0.72–0.90) –2 
Number of sex partners 23 27 0.83 (0.74–0.93) 0.86 
Unprotected sexual activity 22 28 0.70 (0.60–0.82) 0.75 
Protection3 38 50 1.39 (1.19–1.62) 1.13 
Condoms3 33 44 1.45 (1.20–1.74) 1.12 
Oral contraceptives3 9 10 1.29 (0.89–1.85) 1.22 
Dual use3 4 4 1.21 (0.70–2.12) 1.17 
Pregnancy 9 11 0.88 (0.60–1.30) 0.89 
STI 6 8 0.65 (0.47–0.90) 0.69 
HIV 0 0 – – 
Chin et al. 2012131 Notes: 1All self-reported, except for STI which were either laboratory-confirmed or self-reported; 2Couldn’t be 
calculated; 3Odds ratios > 1 for these outcomes indicate beneficial effects (i.e. that the intervention increased the outcome, as 
desired) 
The review authors stated that, overall, most of the comprehensive risk-reduction studies that made a 
comprehensive assessment of the benefits of preventing pregnancy, STIs and HIV, and secondary benefits (such 
as educational attainment) found a positive economic value from investments in such interventions. They noted 
that there are other dimensions of positive behaviours affected by interventions (particularly youth development 
interventions) that are harder to quantify and value in monetary terms (such as reduced crime, better academic 
attainment and improved parenting skills). 
The effectiveness of abstinence education 
The review of abstinence education by Chin et al. included 23 studies, 21 of which were considered suitable for 
meta-analysis. Two of these had good quality of execution and nineteen had fair quality. Fewer than half were 
RCTs. Most outcomes were self-reported but STIs were sometimes confirmed by laboratory testing. Almost all 
participants were aged 10–14 years (only one study evaluated the intervention in older adolescents) and most 
were virgins at baseline. The interventions were mostly curriculum-based educational interventions focussed on 
preventing STIs/HIV and pregnancy which took place in school settings and were delivered by a trained adult.  
The meta-analysis results indicated favourable effects on the primary outcomes of sexual activity and frequency 
of sexual activity but only the reduction in sexual activity was statistically significant. There were no effects 
found for the secondary effects of number of sex partners, unprotected sexual activity, and use of protection 
during sexual activity. The odds ratios for these outcomes were all close to one and not significant. There were 
marked differences between the RCTs and the non-RCTs. For sexual activity – the only outcome with a 
substantial number of data points from both types of studies – there was a significant difference in effect 
estimates: The RCTs had a non-significant odds ratio of 0.94, while the non-RCTs had a significant odds ratio 
of odds ratio 0.66. The RCTs had longer follow-up times (up to 6.5 years with a mean of 3.2 years) compared to 
the non-RCTs (a maximum follow-up of one year and a mean of 0.6 years). There was possible publication bias 
as the studies with small sample sizes (which would be more likely to produce significant results by chance) 
tended to have greater intervention effects than the larger studies. Overall, the findings from the review of 
abstinence education interventions were inconclusive. 
The economic efficiency of abstinence education 
The review authors noted that one expert had stated that, up until 2005, more than $1.5 billion had been spent on 
abstinence education interventions in the US. They stated that the only available estimate for the cost of 
individual programmes is the reported cost of curricula which ranged from $31 to $646 for 21 curricula146 (with 
an average of $220, presumably per teacher copy of the curriculum ± materials such as videos and student 
resources, although this was not explicitly stated) and that the published information about abstinence 
programmes was insufficient for estimating either the economic benefit or cost-effectiveness of these 
programmes. 
Potential harms of interventions 
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There is a concern that comprehensive risk-reduction interventions may encourage earlier initiation of sexual 
activity and greater sexual frequency of sexual activity. The findings of this review, however, indicated that 
comprehensive risk reduction interventions reduce both sexual activity and frequency of sexual activity in 
adolescents receiving such interventions. A similar concern is that abstinence education interventions make it 
more likely that teens will fail to use contraception if they do have sex. Most of the abstinence education studies 
that measured use of protection during sexual activity did not demonstrate any differences between intervention 
and comparison groups. Effects of abstinence interventions on consistent condom use could not be assessed as 
none of the abstinence education studies reported on this outcome. 
Public health impact 
Chin et al. stated that comprehensive risk-reduction interventions would be expected to not only to reduce 
sexual activity but also to increase behaviours that reduce the risks associated with sexual activity whereas 
abstinence education would be expected to only reduce sexual activity. They also stated that comprehensive risk 
reduction interventions would be expected to have a greater public health impact than abstinence education 
interventions even if both interventions had similar effects on sexual activity since, unlike abstinence education 
interventions, comprehensive risk-reduction interventions offer benefits both to adolescents who abstain from 
sexual activity and to those who are sexually active, and to both older and younger adolescents.  
The Community Preventive Services Task Force recommendations 
Based on the findings of the two systematic reviews, the US Community Preventive Services Task Force 
recommended group-based comprehensive risk-reduction delivered to adolescents to promote behaviours that 
prevent or reduce the risk of pregnancy, HIV, and other STIs.147 
Parent interventions 
Several recent systematic reviews have examined studies of interventions with parents and/or families which 
aimed to improve parent-child communication about sex, improve adolescent sexual health, or both.148-152 Table 
157 provides a brief summary of these reviews. In general, interventions with parents did improve parents’ 
communication with adolescents about sexual matters, but there is limited evidence that they were effective in 
changing adolescents’ sexual behaviour. There is considerable variation between parent programmes and in the 
outcome measures used by evaluation studies so it is difficult to determine which kinds of parent interventions 
are most effective in improving parent-child communication. 
Sexual and reproductive health services for young people 
In addition to having a good understanding of sexual and reproductive health issues, young people need access 
to sexual and reproductive health services. These services include the provision of counselling and advice on 
sexuality, sexual abuse, contraception, abortion and sexually transmitted infections; prescription of 
contraceptives of various kinds; pregnancy testing; referrals for abortions; and testing and treatment for sexually 
transmitted infections. Such services can be provided by GPs, youth health services (including school-based 
clinics, youth one-stop shops, and student health services at tertiary education institutions), family planning 
clinics and sexual health clinics. This section looks at issues related to sexual and reproductive health services 
for young people (other than prenatal and obstetric care for expectant mothers). In particular, it considers what is 
known about what makes services effective in improving adolescent health outcomes (such as rates of STIs and 
unintended pregnancy); what adolescents themselves have said about what they value in services; the provision 
of emergency contraception; and the use of long-acting reversible contraceptives by adolescents. 
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Table 157. Findings from recent systematic reviews of parent interventions to improve parent-child 
communication about sex, improve adolescent sexual health, or both 
Author (date) 
Number of studies 
included 
Results for communication Results for sexual behaviour 
Gavin (2015). 
148,153 
16 (all from US) 
12 of 16 studies showed an increase in 
parent-child communication about 
sexual and reproductive health 
4 of 7 studies reported reduced 
sexual risk behaviour 
1 of 2 studies found a marginal 
impact on teen pregnancy 
Santa Maria 
(2015)149 
28 (all from US, by 
intention). Not all 
focused only on 
parent-child 
communication 
Increased parent-child communication 
(meta-analysis of 11 controlled trials); 
increased parental comfort with 




44 (25 RCTs), most 
from US (1 each from 
Mexico, S. Africa, 
Trinidad and Tobago, 
and Nicaragua). 
Parent intervention 
was often a 
component of a 
broader sexual health 
intervention 
31 of 37 had a positive influence on 
parent-child interaction, one had a 
negative influence 
11 of 21 had a positive influence 
on adolescent sexual behaviours; 
two had a negative influence 
Akers (2011)151 
12 (all from US, by 
intention)  
Parents (almost invariably mothers) 
reported improvements in multiple 
communication domains. Effect sizes 
couldn’t be calculated and studies’ 
results couldn’t be compared because 
the studies all used different measures 
to assess communication 
Not assessed 
Downing 2011152 
17 (all from US) 
No relevant studies 
from other countries 
identified 
Parent-based intervention had some 
positive effects on parent child 
communication but family-based 
interventions did not. 
Inconsistent effects 
 
Sexual and reproductive health services in New Zealand 
In New Zealand, there are a number of providers of sexual and reproductive health services. Many offer free 
services to young people. Sexual health clinics are normally free for New Zealand residents. 154 They provide 
testing and treatment for STIs but do not usually provide contraception (other than condoms and the emergency 
contraceptive pill). Attending a family planning clinic is free to New Zealand residents aged under 22 years.155 
Family planning clinics provide a wide range of sexual and reproductive health services including contraception, 
STI testing and treatment, cervical smears, abortion counselling and referrals, and help with sexual dysfunction 
and gynaecological problems.155 Many DHBs fund free sexual health services (including contraception) for 
young people who are enrolled with Primary Health Organisations (age limits vary and there may be a limit on 
the number of free visits per year). These services are often delivered in general practices, particularly in smaller 
towns. Youth One Stop Shops provide a range of free social and health services, including sexual and 
reproductive health services.156 
Most New Zealand high schools provide health services.157 Most commonly these are provided by visiting 
health professionals, but some schools have on-site health professionals.157 Because the government has 
specifically allocated funding for health services in low-decile schools, it is high decile schools and private and 
integrated schools that tend to have no health services beyond first aid provision.157 ( The Ministry of Education 
assigns each school a decile rating: the lower a school’s decile, the higher the proportion of students that are 
from low socio-economic backgrounds.) There is wide variation between schools in the level of sexual health 
services provided by health professionals working in or visiting schools and this is generally related to 
boundaries set by principals and boards of trustees.158 
Barriers to service access 
There are a number of barriers that can prevent a young person accessing services to meet their sexual and 
reproductive health needs or deter them from returning to a service. These barriers can exist at various levels: at 
the policy level (e.g. some counties have laws prohibiting the provision of contraception to under-age or 
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unmarried adolescents); the operational level (e.g. services having inconvenient operating hours, being too far 
away or too expensive); and the personal level (e.g. not recognising the signs of a health problem; not knowing 
what services are available; being too scared or embarrassed to phone or visit a service).159 
A recent review by Bender and Fulbright (2013) presented a content analysis of quantitative and qualitative 
studies (published between 2000 and 2010) dealing with barriers to access and utilisation of sexual and 
reproductive services, as perceived by 10 to 25 year olds.160 It included 17 studies conducted in the Western 
world (12 from the UK, three from Canada and two from the US) and it aimed to answer the question: How do 
young people perceive the barriers to sexual and reproductive health services? 
The review authors classified the barriers identified in the studies into four categories: service access (factors 
which might make it difficult for young people to go to services); service entry (factors related to a young 
person’s experience from the time they entered the clinic until they received attention from a health 
practitioner); quality of services; and personal factors. They regarded personal factors as factors which had 
personal relevance to young people on a cognitive, affective or relational level, and which were related to their 
own integrity. They considered this to be a central category, and they presented the following classification of 
barriers (Figure 160). 
Figure 160. A classification of youth perceptions of barriers to sexual and reproductive health services 
 
Bender SS, Fulbright YK. 2013.160 
They reported that, although the 17 articles in their review identified different types of barriers to sexual and 
reproductive health clinics, they did not give any indication of the degree to which the barriers hindered young 
people accessing sexual and reproductive health clinics. Collectively, the articles reviewed indicated that it was 
the personal perceptions of young people (i.e. the personal factors) that were the most important. Privacy and 
confidentiality were extremely important: young people did not want anyone to find out they had visited a 
clinic. 
Carroll et al.161 investigated both barriers and facilitators to young people’s use of school-based and school-
linked sexual health services in a systematic review of studies that had explored the views and experiences of 
young people (aged 11 to 18 years). In total the review included 19 studies, 12 from the US and seven from the 
UK, none of which were included in Bender and Fulbright’s review.  
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The authors undertook a thematic analysis of the studies and they reported that the principal themes that 
emerged were (in no particular order): 
 awareness and need (students need to know of the existence of services and the reasons they might 
need to visit one) 
 confidentiality and disclosure (students don’t want anyone to find out they have visited a service, or to 
disclose their name, age and the reason for their visit to the receptionist if they can be overheard by 
others in the waiting room) 
 staff attitudes (students value staff who make them feel comfortable and relaxed, and are friendly, 
supportive, helpful, welcoming, non-judgmental and caring) 
 staff gender (students like to be able to choose the gender of the health practitioner they see); location 
(convenience is valued) 
 visibility of service (students don’t want to be seen entering a sexual health service, so discrete signage 
and integrating sexual health services with other health services is helpful) 
 convenient opening hours (e.g. lunchtimes and after school) 
 a pleasant physical environment; cost of services (free is preferred) 
 availability of information, advice and contraception 
Baxter et al. 162 reviewed 59 papers reporting on UK studies examining views of service providers and young 
people concerning delivery of contraceptive services. Important themes they identified were:  
 perceptions of particular services (e.g. family planning is for older couples; clinics are for girls) 
 accessibility of services (young people generally prefer convenient locations although some will travel 
to more distant clinics to reduce the chance of meeting someone they know) 
 opening hours (Saturdays and after school preferred) 
 appointment systems (young people like to drop in, but they also don’t like to wait long) 
 embarrassment, anonymity and confidentiality (young people don’t want to be seen at a clinic or called 
out by name; the use of numbers instead of names was suggested; the possibility of being recognised is 
a greater problem in smaller centres) 
 pleasant clinic environment 
 respectful and non-judgemental staff who are easy to talk to 
 links between services (e.g. between school-based and other services) 
 staff training. 
What makes a service youth-friendly? 
It is important that health service providers make services relevant and attractive to adolescents. The World 
Health Organization has stated that adolescent-friendly health services need to be accessible, equitable, 
acceptable appropriate, comprehensive, effective and efficient.163 
A recent systematic review by Brittain et al.164 aimed to describe key characteristics of youth-friendly family-
planning interventions and summarise the evidence regarding the effect of youth-friendly family planning 
services on reproductive health outcomes. 
Thirteen studies discussed key characteristics of youth-friendly family-planning services: one from the 
perspectives of both providers and young people, nine from the perspectives of young people only, and four 
from the perspectives of providers only. The youth friendly characteristics identified were: (ordered according to 
the number of studies identifying the characteristic) 
 Confidentiality: What is discussed between patient and provider will not be shared with anyone else 
without the patient’s explicit consent (13 studies)  
 Accessibility: Convenient location; low cost or free; access to transport; outreach; opening hours; short 
waiting times; both by appointment and ‘drop in’ visits available; pleasant atmosphere at entrance; 
offering a range of contraceptive options (11 studies)  
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 Provider interaction: Sufficient time is allowed to build a rapport between provider and patient; 
providers engaging in one-to-one vs. group education; providers being respectful and non-judgmental 
(11 studies)  
 Integration: Providing family planning services in setting such as youth clubs, or in settings also 
providing other health services such as mental health services or comprehensive health services 
(7 studies: 4 of young peoples’ and 3 of providers’ perspectives)  
 Specialised staff training: Staff have received training on communicating with young people about 
reproductive health (5 studies; 4 of young peoples’ and 1 of providers’ perspectives 
 Accommodating young people’s preferred provider characteristics: for example being a particular 
gender, or type of practitioner, such as a doctor, nurse or social worker (4 studies of young people’s 
views) 
 Involvement of parents and/or families (4 studies: 2 of young peoples’ and 2 of providers’ views) 
 Peer involvement: the use of peer health providers, peer educators, or peer support groups within the 
clinic (3 studies: 2 of young peoples’ and 1 of providers’ views)  
 Cultural competence: providers and clinics have the behaviours, attitudes and policies to enable 
effective service provision in cross-cultural situations (1 provider study)  
Do youth-friendly services produce better outcomes? 
Brittain et al. 164 also identified six studies that examined the effects of youth-friendly family planning services 
on reproductive health outcomes. Study sample sizes ranged from 163 to 1,590 and the age of study participants 
from 12 to 24 years. There were two prospective cohort studies and one each of the following study types: pre-
post with one study group, analysis of repeated population surveys, cross-sectional, and non-randomised trial.  
Three studies examined impacts on long term outcomes (i.e. teen or unintended pregnancy rates and abortion 
rates). Two of these found that youth-friendly family planning service components were associated with 
statistically significant reductions in teen pregnancies while the third165, an evaluation of a new contraceptive 
clinic for teens in Nottingham, UK for the years 1986 to 1992, found a statistically significant increase in 
pregnancy, birth and abortion rates. 
Three studies examined impacts on medium-term outcomes and all found positive outcomes related to 
contraceptive use including increased odds of consistent use of birth control from first to last visit, increased 
odds of use of effective birth control, increased clinic utilisation (following an intervention at a Teen Clinic), 
and greater use of chosen contraceptive method at six and 12 month follow-up. 
All three studies that examined short term impacts found significant effects, including increased positive ratings 
for aspects of the clinic experience, satisfaction with opening hours, and increased patient knowledge. 
Overall, the review by Brittain et al.164 found that there was limited evidence that youth-friendly family planning 
service improve reproductive health outcomes for young people because the body of evidence lacked rigorous 
study designs and had high risk for bias. The authors were unable to draw definitive conclusions because each 
study examined different youth-friendly services interventions, and each intervention employed different 
strategies to increase young people’s access to services (e.g. hours to suit teenager’s schedules or drop-in 
appointments) or improve quality of care (e.g. specialised staff training). They did, however, note the following 
characteristics of interventions that were associated with reduced teen pregnancy rates and improved use of 
contraceptives: clinic-based services with peer providers, follow-up phone calls, and outreach efforts, and 
services that emphasised in-depth counselling, education tailored to an adolescent’s level of development, and 
provision of social support and reassurance. They also noted that another intervention that offered free services, 
tailored hours, peer group reproductive health discussion, and outreach in local schools was associated with 
increased use of services. 
Emergency contraception 
It is common for young people to have sex without using contraception.101 When young women seeking 
abortion are asked why they did not use contraception, common reasons given are that they were not planning to 
have sex, they were ‘in the moment’, and they had been drinking.166-168 Emergency contraception is the use of 
drugs (the ‘morning after pill ‘) or devices (the copper IUD) to prevent pregnancy after intercourse where no 
contraceptive method has been used or there has been a mishap in contraceptive use (such as a condom breaking 
or forgetting to take oral contraceptive pills).169,170 
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The emergency contraceptive pill 
The most widely used emergency contraceptive pill (ECP) is 1.5 mg levonorgestrel (LNG), taken either as a 
single dose or in two 0.75 mg does roughly 12 hours apart.169 (In New Zealand women are offered Postinor-1, a 
single-dose formulation which contains 1.5mg of levonorgestrel. 171) There has never been a placebo-controlled 
trial of the efficacy of the ECP, but efficacy has been estimated by comparing the number of observed vs. 
expected pregnancies in women given the ECP. Two influential World Health Organization studies have 
indicated that LNG-ECP is highly effective. In the first study172, 11 out of 976 (1.1%) women became pregnant, 
when 76 (7.8%) would have been expected to, indicating an efficacy of 86%. In the second 173, 44 out of 2712 
(1.6%) women became pregnant when 216 (8%) would have been expected to, indicating an efficacy of 80%. 
(Efficacy is not the same as the percentage of women who do not get pregnant. The latter statistic is 
considerably greater than the efficacy because not all women would be expected to get pregnant following a 
single episode of sex, even if they used no contraception. In the two studies cited above the percentage of 
women who did not get pregnant was > 98%.) 
The efficacy of LNG-ECP is reduced in women who have sex during the fertile window of their menstrual cycle 
(from five days before to one day after ovulation), and was found to be 60–68% in two other studies.174 
A 2012 Cochrane review175 found that the one and two dose LNG regimens were of similar effectiveness, and 
that women who took LNG within 72 hours of intercourse were significantly less likely to get pregnant than 
those who took it after 72 hours. Side effects from LNG-ECP are generally tolerable, and include nausea, 
vomiting, heavier than normal menstrual bleeding, fatigue, diarrhoea, dizziness and breast tenderness.176 
Recently, there have been concerns that LNG-ECP is less effective in heavier women (those weighing more than 
70 kg).174 This has led to recommendations that heavier women should be offered a copper intra-uterine device 
instead of the ECP.174,177 
Emergency contraceptive pills can be purchased over-the-counter from pharmacies in many countries169 
including New Zealand (at a cost of $30 to $50178). In New Zealand, at family planning clinics179 and often at 
GPs (through funding from DHBs), the consultation and prescription is free for young people but there is 
normally a $5 charge to fill the prescription at the pharmacy.178 Some DHBs, including Nelson Marlborough180 
and Waikato181 fund pharmacies to provide free emergency contraceptive pills, with or without a prescription. 
Is advance provision of emergency contraceptive pills of benefit? 
Emergency contraceptive pills are most effective if they are taken as soon as possible after unprotected sex.182 
Providing women with a supply of emergency contraception to use as needed allows women rapid access to the 
medication when they need it. A Cochrane review 183 summarised the evidence evaluating advance provision of 
emergency contraceptive pills, published up until November 2009. None of the 11 individual RCTs included in 
the review found significant effects on pregnancy rates, including the two studies that were adequately powered 
to detect such a difference. Results from pooled analyses also showed no significant differences between 
pregnancy rates in the advance provision and control groups. There was no evidence that advance provision had 
a negative impact on sexual and reproductive health behaviours and outcomes. 
Copper IUDs for emergency contraception 
The copper IUD is the most effective method of emergency contraception and the only emergency contraceptive 
method to provide on-going protection against pregnancy.175,184 Cleland et al. reviewed 42 studies published in 
English or Chinese (up until August 2011) with a defined population of women who presented for emergency 
contraception and were provided with an IUD, and in which the number of pregnancies was ascertained and loss 
to follow-up was clearly defined. Almost all reported on copper IUDs. Most studies (31 or 74%) followed the 
standard protocol of inserting the IUD within five days of unprotected intercourse. The pregnancy rate (after one 
outlier study was excluded) was 0.09%, indicating that the copper IUD is by far the most reliable emergency 
contraceptive option. 
There have been a number of recent studies exploring the awareness of and interest in IUDs among women 
seeking emergency contraception. These have identifies barriers to IUD use including cost, waiting time 
(patients cannot always get an IUD on the day they present for emergency contraception), low levels of 
awareness and understanding of IUDs among patients, and lack of provision by providers.185-188 Two US studies 
of adolescents and young women presenting to family planning clinics reported that, when counselled about 
IUDs for emergency contraception, 13%–15% of them would choose an IUD, and that more would do so if 
IUDs could be provided on the same day and at no cost.185,187  
Long-acting reversible contraception 
The effectiveness of condoms and oral contraceptive pills in preventing pregnancy depend on correct and 
consistent use. Typical failure rates for the contraceptives commonly used by teens, such as condoms and the 
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oral contraceptive pill, are much higher than failure rates for perfect use.189 In contrast, the effectiveness of long 
acting reversible contraceptive (LARC) methods, which include copper intra-uterine devices, progestogen-only 
injectable contraceptives, progestogen-only intrauterine devices, and progestogen-only subdermal implants, 
does not depend on daily compliance.189  
 Expert opinion is that LARC methods are generally under-utilised.189 The American College of Obstetricians 
and Gynecologists has stated that, because LARCs have top-tier effectiveness, high rates of satisfaction and 
continuation, and no need for daily adherence, LARC methods should be first-line recommendations for all 
women and adolescents.190 The UK’s National Institute for Health and Care Excellence has stated that all 
currently available LARC methods are more cost effective than the combined oral contraceptive pill even at 
one year of use.191 
There is evidence, including evidence from a New Zealand study192 which explored attitudes to contraception, 
and particularly LARC, among young women seeking abortion, that, when they are provided with accurate 
information, and cost barriers are removed, young women view LARC methods favourably.193  
The contraceptive CHOICE Project was a prospective cohort study of 10,000 women in the St. Louis region of 
the US who were aged 14–45 years, wished to avoid pregnancy for at least one year and were initiating a new 
form of reversible contraception.193 Women recruited into the study were provided with contraceptive 
counselling and offered the contraceptive method of their choice at no cost for three years. Of the first 2,500 
women enrolled, 63% were aged < 26 years. Of the 2,500 women, 67% chose long acting methods: 56% chose 
an intrauterine method (47% a levonorgestrel IUD and 9% a copper IUD) and 11% a subdermal implant. 
Although the study found statistically significant associations between demographic and behavioural factors and 
acceptance of LARCs, these associations were small and considered unlikely to be clinically meaningful. The 
study authors suggested that this indicated that LARC methods are acceptable to and wanted by a wide range of 
women seeking contraception. 
Progestogen-only injectable contraceptives 
Progestogen-only injectable contraceptives are slow release preparations. Depot medroxyprogesterone acetate 
(DMPA, trade name Depo-Provera®), which is given every 12 weeks, is the only progestogen-only injectable 
available in New Zealand.194 It is very effective at preventing pregnancy. The estimated percentage of women 
experiencing an unintended pregnancy during the first year of perfect use is 0.2%, while the percentage for 
typical use in the US has been estimated to be 6%.195 The main factor in less than perfect use is failure to get 
repeat injections on time. 
It is common for women to have irregular or prolonged bleeding in their first three to six months on DMPA. 
Amenorrhoea is common with longer DMPA use.189,196 There have been concerns about the effects of DMPA on 
bone mineral density (BMD), especially in young women who have not yet attained their peak bone mass. 
Cross-sectional studies have indicated that BMD in DMPA users is usually lower than that of non-users, but 
within one standard deviation.197 Longitudinal studies have found that there is a greater decrease in BMD over 
time in DMPA users than non-users, but women gain BMD when they stop using DMPA. 197 A recent Cochrane 
review identified two studies providing moderate quality evidence of increased fracture risk for longer current 
use of DMPA users, plus two lower quality studies, one of which found and increased fracture risk while the 
other did not 198 The review did not provide any data specifically on adolescents. The authors stated that 
adolescents are unlikely to have fractures related to skeletal fragility as these are rare in pre-menopausal women. 
Progestogen-only subdermal implants 
Contraceptive implants are inserted beneath the skin on the inside of the upper arm and slowly release 
progestogens into the circulation. There are two brands available in New Zealand: Jadelle®, which is fully 
subsidised and lasts for up to five years (2 rods, each containing 75mg levonorgestrel) and Implanon NXT® 
which costs around $270 and lasts for up to three years (1 radio-opaque rod containing 68 mg 
etonorgestrel).178,199,200  
Implants are very effective at preventing pregnancy. Their forgettable nature is appealing to women.201 A 2007 
Cochrane review reported on research comparing different implants in RCTs.202 Follow-up data from these 
studies indicated that there were three pregnancies in 2307 women years with Jadelle® and none in 2068 
women years with Implanon®, equating to pregnancy rates of 0.13 and 0 per 100 women years respectively. 
The most common side effect of implants is changes in bleeding patterns, including infrequent, frequent and/or 
prolonged bleeding, as well as amenorrhoea.203 Bleeding disturbances, especially frequent and/or prolonged 
bleeding, are the most common reasons women discontinue implants prematurely.201,203 A Scottish study which 
followed up 324 women who had chosen Implanon® in a community family planning clinic found that, of the 
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68 women who discontinued Implanon® within one year, 62 (91%) did so because of unwanted side effects, the 
most common being frequent and/or unpredictable bleeding (n=42, 62%).204 
There are drugs which can be used to manage troublesome bleeding patterns205,206 but these may not be 
acceptable to all women. One Dutch study found that most women with troublesome bleeding refused to accept 
additional medications and asked for the removal of the implant.203  
Intrauterine devices 
 There are two types of intrauterine device (IUD) available in New Zealand: the copper IUD, which contains 
copper, and the levonorgestrel intrauterine system (LNG-IUS, brand names Mirena® and Jaydess®), which is a 
hormone-releasing IUD that slowly releases progestogen into the uterine cavity. Jaydess® (known as Skyla® in 
the US) is a newer LNG-IUS, which is slightly smaller than Mirena®, lasts for three years, and is promoted as 
being especially suitable for young women who have not had children. There are also small-sized frameless 
copper IUDs which may be especially suitable for nulliparous women with a small uterine cavity, but these are 
not available in New Zealand.207 Only the copper IUD is fully subsidised: young people need to pay around 
$300 for Mirena® or Jaydess®, unless they meet Pharmac’s strict criteria for heavy menstrual bleeding.208 
(Family Planning charges $340 for Mirena® and $275 for Jaydess®.178) Intrauterine devices are very effective at 
preventing pregnancy. Failure rates during the first year of have been estimated to be 0.6% to 0.8% for copper 
IUDs and 0.2% for Mirena.195 
Copper IUDs may cause increased menstrual flow and painful menstruation whereas the LNG-IUS typically 
produces irregular bleeding or spotting in the first months of use followed by oligomenorrhoea or amenorrhoea 
after longer use.209 Unacceptable vaginal bleeding or pain is the most common reason for women requesting 
IUD removal.209 Barriers to increased use of IUDs by adolescents include lack of awareness, cost, and health 
provider reluctance to recommend IUDs to women who have not had children and who may have multiple 
partners (because of outdated worries about STI-induced pelvic inflammatory disease and subsequent 
infertility).210,211 The American College of Obstetricians and Gynecologists has stated that, although few studies 
have focussed exclusively on adolescents, current evidence suggests that the relative risk of pelvic inflammatory 
disease is increased only in the first 20 days after IUD insertion and then returns to baseline, while the absolute 
risk remains small, and that prompt treatment of chlamydia identified at the time of IUD insertion will make 
developing pelvic inflammatory disease unlikely.211 
Another concern is that insertion of an IUD is more difficult and/or painful in a woman who has not had 
children because the cervix is more tightly closed. Bayer et al.212 reported on a retrospective cohort study which 
compared the insertion and post-insertion experiences of 220 nulliparous and 87 parous teenagers (30 of who 
received their IUD post abortion). The mean age of study subjects was 18 years, range 15 to 19 years). The vast 
majority of study subjects (296 out of 307, 96%) had a successful IUD insertion on the first attempt; all of the 
11 unsuccessful insertions were in nulliparous teens. Seven of the 11 had successful insertions on the second 
attempt and there were four failed insertions. Most of the study subjects having interval IUD insertion (i.e. not 
post abortion) received only ibuprofen or paracetamol and topical lidocaine gel or spray to the cervix for relief 
of insertion pain (269/277, 97%). (The 2015 Cochrane review on interventions for IUD insertion found that 
Lidocaine 2% gel, misoprostol, and most NSAIDs did not help reduce pain but that some lidocaine 
formulations, tramadol, and naproxen had some effect on reducing IUD insertion-related pain in specific 
groups.213) 
A prospective study of 109 nulliparous women, aged 18–30 years, who had an IUD placed at a student health 
clinic at Cornell University (88 LNG-IUS users and 21 Copper T 380A IUD users) and were followed up at one, 
six, 12 and 18 months after insertion reported high overall satisfaction.214 At follow-up survey (after mean use 
of 13.4 months) 83% of women were ‘happy’ or ‘very happy’ with their IUD, with no differences in satisfaction 
between users of the two types of IUD. A majority of women (75%) reported that the insertion went ‘very well’ 
even though 78% rated insertion pain as moderate to severe. At 12 months, the continuation rate was 89%. 
Reasons for discontinuation were expulsion (3%), side effects (6%), lack of anticipated benefit (1%) and 
pregnancy (1%). Compared to users of the LNG-IUS, users of the Copper T 380A were more likely to have 
heavy menses (74% vs 2%, p<0.0001) or moderate to severe cramping (68% vs 20%, p=0.0002). During the 
study period, there were no uterine perforations and no diagnoses of pelvic inflammatory disease. The rate of 
failed insertions was 6.2%. 
Conclusions 
In New Zealand, the median age at which women have their first baby is around 28 years215 yet the median age 
at which young people first have sex is around 17 years.110 It is therefore clear that, in our society, most people 
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wish to have sex long before they wish to be a parent and that they need to be able to control their fertility 
through contraception and, as a last resort, through abortion (if that is what they want). Having several sexual 
partners over time is the norm111,216 and having sex with people who have had previous partners put a person at 
risk of contracting a sexually transmitted infection. There is a clear link between alcohol abuse and promiscuity 
and unprotected sex. 113,217 
All over the developed world, governments are concerned about teenage pregnancy rates. There is considerable 
variation in teenage birth rates between developed countries and New Zealand’s rate is high by OECD 
standards.116Teenage birth rates are falling in New Zealand and in other developed countries.116This suggests 
that broader global trends, such as greater educational opportunities for young women along with improved 
contraceptive technology (and access to it), are responsible for the decline rather than any particular national 
public policies.218 
Young people need comprehensive sexuality education at school to equip them with the skills and 
understandings to take care of their sexual health. Research indicates that the effective sexuality education 
addresses the risk and protective factors that are most easily changed by teen pregnancy/STI prevention 
programmes: sexual knowledge and values, perception of peer norms, motivation and self-efficacy. There is no 
evidence that providing young people with comprehensive sexuality education hastens their sexual debut or 
increases their sexual activity. 
In addition to having a good understanding of sexual and reproductive health issues, young people need access 
to sexual and reproductive health services. It is important to minimise barriers that deter young people from 
accessing services. The greatest barriers are probably embarrassment and fear that confidentiality will not be 
maintained. Young people generally don’t want it known that they have visited a sexual health service. Other 
barriers include inconvenient service locations or opening hours, transportation difficulties, and cost. 
Research has identified a number of characteristics that make services youth-friendly: confidentiality, 
accessibility, respectful and non-judgmental staff, integration of sexual and reproductive services with other 
health services, specialised staff training, accommodating young people’s preferred provider characteristics 
(such as wishing to see a provider of a particular gender), involvement of parents of families (where this is 
desired), peer involvement (for example having young staff or peer support groups), and cultural competence. 
Highly effective contraceptive methods are available but awareness and utilisation of these methods, particularly 
long-acting reversible methods, is not as high as it could be. Since it is common for young people to have 
unprotected sex, it is important that all young people have access to emergency contraception. Some DHBs fund 
pharmacies to provide the emergency contraceptive pill free without a prescription. Although there is no high 
quality evidence that providing people with an advance supply of the emergency contraceptive pill reduces 
unintended pregnancies, common sense would suggest that this approach could be of benefit, particularly to 
teenagers in remote and rural areas. The copper IUD is the most effective form of emergency contraception, and 
it is especially recommended for heavier women among whom the emergency contraceptive pill is less 
effective. 
Long active reversible contraceptives (LARCs), including implants, the copper IUD and the levonorgestrel 
intrauterine system (Mirena® and Jaydess®) have very low failure rates and do not require daily compliance, 
characteristics that make them ideal for women determined to avoid pregnancy. There is a lack of awareness 
among health professionals and young people that intrauterine devices are suitable for women who have not had 
children and who may have multiple partners. Given the choice of having either a copper IUD or a 
levonorgestrel intrauterine system, a majority of women would likely choose a levonorgestrel intrauterine 
system because it reduces or eliminates menstrual bleeding whereas the copper IUD tends to increase it. In New 
Zealand this choice is denied to women who cannot afford to pay the high cost of levonorgestrel intrauterine 
system, since Pharmac funds only the copper IUD. 
Providing young people with comprehensive sexuality education and free access to sexual health services will 
not be enough to eliminate sexually transmitted infections and unintended pregnancies in young people. Alcohol 
abuse is a major factor leading to unprotected and risky sexual behaviours so changing New Zealand’s drinking 
culture is an important public health goal. When disadvantaged young women are empowered to see a future for 
themselves that includes completing their education and having a career that will allow them greater economic 
independence and greater ability to provide for any children they may eventually have, then they will be less 
likely to see early motherhood as their only path into adulthood, and less likely to be ambivalent about the 
possibility of pregnancy when they have sex. 
 
 




New Zealand’s teenage fertility rates are relatively high by OECD standards. In 2011, New Zealand’s 
adolescent fertility rate was 22.1 per 1,000 women aged 15–19 years.14 In comparison, rates (per 1,000) were 
35.0 in the US, 23.6 in the UK, 14.6 in Australia, 12.5 in Canada and 5.2 in the Netherlands.14 Teenage fertility 
rates are declining in New Zealand and in other developed countries.117 In New Zealand, the decline in fertility 
has been greatest for younger teenagers so that births to teenage mothers are increasingly occurring to older 
teenagers. Almost three-quarters (71.6%) of all teenage births in 2013 were to 18 and 19 year olds (up from 
66.6% in 2006).117 Teenage fertility rates are considerably higher in areas of high socio-economic deprivation.118 
Māori have long had higher teenage birth rates than non-Māori, but their rates are declining at a similar rate to 
those of non-Māori. The Māori teenage birth rate in 2013 was 53.1 births per 1,000, down from 72.2 per 1,000 
in 2000.117 Māori teenage birth rates are higher than European at all levels of socio-economic deprivation 
(NZDep2013).118 
Research, both internationally and in New Zealand, suggests that the main factors responsible for declining 
teenage fertility rates are a decline in sexual activity among teenagers and increasing use of contraception.117 
The abortion rate for women aged 15 to 19 years in New Zealand has declined, from a high of 26.7 per 1,000 in 
2007 to 11.5 per 1,000 in 2013.219 Data from the Christchurch Health and Development Study, which followed 
children born in 1997 from birth to age 25 years, suggested that teenage motherhood was associated with poorer 
mental health, education and economic outcomes at ages 21–25 years although the association with adverse 
mental health outcomes was no longer significant after controlling for confounding factors.220 For many young 
parents, having a baby can be a turning point in their lives which increases their motivation to take responsibility 
for their future and raise their educational and employment aspirations. Coordinated social services which 
support teen parents into education, training and employment are critical to improving outcomes for teenage 
parents and their children.118 
The following section reports on teenage birth rates using information from the Birth Registration Dataset. 
Policy documents and evidence-based reviews relevant to the support of teenage parents and their children are 
summarised at the end of this section. 
Data sources and methods 
Indicator 
 Teenage birth rates 
Data sources 
Numerator:  Birth registration dataset (live births) 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years). 
Definition:  
Teenager is defined as a woman aged 10–19 years 
Teenage birth rate:  The number of live births per 1,000 women aged 15–19 years 
Age-specific fertility rates: The number of live births per 1,000 women for a particular age group in a given year 
Notes on interpretation 
Unless specified otherwise, the denominator is out of women aged 15–19 years 
In the analysis of total teenage pregnancy rates, miscarriage rates were estimated at 10% of induced abortions and 20% of live 
births using miscarriage methodology based on Dickson, N., et. al.221 
The teenage birth rates presented here may vary slightly from previous years, as the Ministry of Health no longer provides 
stillbirth data in the Birth Registration Dataset due to concerns about data quality. Thus the current analysis is restricted to 
teenage live births (as compared to total teenage birth rates (including stillbirths) which were presented in previous years). 
An overview of the strengths and limitations of the Birth Registration Dataset is provided in the Appendices. 
National trends and distribution 
In 2000 the live birth rate varied by age from 28.1 per 1,000 15–19 year old women to 119.5 per 1,000 25–29 
year olds. Rates were consistently lowest in 15–19 year olds and from 2002 were highest in 30–34 year olds. 
From 2000 to 2014 there was an overall fall in birth rates for women aged 15–19 years, and also for 20–24 and 
25–29 year olds, with more stable rates in other age groups (Figure 161).  
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Among women aged under 20 years the total birth rate fell from 70.7 per 1,000 in 2000 to 36.4 per 1,000 in 
2014. Birth rates were consistently higher by each increasing year of age (Figure 162). Pregnancy outcomes for 
women aged 15–19 years showed an overall fall in pregnancy, live birth, termination and miscarriage rates from 
2008 to 2014 (Figure 163).  
From 2000 to 2014 birth rates for 15–19 year old women declined overall in each ethnic group. Birth rates were 
consistently highest for Māori, followed by Pacific and European and consistently lowest for Asian/Indian 
(Figure 164). 
Figure 161. Livebirths, by age group of women, New Zealand, 2000–2014 
 
Numerator: Birth registration dataset; Denominator: Statistics NZ Estimated Resident Population; * Number of live births per 
1,000 females of childbearing aged between 15–44 years 
Figure 162. Teenage birth rate, by age group, New Zealand, 2000–2014 
 
Numerator: Birth registration dataset (births registered to women aged under 20 years); Denominator: Statistics NZ Estimated 
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Figure 163. Teenage pregnancy, by pregnancy outcome, New Zealand 2000–2014 
 
Numerators: Birth registration dataset (live births); Abortion Supervisory Committee via Statistics New Zealand: Numerator age 
range 11–19; Denominator: Statistics NZ Estimated Resident Population (15–19 year old females); Miscarriages were estimated 
at 10% of terminations (induced abortions) and 20% of live births. Miscarriage methodology based on Dickson, N., et. al. (2000) 
Pregnancies among New Zealand teenagers: trends, current status and international comparisons. NZMJ (April 12) 155–159 
Figure 164. Teenage birth rates by ethnicity, New Zealand 2000–2014 
 
Numerator: Birth registration dataset (births registered to women aged under 20 years); Denominator: Statistics NZ Estimated 
Resident Population (15–19 year old females) 
Distribution by demographic factors 
Between 2010 and 2014 there was a strong social gradient in teenage live birth rates with a significant increase 
in rates between each quintile of NZDep2013 scores compared with the quintile below. Compared with 
European/Other, teenage birth rates were significantly higher for Māori and Pacific and significantly lower for 
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Rate per 1,000 female 
15–19 year olds  
Rate ratio 95% CI 
Teenage births 
New Zealand  
NZDep2013 Index of deprivation quintile 
Deciles 1–2 961 6.68 1.00   
Deciles 3–4 1,581 12.07 1.81 1.67–1.96 
Deciles 5–6 2,495 17.75 2.66 2.47–2.86 
Deciles 7–8 4,466 28.59 4.28 3.99–4.59 
Deciles 9–10 9,085 47.51 7.11 6.66–7.60 
Prioritised ethnicity 
Māori 9,813 58.31 4.45 4.31–4.59 
Pacific 2,741 39.33 3.00 2.87–3.14 
Asian/Indian 371 4.00 0.30 0.27–0.34 
MELAA 117 12.87 0.98 0.82–1.18 
European/Other 5,549 13.11 1.00   
Numerator: Birth registration dataset (births registered to women aged under 20 years); Denominator: Statistics NZ Estimated 
Resident Population (15–19 year old females); Rates are per 1,000 15–19 year old females, Ethnicity is level 1 prioritised; Decile is 
NZDep2013 
The live birth rate was consistently highest for Māori, followed by Pacific, European and Asian/Indian at each 
year of age from 15–19 years (Figure 165). 
Figure 165. Teenage live birth rate, by age and ethnicity, New Zealand 2010–2014 
 
Numerator: Birth registration dataset (births registered to women aged under 20 years); Denominator: Statistics NZ Estimated 
Resident Population; Rate is per 1,000 age-specific female population; Ethnicity is level 1 prioritised 
Distribution by region 
Teenage birth rates were not significantly different from the New Zealand rate in Hutt Valley and South 
Canterbury DHBs and were significantly lower in Waitemata, Auckland, Capital & Coast, Nelson Marlborough, 
Canterbury and Southern DHBs between 2010 and 2014. In the remaining 12 district health boards the teenage 
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Rate per 1,000 
female 15–19 
year olds 
95% CI Rate ratio 
Teenage births 
Northland 1,179 236 44.32 1.82 1.71–1.92 
Waitemata 1,547 309 16.27 0.67 0.63–0.70 
Auckland 1,050 210 13.69 0.56 0.53–0.60 
Counties Manukau 3,156 631 32.89 1.35 1.30–1.40 
Waikato 2,070 414 31.13 1.28 1.22–1.33 
Bay of Plenty 1,161 232 34.49 1.41 1.33–1.50 
Lakes 748 150 42.48 1.74 1.62–1.87 
Tairawhiti 394 79 46.51 1.91 1.73–2.10 
Taranaki 514 103 28.80 1.18 1.08–1.29 
Hawke's Bay 979 196 37.05 1.52 1.43–1.62 
MidCentral 836 167 26.46 1.08 1.01–1.16 
Whanganui 428 86 40.87 1.67 1.52–1.84 
Hutt Valley 615 123 25.63 1.05 0.97–1.14 
Capital & Coast 706 141 13.50 0.55 0.51–0.60 
Wairarapa 203 41 31.16 1.28 1.11–1.46 
Nelson Marlborough 416 83 20.31 0.83 0.76–0.92 
South Canterbury 183 37 21.31 0.87 0.76–1.01 
Canterbury 1,374 275 16.86 0.69 0.65–0.73 
West Coast 157 31 33.20 1.36 1.17–1.59 
Southern 872 174 15.08 0.44 0.40–0.48 
New Zealand 18,620 3,724 24.40 1.00   
Numerator: Birth registration dataset (births registered to women aged under 20 years); Denominator: Statistics NZ Estimated 
Resident Population (15–19 year old females) 
Figure 166. Teenage birth rates, by district health board, New Zealand 2010–2014 
 
Numerator: Birth registration dataset (births registered to women aged under 20 years); Denominator: Statistics NZ Estimated 
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Midland region distribution and trends 
Comparison with New Zealand 
Between 2010 and 2014, teenage birth rates were significantly higher than the national rate in all five Midland 
DHBs (Table 160). 






Rate per 1,000 
female 15–19 
year olds 
Rate ratio 95% CI 
Teenage births 
Waikato 2,070 414 31.13 1.28 1.22–1.33 
Bay of Plenty 1,161 232 34.49 1.41 1.33–1.50 
Lakes 748 150 42.48 1.74 1.62–1.87 
Tairawhiti 394 79 46.51 1.91 1.73–2.10 
Taranaki 514 103 28.80 1.18 1.08–1.29 
New Zealand 18,620 3,724 24.40 1.00   
Numerator: Birth registration dataset; Denominator: Statistics NZ Estimated Resident Population (15–19 year old females) 
Regional trends 
In all the Midland DHBs, teenage birth rates increased during the mid-2000s, reached their highest level in 
2008, and declined steadily thereafter (Figure 167, Figure 168). 
































































































































































































































Numerator: registration dataset; Denominator: Statistics NZ Estimated Resident Population (15–19 year old females) 
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Numerator: registration dataset; Denominator: Statistics NZ Estimated Resident Population (15–19 year old females) 
Declines in teenage birth rates were more marked for Māori and Pacific ethnic groups than for European/Other 
and Asian/Indian in the Midland DHBs. In Waikato, Bay of Plenty, and Lakes DHBs rates were consistently 
highest for Māori, followed by Pacific with the lowest rates for European/Other, while in Tairawhiti and 
Taranaki, teenage birth rates were higher for Māori than for European/Other women (Figure 169, Figure 170). 




























































































































































































































































































Numerator: registration dataset; Denominator: Statistics NZ Estimated Resident Population (15–19 year old females); Ethnicity is 
level 1 prioritised 
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Numerator: registration dataset; Denominator: Statistics NZ Estimated Resident Population (15–19 year old females); Ethnicity is 
level 1 prioritised 
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Evidence for good practice for the support of teenage parents 
Government policy and other documents 
Ministry of Education. 2015. Teen Parent Units. http://www.education.govt.nz/school/property/state-schools/school-
facilities/teen-parent-units/ 
This webpage provides information for schools that are considering establishing a teen parent unit (TPU) at their school. It explains the 
criteria that the Ministry of Education applies when deciding whether to allow a school to establish a teen parent unit. Additional 
information on becoming the host school for a Teen Parent Unit can be found on this page:  
http://www.education.govt.nz/school/running-a-school/managing-the-network-of-schools/changing-your-school-
structure/becoming-the-host-school-for-a-teen-parent-unit/. A list of all the teen parent schools in New Zealand can be found on the 
following page, which also contains links to the Memorandum of Understanding between the Ministry and schools with a TPU, the 
Wellbeing Framework (which sets out the key outcomes and indicators of student success) and the Operational Guidelines (which 
outline the operational policy behind teen parent units). http://alternativeeducation.tki.org.nz/Teen-Parent-Units . 
Social Policy Evaluation and Research Unit (SuPERU). 2014. Effective Parenting Programmes: A review of the 
effectiveness of parenting programmes for parents of vulnerable children. Wellington: Families Commission. 
http://www.socialserviceworkforce.org/system/files/resource/files/Effective-Parenting-Programmes-Report.pdf 
This review is not focussed on children of teen parents, but on vulnerable children at risk of maltreatment. It may be of interest, however, 
since teen parents and their children can belong to families grappling with a multitude of issues such as drug and alcohol use, family 
violence and maternal depression. The review considered international research on parenting programmes that had been evaluated 
using randomised controlled trials or other rigorous research designs with comparison groups. It also reviewed the evidence for the 
effectiveness of New Zealand programmes. It found that, internationally, few programmes have been shown to actually reduce child 
maltreatment, but many have been shown to produce positive changes in parenting, and in children’s health and behaviour, and it 
could be argued that thereby they have reduced the risk of child maltreatment. It notes that there has been more research to support 
the effectiveness of parenting programmes to address children’s behaviour problems than on programmes for parents of younger 
children (e.g. programmes to promote parent child attachment), and that younger, first-time parents are more likely to benefit from 
parenting programmes. Home-visiting and parenting education and support programmes have been shown to have small to moderate 
positive effects on children’s health and development, and on parents’ behaviours, attitudes and beliefs. New Zealand programmes are 
mostly based on overseas programmes and have not been rigorously evaluated so the review authors stated that it was difficult to 
make definitive judgements about their effectiveness. In their conclusions, the review authors stated that programme funders and 
providers need to determine the needs of their community and to match these with appropriate programmes, and that, while investing 
in evidence-based programmes is important, it must be recognised that such programmes are far from perfect and investment to 
innovate and improve on existing programmes is still needed. 
Ministry of Social Development. 2013. Services for Teen Parents and Their Children Practice Guidelines. 
http://www.familyservices.govt.nz/working-with-us/funding-and-contracting/practice-guidelines/teen-parents-and-
their-children-pg.html#July2013PracticeGuidelines3  
These July 2013 Guidelines apply to apply to providers contracted to the Ministry of Social Development to deliver Services for Teen 
Parents and their Children, with contracts starting/renewing in July 2013 or later. The services are of three types: Teen Parent Intensive 
Case Workers, Support for Teen Fathers, and Volunteer Neighbourhood Support. The Guidelines set out the minimum standards for 
the delivery of these services for programmes funded by the Ministry of Social Development through Family and Community Services. 
They cover the target group the programme is designed to support, the services being contracted, and the outcomes to be achieved 
by the programme. They also provide good practice information and set out reporting requirements. 
The following webpage lists the locations of Teen Parent Intensive Case Workers. http://www.familyservices.govt.nz/working-with-
us/programmes-services/early-intervention/teen-parent-initiatives.html. The locations of the Volunteer Neighbourhood Support and 
Parenting Support for Teen Fathers initiatives are listed here :http://www.familyservices.govt.nz/working-with-us/programmes-
services/early-intervention/teen-parent-initiatives.html#VolunteerNeighbourhoodSupport3. 
Ministry of Social Development. 2010. Supporting Teen Fathers: a resource for service providers. Wellington: 
Ministry of Social Development. http://www.msd.govt.nz/about-msd-and-our-work/publications-resources/planning-
strategy/teen-fathers/index.html  
This publication was developed to support the delivery of services for teen fathers. It is organised in three parts: Part One discusses 
what is known about teen fathers in New Zealand, Part Two covers things to consider when working with teen fathers, and Part Three 
contains profiles of five providers currently delivering services to teen fathers in New Zealand. All of the parts include discussion of 
insights gained from the New Zealand and international research literature and lists of resources for each section. There is also a very 
comprehensive list of references at the end. The following webpage, entitled What works best when supporting teen fathers, 
provides an overview of the information contained in the above resource.  
http://www.familyservices.govt.nz/working-with-us/programmes-services/early-intervention/teen-fathers/what-works-best.html  
International guidelines 
National Collaborating Centre for Women's and Children's Health. 2010. Pregnancy and complex social factors. A 
model for service provision for pregnant women with complex social factors. London (UK): National Institute for 
Health and Clinical Excellence (NICE). https://www.nice.org.uk/guidance/cg110  
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These guidelines are based on a comprehensive review of the available evidence, and are complementary to the NICE guidance 
Antenatal care: routine care for the healthy pregnant woman https://www.nice.org.uk/guidance/cg62. Chapter 6 deals with service 
provision for young women under the age of 20. It outlines ways healthcare providers can encourage young women to use antenatal 
services (e.g. offering age-appropriate services, help with other social problems, transport to and from appointments, care in the 
community, and providing opportunities for the father to be involved). There are recommendations for service organisations including 
working in partnership with other agencies, providing antenatal care in a variety of settings (e.g. GP surgeries, children’s centres and 
schools, offering antenatal education in peer groups at the same time and location as clinic appointments and providing a direct-line 
telephone number for a named midwife who provides the majority of antenatal care). There is also guidance on training for healthcare 
staff and providing suitable information to pregnant young women. The full guideline and its appendices, which contain the evidence 
tables for the included studies and details of the excluded studies, can be downloaded from:  
https://www.nice.org.uk/guidance/cg110/evidence . 
Evidence-Based Medicine reviews 
Hodgkinson S, Beers L, Southammakosane C, et al. 2014. Addressing the mental health needs of pregnant and 
parenting adolescents. Pediatrics, 133(1), 114-22. http://pediatrics.aappublications.org/content/133/1/114.long 
This report from the American Academy of Pediatrics provides an overview of the mental health challenges associated with teen 
parenthood, barriers that can often prevent teen mothers from seeking mental health services, and interventions for this population 
that can be incorporated into primary care services. It points out that practitioners providing primary care to teen parents’ children are 
often the first person teen parents may share their emotional and behavioural concerns with and therefore these practitioners are in a 
unique position to facilitate and encourage teen parents’ engagement with mental health treatment. It suggests that it may be easiest 
to engage teen mothers with mental health services when these are delivered in a primary care setting via a multidisciplinary team. It 
notes that the association of teen parenthood with increased risk of mental health problems is likely to be at least partly because teen 
mothers are disproportionately likely to be poor, Latina or African-American, live in low-income communities, be born to parents with 
low educational and employment attainment, have a history of child abuse, reside in chaotic home environments characterized by poor 
interpersonal relationships, and have limited social support networks.  
Lachance CR, Burrus BB, Scott AR. 2012. Building an evidence base to inform interventions for pregnant and 
parenting adolescents: a call for rigorous evaluation. Am J Public Health, 102(10), 1826-32. 
http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2012.300871?url_ver=Z39.88-
2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed  
The authors of this review, two of whom worked with the Office of Adolescent Pregnancy Programs, in the Office of Population Affairs, 
US Department of Health and Human Services, reviewed the published literature to assess the evidence base for interventions for 
pregnant and parenting adolescents. They found that there was a dearth of rigorously evaluated programmes. They suggested that the 
lack of rigorous evaluations may be due to inadequate emphasis on and insufficient funding for evaluation, as well as to challenges 
encountered by programme evaluators working with this population. The authors identified 14 studies that met their quality criteria 
and had been conducted in the US: eight RCTs and six quasi-experimental studies (five of these were retrospective cohort studies). The 
studies mostly enrolled African Americans living in urban centres and aged 15–17 years, but four of the RCTs involved more racially 
and ethnically diverse populations. Interventions most commonly involved home visiting and case management, often in combination, 
together with other approaches such as support groups, parenting education and clinical care. The studies used various outcome 
measures. Repeat pregnancy was the only outcome that was assessed by a majority of the studies: six found significant positive effects, 
and three reported equivocal effects. Three studies measured variables related to educational progress: two reported conflicting results 
for attainment measures, and one found positive effects for attendance and dropout, but only during pregnancy and not in the 
postpartum year. All the remaining outcomes were examined by only one or two studies each and so the authors were unable to analyse 
programme effects across studies. The authors did not identify any evaluations of programmes serving adolescent fathers, and they 
stated that this population is clearly in need of intervention. They also stated that most of the studies had methodological shortcomings: 
many had small sample sizes and high or differential attrition, few had good descriptions of the services received by comparison groups, 
none reported standardised effects sizes and only some reported odds ratios or an effect as a percentage reduction. In their conclusions, 
the authors suggest that it is necessary to remember that although evaluation may seem costly in the short term, in the long term the 
benefits to society from the wellbeing of these adolescents and their children would far outweigh the short term costs. 
Pinzon JL, Jones VF, Blythe MJ, et al. 2012. Care of adolescent parents and their children. Pediatrics, 130(6), e1743-
e56. http://pediatrics.aappublications.org/content/130/6/e1743.full  
This updated clinical report from the American Academy of Pediatrics reviews statistics on adolescent parenting in the US, and discusses 
the medical and psychosocial risks associated with adolescent pregnancy (for both the mother and the baby), the risk of repeat 
adolescent pregnancy, factors associated with better outcomes for adolescent mothers, fathers of infants born to adolescent mothers, 
neurodevelopmental considerations, and models of intervention for adolescent parents. It concludes with brief guidance for the 
paediatrician (who, in the US health system, may be a provider of primary care). 
Buston K, Parkes A, Thomson H, et al. 2012. Parenting interventions for male young offenders: a review of the 
evidence on what works. J Adolesc, 35(3), 731-42. 
http://www.sciencedirect.com/science/article/pii/S0140197111001308 
This paper reviews the evidence on the effectiveness of parenting interventions for young male offenders. It notes that there is a high 
rate of teenage fatherhood among incarcerated young male offenders (one in four in the UK). The authors identified 12 relevant 
evaluations: ten from the UK of programmes for incarcerated young offenders, and two from the US, of programmes for young parolees. 
None used experimental methods or included a comparison group. The evaluations suggested that participants liked the courses and 
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found them useful, and that interventions may improve knowledge of, and attitudes to, parenting. The review authors suggested that 
future interventions should incorporate elements from promising programmes for young fathers in the community and older 
incarcerated fathers. They stated that future evaluations should collect data on longer-term behavioural parent and child outcomes 
and should use comparison groups and, ideally, randomization. 
Chrisler A, Moore K A. 2012. What works for disadvantaged and adolescent parent programs: Lessons from 
experimental evaluations of social programs and interventions. Washington, DC: Child Trends, 
http://www.childtrends.org/wp-content/uploads/2013/04/Child_Trends-2012_08_20_WW_ParentPrograms.pdf 
This fact sheet briefly reviews 20 evidence-based parenting programmes that aim to enhance parents’ development and/or educate 
disadvantaged and teenage parents on effective parenting methods. All programmes were evaluated through random-assignment 
studies. Of the 11 programmes that measured child outcomes, eight programmes found at least one positive impact on a child outcome 
area. In addition, of the 19 programmes that measured parent outcomes, ten programmes found at least one positive impact on a 
parent outcome. There is a table which shows which programmes have been found not to work, which programmes have been found 
to work, and which programmes have had mixed effects, for various child and parent outcomes. The links in the table do not work, 
therefore to find details of the programmes it is necessary to search for the programmes by name in the alphabetical list on this page: 
http://www.childtrends.org/what-works/list-of-programs/ where there are links to a page for each programme on which there is a brief 
description of the programme and its evaluation, as well as links for further information and references. 
Ruedinger E, Cox JE. 2012. Adolescent childbearing: Consequences and interventions. Curr Opin Pediatr, 24(4), 446-
52. 
This concise review reports on recent literature exploring the consequences of teenage childbearing and interventions to ameliorate 
these consequences. It provides an entry point into the literature on this topic. It notes that many of the negative consequences of 
adolescent childbearing, both for the adolescents and their children, are due to associated social and economic factors rather than to 
young maternal age alone. It suggests that increasing educational attainment, preventing repeat pregnancy and improving mother-
child interactions can improve outcomes for mothers and their children. It states that home, community, school and clinic-based 
programmes are all viable models of service delivery to this population. It also states that programmes that are culturally sensitive and 
developmentally appropriate have demonstrated success. Further research on parenting interventions, with larger sample sizes and 
addressing multiple outcomes, is needed to permit comparisons between programmes. The role of the father and co-parenting is 
another avenue for future research. 
Bronte-Tinkew J, Burkhauser M, Metz A J R. 2012. Elements of promising practices in fatherhood programs: 
Evidence-based research findings on interventions for fathers. Fathering, 10(1), 6–30. 
http://www.mensstudies.info/OJS/index.php/FATHERING/article/view/341/pdf_157 
This article reviews key evaluation findings from fatherhood programmes that have been rigorously evaluated (via a study using a 
random assignment design) in order to answer questions about "what works" in fatherhood programmes. The authors identified 12 
rigorously evaluated fatherhood programmes. They identified 15 promising practices that were common to these programmes and 
which reflected different aspects of teaching and the particular context of interventions. They stated that, as yet there is no evidence to 
suggest which combination of these practices contributed to the overall success of these interventions, nor was there evidence that 
each intervention had to incorporate all of these practices in order to be successful. They stated that the 15 promising practices offer a 
starting point for designing and implementing fatherhood programmes that are grounded in in a reliable evidence base. 
Barlow J, Smailagic N, Bennett C, et al. 2011. Individual and group based parenting programmes for improving 
psychosocial outcomes for teenage parents and their children. Cochrane Database of Systematic Reviews, 2011(3). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002964.pub2/abstract  
This review evaluated the effectiveness of programmes for teenage parents in improving psychosocial outcomes for the parents and 
developmental outcomes in their children. It included eight RCTs with 513 participants. Across all the studies there were 47 different 
outcomes compared between intervention and control groups, and in 19 of these there were statistically significant differences, all in 
favour of the intervention group. The authors conducted nine meta-analyses, each of which used data from two studies (data from four 
different studies was used in the meta-analyses). Of the meta-analyses, four showed statistically significant findings in favour of the 
intervention. The outcomes improved by the interventions were: parent responsiveness to the child (standard mean difference (SMD) 
−0.91, 95% CI −1.52 to −0.30, P=0.04), infant responsiveness to mother at follow-up (SMD −0.65, 95% CI −1.25 to −0.06, p= 0.03); and 
an overall measure of parent-child interactions post-intervention (SMD −0.71, 95% CI −1.31 to −0.11, p = 0.02), and at follow-up (SMD 
−0.90, 95% CI −1.51 to −0.30, p = 0.004). The authors concluded that, due to variations in the study populations, the interventions and 
the measures used, there were limits to the conclusions that could be drawn, however they considered that there was some evidence 
that parenting programmes may be effective in improving a number of aspects of parent-child interaction. They stated that more 
research is needed.  
Other relevant publications 
The Royal Australasian College of Physicians. 2015. Position Statement: Sexual and Reproductive Health Care for 
Young People. http://www.racp.edu.au/docs/default-source/advocacy-library/pa-pos-sexual-and-reproductive-
health-care-for-young-people.pdf?sfvrsn=4 
This position paper addresses the importance of sexuality and relationships education and sexual and reproductive health care for 
young people (adolescents and young adults between 12 and 24 years of age) in Australia and New Zealand. It includes 
recommendations for governments, health professionals and health services, and policies and legislative change. Recommendations 
are based on a review of relevant literature and an examination of key issues by the RACP Position Statement Working Party. There are 
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short sections on young people, sexuality, sex and relationships; sexuality and relationships education; youth friendly sexual and 
reproductive healthcare; STI, HIV and viral hepatitis; contraception, termination and teenage pregnancy care; sexual abuse, sexual 
assault and intimate partner violence; sexual and reproductive health care for indigenous young people; young people who are same-
sex attracted or gender diverse, and people with intersex variations; and young people with disabilities and long-term health conditions. 
Myers A, Metzger N. 2014. The importance of whānau, family in the lives of young parents. Auckland: Thrive Teen 
Parent Support Trust. 
http://www.thrive.org.nz/sites/default/files/Young%20Parents%20Research%20Document%20HI%20RES%20final.pdf 
This research was commissioned by Thrive Teen Parent Support Trust. It aimed to identify the support needs of whānau and how the 
pregnancy and parenting sectors can strengthen whānau family support for pregnant teens, young parents, and their children. The 
research used qualitative methods and was based on interviews and focus groups conducted with 10 young parents (aged < 20) and 
eight whānau and family members including parents, siblings, aunties and close family friends. Recommendations arising from the 
research fell into three main areas: supporting whānau and families, supporting young parents, and developing young parent whānau-
friendly communities. 
Berlyn C, Wise S, Soriano G. 2008. Engaging fathers in child and family services. Canberra: Australian Government 
Department of Families, Housing, Community Services and Indigenous Affairs. 
https://www.dss.gov.au/sites/default/files/documents/op22.pdf 
This Australian study describes father participation in selected programmes and services that were part of the Australian Government’s 
Stronger Families and Communities Strategy (SFCS) and identifies successful strategies for engaging with fathers. The research used a 
mixed methodology: a survey of SFCS program managers on father involvement and in-depth fieldwork with a sample of selected 
services and programmes. The researchers had one-on-one interviews with service managers and facilitators and held focus groups 
with father participants. The main findings of the study were: fathers were involved with a diverse range of services across the SFCS, 
although they had a far lower level of participation than mothers; various sociocultural, services and other factors acted as barriers to 
fathers’ access to services and vice versa; by their very nature, services that were most successful in engaging with fathers were 
specifically tailored for men and were exclusive to fathers. Strategies used by service providers included: introducing flexible hours of 
operation; employing male facilitators; developing father-specific services; marketing services to men in male spaces; using male-
friendly language and advertisements; and creating service venues where men felt comfortable. 
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TERMINATIONS OF PREGNANCY 
Introduction 
All District Health Boards in New Zealand are required to provide publicly funded termination of pregnancy 
services, although some DHBs have chosen to sub-contract these services to other DHBs.222 Under New 
Zealand law, grounds for termination of pregnancy include serious danger to the life or mental or physical 
health of the woman and fetal abnormality.223 The vast majority of abortions are carried out on the grounds of 
danger to a woman’s mental health (97.6% in 2014).122 Terminations of pregnancy have a very low rate of 
complications, but the rate of complications increases with gestational age so it is important that women have 
timely access to termination services and referral pathways are not unduly complicated.224 Terminations of 
pregnancy can be conducted either medically or surgically. Medical terminations are less invasive and can be 
conducted much earlier in pregnancy (up until nine weeks’ gestation) than surgical terminations, but in 2013 
only 10% of induced abortions were medical.122 
The 2014 report of the Abortion Supervisory Committee122 contains New Zealand’s latest abortion-related 
statistics. The Committee noted that there have been improvements in the provision of abortion services in 
provincial areas but expressed concern at the lack of a local abortion service for women living in South 
Auckland.122 Abortion rates in New Zealand have been falling steadily over recent years, from 20.1 per 1,000 
(women aged 15–44 years) in 2007 to 15.4 per 1,000 in 2013, but they are still higher than those in some other 
developed countries, such as the Netherlands (which has a rate of around nine per 1,000).122  
The Committee noted the particularly sharp decline in rates for 15–19 year olds, and suggested that this was 
partly attributable to the licensing and funding of a long acting subcutaneous implant (Jadelle®) in August 
2010.122 Intra-uterine devices (IUDs) are another very effective form of long-acting reversible contraception and 
the American College of Obstetricians and Gynecologists states that IUDs are effective and safe in nulliparous 
adolescents.211 Encouraging more effective use of contraception is key to reducing abortion rates as, among 
those having induced abortion in 2013, 54.7% had used no contraception and 25.4% had used condoms.122  
The following section reviews terminations of pregnancy using information from the Abortion Supervisory 
Committee. Policy documents and evidence-based reviews which address the prevention unintended 
pregnancies are summarised at the end of this section. 
Data sources and methods 
Indicator 
Legally induced terminations of pregnancy registered in New Zealand 
Data sources 
Abortion Supervisory Committee 
Notes on interpretation 
Note 1: In New Zealand, information on the domicile of women presenting for a termination of pregnancy has only been 
recorded by the Abortion Supervisory Committee since 2004, with an agreement existing between the Committee and Statistics 
NZ that the only geographical breakdown of termination data will be at regional council level. Thus information on terminations 
of pregnancy by DHB or NZDep Index decile is unavailable.  
Note 2: In its reporting of terminations, Statistics NZ uses total response ethnicity, and thus women will appear in each ethnic 
group with which they identified (in both the numerator and denominator).  
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National trends and distribution 
Termination of pregnancy rates rose from 1980 to 2002 and have since fallen overall particularly since 2007 
(Figure 171). The decline for 15–19 year olds and 20–24 year olds was more marked than for other age groups 
(Figure 172). 
Figure 171. Annual number and rate of terminations of pregnancy, New Zealand, 1980–2014 
 
Abortion Supervisory Committee via Statistics New Zealand; General termination rate corresponds to abortions per 1,000 mean 
estimated number of women aged 15–44 years  
Figure 172. Terminations of pregnancy, by age of woman, New Zealand 1980–2014 
 
Abortion Supervisory Committee via Statistics New Zealand; Termination rate per 1,000 mean female estimated resident 
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In 2014 termination of pregnancy rates were highest in women aged 20–24 years, followed by those aged 25–29 
years, then those aged 30–34 years (Figure 173). 
For women aged under 25 years, termination of pregnancy rates for Māori and Pacific women were higher than 
rates for European and Asian/Indian women in 2014 (Figure 174). 
Figure 173. Terminations of pregnancy by age of women, New Zealand 2014 
 
Abortion Supervisory Committee via Statistics New Zealand; Termination rate per 1,000 mean female estimated resident 
population in each age group 
Figure 174. Termination of pregnancy rates, by ethnicity and age of women, New Zealand 2014 
 
Source: Abortion Supervisory Committee via Statistics New Zealand; Denominator: Statistics NZ usually resident population 
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In 2014 the majority of terminations of pregnancy occurred between 8 and 12 weeks gestation, in all age groups. 
The next most frequent gestations were less than 8 weeks, followed by 13–16 weeks, with women aged 40+ 
years having a higher proportion of terminations at more than 12 weeks than those from other age groups 
(Figure 175). The proportion of women who had a history of previous termination increased with increasing age 
to 35–39 years (Figure 176).  
Figure 175. Proportion of women who had a termination, by age and gestation at termination, New Zealand, 2013 
 
Abortion Supervisory Committee 2014 annual report; TOP corresponds to termination of pregnancy (i.e. induced abortion) 
Figure 176. Proportion of women who had a termination, by age and number of previous terminations, New 
Zealand 2013 
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Distribution by region 
Between 2010 and 2014 the number of terminations of pregnancy varied around the country (Table 161). 
Table 161. Terminations of pregnancy, by regional council of residence, New Zealand 2010–2014 
Regional council 
Number of terminations 
2010 2011 2012 2013 2014 
Northland 529 532 474 450 431 
Auckland 6,553 6,412 5,919 5,530 5,138 
Waikato 1,429 1,318 1,307 1,214 1,046 
Bay of Plenty 837 821 773 726 667 
Gisborne 184 159 146 158 140 
Hawke's Bay 523 534 496 455 413 
Taranaki 360 342 296 323 272 
Manawatu-Wanganui 813 729 696 614 601 
Wellington 2,009 1,898 1,666 1,589 1,521 
Tasman 116 122 124 103 108 
Nelson 168 197 177 171 160 
Marlborough 120 134 125 117 95 
West Coast 100 91 94 87 88 
Canterbury 1,906 1,645 1,544 1,620 1,628 
Otago 652 590 610 604 552 
Southland 231 272 257 272 249 
New Zealand 16,630 15,863 14,745 14,073 13,137 
Abortion Supervisory Committee Annual Reports via Statistics NZ 
Evidence for good practice for the prevention of unintentional 
pregnancies 
Ministry of Health publications 
Ministry of Health. 2003. Sexual and Reproductive Health: A resource book for New Zealand health care organisations. 
Wellington: Ministry of Health. http://www.health.govt.nz/publication/sexual-and-reproductive-health-resource-book-new-
zealand-health-care-organisations  
This publication supports the Sexual and Reproductive Health Strategy and is designed to help DHBs and PHOs find ways of improving the 
uptake of effective contraception and safe sex practices in their populations. It notes that compared to some other developed countries, New 
Zealand has high rates of both abortions and teenage births. There is information on designing services, strategies for action, strategies for 
Māori, strategies for Pacific peoples, unintended and unwanted pregnancies, sexually transmitted infections, HIV and AIDS.  
Ministry of Education publications 
Ministry of Education. 2015. Sexuality education: A guide for principals, boards of trustees and teachers. Wellington: 
Ministry of Education. http://health.tki.org.nz/Teaching-in-HPE/Policy-guidelines/Sexuality-education-a-guide-for-
principals-boards-of-trustees-and-teachers 
This guide is a revision of the 2002 guide of the same name. The overall aim of the revised guide is to support school boards, principals, and 
teachers to deliver effective, quality sexuality education programmes and, through them, to support the positive and holistic development 
and health of all students in New Zealand primary, intermediate, and secondary schools. It will also assist boards of trustees, principals, and 
teachers in all New Zealand state and state-integrated schools to comply with the requirements of the Education Act 1989 (as amended in 
2001) to consult with the school community on the way in which the health curriculum should be implemented. 
Other government publications 
Families Commission. 2011. Teenage pregnancy and parenting: An overview. Wellington: Families Commission. 
http://www.superu.govt.nz/sites/default/files/teenage-pregnancy.pdf 
This report was produced in response to a Ministerial request that the Families Commission conduct research addressing two distinct 
questions: 
 What are the reasons behind high rates of teenage parenthood amongst young teenagers in specific regions of New Zealand? 
 What would discourage second or repeat teenage pregnancies? 
The report is divided into two sections. The first examines regional statistics for teenage pregnancy and parenthood. The second discusses 
how to prevent subsequent teenage births, by analysing the implications and motivations of first and subsequent pregnancies and by 
considering ways to strengthen support for teenage parents and prevent teenage pregnancies. 
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Families Commission. 2010. Young people’s relationships: Supporting young people as they have their first relationship. 
Issues Paper 02. Wellington: Families Commission. http://www.superu.govt.nz/sites/default/files/young-peoples-
relationships.pdf  
This is the report of a project which aimed to find out what support young people need as they have their first relationships. The project 
involved the Families Commission reviewing the limited literature and conducting focus groups and interviews with young people (77 
participants), parents, grandparents and whānau (23 participants), youth workers (n= 14), school counsellors (n= 7) and social workers (n=3). 
Key messages that emerged from the study were: 
 Young people learn about relationships by watching their parents, whānau and the adults around them  
 Parents, whānau and other adults are key sources of support for young people 
 Young people want to learn more about the emotional side of relationships through the school curriculum 
 School support services may be under-resourced and need to be better connected with the young person’s family and community 
services.  
International Guidelines 
Gavin L, Moskosky S, Carter M, et al. 2014. Providing quality family planning services: Recommendations of CDC and 
the U.S. Office of Population Affairs. MMWR Recomm Rep, 63(Rr-04), 1-54. http://www.cdc.gov/mmwr/pdf/rr/rr6304.pdf  
This report provides recommendations developed collaboratively by CDC and the Office of Population Affairs (OPA) of the U.S. Department 
of Health and Human Services (HHS). It is intended for use by providers of family planning services. It provides recommendations for how to 
help prevent and achieve pregnancy, emphasizes offering a full range of contraceptive methods for persons seeking to prevent pregnancy, 
highlights the special needs of adolescent clients, and encourages the use of the family planning visit to provide selected preventive health 
services for women, in accordance with the recommendations for women issued by the Institute of Medicine and adopted by HHS. 
National Institute for Health and Care Excellence. 2014. Contraceptive services with a focus on young people up to the 
age of 25. London: National Institute for Health and Care Excellence. http://www.nice.org.uk/guidance/ph51 
The recommendations in the NICE guidance cover: Assessing local need and capacity to target services; Commissioning coordinated and 
comprehensive services; Providing contraceptive services for young people; Tailoring services for socially disadvantaged young people; 
Seeking consent and ensuring confidentiality; Providing contraceptive services after a pregnancy; Providing contraceptive services after an 
abortion; Providing condoms in addition to other methods of contraception; Communicating with young people; and Training and continuing 
professional development. The evidence used as the basis for the recommendations, and supporting documents, can be found in the 
appendices. 
World Health Organization Regional Office for Europe. 2011. Evidence for gender-responsive actions to prevent and 
manage adolescent pregnancy. Copenhagen: WHO Regional Office for Europe. 
http://www.euro.who.int/__data/assets/pdf_file/0008/158093/316637_WHO_brochure_226x226_5-
AdolecentPregnancy.pdf?ua=1 
This publication summarises current knowledge on what works in preventing and managing adolescent pregnancy. It takes the standpoint 
that young people’s health is the responsibility of the whole society, and that interventions need to be gender responsive in order to be 
successful. It therefore looks at actions at various levels, such as cross-sector policies, families and communities’ actions, and interventions by 
health systems and health services. It is intended to stimulate countries to further refine their national policies to make them more effective 
in contributing to the health and well-being of young people, and does not prescribe or recommend any particular course of action. 
Clinical Effectiveness Unit. 2010. Contraceptive Choices for Young People. London: Faculty of Sexual and Reproductive 
Healthcare. http://www.fsrh.org/pdfs/ceuGuidanceYoungPeople2010.pdf 
This British guideline is intended for use by health professionals providing contraceptive health services to young people. Recommendations 
are based available evidence and expert consensus opinion, and graded according to the level of evidence. 
National Institute for Health and Care Excellence. 2007. Prevention of sexually transmitted infections and under 18 
conceptions. London: National Institute for Health and Care Excellence. http://www.nice.org.uk/guidance/ph3 
This guideline is intended for professionals working in sexual health services, including those working in contraceptive services, genito-urinary 
medicine, and school-based clinics. It provides guidance on one-to-one interventions to prevent sexually transmitted infections and under 
18 conceptions. The evidence supporting the recommendations can be found at: 
 http://www.nice.org.uk/guidance/ph3/evidence.  
National Institute for Health and Care Excellence. Long-acting reversible contraception (update). London: National 
Institute for Health and Care Excellence, 2005 http://www.nice.org.uk/guidance/cg30 
This guideline offers best-practice advice for all women of reproductive age who may wish to regulate their fertility using long-acting 
reversible contraception (LARC) methods. It covers specific issues for the use of these methods during the menarche and before the 
menopause, and by particular groups, including women who are younger than 16 years, women who have HIV, and women who have learning 
or physical disabilities. The full guideline, which includes the supporting evidence, and a 2014 addendum which provides updated 
recommendation’s relating to progestogen-only subdermal implants, can be found here: 
 http://www.nice.org.uk/Guidance/CG30/Evidence. 
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Evidence-based medicine reviews 
Brittain AW, Williams JR, Zapata LB, Pazol K, Romero LM, Weik TS. 2015. Youth-Friendly Family Planning Services for 
Young People: A Systematic Review. American journal of preventive medicine: 49(2 Suppl 1):S73-84. Epub 2015/07/21.  
The aims of this review, which was conducted in 2011, were to summarise the effects of youth-friendly family planning services on reproductive 
health outcomes and to describe key characteristics of youth-friendly family planning interventions. Studies included in the review were 
published in English from January 1, 1985 through February 28, 2011 and were conducted in the US, Canada, Europe, Australia, or New 
Zealand. Earlier studies, those conducted in other countries, and those that focused exclusively on HIV or sexually transmitted diseases were 
excluded. The review team identified nineteen articles meeting their inclusion criteria. Six of these evaluated outcomes relevant to unintended 
pregnancy, contraceptive use, and knowledge or patient satisfaction. None of the six were RCTs. Risk of bias was rated high in four and 
moderate in two. Sample sizes ranged from 163 to 1,590. The other thirteen studies identified viewpoints on youth-friendly services. Most of 
the studies examining outcomes found positive effects (two of three for unintended pregnancy, three of three for contraceptive use, and 
three of three for knowledge or patient satisfaction). The studies that did not evaluate outcomes described nine key characteristics of youth-
friendly family planning services. The review team concluded that there was limited evidence that youth-friendly services may improve 
reproductive health outcomes and they stated that they had identified service characteristics that might increase young people’s receptivity 
to using these services. They also stated that although more rigorous studies are needed, the interventions and characteristics identified in 
their review should be considered in the development and evaluation of youth-friendly family planning interventions in clinical settings. 
Brittain AW, Williams JR, Zapata LB, Moskosky SB, Weik TS. 2015. Confidentiality in Family Planning Services for Young 
People: A Systematic Review. American journal of preventive medicine: 49(2 Suppl 1):S85-92. Epub 2015/07/21. 
Young people may be deterred from accessing family planning services if they fear that providers will not maintain confidentiality. This 
systematic review, conducted in 2011, summarises the evidence on the effect (as measured by reproductive health outcomes) of assuring 
confidentiality in family planning service to young people aged 10–24 years. Studies included in the review were published from January 1985 
through February 2011 and were conducted in the US, Canada, Europe, Australia, or New Zealand. Earlier studies, those conducted in other 
countries, and those that focused exclusively on HIV or sexually transmitted diseases were excluded. The review authors identified nine studies 
meeting their criteria, four of which examined outcomes, including use of clinical services and intention to use services. The four outcomes 
studies were: one RCT, one pre-post study and two cross-sectional studies. Only the RCT was considered at low risk of bias. Sample sizes 
ranged from 53 to 1,715. Of the four outcome studies, three found a positive association between assurance of confidentiality and at least 
one outcomes of interest. Five studies provided information on the views of young people and these indicated that young people place a 
high value on confidentiality when receiving family planning services. The review authors concluded that there is limited research evidence 
examining whether confidentiality in family planning services for young people affects reproductive health outcomes and that, given the 
importance young people place on confidentiality, robust research in this area is needed. This review, and the one above, were used to inform 
the guideline: Providing quality family planning services: Recommendations of CDC and the U.S. Office of Population Affairs (see the 
International Guidelines above). 
Cochrane Reviews on topics related to contraception 
http://www.cochranelibrary.com/topic/Gynaecology/Contraception/?per-page=100&stage=review 
The Cochrane collection contains many reviews on topics related to contraception. Only recent reviews of a more general nature and/or 
especially relevant to teenagers have been summarised below. The above link provides access to all the Cochrane reviews on contraception. 
Krashin J, Tang JH, Mody S, Lopez LM. 2015. Hormonal and intrauterine methods for contraception for women aged 25 
years and younger. Cochrane Database of Systematic Reviews (8). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009805.pub3/abstract 
The majority of women between the ages of 15 and 24 years wish to avoid pregnancy yet contraceptive failure rates are higher in young 
women than in older women. This review aimed to compare contraceptive failure (i.e. pregnancy) rates and continuation rates for hormonal 
and intrauterine contraception in women aged 25 years and younger. Five RCTs were included, involving a total of 1,503 women. Two studies 
compared different methods of intrauterine contraception (copper T308A IUD vs. the levonorgestrel intrauterine system with 20 µg/day initial 
release (LNG-IUS 20), 23 teenage participants; and LNG 12 vs.16 µg/day initial release, 2884 women most of whom had borne children, and 
of whom 1130 were aged 18–25 years). Three studies compared a combined oral contraceptive (COC) with another hormonal method: COC 
vs. LNG-IUS 20, 200 women aged 18–25 years; COC vs. transdermal contraceptive patch 20 women aged 15–19 years; COC vs. vaginal ring 
130 women aged 15–21 years. In the three trials comparing two different types of methods there were no differences between study arms 
for contraceptive efficacy or continuation. The study comparing COC vs. LNG-IUS 20 found that in the group assigned to COC a significantly 
higher proportion of women discontinued use for ‘other personal reasons’ compared to the group assigned to the LNG-IUS 20 (OR 0.27, 95% 
CI 0.09 to 0.85). The review authors stated that this finding may have little clinic relevance. The trial that compared LNG-IUS 12 vs LNG-IUS 
16 found similar efficacy over one and three years. In the trials examining different LNG-IUS, continuation was at least 75% at six to 36 months. 
The review authors concluded that the overall quality the evidence was moderate to low and that the current evidence was insufficient to 
compare efficacy and continuation rates in women aged 25 years and younger. 
Smith C, Gold J, Ngo TD, et al. 2015. Mobile phone-based interventions for improving contraception use. Cochrane 
Database of Systematic Reviews (6). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011159.pub2/abstract 
Interventions delivered by mobile phone have been shown to be effective in non-contraceptive healthcare. This review aimed to assess the 
effects of mobile phone-based interventions for improving use of contraception. There were five RCTs that met the review’s inclusion criteria. 
Three trials compared automated text messages vs. standard care for improving adherence to a specific method of contraception amongst 
existing or new contraception users. Two trials aimed to improve both uptake and adherence, to any effective method, in both users and 
non-users of contraception. No trials were at low risk of bias in all areas assessed. One US trial assessed an intervention comprising a range 
of uni-directional and interactive text messages and reported improved self-reported oral contraceptive (OC) continuation at six months (RR 
1.19, 95% CI 1.05 to 1.35). One trial in Cambodia assessed an intervention involving automated interactive voice messages and phone 
counsellor support and found increased self-reported use of effective contraception at four months post abortion (RR 1.39, 95% CI 1.17 to 
1.66). A US feasibility trial used reminder and healthy self-management text messages and reported a lower mean number of days between 
scheduled and completed attendance for the first but not subsequent Depo-Provera appointments using clinic records (mean difference (MD) 
−8.60 days, 95% CI −16.74 to −0.46). A small US trial found that simple text message OC reminders had no effect on missed pills as assessed 
by electronic medication monitoring (MD 0.5 missed pills, 95% CI −1.08 to 2.08). An intervention in Israel found no effect on reported 
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contraception use amongst users of isotretinoin (a drug used for acne) from an intervention that provided health information via text 
messages and mail. One trial assessed potential adverse effects of the intervention and reported no evidence of effects on road traffic 
accidents or domestic abuse. The review authors concluded that there was limited evidence that mobile phone interventions can improve use 
of contraception but the cost-effectiveness and long-term effects of such interventions remains unknown. 
Goesling B, Colman S, Trenholm C, et al. 2014. Programs to reduce teen pregnancy, sexually transmitted infections, and 
associated sexual risk behaviors: A systematic review. The Journal of adolescent health: official publication of the Society 
for Adolescent Medicine. 54(5):499-507. Epub 2014/02/15.  
This systematic review deals only with studies evaluating programmes conducted in the US. It is, however, based on a systematic review of 
the literature, published or released from 1989 through early 2011. Studies were deemed eligible for inclusion if they: examined the impacts 
of an intervention using quantitative data and statistical analysis and hypothesis testing (both RCTs and quasi-experimental studies were 
included); measured programme impacts in terms of at least one measure of pregnancy, sexually transmitted infections (STIs), or associated 
sexual risk behaviours; examined programmes intended to reduce rates of teen pregnancy, STIs, or associated sexual risk behaviours through 
any combination of educational, skill-building, and/or psychosocial intervention. In total, 88 studies were included, 87% of which were RCTs. 
Studies assessed a range of programmes delivered in diverse settings. Analysis of the studies’ findings identified 31 programs with evidence 
of effectiveness. The review authors stated that there is no single recipe for success in improving adolescent sexual health outcomes, and no 
single programme model is right for every population and setting, therefore it is important to have a variety of programmes available for 
implementation. They noted that most of the evidence comes from small scale trials conducted in closely managed settings, often by the 
programme developers, and they suggested that in the real world programme efficacy is likely to be less. 
Lopez LM, Stockton LL, Chen M, et al.2014. Behavioral interventions for improving dual-method contraceptive use. 
Cochrane Database of Systematic Reviews (3). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010915.pub2/abstract 
Dual-method contraception is the use of condoms in addition to another modern method of contraception, such as oral contraceptives or 
an intra-uterine device. Dual protection can offer better protection against unintended pregnancy and sexually transmitted infections (STIs). 
This review examined comparative studies of behavioural interventions for improving use of dual method contraception. Studies were deemed 
eligible for inclusion if they were randomised or non-randomised studies that examined a behavioural intervention with an educational or 
counselling component to encourage or improve the use of dual methods and addressed the prevention of both pregnancy and STIs. The 
comparison could be another behavioural intervention to improve contraceptive use, usual care, other health education, or no intervention. 
The main outcome measure of interest was the investigator’s assessment of consistent dual-method use or use at last sex and outcomes had 
to be measured at least three months after the behavioural intervention began. The review authors identified four studies meeting their 
criteria: three RCTs and a pilot study for one of the trials. The studies assessed diverse interventions: computer-delivered, individually tailored 
sessions; phone counselling added to clinic counselling; and case management plus a peer-leadership program. Only the latter study showed 
any significant effects. The intervention, which addressed multiple risks, showed an effect on contraceptive use. Compared to the control 
group, the intervention group were more likely to report consistent dual-method use: Relative risk (RR) at 12 months: 1.58 (95% CI 1.03 to 
2.43) and RR at 24 months1.36 (95% CI 1.01 to 1.85). The other two RCTs did not show any significant difference between the study groups 
in reported dual-method use or in test results for pregnancy or STIs at 12 or 24 months. In their conclusions, the review authors stated that 
they found few behavioural interventions for improving dual-method contraceptive use and little evidence of effectiveness. The multi-faceted 
intervention that showed some effect only had self-reported outcomes. The two trials that were more applicable to clinical settings did have 
objective outcome measures, but neither showed any effect. Although the included studies had adequate information on intervention fidelity 
and follow-up periods long enough for change to occur, the overall quality of the evidence was judged to be low because two trials had 
design limitations and two had high losses to follow up, as often occurs in contraceptive trials. The review authors stated that there is still a 
need for good quality studies of carefully designed and implemented programmes or services. 
Halpern V, Raymond EG, Lopez LM. 2014. Repeated use of pre- and postcoital hormonal contraception for prevention 
of pregnancy. Cochrane Database of Systematic Reviews (9). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007595.pub3/abstract 
Regular use of post-coital contraception (the ”morning after pill”) is not currently recommended because it is less effective and has a higher 
incidence of side effects compared to other modern methods of contraception, but many women wish to use such a method. This review 
aimed to determine the effectiveness and safety of repeated use of pre- and post-coital hormonal contraception for pregnancy prevention. 
The review authors identified 22 relevant studies involving 12,400 women in total. Most studies were prospective non-randomised trials or 
case series. The results of these indicated that pericoital levonorgestrel (LNG) was reasonably efficacious and safe. The pooled Pearl Index 
(number of pregnancies per 100 woman-years) for the 0.75 mg dose of LNG was 5.4 (95% CI 4.1 to 7.0). The pooled Pearl Index for all doses 
of LNG was 5.0 (95% CI 4.4 to 5.6). Other hormonal drugs appeared promising but most had not been studied extensively. Menstrual 
irregularities were the most common side effects reported but there was no consistent evidence from the studies for a relationship between 
bleeding abnormalities and either frequency of pill intake or total dose of the drug. Non-menstrual side effects were reportedly mild and not 
tabulated in most studies. Most women liked the pericoital method despite frequent menstrual irregularities. The review authors noted that 
most studies were decades old and many had serious methodological issues, but they considered that the evidence was of moderate quality 
because of the large number of participants from diverse populations, the low pregnancy rates, and the consistent results across studies. 
They stated that there is still a need for rigorous research to confirm the efficacy and safety of pericoital use of LNG as a primary means of 
contraception among women with infrequent intercourse.  
Halpern V, Lopez Laureen M, Grimes David A, et al. 2013. Strategies to improve adherence and acceptability of 
hormonal methods of contraception. Cochrane Database of Systematic Reviews (10). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004317.pub4/abstract 
Although hormonal contraceptive methods (birth control pills and injections) are theoretically very effective, in practice they are not as 
effective as they could be, partly because of difficulties in adherence to the contraceptive regimen (e.g. remembering to take pills) and low 
rates of long-term continuation. This review aimed to determine the effect of special counselling techniques to improve adherence to, and 
continuation of, hormonal methods of contraception. It included RCTs comparing an intensive counselling technique or other client-provider 
intervention to routine family planning counselling. 
The review authors identified nine RCTs meeting their criteria. Five involved direct counselling and two of these also provided multiple 
telephone contacts. Four other trials provided intensive reminders, and two of these also provided health education information Three trials 
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showed some benefit from the intervention under investigation. In a counselling intervention, compared to women who had routine 
counselling, women who received repeated structured information about the injectable depot medroxyprogesterone acetate (DMPA) were 
less likely to discontinue the method by 12 months (odds ratio 0.27; 95% CI 0.16 to 0.44) and also less likely to discontinue due to menstrual 
disturbances (OR 0.20; 95% CI 0.11 to 0.37). Another trial showed a group receiving phone calls in addition to special counselling was more 
likely than the special-counselling alone group to report consistent use of oral contraceptives (OC) at three months (OR 1.41; 95% CI 1.06 to 
1.87), though not at 12 months. There were no significant differences between the special counselling only group and the group receiving 
standard care for any outcomes. The third trial compared daily text-message reminders about OCs plus health information to standard care. 
Women in the text-message group were more likely than the standard-care group to continue OC use by six months (OR 1.54; 95% CI 1.14 
to 2.10). The text-message group was also more likely to avoid an interruption in OC use longer than seven days (OR 1.53; 95% CI 1.13 to 
2.07). 
The review authors considered the evidence to be of moderate quality and noted that several trials had small sample sizes and most had high 
losses to follow up. They stated that good personal communication between clients and providers is generally considered to be important 
for successful use of hormonal contraception and that there is some evidence from RCTs that the use of oral contraceptive and injectables 
can be improved with enhanced counselling or intensive reminders plus health information. They suggested that a combination of intensive 
counselling and multiple contacts and reminders may help improve adherence to, and acceptability of, these contraceptive methods. 
Okusanya BO, Oduwole O, Effa EE. 2014. Immediate postabortal insertion of intrauterine devices. Cochrane Database of 
Systematic Reviews (7). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001777.pub4/abstract 
Immediate insertion of an IUD after an abortion can be advantageous as the pain of insertion may be less because the cervix is already open 
but there may be a higher risk that the device will be spontaneously expelled. This review aimed to assess the safety and efficacy of IUD 
insertion immediately after spontaneous or induced abortion. It included 12 RCTs, involving a total of 7,119 women, which either compared 
times for IUD insertion or compared different types of IUD. Five trials compared immediate to delayed insertion. One trial indicated that 
immediate insertion of the Copper 7 was associated with a higher risk of expulsion than delayed insertion (RR 11.98, 95% CI 1.61 to 89.35,1 
study, 259 participants, moderate quality evidence). Moderate quality evidence from three trials (878 participants) suggested that both use 
and expulsion of levonorgestrel-releasing intrauterine system or CuT380A were more likely for immediate compared to delayed insertion risk 
ratio (RR) 1.40 (95% CI 1.24 to 1.58) and RR 2.64 (95% CI 1.16 to 6.00) respectively. Another trial, which randomised women to receive either 
the levonorgestrel IUD or Nova T provided moderate quality evidence that discontinuation rates due to pregnancy were likely to be higher 
for women in the Nova T group. (MD 8.70, 95% CI 3.92 to 13.48; 438 participants). Seven trials examined immediate insertion only and 
compared different types of IUD. Meta-analysis of two multi-centre trials indicated that pregnancy was less likely for the TCu 220C versus the 
Lippes Loop (RR 0.43, 95% CI 0.24 to 0.75; 2 studies; 2257 participants) as was expulsion (RR 0.61, 95% CI 0.46 to 0.81; 2 studies; 2257 
participants). Estimates for the TCu 220 versus the Copper 7 were RR 0.42 (95% CI 0.23 to 0.77; 2 studies, 2,274 participants) and RR 0.68, 
(95% CI 0.51 to 0.91); 2 studies, 2,274 participants), respectively. Another study, with 400 participants, indicated that adding copper sleeves 
to the Lippes Loop improved efficacy (RR 3.40, 95% CI 1.28 to 9.04) and reduced expulsion (RR 3.00, 95% CI 1.51 to 5.97). 
The review authors concluded that there is moderate quality evidence that insertion of an IUD immediately after an abortion is both safe and 
practical but that expulsion rates appear to be higher than for delayed insertions. However, IUD use at six months post abortion is greater 
among women who had immediate insertion instead of delayed insertion. 
Lopez LM, Tolley EE, Grimes DA, et al. 2013. Theory-based interventions for contraception. Cochrane Database of 
Systematic Reviews (8). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007249.pub4/abstract 
Theories and models help to explain how behaviour change occurs. Most of the commonly theories and models in health behaviour are based 
on a social cognition approach. They include the Health Belief Model (HBM), Social Cognitive Theory (SCT), the Theory of Reasoned Action 
(TRA), the Theory of Planned Behaviour (TPB), and Protection Motivation Theory. Although theories and models have been used extensively 
in HIV-prevention research and in interventions for preventing sexually transmitted infections (STIs), educational interventions for 
contraception often have no stated theoretical base. This review assessed RCTs that tested a theoretical approach to inform contraceptive 
choice; encourage contraceptive use; or promote adherence to, or continuation of, a contraceptive regimen. Trials primarily related to HIV or 
STI prevention were excluded. Included trials had the following primary outcomes: pregnancy, contraceptive choice or use, and contraceptive 
adherence or continuation. 
The review included 17 trials, three of which were new since the previous Cochrane review on this topic. Eight were rated as good quality. 
Eleven targeted adolescents. Twelve trials reported pregnancy and birth data and two of these had better results for a theory-based group. 
Twelve trials had data on birth control use (other than condoms) and six showed some positive effects of a theory-based intervention. Five 
out of 12 trials with data on condom use found a positive effect of a theory-based group. Almost all trials involved multiple sessions or 
contacts. Seven trials focussed on adolescents were based on SCT, of which five reported some effectiveness. Two other trials based on other 
social cognition models had some positive results with adolescents. The review authors suggested that family planning researchers and 
practitioners could adapt the effective interventions for their own use. They noted that most of the reviewed interventions focussed on 
teenagers and had group sessions.  
Abdel-Aleem H, d'Arcangues C, Vogelsong KM, et al. 2013. Treatment of vaginal bleeding irregularities induced by 
progestin only contraceptives. Cochrane Database of Systematic Reviews (10). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003449.pub5/abstract 
Progestin-only contraceptives are very effective but women often have irregular bleeding when using them. This review evaluated preventive 
and therapeutic approaches to normalise bleeding irregularities associated with the use of progestin-only contraceptives. It included 33 RCTs 
enrolling 3,677 participants. Two-thirds of these were assessed as having low to moderate risk of bias. The treatments investigated included 
estrogen, combinations of oral ethinyl estradiol and levonorgestrel (i.e. combined oral contraceptives), mifepristone (alone and combined 
with estrogen), various NSAIDS, tamoxifen, tranexamic acid, and doxycycline. The review authors concluded that some women may benefit 
from these interventions, particularly for cessation of current bleeding. They stated that several interventions appear promising for regulating 
bleeding but larger trials are needed to reproduce positive findings. They also stated that the findings of their review do not support the 
routine clinical use of any of the regimens included in the trials particularly for long term effect. 
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Lopez LM, Otterness C, Chen M, et al. 2013. Behavioral interventions for improving condom use for dual protection. 
Cochrane Database of Systematic Reviews (10). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010662.pub2/abstract 
When used correctly and consistently, condoms can provide protections against both pregnancy and sexually transmitted infections (STIs), 
including HIV. This review examined comparative studies of behaviour interventions for condom use that had used objective biological 
outcome measures (such as pregnancy or STI test results). Seven RCTs were identified as meeting the review’s inclusion criteria. Six randomised 
clusters and one, individuals. Five studies provided data on pregnancy, either from pregnancy tests or national records of abortions and live 
births. Four trials assessed the incidence or prevalence of HIV and HSV-2 (Herpes simplex type 2). Three trials examined other STIs. The trials 
showed or reported no significant differences between study groups for pregnancy or HIV, but favourable effects were evident for some STIs. 
The review authors concluded that there was little clinical evidence for interventions promoting condom use for dual protection. They state 
that the overall quality of evidence was moderate to low and losses to follow up were high. They stated that there is a need for effective 
interventions to promote condom use for dual protection and that interventions need to be feasible for resource-limited settings and tested 
using valid and reliable outcome measures (not self-report). 
The American College of Obstetricians and Gynecologists. 2012. Committee opinion no. 539: adolescents and long-
acting reversible contraception: implants and intrauterine devices. Obstetrics and gynecology: 120(4):983-8. Epub 
2012/09/22.  
This publication states that increasing adolescent access to long-acting reversible contraception (LARC) is a clinical and public health 
opportunity for obstetrician gynaecologists and that, because LARCs have top-tier effectiveness, high rates of satisfaction and continuation, 
and no need for daily adherence, LARC methods should be first-line recommendations for all women and adolescents. It provides information 
on: sexual behaviour and contraceptive use among American adolescents; counselling, consent, confidentiality and cost; guidance for 
adolescent health care providers to address common misconceptions; and postabortal long acting reversible contraception. 
Chin HB, Sipe TA, Elder R, et al. 2012.The Effectiveness of Group-Based Comprehensive Risk-Reduction and Abstinence 
Education Interventions to Prevent or Reduce the Risk of Adolescent Pregnancy, Human Immunodeficiency Virus, 
and Sexually Transmitted Infections: Two Systematic Reviews for the Guide to Community Preventive Services. 
American journal of preventive medicine: 42(3):272-94.  
These systematic reviews were conducted to provide a basis for recommendations by the US Community Preventive Services Task Force, an 
independent non-federal body of experts in public health research, practice and policy. They synthesised scientific evidence on the 
effectiveness of two strategies for group-based behavioural interventions for adolescents: (1) comprehensive risk reduction and (2) abstinence 
education, on preventing pregnancy, HIV, and other STIs. The outcomes measures used to assess the effectiveness of the interventions were 
reductions in sexual risk behaviours, pregnancy, HIV and other STIs and increases in protective sexual behaviours. In the US, until 2010, states 
could receive federal funding only to implement abstinence education programmes that taught that people should abstain from sexual 
activity until marriage. The literature search identified 66 US-based studies of comprehensive risk reduction risk reduction and 23 studies of 
abstinence education that assessed the effects of group-based interventions that addressed the sexual behaviour of adolescents and these 
were included in the review. The review team conducted meta-analyses for each strategy on the seven key outcomes identified by the team: 
current sexual activity; frequency of sexual activity; number of sex partners; frequency of unprotected sexual activity; use of protection 
(condoms and/or hormonal contraception); pregnancy; and STIs. The results of these meta-analyses indicated that comprehensive risk 
reduction strategies had favourable effects for all of the outcomes reviewed. For abstinence education, education, the meta-analysis showed 
a small number of studies, with inconsistent fındings across studies that varied by study design and follow-up time, leading to considerable 
uncertainty around effect estimates. The reviews authors concluded that group-based comprehensive risk reduction is an effective strategy 
to reduce adolescent pregnancy, HIV and STIs but that no conclusions could be drawn regarding the effectiveness or otherwise of group-
based abstinence education. 
The methods used for the above review are detailed in this paper: 
Sipe TA, Chin HB, Elder R, Mercer SL, Chattopadhyay SK, Jacob V. 2012. Methods for conducting community guide systematic reviews of 
evidence on effectiveness and economic efficiency of group-based behavioral interventions to prevent adolescent pregnancy, 
human immunodeficiency virus, and other sexually transmitted infections: comprehensive risk reduction and abstinence education. 
American journal of preventive medicine. 42(3):295-303. Epub 2012/02/22.  
A summary of the recommendations derived from the review is contained in the following paper: 
Community Preventive Services Task Force. 2012. Recommendations for Group-Based Behavioral Interventions to Prevent Adolescent 
Pregnancy, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections: Comprehensive Risk Reduction and 
Abstinence Education. American journal of preventive medicine: 42(3):304-7.  
Tolli MV. 2012. Effectiveness of peer education interventions for HIV prevention, adolescent pregnancy prevention 
and sexual health promotion for young people: a systematic review of European studies. Health education research: 
27(5):904-13. Epub 2012/05/30. http://her.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=22641791 
Peer education has been defined as ‘the teaching or sharing of health information, values and behaviours by members of similar age or 
status”. Peer education has been used for sexual health interventions on the assumption that a young person’s peer group has a strong 
influence on the way he or she behaves. This review aimed to appraise all studies that described and evaluated interventions designed to be 
implemented, in full or partially, by peer educators, and that had as an objective the prevention of HIV, the prevention of adolescent pregnancy 
and/or the promotion of sexual health in young people, aged between 10 and 24 years, and met the following criteria: they were conducted 
in European Union countries; they were RCTs, non-randomised controlled studies or studies using a before-and-after design; they evaluated 
at least one of the review’s outcomes of interest; they compared an intervention to no intervention or standard practice; and they were 
available in English, German or Spanish. The review authors identified 17 publications, corresponding to five interventions that met their 
criteria. Three interventions were sex education programmes and two were HIV prevention programmes. One intervention evaluated 
unintended pregnancy using data for abortions and live births and found no statistically significant difference between the intervention and 
control groups in the proportion of girls who had one or more live births by age 20.5 years. One study evaluated STDs using self-report and 
found no statistically significant difference between the intervention and control group. Three studies evaluated condom use and none found 
statistically significant effects. One study assessed sexual experience and found a statistically significant increase in sexual experience in the 
intervention group. All studies assessed knowledge as an outcome but only one found a statistically significant effect. Three studies evaluated 
skills for communication and negotiation: one found a non-significant trend in favour of the intervention group and two found non-significant 
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differences. Three studies evaluated attitudes and one reported significant differences in favour of the intervention group. One study assessed 
intention to use a condom and found no statistically significant effects of the intervention. The review authors concluded that, overall, 
compared to standard practice or no intervention, there is no clear evidence for the effectiveness of peer education concerning HIV 
prevention, adolescent pregnancy prevention and sexual health promotion for young people in the countries of the European Union. They 
stated that further research is needed. 
The CRD reviewed this review and found that its conclusions were likely to be reliable based on the evidence presented. The CRD summary 
can be found here: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0049936/.  
Cheng L, Che Y, Gülmezoglu AM. 2012. Interventions for emergency contraception. Cochrane Database of Systematic 
Reviews (8). http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001324.pub4/abstract 
Emergency contraception involves either taking a drug (the “morning after pill”) or getting a copper intrauterine device (Cu-IUD) shortly after 
unprotected intercourse. This review aimed to determine which EC method is the most effective, safe and convenient way to prevent 
pregnancy after unprotected intercourse. It included 100 trials involving 55,666 women, both RCTs and controlled clinical trials. Eighty-six 
were conducted in China. The review’s conclusions were as follows: “Intermediate-dose mifepristone (25-50 mg) was superior to 
levonorgestrel (LNG) and Yuzpe regimens. Mifepristone low dose (< 25 mg) may be more effective than LNG (0.75 mg two doses), but this 
was not conclusive. UPA may be more effective than LNG. LNG proved to be more effective than the Yuzpe regimen. The copper IUD was the 
most effective EC method and was the only EC method to provide ongoing contraception if left in situ.” The findings of this review relating 
to drugs for emergency contraception are of limited relevance to women in New Zealand where levonorgestrel is the only drug used for 
emergency contraception. (Mifepristone is used in higher dose in terminations of pregnancy and induction of labour for expulsion of a dead 
fetus following fetal death in utero.) 
Arrowsmith ME, Aicken CRH, Saxena S, et al. 2012. Strategies for improving the acceptability and acceptance of the 
copper intrauterine device. Cochrane Database of Systematic Reviews (3). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008896.pub2/abstract 
Despite being highly effective (and reversible), IUDs are among the least commonly used methods of contraception. This review aimed to 
evaluate the effects of interventions intended to increase uptake of the copper IUD. It included nine studies involving 7690 women (seven 
RCTs and two controlled before and after studies) that reported IUD uptake following intervention. The review authors rated the quality of 
evidence moderate to low. Three studies on contraceptive counselling and referrals by community workers showed an increase in uptake of 
the IUD among intervention groups (Peto OR 2.00; 95% CI 1.40 to 2.85). Two studies on antenatal contraceptive counselling also favoured 
the intervention groups (Peto OR 2.33; 95% CI 1.39 to 3.91). One study on postnatal couple contraceptive counselling also showed an increase 
in IUD uptake compared to control (Peto OR 5.73; 95% CI 3.59 to 9.15). The results of one study evaluating postnatal home visits and two 
studies on enhanced post-abortion contraceptive counselling did not reach statistical significance. The review authors concluded that both 
community-based and antenatal contraceptive methods improved uptake of copper IUDs for contraception and they suggested that primary 
care practitioners could consider adopting these interventions. They also suggested that a cost-benefit analysis may be required to evaluate 
applicability. 
Wakhisi AS, Allotey P, Dhillon N, Reidpath DD. 2011. The Effectiveness of Social Marketing in Reduction of Teenage 
Pregnancies: A Review of Studies in Developed Countries. Social Marketing Quarterly: 17(1):56-90.  
This review aimed to determine the effectiveness of a social marketing approach in reduction of unintended teenage pregnancies. A social 
marketing intervention was defined as one which included the following six basic characteristics: consumer research, specific behaviour 
change goal, segmentation and targeting, marketing mix, exchange, and competition. Through a literature search for the years between 1990 
and 2008 the review authors identified 12 studies meeting their criteria. Nine were RCTs and three were before-and-after studies. There was 
variation between studies in intervention effects across specified outcomes (reduction in unintended pregnancies, delayed sexual initiation, 
contraceptive use at last intercourse, knowledge of contraception and reproductive health, and self-efficacy to refuse unwanted sex). Nine of 
the 12 studies reported significant effects on a least one of the outcomes. Long term interventions tended to be more effective than short 
term ones for most outcomes. In most studies there was minimal impact of the intervention on male participants’ sexual behaviour. The 
authors concluded that, overall, social marketing seems to be an effective approach for reducing teenage pregnancies and influencing 
behaviour change, but the evidence is limited to particular outcomes and context. They stated that there is a need for more primary studies 
specifically designed around social marketing principles for more robust evaluations. They also stated that the minimal impact of interventions 
on male participants’ behaviour warrants further investigation. 
Oringanje C, Meremikwu M, Eko H, et al. 2009. Interventions for preventing unintended pregnancies among 
adolescents. Cochrane Database of Systematic Reviews, 2009(4). 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005215.pub2/abstract 
This review included 41 RCTs involving 95,662 adolescents in many different countries and assessing a wide variety of interventions. There 
were both individual and cluster-randomised trials. The results indicated that combination interventions involving both education and 
contraceptive provision were effective in lowering rates of adolescent pregnancy. The evidence on the effect of interventions on secondary 
outcomes (age at first intercourse, use of birth control methods, abortion rates, childbirth rates and sexually transmitted diseases) was 
inconclusive. The variability in study populations, types of interventions, and outcomes measured and also the paucity of trials comparing 
different interventions made it impossible to draw any conclusions about which type of intervention is most effective. 
Other relevant publications 
National Institute of Demographic and Economic Analysis, University of Waikato. 2015. Current trends for teenage births 
in New Zealand. Hamilton: National Institute of Demographic and Economic Analysis, University of Waikato. 
http://www.superu.govt.nz/sites/default/files/Teen_Births_Report_0.pdf 
This report outlines trends in teenage births in New Zealand and provides contextual information on age-related trends, ethnic trends, and 
international comparisons. This is followed by a discussion of the potential drivers of these trends, including direct drivers, such as 
contraceptive use and sexual activity, and also underlying drivers such as socio-economic circumstances, ethnic and cultural differences, and 
family characteristics. The report concludes by discussing the implications of these trends and offering suggestions for further research and 
action. 
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Clark TC, Crengle S, Sheridan J, et al. 2014. Factors associated with consistent contraception and condom use among 
Māori secondary school students in New Zealand. Journal of Paediatrics & Child Health, 50(4), 258-65. 
This study used multivariate analysis to determine relationships between self-reported consistent contraception and condom use among all 
2059 sexually active Māori participants in the 2007 New Zealand youth health and well-being survey of secondary school students. The results 
indicate that 40% of Māori students were currently sexually active; of these, 55.3% always used contraception, and 41.1% always used 
condoms. The following groups of students were less likely to use regular contraception: those with more than three sexual partners (males 
odds ratio (OR) 0.55, P = 0.04, females OR 0.35, P = 0.04) and females who were regular cigarette users (OR 0.52, P = 0.02). Students less 
likely to use condoms were 13- to 15-year-old females (OR for older students vs. younger students 1.95, P < 0.01) and females who enjoyed 
sex (vs. other female students OR 0.52, P = 0.02). Family connection was associated with increased use of condoms among males (OR 1.07, P < 
0.01). The study authors stated that there is a need to improve the sexual health of Māori youth though reducing sexual risks, increasing 
opportunities for healthy youth development and family connectedness, and ensuring access to appropriate services. 
Kaipuke Consultants Ltd. 2012. Regional trends in teenage parenthood. 
http://www.superu.govt.nz/sites/default/files/regional-trends-teenage-parenthood.pdf 
This report was written as a background report to the Families Commission research report: Teen Pregnancy and Parenting: An overview 
(above). It analyses regional variation in teenage births and parenthood in New Zealand. It begins with an overview of New Zealand fertility 
trends over the past 50 years. This is followed by an analysis of national and regional trends in teenage births by age, ethnicity and socio-
economic status (NZDep). Finally, there is a detailed analysis of nine selected regions with the highest rates and numbers of teenage births. 
Rose SB, Lawton BA. 2012. Impact of long-acting reversible contraception on return for repeat abortion. Am J Obstet 
Gynecol, 206(1), 37.e1-6 
This paper reports on a New Zealand study which aimed to determine the relationship between likelihood of return for repeat abortion and 
choice of contraceptive method, in the 24 months after an abortion. The study followed on from an intervention study which ran over 10 
weeks at a public hospital abortion clinic and was designed to promote use of long-acting reversible contraception (LARC) methods that 
included depot medroxyprogesterone acetate (DMPA), the levonorgestrel intrauterine system (LNG-IUS), and copper multiload Cu375 (Cu-
IUD). The intervention increased the use of LARC methods from 45% at baseline to 61% during the intervention, with a 6-fold increase in the 
choice of the LNG-IUS, from 6% to 36%. The follow up study was a prospective cohort study involving review of hospital notes for 510 women 
aged 13 to 44 years. It found that women using long-acting reversible contraceptive (LARC) methods (intrauterine device [IUD] and depot 
medroxyprogesterone acetate) had significantly lower return rates for repeat abortion (6.45%; 95% CI 4.0 to 9.8) than non-LARC users, of 
whom 14.5% returned (95% CI 9.9 to 20.2). A Cox proportional hazard analysis indicated that, after controlling for demographic factors and 
previous pregnancy history, the post-abortion method choice was significantly related to the likelihood of returning for a repeat abortion (P 
= .002). Using the pill as a reference group for risk of repeat abortion, the IUD hazard ratio (HR) was 0.36 (95% CI, 0.17 to 0.77), the depot 
medroxyprogesterone acetate HR was 0.55 (95% CI, 0.21 to 1.45), and the HR for all other methods was 1.8 (95% CI, 0.83 to 3.92). The authors 
stated that their study provided strong support for promoting immediate post-abortion access to LARC methods (especially IUDs) to prevent 
repeat abortions. 
Rose SB, Wei Z, Cooper AJ, et al. 2012. Peri-Abortion Contraceptive Choices of Migrant Chinese Women: A 
Retrospective Review of Medical Records. PLoS One, 7(6). 
http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0040103&representation=PDF 
It has been reported that migrant Asian women in New Zealand have low levels of contraceptive use and high rates of abortion. Chinese are 
the largest group of migrant Asians in New Zealand. This study aimed to describe the contraceptive choices of Chinese women seeking 
abortion, to investigate relationships between method choice and demographic characteristics (including length of stay), and to determine 
whether Chinese women were over-represented among women attending abortion clinics. It involved a retrospective review of medical 
records at a public hospital abortion clinic. Records for 305 Chinese women were compared with previously collected data for 277 European 
and 128 Māori women. Correlated of contraceptive choice were explored via regression analysis. Census data was used to determine rates of 
clinic attendance for each ethnic group. Analysis results indicated that Chinese women were not over-represented among clinic attendees, 
and had rates of contraceptive non-use pre-abortion similar to those of other women. Chinese women had lower rates of oral contraceptive 
pill use pre-abortion than other ethnic groups, but post abortion Chinese women’s rates were similar to European women’s (46.9%, 95% CI 
41–52.7 and (43.7%, 95% CI 37.8–49.7, respectively). Post-abortion choice of an intrauterine device did not differ significantly between Chinese 
(28.9%, 95% CI 23.8–34.3) and Māori women (37%, 95% CI 28.4–45.7), but was higher than uptake of this method by European women (21.7%, 
95% CI 17–27.0). Age, parity and previous abortion were significant predictors of post-abortion method choice by Chinese women (p < 0.05). 
The study authors concluded that, after counselling at the clinic, Chinese women chose post-abortion contraceptive methods that were more 
effective than those they had used previously. They stated that as the number of Chinese migrant women continues to increase, there is an 
urgent need for strategies to ensure that new arrivals are provided with appropriate information and advice about contraception and how to 
access it, so that they can avoid unplanned pregnancy. 
Denny S, Robinson E, Lawler C, et al. 2012. Association Between Availability and Quality of Health Services in Schools 
and Reproductive Health Outcomes Among Students: A Multilevel Observational Study. Am J Public Health, 102(10), 
e14-20. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490681/pdf/AJPH.2012.300775.pdf 
This paper reports on a New Zealand study which used a 2-stage random sampling design to gather nationally representative data from 917 
students from 96 high schools (the Youth ’07 survey). Students self-reported whether they were sexually active, how often they used condoms 
or contraceptives, and whether they had contributed to a pregnancy. School administrators completed questionnaires about their school-
based health services, providing information on team-based services, doctor and nurse hours per week, and health screening. The study 
authors undertook data analysis using multi-level models controlling for individual variables, with schools treated as random effects. The 
results indicated that there was an inverse association between hours of nursing and doctor time and pregnancy involvement among sexually 
active students, with fewer pregnancies among students in schools with more than 10 hours of nursing and doctor time per 100 students. 
There was no association between doctor visits, team-based services, health screening, and reproductive health outcomes. The study authors 
concluded that school health services are associated with fewer pregnancies among students, but only when the availability of doctor and 
nursing time exceeds 10 hours per 100 students per week. 
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Denny S, Farrant B, Cosgriff J, et al. 2012. Access to private and confidential health care among secondary school 
students in New Zealand. J Adolesc Health, 51(3), 285-91. 
This study aimed to determine the prevalence of health care utilisation and private and confidential health care among a nationally 
representative population of New Zealand high school students (the Youth ’07 survey). A total of 9107 students from 96 high schools 
participated (a two–stage cluster sample). Questions in the survey asked students when and where they had accessed health care, if their 
health care provider had explained that their health care was confidential, and if they had been seen in private by their health care provider. 
The results indicated that, although 83% of students had accessed health care in the previous 12 months, only 27% of students reported 
receiving private and confidential health care. Students who had accessed health care from a school-based health centre (adjusted relative 
risk 1.54, 95% CI 1.42 to 1.66) or family planning/sexual health clinics (adjusted relative risk 2.1, 95% CI 1.9 to 2.26) were more likely to report 
receiving private and confidential health care compared with students who had not accessed health care from these settings. The study 
authors stated that, while most young people access health care from their family doctor or general practitioner’s clinic, rates of private and 
confidential health care were low which suggests that opportunities to adequately explore and respond to important yet sensitive topics are 
compromised in primary care settings. 
Pihama L. 2011. Overview of Māori teen pregnancy. Wellington: Indigenous Analysis Ltd., for the Families Commission. 
http://www.superu.govt.nz/publication/overview-m%C4%81ori-teen-pregnancy 
This was prepared for the Families Commission by Leonie Pihama of Māori and Indigenous Analysis Ltd. and is a background literature review 
for the Families Commission research report: Teenage Pregnancy and Parenting. An Overview (above). It provides an overview of views relating 
to Māori teen pregnancy. The author noted that there has been little dedicated research that is specific to the issue of Māori and teen 
pregnancy and she states that Western research which has taken deficit-based approaches to the “problem” of teen pregnancy is of limited 
usefulness for understanding Māori teen pregnancy. She cites research reporting that teen parents themselves have recognised many positive 
outcomes from parenthood including: a sense of direction and purpose, positive life changes such as getting off drugs and alcohol, re-
engaging with their families and with education, and the joy and satisfaction of motherhood. 
Copland RJ, Denny SJ, Robinson EM, et al. 2011. Self-reported pregnancy and access to primary health care among 
sexually experienced New Zealand high school students. J Adolesc Health, 49(5), 518-24 
This study used data from the Youth ’07 survey to determine the prevalence of self-reported pregnancy among sexually experienced New 
Zealand high school students, and the association between teenage pregnancy and access to primary health care. The dataset included 2,620 
year 9 through 13 students who reported ever having sexual intercourse and responded to a question about whether they had ever been 
pregnant or ever caused a pregnancy (1,217 females and 1,403 males). Analysis of the data indicated that, nationwide, 10.6% of sexually 
experienced high school students self-reported that they had been pregnant (11.6%) or caused a pregnancy (9.9%). Māori (15.3%) and Pacific 
Island (14.1%) students had the highest self-reported pregnancy rates. Foregone health care was reported by 24.2% of sexually experienced 
students. Students who self-reported pregnancy reported greater difficulty accessing health care (41.7% vs. 20.6%; odds ratio: 2.6); however, 
when they accessed care, the majority received confidential care (67.4%) as compared with pregnancy-inexperienced peers (51.6%). The most 
common reason for not accessing health care was concern about privacy. Other barriers included uncertainty about how to access care and 
lack of transportation (all p values <.05). The study authors concluded that self-reported pregnancy rates are high among sexually active New 
Zealand high school students and that there are ethnic disparities. They noted that being pregnant or causing a pregnancy is associated with 
difficulty accessing health care and they stated that further research is needed to identify the drivers of ethnic disparities and the nature of 
the cause-and-effect relationship between teenage pregnancy and access to health care. 
Clark T, Robinson E, Crengle S, et al. 2006. Contraceptive use by Māori youth in New Zealand: associated risk and 
protective factors. N Z Med J, 119(1228), U1816. https://www.nzma.org.nz/__data/assets/pdf_file/0003/17859/Vol-119-No-
1228-27-January-2006.pdf 
This study used data from the Youth2000 survey in a multiple logistic regression model to identify risk and protective factors associated with 
consistent contraception use by sexually active Māori secondary school students. There were 2340 survey participants (out of 9570 randomly 
selected secondary school students) who reported that they were Māori, 52.9% of whom were male and 76.1% of whom were aged 15 years 
or younger. The results indicated that half of the Māori students had experienced sexual intercourse and a third were currently sexually active 
(33% males; 34% females). Most Māori youth who had ever had sex used condoms for contraception (82%) and most sexually active Māori 
youth reported consistent use of contraception (71% males; 70% females). Māori youth who used contraception consistently were more likely 
to report getting enough time with a parent (OR 1.50; 95% CI 1.05 to 2.14; p=0.03) and less likely to report weekly marijuana use (OR 0.53; 
95% CI 0.37 to 0.76; p=0.0006). The study authors concluded that, although consistent use of condoms is a common self-reported 
contraceptive practice by many young Māori, this behaviour is not universal and, in view of the significant sexual and reproductive health 
disparities that exist for Māori youth, sexual and reproductive health programmes need to adopt a broader strategy which promotes 
protective factors such as strengthening youth-parent relationships and discourages risk factors such as substance misuse. 
Websites 
The National Campaign to Prevent Teen and Unplanned Pregnancy. http://thenationalcampaign.org/ 
This US website contains a wealth of information and data on teen pregnancy and how to prevent it. The database of research reports, 
publications, fact sheets, videos, podcasts, PowerPoints, and other materials is searchable here:  
http://thenationalcampaign.org/search/resource/results  
Office of Adolescent Health, US Department of Health and Human Services. 2015. Evidence-Based TPP Programs. 
http://www.hhs.gov/ash/oah/oah-initiatives/tpp_program/db/  
This web page provides a searchable database of evidence-based teen pregnancy prevention programmes identified by the US Department 
of Health and Human Services that have been shown, in at least one programme evaluation, to have a positive impact on preventing teen 
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IN-DEPTH TOPIC: MENTAL HEALTH ISSUES IN YOUTH 
AND YOUNG PEOPLE 
By Dr Michael Butchard 
Introduction 
This chapter focuses on youth and young adults aged 15–24 years. The In-Depth chapter: In-Depth Topic: 
Mental Health Issues in Children in a previous NZCYES publication: The Determinants of Health for Children 
and Young People focused on children aged 0–14 years.103 Most of the literature covered in this chapter is from 
research and policy concerning 15–19 years. There is much less research and policy covering the 20–25 years 
age group.  
This chapter is not designed to review specialist treatments for specific disorders; its general focus is on the 
mental health service structure and primary level care. The first section of the chapter gives a brief historical 
context to mental health services in New Zealand. The current services and access for youth and young adults 
are then summarised. Various issues regarding the organisation of youth and young adult mental health services 
identified from the literature are discussed, including barriers to access, transitioning from child to adult care, 
workforce issues, the role of primary care, and school-based health services.  
Secondly, the chapter examines the literature on primary level mental health, alcohol and other drug 
interventions. These interventions are mainly from health and educational settings, are delivered via traditional 
face-to-face, and computer and web-based interventions, and cover mental health disorders and alcohol and drug 
misuse. Lessons from some comprehensive systematic reviews are summarised. Suicide interventions and 
policy are not covered as a separate section within this In-depth chapter, but the recent literature since the 
previous 2012 NZCYES publication is summarised in a later section within this publication.  
The final section focuses on three groups within the youth and young adult population who are at higher risk of 
mental illness, including suicide. Mental health services for Māori, Pacific and sexual minority youth and young 
adults are discussed. These are not the only groups at higher risk of mental health illness, and while some other 
vulnerable groups are not covered directly (including out-of-home care, the Youth Justice population, and 
refugees and migrants), some of the lessons drawn have general applicability. 
Background 
The previous NZCYES In-depth topic “Mental Health Issues in Children” provides a general historical 
background to children’s mental health, and the key documents from the mid-1990s to 2012.103 This chapter 
briefly summarises the recent historical context of mental health services in New Zealand since the mid-1990s, 
in as far as they relate to the evolving focus of present mental health services. 
In New Zealand in the mid-1990s many people who needed specialist mental health services for serious 
disorders were not receiving them. The 1994 Ministry of Health document Looking Forward: Strategic 
direction for the mental health services noted that generally, services were under funded.225 There was a lack of 
resources targeting children and their families, with youth mostly having to access adult services. Looking 
Forward set out a strategic direction of establishing youth services based on regional community mental health 
teams catering for Māori and non-Māori.225 It also called for a coordinated approach between the Ministry of 
Health, the Department of Social Welfare and the Ministry of Education in developing services, and set a 
benchmark that specialist mental health services reach 3% of youth. In 1995 only 0.83% of the national 
population under 20 years of age were receiving specialist mental health services, with regional differences 
ranging from 0.54% to 1.26%.226 
Over the following four years, the mental health service access target for the most severely affected youth was 
increased to 5%,227 then refined in the 1998 Ministry of Health mental health strategy document, New Futures228 
to 1% for 0–9 year olds, 3.9% for 10–14 year olds, 5.5% for 15–19 year olds, and 3% for adults. The new 
targets were based on work by the Mental Health Commission for the Blueprint for Mental Health Services in 
New Zealand.229 These targets are still used today in publications assessing mental health services.230 
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By 2003, access rates for 15–19 year olds were 2.0%.231 Nationally, the service access target of 5.5% for 15–19 
year olds was finally met in 2012.230 In 2013, the latest published data, the access rate for 15–19 year olds was 
5.84%, however the target has only been met by three of the four regional DHB groupings; the Northern DHBs’ 
access rate for 15–19 year olds is 5.01%.230 There are no published figures on access for 20–24 year olds, but in 
2013, 3.5% of the whole population accessed specialist mental health and addiction services,232 compared to 
around 1.5% in 1998. 233 
Over the past two decades, as more people have been accessing specialist services, the focus of key Mental 
Health Commission documents, such as Blueprint II, 234,235 and the Ministry of Health document, Rising to the 
Challenge: The Mental Health and Addiction Service Development Plan 2012–2017, 236 have broadened to 
address the needs of those who have mild to moderate mental health issues, recognising the benefits of early 
intervention in a person’s life course and course of illness, and on building resilience. While noting several 
improvements, such as a strong NGO sector, culturally specific services, and increased involvement of service 
users, family and whānau in planning and delivery, Rising to the Challenge identified challenges for mental 
health services. These included that New Zealand has one of the highest youth suicide rates in the OECD; there 
is variation in access to services, especially for children and youth; and there are limited and variable primary 
mental health responses, variable waiting times, variable integration between DHBs and NGOs, and also 
between primary and specialist services.236 
Rising to the Challenge has four overarching goals: using current resources more effectively; building 
infrastructure for integration between primary and specialist services; cementing and building on the gains in 
resilience and recovery for those with high needs, Māori, Pacific, refugees, people with disabilities and other 
groups; and increased access for infants, children and youth, adults with mild to moderate illness, and the 
growing older population.236 
Current mental health services 
This section summarises the 2014 Stocktake of Infant, Child and Adolescent Mental Health and Alcohol and 
Other Drug Services in New Zealand. 230 For more detail, including regional breakdowns, please refer to that 
document. 
The Mental Health Commission recommended infant, child and adolescent mental health services (ICAMHS) 
should receive 26% of total mental health funding, based on estimated need.229 In 2013, children 0–19 years old 
made up 27% of the New Zealand population. Infant, Child and Adolescent Mental Health/ Alcohol and Other 
Drugs (ICAMH/AOD) services received 13% of mental health funding.230 The 13% figure includes primary 
mental health funding for ICAMH. However, The Werry Centre noted that there are several unknown factors 
which make it difficult to assess the degree of underfunding: it is unknown what the relative cost of treatment of 
infants, children and adolescents is compared to adults; it is unknown what the cost impact on secondary 
services is of the increasing provision of primary health services; and it is also unknown how much provision of 
services for 17–19 year olds is provided by adult services.230 
The 20 District Health Boards (DHBs) provide a range of inpatient and community based ICAMH/AOD 
services. Auckland, Capital & Coast, and Canterbury DHBs provide regional Child and Adolescent Mental 
Health (CAMH) inpatient services. ICAMH/AOD services are also provided by non-governmental organisations 
(NGOs) and Primary Health Organisations (PHOs) funded by DHBs. From June 2013 to July 2014, 112 NGOs 
provided DHB funded ICAMH/AOD.  
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Table 162. Child and Adolescent Mental Health/Alcohol and Other Drugs Services in New Zealand, 2014 
Services ICAMH/AOD service providers 
Youth forensic 
DHBs: 
Northland, Auckland, Taranaki, Capital & Coast, Nelson Marlborough, West Coast, 
Canterbury, South Canterbury & Southern 
NGOs: 
Waikato: Nga Ringa Awhina O Hauora Trust 
MidCentral: Te Upoko O Nga Oranga O Te Rae 
Canterbury: Odyssey House Trust 
Southern: Adventure Development & Miramare Ltd 






Auckland, Hutt Valley & Canterbury; 14 additional DHBs provide Eating Disorder 
Services 
NGOs: 
Northland: Rubicon Charitable Trust 
Counties Manukau: Ohomairangi Trust 
Whanganui: Te Oranganui Trust 
Canterbury: St John of God Hauora Trust 
Southern: Miramare Ltd 
AOD school-based programmes 
Auckland: Odyssey House Trust: Amplify School Programme 
Counties Manukau: Odyssey House Trust: Stand Up; Youthline: AOD School Based 
Programme 
Conduct disorder service 
DHB:  
MidCentral DHB: CAMHS in collaboration with Group Special Education 
Peer support 
DHBs: 
Waikato, Whanganui, Capital & Coast, Wairarapa & South Canterbury 
NGOs: 
Counties Manukau: Raukura Hauora O Tainui Trust 
Bay of Plenty: Te Manu Toroa, Te Runanga Ngai Tamawhariua & Whakatohea 
Māori Trust Board 
Tairawhiti: Te Kupenga Net 
MidCentral: Te Upoko O Nga Oranga O Te Rae 
Canterbury: Depression Support Network. 
Services for Māori 
Two dedicated DHB Māori ICAMH services/teams: 
Counties Manukau: He Kakano Māori Mental Health Team 
Capital & Coast: Te Whare Marie Specialist Māori Mental Health Service 
Three DHB Māori services funded under adult services: 
Waitemata: Moko Māori Mental Health Service and Te Atea Marino Regional 
Māori AOD Service 
MidCentral: Oranga Hinengaro Māori Mental Health Services 
22 NGOs: 
Northland: Ngati Hine Health Trust 
Counties Manukau: Mahitahi Trust & Raukura Hauora O Tainui Trust 
Waikato: Hauora Waikato, Pai Ake Solutions Ltd, Raukawa Charitable Trust, Waahi 
Whaanui Trust 
Lakes: Te Utuhina Manaakitanga 
Bay of Plenty: Maketu Health & Social Services, Pirirakau Hauora, Manu Toroa, 
Tuwharetoa Ki 
Kawerau Health, Education & Social Services, Whakatohea Māori Trust Board 
Tairawhiti: Ngati Porou Hauora Charitable Trust 
Taranaki: Tui Ora Ltd 
Hawke’s Bay: Te Taiwhenua O Heretaunga 
MidCentral: Best Care (Whakapai Hauora) Charitable Trust, Te Runanga O 
Raukawa 
Nelson Marlborough: Te Kahui Hauora O Ngati Koata 
South Canterbury: Arowhenua Whānau Services 
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Table 161. Child and Adolescent Mental Health/Alcohol and Other Drugs Services in New Zealand, 2014 (cont) 




Three dedicated DHB Pacific ICAMH services - 
Waitemata DHB: Isa Lei Pacific Mental Health Service 
Counties Manukau DHB: Vaka Toa Pacific Island Team 
Capital & Coast DHB: Health Pasifika 
One DHB Pacific services funded under adult services: 
Waitemata DHB: Tupu Pacific Alcohol & Drug Service. 
NGOs: 
Counties Manukau: Penina Trust 
Waikato: K’aute Pasifika, Raukawa Charitable Trust 
Capital & Coast: Taeaomanino Trust 
Hutt: Q-Nique/WellTrust 




There are Asian services that are available to Asian people operating within DHBs which are funded under 
adult services: in Auckland; the Asian Mental Health Team, and Waitemata: the Asian Health Support 
Services which includes the Asian Mental Health Client Coordination and Support Service. 
Counties Manukau: Asian Mental Health Service which is mainly a coordination service providing advice on 






Nelson Marlborough & Canterbury 
NGOs: 
Capital & Coast: Refugee Trauma Recovery 
Southern: Miramare Ltd. 
*COPMIA and Early Intervention services not included in this summary. (p.24–26).230 
Youth Mental Health Project 
The Youth Mental Health Project (YMHP) consists of 26 initiatives targeting the needs of young people aged 
12–19 with mild to moderate mental health issues.237 
The four-year expected outcomes are: 
 Improved knowledge of what works to improve youth mental health 
 Increased resilience among youth 
 More supportive schools, communities and health services 
 Better access to appropriate information for youth and their families/whānau 
 Early identification of mild to moderate mental health issues in youth 
 Better access to timely and appropriate treatment and follow-up237 
The initiatives span several settings: health, family and community, school, and online. The Werry Centre 
summarises these as presented in Table 163. 
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Table 163. The Youth Mental Health Project Initiatives 
Health sector initiatives: 
 Making primary health care more youth friendly ($11.3 million over four years for GPs, School Based Health 
Services & Youth One Stop Shops) 
 Improving wait-times in CAMHS and follow-up primary care especially for young people with AOD concerns 
 Reviewing referral pathways actioned by the Ministry of Social Development 
 Reviewing alcohol and drug education programmes 
Family and community initiatives: 
 Providing mental health information for parents, families and friends (NGO sector) 
 Providing a whānau ora approach to youth mental health 
 Training for providers working with truants and disengaged young people (Ministries of Education and Social 
Development) 
 Ensuring young people have a say on the types of services they need (Ministry of Youth Development) 
School‐based initiatives: 
 Encouraging nurses in decile 3 secondary schools to use the HEEADSSS screening tool to increase access to health 
services and improve access to primary care services and referrals to mental health services. [deciles 1–2 already 
covered since 2008 (Denny et al., 2014)] 
 Training youth workers in mental health in low decile schools to work alongside existing health workers in schools 
with linkages to community based services (NGOs funded by Child, Youth and Family) 
 Trialling of the Check and Connect mentoring and monitoring programme for disengaged youth 
 Making schools more responsible for student well-being (Education Review Office, Ministry of Education) 
 Encouraging a positive culture in secondary schools with the implementation of Positive Behaviour School Wide 
(Ministry of Education) 
Online initiatives: 
 Providing accessible interactive computer based e‐therapy for mild mental health issues that can help reduce a 
variety of barriers to accessing services. 
 Improving youth‐friendliness of mental health resources. 
 Funding youth providers to keep their services technologically up to date via the Social Media Innovations Funds 
to enhance youth engagement. 
Source: The Werry Centre 230 (p.12) 
A recent formative evaluation noted that “the five largest initiatives focused predominantly on three outcomes: 
more supportive schools, communities and health services; early identification of mild to moderate mental 
health issues in youth; and better access to timely and appropriate treatment and follow-up” (p.56).237 
The formative evaluation found that: 
 The project is moderately comprehensive in its coverage and settings, with family settings less 
obviously targeted. 
 The initiatives are on track to achieve their intended goals, however: 
1) it is not known if the needs of Māori and Pacific youth are being met. Few initiatives have 
incorporated cultural components in design or implementation strategies. The review recommends that 
the project monitors whether initiatives adequately target and are being taken up by Māori and Pacific 
youth.  
2) there is no agreed monitoring framework to measure outcomes and most initiatives have not 
collected baseline data against which to measure improvement. 
 It has taken more time than expected to establish effective collaboration between agencies and 
programmes. Linking YMHP services to the wider primary care system was identified as a general 
issue.  
There are early signs that school based health services initiatives to treat mild to moderate mental health issues 
are having a positive effect. Specifically, Denny and colleagues report “there was less depression and suicide 
risk among students in schools that had higher levels of health services”(p.4).158  
The initiatives have been designed and set up to deliver value, but there are not consistent metrics to measure 
individual initiative outcomes (clear baselines and budget mechanisms and meeting needs of target groups). A 
KPMG ‘value for money’ analysis identified the Primary Mental Health initiative and the CAMHS and Youth 
AOD Access initiative as requiring significant improvement. For the former, “a key challenge is to understand 
how the level of funding provided will achieve the overarching desired outcome, and whether this will be 
sustainable over the long term”(p.58).237 For the latter, there is a “lack of knowledge of both take-up and the 
sustainability and impacts of outcomes” (p.58).237  
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The Children’s Action Plan 
The Children’s Action Plan is an interagency service response (Ministry of Social Development, Ministry of 
Health, Ministry of Education, Ministry of Justice, NZ Police, the Ministry of Business, Innovation, and 
Employment, and Te Puni Kōkiri) targeted at vulnerable children. The key features are: a Vulnerable Children’s 
Hub - a single point of contact for frontline professionals with concerns about a vulnerable child, in 
circumstances when concerns are not serious enough to contact Child, Youth and Family or the Police directly; 
Children’s Teams - community professionals from across sectors, tasked with ensuring children at risk are 
identified early, assessed and receive appropriate services (including mental health and addiction services); the 
Vulnerable Kids Information System (ViKI), an electronic system to record and manage concerns about 
vulnerable children, and Common assessment and planning – a single plan, based on a whole-of-child 
assessment, co-ordinated by a lead professional.238 
The Children’s Action Plan is in its early stages, so there are no evaluations to date. The recent Report to the 
Vulnerable Children’s Board – March 2015 notes that establishing the Children’s Teams has taken longer than 
anticipated due to the realisation that increased engagement with local communities was required, since the 
communities held the resources, and success depended on their will to succeed.239  
Six Children’s Teams are currently operating, in Whangarei, Rotorua, Horowhenua/Otaki, Marlborough, 
Hamilton and Tairāwhiti. There are plans to establish four more teams, in Eastern Bay of Plenty, Whanganui, 
Christchurch, and Clendon/Manurewa/Papakura.238  
New Zealand Suicide Prevention Strategy 
The New Zealand Suicide Prevention Strategy 2006–2016 comments that the previous suicide prevention 
strategy had a major focus on the 15–24 age group, and it is now appropriate to broaden the focus to all ages, 
since 80% of suicides in New Zealand occur in those aged 25 years and over.240 The strategy notes that risk 
factors for youth suicide vary to those for older adults. Mental health issues are important for both age groups, 
but family related issues and trauma play a more significant role for youth.240  
The New Zealand Suicide Prevention Action Plan 2013 – 2016 outlines 30 actions, grouped under 11 areas.241 
Youth and young people are specifically mentioned in relation to:  
 Supporting community-based organisations in creating opportunities for young people to be involved 
in community development projects (Ministry of Youth Development to lead) 
 Improving services and support for children and young people in contact with Child, Youth and Family 
(CYF), through specialist training to CYF carers and all care and protection and youth justice 
residential staff (CYF to lead) 
 Ensuring information, tools and resources on good cyber citizenship and reducing cyber-bullying, 
continue to be available to schools, parents and young people (Ministry of Education to lead).  
Issues identified in the literature 
Barriers to accessing mental health services 
A systematic review of factors that young people perceived to make health care youth-friendly found that 
accessibility, staff attitude (respectful and supportive, honest, trustworthy and friendly), communication (clarity 
of information and listening skills of the clinician), medical competency, guideline driven care (confidentiality, 
autonomy, and well-managed transition to adult health care), age appropriate environments, youth involvement 
and health outcomes were central to young people’s positive experience of care.242 This review was of health 
care in general, rather than mental health specifically, although these factors are universal.  
Systematic reviews identified perceived barriers to help-seeking in young people, including severe depressive 
illness, lack of perceived need and poor mental health literacy, a preference for self-management and self-
reliance, structural access issues (location of services, transport, cost, time), perceptions that treatment is 
ineffective, fear of being hospitalised, stigma and embarrassment (perhaps more prevalent for males), difficulty 
trusting adults, and perceived lack of culturally competent services (for example for sexual minority or ethnic 
minority youth).243-245 Factors that encouraged help-seeking were positive past experiences, social support and 
encouragement from others, and the number of community mental health services for adolescents.243-245  
Specifically regarding suicidal individuals, a review of factors and interventions that influence help-seeking 
found that for those with suicidal ideation, plans and/or attempts in the past year, only around 28% of 
adolescents and young adults sought mental health services.244 The review found that limited progress has been 
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made in developing and testing interventions to improve help-seeking and service utilisation. Four types of 
interventions were identified: psychoeducation; peer training; gatekeeper training; and screening. Apart from 
screening interventions, behavioural changes in help-seeking have rarely been assessed, so the research has done 
little to progress improvements in treatment engagement.244 In the North American context, a meta-analysis 
found that from 1968 to 2008, attitudes towards seeking mental health services among University students have 
become increasingly negative.246  
In the New Zealand secondary school context, 82% of students with significant mental health issues had not 
sought help from a general practitioner (GP).247 Rates of help seeking increased with age for girls, but decreased 
for boys. For students, factors associated with help-seeking behaviour were having a teacher get to know them 
and having a non-family adult to talk to.247 
Stigma has been the focus of study internationally248,249 and nationally.250 A systematic review found that youth, 
ethnic minorities, men, military and health professionals were more likely to be deterred by stigma.248 Stigma 
and silence surrounding mental health problems has also been identified as an issue for staff and students in 
universities.251 A review of anti-stigma interventions for school and college students found that knowledge and 
attitudes can be influenced by education, that an education approach was more successful than direct contact 
with someone who has a mental health problem, that impacts were generally short-term, and that studies did not 
assess behavioural outcomes.249 
In New Zealand, a review of the anti-stigma programme “Like Minds, Like Mine” based on 1135 survey 
responses (17% from 16–24 year olds) from mental health service users found that over half reported 
improvement in discrimination over the past 5 years, and 48% thought the “Like Minds, Like Mine” programme 
had assisted “moderately” or “a lot”.250 Despite this, 89% had experienced at least “a little” unfair treatment in 
the past year due to mental health problems. 
Transition from child and adolescent to adult services 
The Office of the Prime Minister’s Science Advisory Committee publication Improving the Transition: 
Reducing Social and Psychological Morbidity During Adolescence notes that the regions of the brain associated 
with higher levels of executive functioning, such as judgement, impulse control, managing strong emotion, and 
task initiation and management only fully mature well into the 20s.252 Adolescence and emerging adulthood is a 
more prolonged and unstable developmental stage than previously appreciated.252-254 Adolescents are “more 
vulnerable to poor decision making and risk taking behaviour and… more sensitive to reward inducing stimuli 
such as peer pressure, drugs and alcohol” (p.24).252 Young people moving into adulthood with serious mental 
health conditions often have poor functioning, high rates of homelessness, arrests, school dropout and 
unemployment.255  
Lamb and Murphy give the context to the differences in theory and practice between CAMHS and adult mental 
health services (AMHS), often referred to as the ‘CAMHS – AMHS divide’.256 CAMHS caters for a wider range 
of clinical presentations, and circumstances, such as those in out-of-home care, young people involved with the 
criminal justice system, and young people who have experienced abuse and neglect. There are different training 
programmes for professionals working in each service, care between CAMHS and AMHS is often provided by 
different organisations, and governments often have separate policy and plans for each service.256. Young 
people, their families and carers want their views to be taken seriously, want to participate actively, want good 
information, consistent support from a key worker, and want flexible, non-stigmatising community-based age-
appropriate services.256 When moving from CAMHS to AMHS there is a change in service philosophy 
regarding the role of family, and there is also a gap for those who have been under CAMHS but will not qualify 
for AMHS.256  
Specialist mental health services have traditionally followed a paediatric-adult split, with child and adolescent 
services catering for young people “until the largely arbitrary ages of 16 or 18 years”. (p.103)257 McGorry and 
colleagues label the 18 years old boundary as “artificial”, resulting in “fundamentally flawed” service 
structures.254 The Ministry of Health has previously stated that this age limit should be applied “positively and 
with sensitivity, rather than restrictively”(p. 2).228 However, institutions are often bound by bureaucratic and 
legal definitions of adolescence.258 Jones notes “from the perspective of brain development, services may 
require re-engineering to provide an appropriately seamless and developmentally sensitive approach to 
individuals on the two-decade journey from puberty to adulthood” (p.s9).253 Several publications recommend 
aligning institutional and developmental transitions to achieve better mental health outcomes for young 
people.254,255,257-262 
Newman and Birleson argue for a developmental approach, but note that youth mental health models that do not 
conform to the traditional CAMHS age boundaries raise the following questions. How separate should the 
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services be from AMHS? What are the most appropriate age boundaries? How should these services be 
integrated to minimise transition problems? What is the most cost-effective balance of community-based and 
hospital based services? Should services and teams be organised based on presenting problems/disorders or 
regionally or developmental phase-specific or treatment specific?262 They note there is minimal evidence to 
date, so debate has been mostly “opinion based”(p.95).262  
The Ministry of Health and a recent systematic review of the literature on transitioning to adult services 
concluded that there is a lack of high-quality evidence of transitional care models.263,264 Some themes from the 
19 studies in the review were that services needed to address stigma, provide accessible, age-appropriate 
services, and that parents/carers wanted more involvement with adult services.  
McGorry and colleagues provide examples, from Australia, Ireland and the UK, that are redefining service 
structures for young people up to 25 years of age.254 Headspace is a primary care model for youth mental health 
in Australia, which promotes and supports early intervention for young people aged 12–25 years.254,265 The 
central feature is the creation of multidisciplinary, youth-friendly, highly accessible ‘one-stop shops’ with close 
links to specialist services and schools, and which complement existing primary care services. Preliminary 
evaluation results have been positive. Another Australian example of organising care according to 
developmental transition ages is Orygen Youth Health (evolved from the Early Psychosis Prevention and 
Intervention Centre (EPPIC) model), a Melbourne organisation providing specialised early intervention to 15–
25 year olds with severe or complex mental health presentations. This model will be scaled up nationally in 
Australia to provide 16 early psychosis services catering for 15–24 year olds, and linked, where possible, to 
Headspace. The expansion of the EPPIC model is the subject of intensive debate regarding its merits.266  
In Ireland, Headstrong, the National Centre for Youth Mental Health, implemented the Jigsaw model of service 
delivery, which caters for 15–25 year olds.254 This model involved youth in the design, implementation and 
review of programmes, with the aim of making them accessible and non-stigmatising. The Jigsaw model 
partnered with key stakeholders, such as CAMHS, AMHS, primary care, youth sector services, education and 
local development groups. A commitment has been made by the Irish government to expand the service to 12 
sites. 
In Birmingham, England, the Birmingham and Solihull Mental Health Foundation Trust, in partnership with the 
Prince’s Trust (a youth agency providing education, skills training and entrepreneurship programmes for young 
people), created the youth service programme, Youthspace, which delivers mental health services to young 
people up to 25 years of age.254 The development of Youthspace involved extensive consultation with young 
people, and focuses on social inclusion and employment. Appelton and Pugh summarise further UK examples. 
267 Young and colleagues point out that a national review of UK CAMHS concluded that transition should be 
flexible to the needs of young adults rather than focusing on age. 268 
New Zealand also has examples of models of care that span the traditional CAMHS – AMHS divide. One of 
these is Evolve Wellington Youth Service, part of Well Health Trust Primary Health Organisation.269 Evolve is 
a Youth One Stop Shop for young people aged 10 to 25. The clinical team has 6 nurses, (3.6 Full-time 
equivalents (FTEs)), six doctors (1 FTE), a social worker, two youth workers, and counsellors. Relationships 
have been built with secondary mental health services, and referral and discharge meetings are held at Evolve 
with clients’ key worker to improve transitions.  
Sukhera and colleagues condense transition models into two categories: Age-continuum (of which Headspace, 
Orygen, Jigsaw and Youthspace are examples), which are designed for first episode presentation; and Shared 
management, which utilises transition coordinators, and targets young people with moderate to severe 
disorders258. There are pros and cons for both models compared to not using a transition model: age-continuum 
has potential cost savings, is youth focused and community based, but has high initial costs and increased 
transition points.258 Shared management improves attendance, has less youth lost to follow up and has positive 
outcome data, but requires time and financial resources, and is not ideal for mild disorders or first 
presentations.258  
Sukhera notes that a previous study 270 found “consistency in service, continuity of care, seamless transitions, 
clarity of roles, information sharing, alignment of assessment processes, resolution of funding issues, joint 
working prior to transfer, cooperation and flexibility and user and caregiver involvement were among the main 
factors” in ensuring a smooth transition from CAMHS to AMHS (p.3).258 
The Ministry of Health published Transition Planning Guidelines for Infant, Child and Adolescent Mental 
Health/Alcohol and Other Drugs Services 2014 as a guide to assist child and adolescent services in developing 
and implementing effective transition planning processes for young people transitioning from their service.264 
The guidelines are intended to cover various reasons for transitioning, including young people having achieved 
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the agreed goals of treatment, no longer wishing to continue with treatment, and transitioning to adult mental 
health services. 
The guidelines list key aims: 
Service provision is matched as closely as possible to the needs of the young person and delivered by the most 
appropriate service/s to meet those needs  
The young person and their family/whānau are the key decision-makers regarding the services they receive  
Care is delivered across a dynamic continuum of specialist and primary level services with decisions based on 
the needs and wishes of the young person and their family/whānau and not service boundaries  
Processes are in place to identify and respond early should the young person experience a re-emergence of any 
mental health or AOD concern  
ICAMH/AOD service resources are used efficiently, with regular reviews of the flow of young people through 
the services. (p.1) 
The guidelines identify six principles from the transition planning literature: 
 Transition planning is a structured process that begins at entry 
 Health services should actively encourage young people to be involved in all aspects of planning for 
their treatment and follow-up 
 A whānau/family inclusive approach should be encouraged whenever possible 
 Clear, effective and timely communication is required between the service, the young person, the 
whānau/family, primary care and other key stakeholders 
 A ‘stepped care’ approach, which is where services intervene in an optimally supportive level, 
depending on level of need, enabling a young person to enter and exit the service system at any point 
depending on their level of need  
 Shared decision-making, involving the young person and their whānau/family, and members of the 
multi-disciplinary team 
The New Zealand guidelines264 are consistent with the shared management model identified by Sukhera,258 but 
they do not contain reference to transition coordinators. Shared management models are a good way of meeting 
the needs of children with an established relationship with services, but not as good as age-continuum services 
for first presentations. The Government’s YMHP initiative to support ‘one stop shops’ is an example of age-
continuum services, but the 12–19 age range of the YMHP is not consistent with developmental age range 
evidence.  
Workforce 
Workforce development has been identified as an issue from at least 1994, particularly a lack of Māori mental 
health workers.225 Workforce issues have been previously documented by the Werry Centre, who in 2006 made 
38 recommendations to address them.271 Rising to the Challenge notes that there is also need to enhance the 
skills and confidence of the primary care workforce to be able to deliver brief, effective interventions.236 The 
Werry Centre notes there are still significant workforce shortages in the mental health sector, with a total 
vacancy rate of 8%, mostly in DHB clinical roles, and estimates that an additional 202 full time equivalent 
positions need to be filled to meet the Mental Health Commission’s Resource Guidelines.230 It also notes that 
while the shortages are acknowledged by services, there is a shortage of qualified clinical staff, and barriers to 
up skilling staff.230  
The Werry Centre recommends:230 
 Continued investment in the targeted recruitment of the workforce across all roles for Māori and other 
ethnicities 
 Recruiting new graduates and training them in specialist ICAMH services 
 Working to retain and develop the current ICAMH/AOD workforce 
 Increasing the focus on developing the NGO workforce, since 25% of all clients are seen there 
 Continuing to develop primary care services, since this may reduce demand on CAMH/AOD services 
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 Ensuring local schools, Youth One Stop Shops, PHOs, NGOs and DHBs are part of the strategic 
planning process 
 Providing enhanced training, especially to those in the unregulated workforce, so they can support the 
specialist workforce 
 Increasing dual clinical/cultural competency in mainstream services 
The role of primary care 
The Mental Health Commission, through Blueprint II, called for an increased role for primary health in mental 
health services.234,235 For youth, Blueprint II called for increased screening and assessment of psychological and 
social functioning, use of brief problem solving consultations, motivational interventions or talking therapies 
such as Cognitive Behavioural Therapy (CBT) and phone support, and monitoring progress, especially for those 
on medication.234,235 Blueprint II also called for increased availability of specialist advice and support. 
Rising to the Challenge, the Ministry of Health’s current mental health and addiction service development plan, 
calls on primary care to view responses to mental health needs as being as equally important as responses to 
physical health needs.236 The Ministry of Health calls on primary care providers to work closely with DHB and 
NGO services to implement a seamless and well-integrated stepped-care approach to improve accessibility. As 
part of this, the Ministry of Health calls on youth specialist services to provide support and advice to primary 
care, such as: 
 Consultation and liaison services (including one-off assessments)  
 Prompt telephone advice  
 Access to advice via telemedicine for primary care and general health teams in rural areas  
 Urgent assessments for young people and their families and whānau in crisis  
 Shared care arrangements that allow young people and their families and whānau to move quickly and 
efficiently between primary care and specialist services as their needs dictate  
 Delivery of specialist services from schools and primary care sites, including youth one-stop shops, in 
combination with processes to ensure collegial working between specialist services, primary care and 
school-based guidance and health services  
 Discharge planning that ensures effective hand-over to an identified primary care provider, with 
provision for on-going specialist advice as needed.236 
The Ministry of Health asks primary care to build the skills and knowledge of staff so that they can: 
 Identify emerging issues early, including by screening 
 Involve and support family, whānau and friends 
 Provide advice or brief interventions to address emerging mental health and AOD issues 
 Recognise when specialist advice or referral is needed.236 
The Ministry of Health also calls on primary care to implement youth-centred models of care to improve the 
responsiveness and effectiveness of mental health and AOD services, “including improving the integration with 
school-based health services, co-location of services in ‘youth one-stop-shops’ and wherever possible having the 
flexibility to respond to ‘walk ins’” (p.43).236 The sections that follow discuss some of the issues raised by 
Blueprint II and the Ministry of Health regarding calls to action for primary care. 
Screening 
Screening for paediatric mental health problems and adolescent depression is recommended in international 
literature, although Wissow and colleagues in a recent systematic review of universal mental health screening in 
paediatric primary care found the literature had few details regarding how screening tools should be used by 
clinicians, including how to explain their purpose and confidentiality to clients, how they should be 
administered, and how to explore screen results.272 Another primary care focused systematic review of screening 
for and treatment of suicide risk by O’Connor and colleagues found that primary care screening tools have 
limited ability to detect suicide risk in adolescents, but might identify some adults at risk.273 The review also 
found that effective interventions for high-risk adolescents are not proven. Stockings and colleagues conducted a 
systematic review and meta-analysis of reliability, validity and diagnostic utility of symptom screening scales 
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for detecting major depressive disorder in children and adolescents.274 The review found that internal reliability 
was good, sensitivity and specificity were moderate and positive predictive power for identifying true cases was 
mostly poor, so may result in many false-positives.  
Wissow and colleagues found that screening can increase willingness of parents, youth and primary care 
providers to discuss mental health issues.272 The review found there is some evidence that parents and youth 
prefer screening that is framed as universal, confidential and designed to improve communication. Factors that 
promoted effective screening were: informing patients about clinical goals; using plain language; and discussing 
confidentiality. Wissow and colleagues also noted that there are risks involved in screening when there is 
insufficient support for clinical decision making, first-line treatment or linkage to specialty care.272  
An earlier review of screening young people for emotional disorders by Sanci and colleagues found that 
improved outcomes and cost-effectiveness was not demonstrated.275 The review found that readiness for care 
and availability of effective treatments may also affect results. Debated potential harms of false positives are 
related to stigma, and the increased burden on the health system, although the review found no strong evidence 
for these.275 Sanci and colleagues conclude that if screening in primary care is to be effective, it needs to be 
paired with facilitated access to treatment, and best results are obtained through collaborative care models.275 
Consultation liaison and collaborative models 
In the above discussion, two models of care have been mentioned: consultation liaison (The Ministry of Health 
calls on specialists to provide this to primary health care)236; and collaborative models (Sanci and colleagues 
found that when screening is paired with this model, it delivers the best results).275 Three recent systematic 
reviews define these two models of care and assess their effectiveness.276-278 Two are Cochrane reviews, and 
used the traditional child – adult age boundary of 18 years, with the bulk of the studies involving adults,276,278 
while the other, by Asarnow and colleagues, used a search criteria of up to 21 years old.277 
In the consultation liaison model, the primary care provider has the central role in delivering care, with the 
mental health specialist (psychiatrist, mental health nurse, psychologist, social worker, or a team of mental 
health care providers) providing consultative support.278 A collaborative model involves a number of health 
professionals (often a medical doctor, a case manager with training in depression and anxiety, and a psychiatrist 
or other mental health specialist) working together to improve the mental health outcomes of the client.276 
Gillies and colleagues found that there was no data that could inform consultation liaison practice for children 
and adolescents.278 However, for the adult population there was evidence consultation liaison improved mental 
health, satisfaction with care, adherence to treatment, particularly in those with depression, and improved care 
by primary providers.278 There was also some evidence that consultation liaison may not be as effective as 
collaborative care.278  
In adolescents with depression, Archer and colleagues found that collaborative care was significantly more 
effective than usual care at six months when measured using dichotomous outcomes, but not when using 
continuous outcomes.276 For the adult population, collaborative care was associated with significant 
improvement in depression and anxiety outcomes compared with usual care.276  
Asarnow and colleagues 2015 systematic review and meta-analysis of integrated care (both collaborative care 
and other forms of integrated care, including consultation and colocation) is the only one to date for child and 
adolescent mental health and substance use.277 They found integrated care models had an advantage over usual 
care. Overall, 66% of youth experienced better depression, anxiety and behavioural outcomes (a grouping that 
included conduct, attention and hyperactivity) following integrated treatment. Collaborative care had the 
strongest effect; 73% of youth experienced better outcomes. Treatment interventions had a greater effect than 
prevention interventions, which had a small, not statistically significant effect. Substance use treatment 
intervention effects were also not statistically significant. Asarnow and colleagues argue that it is not enough to 
adopt a collaborative care model; treatments with demonstrated efficacy and effectiveness need to be used.277 
Collaborative care has been criticised for being unlikely to be cost effective.279 Kates and colleagues describe a 
long-running working example from Canada, however no cost-effectiveness comparison has been done with 
primary practices not involved in the programme.280  
Taylor and Briggs describe a collaborative model of care in South Canterbury, New Zealand, where the Mental 
Health Brief Intervention Service allows primary care physicians to refer patients with mild to moderate mental 
health problems to up to 4 free sessions with a mental health clinician (nurse, social worker or occupational 
therapist).281 Survey results from physicians found that they thought the programme improved outcomes by 
facilitating treatment for patients with depression, and reduced the need for referrals to secondary mental health 
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services. The authors do not provide information regarding the age of patients participating in the service, and 
do not discuss youth, adolescent or young people’s mental health.  
GP skills and training 
General Practice care has strengths in continuity of care and frequency of contact, so educating GPs to perform 
brief assessments and management techniques could facilitate GPs to take the lead in early intervention in youth 
mental health and addiction.282 Brown and Wissow describe a framework of skills required by primary care staff 
that includes: cross-cutting skills to build therapeutic alliance; broad-based, brief interventions for major clusters 
of mental health symptoms; and evidence-based interventions for diagnosis specific disorders.283 Brown and 
Wissow, who are from the United States, are unaware of a curriculum for primary care staff that includes 
training in all three levels.  
The factor within mental health treatment that has the greatest impact on outcomes is the therapeutic 
alliance.284Timimi and colleagues note that outcomes achieved by mental health interventions are similar to 
those achieved 30 years ago, and there is little evidence to support that any particular components of a 
therapeutic model are actually crucial. They advocate for a child and adolescent mental health service model 
that incorporates patient feedback on outcomes of therapy, and building the therapeutic alliance.284 
Kolko and Perrin summarise some efforts to improve clinical outcomes through training primary care providers 
(PCPs).285 They found some success regarding outcomes for children with ADHD following PCPs receiving 
focused academic detailing (face-to-face, non-commercial educational outreach training on evidenced-based 
care, commonly relating to prescription medication), and mixed results following training in broad health 
management skills, such as the cross-cutting skills mentioned above, or for training encouraging greater use of 
screening for depression.285 Ambresin and colleagues found that providing a 9 hour training session on 
screening and motivational interviewing and two follow-up visits to practices was no better than a brief standard 
talk at increasing GPs’ detection of mental health needs among young people.286 The authors concluded that 
further research on other barriers to screening young people in primary care should be done before further 
training interventions. 
In the New Zealand context, bpacnz have recently published the first of a series addressing mental health in 
young people.287 This article has a section on maximising engagement with young people in primary care, and 
includes information on continuing medical education resources and courses available in New Zealand. Training 
in youth mental health for frontline health and social sector staff is also offered as part of The Youth Mental 
Health Project.288 
School-based health services 
A systematic review of the effect of school environments on the emotional health of adolescents found limited 
evidence that the school environment has a major influence on mental health, although there was some evidence 
that individual perceptions of school connectedness and teacher support were associated with better emotional 
health.289 In a New Zealand study of school influence on behavioural and emotional health symptoms, Denny 
and colleagues also found that overall, school effects were modest.290 The study used survey data to measure the 
association between six school environment measures and two measures of provision of health and welfare 
services with alcohol problems, depressive symptoms and suicide behaviours (among other risk behaviours). For 
the first two of these three behaviours or symptoms, only one of the eight measures was found to be associated. 
For alcohol problems, ‘school climate’ was associated, and for depressive symptoms, ‘wellbeing of staff was 
associated. None of the measures were associated with suicide behaviours. 
Surveys of New Zealand secondary school students have revealed that between 2007 and 2012, there appear to 
have been slight increases in the proportion of students reporting low mood, depressive symptoms, emotional 
symptoms, hyperactivity, peer problems, and, self-harm (for those over 15 years), and there has been no change 
in reported suicidal ideation and attempts.291 This last point is of particular concern, since the Ministry of Health 
recently noted the New Zealand youth suicide rate was the highest in the OECD.292  
As part of a strategy to improve the mental health of youth, the New Zealand government currently funds school 
nurses or school-based health services in decile 1–3 secondary schools, teen parent units and alternative 
education facilities.158 A recent review by Denny and colleagues revealed considerable variability in the 
provision of health services to New Zealand schools.158 Twelve percent had no services other than the minimum 
first aid provisions. The review analysed survey data on the health and wellbeing of students at schools with and 
without services and found that “there was less depression and suicide risk among students in schools that had 
higher levels of health services” (p.4).158 Services associated with less depression and suicide risk were: having 
health professionals on site; higher health professional time per week per student; health professionals trained in 
youth health and well supported by peer review; and where health professionals were well integrated with the 
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school and local community.158 The review also found that students in schools with health services reported less 
hospital accident and emergency department use. 
Primary care level interventions 
In this section, primary care is defined broadly, including the settings of general practice, school, university and 
community settings. This is because the systematic review literature is sometimes ordered by illness category 
(Alcohol and drug interventions, anxiety and depression interventions, or all mental health interventions) in a 
combination of settings, and sometimes structured by settings, covering all mental health interventions. Also, 
there is a growing interest in computer and internet interventions (e-interventions), which are sometimes 
reviewed separately, and sometimes included with face-to-face interventions. This section will begin by 
summarising findings of systematic reviews based on the area of mental illness, starting with alcohol and other 
drug interventions. The next section will focus on computer and internet based interventions (e-interventions), 
which is a growing research area. There is some overlap with respect to mental illness in this final section, since 
e-interventions are now applied to various mental health conditions. The main settings covered are general 
practice, other health care, and education. These are not given separate sections, since much of the literature is 
organised by specific mental illness or broad age range, rather than by setting. Where a systematic review has 
focused on one setting, this will be noted.  
The research literature makes a distinction between universal, selected and indicated interventions.293 Universal 
interventions are applied to a whole population, such as a whole school or classroom; selected interventions 
target a subgroup deemed to be at higher-risk of developing symptoms, and indicated (also called ‘treatment’) 
interventions target people already exhibiting symptoms. Selected and indicated intervention studies are also 
sometimes referred to informally as ‘targeted’ interventions. Universal, selected and indicated interventions are 
complimentary, and schools are an ideal setting to implement a combination of all three.293  
Alcohol and other drugs interventions 
The Ministry of Health has asked for primary care to provide brief interventions to address emerging mental 
health and AOD issues.236 The international literature focusing on brief interventions has a strong focus on 
alcohol and other drug use. Several major US organisations recommend to follow the screening, brief 
interventions and referral to treatment (SBIRT) model, which has been shown to reduce alcohol consumption 
among adults when delivered in primary practice.294 A systematic review focusing on SBRIT for alcohol and 
drug use in adolescents found that there was limited evidence for effectiveness, and called for further 
research.295 The review included one study in general practice, several in schools and several in emergency 
departments. 
A 2015 systematic review and meta-analysis by Tanner-Smith and Lipsey, also focusing on brief alcohol 
interventions, included 185 studies and found modest but significant reductions in alcohol consumption and 
alcohol-related problems in adolescents (11–18 years), and smaller reductions for young adults (19–30 years).296 
The meta-analysis was used to model the hypothetical profile of characteristics of the most effective 
interventions. For adolescents, this is a single 15 minute motivational enhancement therapy (MET) session 
delivered in school that includes decision balance, goal-setting and norm referencing, and would not include 
blood alcohol concentration information, basic education/information, or personalised feedback. 
According to the National Institute on Drug Abuse, MET “is a counseling approach that helps individuals 
resolve their ambivalence about engaging in treatment and stopping their drug use. This approach aims to evoke 
rapid and internally motivated change, rather than guide the patient stepwise through the recovery process. This 
therapy consists of an initial assessment battery session, followed by two to four individual treatment sessions 
with a therapist. In the first treatment session, the therapist provides feedback to the initial assessment, 
stimulating discussion about personal substance use and eliciting self-motivational statements. Motivational 
interviewing principles are used to strengthen motivation and build a plan for change”.297  
Tanner-Smith and Lipsey found that for young adults, the most effective hypothetical profile of an intervention 
would be a self-administered computerised expectancy challenge intervention conducted on a university 
campus, including blood alcohol concentration information, decisional balance, goal-setting, and money/cost 
information.296 It would not include basic education/information or norm referencing. This is consistent with a 
systematic review by Foxcroft and colleagues, which found that social norm interventions were not effective 
enough to reduce alcohol misuse enough tertiary students.298  
For both adolescents and young adults, Tanner-Smith and Lipsey found that the worst-case scenario included 
multi-session interventions, and delivery in an emergency department (as opposed to school or university 
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campus, primary care or self-administered).296 While there are some commonalities between the profiles for 
adolescents and young adults, this review also illustrates that interventions are likely to be most successful when 
they tailor the settings, methodologies and content to the particular age-group. However, the meta-analysis 
indicated that the effects of brief alcohol interventions were similar across different formats (computerized, non-
computerized, one-on-one, and group).296 
A systematic review on alcohol screening and brief intervention for adolescents (10–21 years of age) concluded 
that “despite an increasing interest in applying screening and brief interventions to an adolescent population, 
there are no clear indications of which target population, setting, screening tool or intervention approach can be 
recommended”(p.210).299 Most of the interventions were in acute medical or educational settings, and the 
review recommends further research to be done on adolescent specific health settings. 
Two systematic reviews have focused solely on school-based alcohol interventions, and don’t have a specific 
focus on brief interventions.300,301 One was of universal school-based prevention programmes, and found a small 
but positive effect, regardless of the intensity of the programmes.300 This effect was only found with studies that 
recorded continuous outcomes (frequency and quantity of alcohol use), but no effect was found with studies that 
measured categorical outcomes (proportion of students who drank alcohol). Age and gender were not 
moderators for effectiveness. The review found positive outcomes a year after completion of the intervention, 
but no significant findings beyond one year post-intervention.300  
The other systematic review with a focused solely on school-based interventions, which included universal and 
indicated interventions, and found that some may be effective in reducing alcohol use. On average, the 
interventions were associated with 1.4 days reduction in drinking in the past month. 301 The review found that 
the most effective methodology was motivational enhancement therapy, and that individual, rather than group 
implementation was more effective. The authors warn that some therapies that work on an individual level may 
not be successful when used in groups. They speculate that this may be due to deviancy training; however, they 
also note that group interventions did not tend to use the most effective methodology - motivational 
enhancement therapy, so it may be successful if this methodology is incorporated.  
In the New Zealand context, Gifford and colleagues tested the feasibility of routine alcohol screening in primary 
care for those aged 15 and over.302 Data and analysis were not reported separately for 15–24 year olds. For the 
general population, over an eight month period in Whanganui general practices, 43% of patients were screened, 
24% were drinking above recommended levels of the Alcohol Advisory Council of New Zealand, and of those, 
36% received brief advice or referral. Behavioural outcomes were not assessed. The authors argue that the study 
demonstrated primary care can “routinely query patient alcohol use and offer brief advice” (p.17).302  
Sellman and colleagues argue that the Whanganui primary care example is important, since increasing the 
availability of brief interventions for heavy drinkers is part of the World Health Organization’s measures to 
reduce alcohol harm, summarised as the 5+ Solution.303 However, they argue that it may require a 90% 
screening rate across 90% of practices in New Zealand for there to be an impact on public health. Sellman and 
colleagues also point out that the Whanganui intervention was well funded and resourced, and had good 
leadership, yet still only managed to reach 43% of patients.304 In an international context, Heather discusses 
whether general practice screening and brief intervention can lead to population-level reductions in alcohol-
related harm, and makes the same points: that if success is possible, high screening rates and implementation of 
environmental alcohol control measures will be needed.305  
Other drugs 
One systematic review of primary prevention of cannabis use in youth and young adults found that primary 
prevention programmes can be effective, but effect sizes are often small or not significant.306 The authors also 
found that universal multi-modal approaches (which utilize family, peer, community, and school-based 
components) may be better than uni-modal or targeted interventions; non-teacher facilitators or multiple 
facilitators may be more effective than using teachers only; programmes involving early and middle adolescence 
may yield results, albeit small, whereas late adolescence may not be effective; programmes with booster 
sessions were generally more effective; and, inconsistent with some previous cannabis research, shorter 
interventions may be more effective than longer ones.306 Apart from e-interventions for cannabis use, which are 
discussed in a later section, no systematic reviews of interventions for youth and young adult other drug use 
were found in the literature.  
The Ministry of Health has recently published New Zealand Practice Guidelines for Opioid Substitution 
Treatment 2014, which while not specifically directed at young people, is relevant to this group. The guidelines 
also covers the effects of adult use of opioids on family members who are children.307 
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Other mental health intervention studies 
In the past few years, several systematic reviews or meta-analyses assessing the effects of adolescent and youth 
interventions for various mental health issues have been published, including for preventing depression,308-313 
anxiety,308,309,311-313 stress,314 and eating disorders.312 Three of these reviews exclusively cover school-based 
interventions,308,309,312 one covers university students,314 and the other reviews were not limited to a specific 
setting. No systematic reviews were found in the literature of the last five years that exclusively focused on 
general practice interventions for mental health issues for youth or young adults. 
One systematic review illustrated that not all studies purporting to be prevention interventions are correctly 
defined, and many have no effect.312 The review of universal school-based studies defined a ‘prevention effect’ 
as one where the control group has increased symptoms or cases at time of follow-up. If the intervention group 
showed reduced symptoms and cases at the time of follow-up, these studies were defined as ‘treatment studies’. 
Of 18 depression prevention studies, three demonstrated prevention effects, eight demonstrated treatment effects 
and seven demonstrated no effects. Of four anxiety prevention studies, none demonstrated prevention effects, 
and four demonstrated treatment effects. Of 14 eating disorder interventions, three demonstrated a prevention 
effect, five demonstrated a treatment effect and six demonstrated no effect. Another systematic review of 
universal school-based prevention interventions, as opposed to selective or indicated interventions, found that 
the majority of interventions for depression (65%) and anxiety (73%) were effective, however effect sizes were 
small.308 
Two meta-analyses examined universal, selective and indicated interventions for depression.309,311 Depression 
intervention effect sizes in these reviews followed a gradient from smallest effect with universal, to greatest 
effect with indicated interventions. Nehmy and Wade note that for universal prevention programmes, a small 
effect size is to be expected, especially compared to selected and indicated interventions.312 The authors explain 
this is because universal interventions by definition, are working with healthy individuals, so there is less scope 
for change or improvement in participant and control groups compared with selected or indicated interventions. 
Selected or indicated interventions are, by definition, working with participant and control groups who are either 
at high risk of developing symptoms or symptomatic already, and therefore have more scope to show 
measurable changes from baseline. Decisions on which approach to follow should not be based on looking at the 
effect size alone, since this makes the mistake of not appreciating the relative population health benefits of each 
approach. A universal intervention with a small but true effect can have a large impact on population health, due 
to the large numbers of people participating.312,315 
Stockings and colleagues found a gradient for anxiety in the opposite direction to depression, and postulate that 
this finding could be due to the lack of data for selective and indicated samples.311 A similar gradient for anxiety 
was found by an older systematic review, although the gradient was not tested for statistical significance.316  
Having a psychological component, such as cognitive behavioural therapy (CBT) was a characteristic of 
successful interventions in two reviews310,311 as opposed to exclusively educational (information provision 
without any cognitive restructuring techniques) or physical (for example, team sport).311 However, one review 
found the same elements in both successful and unsuccessful interventions.312 The number and duration of 
intervention sessions was not associated with a difference in outcomes.309,311 One review found no difference 
between health clinic, prison, or home settings compared to school-based settings.311 
For universal prevention interventions, one review found no significant difference between school staff versus 
research staff implementers,309 while another found that after 12 months, there was a greater effect for teacher or 
school employee implementers as opposed to clinicians.311 Duration of effect was generally found to be short 
term,310 returning to baseline after 12 months.309,311 Stockings and colleagues ask whether this is due to natural 
decay or a reduction in power. If the former, then participants of depression and anxiety interventions may need 
to have repeated exposures.311 If the latter, then repeat exposures may not be justified. Gearing and colleagues 
found support for booster sessions in CBT interventions for youth managing mood or anxiety disorders.313 
Studies suggest that approximately 50% of tertiary students experience significant levels of anxiety and/or 
depression.314 A meta-analysis by Regehr and colleagues found that cognitive, behavioural and mindfulness 
interventions were effective in reducing stress in university students, with an important secondary outcome 
being lower levels of depression.314 Results of studies were consistent and similar, despite variations in length of 
approach (most commonly 4–8 weekly sessions, but sometimes one session followed by independent practice) 
and components, such as cognitive restructuring, relaxation and meditation. Males were underrepresented in the 
studies, therefore approaches are needed that meet their needs.314 
An comprehensive systematic review by Weare and Nind, of 52 systematic reviews and meta-analyses from 
1990 to 2011 extracted general principles from the more effective school based interventions.317 Similar to the 
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reviews above, the effect sizes were generally small, although Weare and Nind argue that the real-world impacts 
were relatively large and were similar or higher than many other established preventive and treatment 
interventions. The review found that the characteristics of more effective interventions included:  
 Teaching social and emotional skills focusing on positive mental health, integrated into the general 
classroom curriculum, rather than in isolation 
 Embedding work within a whole-school approach, involving the school ethos, teacher education, 
liaison with parents, and coordinated work with outside agencies 
 Starting early with the youngest children and continuing with older children. Booster sessions for older 
students can help overcome the diminution of effects  
 Being long-term, including over several years. Nine months to a year was generally found to be more 
effective than shorter durations, and no reviews concluded that single, brief interventions have any 
worthwhile role  
 Having a combination of a universal programme focus with robust targeted components added. The 
review was unable to conclude the best balance between the two  
 Being implemented consistent with principles of empowerment, autonomy, democracy and local 
adaptability, but also with clarity and fidelity, so that whole-school approaches do not become too 
diluted.317  
Sandler and colleagues undertook a meta-analysis of 48 meta-analyses from 2000 to May 2013, which covered 
the effects of mental health related prevention and promotion programmes for children, youth and young 
adults.318 They found small but significant effects to reduce depression, anxiety, antisocial behaviour and 
substance use. Other findings were: 
 The largest effect size was for anxiety interventions, followed by those that promote healthy 
development, and the smallest effect sizes were for depression, substance use, and crime/antisocial 
behaviour  
 Effects were sustained over time, with benefits on many outcomes lasting one or more years. Further 
detail of which interventions maintained an effect for more than one year was not given 
 Effects were larger for those at higher risk, although universal interventions with a smaller effect size 
might have a larger impact on population health because they reach more people 
 Interventions that use interactive strategies, such as discussion of the programme material and practice 
of programme skills were more effective than didactic learning approaches. Interactive strategies were 
consistent with CBT approaches, which were common 
 Motivational interviewing for alcohol use in college was successful, but this methodology was not 
applied to any other problems in the meta-analyses 
 There were inconsistent findings regarding what length of programme was most successful 
 In general, insufficient detail was provided regarding the comparison conditions compared to the 
intervention group 
 Better quality implementation was associated with better results, although the level of detail of analysis 
was limited to whether an intervention had ‘any problems’ or ‘no problems’ 
 Regarding the implementer, findings were mixed, making it important to identify the conditions under 
which different providers will be more effective: 
 Several meta-analyses found mental health professionals were more effective providers than non-
professionals or teachers 
 One meta-analysis of an anti-social behaviour prevention intervention found the professional level of 
provider made no difference 
 Several meta-analyses of substance use prevention found larger effects for peer leaders compared to 
teachers or non-peers 
 Several meta-analyses found that higher levels of provider training were associated with larger effects 
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 Contextual factors such as stressors or environmental factors such as poverty, cultural incompatibility, 
gangs, social network influences on substance abuse, and school discipline policies, have rarely been 
studied.318 
Recent New Zealand literature: 
Clark and colleagues found that young people aged 10–24 who received free counselling support in schools, 
homes and community-based services that were convenient to the young person, through the Your Choice 
programme reported significant improvements in global social and psychiatric functioning.319 The most 
common reason for referral was for personal relationships, followed by family stressors, low mood, anxiety, 
grief and loss, alcohol and drugs, and on medication for mental health concerns. The programme consisted of 
one paid coordinator and a multidisciplinary team and cross agency triage team (public health nurses, general 
practitioner, public health registrar, psychiatric nurses from Child and Adolescent Mental Health Services, 
specialist youth health doctor, adolescent nurse specialist, social worker, Tobacco, Alcohol, and Drugs worker, 
and a psychiatrist).  
Collings and colleagues, in the setting of general practices in Wellington, tested clinician and patient satisfaction 
of a brief intervention for sub-threshold mental health syndromes, consisting of three 15–30 minute coaching 
sessions over a 5-week period, and found that the intervention was regarded positively and appeared to improve 
the psychological well-being of the patients.320 This small feasibility test excluded those under 18 years, but the 
intervention is currently the subject of a large randomized controlled trial in the Wellington region, involving 
youth, low income, or people with Māori or Pacific Island heritage, with results due in 2016.321 A small pilot 
study found that a version of the intervention specially adapted for Māori was rated favourably by Māori 
patients and clinicians.322  
Dath and colleagues found that a brief psychological intervention by a visiting clinical psychologist in a general 
practice setting had substantial benefits for the patients (as measured by pre and post scores on patient-
completed rating scales) and for the practice, however, the intervention was limited to those 18 years and over, 
and only included 5 people between the ages of 18 to 30.323 
e-interventions: computer and web-based interventions 
Rising to the Challenge, and Hīkaka te Manawa: making a difference for rangatahi, published by the Health and 
Disability Commissioner and Te Rau Matatini, both call for the use of “e-therapies” to improve accessibility of 
treatment.236,324 Using the term ‘therapy’ in ‘e-therapy’ is potentially confusing or over restrictive, since many 
mental health interventions are not therapies for an illness; they are prevention programmes for asymptomatic 
individuals, designed to prevent symptoms of illness. Therefore, this section generally uses the term ‘e-
interventions’. 
In recent years there have been several systematic reviews of e-intervention effectiveness for youth and young 
people, covering mental health promotion, and prevention and treatment of many mental health disorders, most 
commonly, anxiety and depression, and substance misuse 325-337. Of these, four specifically limit the reviews to 
tertiary education-based interventions,326-328,335 and one limits to school-based interventions.333 
The most comprehensive of these reviews of mental health conditions was a 2014 publication by the National 
Collaborating Centre for Mental Health, UK, that included 63 e-interventions for mental health disorders, 
including anxiety and depression, phobias, obsessive compulsive disorder (OCD), post-traumatic stress disorder 
(PTSD), eating disorders, attention deficit hyperactivity disorder (ADHD), conduct disorder, substance misuse, 
autism, Tourette syndrome, and psychosis.337 
Several meta-analyses for anxiety and depression report positive effects for universal, selected and indicated e-
interventions, mostly using CBT.325,326,329,334-337 e-interventions for depression using social networking appear to 
be less effective.336 One meta-analyses showed a positive effect compared to inactive controls, but not compared 
to ‘active-controls’, such as control participants viewing computer-based materials about depression and 
anxiety.335 Web-based and face-to-face additional support from therapists was associated with improved 
efficacy,325,326 while parental involvement was not.334 Completion rates were often low, although highest in 
school settings.325 Poor study design and study variability limited the ability to draw further conclusions about 
successful study characteristics.325,326,336 
Findings for social phobia/social anxiety showed some promise with CBT.337 or were inconclusive,329 
Inconclusive or no effects were found for other phobias and PTSD.329,337 For OCD, one review found no 
effect,329 while another found some effect for group videoconference CBT, although this was based on one 
study.337 For ADHD, cognitive training (attention and working memory training) showed some promise, as did 
computerised parent training for conduct disorder.337 
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There is some evidence of effectiveness for e-interventions for several other conditions, but positive findings 
were based on one intervention only: online group CBT for eating disorders (but not for CBT for general eating 
disorders or for binge eating disorder); video conference CBT for OCD; video conference behaviour therapy for 
Tourette syndrome; and computerised social skills training for autism.337 
There is some evidence that e-interventions have a small benefit on alcohol use in school students333 and tertiary 
students.328,337 The one review of school-based e-interventions found that four out of four studies were 
associated with small reductions in alcohol use.333 Characteristics that may be associated with positive outcomes 
were having at least 4 sessions, having booster lessons, using social learning or social cognitive principles, and 
the inclusion of a parenting component.333  
One review that was mainly of interventions for at-risk tertiary students, found positive outcomes associated 
with using personalised normative feedback and multi-component interventions (personalised feedback, CBT 
based protective behavioural strategies, alcohol facts, and resources for those interested in taking action)328. 
Another review found weak evidence for e-interventions reducing alcohol use for the general adolescent 
population, with or without personalised normative feedback.337 No effect was found for alcohol-related 
problems.328 
Evidence to support e-interventions for cannabis use was either weak337 or based on one study which had a small 
effect size333 or only showed results in the short-term and not as effective as in-person treatment338 or e-
interventions have shown no effect.327 Given the lack of success, it has been suggested that strategies should try 
targeting individuals who already have high contemplation of reducing use.327 
New Zealand e-interventions for youth and young adults 
The New Zealand e-intervention SPARX is currently supported as part of the Prime Minister’s Youth Mental 
Health Project. It is a CBT e-intervention for adolescents seeking help for clinically significant depression.339-341 
SPARX is an interactive fantasy game, comprising of seven modules, delivered over four to seven weeks. 
Studies found that SPARX appears to be a promising treatment, and not inferior to treatment-as-usual,341 
including for those excluded from mainstream education.339 Those deemed to be of high risk of self-harm were 
excluded from these studies. SPARX has also been successfully adapted for sexual minority youth. A small trial 
in 21 13–19 year old sexual minority youth found that the e-intervention ‘Rainbow SPARX’ was thought to be 
useful and liked by participants, and depressive symptoms decreased.342  
The e-intervention ‘Reach Out, Rise Up’, a text-message based intervention for mild to moderate depression and 
anxiety, was trialled for use on 21 young people in New Zealand.343 In this pre-post assessment design, the 10-
week e-intervention pilot showed positive outcomes, as assessed by the GAD-7 for anxiety and the PHQ-9 for 
depression. Half of the participants were randomly assigned a trained supporter, who phoned once a week. 
Support from trained supporters or family and friends did not significantly change anxiety and depression 
scores. Having a trained supporter increased scores on ‘Feeling encouraged and supported’. Having support 
from friends and family did not increase this score.  
A web-based brief intervention for hazardous or harmful drinking was trialled on Māori students who had 
screened positive, at seven New Zealand universities344. The intervention included personalised feedback of 
screening scores, associated health risks, blood alcohol levels, traffic crash relative risk, monetary expenditure, 
comparisons of drinking with other students and the general population, and links to further information and 
support services. Compared to controls, those receiving the <10 minute e-intervention drank less often, less per 
drinking occasion, less overall and had fewer academic problems.  
The same study reported findings separately for non-Māori students.345 Non-Māori students who received the e-
intervention compared to non-Māori students who did not, consumed less alcohol per drinking occasion, but did 
not drink less often, nor less overall, did not have fewer academic problems, and effects on binge drinking were 
not statistically significant. Non-Māori participants reduced their total alcohol consumption by 5% (not 
statistically significant) compared to 22% for Māori students in the same trial. The authors postulate that this 
could be because Māori students may be more influenced by social norm feedback, due to having “a stronger 
group identity, enhanced by being a small minority in the university setting, a view consistent with social 
identity theory” (p.1223).345 
The authors conclude that web-based alcohol screening and brief intervention alone cannot be relied upon to 
reduce unhealthy alcohol use in the university student population; it has to be paired “with environmental 
interventions such as restriction in the physical availability and promotion of alcohol” (p.1223).345 Some 
recommendations for alcohol legislation in the New Zealand context have been made by the Law Commission, 
including increasing the price, reducing the availability, increasing the minimum purchasing age, and restricting 
advertising and promotion.346  
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Further e-intervention issues identified in the literature  
The National Collaborating Centre for Mental Health conducted focus groups with young people, which 
concluded that young people’s views must be taken into account in the design of e-interventions.337 Other 
conclusions were that e-interventions need to be interactive, engaging and up to date with current new 
technology, integrated with other services, and that “it was evident that young people want e-therapies to be a 
part of the help they are offered, not a replacement for face-to-face therapies, and to foster a young person’s 
autonomy and agency”(p.115).337  
A large number of e-interventions are available, so it is important the public is informed about which e-
interventions have been evaluated and shown to work, and which have not yet been evaluated.330 The Beacon 
website,1 developed and delivered by the National Institute for Mental Health Research at the Australian 
National University, “provides users with a comprehensive directory of e-health applications (websites, mobile 
applications and internet support groups), and includes reviews, expert ratings and user comments”.347 Stasiak 
and colleagues note that most e-interventions have predominantly been of a Western culture.330 They also point 
out that technology moves fast, so e-interventions are at risk of being outdated quickly; and development, 
maintenance and security is expensive, so cost-effectiveness, relative to traditional therapies, needs to be 
considered.  
In an analysis that examines the generalizability or otherwise of anxiety and depression e-interventions, a 
systematic review of 34 e-interventions covering all ages found that 50% of participants receiving CBT 
experienced clinically significant change.348 However, in these studies, 49% of people were excluded from 
participating, most commonly for risk of suicide (91.7% of studies), and for substance or alcohol abuse (75% of 
studies).348 Wilks and colleagues found that the number of exclusion criteria was strongly and positively 
correlated with the proportion of participants experiencing clinically significant change for anxiety studies and 
conclude that effectiveness of CBT e-interventions may decline with clinical complexity.348 The problem of 
limited generalizability due to exclusion criteria is not limited to e-interventions.284 
Selected high-needs groups 
Māori, Pacific and sexual minority youth are at high risk of poor mental health outcomes or have been identified 
as priority groups by the Ministry of Health.  
Māori youth and young adult mental health 
Te Puāwaiwhero: The Second Māori Mental Health and Addiction National Strategic Framework 2008–2015 
notes that Māori youth (rangatahi) are particularly vulnerable, and addressing their needs is a priority.349 Te 
Puāwaiwhero calls on DHBs to have early intervention strategies for rangatahi, and increased access to 
specialist mental health and addiction services.349 In Rising to the Challenge, the Ministry of Health 
acknowledges that the Māori population experience more mental health issues, inpatient admissions, seclusion, 
compulsory treatment and have higher rates of youth suicide than non-Māori.236 The Ministry of Health also 
acknowledges that Māori rates of mental disorders are not fully explained by socioeconomic status and age 
structure,236 referencing findings in Te Rau Hinengaro: The New Zealand Mental Health Survey.350 Baxter 
provides more detailed analysis of the prevalence of mental disorder among Māori from this survey.94  
To address Māori mental health, the government aims to increase access to kaupapa Māori interventions, and 
calls on DHBs to offer kaupapa Māori services “where the number of Māori who need a service is sufficiently 
high and Māori are not achieving equitable outcomes relative to other populations from mainstream service use” 
(p. 35).236 Since most Māori still access mainstream services, mental health clinicians are asked to “incorporate 
knowledge of tikanga, whānau ora and Māori models of care and cultural competence in working with Māori” 
(p 60).236 There is evidence supporting this general approach; a systematic review found that making cultural 
adaptations to psychological treatments for depression improves outcomes.351 The Ministry of Health strategy 
also makes reference to “developing a workforce that reflects the population served” (p 32),236 which will be 
discussed in relation to the Māori workforce below. 
The Werry Centre provides an overview of current Māori mental health services and access for 0–19 year 
olds.230 An important finding is that secondary service access rates for Māori children and adolescent have 
improved in recent times, and are higher than the national average access rate, and higher than access rates for 
Pacific and Asian 0–19 year olds. For the 15–19 year olds, the access rate for Māori is 8.07%, compared to the 
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whole population rate of 5.84%. All four DHB regions exceeded the national target for 15–19 year olds of 5.5%; 
from 7.58% in Midland to 8.45% in Northern.  
The Werry Centre note that Māori have double the prevalence rates of mental health disorders compared to the 
general population, so rangatahi continue to be a population of high need for mental health services.230 It is not 
clear from the literature whether Māori youth and young people have double the rates of all mental health 
disorders. Te Rau Hinengaro: The New Zealand Mental Health Survey data from 2003/2004 found that the 12 
month prevalence of mental disorder for 16–24 year old Māori was 33.2% (95% CI 27.1, 40.1), slightly higher, 
but not statistically significantly different to the 12 month prevalence for all New Zealand 16–24 year olds, 
which was 28.6% (95% CI 25.1, 32.3).94,350  
The 2012 national health and wellbeing survey of secondary school students found that 13.9% of Māori students 
reported depressive symptoms (up from 10.6% in 2007), which was not different from New Zealand 
European/Pakeha students.338 However, 6.5% (compared to 6.9% in 2007) of Māori students reported making a 
suicide attempt in the previous 12 months (9.2% for females compared to few or none for males), which is twice 
that reported by New Zealand European/Pakeha students.338 Among Māori students, 22.2% saw a health 
professional for emotional worries compared to 18.4% of the whole student population, although the difference 
was not statistically significant.2112,338 The proportion of Māori students reporting good emotional wellbeing was 
similar to the whole student population (75.1% compared to 76.2%).112 The 2012 national health and wellbeing 
survey found that among female students 15 years or older, Māori were more likely to drink alcohol weekly than 
New Zealand European/Pakeha students.338 There was no difference for males.338 Analysis of the Māori sample 
from the 2007 national youth health survey found that “Binge drinking was associated with poorer school 
performance, unsafe sex, unwanted sex, an injury, injuring someone else, motor vehicle crashes and ‘doing 
things that could cause trouble’”(p.55).112 Māori students were more likely to report using marijuana on a 
weekly basis than New Zealand European/Pakeha students.338  
Youth suicide is an area where Māori youth have consistently had substantially higher rates than non-Māori.292 
In 2012, the Māori youth suicide rate (15–24 year olds) was 2.8 times the rate for non-Māori youth.292 Māori 
youth suicide rates have been at least 1.7 times higher than for non-Māori from 2003 to 2012.292 Provisional 
figures released by the Chief Coroner show that from 2007/2008 to 2014/2015, the number of Māori youth 
suicides peaked at 2011/2012 with 56 and has decreased since then to 42 in 2014/2015.352  
The Werry Centre found a 12% increase in the total Māori ICAMH/AOD workforce between 2012 and 2014, 
which now makes up 18% of the total ICAMH/AOD workforce.230 Given that Māori 0–19 year olds make up 
25% of the total population and 31% of those accessing mental health and AOD secondary services,230 the 
workforce still does not reflect the population served, which is an aim of Rising to the Challenge.292 
Hīkaka te Manawa: making a difference for rangatahi, acknowledged that there was little evidence of which 
mental health services worked best for rangatahi, so gathered information from 21 Māori mental health services 
from across New Zealand to identify factors of success and common challenges.324 The Factors facilitating 
positive outcomes were: implementing the Choice and Partnership Approach; incorporating Māori values and 
cultural models into service philosophy and delivery, which was most evident in kaupapa Māori services; using 
rangatahi-focused care settings; peer support, for example rangatahi using services encouraged to take on peer 
support roles; using a whānau-inclusive model, generally engaging with whānau in their own environments, on 
their terms; community involvement an cross-agency collaboration, for example, with school and youth justice 
system; having a committed, skilled and culturally competent workforce; and having a collaboratively planned 
exit strategy from the service. 
The Choice and Partnership Approach is a clinical system that “aims to provide services to young people that 
are user-friendly, designed around their needs, accessible, safe and effective. The system uses quality 
parameters combined with processes to facilitate pathways through the service, attempting to avoid unnecessary 
waits. In doing so, it attempts to place the needs of families at the centre of CAMHS. There is a shift in clinician 
stance from ‘expert with power’ to ‘facilitator with expertise’”(p.6).353 
There were a number of challenges identified in Hīkaka te Manawa including the complexity of clinical 
presentations, the need for additional focusing or resources in several service areas, having to have multiple 
short-term contracts with differing reporting structures, contract parameters that restrict access to certain age 
groups, engaging whānau in the face of logistical and economic challenges, a shortage of specialist child and 
adolescent psychiatrists and clinicians, and a major shortage of a trained Māori workforce.324  
Hīkaka te Manawa makes 14 recommendations to build on the strengths and address these challenges:324 
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Funding and planning  
 Prioritise funding and planning for rangatahi mental health and addiction services that foster growth 
and development.  
 Increase the capacity of NGOs, particularly kaupapa Māori NGOs in the specialist area as well as 
improving access to early intervention through primary care.  
 Increase the availability of parenting programmes that work for whānau and rangatahi who are parents.  
 Build the capacity and capability of funding and planning teams to strengthen links within the sector 
and between providers.  
 Adopt a life-course approach to funding for rangatahi and for consistency in contracting, and close the 
gaps in service provision due to differing age groups in provider contracts.  
 Adopt a more flexible funding model for contracting and reporting.  
Workforce  
 Prioritise activity to address youth workforce shortages to respond to the needs of rangatahi and 
whānau.  
 Workforce centres must provide development and training solutions to increase competence in both 
clinical and cultural domains.  
 Professional bodies should also support clinical and cultural competency requirements in the 
workforce.  
A model/philosophy for services for rangatahi  
 Promote a rangatahi development model at the primary care level whereby providers offer a range of 
services required for rangatahi development.  
 Services must adopt an outward-looking approach in the sector and participate in community forums 
and networks to support the improved communication and linkages with other relevant services for 
their populations.  
 Increase accessibility of e-therapies and other self-help options that increase access and positive 
outcomes for rangatahi.  
Conduct disorder  
 Early access to psychological support and therapies.  
 Enable access and availability of psychological therapies or a rangatahi development model of service 
in primary care settings.  
A study based on 30 interviews with rangatahi from six DHB CAMHS found several factors that rangatahi 
appreciated: formal and informal entry referral pathways into CAMHS, such as the emergency department or 
through whānau supporting them to access services; whānau being able to accompany them to the first referral, 
and clinicians with good listening skills, who valued rangatahi views; a whānau type environment rather than 
clinical, and a whānau partnership approach; services that helped rangatahi through cultural processes to 
enhance cultural identity; and help with goal setting and plans.354 
Pacific youth and young people’s mental health 
In 2008, the Ministry of Health published Pacific Peoples and Mental Health,355 which noted Pacific under 20 
year olds had the lowest rates of use of services of all ethnicities. The publication noted the need for improved 
information and evidence to inform policy. In Rising to the Challenge, Pacific peoples are listed as a priority 
group.236 In areas where there is a sufficiently large population of Pacific people experiencing inequities in 
mental health or addiction issues, DHBs are expected to reprioritised funding to Pacific services and evaluate 
whether these are more effective than mainstream services.236 
The latest Ministry of Health plan for improving health outcomes for Pacific people is ‘Ala Mo’ui: Pathways to 
Pacific Health and Wellbeing 2014 – 2018.356 This reiterates the strategies of Rising to the Challenge,236 and 
documents DHB initiatives and progress on access rates to mental health services (but not specifically for 
youth).357  
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The Pacific population in New Zealand is diverse, made up of more than 22 different ethnic groups.358 It is also 
comparatively young; 41% of the Pacific population is aged 0–19 years.230 Among the 0–19 years age group, 
71% live within the Northern DHB regions, and of these, 55% live in Counties Manukau.230 The Werry Centre 
Stocktake reports on services and service use of CAMH/AOD for the Pacific child and youth population, using 
prioritised ethnicity,230 which may underestimate the Pacific population359-361. The Werry 2014 Stocktake 
findings are summarised below.230 
Two DHBs, Counties Manukau and Capital & Coast, provide dedicated Pacific CAMH/AOD services. In 
Waitemata, Pacific children and youth have access to two services funded under adult services. Also, six NGOs 
across the country provide dedicated pacific CAMH/AOD services; one in each of Northern, Midland, and 
Southern region, and two in Central region. For 15–19 year olds, access rates to any CAMH/AOD service was 
4.16%, below the Government target of 5.5%228,230. By DHB regions, access for Northern was 4.25%, Midland, 
3.42%, Central, 4.56%, and Southern, 3.06%230.  
From 2012 to 2014 there was a 26% increase in the total Pacific ICAMH/AOD workforce, 13% in clinical roles. 
The Pacific workforce makes up 7% of the total ICAMH/AOD workforce. This compares with Pacific 0–19 
year olds making up 10% of the 0–19 year old population and accounting for 6% of CAMH/AOD service use. 
This appears to show that the Pacific proportion of the workforce matches current Pacific access use. However, 
access use is lower than what would be expected if compared to the percentage of 0–19 year olds who are 
Pacific, especially since Pacific people are reported to have a higher burden of mental disorder than the general 
population.355 Survey responses from Pacific CAMH/AOD services stated that some of the workforce staffing 
difficulties were related to shortages of senior qualified Pacific health professionals, loss of funding for targeted 
recruitment initiatives, and no positions available to fund any more staff.230 
As is the case in Māori mental health, it is not clear from the literature whether Pacific youth and young people 
have higher rates of all mental health disorders, although high rates of deprivation exacerbate the Pacific 
population’s poor mental health outcomes.362 From Te Rau Hinengaro: The New Zealand Mental Health Survey 
data (2003/2004), 12 month prevalence of mental disorder for 16–24 year old Pacific people was 29.0% (95% 
CI 22.0, 37.0), slightly higher, but not statistically significantly different to that of all New Zealand 16–24 year 
olds, which was 28.6% (95% CI 25.1, 32.3).350  
Pacific results for the 2012 national health and wellbeing survey of secondary school students have not been 
published to date.363 Results from the 2007 survey found that compared to New Zealand European/Pakeha 
students, a higher proportion of Pacific students reported depressive symptoms and making an attempt to kill 
themselves.364 The 2007 survey also reported that there was no difference in the prevalence of binge drinking 
and other illegal drug taking between Pacific and New Zealand European students, but Pacific students were 
more likely to be weekly marijuana smokers.364 
Te Pou o Te Whakaaro Nui published a practice guide for effective talking therapies for Pasifika Peoples.365 
Youth are not the focus of the publication, although for child, adolescent and family services, the importance of 
storytelling and externalising difficulties is noted. The practice guide used a practice-based observations 
approach, due to limited published research on interventions for Pacific peoples. General features of successful 
therapies were that they used a strength-based approach, were holistic, and adapted to Pacific culture.365 Pacific 
culture generally places importance on building relationships, spirituality, and has a “collective approach… 
governed by a complex set of inter-relationships between individuals, their families and their communities… 
often upheld through adherence to a set of core values and practices.” (p.14)365 
Regarding youth suicide in the New Zealand Samoan population, Tiatia notes that Samoan constructs of 
emotion, particularly anger and shame, must be considered for effective service delivery.366 Other essential 
factors identified through interviews with Samoans who had made a suicide attempt and/or had suicidal ideation 
and were engaged in a mental health service, were the importance of cultural competency, family inclusion, and 
recognising the differences in Samoan and Western views of mental illness.358 Regarding alcohol and Pacific 
youth, Suaalii-Sauni and colleagues found that key communities of influence on decision making were families 
(especially siblings), peers and the church.367  
Sexual minority youth 
Internationally, sexual minority youth (which can include lesbian, gay, bisexual, transsexual, intersex (LGBTI) 
or gender nonconforming, and questioning) are more likely to experience depression, suicidality, including 
attempts requiring medical attention, problematic substance use and alcohol use, and peer victimisation.368-370 
Homophobia and minority stress3 status have been noted as the main threats to sexual minority youth mental 
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health.369 The past decade has seen the development of several services tailored to sexual minority youth, 
offering “barrier-free” care, typically in urban ‘one-stop-shop’ settings.368 Cultural competence of mainstream 
services and staff is important, since most sexual minority youth will be cared for in traditional health care 
settings.368,369,371 
Results from 12 unique studies of lesbian, gay and bisexual youth indicated that the strongest risk factors for 
substance use were victimization, lack of supportive environments, psychological stress, 
internalizing/externalizing problem behaviour, negative disclosure reactions, and housing status.371 The review 
suggests that interventions that address ways to avoid and cope with peer victimisation or provide mentoring to 
strengthen perceived support from adults at school may be more effective than universal interventions. 
Clinicians need to be prepared to promote positive relationships with family and friends, policies of no-tolerance 
of bullying in schools, inclusion of resources in schools, and promote on-site mental health services.370  
In primary care, sexual minority youth often do not feel comfortable discussing issues related to their sexuality 
unless broached first by the clinician.369 Factors that make discussing issues easier are having sexual minority 
brochures and symbols on display, having clinical and non-clinical staff use non-discriminatory language 
consistently, having unisex bathrooms, and just asking.369  
In New Zealand, the Christchurch Health and Development Study and the Dunedin Multidisciplinary Health and 
Development Study have found increased risk of suicide attempts and other mental health problems in non-
heterosexual youth and young people.372 The New Zealand National Youth and Health Wellbeing Survey in 
2012 found that sexual minority youth had higher odds of attempting suicide and were 3.7 times as likely to 
have depressive symptoms as other youth, which had increased from 2.4 times as likely in 2001.340,373  
An email survey of mental health service providers and LGBTI stakeholders in New Zealand revealed five 
LGBTI-focused mental health services, from Auckland, Wellington and Christchurch.372 These are Auckland 
CADS (Community Alcohol and Drug Services), OUTLine New Zealand, New Zealand AIDS Foundation 
(NZAF), Rainbow Youth, and City Associates. In relation to mental health, these services work mainly at a 
settings level (e.g. in schools) or at the personal level (e.g. counselling).372 The 124 stakeholder informants and 
respondents (nine aged 20 years and under and 30 aged from 21–30 years) identified various issues in mental 
health services. Access to and competency of mental health services were the overarching issues. A lack of 
services, programmes and funding for LGBTI mental health initiatives by DHB public health units was 
identified. Cost was seen as a financial barrier to accessing services. Ensuring culturally safe and appropriate 
services was important, including mental health staff displaying appropriate attitudes, having the necessary 
skills for working with LGBTI, and avoiding making assumptions regarding sexual and gender identity. The 
safety of young people in schools was seen as important. Teachers need to be trained in suicide prevention, 
mental health promotion, preventing bullying and challenging homophobia.372  
In 2013, the symposium “LGBTTI4 Well-Being and Suicide” was held involving Affinity, Auckland DHB, the 
Mental Health Foundation, Rainbow Youth and Outline. A report following on from this symposium, Rainbow 
Health: The Public health Needs of LGBTTI Communities in Aotearoa New Zealand with Policy 
Recommendations, made five recommendations for the New Zealand health system (p.9): 
 Rainbow community service users will receive equitable and culturally safe access to general and 
mental health services across their lifespan. 
 The particular health needs of tangata takatāpui will be considered and addressed in line with the 
state’s obligations and commitments under the Treaty of Waitangi and the principles of partnership, 
protection and participation. 
 All health services will be supported and resourced to deliver culturally sensitive and appropriate 
services for Rainbow communities 
 Rainbow communities will be actively involved with and consulted about the development and 
delivery and evaluation of appropriate policies, programmes and services. 
 Research and data collection on the physical and mental health needs of Rainbow communities will be 
a priority for health research.374  
Some other high-needs groups not covered in this chapter due to space are youth in out-of-Home Care, youth 
and young people in Forensic Services, and refugee youth and young people. Some of the lessons and 
recommendations in the literature from analysis of Māori, Pacific and sexual minority youth are also relevant to 
                                                     
4 Lesbian, Gay, Bisexual, Transsexual, Transgender and Intersexual 
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these populations, such as having a culturally competent workforce and services, sensitive to and accepting of 
diversity.  
For more information regarding youth In out of Home Care, see Mental Health Services for Vulnerable Children 
and Young People: Supporting children who are, or have been, in foster care.375 For youth and young people in 
Forensic Services, see Youth Forensic Services Development Guidance for the health and disability sector on 
the development of specialist forensic mental health, alcohol and other drug, and intellectual disability services 
for young people involved in New Zealand’s justice system,376 A Literature Review: Mental health & alcohol 
and other drug screening, assessment and treatment for Youth Justice populations,377 and Richardson and 
colleagues.378 For refugee youth, see Refugee Health Care: A Handbook for Health Professionals,379and Tyrer 
and colleagues.380  
Conclusion 
There has been considerable change in mental health specialist service access for youth and young people over 
the past two decades. Access rates for 15–19 year olds are above current targets, and are highest for Māori, 
although Pacific youth are accessing services below target rates. Access rates for 20–25 year olds are not 
covered as well in the literature.  
The focus twenty years ago was to increase access to those needing specialist services, and has now broadened 
to include the larger population of people who have mild to moderate illness. The Youth Mental Health Project 
and to a lesser extent, the Children’s Action Plan cater for this population, through integrated services involving 
several government agencies and sectors. 
Barriers still prevent most youth and young people with mental illness accessing mental health services. Social 
support, culturally competent and friendly health care workers, and services specifically tailored to this age 
group, such as Youth One Stop Shops, can increase access. Services are mostly not organised by children’s 
developmental stages, causing problems when children transition from child to adult services. A combination of 
Age-continuum services, which cater for a wider age range, usually up to 25 years of age, and Shared 
management services, which utilise transition coordinators who help ease the transition from child to adult 
services, are needed in all mental health systems. Several examples of these models of care are operating 
internationally, and to a lesser extent, in New Zealand. 
Workforce shortages and workforce development have been identified as issues for at least 20 years, and 
continue to be an issue, especially regarding recruiting a workforce that reflects the population of New Zealand 
(particularly Māori), and a general lack of specialist CAMH clinicians. In line with the focus on increasing 
services for those with mild to moderate illness, up skilling the primary care and mainstream workforce has 
been recommended.  
Primary care has been given a greater focus in recent Mental Health strategies. General practice has been asked 
to take a greater role by screening for mental health illness and treating mild to moderate illness using integrated 
models of care involving mental health specialists. The literature has identified that more guidance and research 
is needed for primary care level screening tools, and specialist care must be accessible to the primary care 
clinician. This can be in the form of consultation liaison or collaborative models; the latter appears to more 
effective, although may not be cost-effective.  
GP training, including in skills that increase the therapeutic alliance, may make clinicians and services more 
appealing for youth and young adults, and may reduce the burden on specialist services. GP training in brief 
interventions for general pretentions and in evidence-based interventions for specific diagnoses has been 
recommended, but there is no clear evidence on what this training should be.  
School environments can influence the mental health of their students. The mental health of students is 
associated with schools with more health services. Students are also more likely to seek help for a mental health 
issue if a teacher at school knows them.  
There is evidence that primary care mental health and alcohol interventions, e-interventions or otherwise, can 
have positive outcomes. However, not all interventions do. There is a vast amount of literature covering many 
settings, illnesses, and populations. The same programme characteristics are found in successful and 
unsuccessful programmes, making it difficult to make general conclusions for future programme implementers 
to follow. To some extent, what will work best will depend on the local situation. However, the discussion 
above includes guidance from several systematic reviews and meta-analyses. Given many interventions have no 
effect and that studies’ exclusion criteria may limit generalisability, evaluation of outcomes is important.  
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Special attention needs to be paid to several high risk youth and young person groups, including Māori, Pacific, 
and sexual minority youth and young people. Some themes are common to many of these groups, including 
having culturally competent, friendly, non-judgemental mental health staff, who are aware of the increased 
mental health needs of these groups. The mainstream health workforce and others who work with youth and 
young adults also need these skills and knowledge. Having a mental health workforce that reflects the 
population it is serving is also important. The aim is to provide culturally sensitive and developmentally 
appropriate services designed around youth and young people. Having youth and young people involved in the 
service design and incorporating Māori, Pacific and other cultural models into practice will assist with this. 
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ACCESS TO MENTAL HEALTH SERVICES 
Introduction 
Globally, mental health and substance use disorders are the leading cause of disability in those aged 0–24 
years.381 Most high prevalence disorders emerge during adolescence and early adulthood, with an earlier age of 
onset associated with a longer duration of untreated illness and poorer outcomes.382 Risk factors for the 
development of mental disorders in children can be divided into child characteristics and family 
characteristics383-386. Child characteristics include gender, age, ethnicity, sexual orientation, physical health, 
alcohol, drugs, lifetime history of environmental exposures to toxins (lead), social environment and stressful life 
events. Family characteristics include parental education, age, social class, employment, psychiatric and medical 
history, family function and structure, and neighbourhood and broader contextual influences on the health of 
children and their families. Neighbourhood problems that have been linked to common mental disorders are 
poverty, poor living conditions and social stressors such as violence and victimisation. A parental history of 
mental disorders is one of the most consistent risk factors for the development of mental disorders in children. 
In New Zealand, research on the community prevalence of mental health disorders in children and young people 
is scarce. The most recent data are from the Youth2000 Survey Series.112 The 2012 survey found that among 
secondary students almost 9% of males and over 16% of females had significant depressive symptoms and 
slightly higher percentages of males and females had suicidal ideation.291 The 12-month prevalence for any 
mental disorder in 16–24 year olds was almost 30%350 and was highest for Māori, followed by Pacific people 
and non-Māori non-Pacific peoples, although these differences reduced after adjustment for age, sex, education 
and household income.96 Older studies showed that at the age of 15 years, almost 30% of females and over 15% 
of males met diagnostic criteria for at least one mental health condition. By 18 years, this had increased to 
almost 45% of females and 42% of males.386 For those aged 18 years the 12-month prevalence of mental health 
disorders was over 36% and the most prevalent disorders being major depressive episode, alcohol dependence 
and social phobia.387  
In most countries provision of mental healthcare for children and young people does not provide satisfactory 
care, and the gap between need and access is broadest for those aged 12–25 years.388 Those with the most severe 
disorders tend to receive mental health services, but fewer than half of young people with current mental 
disorders receive mental health specialty treatment.384 Some factors affecting access are stigma, healthcare costs, 
restricted human resources, cultural aspects, artificial age boundaries of services, and clinical presentation. 
However e-technologies, collaborative care and innovative models based on developmental stages of children 
and young people are being implemented to improve access.388 Help-seeking, clinical diagnosis and treatment of 
child and adolescent mental health disorders has increased over recent decades with evidence for increased 
prevalence of some conditions but not all.389  
In New Zealand the proportion of children and young people accessing specialist services has increased.230,231 
and the focus of services has broadened to address the needs of those who have mild to moderate mental health 
issues, recognising the benefits of early intervention in a person’s life course and course of illness, and on 
building resilience.234-236 Pacific peoples and Māori were significantly less likely than non-Māori non-Pacific 
peoples to have had a visit to any service for a mental health problem, suggesting that relative to need, Pacific 
people and Māori are less likely than non-Māori non-Pacific peoples to have contact with services.96  
The following section uses data from the Programme for the Integration of Mental Health Data (PRIMHD) to 
review mental health service provision including substance use disorders for 0-24 year olds. In addition an in-
depth topic mental health issues in 15–24 year olds explores mental health issues and services with a focus on 
the mental health service structure and primary level care. Guidelines and international systematic reviews that 
consider the effectiveness of interventions to improve mental health outcomes for children published since the 
NZCYES 2012 report103 are summarised at the end of this section. 
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Data source and methods 
Indicators 
Number of 0–24 year olds accessing mental health services 
Data sources 
Numerator: PRIMHD (Programme for the Integration of Mental Health Data) 
Denominator: Statistics NZ Estimated Resident Population  
Definition 
Clients accessing mental health services refers to any individual that has had a contact within the period of interest as captured 
within PRIMHD 
Notes on interpretation 
Note 1: PRIMHD is the Ministry of Health’s national database covering the provision of publicly funded secondary mental health 
and alcohol and drug services. Commencing on 1 July 2008, it integrates information from the previous Mental Health 
Information National Collection (MHINC) and the MH-SMART data collection. It includes secondary inpatient, outpatient and 
community care provided by hospitals and non-government organisations (although data from NGOs are incomplete). It does 
not include information on outpatient visits to paediatricians. If local referral pathways result in children seeing a paediatrician 
rather than a mental health professional for behavioural or emotional problems, this may significantly underestimate the 
prevalence of mental health issues (e.g. autism, ADHD, learning disorders) in the community. Referral pathways are likely to vary 
both by region (depending on the availability of specialist child and youth mental health services) and by age (with the role of 
the paediatrician decreasing with increasing age). Paediatric outpatient data are currently not coded by diagnosis, making it 
difficult to assess the underlying prevalence of mental health conditions in the community. The PRIMHD may provide a better 
reflection of access to secondary services for mental and behavioural issues in young people. 
Note 2. Between 2009 and 2012 more NGOs began reporting to PRIMHD and some of the reported rate increases will represent 
an increase in reporting rather than an increase in services accessed.390 
Note 3: Age is derived from first contact in year. 
Note 4: The known practice and data quality issues with PRIMHD data may be more significant for children and youth than for 
adults, as practitioners may be reluctant to confirm a diagnosis at a young age due to developmental stage, uncertainties about 
diagnosis, and the potential stigma and discrimination. PRIMHD has utilised multiple coding systems for capturing mental 
health diagnoses. It also records principal, secondary, and provisional diagnoses for clients at each contact, in a large number of 
cases diagnoses were missing or deferred. Therefore analyses on diagnoses have not been presented. 
National trends and distribution 
The number and rates of 0–24 year olds being seen by mental health services, as captured within PRIMHD, 
steadily increased from 2009 to 2012 before starting to flatten to 2014 (Figure 177). Similar patterns were seen 
within the age groups, although the rates of 0–14 year olds accessing services were considerably lower than for 
15–24 year olds (Figure 178). It must be remembered that there are significant practice and data quality issues 
with PRIMHD and these apparent increases may be a reflection of other factors, such as increased reporting and 
data capture, rather than solely an increase in engagement.390 
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Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population; Some clients may be seen in multiple years 































Mental health0–14 year olds
15–24 year olds
 
Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population; Age is derived from first contact in year; Some 
clients may be seen in multiple years 
Rates at which 0–24 year olds were recorded as being seen by mental health services from 2009 to 2012 were 
consistently highest for Māori, followed by European/Other, Pacific and then Asian/Indian. Rates for 15–24 
year olds followed the same pattern by ethnicity as for 0–24 year olds. For 0–14 year olds, rates for Māori and 
European/Other were similar and highest, followed by Pacific, then Asian/Indian (Figure 179).  
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Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population; Ethnicity is level 1 prioritised 
Distribution by demographic factors 
In 2014 few children aged less than three years were seen by mental health services. From ages 3–8 years, there 
was a steady increase in the rate of being seen with increasing age. The increase until the age of 11 years was 
more gradual but from 12–15 years, there was a steep increase in young people being seen which peaked at 15 
years before a steady decrease in the late teenage years. Rates were similar for young people through their early 
20s (Figure 180). 




































Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population; Age is derived from first contact in year 
Similar patterns of being seen by mental health services were seen by age for all ethnic groups in 2014. Until 
age 12 years, European/Others had the highest rates, followed by Māori, Pacific and Asian/Indian. From age of 
2–24 years Māori had the highest rates, followed by European/Other, Pacific and Asian/Indian. By age 24 years, 
the rates for Pacific and European/Others converged (Figure 181).  
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Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population; Age is derived from first contact in year; 
Ethnicity is level 1 prioritised 
In 2014 the rates for 0–14 year olds seen by mental health services were higher for Māori and European/Others, 
followed by Pacific and Asian/Indian. Rates for 15–24 year olds were highest for Māori followed by 
European/Other then Pacific and then Asian/Indian. Rates for males were higher than for females for both age 
groups. There was a social gradient and rates increased with each quintile of increasing NZDep2013 deprivation 
scores for both age groups (Figure 182). 















































































































Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population; Rate ratios are unadjusted; Ethnicity is level 1 
prioritised; Decile is NZDep2013 
Distribution by region 
During 2014 the rates for 0–24 year olds being seen by mental health services were significantly higher than the 
national rate in the Northland, Bay of Plenty, Lakes, Tairawhiti, Taranaki, Hawke’s Bay, Whanganui, Hutt 
Valley, Wairarapa, Nelson Marlborough, South Canterbury, West Coast and Southern DHBs. The rates for 
Waitemata, Auckland, Counties Manukau, Waikato, and Canterbury DHBs were significantly lower than the 
New Zealand rate. Rates in the remaining DHBs were not significantly different from the national rate (Figure 
183, Table 164). 
 
Mental health: Access to mental health services 
397 














































































































































































































Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population 
Table 164. Clients aged 0–24 years seen by mental health services, by district health board, New Zealand 2014 
DHB Number: 2014 
Rate per 100,000 
population 
Rate ratio 95% CI 
Clients seen by mental health services 
0–24 year olds 
Northland 2,788 4,959.97 1.32 1.27–1.37 
Waitemata 5,701 2,968.98 0.79 0.77–0.81 
Auckland 4,414 2,782.88 0.74 0.72–0.76 
Counties Manukau 6,569 3,332.49 0.89 0.86–0.91 
Waikato 4,391 3,198.64 0.85 0.82–0.88 
Bay of Plenty 3,878 5,446.63 1.45 1.40–1.49 
Lakes 1,691 4,617.88 1.23 1.17–1.29 
Tairawhiti 1,075 5,955.21 1.58 1.49–1.68 
Taranaki 1,603 4,222.23 1.12 1.07–1.18 
Hawke's Bay 2,286 4,212.72 1.12 1.07–1.17 
MidCentral 2,261 3,804.38 1.01 0.97–1.05 
Whanganui 923 4,507.46 1.20 1.12–1.28 
Hutt Valley 2,161 4,457.90 1.18 1.14–1.24 
Capital & Coast 3,822 3,748.69 1.00 0.96–1.03 
Wairarapa 677 5,096.25 1.35 1.26–1.46 
Nelson Marlborough 2,152 5,115.46 1.36 1.30–1.42 
South Canterbury 990 5,769.23 1.53 1.44–1.63 
Canterbury 5,707 3,431.37 0.91 0.89–0.94 
West Coast 612 6,153.40 1.63 1.51–1.77 
Southern 4,164 4,013.38 1.07 1.03–1.10 
New Zealand 58,047 3,763.58 1.00   
Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population; Rate ratios are unadjusted 
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Midland region distribution and trends 
During 2014 the rates for 0–24 year olds being seen by mental health services were significantly higher than the 
national rate in Bay of Plenty, Lakes DHB, Tairawhiti and Taranaki and significantly lower than the national 
rate in Waikato. Similar patterns were seen within the 0–14 and 15–24 age groups although the rate for 0–14 
year olds in Taranaki was not significantly different to the national rate (Table 165).  
Table 165. Clients aged 0–24 years seen by mental health services, Midland DHBs vs New Zealand 2014 
DHB Number: 2014 
Rate per 100,000 
population 
Rate ratio 95% CI 
Clients seen by mental health services 
0–24 year olds 
Waikato 4,391 3,198.64 0.85 0.82–0.88 
Bay of Plenty 3,878 5,446.63 1.45 1.40–1.49 
Lakes 1,691 4,617.88 1.23 1.17–1.29 
Tairawhiti 1,075 5,955.21 1.58 1.49–1.68 
Taranaki 1,603 4,222.23 1.12 1.07–1.18 
New Zealand 58,047 3,763.58 1.00   
0–14 year olds 
Waikato 1,319 1,598.32 0.70 0.67–0.74 
Bay of Plenty 1,603 3,505.14 1.55 1.47–1.62 
Lakes 594 2,555.31 1.13 1.04–1.22 
Tairawhiti 504 4,320.88 1.91 1.75–2.08 
Taranaki 566 2,338.43 1.03 0.95–1.12 
New Zealand 20,675 2,267.76 1.00   
15–24 year olds 
Waikato 3,072 5,610.67 0.95 0.91–0.98 
Bay of Plenty 2,275 8,933.08 1.51 1.45–1.57 
Lakes 1,097 8,203.18 1.38 1.31–1.47 
Tairawhiti 571 8,939.83 1.51 1.39–1.63 
Taranaki 1,037 7,535.55 1.27 1.20–1.35 
New Zealand 37,372 5,926.03 1.00   
Numerator: PRIMHD; Denominator: Statistics NZ Estimated Resident Population; Rates are per 1,000 age-specific population 
Evidence based reviews relevant to mental health issues in children 
International guidelines 
National Institute for Health and Care Excellence. 2015. Addendum to clinical guideline 28, depression in children and 
young people: Clinical guideline addendum 28.1 Methods, evidence and recommendations 
http://www.nice.org.uk/guidance/cg28/evidence/addendum-193488882 
Hopkins K, et al. 2015. Diagnosis and management of depression in children and young people: summary of 
updated NICE guidance. Bmj, 350, h824. http://www.bmj.com/content/350/bmj.h824 
This update to the NICE clinical guideline 28 makes recommendations on the choice of psychological therapy and the combination of 
antidepressant treatment with psychological therapy. It found there was little clear evidence to recommend one psychological therapy over 
another for the treatment of depression in children and young people. Recommendations included the following. For initial treatment of 
mild depression, after 4 weeks of watchful waiting, offer psychological therapy. For moderate to severe depression, offer 3 months of 
psychological therapy. Do not offer antidepressant medication except in combination with a concurrent psychological therapy. Combined 
therapy (Fluoxetine and psychological therapy) for initial treatment of moderate to severe depression in 12–18 year olds can also be 
considered. If there is no response to psychological therapy alone, following multidisciplinary review, offer fluoxetine to 12–18 year olds, 
but for 5–11 year olds, fluoxetine’s effectiveness is not established, so it’s use should be cautiously considered. Fluoxetine was the only 
antidepressant with UK marketing authorisation for use for children and young people aged 8 to 18 years. 
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Maglione MA, et al. 2012. Nonmedical interventions for children with ASD: Recommended guidelines and further 
research needs. Pediatrics, 130(Supplement 2), S169-S78.  
This systematic review of 33 systematic reviews and 68 intervention studies summarised findings to formulate consensus guidelines on 
non-medical interventions that address cognitive function and core deficits in children with autism spectrum disorder (ASD). There was 
some evidence that more hours of treatment per week, and greater duration of treatment led to better outcomes. The guidelines 
recommend at least 25 hours per week of comprehensive intervention to address social communication, language, play skills, and 
maladaptive behaviour. Several interventions have shown efficacy, including applied behavioural analysis, integrated 
behavioural/developmental programs, the Picture Exchange Communication System, and various social skills interventions.  
Evidence-based medicine reviews: attention-deficit/hyperactivity disorder, oppositional defiant disorder and 
conduct disorder 
Charach A, et al. 2013. Interventions for preschool children at high risk for ADHD: a comparative effectiveness 
review. Pediatrics, 131(5), 2012-0974. 
This review assessed 55 studies, covering parent behaviour training (PBT), combined home and school/day care interventions, and 
methylphenidate use in children less than 6 years of age with clinically significant disruptive behaviour, including attention-
deficit/hyperactivity disorder (ADHD). There were eight good quality studies examining PBT in a total of 424 participants. The strength of 
evidence was high for PBT improving child behaviour. Only one good study evaluated methylphenidate, in 114 participants, so the strength 
of evidence was low. Combined home and school/day care interventions showed inconsistent results. 
Daley D, et al. 2014. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of 
randomized controlled trials across multiple outcome domains. Journal of the American Academy of Child & 
Adolescent Psychiatry, 53(8), 835-47. 
This review assessed 32 randomised controlled trials (RCTs) of behavioural interventions for ADHD in 2,057 children and adolescents. When 
assessment was probably unblended, there were significant improvements in parenting quality, parenting self-concept, and child ADHD, 
conduct problems, social skills, and academic performance. When assessment was probably blinded to the intervention, the review found 
a lack of evidence of ADHD symptom decrease, however behavioural interventions still had positive effects on parenting, conduct problems, 
and possibly a more positive parenting self-concept, but not improved parent wellbeing. 
Furlong M, et al. 2013. Cochrane Review: Behavioural and cognitive‐behavioural group‐based parenting 
programmes for early‐onset conduct problems in children aged 3 to 12 years (Review). Evidence‐Based Child Health: 
A Cochrane Review Journal, 8(2), 318-692. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008225.pub2/pdf 
This review included 13 trials (10 RCTs and three quasi-randomised trials) of behavioural and cognitive-behavioural group-based parenting 
programmes, including 1,078 participants, and assessed the effects on child conduct problems, parent mental health and parenting skills. 
The review found that whether assessed by parents or by independent assessors, the interventions were effective and cost-effective for 
improving child conduct problems, parental mental health, and reduced negative or harsh parenting practices in the short term. The cost 
of programme delivery compared to a waiting list control group was approximately $2,500 USD, which the review considered to be modest 
when compared to the long-term health, social, educational and legal costs associated with childhood conduct problems.  
Tarver J, et al. 2014. Are self-directed parenting interventions sufficient for externalising behaviour problems in 
childhood? A systematic review and meta-analysis. European child & adolescent psychiatry, 23(12), 1123-37. 
This review assessed 11 RCTs of self-directed (SD) parenting interventions for externalising behaviour problems (ADHD, oppositional-
defiant disorder (ODD) and conduct disorder) in childhood. SD interventions had a large effect on parent-reported externalising child 
behaviour, but this was not upheld by analysis of observed child behaviour. There were small to moderate effects for parenting behaviour, 
parental mood and stress and parenting efficacy. On parent-reported measures of externalising child behaviour, there was no significant 
difference between SD interventions and therapist-led parenting interventions. 
Evidence-based medicine reviews: anxiety 
James AC, et al. 2015. Cognitive behavioural therapy for anxiety disorders in children and adolescents The Cochrane 
Library. DOI: 10.1002/14651858.CD004690.pub4 
http://onlinelibrary.wiley.com/enhanced/doi/10.1002/14651858.CD004690.pub4 
This review included 41 studies of CBT interventions for children and adolescents with diagnosed anxiety. The studies included 1,806 child 
and adolescent participants. The review found that CBT was more effective than no therapy in reducing symptoms of anxiety; however CBT 
was not more effective than non-CBT active control treatments or treatment as usual in the 6 studies which examined this. No difference 
in outcome was found between individual, group and family/parental interventions. In the four studies that examined longer-term 
outcomes, evidence for treatment gains was limited and inconclusive. Only three studies included participants younger than 7 years of age. 
Analysis of separate age groups was limited by use of age-stratification in studies. The review references one study that indicated younger 
children may respond better to behavioural components, rather than the more demanding cognitive components, but concludes that more 
research is required.  
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Sawyer MC & Nunez DE. 2014. Cognitive‐Behavioral Therapy for Anxious Children: From Evidence to Practice. 
Worldviews on Evidence‐Based Nursing, 11(1), 65-71. http://onlinelibrary.wiley.com/doi/10.1111/wvn.12024/epdf 
This review included 10 studies, which each included a minimum of 12 hour-long sessions of individual CBT for anxiety in children. The age 
range of participants was 4–18 years, with all studies including children aged at least as young as 8 years. The review found that anxiety 
was reduced in children who received individual CBT, compared to controls. Other findings were that individual CBT was as effective or 
superior to comparison therapies, with one exception; CBT combined with pharmacological management was more effective. 
Thulin U, et al. 2014. The effect of parent involvement in the treatment of anxiety disorders in children: a meta-
analysis. Cognitive behaviour therapy, 43(3), 185-200. 
This review included 16 studies, which directly compared parent-involved CBT treatments with child only CBT treatments for children with 
anxiety disorders. For the 1,102 participants, aged from 5 to 17 years, with a mean age of 10.6 years, the results showed a small effect in 
favour of child only treatments. The authors explain the results by proposing that interactions between anxious children and their parents 
are characterised by factors that maintain, rather than reduce the anxious behaviours. 
Evidence-based medicine reviews: depression 
Arnberg A & Öst L-G. 2014. CBT for children with depressive symptoms: A meta-analysis. Cognitive behaviour therapy, 
43(4), 275-88. 
This review included 10 RCTs assessing the effectiveness of CBT for depressive symptoms, in participants aged 12 years or less that were 
diagnosed with depression or reported elevated depressive symptoms. A total of 523 participants were included in either intervention or 
comparison groups. The effect size of CBT was moderate, and was more effective that attention placebo and wait-list. Earlier publication 
year, older participants and more treatment sessions were associated with a larger effect size.  
Cox GR, et al. 2014. Psychological therapies versus antidepressant medication, alone and in combination for 
depression in children and adolescents. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD008324. 
DOI: 10.1002/14651858.CD008324.pub3. 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008324.pub3/epdf/standard 
This review included 11 studies, involving 1,307 participants, aged eight to 18 years old. Separate analysis was not done for younger children 
compared to adolescents. The main conclusion of the review was that there was insufficient evidence to determine whether psychological 
therapy, antidepressant medication or a combination of the two is most effective in treating depression in children and adolescents. The 
review was limited by the small number of studies, which varied regarding the comparisons used. The review found limited evidence (based 
on two studies involving 220 participants) that antidepressant medication was more effective than psychotherapy on measures of clinician 
defined remission immediately post-intervention; limited evidence (based on three studies involving 378 participants) that combination 
therapy was more effective than antidepressant medication alone in achieving higher remission from a depressive episode immediately 
post-intervention; and no evidence that combination therapy was more effective than psychological therapy alone, based on clinician rated 
remission immediately post-intervention. The review found that in one study involving 188 participants, rates of suicidal ideation were 
significantly higher in the antidepressant medication group (18.6%) compared with the psychological therapy group (5.4%). 
Hetrick SE, et al. 2012. Newer generation antidepressants for depressive disorders in children and adolescents. 
Cochrane Database Syst Rev, 11. Art. No.: CD004851. DOI:10.1002/14651858.CD004851.pub3. 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004851.pub3/pdf 
This review included 19 trials of a range of newer antidepressants (those made available since tricyclic antidepressants) compared with 
placebo, containing 3,335 children and adolescents with clinically diagnosed depression. Based on 14 of the studies, there was evidence 
that newer antidepressants reduced depression severity by a small amount, compared to placebo. Based on 17 studies, there was evidence 
of an increased risk of suicide, compared to placebo. There was no evidence that one antidepressant had a larger effect than another, 
although the review suggested that fluoxetine is likely to be the first choice, given guidelines. For subgroup analysis on children aged 6–12 
receiving newer antidepressants, compared to placebo: there was a statistically significant reduction in depression symptoms compared to 
placebo; in two trials, there was no significantly significant increase in the percentage of those who responded/remitted; in two trials , there 
was no evidence that antidepressants improved functioning; and there was a non-statistically significant increase in the risk of suicide. 
Evidence-based medicine reviews: autism spectrum disorder 
Oono IP, et al. 2013. Parent‐mediated early intervention for young children with autism spectrum disorders (ASD). 
Cochrane Database of Systematic Reviews 2013, Issue 4. Ar t. No.: CD009774. DOI: 10.1002/14651858.CD009774.pub2. 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009774.pub2/pdf/standard 
This review of parent-mediated early intervention for ASD included 17 studies, which recruited 919 children. There was some evidence for 
the intervention’s effectiveness in positively changing parent-child interactions and for parent-reported improvements in child language 
comprehension. There was no statistical evidence for most aspects of language communication, whether directly assessed or reported; 
frequency of child initiations in observed parent-child interaction; child adaptive behaviour; and parents’ stress. The review was limited by 
differences in outcome measures between studies. 
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Reichow B, et al. 2012. Early intensive behavioral intervention (EIBI) for young children with autism spectrum 
disorders (ASD). Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD009260. DOI: 
10.1002/14651858.CD009260.pub2. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009260.pub2/epdf 
This review included one RCT and four clinical control trials (CCTs), with a total of 203 participants. The review found that children receiving 
EIBI treatment performed better than children in the comparison groups after about two years of treatment on tests of adaptive behaviour, 
intelligence, social skills, communication and language, autism symptoms, and quality of life. The review warns that the current state of 
evidence is limited because of the reliance on a small number of children, and non-randomised studies.  
Strauss K, et al. 2013. Parent inclusion in early intensive behavior interventions for young children with ASD: a 
synthesis of meta-analyses from 2009 to 2011. Research in developmental disabilities, 34(9), 2967-85. 
This paper synthesised six meta-analyses on early intensive behavioural interventions (EIBI) for young children with ASD. Results suggested 
that EIBI generally had positive medium to large effects for intellectual functioning, language skills and adaptive behaviours. Meta-analysis 
found that EIBI programmes including parents in treatment provision were more effective. Treatment intensity and presence of parent 
training improved outcomes. Higher language and adaptive behaviour functioning at intake benefited most from EIBI. The review was 
limited by only two studies using random allocation of participants, and the literature generally lack studies that use a treatment as usual 
or treatment comparison for controls. 
Reichow B, et al. 2013. Non-specialist psychosocial interventions for children and adolescents with intellectual 
disability or lower-functioning autism spectrum disorders: a systematic review. PLoS Med 10(12): e1001572. 
doi:10.1371/journal.pmed.1001572.  
http://www.plosmedicine.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pmed.1001572&representation=PDF 
This review included 29 studies of psychosocial interventions delivered by non-specialist providers to children with intellectual disabilities 
or lower-functioning ASD. 1,305 participants were included.  Fifteen of the studies included children exclusively with ASD, and 15 of the 
studies were RCTs. For behaviour analytic interventions, the best outcomes were shown for development and daily skills. Cognitive 
rehabilitation, training, and support interventions were found to be most effective for improving developmental outcomes. Parent training 
interventions were found to be most effective for improving developmental, behavioural, and family outcomes. Limitations included reliance 
on non-randomised studies and performance bias.  
Evidence-based medicine reviews: post-traumatic stress disorder 
de Arellano MAR, et al. 2014. Trauma-focused cognitive-behavioral therapy for children and adolescents: assessing 
the evidence. Psychiatric Services, 65(5), 591-602.  
This review assessed ten RCTs of Trauma-focused cognitive-behavioural therapy (TF-CBT) interventions applied to post-traumatic stress 
disorder (PTSD), depression, and behavioural problems. The review found that there was high-level evidence for TF-CBT interventions for 
PTSD, but the evidence was less clear for symptoms of depression or behaviour problems. Of the ten RCTs, 7 involved TF-CBT developers, 
so the authors had concerns regarding investigator bias. The authors also conclude that more research is needed on implementation in 
different settings, and in individuals with varied ethnic and trauma histories, symptoms and cognitive, social and emotional development. 
Gillies D, et al. 2013. Psychological therapies for the treatment of post‐traumatic stress disorder in children and 
adolescents (Review). Evidence‐Based Child Health: A Cochrane Review Journal, 8(3), 1004-116. 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006726.pub2/epdf 
This review included 14 RCTs including 758 children and adolescents ranging in age from 3 to 18 years. Separate analysis was not done for 
younger older children within this age range. The types of trauma related to PTSD were sexual abuse, civil violence, natural disaster, domestic 
violence and motor vehicle accidents. Psychological therapies used in the studies were CBT, exposure-based, psychodynamic, narrative, 
supportive counselling, and eye movement desensitisation and reprocessing (EMDR). Most studies compared a psychological therapy to a 
control group. No study compared psychological therapies to medications or medications in combination with a psychological therapy. 
The review found that across all psychological therapies, improvement was significantly better, and symptoms of PTSD, anxiety and 
depression were significantly lower within a month of completing therapy compared to a control group. CBT therapy had the best evidence 
for effectiveness, with improvements and lower PTSD scores still significant after one year compared with controls; however there was no 
clear evidence for one psychological therapy compared to others.  
Other evidence-based medicine reviews 
Arbesman M, et al. 2013. Systematic review of occupational therapy and mental health promotion, prevention, and 
intervention for children and youth. American journal of occupational therapy, 67(6), e120-e30.  
This systematic review of 124 articles included studies with occupational therapy interventions, and outcome measures of social or peer 
interactions or compliance with adult directives or social rules and norms. The age range of participants was 3–21 years. The review 
concludes there was strong evidence universal occupation- and activity-based interventions focusing on social–emotional learning; school 
wide bullying prevention; and after-school, performing arts, and stress management activities were effective. At the targeted level, the 
review found strong evidence indicating that social and life skills programmes for children who were aggressive, had been rejected, or who 
were teenage mothers were effective. The review reported strong evidence that children with intellectual impairments, developmental 
delays, and learning disabilities benefited from social skills programming and play, leisure, and recreational activities. The review also found 
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MENTAL HEALTH HOSPITALISATIONS 
Introduction 
The following section contains information on hospitalisations in New Zealand using the National Minimum 
Dataset. 
Data source and methods 
Indicator 
Hospitalisations of 15–24 year olds with a mental health diagnosis 
Data sources 
Numerator:  National Minimum Dataset 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years). 
Definition 
Hospitalisations of 15–24 year olds with a primary diagnosis of a mental or behavioural disorder, excluding hospitalisations with 
an Emergency Medicine specialty code on discharge. Refer to Appendix 6 for the codes included. 
Notes on interpretation 
Note 1: The limitations of the National Minimum Dataset are discussed in the appendices. The reader is urged to review this 
information before interpreting any analyses based on hospital admission data. In particular, due to inconsistent uploading of 
Emergency Department (ED) cases to the NMDS, all admissions with an ED health specialty code on discharge have been 
excluded. 
National trends and distribution 
There were 20,063 hospitalisations of 0–24 year olds for mental health conditions between 2010 and 2014, of 
which 17,759 (88.5%) were of 15–24 year olds (Table 166). 






Rate per 100,000 
population 
95% CI 
Mental health hospitalisations 
New Zealand 
0–14 year olds 2,304 461 50.87 48.83–52.99 
15–24 year olds 17,759 3,552 569.04 560.75–577.44 
0–24 year olds 20,063 4,013 262.26 258.66–265.91 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population 
The most common mental health diagnoses among hospitalised 0–14 year olds were eating disorders, followed 
by mood (affective) disorders, pervasive developmental disorders, and mental and behavioural disorders due to 
substance use. For 15–24 year olds, the most common diagnoses were mood (affective) disorders, followed by 
schizotypal and delusional disorders, schizophrenia, and mental and behavioural disorders due to substance use 
(Table 167). 
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Table 167. Hospitalisations for mental health conditions in 0–24 year olds, by age group and primary diagnosis, 










95% CI Per cent 
Mental health hospitalisations  
0–14 years olds 
Eating disorders 314 63 6.93 6.21–7.74 13.6 
Mood (affective) disorders: total 297 59 6.56 5.85–7.35 12.9 
Depression (single and recurrent) 231 46 5.10 4.48–5.80 10.0 
Mania or bipolar affective disorders 26 5 0.57 0.39–0.84 1.1 
Other mood disorders 40 8 0.88 0.65–1.20 1.7 
Pervasive developmental disorders 212 42 4.68 4.09–5.35 9.2 
Mental and behavioural disorders due to 
substance use: total 
142 28 3.14 2.66–3.69 6.2 
Alcohol 112 22 2.47 2.06–2.98 4.9 
Cannabis 16 3 0.35 0.22–0.57 0.7 
Other specified drugs 14 3 0.31 0.18–0.52 0.6 
Reaction to severe stress and/or 
adjustment disorder 
131 26 2.89 2.44–3.43 5.7 
Anxiety disorders 121 24 2.67 2.24–3.19 5.3 
Conduct disorders 120 24 2.65 2.22–3.17 5.2 
Other mental health and behavioural issues 967 193 21.35 20.05–22.74 42.0 
Total 2,304 461 50.87 48.83–52.99 100.0 
15–24 years olds 
Mood (affective) disorders: total 4,591 918 147.11 142.91–151.42 25.9 
Depression (single and recurrent) 2,862 572 91.70 88.41–95.12 16.1 
Mania or bipolar affective disorders 1,409 282 45.15 42.85–47.57 7.9 
Other mood disorders 320 64 10.25 9.19–11.44 1.8 
Schizophrenia 2,878 576 92.22 88.91–95.65 16.2 
Schizotypal and delusional disorders 2,917 583 93.47 90.14–96.92 16.4 
Mental and behavioural disorders due to 
substance use: total 
1,973 395 63.22 60.49–66.07 11.1 
Alcohol 806 161 25.83 24.10–27.67 4.5 
Cannabis 530 106 16.98 15.60–18.49 3.0 
Other specified drugs 637 127 20.41 18.89–22.06 3.6 
Reaction to severe stress and/or 
adjustment disorder 
1,464 293 46.91 44.57–49.37 8.2 
Eating disorders 1,055 211 33.80 31.83–35.91 5.9 
Personality and behaviour disorders 1,081 216 23.87 32.63–36.76 6.1 
Other mental health and behavioural issues 1,800 360 39.74 55.07–60.40 10.1 
Total 17,759 3,552 569.04 560.75–577.44 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population 
Distribution by region 
From 2010 to 2014, mental health hospitalisation rates for 0–24 year olds were significantly higher than the 
national rate in the Northland, Bay of Plenty, Tairawhiti, Taranaki, MidCentral, Whanganui, Capital & Coast, 
South Canterbury, Canterbury, West Coast, and Southern DHBs. Rates were significantly lower than the 
national rate in the Waitemata, Auckland, Counties Manukau, Waikato, Wairarapa and Nelson Marlborough 
DHBs. Rates in the remaining DHBs were not significantly different from the New Zealand rate (Figure 184, 
Table 168). 
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Figure 184. Hospitalisations for mental health conditions in 0–24 year olds, by district health board, New Zealand 
2010–2014 
 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population 







Rate per 100,000 
population 
Rate ratio 95% CI 
Mental health hospitalisations 
0–24 year olds 
Northland 1,033 207 371.78 1.42 1.33–1.51 
Waitemata 2,141 428 226.56 0.86 0.83–0.90 
Auckland 1,356 271 173.13 0.66 0.62–0.70 
Counties Manukau 1,473 295 151.64 0.58 0.55–0.61 
Waikato 1,680 336 247.89 0.95 0.90–0.99 
Bay of Plenty 1,115 223 316.40 1.21 1.14–1.28 
Lakes 488 98 264.92 1.01 0.92–1.10 
Tairawhiti 423 85 468.74 1.79 1.62–1.97 
Taranaki 572 114 303.49 1.16 1.07–1.26 
Hawke's Bay 661 132 244.02 0.93 0.86–1.01 
MidCentral 845 169 283.71 1.08 1.01–1.16 
Whanganui 333 67 318.01 1.21 1.09–1.35 
Hutt Valley 674 135 274.41 1.05 0.97–1.13 
Capital & Coast 1,468 294 290.97 1.11 1.05–1.17 
Wairarapa 132 26 200.67 0.77 0.64–0.91 
Nelson Marlborough 437 87 208.44 0.79 0.72–0.87 
South Canterbury 344 69 403.76 1.54 1.38–1.71 
Canterbury 2,708 542 326.93 1.25 1.20–1.30 
West Coast 172 34 344.89 1.32 1.13–1.53 
Southern 1,875 375 363.00 1.38 1.32–1.45 
New Zealand 20,063 4,013 262.26 1.00   
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Midland region distribution and trends 
From 2010 to 2014 mental health hospitalisation rates for 0–24 year olds were significantly higher than the 
national rate in Bay of Plenty, Tairawhiti and Taranaki, while rates were significantly lower in Waikato and not 
significantly different in Lakes DHB. Rates for 0–14 year olds were significantly higher than the national rate in 
Tairawhiti, significantly lower in Waikato and not significantly different in the remaining Midland DHBs. For 
15–24 year olds hospitalisation rates were not significantly different from the national rate in Waikato but were 
significantly higher than the national rate in all other Midland DHBs (Table 169). 










Rate ratio 95% CI 
Mental health hospitalisations 
0–24 year olds 
Waikato 1,680 336 247.89 0.95 0.90–0.99 
Bay of Plenty 1,115 223 316.40 1.21 1.14–1.28 
Lakes 488 98 264.92 1.01 0.92–1.10 
Tairawhiti 423 85 468.74 1.79 1.62–1.97 
Taranaki 572 114 303.49 1.16 1.07–1.26 
New Zealand 20,063 4,013 262.26 1.00   
0–14 year olds 
Waikato 106 21 25.98 0.51 0.42–0.62 
Bay of Plenty 117 23 51.56 1.01 0.84–1.22 
Lakes 56 11 47.63 0.94 0.72–1.22 
Tairawhiti 44 9 75.11 1.48 1.10–1.99 
Taranaki 57 11 47.63 0.94 0.72–1.22 
New Zealand 2,304 461 50.87 1.00   
15–24 year olds 
Waikato 1,574 315 583.53 1.03 0.97–1.08 
Bay of Plenty 998 200 795.45 1.40 1.31–1.49 
Lakes 432 86 648.30 1.14 1.04–1.25 
Tairawhiti 379 76 1,196.93 2.10 1.90–2.33 
Taranaki 515 103 748.62 1.32 1.21–1.44 
New Zealand 17,759 3,552 569.04 1.00   
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population 
Midland region distribution by cause 
In the Midland DHBs the most common mental health diagnoses among hospitalised 0–24 year olds were mood 
disorders, schizophrenia, schizotypal and delusional disorders and substance use disorders, although the order of 
these diagnoses varied between DHBs (Table 170, Table 171). 
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Table 170. Hospitalisations for mental health conditions in 0–24 year olds, by primary diagnosis, Waikato, Bay of 










95% CI Per cent 
Mental health hospitalisations of 0–24 years olds 
Waikato 
Mood (affective) disorders: total 427 85 63.01 57.31–69.27 25.4 
Depression (single and recurrent) 257 51 37.92 33.56–42.85 15.3 
Mania or bipolar affective disorders 129 26 19.03 16.02–22.61 7.7 
Other mood disorders 41 8 6.05 4.46–8.21 2.4 
Schizotypal and delusional disorders 280 56 41.32 32.18–41.28 16.7 
Schizophrenia 247 49 36.45 36.75–46.45 14.7 
Substance use disorders* 207 41 30.54 26.66–35.00 12.3 
Alcohol 63 13 9.30 7.27–11.89 3.8 
Cannabis 70 14 10.33 8.18–13.05 4.2 
Other specified drugs 74 15 10.92 8.70–13.71 4.4 
Stress or adjustment disorder† 181 36 26.71 23.09–30.89 10.8 
Eating disorders 86 17 12.69 10.28–15.67 5.1 
Other mental health and behavioural issues 252 50 37.18 32.87–42.07 15.0 
Total 1,680 336 247.89 236.33–260.02 100.0 
Bay of Plenty 
Schizotypal and delusional disorders 185 37 52.50 45.46–60.62 16.6 
Substance use disorders* 176 35 49.94 43.09–57.88 15.8 
Alcohol 53 11 15.04 11.50–19.67 4.8 
Cannabis 76 15 21.57 17.23–26.99 6.8 
Other specified drugs 47 9 13.34 10.03–17.73 4.2 
Mood (affective) disorders: total 173 35 49.09 42.30–56.97 15.5 
Depression (single and recurrent) 79 16 22.42 17.99–27.94 7.1 
Mania or bipolar affective disorders 78 16 22.13 17.74–27.62 7.0 
Other mood disorders 16 3 4.54 2.79–7.38 1.4 
Schizophrenia 132 26 37.46 31.59–44.41 11.8 
Personality disorders 114 23 32.35 26.93–38.86 10.2 
Eating disorders 95 19 26.96 22.06–32.95 8.5 
Stress or adjustment disorder† 62 12 17.59 13.73–22.55 5.6 
Other mental health and behavioural issues 178 36 50.51 43.62–58.49 16.0 
Total 1,115 223 316.40 298.39–335.49 100.0 
Lakes DHB 
Schizophrenia 108 22 58.63 48.57–70.77 22.1 
Mood (affective) disorders: total 102 20 55.37 45.62–67.21 20.9 
Depression (single and recurrent) 61 12 33.11 25.78–42.53 12.5 
Mania or bipolar affective disorders 36 7 19.54 14.12–27.05 7.4 
Other mood disorders 5 1 2.71 1.16–6.35 1.0 
Schizotypal and delusional disorders 76 15 41.26 32.97–51.63 15.6 
Substance use disorders* 56 11 30.40 23.41–39.47 11.5 
Alcohol 13 3 7.06 4.12–12.08 2.7 
Cannabis 23 5 12.49 8.32–18.74 4.7 
Other specified drugs 20 4 10.86 7.03–16.77 4.1 
Personality disorders 45 9 24.43 18.26–32.68 9.2 
Stress or adjustment disorder† 29 6 15.74 10.96–22.61 5.9 
Other mental health and behavioural issues 72 14 39.09 31.04–49.21 14.8 
Total 488 98 264.92 242.46–289.45 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Substance use disorders = 
Mental and behavioural disorders due to substance use; † Stress or adjustment disorder = Reaction to severe stress and/or 
adjustment disorder 
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Table 171. Hospitalisations for mental health conditions in 0–24 year olds, by primary diagnosis, Tairawhiti and 










95% CI Per cent 
Mental health hospitalisations of 0–24 years olds 
Tairawhiti 
Schizophrenia 125 25 138.52 116.28–165.00 29.6 
Mood (affective) disorders: total 103 21 114.14 94.13–138.39 24.3 
Depression (single and recurrent) 65 13 72.03 56.52–91.79 15.4 
Mania or bipolar affective disorders 31 6 34.35 24.20–48.75 7.3 
Other mood disorders 7 1 7.76 3.76–16.01 1.7 
Schizotypal and delusional disorders 60 12 66.49 51.66–85.56 14.2 
Substance use disorders* 55 11 60.95 46.83–79.31 13.0 
Alcohol 14 3 15.51 9.24–26.04 3.3 
Cannabis 30 6 33.24 23.29–47.45 7.1 
Other specified drugs 11 2 12.19 6.81–21.83 2.6 
Stress or adjustment disorder† 27 5 29.92 20.56–43.53 6.4 
Other mental health and behavioural issues 53 11 58.73 44.91–76.81 12.5 
Total 423 85 468.74 426.23–515.46 100.0 
Taranaki 
Mood (affective) disorders: total 187 37 99.22 85.99–114.49 32.7 
Depression (single and recurrent) 120 24 63.67 53.25–76.12 21.0 
Mania or bipolar affective disorders 50 10 26.53 20.13–34.97 8.7 
Other mood disorders 17 3 9.02 5.63–14.45 3.0 
Schizotypal and delusional disorders 74 15 39.26 31.28–49.28 12.9 
Substance use disorders* 71 14 37.67 29.87–47.51 12.4 
Alcohol 24 5 12.73 8.56–18.95 4.2 
Cannabis 20 4 10.61 6.87–16.39 3.5 
Other specified drugs 27 5 14.33 9.85–20.84 4.7 
Stress or adjustment disorder† 72 14 38.20 30.34–48.10 12.6 
Schizophrenia 36 7 19.10 13.80–26.44 6.3 
Other mental health and behavioural issues 132 26 70.04 59.07–83.04 23.1 
Total 572 114 303.49 279.65–329.36 100.0 
Numerator: National Minimum Dataset; Denominator: Statistics NZ Estimated Resident Population; * Substance use disorders = 
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SUICIDE AND SELF-HARM 
Introduction 
New Zealand has the highest youth suicide rate in the OECD, based on the latest country data available.292 In 
New Zealand, 15–24 year old males have the highest rate of suicide of any age group. The Māori youth suicide 
rate is around twice the non-Māori rate.292 For the population as a whole, suicide rates are higher in areas with 
the highest index of deprivation scores and in rural areas.292  
Population-level risk factors for suicide include: barriers to accessing health care; stigma associated with help-
seeking behaviour; assimilation, disruption of traditional social structure, and stressors of acculturation 
particularly for indigenous and displaced people; economic crises resulting in unemployment, particularly for 
men; disasters; media reporting, especially if methods of suicide are provided, if the decedent was a celebrity, 
and if the suicide was romanticised rather than reported in association with relevant mental illness and the effect 
the suicide had on survivors; direct access or proximity to means (including pesticides, firearms, heights, 
railway tracks, poisons, and medications).391-394 Individual risk factors include: past suicide attempts, 
psychopathology; feelings of hopelessness; male gender; a family history of suicidal behaviours; genetic factors; 
sexual minority status; exposure to early-life adversity such as parental neglect, childhood physical, sexual or 
emotional abuse; status-loss, such as job-loss, loss of property or home, or divorce; discrimination and isolation; 
and exposure to suicidal behaviour from others. Interpersonal conflict; impulsive aggression; conduct disorder; 
antisocial behaviour and substance misuse are particularly important risk factors for young people.391,393-397 
Māori ethnicity, socioeconomic disadvantage and child welfare care are also associated with higher suicide rates 
among young people in New Zealand.398,399  
The degree to which mental illness contributes to suicide is debated400-404 although around 90% of suicide cases 
may have a mental disorder.405 The mental disorder with the highest relative risk of suicide is borderline 
personality disorder, followed by depression and bipolar disorder.406 Major depressive episodes account for at 
least half of deaths by suicide.391 Younger age at suicide is associated with cluster B personality disorders and 
substance misuse disorders.391  
The evidence base for suicide and self-harm interventions in young people is not well-established.407,408 
Interventions with the strongest evidence are teaching those who are primary points of contact for high-risk 
youth, to identify, assess and manage risk of suicidality and refer when appropriate (gatekeeper training), 
reduction in access to the means of suicide, and good-quality mental health care.409 There are few studies of 
suicide prevention programmes targeting indigenous youth, and the study designs make drawing conclusions 
difficult.410,411 A caring parent or other family member and a fair, safe school environment with higher levels of 
health services appear to be protective against suicide attempts.158,396 
The risk factor profiles for suicide mortality and hospital admissions for intentional self-harm differ; in 2012 
hospitalisation rates for self-harm were highest for young women aged 15 to 19 years.292 The 2012 Youth2000 
secondary school survey found that in the past year, among secondary students, over one-fifth of females and 
almost 10% of males had suicidal ideation; 6% of females and 2% of males had attempted suicide; and 29% of 
females and 18% of males had self-harmed.291 Risk of suicidal ideation, a suicide plan, or a suicide attempt are 
significantly higher in young people, compared to those aged over 25 years.350 The risk of suicidal behaviours 
was also increased in those with low household incomes and those living in areas with high index of deprivation 
scores.350 For Māori youth, risk factors for suicide attempt were found to be depressive symptoms, having a 
close friend or family member commit suicide, being 12–15 years old compared to 16–18 years old, having 
anxiety symptoms, witnessing family violence, and being uncomfortable in New Zealand European social 
settings.412 
A variety of psychosocial interventions for self-harm are probably efficacious including cognitive and other 
behavioural therapies; family, interpersonal, and psychodynamic approaches; and mentalisation-based 
therapy.413,414 Some school, community and healthcare based interventions have a significant effect on suicidal 
ideation, suicide attempts or deliberate self-harm including psychotherapeutic interventions and also less formal 
approaches such as social support, psychoeducation and motivational interviewing. A combination of individual 
therapy, particularly for suicidal ideation, and group therapy for suicide attempts, may achieve the best 
results.415 Early intervention is important to support young people who self-injure and successful interventions 
may be those that promote mindfulness, resilience and self-esteem.416 
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The following section uses information from the National Minimum Dataset and the National Mortality 
Collection to review hospital admissions for intentional self-harm and mortality from suicide in 0–24 year olds. 
Data source and methods 
Indicator 
Deaths from suicide among 0–24 year olds 
Data sources 
Numerator:  National Mortality Collection 
Denominator:  Statistics NZ Estimated Resident Population (with linear extrapolation being used to calculate denominators 
between Census years) 
National suicide trends and distribution 
From 2000 to 2011 suicide rates in 0–24 year olds remained relatively stable and the apparent rate increase in 
2012 is not significantly different to 2008–09 and 2010–11 rates. On average during this period, 118 young 
people aged under 25 years died each year as the result of suicide (Figure 185). Suicide rates for 15–24 year 
olds were significantly higher than rates for 0–14 year olds in this time period (Figure 186). 
Figure 185. Deaths from suicide among 0–24 year olds, New Zealand 2000–2012 
 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Numbers and rates are per 
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Figure 186. Deaths from suicide in 0–24 year olds, by age group, New Zealand 2000–2012 
 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Rates are per two year 
period except for 2012, which is for a single year 
From 2000 to 2012 the suicide rate was consistently highest for Māori and lowest for Asian/Indian, and within 
this time period from 2008–09 to 2012 the suicide rate for Māori rose substantially compared with other ethnic 
groups (Figure 187).  
Figure 187. Deaths from suicide in 0–24 year olds, by ethnicity, New Zealand 2000–2012 
 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Rates are per two year 
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Distribution by demographic factors 
Between 2008 and 2012 there were no deaths from suicide at ages eight years or under and few deaths from age 
9–13 years. From age 14, suicide rates increased sharply with increasing age, before peaking in the early 20s. 
For 16–24 year olds the suicide rates were not statistically different by year of age (Figure 188). Suicide rates 
were higher for males than females from age 15 years (Figure 189). 
Figure 188. Deaths from suicide in 0–24 year olds, by age, New Zealand 2008–2012 
 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Caution: rates for those 
aged less than 14 years are affected by small number variation 
Figure 189. Deaths from suicide in 0–24 year olds, by age and sex, New Zealand 2008–2012 
 
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Rates suppressed for those 
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Between 2008 and 2012 there was a social gradient in suicide rates for 0–24 year olds; areas with higher 
NZDep2013 scores (deciles 5–10) had significantly higher suicide rates than areas with the lowest scores 
(deciles 1–2). Compared with European/Other, rates were significantly higher for Māori, significantly lower for 
Asian/Indian, and not significantly different for Pacific. Male suicide rates were significantly higher than female 
rates. The suicide rate was much higher for 15–24 year olds compared with 0–14 year olds; 625 deaths (94.1%) 
were in the older age group and 39 deaths (5.9%) in 0–14 year olds (Table 172). 
Table 172. Deaths from suicide in 0–24 year olds, by demographic factors, New Zealand 2008–2012 
Variable 
 Number:  
2008−2012  
 Rate per 100,000  
0–24 year olds  
 Rate ratio  95% CI 
Suicide among 0–24 year olds 
New Zealand 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 71 5.18 1.00   
Deciles 3–4 84 6.39 1.23 0.90–1.69 
Deciles 5–6 135 9.45 1.82 1.37–2.43 
Deciles 7–8 140 8.69 1.68 1.26–2.23 
Deciles 9–10 233 12.50 2.41 1.85–3.15 
Prioritised ethnicity 
Māori 247 14.19 1.86 1.57–2.19 
Pacific 70 10.22 1.34 1.03–1.73 
Asian/Indian 26 2.90 0.38 0.25–0.57 
MELAA <5 s s s 
European/Other 319 7.65 1.00 0.86–1.17 
Gender 
Female 186 5.01 1.00 0.82–1.23 
Male 478 12.34 2.47 2.08–2.92 
Age group 
0–14 years 39 0.87     
15–24 years 625 20.24     
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Rates are per 100,000 0–24 
year olds; Rate ratios are unadjusted; Decile is NZDep2013 
Distribution by region 
Between 2008 and 2012 suicide rates among 0–24 year olds varied by district health board (Figure 190). For the 
same period, suicide rates for 15–24 year olds were significantly higher than the national rate in Northland, Bay 
of Plenty, Tairawhiti, and South Canterbury DHBs, and significantly lower in Waitemata, Auckland and Capital 
& Coast DHBs. In remaining district health boards there was no significant difference from the national rate 
(Table 173).  
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Figure 190. Deaths from suicide in 0–24 year olds, by District Health Board, New Zealand 2008–2012 
  
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Rate ratios are unadjusted 






Rate per 100,000 
population 
Rate ratio 95% CI 
Suicide 
15–24 year olds 
Northland 29 6 30.56 1.51 1.04–2.19 
Waitemata 53 11 14.08 0.70 0.53–0.92 
Auckland 52 10 14.17 0.70 0.53–0.93 
Counties Manukau 85 17 23.05 1.14 0.91–1.43 
Waikato 52 10 19.57 0.97 0.73–1.28 
Bay of Plenty 37 7 29.94 1.48 1.06–2.06 
Lakes 19 4 28.61 1.41 0.90–2.23 
Tairawhiti 13 3 41.41 2.05 1.18–3.54 
Taranaki 11 2 15.99 0.79 0.44–1.43 
Hawke's Bay 26 5 26.80 1.32 0.89–1.96 
MidCentral 35 7 27.68 1.37 0.97–1.92 
Whanganui 9 2 22.48 1.11 0.58–2.15 
Hutt Valley 19 4 19.87 0.98 0.62–1.55 
Capital & Coast 28 6 12.30 0.61 0.42–0.89 
Wairarapa 9 2 38.67 1.91 0.99–3.69 
Nelson Marlborough 12 2 15.83 0.78 0.44–1.38 
South Canterbury 20 4 63.18 3.12 2.00–4.87 
Canterbury 63 13 17.84 0.88 0.68–1.14 
West Coast 0 .. .. .. .. 
Southern 52 10 22.00 1.09 0.82–1.44 
New Zealand 625 125 20.24 1.00   
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population; Rate ratios are unadjusted 
Midland region distribution and trends 
Between 2008 and 2012, the suicide rate in 0−24 year olds was significantly higher than the national rate in Bay 
of Plenty and Tairawhiti. Suicide rates were not significantly different from the national rate in the other 
Midland DHBs. In all the Midland DHBs, the majority of suicides were of 15−24 year olds. The same pattern of 
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Rate ratio 95% CI 
Suicide 
0–24 year olds 
Waikato 53 11 7.92 0.91 0.68–1.20 
Bay of Plenty 42 8 12.04 1.38 1.01–1.88 
Lakes 21 4 11.33 1.30 0.84–2.00 
Tairawhiti 14 3 15.52 1.77 1.04–3.01 
Taranaki 11 2 5.88 0.67 0.37–1.22 
New Zealand 664 133 8.75 1.00   
0–14 year olds 
Waikato <5 s s s s 
Bay of Plenty 5 1 2.22 2.56 1.01–6.50 
Lakes <5 s s s s 
Tairawhiti <5 s s s s 
Taranaki 0 .. .. .. .. 
New Zealand 39 8 0.87 1.00   
15–24 year olds 
Waikato 52 10 19.57 0.97 0.73–1.28 
Bay of Plenty 37 7 29.94 1.48 1.06–2.06 
Lakes 19 4 28.61 1.41 0.90–2.23 
Tairawhiti 13 3 41.41 2.05 1.18–3.54 
Taranaki 11 2 15.99 0.79 0.44–1.43 
New Zealand 625 125 20.24 1.00   
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
Regional trends 
From 2000 to 2012, the year to year variations in rates (the result of small numbers) make interpretation of 
suicide trends difficult (Figure 191). 
























































































































































































































































































Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
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Intentional self-harm 
New Zealand trends 
From 2000 to 2011 hospitalisation rates of 0–24 year olds for intentional self-harm remained stable between 40 
and 60 hospitalisations per 100,000. Since 2012 rates have increased, and in 2014 reached a high of 79.88 
hospitalisations per 100,000, significantly higher than for the period 2000–2012. On average from 2000 to 2014 
there were 827 hospitalisations of 0–24 year olds each year due to intentional self-harm (Figure 192). From 
2000 to 2014 hospitalisations for intentional self-harm for 15–24 year olds were significantly higher than for   
0–14 year olds (Figure 193). 
Figure 192. Hospitalisations for intentional self-harm in 0–24 year olds, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (excludes emergency department cases); Denominator: Statistics NZ Estimated Resident 
Population  
Figure 193. Hospitalisations for intentional self-harm in 0–24 year olds, by age group, New Zealand 2000–2014 
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Intentional self-harm hospitalisation rates for 0–24 year olds differed by ethnic group. From 2000 to 2014 
European/Other hospitalisation rates for intentional self-harm were consistently higher than for all other ethnic 
groups, though only marginally so in 2009. Since 2011, European/Other and Māori hospitalisation rates have 
increased more than Pacific and Asian/Indian rates (Figure 194).  
Figure 194. Hospitalisations for intentional self-harm in 0–24 year olds, by ethnicity, New Zealand 2000–2014 
 
Numerator: National Minimum Dataset (excludes emergency department cases); Denominator: Statistics NZ Estimated Resident 
Population 
Distribution by demographic factors 
From 2010 to 2014 there were no hospitalisations for intentional self-harm for children aged under eight years, 
fewer than five hospitalisations each at ages eight, nine and ten, and few hospitalisations for 11–12 year olds. 
From age 13 years, age-specific hospitalisation rates for intentional self-harm increased sharply before peaking 
in the mid-teenage years. Hospitalisation rates for 22–24 year olds were significantly lower than for those in 
their mid-teenage years (Figure 195). 
Figure 195. Hospitalisations for intentional self-harm in 0–24 year olds, by age, New Zealand 2010–2014 
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From 2010 to 2014 hospitalisation rates for intentional self-harm for 0–24 year olds were significantly higher in 
areas with higher NZDep2013 scores (deciles 3–10) compared with areas with the lowest scores (deciles 1–2). 
Compared with European/Other, hospitalisation rates were significantly lower for Māori, Pacific and 
Asian/Indian and not significantly different for MELAA. The rates for females were significantly higher than for 
males. The majority (86.6%) of intentional self-harm hospitalisations were for 15–24 year olds (Table 175). 
Table 175. Hospitalisations for intentional self-harm in 0–24 year olds, by demographic factor, New Zealand 
2010–2014 
Variable 
 Number:  
2010−2014  
 Rate per 100,000  
0–24 year olds  
Rate ratio 95% CI 
Intentional self-harm in 0–24 year olds 
New Zealand 
NZDep2013 Index of deprivation quintile 
Deciles 1–2 704 50.19 1.00   
Deciles 3–4 878 66.05 1.32 1.19–1.45 
Deciles 5–6 895 62.27 1.24 1.12–1.37 
Deciles 7–8 1,259 77.71 1.55 1.41–1.70 
Deciles 9–10 1,160 62.37 1.24 1.13–1.36 
Prioritised ethnicity 
Māori 1,131 63.44 0.80 0.74–0.85 
Pacific 230 32.82 0.41 0.36–0.47 
Asian/Indian 169 18.01 0.23 0.19–0.26 
MELAA 61 62.19 0.78 0.61–1.01 
European/Other 3,290 79.66 1.00   
Gender 
Female 3,609 96.46 1.00   
Male 1,305 33.39 0.35 0.32–0.37 
Age group 
5–14 years 658 22.02     
15–24 years 4,256 136.37     
Numerator: National Minimum Dataset (excludes emergency department cases); Denominator: Statistics NZ Estimated Resident 
Population; Rate ratios are unadjusted; Ethnicity is level 1 prioritised; Decile is NZDep2013  
Distribution by region 
Between 2010 and 2014 hospitalisation rates for intentional self-harm in 0–24 year olds were significantly 
higher than the New Zealand rate in Waitemata, Bay of Plenty, Capital & Coast, Wairarapa, Nelson 
Marlborough, South Canterbury, and West Coast. Rates were significantly lower than the New Zealand rate in 
Auckland, Counties Manukau, Waikato, Taranaki and Hawke’s Bay. Rates in the remaining DHBs were not 
significantly different from the New Zealand rate (Figure 196, Table 176).  
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Figure 196. Hospitalisations for intentional self-harm in 0–24 year olds, by district health board, New Zealand 
2010–2014 
  
Numerator: National Minimum Dataset (excludes emergency department cases); Denominator: Statistics NZ Estimated Resident 
Population  







Rate per 100,000 
0–24 year olds 
Rate ratio 95% CI 
Intentional self-harm 
0–24 year olds 
Northland 206 41 74.14 1.15 1.00–1.33 
Waitemata 669 134 70.79 1.10 1.02–1.19 
Auckland 135 27 17.24 0.27 0.23–0.32 
Counties Manukau 173 35 17.81 0.28 0.24–0.32 
Waikato 314 63 46.33 0.72 0.64–0.81 
Bay of Plenty 320 64 90.81 1.41 1.26–1.58 
Lakes 121 24 65.69 1.02 0.85–1.22 
Tairawhiti 71 14 78.68 1.22 0.97–1.55 
Taranaki 98 20 52.00 0.81 0.66–0.99 
Hawke's Bay 96 19 35.44 0.55 0.45–0.68 
MidCentral 168 34 56.41 0.88 0.75–1.02 
Whanganui 62 12 59.21 0.92 0.72–1.18 
Hutt Valley 183 37 74.50 1.16 1.00–1.34 
Capital & Coast 831 166 164.71 2.56 2.38–2.76 
Wairarapa 110 22 167.23 2.60 2.16–3.14 
Nelson Marlborough 277 55 132.12 2.06 1.82–2.32 
South Canterbury 105 21 123.24 1.92 1.58–2.33 
Canterbury 549 110 66.28 1.03 0.94–1.13 
West Coast 67 13 134.35 2.09 1.64–2.66 
Southern 347 69 67.18 1.05 0.94–1.17 
New Zealand 4,914 983 64.23 1.00   
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Midland region distribution and trends 
Between 2010 and 2014 hospitalisation rates for intentional self-harm in 0–24 year olds were significantly 
higher than the national rate in the Bay of Plenty, significantly lower in Waikato and Taranaki, and not 
significantly different in the Lakes and Tairawhiti DHBs (Table 177). 






Rate per 100,000 
0–24 year olds 
Rate ratio 95% CI 
Intentional self-harm 
0–24 year olds 
Waikato 314 63 46.33 0.72 0.64–0.81 
Bay of Plenty 320 64 90.81 1.41 1.26–1.58 
Lakes 121 24 65.69 1.02 0.85–1.22 
Tairawhiti 71 14 78.68 1.22 0.97–1.55 
Taranaki 98 20 52.00 0.81 0.66–0.99 
New Zealand 4,914 983 64.23 1.00   
Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
Regional trends 
From 2000 to 2014 in Lakes, Tairawhiti and Taranaki DHBs self-harm hospitalisation rates in 0–24 year olds 
were variable, but generally similar to national rates. In Waikato the rate rose over time since 2010 but less 
steeply than the national rate increase. In the Bay of Plenty there was a steep and significant rise in rates from 
2012 to 2014 (Figure 197, Figure 198). 
Figure 197. Hospitalisations for intentional self-harm in 0–24 year olds, Waikato, Bay of Plenty and Lakes DHB vs 


































































































































































































































Numerator: National Mortality Collection; Denominator: Statistics NZ Estimated Resident Population 
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APPENDIX 1: SEARCH METHODS FOR POLICY 
DOCUMENTS AND EVIDENCE-BASED REVIEWS 
One of the features of this reporting series is the inclusion of sections which briefly review local policy 
documents (e.g. Ministry of Health Strategies and Toolkits) and international evidence-based reviews that are 
relevant to the prevention and or management of child and youth health issues. The approaches taken in these 
sections borrow heavily from the principles of the Evidence-Based Medicine (EBM) movement, which has 
emerged in recent years as a means of providing busy clinicians with up to date overviews of the evidence in 
particular areas.417,418 Such overviews generally rely on reviewers collating all of the available evidence 
(published and unpublished trials, observational studies etc.), evaluating it in a rigorous manner, and then 
publishing the resulting synthesis of the evidence in a format which allows clinicians to evaluate quickly the 
effectiveness of the intervention(s) reviewed. While the evidence base for population level interventions is much 
less developed than that for individual patient therapies (as such interventions often have longer follow up times, 
more diffuse outcomes, and less readily identifiable “control” groups419), there is nevertheless a reasonable body 
of evidence emerging about the effectiveness of specific population level interventions.  
 
The brief overviews presented in this report therefore aim to provide busy DHB staff with a logical starting 
point from which to consider the types of interventions available to address particular child and youth health 
issues. In preparing these overviews the methodology used was not exhaustive but rather involved searching a 
number of EBM journals and databases (e.g. the Cochrane Library) as well as Ovid MEDLINE and PubMed for 
systematic reviews of population level interventions in child and youth health (see Text Box below). 
 
Methodology used in preparing policy/evidence-based review sections 
New Zealand (health) policy documents  
Each review section aims to provide an overview of Ministry of Health (or where appropriate, other Government Agency) policy 
documents and strategies relevant to the area. The Ministry of Health’s website (http://www.moh.govt.nz/moh.nsf) was searched 
for key documents. All identified documents were then scanned and the most relevant summarised, focussing on those which 
provided strategic guidance to DHBs on the prevention/population level management of the issues in question.  
Evidence-based and other reviews 
The five databases listed below were searched for reviews considering the effectiveness of population level interventions to 
prevent and/or manage each of the issues in question. While this list is not exhaustive, the databases were selected on the basis 
of the calibre of the institutions publishing the reviews. In addition, the search strategy concentrated on publications which 
attempted to synthesise all of the available evidence, thereby providing as broad as possible coverage of the relevant literature. 
In general, only literature from 2000 onwards was searched, although earlier publications were included if there was a paucity of 
more recent information. While individual trials and protocols were not specifically sought, if there was no other relevant 
information available, an attempt was made to locate individual research reports or recommendations. While they are not 
totally comprehensive, it is nevertheless hoped that these brief overviews will provide a useful starting point for DHBs wishing 
to explore strategies to address particular child and youth health issues. 
Evidence-Based Medicine Reviews This database allows seven EBM resources to be searched at once including The Database of 
Reviews of Effects (DARE), Health Technology Assessments (HTA) and the NHS Economic Evaluation Database (NHSEED) all 
produced by National Health Services’ Centre for Reviews and Dissemination at the University of York, U.K., The Cochrane 
Database of Systematic Reviews, and the ACP Journal Club. 
National Guideline Clearinghouse http://www.guideline.gov/  This is a searchable database of evidence-based clinical practice 
guidelines maintained by the Agency for Healthcare Research and Quality in the United States. 
Centre for Reviews and Dissemination (CRD): This is a department of the University of York and is part of the National Centre for 
Health Research (NCHR) (http://www.york.ac.uk/inst/crd/). While CRD produces the database of Review Effects (DARE), captured 
in the Evidence-Based Medicine Review Database, searching the CRD site identifies other reviews not captured by DARE. This 
database is available through most local library services.  
National Institute for Health and Clinical Excellence (NICE): This is an independent organisation based in the United Kingdom 
which provides national guidance on the promotion of good health and the prevention and treatment of ill health. 
(http://www.nice.org.uk/ )  
Guide to Community Preventive Services: Systematic Reviews and Evidence Based Recommendations: This guide was 
developed by the non-federal Task Force on Community Preventive Services whose members are appointed by the Director of 
the Centre for Disease Control and Prevention (CDC). The Community Guide summarises what is known about the effectiveness, 
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While undertaking this task it quickly became apparent that the quality of evidence varied considerably 
depending on the issue reviewed. In addition, in many cases, the research provided reasonably strong guidance 
about what did not work (e.g. current evidence suggests additional social support is ineffective in preventing 
preterm birth in high-risk women), but little advice on effective interventions.  
 
Thus in many cases these brief overviews serve to highlight the current paucity of evidence on population level 
interventions to address child and youth health needs (although the absence of systematic/other reviews does not 
rule out the existence of individual studies in particular areas). In this context, while the search strategy utilised 
did not primarily aim to identify individual studies, or reviews of individual patient therapies, in cases where 
such studies were identified, and where no other systematic reviews were available, they were included under 
the heading of Other Relevant Publications. In such cases the reader needs to be aware that these studies were 
identified in a non-systematic manner and that their findings should therefore not be given the same weight as 
systematic reviews (e.g. Cochrane reviews) where all of the available evidence has been rigorously evaluated. 
The evidence-based review tables also include some topical New Zealand research publications. 
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APPENDIX 2: STATISTICAL SIGNIFICANCE TESTING  
Inferential statistics are used when a researcher wishes to use a sample to draw conclusions about a larger 
population as a whole (for example, weighing a class of 10 year old boys, in order to estimate the average 
weight of all 10 year old boys in New Zealand). The findings obtained from the sample provide an estimate for 
the population, but will always differ from it to some degree, simply due to chance. Similarly, samples are used 
when a researcher questions whether the risk of developing a particular condition is different between two 
groups, and the fit of the estimate obtained from the samples to the actual population needs to be carefully 
considered. An example of this would be a study examining whether lung cancer is more common in smokers or 
non-smokers: researchers using sample groups would have to consider the possibility that some of the 
differences observed arose from chance variations in the populations sampled.  
 
Over time, statisticians have developed a range of measures to quantify the uncertainty associated with random 
sampling error. These measures can assign a level of confidence to estimates and conclusions drawn from 
samples, allowing researchers to assess, for example, whether the average weight of boys in the sample reflects 
the true weight of all 10 year old boys, or the rates of lung cancer in smokers are really different to those in non-
smokers. Two of the most frequently used statistical significance tests are: 
 
P values: The p value from a statistical test measures the probability of finding a difference at least as large as 
the one observed between groups, if there were no real differences between the groups studied. For example, if 
statistical testing of the difference in lung cancer rates between smokers and non-smokers resulted in a p value 
of 0.01, this tells us that the probability of such a difference occurring if the two groups were identical is 0.01 or 
1%. Traditionally, results are considered to be statistically significant if the p value is <0.05; that is, when the 
probability of the observed differences occurring by chance is less than 5%.420 
 
Confidence Intervals: When sampling from a population a confidence interval is a range of values that 
contains the measure of interest. While a confidence interval for the average height of 10 year old boys could be 
20cm to 200cm, for example, the smaller range of 130cm to 150cm is a more informative statistic. A 95% 
confidence interval suggests that if you were to repeat the sampling process 100 times, 95 times out of 100 the 
confidence interval would include the true value.420 
Statistical significance testing in this report 
When tests of statistical significance have been applied in a particular section, the statistical significance of the 
associations presented has been signalled in the text with the words significant, or not significant in italics. 
Where the words significant or not significant do not appear in the text, then the associations described do not 
imply statistical significance or non-significance.  
Several data sources are used in this report... In general they belong to one of two groups: 1) population surveys 
or 2) routine administrative datasets. The relevant statistical testing for each of these data sources are as follows: 
 
Population surveys: Some of indicators reported on here are derived from data from national surveys where 
information from a sample has been used to make inferences about the population as a whole. In this context, 
statistical significance testing is appropriate and, where such information is available in published reports, it has 
been included in the text accompanying graphs and tables. In a small number of cases, information on statistical 
significance was not available, and any associations described do not imply statistical significance. 
 
Numbers derived from routine administrative data: A large number of the indicators included in this report 
are based on data from New Zealand’s administrative datasets, for example the National Mortality Collection, 
which capture information on all of the events occurring in a particular category.  
 
Rate ratios derived from routine administrative data: To facilitate comparisons between different time 
periods, and for examining the data from New Zealand in a wider context, whenever measures of association 
(rate ratios) are presented in this report, 95% confidence intervals have been provided.421 
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APPENDIX 3: DATASETS USED IN THIS REPORT 
This report contains information derived from several national administrative datasets. These are described 
briefly below, and limitations to be aware of when interpreting results drawn from these sources are outlined. 
The National Mortality Collection 
The National Mortality Collection is a dataset managed by the Ministry of Health which contains information on 
the underlying cause, or causes, of death along with basic demographic data for all deaths registered in New 
Zealand since 1988. Fetal and infant death data are a subset of the Mortality Collection, with cases in this subset 
having additional information on factors such as birth weight and gestational age.2 Each of the approximately 
28,000 deaths occurring in New Zealand each year is coded manually by Ministry of Health staff. For most 
deaths the Medical Certificate of Cause of Death provides the information required, although coders also have 
access to information from other sources such as Coronial Services, Police, NZ Transport Agency, the NZ 
Cancer Registry, the Institute of Environmental Science and Research, and Water Safety NZ.422 
The National Minimum Dataset 
The National Minimum Dataset (NMDS) is national hospital discharge dataset and is maintained by the 
Ministry of Health. It is used for policy formation, performance monitoring, and research purposes, providing 
key information about the delivery of hospital inpatient and day patient health services both nationally and on a 
provider basis. It is also used for funding purposes.423 
Information in the NMDS includes principal and additional diagnoses, procedures, external causes of injury, 
length of stay and sub-specialty codes; and demographic information such as age, ethnicity and usual area of 
residence. Data have been submitted by public hospitals electronically since the original NMDS was 
implemented in 1993, with additional data dating back to 1988 also included. The private hospital discharge 
information for publicly funded events has been collected since 1997. The current NMDS was introduced in 
1999.423 
The Birth Registration Dataset 
Since 1995 all NZ hospitals and delivering midwives have been required to notify the Department of Internal 
Affairs within five working days of the birth of a live or stillborn baby. This applies to stillborn babies born at or 
more than 20 weeks gestation, or those weighing 400g or more; prior to 1995, only stillborn babies reaching 
more than 28 weeks of gestation required birth notification. Information on the hospital’s notification form 
includes maternal age, ethnicity, multiple birth status, and the baby’s sex, birth weight and gestational age. In 
addition, parents must jointly complete a birth registration form as soon as reasonable practicable after the birth, 
and within two years of delivery, which duplicates the above information with the exception of birth weight and 
gestational age. Once both forms are received by Internal Affairs the information is merged into a single entry. 
This two-stage process it is thought to capture 99.9% of births occurring in New Zealand and cross-checking at 
the receipting stage allows for the verification of birth detail.424 
PRIMHD 
PRIMHD (Programme for the Integration of Mental Health Data) is the Ministry of Health’s dataset that 
contains information on mental health and addiction service activity and outcomes for people using services. 
The district health boards and non-governmental organisations (NGOs) working in mental health provide data 
on client referrals and service activities to the Ministry and DHBs also provide information on any outcomes.  
 
The Ministry of Health’s “NGO Guide to PRIMHD” explains that the information gathered is intended to 
enhance service planning and provision by service providers at national and local levels.  The intention is for 
PRIMHD to help determine whether services are being provided to people who need them, whether services are 
being provided at the right time and in the right place, and what effects on outcomes services are having. Further 
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Dataset limitations 
There are limitations when using any of these datasets. The following are of particular relevance to this report. 
Clinical coding accuracy and coding changes over time 
The quality of data submitted to the administrative national datasets may vary. While the data for the National 
Mortality Collection and the Birth Registration Dataset are coded by single agencies, the clinical information 
held in the NMDS is entered by health providers before being collated by the Ministry of Health. In a 2001 
review of the quality of coding in the data submitted to the NMDS, 2,708 events were audited over ten sites 
during a three month period. Overall the audit found that 22% of events required a change in coding, although 
this also included changes at a detailed level. Changes to the principal diagnosis involved 11% of events, to 
additional diagnoses 23%, and to procedure coding, 11%. There were 1,625 external causes of injury codes, of 
which 15% were re-coded differently.425 These findings were similar to an audit undertaken a year previously. 
While the potential for such coding errors must be taken into consideration when interpreting the findings of this 
report, the average 16% error rate indicated by the 2001 review may be an overestimate as, in the majority of the 
analyses undertaken in this report, only the principal diagnosis is used to describe the reason for admission. 
Changes in the coding systems used over time may result in irregularities in time series analyses.422 New 
Zealand hospitals use the clinical coding classification developed by the World Health Organization and 
modified by the National Centre for Classification in Health, Australia. The current classification is called The 
International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian 
Modification (ICD-10-AM), the Australian Classification of Health Interventions (ACHI) and Australian 
Coding Standards (ACS). The introduction of ICD-10-AM represented the most significant change in 
classification in over 50 years, expanding the number of codes from ~5,000 to ~8,000, to provide for recently 
recognised conditions and allow greater specificity about common diseases. 
 
From 1988 until 1999, clinical information in the NMDS was coded using versions of the ICD-9 classification 
system. From July 1999 onwards, the ICD-10-AM classification system has been used. Back and forward 
mapping between the two systems is possible using predefined algorithms,426 and for most conditions there is a 
good correspondence between ICD-9 and ICD-10-AM codes. Care should still be taken when interpreting time 
series analyses which include data from both time periods as some conditions may not be directly comparable 
between the two coding systems. 
 
Variation in reporting hospitalisations to the NMDS  
Historically, there have been differences in the way New Zealand’s 20 district health boards (DHBs) have 
reported their emergency department (ED) hospitalisations to the NMDS, which can affect the interpretation of 
hospitalisation data. Inconsistent recording of ED cases has resulted from differing definitions of the time spent 
in the ED, and at what point this time constitutes an admission. This is important in paediatrics where 
hospitalisations for acute onset infectious and respiratory diseases in young children especially are mainly of 
short duration. In addition, there are regional differences in treatment processes for paediatric emergency cases.  
This report includes all ED day cases in its analyses of hospitalisations for medical conditions. This approach 
differs from that commonly used by the Ministry of Health when analysing NMDS hospital discharge data, 
which the Ministry of Health uses to minimise the impact of the inconsistent reporting of ED cases. Short stay 
ED events are often excluded from the Ministry’s analyses to improve comparability between regions. However, 
as noted above, the treatment of children in acute cases differs from that of adults, and the inclusion of ED day 
cases is justified when considering hospitalisations for medical conditions, despite inconsistencies in the dataset. 
The Ministry of Health’s practice of filtering out ED day cases for hospitalisations for injuries is followed in this 
report as it is considered that the processes for injury assessments are relatively consistent around the country.  
Further information on the details of the inconsistencies can be seen in earlier reports by the NZCYES 
www.otago.ac.nz/ncyes 
 
Changes in the way ethnicity information has been recorded over time 
Due to inconsistencies in the way ethnicity information was recorded in the health sector, and in census data 
before 1996, all ethnic group specific analyses in this report are for the year 1996 onwards. See Appendix 4 for 
a brief review of the changes in the recording of ethnicity information over the past 35 years in New Zealand. 
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APPENDIX 4: ETHNICITY DATA 
Because of inconsistencies in the manner in which ethnicity information in New Zealand was collected prior to 
1996, all ethnic group specific analyses presented in this report are for the 1996 year onwards, and reflect self-
identified concepts of ethnicity. Details of the changes made in the census question on ethnicity, and why they 
were made, can be found on the Statistics New Zealand website www.stats.govt.nz  
 
This report presents ethnic-specific analyses for 1996 onwards and, unless otherwise specified, prioritised ethnic 
group has been used to ensure that each health event is only counted once.  
 
Despite significant improvements in the quality of ethnicity data in New Zealand’s national health collections 
since 1996, care must still be taken when interpreting the ethnic-specific rates as the potential still remains for 
Māori and Pacific children and young people to be undercounted in our national data collections. The authors of 
Hauora IV developed a set of adjusters which could be used to minimise the bias such undercounting introduced 
when calculating population rates and rate ratios. These, or similar, adjusters were not utilised in this report 
because previous research has shown that ethnicity misclassification can change over time and ethnic 
misclassification may vary significantly by district health board.22 Adjusters developed using national level 
data (as in Hauora IV21) may not be applicable to district health board level analyses, with separate adjusters 
needing to be developed for each. 
 
In addition, the development of adjusters requires the linkage of the dataset under review with another dataset 
for which more reliable ethnicity information is available, and this process is resource-intensive and not without 
error, particularly if the methodology requires probabilistic linkage of de-identified data. The development of a 
customised set of period and age specific adjusters was seen as being beyond the scope of the current project. 
The data presented in this report may undercount Māori and Pacific children to a variable extent depending on 
the dataset used, and that in the case of the hospital admission dataset for Māori, this undercount may be as high 
as 5–6%. 
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APPENDIX 5: NZ DEPRIVATION INDEX 
The NZ index of deprivation (NZDep) was first created using information from the 1991 census, and has been 
updated following each census. It is a small area index of deprivation, and is used as a proxy for socioeconomic 
status. The main concept underpinning small area indices of deprivation is that the socioeconomic environment 
in which a person lives can confer risks or benefits which may be independent of their own social position 
within a community.427 They are aggregate measures, providing information about the wider socioeconomic 
environment in which a person lives, rather than information about their individual socioeconomic status.  
 
The latest index, NZDep2013, combines nine variables from the 2013 census to reflect eight dimensions of 
material and social deprivation (Table 178). Each variable represents a standardised proportion of people living 
in an area who lack a defined material or social resource. These are combined to give a score representing the 
average degree of deprivation experienced by people in that area. Individual area scores are ranked and placed 
on an ordinal scale from 1 to 10, with decile 1 reflecting the least deprived 10% of small areas and decile 10 
reflecting the most deprived 10% of small areas.428 
 
The advantage of the NZDep2013 is its ability to assign measures of socioeconomic status to the older 
population, the unemployed and to children, to whom income and occupational measures often don’t apply, as 
well as to provide proxy measures of socioeconomic status for large datasets when other demographic 
information is lacking. Small area indices have limitations, however, as not all individuals in a particular area 
are accurately represented by their area’s aggregate score. While this may be less of a problem for very affluent 
or very deprived neighbourhoods, in average areas, aggregate measures may be much less predictive of 
individual socioeconomic status.427 Despite these limitations, the NZDep2013 has been shown to be predictive 
of mortality and morbidity from a number of diseases in New Zealand. 
Table 178. Variables used in the NZDep2013 
Dimension Variable in order of decreasing weight in the index 
Communication People aged < 65 with no access to the Internet at home  
Income People aged 18 - 64 receiving a means tested benefit 
Income People living in equivalised* households with income below an income threshold  
Employment People aged 18 - 64 unemployed  
Qualifications People aged 18 - 64 without any qualifications  
Owned home People not living in own home  
Support People aged < 65 living in a single parent family  
Living space People living in equivalised* households below a bedroom occupancy threshold  
Transport People with no access to a car  
*The setting of the household equivalised income threshold was based on two principles: 1) the proportion of the population 
identified as being socioeconomically deprived by the threshold should be broadly consistent with the other variables in the 
index, and 2) the threshold should be broadly consistent with other measures of income poverty.428 
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APPENDIX 6: CLINICAL CODES USED  
Select health specialty codes 
Category Health specialty codes 
Emergency Medicine  M05–M08 
 
Select procedures 
Category ICD-10-AM codes   
Grommets 41632-00, 41632-01  
Tonsillectomy ± adenoidectomy 41789-00, 41789-01  
 
Diagnosis codes used for identifying ambulatory sensitive hospitalisations 
Category ICD-10-AM codes ICD-9-CM codes 
Asthma and wheeze J45–46, R06.2 493.00, 493.01 
Bronchiectasis J47 494 
Skin infections 
H00.0, H01.0, J340, L01–L04, 
L08, L98.0 
680–684, 685.0, 686, 
910.(1,3,5,7,9)–917.(1,3,5,7,9), 
919.(1,3,5,7,9) 
Constipation K59.0 564.0 
Dental caries/other dental conditions K02, K04, K05 521.0, 522, 523 
Dermatitis and Eczema L20–30 690–693, 698 
Gastroenteritis A02–A09, R11, K529 001–009, 787.0, 558.9 
Gastro-oesophageal reflux K21 530.11, 530.81 
Nutritional Deficiency 
D50–D53, E40–E46, E50–E56, 
E58–E61, E63–E64 
260–269, 280–281 
Bacterial or non-viral pneumonia J13–J16, J18 481–483, 485, 486 
Rheumatic fever and /or rheumatic heart disease I00–I09 390–398 
Otitis media H65–H67 381.0–381.4, 382 
Acute upper respiratory tract infections* J00–J03, J06 
460–463, 465, 464.0, 464.1, 
464.2 
Urinary Tract Infections 
N10, N12, N30.0, N39.0, 
N30.9, N13.6 
590, 595.0–595.3, 595.9, 599.0 
Vaccine-preventable:   
Neonatal or obstetric tetanus A33, A34 771.3, 670.04 
Congenital Rubella P35.0 771.0 
Pertussis A37 033 
Diphtheria A36 032 
Hepatitis B B16, B18.0, B18.1 070.2, 070.3 
Polio A80 045 
Tetanus A35 037 
Measles, Mumps, Rubella B05, B06, B26, M01.4 055, 056, 072, 056.71 
 
Selected diagnosis codes 
Category ICD-10-AM codes ICD-9-CM codes 
Acute upper respiratory tract infections excl croup J00–J03, J06 
460–463, 465, 464.0, 464.1, 
464.2 
Acute URTI: Acute nasopharyngitis (common cold) J00 460 
Acute URTI: Acute pharyngitis J02 462 
Acute URTI: Acute sinusitis J01 461 
Acute URTI: Acute tonsillitis J03 463 
Acute URTI: Croup, acute laryngitis, or tracheitis J04, J05.0 464.0–464.2, 464.4–464.5 
Acute URTI: multiple or unspecified sites J06 465 
Asthma and wheeze J45–46, R06.2 493.00, 493.01 
Bronchiectasis J47 494 
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Bronchiolitis J21 466.1 
Chorioamnionitis P02.7 762.7 
Compression of umbilical cord P02.5 762.5 
Congenital anomalies Q00–Q99 740–759 
Congenital anomalies: chromosomal Q90–Q99 758 
Congenital anomalies: CNS Q00–Q07 740–742 
Congenital anomalies: CVS Q20–Q28 745–747 
Congenital anomalies: other Q08–Q89 743–759 
Congenital pneumonia P23 770 
Constipation K59.0 564.0 
Dental caries or other dental conditions K02, K04, K05 521.0, 522, 523 
Dermatitis and eczema L20–30 690–693, 698 
Epiglottitis J05.1 464.3 
Extreme prematurity P07.2 765 
Fetal blood loss P50 772.0 
Gastroenteritis A00–A09, R11, K52.9 001–009, 558.9, 787.0 
Hydrops fetalis (non-haemolytic disease) P832 778 
Hypertrophy of the tonsils and/or adenoids J35.1–J35.3 474.10–474.12 
Incompetent cervix or premature rupture of membranes P01.0, P01.1 761.0, 761.1 
Infections specific to perinatal period P35–P39 771 
Inhalation and ingestion of food causing obstruction of the 
respiratory tract 
W79  
Inhalation of gastric contents W78  
Injury S00–T79 800–904,  910–995 
Injury or poisoning V01–Y36 800–999 
Intentional self-harm X60–X84 950–959 
Intrauterine hypoxia P20.0 768.0–768.4 
Intrauterine hypoxia or birth asphyxia P20, P21 768 
Malnutrition or slow fetal growth P05 764 
Maternal hypertensive disorders P00.0 760.0 
Meningococcal disease A39 036.0–036.9 
Middle ear or mastoid: Cholesteatoma of the middle ear  H71 385.3 
Middle ear or mastoid: Chronic tonsillitis J35.0 474.0 
Middle ear or mastoid: Eustachian tube disorders H68, H69 381.5–381.9 
Middle ear or mastoid: Mastoiditis and related disorders H70 383 
Middle ear or mastoid: Other disorders of the middle ear 
or mastoid 
H74–H75 385.0–385.2, 385.4–385.9 
Middle ear or mastoid: Otitis media H65–H67 381.0–381.4, 382 
Middle ear or mastoid: Perforation or other disorders of 
the tympanic membrane  
H72–H73 384 
Multiple pregnancy P01.5 761.5 
Neonatal aspiration of meconium, amniotic fluid, or mucus P240, P241 770.1 
Nutritional deficiency 
D50–D53, E40–E46, E50–E56, 
E58–E61, E63–E64 
260–269, 280–281 
Oligohydramnios P01.2 761.2 
Other abnormalities of placenta P02.2 762.2 
Other or unspecified chronic diseases of tonsils or 
adenoids 
J35.8–J35.9 474.2–474.9 
Other perinatal conditions P00–P19; P22–P96 760–779 
Pertussis or whooping cough A37 033 
Pertussis: Whooping cough due to Bordetella parapertussis A37.1 033.1 
Pertussis: Whooping cough due to Bordetella pertussis A37.0 033.0 
Pertussis: Whooping cough due to other Bordetella species A37.8 033.8 
Pertussis: Whooping cough, unspecified A37.9 033.9 
Placenta praevia or placental separation and haemorrhage P02.0, P02.1 762.0, 762.1 
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Placental transfusion syndromes P02.3 762.3 
Pneumonia: bacterial, non-viral, or unspecified  J13–J16, J18 
481–483, 078.88, 485, 486, 
514 
Pneumonia: viral J10.0, J11.0, J12 487.0, 480 
Polycythaemia neonatorum P611 776.4 
Prematurity or low birthweight P07.0, P07.2 765 
Rheumatic Fever and Rheumatic Heart Disease I00–I09 390–398 
Skin infections: Acute lymphadenitis L04 683 
Skin infections: Cellulitis L03 682 
Skin infections: Cutaneous abscess, furuncle, or carbuncle L02 680 
Skin infections: Impetigo L01.0, L01.1 684 
Skin infections: Infected, unspecified, or other dermatitis L30.3, L30.8, L30.9 690.8, 702.8 
Skin infections: Infections of other anatomical sites 
A46, H00.0, H05.0, H60.0, 
H60.1, H60.2, H60.3, H62.0, 
H62.4, J34.0, K61.0, N48.2, 
N49.2, N49.9, N76.4 
035, 373.1, 376.01, 380.10, 
380.14, 380.13, 478.1, 566, 
607.2, 608.4, 616.4 
Skin infections: Insect or spider bites 
S10.13, S10.83, S10.93, S20.13, 
S20.33, S20.43, S20.83, S30.83, 
S30.93, S40.83, S50.83, S60.83, 
S70.83, S80.83, S90.83, T09.03, 
T11.08, T13.03, T14.03, T63.3, 
T63.4, T00.9 
910.4, 910.5, 911.4, 911.5, 
912.5, 912.6, 913.4, 913.5, 
914.5, 915.5, 916.4, 916.5, 
917.4, 917.5, 919.4, 919.5, 
919.8, 989.5 
Skin infections: Other infections of skin and subcutaneous 
tissue 
L08 686 
Skin infections: Pilonidal cyst with abscess L05.0 685.0 
Skin infections: Post traumatic or open wound infection T79.3, T89.01, T89.02 958.3 
Skin infections: Scabies B86 133.0 
Skin infections: Varicella with other complications B01.8 052.7, 052.8 
Sleep apnoea G47.3 780.51 
SUDI: inhalation of gastric contents or food W78, W79 E911 
SUDI: SIDS R95 798 
SUDI: suffocation or strangulation in bed W75 E913.0 
SUDI: unspecified R96, R98, R99 798.1, 798.2, 798.9 
Tuberculosis A15–A19 010–018 
Unspecified cause of fetal death P95, R99 768.0, 799.9 
 
Selected diagnosis codes for unintentional injury 
Category ICD-10-AM codes ICD-9-CM codes 
Falls W00–W19  880–888 
Inanimate mechanical forces W20–W49 914–916, 918–925 
Animate mechanical forces W50–W64 906, 917 
Drowning or submersion W65–W74 910 
Suffocation W75–W84 911–915 
Thermal injury W85–X19 890–899, 926 
Poisoning X40–X49 850–869 
Intentional self-harm X60–X84 950–959 
Assault X85–Y09 960–969 
Undetermined intent Y10–Y34 980–989 
   
Road traffic   
Vehicle occupant 
V40–V48.(5, 6, 7, 9), V50–
V58.(5, 6, 7, 9), V60–V68.(5, 6, 
7, 9), V70–V78.(5, 6, 7, 9) 
810–819.(0, 1) 
Motorbike 
V20–V28.(4, 5, 9), V29.(4, 5, 6, 
9) 
825.2, 81x.(2, 3) 
Cyclist 
V10–V18.(4, 5, 9), V19.(4, 5, 6, 
9) 
81x.6 
Pedestrian V00–V06.(1), V09.(2, 3)  814, 81x.7 
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Other land transport 
V30–V38.(5, 6, 7, 9), V39.(4, 5, 
6, 9), V81.1, V82.(1, 9), V83–
V86.(0, 1, 2, 3) 
 
Non-traffic land transport incidents   
Vehicle occupant 
V40–V48.(0, 1, 2, 3), V50–
V58.(0, 1, 2, 3), V60–V68.(0, 1, 
2, 3), V70–V78.(0, 1, 2, 3), 
V49.(0, 1, 2, 3), V59.(0, 1, 2, 3), 
V69.(0, 1, 2, 3), V79.(0, 1, 2, 3) 
820–825.(0, 1) 
Motorbike 




V10–V18.(0, 1, 2), V19.(0, 1, 2, 
3) 
826, 82x.6 
Pedestrian V00–V06.(0), V09.(0, 1)  82x.7 
Other land transport 
V30–V38.(0, 1, 2, 3), V39.(0, 1, 
2, 3), V87, V89.(2, 3), V81.0, 
V82.0, V83–V86.(5, 6, 7, 9), 
V88, V89.(0, 1) 
 
Land transport: other or unspecified V00–V89, V98–V99 800–829 
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